



(51) International Patent Classification:

C07D 403/14 (2006.01) C07D 413/14 (2006.01)
C07D 271/02 (2006.01)

(21) International Application Number:

PCT/US2017/058144

(22) International Filing Date:

24 October 2017 (24.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/412,119	24 October 2016 (24.10.2016)	US
62/443,040	06 January 2017 (06.01.2017)	US
62/534,990	20 July 2017 (20.07.2017)	US

(71) Applicant: YUMANITY THERAPEUTICS [US/US];
790 Memorial Drive, Suite 2C, Cambridge, MA 02139
(US).

(72) Inventors: LUCAS, Matthew; 48 Parker Street, Lexington, MA 02421 (US). LE BOURDONNEC, Bertrand; 2 Mohican Avenue, Northborough, MA 01532 (US). WRONA, Iwona; 17 Harding Street, Sharon, MA 02067


(US). PANDYA, Bhaumik; 325 Springs Road, Bedford, MA 01730 (US). TIVITMAHAISOON, Parcharee; 580 Commonwealth Ave. #606, Boston, MA 02215 (US). OZBOYA, Kerem; 11 Ellery Street Apt #1, Cambridge, MA 02138 (US). VINCENT, Benjamin; 9 Locke Street Apt#2, Cambridge, MA 02140 (US). TARDIFF, Daniel; 48 Newland Road, Arlington, MA 02474 (US). PIOTROWSKI, Jeff; 171 Walnut Street #3, Somerville, MA 02145 (US). SOLIS, Eric; 29 Princess Pine Lane, Milford, MA 01757 (US). SCANNEVIN, Robert; 26 Huckleberry Road, Hopkinton, MA 01748 (US). CHUNG, Chee-Yeun; 416 Clinton Road, Brookline, MA 02445 (US). ARON, Rebecca; 1 Whittemore Avenue #104, Cambridge, MA 02140 (US). RHODES, Kenneth; 86 Juniper Road, Belmont, MA 02478 (US).

(74) Agent: BIEKER-BRADY, Kristina; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: COMPOUNDS AND USES THEREOF

FIG. 1A



(57) Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.



KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))


COMPOUNDS AND USES THEREOF

Background

An incomplete understanding of the molecular perturbations that cause disease, as well as a limited arsenal of robust model systems, has contributed to a failure to generate successful disease-modifying therapies against common and progressive neurological disorders, such as Parkinson's Disease (PD) and Alzheimer's Disease (AD). Progress is being made on many fronts to find agents that can arrest the progress of these disorders. However, the present therapies for most, if not all, of these diseases provide very little relief. Accordingly, a need exists to develop therapies that can alter the course of neurodegenerative diseases. More generally, a need exists for better methods and compositions for the treatment of neurodegenerative diseases in order to improve the quality of the lives of those afflicted by such diseases.


Summary of the Invention

This disclosure provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula I:



Formula Ia

wherein B is absent or has the structure:



Formula Ib

Formula Ic

Formula Id

Formula Ie

Formula If

the dashed lines represent an optional double bond;

Het is -C(O)NH- or an optionally substituted C₂-C₉ heteroaryl;

m is 0 or 1;

n is 0, 1, or 2;

o is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

p, p', r, and r' are, independently, 0 or 1;

X¹ and X² are each, independently, N or CR⁶;

L¹ is -O-, -SO₂-, NR², optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ alkenylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₂-C₉ heteroaryl, an optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heterocycle;

L² is absent, -O-, -SO₂-, NR², or -CR²R³-;

R¹ is hydrogen, amino, hydroxy, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₆-C₁₀ aryl C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇ cycloalkyl C₁-C₆ alkyl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₉ heteroaryl C₁-C₆ alkyl, optionally substituted C₂-C₉ heterocycle, or optionally substituted C₂-C₉ heterocycle C₁-C₆ alkyl;

R² and R³ are each, independently, hydrogen, halogen, hydroxyl, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or combine with the carbon to which they are attached to form a carbonyl or an optionally substituted C₃-C₇ cycloalkyl;


each R⁴ is, independently, halogen, hydroxyl, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or two R⁴ combine with the carbon to which they are attached to form a carbonyl or optionally substituted C₃-C₇ cycloalkyl;

R⁵ is optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₁-C₆ alkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted C₂-C₉ heterocycle, optionally substituted C₆-C₁₀ aryl C₁-C₆ alkyl, optionally substituted C₂-C₉ heterocycle C₁-C₆ alkyl, or optionally substituted C₂-C₉ heteroaryl C₁-C₆ alkyl; and


each R⁶ is, independently, hydrogen, halogen, hydroxy, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₁-C₆ alkyl.

In some embodiments, B is absent.


In some embodiments, B has the structure of Formula Ib:




In some embodiments, X¹ is N and X² is CR⁶. In some embodiments, o is 0, 1, or 2. In some embodiments, R⁴ is halogen (e.g., fluoro), optionally substituted C₁-C₆ alkyl (e.g., methyl), or two R⁴ combine with the carbon to which they are attached to form a carbonyl. In some embodiments, R⁶ is hydrogen. In some embodiments, R⁶ is halogen (e.g., fluoro). In some embodiments, R⁶ is optionally substituted C₁-C₆ alkyl (e.g., methyl). In some embodiments, the dashed line represents a double bond. In some embodiments, both dashed lines represent a single bond. In some embodiments, p is 1 and r is 1. In some embodiments, p is 1 and r is 0. In some embodiments, p is 0 and r is 0. In some embodiments, B has the structure:



In some embodiments, X^1 is CR^6 and X^2 is N. In some embodiments, o is 0, 1, or 2. In some embodiments, R^4 is halogen (e.g., fluoro), optionally substituted C_1 - C_6 alkyl (e.g., methyl), or two R^4 combine with the carbon two which they are attached to form a carbonyl. In some embodiments, R^6 is hydrogen. In some embodiments, R^6 is halogen (e.g., fluoro). In some embodiments, R^6 is optionally substituted C_1 - C_6 alkyl (e.g., methyl). In some embodiments, the dashed line represents a double bond. In some embodiments, the dashed line represents a single bond. In some embodiments, p is 1 and r is 1. In some embodiments, p is 1 and r is 0. In some embodiments, p is 0 and r is 0. In some embodiments, B has the structure:




In some embodiments, X^1 is N and X^2 is N. In some embodiments, o is 0, 1, or 2. In some embodiments, R^4 is halogen (e.g., fluoro), optionally substituted C_1 - C_6 alkyl (e.g., methyl), or two R^4 combine with the carbon two which they are attached to form a carbonyl. In some embodiments, the dashed line represents a double bond. In some embodiments, the dashed line represents a single bond. In some embodiments, p is 1 and r is 1. In some embodiments, p is 1 and r is 0. In some embodiments, p is 0 and r is 0. In some embodiments, p is 1 and r is 2. In some embodiments, B has the structure:




In some embodiments, X^1 is CR^6 and X^2 is CR^6 . In some embodiments, o is 0, 1, or 2. In some embodiments, R^4 is halogen (e.g., fluoro), optionally substituted C_1 - C_6 alkyl (e.g., methyl), or two R^4 combine with the carbon two which they are attached to form a carbonyl. In some embodiments, the dashed line represents a double bond. In some embodiments, the dashed line represents a single bond. In some embodiments, p is 1 and r is 1. In some embodiments, p is 1 and r is 0. In some embodiments,


p is 0 and r is 0. In some embodiments, B has the structure:




In some embodiments, B has the structure of Formula Ic:




In some embodiments, X^1 is N and X^2 is N. In some embodiments, o is 0. In some embodiments, p, p', r, and r' are 0. In some embodiments, p and r are each 1 and p' and r' are 0. In some embodiments, B has the structure:




In some embodiments, B has the structure of Formula Id:



In some embodiments, X^1 is N and X^2 is N. In some embodiments, o is 0. In some embodiments, B has the structure:




In some embodiments, B has the structure of Formula 1e:




5

In some embodiments, X^1 is N and X^2 is N. In some embodiments, o is 0. In some embodiments, B has the structure:




In some embodiments, B has the structure of Formula 1f:



10

In some embodiments of any of the foregoing compounds, Het is $-C(O)NH-$ or:




wherein X^3 is O or S.


In some embodiments, Het is $-C(O)NH-$.

15


In some embodiments, Het is




In some embodiments, Het is



In some embodiments, Het is



In some embodiments, Het is





20





In some embodiments, L^2 is absent. In some embodiments, L^2 is $-NR^2-$ (e.g., $-NH-$). In some embodiments, L^2 is $-O-$. In some embodiments, L^2 is $-SO_2-$. In some embodiments, L^2 is $-CR^2R^3-$. In some embodiments, R^2 and R^3 combine with the carbon to which they are attached to form a carbonyl. In some embodiments, R^2 and R^3 combine with the carbon to which they are attached to form an optionally



substituted C₃-C₇ cycloalkyl (e.g., cyclopropyl). In some embodiments, R² and R³ are both hydrogen. In some embodiments, R² is hydrogen and R³ is optionally substituted C₁-C₆ alkylene (e.g., methylene).

In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, L¹ is -NR²- (e.g., -NH- or -N(Et)-). In some embodiments, L¹ is -O-. In some embodiments, L¹ is -SO₂-.


5 In some embodiments, L¹ is optionally substituted C₁-C₆ alkylene (e.g., methylene or hydroxy-methylene). In some embodiments, L¹ is optionally substituted C₁-C₆ heteroalkylene (e.g., -NH-CH₂-, -O-CH₂-, -O-CH₂-

CH₂-, -CH₂-O-CH₂-, -CH₂-O-, , or ). In some embodiments, L¹



is optionally substituted C₂-C₉ heterocycle (e.g., , , , ,


, or ).


10 In some embodiments, R¹ is cyano, optionally substituted C₁-C₆ alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, trifluoromethyl, trifluoroethyl, pentafluoro-ethyl, 2-chloro-ethyl, 1-chloro-3-hydroxy-isopropyl, 2-methoxy-ethyl, or hexafluoro-isopropyl). In some embodiments, R¹ is optionally substituted C₆-C₁₀ aryl (e.g., phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-cyano-phenyl, 3-cyano-phenyl, 4-cyano-phenyl, 3-isopropyl-phenyl, 4-isopropyl-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 4-methoxy-phenyl, 4-difluoromethoxy-phenyl, 4-trifluoromethoxy-phenyl, 2-chloro-5-fluoro-phenyl, 2-fluoro-4-chloro-phenyl, 3-fluoro-4-chloro-phenyl, 2-bromo-4-methoxy-phenyl, 2-trifluoromethyl-5-fluoro-phenyl, 2-trifluoromethyl-

5-chloro-phenyl, ). In some embodiments, R¹ is


20 optionally substituted C₆-C₁₀ aryl C₁-C₆ alkyl (e.g., naphthylmethyl). In some embodiments, R¹ is optionally substituted C₃-C₇ cycloalkyl (e.g., cyclopropyl, cyclohexyl, 6-methoxy-cyclohexyl, 1-cyano-cyclopropyl, bicycle[1.1.1]pentane, 1-methyl-cyclopropyl, 1-ethyl-cyclopropyl, 1-fluoro-cyclopropyl, 1-methoxy-cyclopropyl, 1-hydroxy-cyclopropyl, 2,2-dimethyl-cyclopropyl, 2,2-difluoro-cyclopropyl,

cyclobutyl, , or ). In some embodiments, R¹ is optionally substituted C₃-C₇ cycloalkyl C₁-C₆ alkyl (cyclopropylmethyl). In some embodiments, R¹ is








In some embodiments, R⁵ is optionally substituted C₆-C₁₀ aryl (e.g., phenyl, 3,4-dimethoxy-
 5 phenyl, 3-methoxy-4-ethoxy-phenyl, 3,5-dimethoxy-phenyl, 3-methoxy-4-cyclopropoxy-phenyl, 3-




R⁵ is optionally substituted C₂-C₉ heteroaryl (e.g.,








5




embodiments, R^5 is an optionally substituted indazole. In some embodiments, R^5 is optionally substituted

C_2 - C_9 heterocycle (e.g., a nitrogen containing heterocycle such as), or).




In some embodiments, R^5 is a bicyclic heterocycle. For example, a bicyclic heterocycle such as

an indazole. In some embodiments, R^5 is an indazole having the structure:




wherein R^{5a} is hydrogen or optionally substituted C_1 - C_6 alkyl (e.g., methyl) and R^{5b} is optionally
 substituted C_1 - C_6 alkyl (e.g., methyl or iso-propyl), optionally substituted C_2 - C_9 heterocyclyl (e.g.,
 oxetane), or optionally substituted C_3 - C_7 cycloalkyl (e.g., cyclopropyl).

In some embodiments, B has the structure:



In some embodiments, R^1 is optionally substituted C_1 - C_6 alkyl (e.g., methyl, ethyl, iso-propyl, or
 tert-butyl), optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, m is 0, n is 1, L^1 is $-O-$, and L^2 is $-C(O)-$. In some embodiments, m is 0,




n is 0, and L^2 is $-C(O)-$. In some embodiments, m is 0, n is 1, L^1 is


some embodiments, m is 1, n is 1, L^1 is

 , and L^2 is $-C(O)-$.

In some embodiments, R^5 is an indazole having the structure:




wherein R^{5a} is hydrogen or optionally substituted C_1 - C_6 alkyl (e.g., methyl) and R^{5b} is optionally
 substituted C_1 - C_6 alkyl (e.g., methyl or iso-propyl), optionally substituted C_2 - C_9 heterocyclyl (e.g.,
 oxetane), or optionally substituted C_3 - C_7 cycloalkyl (e.g., cyclopropyl); B has the structure:




R^1 is optionally substituted C_1 - C_6 alkyl (e.g., methyl, ethyl, iso-propyl, or tert-butyl), optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl; and

m is 0, n is 1, L^1 is $-O-$, and L^2 is $-C(O)-$, m is 0, n is 0, and L^2 is $-C(O)-$, m is 0, n is 1, L^1 is





5


, and L^2 is $-C(O)-$, or m is 1, n is 1, L^1 is , and L^2 is $-C(O)-$.

In some embodiments, m is 0, n is 1, L^1 is $-O-$, L^2 is $-C(O)-$ and R^1 is optionally substituted C_1 - C_6 alkyl (e.g., methyl, ethyl, iso-propyl, or tert-butyl).


In some embodiments, m is 0, n is 0, L^2 is $-C(O)-$, and R^1 is optionally substituted C_6 - C_{10} aryl.



10 In some embodiments, m is 0, n is 1, L^1 is , L^2 is $-C(O)-$, and R^1 is optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, m is 1, n is 1, L^1 is , L^2 is $-C(O)-$, and R^1 is optionally substituted C_6 - C_{10} aryl.

In some embodiments, the compound has the structure of Formula Ig:



15

Formula Ig

wherein Het is an optionally substituted oxadiazole;

o is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

X^2 is N or CR^6 ;

20 R^1 is optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_6 - C_{10} aryl C_1 - C_6 alkyl, optionally substituted C_3 - C_7 cycloalkyl, optionally substituted C_3 - C_7 cycloalkyl C_1 - C_6 alkyl, optionally substituted C_2 - C_9 heteroaryl, optionally substituted C_2 - C_9 heteroaryl C_1 - C_6 alkyl, optionally substituted C_2 - C_9 heterocycle, or optionally substituted C_2 - C_9 heterocycle C_1 - C_6 alkyl;

25 each R^4 is, independently, halogen, hydroxyl, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, or two R^4 combine with the carbon two which they are attached to form a carbonyl or optionally substituted C_3 - C_7 cycloalkyl;


R^5 is optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_1 - C_6 alkyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, optionally substituted C_2 - C_9 heterocycle,

optionally substituted C₆-C₁₀ aryl C₁-C₆ alkyl, optionally substituted C₂-C₉ heterocycle C₁-C₆ alkyl, or optionally substituted C₂-C₉ heteroaryl C₁-C₆ alkyl; and


each R⁶ is, independently, hydrogen, halogen, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₁-C₆ alkyl.

5

In some embodiments, Het is



In some embodiments, Het is




In some embodiments, X² is N or CH. In some embodiments, X² is N. In some embodiments, X² is CH.

10

In some embodiments, R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or optionally substituted C₆-C₁₀ aryl.



In some embodiments, R⁵ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl (e.g., bicyclic heteroaryl such as an indazole). In some embodiments, R⁵ has the structure:




15

wherein R^{5a} is hydrogen or optionally substituted C₁-C₆ alkyl (e.g., methyl) and R^{5b} is optionally substituted C₁-C₆ alkyl (e.g., methyl or iso-propyl), optionally substituted C₂-C₉ heterocyclyl (e.g., oxetane), or optionally substituted C₃-C₇ cycloalkyl (e.g., cyclopropyl). In some embodiments, R^{5a} is hydrogen.


20

In some embodiments, Het is  or ; o is 0; X² is N or CH; R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl (e.g., C₁-C₆ alkoxy or C₁-C₆ alkylamino), or optionally substituted C₆-C₁₀ aryl; and R⁵ has the structure:



wherein R^{5b} is optionally substituted C₁-C₆ alkyl (e.g., methyl or iso-propyl), optionally substituted C₂-C₉ heterocyclyl (e.g., oxetane), or optionally substituted C₃-C₇ cycloalkyl (e.g., cyclopropyl).

In some embodiments the compound has the structure of Formula I:



25

Formula I

wherein Het is an optionally substituted optionally substituted C₂-C₉ heteroaryl;

m is 0 or 1;

n is 0, 1, or 2;

o is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

5 X¹ and X² are each, independently, N or CR⁶;

L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ alkenylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocycle;

10 R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocycle;

R² and R³ are each, independently, hydrogen, optionally substituted C₁-C₆ alkyl, or combine with the carbon to which they are attached to form a carbonyl;


15 each R⁴ is, independently, halogen, hydroxyl, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or two R⁴ combine with the carbon two which they are attached to form a carbonyl;

R⁵ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl; and

each R⁶ is, independently, hydrogen or optionally substituted C₁-C₆ alkyl.


20 In some embodiments of any of the foregoing compounds, R² and R³ combine with the carbon to which they are attached to form a carbonyl. In some embodiments of any of the foregoing compounds, R² and R³ are both hydrogen.

In some embodiments of any of the foregoing compounds, Het is:



wherein X³ is O or S.

25 In some embodiments, the compound has the structure of Formula II or IIa:



Formula II

Formula IIa

In some embodiments of any of the foregoing compounds, X³ is O. In some embodiments of any of the foregoing compounds, X³ is S.


30 In some embodiments of any of the foregoing compounds, X¹ is N and X² is CR⁶. In some embodiments of any of the foregoing compounds, X¹ is N and X² is N. In some embodiments of any of the foregoing compounds, X¹ is CR⁶ and X² is N. In some embodiments of any of the foregoing compounds, R⁶ is hydrogen.

In some embodiments of any of the foregoing compounds, R⁵ is optionally substituted C₆-C₁₀ aryl.

35 For example, in some embodiments, R⁵ is a C₆-C₁₀ aryl substituted with 1, 2, 3, or 4 substituents independently selected from C₁-C₆ alkyl (e.g., methyl), halogen (e.g., fluoro, chloro, or bromo), C₁-C₆

alkoxy (e.g., methoxy or ethoxy), nitrile, or two substituents combine to form a 5 or 6-membered heterocycle (e.g., 2,2-difluoro-1,3-benzodioxole). In some embodiments of any of the foregoing compounds, R⁵ is phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 3,4-dimethyl-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 3,4-difluoro-phenyl, 3,4-dichloro-phenyl, 3-methoxy-4-ethoxy-phenyl, 3-chloro-4-ethoxy-phenyl, 3-fluoro-4-ethoxy-phenyl, 3-bromo-4-ethoxy-phenyl, 3-cyano-4-ethoxy-phenyl, or 2,2-difluoro-1,3-benzodioxole.

In some embodiments, the compound has the structure of Formula III or IIIa:



Formula III


Formula IIIa

wherein p is 1, 2, 3, 4, or 5;

each R⁷ is, independently, halogen, nitrile, OR⁸, or optionally substituted C₁-C₆ alkyl; and

each R⁸ is, independently, hydrogen or optionally substituted C₁-C₆ alkyl.

In some embodiments, the compound has the structure of Formula IV or IVa:





Formula IV

Formula IVa


In some embodiments, each R⁷ is OR⁸. In some embodiments, each R⁸ is optionally substituted C₁-C₆ alkyl (e.g., methyl or ethyl).

In some embodiments of any of the foregoing compounds, R⁵ is optionally substituted C₂-C₉ heteroaryl (e.g., bicyclic heteroaryl). In some embodiments of any of the foregoing compounds, R⁵ is:








In some embodiments of any of the foregoing compounds, R⁵ is:



- 5 In some embodiments of any of the foregoing compounds, R¹ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl. In some embodiments, R¹ is optionally substituted C₆-C₁₀ aryl. For example, phenyl or a C₆-C₁₀ aryl substituted with 1, 2, 3, 4, or 5 substituents independently selected from C₁-C₆ alkyl (e.g., methyl or iso-propyl), C₁-C₆ alkoxy (e.g., methoxy), or halogen (e.g., chloro). In some embodiments of any of the foregoing compounds R¹ is 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 3,4-methyl-phenyl, 4-iso-propyl-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, or 4-chloro-phenyl. In some embodiments of any of the foregoing compounds, R¹ is a bicyclic C₆-C₁₀ aryl (e.g., naphthalene). In some embodiments of any of the foregoing compounds, R¹ is C₃-C₇ cycloalkyl (e.g., cyclohexyl). In some embodiments of any of the foregoing compounds, R¹ is optionally substituted C₂-C₉ heteroaryl or optionally substituted C₂-C₉ heterocycle. For example, in some embodiments, R¹ is:





In some embodiments of any of the foregoing compounds, the compound has the structure of Formula V or Va:

**Formula V****Formula Va**

wherein q is 1, 2, 3, 4, or 5; and


R⁹ is halogen or optionally substituted C₁-C₆ alkyl.

- 5 In some embodiments of any of the foregoing compounds, the compound has the structure of Formula VI or VIa:

**Formula VI****Formula VIa**


- 10 In some embodiments of any of the foregoing compounds, n is 1. In some embodiments of any of the foregoing compounds, n is 0.

In some embodiments of any of the foregoing compounds, L¹ is optionally substituted C₁-C₆ alkyl. For example, L¹ has the structure:




- 15 In some embodiments of any of the foregoing compounds, L¹ is optionally substituted C₁-C₆ alkenylene (e.g., ethenylene).


In some embodiments of any of the foregoing compounds, L¹ is optionally substituted C₂-C₉ heterocyclene or optionally substituted C₂-C₉ heteroarylene. For example,



- 20 In some embodiments, L¹ is

In some embodiments of any of the foregoing compounds, L¹ is optionally substituted C₁-C₆ heteroalkylene. For example, in some embodiments, L¹ is:

























In some embodiments of any of the foregoing compounds, L^1 is $-\text{NH}-(\text{CR}^{10}\text{R}^{11})_r-$, wherein r is 1, 2, 3, 4, 5, or 6, and each R^{10} and R^{11} is, independently, hydrogen or optionally substituted C_1 - C_6 alkyl. For example, in some embodiments, L^1 is $-\text{NH}-\text{CH}_2-$, $-\text{NH}-\text{CR}^{10}\text{R}^{11}-$, wherein each of R^{10} and R^{11} is methyl, or $-\text{NH}-\text{CHR}^{11}-$, wherein R^{11} is methyl.

In some embodiments of any of the foregoing compounds, m is 1. In some embodiments of any of the foregoing compounds, m is 0.

In another aspect, the disclosure provides a compound, or pharmaceutically acceptable salt thereof, having the structure of any one of compounds 1-966 in Table 1. In some embodiments, the compound is any one of compounds 1-264, 266-271, 274-276, 278-299, 302-318, 320-329, 331-340, 344-354, 358, 362-364, 367, 369, 371-378, 385, 388-392, 396, 397, 399-401, 403, 406-411, 414, 418-420, 422, 425-432, 434-436, 438, 440-444, 446, 450-454, 456, 458, 460, 461, 464, 466, 470, 472-474, 476, 477, or 481-746 in Table 1. In some embodiments, the compound is any one of compounds 1-347, 349, 350, or 354-746 in Table 1. In some embodiments, the compound is any one of compounds 1-387, 389, 393-405, 407-430, 432-439, 441-449, 452, 454-457, 459-472, 475, 477-480, 482-487, or 489-746 in Table 1. In some embodiments, the compound is any one of compounds 1-483 or 491-746 in Table 1. In some embodiments, the compound is any one of compounds 747-966. In some embodiments, the compound is any one of compounds 27, 40, 96, 128, 140, 168, 184, 204, 226, 244, 265, 268, 269, 284, 286, 291, 294, 302, 305, 306, 308, 317, 319, 343, 344, 345, 346, 349, 355-357, or 359-364. In some embodiments, the compound is any one of compounds 244, 265, 269, 319, 345, 349, 355-357, 361, or 364. In some embodiments, the compound is any one of compounds 750, 767, 775-778, 780, 784, 785, 789-792, 795, 799, 812, 813, 817, 828, 838, 839, 842-844, 846, 848, 850, 851, 853, 854, 861, 862, 865, 874-881, 884-888, 890-898, 902, 903, 907, 910, 916, 928, 932, 934, 953, 957, 960, 964, or 965.

Table 1. Compounds of the Invention

#	Structure	#	Structure
1		374	
2		375	
3		376	
4		377	
5		378	
6		379	
7		380	
8		381	

#	Structure	#	Structure
9		382	
10		383	
11		384	
12		385	
13		386	
14		387	
15		388	
16		389	
17		390	
18		391	

#	Structure	#	Structure
19		392	
20		393	
21		394	
22		395	
23		396	
24		397	
25		398	
26		399	

















#	Structure	#	Structure
27		400	
28		401	
29		402	
30		403	
31		404	
32		405	
33		406	
34		407	
35		408	

#	Structure	#	Structure
36		409	
37		410	
38		411	
39		412	
40		413	
41		414	
42		415	
43		416	
44		417	
45		418	

#	Structure	#	Structure
46		419	
47		420	
48		421	
49		422	
50		423	
51		424	
52		425	
53		426	
54		427	



















#	Structure	#	Structure
55		428	
56		429	
57		430	
58		431	
59		432	
60		433	
61		434	
62		435	

#	Structure	#	Structure
63		436	
64		437	
65		438	
66		439	
67		440	
68		441	
69		442	

#	Structure	#	Structure
70		443	
71		444	
72		445	
73		446	
74		447	
75		448	
76		449	
77		450	

















#	Structure	#	Structure
78		451	
79		452	
80		453	
81		454	
82		455	
83		456	
84		457	
85		458	
86		459	

#	Structure	#	Structure
87		460	
88		461	
89		462	
90		463	
91		464	
92		465	
93		466	
94		467	
95		468	

#	Structure	#	Structure
96		469	
97		470	
98		471	
99		472	
100		473	
101		474	
102		475	
103		476	
104		477	

#	Structure	#	Structure
105		478	
106		479	
107		480	
108		481	
109		482	
110		483	
111		484	
112		485	
113		486	

#	Structure	#	Structure
114		487	
115		488	
116		489	
117		490	
118		491	
119		492	
120		493	
121		494	
122		495	

#	Structure	#	Structure
123		496	
124		497	
125		498	
126		499	
127		500	
128		501	
129		502	
130		503	

#	Structure	#	Structure
131		504	
132		505	
133		506	
134		507	
135		508	
136		509	
137		510	
138		511	

#	Structure	#	Structure
139		512	
140		513	
141		514	
142		515	
143		516	
144		517	
145		518	
146		519	
147		520	

#	Structure	#	Structure
148		521	
149		522	
150		523	
151		524	
152		525	
153		526	
154		527	
155		528	
156		529	

#	Structure	#	Structure
157		530	
158		531	
159		532	
160		533	
161		534	
162		535	
163		536	
164		537	
165		538	
166		539	

#	Structure	#	Structure
167		540	
168		541	
169		542	
170		543	
171		544	
172		545	
173		546	
174		547	
175		548	

#	Structure	#	Structure
176		549	
177		550	
178		551	
179		552	
180		553	
181		554	
182		555	
183		556	
184		557	

#	Structure	#	Structure
185		558	
186		559	
187		560	
188		561	
189		562	
190		563	
191		564	
192		565	
193		566	
194		567	

#	Structure	#	Structure
195		568	
196		569	
197		570	
198		571	
199		572	
200		573	
201		574	
202		575	
203		576	
204		577	

#	Structure	#	Structure
205		578	
206		579	
207		580	
208		581	
209		582	
210		583	
211		584	
212		585	
213		586	
214		587	





















#	Structure	#	Structure
215		588	
216		589	
217		590	
218		591	
219		592	
220		593	
221		594	
222		595	
223		596	
224		597	

















#	Structure	#	Structure
225		598	
226		599	
227		600	
228		601	
229		602	
230		603	
231		604	
232		605	
233		606	

#	Structure	#	Structure
234		607	
235		608	
236		609	
237		610	
238		611	
239		612	
240		613	
241		614	
242		615	

#	Structure	#	Structure
243		616	
244		617	
245		618	
246		619	
247		620	
248		621	
249		622	
250		623	
251		624	
252		625	

#	Structure	#	Structure
253		626	
254		627	
255		628	
256		629	
257		630	
258		631	
259		632	
260		633	
261		634	

#	Structure	#	Structure
262		635	
263		636	
264		637	
265		638	
266		639	
267		640	
268		641	
269		642	
270		643	
271		644	

#	Structure	#	Structure
272		645	
273		646	
274		647	
275		648	
276		649	
277		650	
278		651	
279		652	

#	Structure	#	Structure
280		653	
281		654	
282		655	
283		656	
284		657	
285		658	
286		659	
287		660	
288		661	





















#	Structure	#	Structure
289		662	
290		663	
291		664	
292		665	
293		666	
294		667	
295		668	
296		669	
297		670	

#	Structure	#	Structure
298		671	
299		672	
300		673	
301		674	
302		675	
303		676	
304		677	
305		678	
306		679	























#	Structure	#	Structure
307		680	
308		681	
309		682	
310		683	
311		684	
312		685	
313		686	
314		687	
315		688	
316		689	

#	Structure	#	Structure
317		690	
318		691	
319		692	
320		693	
321		694	
322		695	
323		696	
324		697	
325		698	

#	Structure	#	Structure
326		699	
327		700	
328		701	
329		702	
330		703	
331		704	
332		705	
333		706	
334		707	

#	Structure	#	Structure
335		708	
336		709	
337		710	
338		711	
339		712	
340		713	
341		714	
342		715	
343		716	
344		717	

#	Structure	#	Structure
345		718	
346		719	
347		720	
348		721	
349		722	
350		723	
351		724	
352		725	
353		726	
354		727	

#	Structure	#	Structure
355		728	
356		729	
357		730	
358		731	
359		732	
360		733	
361		734	
362		735	
363		736	
364		737	
365		738	

#	Structure	#	Structure
366		739	
367		740	
368		741	
369		742	
370		743	
371		744	
372		745	
373		746	

Table 2. Compounds of the Invention

#	Structure	#	Structure
747		858	
748		859	

#	Structure	#	Structure
749		860	
750		861	
751		862	
752		863	
753		864	
754		865	
755		866	
756		867	
757		868	
758		869	





















#	Structure	#	Structure
759		870	
760		871	
761		872	
762		873	
763		874	
764		875	
765		876	
766		877	
767		878	
768		879	

#	Structure	#	Structure
769		880	
770		881	
771		882	
772		883	
773		884	
774		885	
775		886	
776		887	
777		888	



















#	Structure	#	Structure
778		889	
779		890	
780		891	
781		892	
782		893	
783		894	
784		895	
785		896	
786		897	

#	Structure	#	Structure
787		898	
788		899	
789		900	
790		901	
791		902	
792		903	
793		904	
794		905	
795		906	
796		907	

#	Structure	#	Structure
797		908	
798		909	
799		910	
801		911	
802		912	
803		913	
804		914	
805		915	
806		916	
807		917	






#	Structure	#	Structure
808		918	
809		919	
810		920	
811		921	
812		922	
813		923	
814		924	
815		925	
816		926	
817		927	

#	Structure	#	Structure
818		928	
819		929	
820		930	
821		931	
822		932	
823		933	
824		934	
825		935	
826		936	

#	Structure	#	Structure
827		937	
828		938	
829		939	
830		940	
831		941	
832		942	
833		943	
834		944	
835		945	

#	Structure	#	Structure
836		946	
837		947	
838		948	
839		949	
840		950	
841		951	
842		952	
843		953	
844		954	

#	Structure	#	Structure
845		955	
846		956	
847		957	
848		958	
849		959	
850		960	
851		961	
852		962	
853		963	
854		964	

#	Structure	#	Structure
855		965	
856		966	
857			

In another aspect, the disclosure provides pharmaceutical composition comprising any of the foregoing compounds, or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient.

5 In another aspect, the disclosure provides a method of treating a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or any of the foregoing pharmaceutical compositions.

10 In another aspect, the disclosure provides a method of inhibiting toxicity in a cell (e.g., a mammalian neural cell) related to a protein (e.g., toxicity related to protein misfolding and/or aggregation such as protein aggregation related to misfolding of proteins such as α -synuclein or ApoE4), the method comprising administering, or contacting the cell with, an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof. In some embodiments, the toxicity is α -synuclein-related toxicity. In some embodiments, the toxicity is ApoE4-related toxicity.

15 Non-limiting exemplary neurological disorders include, but are not limited to Alexander disease, Alper's disease, AD, amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, PD, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Ref sum's disease, Sandhoff disease, Schilder's disease, Steele-Richardson-Olszewski disease, tabes dorsalis, frontal temporal dementia, vascular dementia, Down's syndrome, and Guillain-Barre Syndrome.

20 In another aspect, the disclosure provides a method of treating a stearyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering, or contacting the cell with, an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof.

25 Non-limiting exemplary SCD-associated disorders include, but are not limited to metabolic disorders (e.g., diabetes (e.g., Type I diabetes and Type II diabetes), hyperglycemia, metabolic syndrome, obesity, lipid disorders, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hypertension), cancer, cardiovascular diseases, cerebrovascular diseases, kidney

diseases, liver diseases, skin disorders (e.g., acne (e.g., acne vulgaris)), central nervous system (CNS) disorders, dementia, multiple sclerosis, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, and dementia associated with Down Syndrome.

5 Chemical Terms

It is to be understood that the terminology employed herein is for the purpose of describing particular embodiments and is not intended to be limiting.

The term "acyl," as used herein, represents a hydrogen or an alkyl group, as defined herein, that is attached to a parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl, propionyl, and butanoyl. Exemplary unsubstituted acyl groups include from 1 to 6, from 1 to 11, or from 1 to 21 carbons.

The term "alkyl," as used herein, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms). An alkylene is a divalent alkyl group.

The term "alkenyl," as used herein, alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

The term "alkynyl," as used herein, alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

The term "amino," as used herein, represents $-N(R^{N1})_2$, wherein each R^{N1} is, independently, H, OH, NO_2 , $N(R^{N2})_2$, SO_2OR^{N2} , SO_2R^{N2} , SOR^{N2} , an *N*-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), wherein each of these recited R^{N1} groups can be optionally substituted; or two R^{N1} combine to form an alkylene or heteroalkylene, and wherein each R^{N2} is, independently, H, alkyl, or aryl. The amino groups of the invention can be an unsubstituted amino (i.e., $-NH_2$) or a substituted amino (i.e., $-N(R^{N1})_2$).

The term "aryl," as used herein, refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl.

The term "arylalkyl," as used herein, represents an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C_{1-6} alkyl C_{6-10} aryl, C_{1-10} alkyl C_{6-10} aryl, or C_{1-20} alkyl C_{6-10} aryl), such as, benzyl and phenethyl. In some embodiments, the alkyl and the aryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term "azido," as used herein, represents a $-N_3$ group.

The term "cyano," as used herein, represents a $-CN$ group.

The terms "carbocyclyl," as used herein, refer to a non-aromatic C_{3-12} monocyclic, bicyclic, or tricyclic structure in which the rings are formed by carbon atoms. Carbocyclyl structures include cycloalkyl groups and unsaturated carbocyclyl radicals.

The term "cycloalkyl," as used herein, refers to a saturated, non-aromatic, monovalent mono- or polycarbocyclic radical of three to ten, preferably three to six carbon atoms. This term is further

exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.

The term "halogen," as used herein, means a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) radical.

5 The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. Examples of heteroalkyl groups are an "alkoxy" which, as used herein, refers alkyl-O- (e.g., methoxy and ethoxy). A heteroalkylene is a divalent heteroalkyl group.

10 The term "heteroalkenyl," as used herein, refers to an alkenyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkenyl groups. Examples of heteroalkenyl groups are an "alkenoxy" which, as used herein, refers alkenyl-O-. A heteroalkenylene is a divalent heteroalkenyl group.

15 The term "heteroalkynyl," as used herein, refers to an alkynyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkynyl groups. Examples of heteroalkynyl groups are an "alkynoxy" which, as used herein, refers alkynyl-O-. A heteroalkynylene is a divalent heteroalkynyl group.

20 The term "heteroaryl," as used herein, refers to an aromatic mono- or polycyclic radical of 5 to 12 atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, with the remaining ring atoms being C. One or two ring carbon atoms of the heteroaryl group may be replaced with a carbonyl group. Examples of heteroaryl groups are pyridyl, pyrazoyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl, imidazolyl, oxazolyl, and thiazolyl.

25 The term "heteroarylalkyl," as used herein, represents an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁₋₆ alkyl C₂₋₉ heteroaryl, C₁₋₁₀ alkyl C₂₋₉ heteroaryl, or C₁₋₂₀ alkyl C₂₋₉ heteroaryl). In some embodiments, the alkyl and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

30 The term "heterocyclyl," as used herein, denotes a mono- or polycyclic radical having 3 to 12 atoms having at least one ring containing one, two, three, or four ring heteroatoms selected from N, O or S, wherein no ring is aromatic. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, furyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, and 1,3-dioxanyl.

35 The term "heterocyclylalkyl," as used herein, represents an alkyl group substituted with a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁₋₆ alkyl C₂₋₉ heterocyclyl, C₁₋₁₀ alkyl C₂₋₉ heterocyclyl, or C₁₋₂₀ alkyl C₂₋₉ heterocyclyl). In some embodiments, the alkyl and the heterocyclyl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

40 The term "hydroxyl," as used herein, represents an -OH group.

The term "*N*-protecting group," as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used *N*-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999). *N*-protecting groups include acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, *t*-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, *o*-nitrophenoxyacetyl, α -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl, and *p*-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, *p*-chlorobenzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, *p*-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(*p*-biphenyl)-1-methylethoxycarbonyl, α,α -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, *t*-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexylloxycarbonyl, and phenylthiocarbonyl, arylalkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl, and silyl groups, such as trimethylsilyl. Preferred *N*-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, *t*-butylacetyl, alanyl, phenylsulfonyl, benzyl, *t*-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

The term "nitro," as used herein, represents an --NO_2 group.

The term "thiol," as used herein, represents an --SH group.

The alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl, and heterocyclyl groups may be substituted or unsubstituted. When substituted, there will generally be 1 to 4 substituents present, unless otherwise specified. Substituents include, for example: aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halogen (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino (e.g., NH_2 or mono- or dialkyl amino), azido, cyano, nitro, or thiol. Aryl, carbocyclyl (e.g., cycloalkyl), heteroaryl, and heterocyclyl groups may also be substituted with alkyl (unsubstituted and substituted such as arylalkyl (e.g., substituted and unsubstituted benzyl)).

Compounds of the invention can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbents or eluant). That is, certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are

stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as, for example, chiral chromatography and separation methods based thereon. The appropriate technique and/or method for separating an enantiomer of a compound described herein from a racemic mixture can be readily determined by those of skill in the art. "Racemate" or "racemic mixture" means a compound containing two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light. "Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. "R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule. Certain of the disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure. Percent optical purity is the ratio of the weight of the enantiomer or over the weight of the enantiomer plus the weight of its optical isomer. Diastereomeric purity by weight is the ratio of the weight of one diastereomer or over the weight of all the diastereomers. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure. Percent purity by mole fraction is the ratio of the moles of the enantiomer or over the moles of the enantiomer plus the moles of its optical isomer. Similarly, percent purity by moles fraction is the ratio of the moles of the diastereomer or over the moles of the diastereomer plus the moles of its isomer. When a disclosed compound is named or depicted by

structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound or mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has two or more chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a number of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) or mixtures of diastereomers in which one or more diastereomer is enriched relative to the other diastereomers. The invention embraces all of these forms.

Definitions

In the practice of the methods of the present invention, an “effective amount” of any one of the compounds of the invention or a combination of any of the compounds of the invention or a pharmaceutically acceptable salt thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination.

The term “pharmaceutical composition,” as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation.

A “pharmaceutically acceptable excipient,” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

As used herein, the term “pharmaceutically acceptable salt” means any pharmaceutically acceptable salt of the compound of formula (I). For example pharmaceutically acceptable salts of any of the compounds described herein include those that are within the scope of sound medical judgment,

suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., *J. Pharmaceutical Sciences* 66:1-19, 1977 and in *Pharmaceutical Salts: Properties, Selection, and Use*, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting a free base group with a suitable organic acid.

The compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparation of the appropriate salts are well-known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases.

Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.

As used herein, the term "stearyl-CoA desaturase (SCD)-associated disorder" refers to an undesired physiological condition, disorder, or disease that is associated with and/or mediated at least in part by an SCD protein. In some instances, SCD-associated disorders are associated with excess SCD levels and/or activity. SCDs introduce a double bond in the C9-C10 position of saturated fatty acids such as palmitoyl-CoA and stearyl-CoA which are converted to palmitoleoyl-CoA and oleoyl-CoA, respectively. One SCD gene, SCD1, has been characterized in humans for which there are two isoforms, SCD1 and SCD5. An SCD-associated disorder may be associated with and/or mediated at least in part by SCD1 and/or SCD5. Exemplary SCD-associated disorders include SCD-associated disorders include, but are not limited to metabolic disorders (e.g., diabetes (e.g., Type I diabetes and Type II diabetes), hyperglycemia, metabolic syndrome, obesity, lipid disorders, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hypertension), cancer, cardiovascular diseases, cerebrovascular diseases, kidney diseases, liver diseases, skin disorders (e.g., acne (e.g., acne vulgaris)), central nervous system (CNS) disorders, dementia, multiple sclerosis, schizophrenia, mild

cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, and dementia associated with Down Syndrome. Additional SCD-associated disorders are described herein or known in the art.

As used herein, the term "subject" refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be a human or animal who is under care by a trained professional for a particular disease or condition.

As used herein, the terms "treat," "treated," or "treating" mean both therapeutic treatment and prophylactic or preventative measures wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.

Brief Description of the Drawings

FIGS. 1A and 1B are graphs showing that growth inhibition by 1,2,4-oxadiazoles occurs through same mechanism as the rescue of toxicity in the apolipoprotein E4 (ApoE4) Alzheimer's disease yeast model. (**Fig. 1A**) Compound 7, a representative 1,2,4-oxadiazole, was profiled in ApoE4 (top) and control (bottom) non-inducing conditions at 12-point dose (x-axis). The Y-axis shows raw OD₆₀₀. Compound 7 exhibited a bell-shaped dose-response curve (DRC) in the ApoE4 model. Rescue decreased at concentrations just above the maximal efficacy (Emax). In the control condition (bottom panel), growth decreased at this same concentration. (**Fig. 1B**) The relationship between Emax (rescue in ApoE4) and growth inhibition (in control condition) correlated across 34 tested 1,2,4-oxadiazoles. The maximal rescue dose (EC100) is shown on the y-axis for ApoE4 and minimal inhibitory dose (IC100) in the control condition is shown on the x-axis. This correlation indicates that growth inhibition is caused by the same on-target activity that rescues ApoE4 toxicity.

FIGS. 2A and 2B are graphs showing that exogenous oleic acid reverses growth inhibition and model rescue by Ole1/SCD-targeting 1,2,4-oxadiazoles. Growth was measured by reading OD₆₀₀ in a microplate reader and normalized to solvent control DMSO samples. (**Fig. 2A**) Growth inhibition (24 h) of strain GM *yap1 flr1* by Ole1/SCD-targeting 1,2,4-oxadiazoles is reversed by exogenous 0.5 mM oleic/palmitoleic acid, which did not affect growth inhibition by other compounds (black dots indicate other scaffolds tested). Maximal growth inhibition across a dose range from 33 nM to 33 μM is plotted. (**Fig. 2B**) Rescue (40 h) of the yeast alpha-synuclein ("aSyn") model by 1,2,4-oxadiazoles was reversed by exogenous 0.5 mM oleic/palmitoleic acid, which did not affect rescue by other scaffolds. Maximal model rescue across a dose range from 33 nM to 33 μM is plotted.

FIGS. 3A and 3B are graphs showing that point mutations in yeast *OLE1* confer resistance to growth inhibition and alpha-synuclein model rescue by 1,2,4-oxadiazoles. Growth was measured by reading OD₆₀₀ in a microplate reader. (**Fig. 3A**) Yeast cells deleted for the chromosomal copy of *OLE1* and expressing *OLE1* (wild-type), *ole1P123T*, or *ole1E188Q* mutants from a pRS316-based plasmid were grown in complete synthetic medium (CSM)-glucose media at the indicated doses of 1,2,4-oxadiazole Compound 95 for 24 h. Growth was normalized to samples treated with the solvent control dimethyl sulfoxide (DMSO), set as “1”. (**Fig. 3B**) Yeast cells deleted for the chromosomal copy of *OLE1* and expressing *OLE1* (Wild-type), *ole1P123T*, or *ole1E188Q* mutants from a pRS316-based plasmid were grown in CSM-galactose media (inducing expression of alpha-Synuclein) at the indicated doses of the 1,2,4-oxadiazole Compound 95 for 40 h. Growth was normalized to samples treated with the solvent control DMSO, where rescue is set as “1”.

FIG. 4 is a graph showing that a *ole1Δ* deletion mutant is resistant to the growth-inhibitory effects of 1,2,4-oxadiazoles, but not other compounds. Twenty-four hour growth (presented as raw OD₆₀₀) of the *ole1Δ* deletion strain in yeast extract-peptone-dextrose (YPD) media is shown, with drugs added at the indicated concentrations.

FIG. 5 is a graph showing that reducing *OLE1* expression by deleting *MGA2* rescues the growth of the ApoE4 yeast model. Yeast cells expressing ApoE4 were deleted for the *MGA2* gene and their growth was assessed over time (compared to their isogenic, *MGA2* wild-type counterpart). Growth was assessed by OD₆₀₀. Where indicated, 0.08 or 0.32 mM of oleic and palmitoleic acids (each) as added to the growth media in 0.01% tween (final).

FIG. 6 is a series of graphs showing that commercial Scd inhibitors target human SCD1/SCD5 in yeast. Yeast surviving solely on yeast *OLE1*, or human SCD1 or SCD5, were treated with four commercial Scd inhibitors at indicated concentrations. Data are expressed as a percent of the DMSO-treated condition. All four compounds potently reduced growth of both SCD1-expressing yeast and SCD5-expressing yeast, but not the strain expressing Ole1. This growth inhibition was reversed by oleic/palmitoleic acid competition, similar to the results shown in Figs. 2A and 2B.

FIG. 7 is a series of graphs showing that 1,2,4-oxadiazoles target human SCD1 and SCD5. Three “SCD” strains expressing yeast *OLE1* or human SCD1 or SCD5 were treated with five representative 1,2,4-oxadiazoles and a cycloheximide toxicity control at concentrations indicated on the log₁₀ x-axis. The y-axis indicates the percent of the DMSO-treated condition. All of the 1,2,4-oxadiazole compounds potently inhibited Ole1-expressing yeast and showed variable growth inhibition of the SCD1 or SCD5 yeast strains. These data confirm that 1,2,4-oxadiazoles target the human protein and link Scd inhibition to rescue of neurodegenerative disease models. Approximately one half of all (250) 1,2,4-oxadiazoles tested inhibited SCD1 or SCD5 in a manner that was reversed by oleic/palmitoleic acid treatment. Cyclohexamide, a translation inhibitor (top left panel), inhibited growth of all three strains with the same potency, indicating differences in growth inhibition was due to targeting the human protein.


FIGS. 8A-8D are graphs showing that treatment of yeast cells with the 1,2,4-oxadiazole Compound 95 inhibits lipid desaturation. Exponentially-growing wild-type yeast cells were treated with the indicated doses of the 1,2,4-oxadiazole Compound 95 for the indicated times before cellular lysis, lipid extraction, and analysis by global LC-MS/MS profiling. The relative abundance (fraction of total cellular lipid signal) after 1.5 h and 8 h of the most abundant saturated lipid, phosphatidylcholine 26:0, is depicted

in Figs. 8A and 8B, respectively. The relative abundance after 1.5 h and 8 h drug treatment of the most abundant lipid with 2 or more degrees of unsaturation, phosphatidylcholine 16:1; 18:1, is depicted in Figs. 8C and 8D, respectively. The data indicate a >300-fold increase in the abundance of the saturated lipid phosphatidylcholine 26:0 after 8 h treatment with Compound 95, and a >12-fold decrease in the abundance of the unsaturated lipid phosphatidylcholine 16:1, 18:1, indicating that Compound 95 blocks cellular fatty acid desaturase activity (Ole1 is the only fatty acid desaturase in yeast).

FIG. 9 shows *OLE1* mutations conferring resistance to growth inhibition to 1,2,4-oxadiazoles identified by genome sequencing of resistant mutants. Cells were plated on media containing 10 μ M of the 1,2,4-oxadiazole Compound 155 and resistant colonies that emerged were isolated, and genomic DNA was prepared from mutants and the parental, drug-sensitive control strain. Genomic DNA sequence was aligned to the *Saccharomyces cerevisiae* reference and unique mutations in the 1,2,4-oxadiazole-resistant mutants were identified. The position of the mutations, the amino acid changes they encode, and the fold resistance (increase in minimal inhibitory concentration) of Compound 155 are shown.

Detailed Description of the Invention

The invention features compounds useful for the treatment of neurological disorders, e.g., by inhibiting α -synuclein toxicity in a cell such as a neural cell. Exemplary compounds described herein include compounds having a structure according to formula I or formula Ia:



or pharmaceutically acceptable salts thereof.

In some embodiments, the compound has the structure of any one of compounds 1-746 in Table 1.

Other embodiments, as well as exemplary methods for the synthesis or production of these compounds, are described herein.

Pharmaceutical Uses

The compounds described herein are useful in the methods of the invention and, while not bound by theory, are believed to exert their desirable effects through their ability to inhibit toxicity caused by protein aggregation, e.g., α -synuclein aggregation, in a cell.

Another aspect of the present invention relates to methods of treating and/or preventing a neurological disorders such as neurodegenerative diseases in a subject in need thereof. The pathology of neurodegenerative disease, may be characterized by the presence of inclusion bodies in brain tissue of affected patients.

In certain embodiments, neurological disorders that may be treated and/or prevented by the inventive methods include, but are not limited to, Alexander disease, Alper's disease, AD, amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration,

Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, PD, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Ref sum's disease, Sandhoff disease, Schilder's disease, Steele-Richardson-Olszewski disease, tabes dorsalis, and Guillain-Barre Syndrome.

5 The compounds described herein are useful as inhibitors of stearoyl-CoA desaturase (SCD), including SCD1 and/or SCD5. SCD inhibitors are known in the art to be useful in methods of treating and/or preventing SCD-associated disorders. SCD-associated disorders are described, for example, in U.S. Patent No. 8,148,378, and in International Patent Application Publication Nos. WO 2011/047481, WO 2010/112520, WO 2010/045374, WO 2010/028761; WO 2009150196, and WO
10 2009/106991. Accordingly, another aspect of the present invention relates to methods of treating and/or preventing an SCD-associated disorder in a subject in need thereof.

SCD-associated disorders include metabolic disorders (e.g., insulin resistance, diabetes mellitus (e.g., Type I diabetes, Type II diabetes, non-insulin-dependent diabetes mellitus, gestational diabetes, and diabetic complications (e.g., diabetic peripheral neuropathy, diabetic nephropathy diseases, diabetic
15 retinopathy, diabetic macroangiopathy, vascular complications of diabetes, and diabetic arteriosclerosis)), hyperglycemia, metabolic syndrome, hyperinsulinemia, glucose intolerance, impaired glucose tolerance, body weight disorders (e.g., obesity (e.g., abdominal obesity), overweight, cachexia, body mass index, and anorexia), lipid disorders (e.g., abnormal lipid levels (e.g., elevated lipid levels, for example, in plasma), dyslipidemia (e.g., diabetic dyslipidemia), mixed dyslipidemia, hyperlipidemia,
20 hypertriglyceridemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, atherosclerosis, hypercholesterolemia (e.g., familial hypercholesterolemia), low HDL, high LDL, diseases related to accumulation of lipids in liver, familial histiocytic reticulosis, lipoprotein lipase deficiency, polyunsaturated fatty acid (PUFA) disorder, fatty acid desaturation index (e.g. the ratio of 18:1/18:0 fatty acids, or other fatty acids), and abnormal lipid metabolism disorders), disorders of abnormal plasma lipoprotein,
25 disorders of pancreatic beta cell regeneration, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), hypertension, and microalbuminemia, leptin related diseases, hyperleptinaemia, appetite disorder, essential fatty acid deficiency, and adverse weight gain associated with a drug therapy).

Additional SCD-associated disorders include cancer, including solid tumors or hematological
30 malignancies (e.g., esophageal cancer, pancreatic cancer, endometrial cancer, kidney cancer, hepatoma, thyroid cancer, gallbladder cancer, prostate cancer, leukemia (e.g., lymphomas and myelomas), ENT-related cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, uterine cancer, breast cancer, skin cancer, and prostate cancer), neoplasia, malignancy, metastases, tumors (benign or malignant), carcinogenesis, and hepatomas.

35 Further SCD-associated disorders include cardiovascular disease (e.g., heart disease, atherosclerosis, hypertension, lipidemia, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, arteriosclerosis, coronary artery disease, myocardial infarction, vascular complications of diabetes, and diabetic arteriosclerosis), inflammation, sinusitis, asthma, pancreatitis, osteoarthritis, rheumatoid arthritis, hepatitis (e.g., sexual
40 hepatitis), meibomitis, cystic fibrosis, pre-menstrual syndrome, osteoporosis, thrombosis, cardiovascular risks, weight loss, angina, high blood pressure, ischemia, cardiac ischemia, reperfusion injury,

angioplastic restenosis, infertility, liver disease (e.g., fatty liver, cirrhosis, nonalcoholic steatohepatitis, liver fibrosis, and hepatitis C related steatosis), kidney disease (e.g., tubulointerstitial fibrosis, kidney lipid accumulation, glomerular sclerosis, and proteinuria), osteoarthritis (e.g., osteoarthritis of the knee), gastro-esophageal disease, sleep apnea, secondary hyperparathyroidism of renal osteodystrophy, peripheral vascular disease, cerebrovascular disease (e.g., stroke, ischemic stroke and transient ischemic attack (TIA), and ischemic retinopathy), hyperandrogenism, malignant syndrome, extrapyramidal symptoms, hyperuricemia, hypercoagulability, syndrome X, cataract, polycystic ovary syndrome, breathing abnormalities, sleep-disordered breathing, low back pain, gout, gallstone disease, myopathies, lipid myopathies (e.g., carnitine palmitoyltransferase deficiency (CPT I or CPT II)), autoimmune diseases (e.g., lupus, host versus graft rejection, and rejection of organ transplants), asthma, inflammatory bowel diseases, nephropathy, retinopathy, erythrohepatic protoporphyria, iron overload disorders, and hereditary hemochromatosis.

Still further SCD-associated disorders include central nervous system (CNS) disorders, dementia, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, dementia associated with Down Syndrome, other neurodegenerative diseases, psychiatric disorders, eye diseases, immune disorders, multiple sclerosis, neuropathy, and depression.

Additional SCD-associated disorders include skin disorders (e.g., acne (e.g., acne vulgaris), psoriasis, hirsutism, rosacea, seborrheic skin, oily skin (syn seborrhea), seborrheic dermatitis, hyperseborrhea, eczema, keloid scar, skin ageing, diseases related to production or secretions from mucous membranes, wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, insufficient sebum secretion, oily hair, shiny skin, greasy-looking skin, greasy-looking hair, and other skin conditions caused by lipid imbalance).

An SCD-associated disorder can also include a disease or condition which is, or is related to, viral diseases or infections.

In some embodiments, the SCD-associated disorder is acne (e.g., acne vulgaris). In some embodiments, the SCD-associated disorder is diabetes (e.g., type II diabetes, including diabetes with inadequate glycemic control). In some embodiments, the SCD-associated disorder is nonalcoholic fatty liver disease (NAFLD). In some embodiments, the SCD-associated disorder is nonalcoholic steatohepatitis (NASH). In some embodiments, the SCD-associated disorder is cancer. In some embodiments, the SCD-associated disorder is obesity. In some embodiments, the SCD-associated disorder is metabolic syndrome (e.g., dyslipidemia, obesity, insulin resistance, hypertension, microalbuminemia, hyperuricaemia, and hypercoagulability), syndrome X, diabetes, insulin resistance, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, diabetic complications, body weight disorders (e.g., obesity, overweight, cachexia, and anorexia), weight loss, body mass index, leptin related diseases, or a skin disorder (e.g., eczema, acne, psoriasis, and keloid scar). In some embodiments, the SCD-associated disorder is diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer's disease.

Combination Formulations and Uses Thereof

The compounds of the invention can be combined with one or more therapeutic agents. In particular, the therapeutic agent can be one that treats or prophylactically treats any neurological disorder described herein.

Combination Therapies

A compound of the invention can be used alone or in combination with other agents that treat neurological disorders or symptoms associated therewith, or in combination with other types of treatment to treat, prevent, and/or reduce the risk of any neurological disorders. In combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone. For example, doses may be determined empirically from drug combinations and permutations or may be deduced by isobolographic analysis (e.g., Black et al., *Neurology* 65:S3-S6, 2005). In this case, dosages of the compounds when combined should provide a therapeutic effect.

Pharmaceutical Compositions

The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration *in vivo*. Accordingly, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a suitable diluent, carrier, or excipient.

The compounds of the invention may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention. In accordance with the methods of the invention, the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.

A compound of the invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers.

A compound of the invention may also be administered parenterally. Solutions of a compound of the invention can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in

Remington's Pharmaceutical Sciences (2003, 20th ed.) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19), published in 1999.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders. Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant, which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, gelatin, and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.

The compounds of the invention may be administered to an animal, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.

Dosages

The dosage of the compounds of the invention, and/or compositions comprising a compound of the invention, can vary depending on many factors, such as the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and extent of the symptoms; the frequency of the treatment, and the type of concurrent treatment, if any; and the clearance rate of the compound in the animal to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. The compounds of the invention may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, satisfactory results may be obtained when the compounds of the invention are administered to a human at a daily dosage of, for example, between 0.05 mg and 3000 mg (measured as the solid form). Dose ranges include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered. Preferred dose ranges include, for example, between 0.05-15 mg/kg or between 0.5-15 mg/kg.


Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of a compound, or pharmaceutical composition thereof, administered to a patient may range from 0.1-50 mg/kg (e.g., 0.25-25 mg/kg). In exemplary, non-limiting embodiments, the dose may

range from 0.5-5.0 mg/kg (e.g., 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg/kg) or from 5.0-20 mg/kg (e.g., 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg).

EXAMPLES


- 5 The synthesis of compounds of this invention can be synthesized according to one or more of the general schemes 1-10 shown below. The variables recited in the general schemes below are as defined for Formulae I, II, III, and IV.

General scheme 1



10 An appropriately substituted carboxylic acid **I** can be coupled with an appropriately substituted piperidine **II** to provide ester **III**. This can be hydrolysed under variety of conditions to provide carboxylic acid intermediate **IV**. This can be condensed with a substituted N-hydroxyimide **V** to give the desired 1,2,4-oxadiazole compound **VI**.


General Scheme 2



20 An appropriately substituted carboxylic acid **VII** can be coupled with an appropriately protected (where PG is an N -protecting group) and substituted piperidine carboxylic acid **VIII** to provide intermediate **IX**. This can be deprotected using a variety of conditions to provide free amine intermediate **X**. This compound can be coupled using metal catalysis or under thermal conditions with a halogenated


heterocycle such as **XI** to give the desired 1,2,4-oxadiazole ($X^3 = O$) or 1,2,4-thiadiazole ($X^3 = S$) compound **XII**.

General scheme 3




An appropriately substituted carboxylic acid **I** can be coupled with an appropriately substituted piperidine **XIII** to provide the desired heterocyclic compound **XIV**.

General scheme 4




An appropriately substituted acyl halide **XV** (where X is a halogen atom, e.g., chlorine) can be coupled with an appropriately substituted piperidine **XIII** to provide the desired heterocyclic compound **XIV**.

General scheme 5




An appropriately substituted alkyl intermediate **XVI** (where X is a good leaving group, e.g., a halogen atom or triflate) can undergo nucleophilic displacement with an appropriately substituted piperidine **XIII** to provide the desired heterocyclic compound **XIV**.

General scheme 6




An appropriately substituted carboxylic acid **IV** can be coupled with an appropriately substituted ketone **XVII** (where X is a leaving group, e.g., bromine) to provide the intermediate compound **XVIII**. This compound can be condensed with ammonium acetate to provide oxazole **IX**.

General scheme 7




An appropriately protected and substituted thiomide **XX** can be coupled with an appropriately substituted ketone **XVII** (where X is a leaving group, most commonly bromine) to provide the protected (where PG is an amine protecting group, such as tert-butoxycarbonyl) thiazole compound **XXI**. This compound can be deprotected under appropriate conditions to give intermediate piperidine **XXII**. This can be coupled with and appropriately substituted carboxylic acid **IV** to provide thiazole **XXIII**.

General scheme 8




An appropriately protected and substituted ester **III** can be treated with hydrazine to provide the hydrazide compound **XXIV**. This compound can be coupled with an appropriately substituted acetimidate **XXV** to provide 1,3,4-oxadiazole **XXVI**.

General scheme 9



An appropriately substituted carboxylic acid **IV** can be coupled with an appropriately substituted piperidine compound **XXVII** to give a compound **XXVIII**. This compound can be converted to the corresponding hydroxyimide compound **XXIX**. This can be treated with an appropriately substituted acid halide (most commonly an acid chloride, where $\text{X}=\text{Cl}$) **XXX** to provide 1,2,4-oxadiazole **XXXI**.

General scheme 10



An appropriately substituted oxadiazolone **XXXII** can be converted to the appropriately substituted compound **XXXIII**. This compound can be coupled with the appropriate protected piperazine compound **XXXIV** (where PG is an *N*-protecting group, for example, a tert-butyloxycarbonyl group) to give compound **XXXV**. This compound can be deprotected under the appropriate conditions to give piperazine compound **XXXVI**. This can be coupled with a carboxylic acid **IV** to provide 1,2,4-oxadiazole **XXXVII**.

10 Experimental procedures

The compounds of the invention can be synthesized according to the following procedures.

In the examples below, when purification by preparative HPLC was performed, a Gilson 281 semi-preparative HPLC system was used, using a variety of stationary and mobile phases which are described in the experimental section. For example, (column: Waters X bridge 150x2.5mm 5μm; mobile phase: [water (10 mM NH₄OAc)-acetonitrile]; B%: 36%-66%, 12 min) indicates that the following purification conditions were used:

Mobile phase: A: 10mM NH₄OAc in H₂O; B: acetonitrile

Column: Waters Xbridge 150x2.5mm dimensions, 5 μm particle size


Flow rate: 25mL/min

Monitor wavelength: 220&254nm


Gradient:

Time / minutes	B %
0.0	36
12.0	66
12.2	100
14.0	100
14.2	36
16.0	36

Example 1. Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one




5 Step 1: Preparation of 1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carboxylic acid



A mixture of 2-methylenesuccinic acid (2.0 g, 1.27 mL, 15.37 mmol) and 3,4-dimethylaniline (1.86 g, 15.37 mmol) in water (20 mL) was stirred at 120 °C (reflux) for 16 h. The mixture was cooled to 25 °C and filtered. The filter cake was washed with cold water (5 mL) to give 1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carboxylic acid (3.0 g, 12.9 mmol, 84 %) as a yellow solid. This material was used directly in the next step without further purification. ¹H NMR (400MHz, DMSO-d₆) δ 7.40-7.35 (m, 2H), 7.13-7.11 (d, 1H), 4.01-3.93 (m, 2H), 3.34-3.30 (m, 1H), 2.75-2.67 (m, 2H), 2.22 (s, 3H) 2.19 (s, 3H); LCMS (ESI) m/z: [M-H]⁻ = 232.1.


15 Step 2: Preparation of methyl 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylate



To a stirred solution of 1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carboxylic acid (1.0 g, 4.29 mmol) and methyl piperidine-4-carboxylate (737 mg, 5.15 mmol) in N,N-dimethylformamide (10 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.63 g, 4.29 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (1.11 g, 8.58 mmol, 1.50 mL). After stirring at 15 °C for 16 h, to the mixture was added water (20 mL) and the mixture extracted with ethyl acetate (20 mL x 4). The organic layer was washed with water (10 mL), saturated aqueous sodium chloride solution (10 mL), then dried over anhydrous sodium sulfate, filtered and concentrated to give crude product that was purified by chromatography on silica gel eluted with Petroleum ether/ethyl acetate from 1/1 to 0/1 to give methyl 1-(1-


(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylate (1.90 g, 5.30 mmol, quantitative) as a red oil. LCMS (ESI) m/z : $[M+H]^+ = 359.3$.

Step 3: Preparation of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid




To a stirred solution of methyl 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylate (400 mg, 1.12 mmol) in tetrahydrofuran (4 mL) was added aqueous sodium hydroxide (2 M, 1.68 mL). The mixture was stirred at 40 °C for 2 h, then the mixture was acidified with concentrated hydrochloric acid until pH 1. The mixture was extracted with dichloromethane (20 mL x 3), then the organic layer was washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (300 mg, 871 μ mol, 78 %) as a white solid that was used directly without further purification.

Step 4: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one




To a stirred solution of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (253 mg, 734 μ mol) in N,N-dimethylformamide (1 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (279 mg, 734 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (285 mg, 2.20 mmol, 384 μ L). The mixture was stirred at 25 °C for 5 min, then N-hydroxybenzimidamide (100 mg, 734 μ mol) was added. The mixture was warmed to 25 °C, stirred for 16 h, then the mixture was diluted with water (5 mL) and extracted with ethyl acetate (20 mL x 3). The organic layers were combined and washed with water (5 mL x 2) and saturated aqueous sodium chloride solution (5 mL), then dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product which was dissolved in N,N-dimethylformamide (2 mL) and then heated at 120 °C for 3 h. Without any additional work-up, the mixture was purified by prep-HPLC (Waters X bridge 150x25 5 μ m column; 36-66 % acetonitrile in a 10 mM ammonium acetate solution in water, 12 min gradient) to give 1-(3,4-dimethylphenyl)-4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one (73 mg, 164 μ mol, 22 %) as a white solid. ^1H NMR (400MHz, CDCl_3) δ 8.10-8.09 (m, 2H), 7.55-7.49 (m, 3H), 7.39 (s, 1H), 7.30 (s, 1H), 7.15-7.13 (d, 1H), 4.54-4.53 (m, 1H), 4.31-4.27 (m, 1H), 3.98-3.90 (m., 2H), 3.60-3.56 (m, 1H), 3.42-3.36 (m, 2H). 3.15-2.95 (m, 2H), 2.86-2.79 (m, 1 H), 2.29-2.26(m, 8H), 2.03-1.97 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 445.3$.

Example 2: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one




5 Step 1: Preparation of N-hydroxy-4-methylbenzimidamide



To a stirred solution of 4-methylbenzonitrile (1.0 g, 8.54 mmol, 1.02 mL) in ethanol (10 mL) and water (1 mL) was added hydroxylamine hydrochloride (1.19 g, 17.1 mmol) and triethylamine (1.73 g, 17.1 mmol, 2.37 mL). The mixture was heated at 75 °C for 16 h, then the reaction mixture was concentrated under reduced pressure to give a residue that was diluted with water (5 mL), and then extracted with dichloromethane (8 mL x 10). The combined organic layers were washed with saturated aqueous sodium chloride solution (8 mL x 5), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a N-hydroxy-4-methylbenzimidamide (900 mg, 5.99 mmol, 70 %) as a light green solid. ¹H NMR (400MHz, METHANOL-d₄) δ = 7.49 (d, J=8.2 Hz, 2H), 7.18 (d, J=7.9 Hz, 2H), 2.33 (s, 3H).


Step 2: Preparation of methyl 1-(3,4-dimethylphenyl)-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one




To a stirred solution of methyl 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidin-3-carbonyl)piperidine-4-carboxylate (229 mg, 666 μmol) in N,N-dimethylformamide (1 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (253 mg, 666 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (258 mg, 2.00 mmol, 349 μL). The mixture was stirred at 25 °C for 5 mins, then N-hydroxy-4-methylbenzimidamide (100 mg, 666 μmol) was added. After 16 h, the reaction mixture was extracted with ethyl acetate (5 mL x 3). The organic layers were combined, washed with saturated aqueous sodium chloride solution (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue that was purified by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water(10mM NH₄HCO₃)-acetonitrile]; B%: 40%-70%, 12min) to give 1-(3,4-dimethylphenyl)-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one (38 mg, 81 μmol, 12%, 98.4% purity) as a white solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.89 (d, J=7.1 Hz, 2H), 7.29 (s, 1H), 7.22 (t, J=7.9 Hz, 3H), 7.05 (d, J=8.2 Hz, 1H), 4.50 - 4.38 (m, 1H), 4.20 (t, J=8.4 Hz,

1H), 3.95 - 3.79 (m, 2H), 3.49 (td, J=8.5, 16.9 Hz, 1H), 3.36 - 3.20 (m, 2H), 3.12 - 2.97 (m, 1H), 2.89 (td, J=8.7, 17.1 Hz, 1H), 2.79 - 2.69 (m, 1H), 2.35 (s, 3H), 2.18 (d, J=13.0 Hz, 7H), 2.00 - 1.82 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 459.3.

5 Example 3: Preparation of 1-(3,4-dimethylphenyl)-4-[4-[3-(m-tolyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one




Step 1: Preparation of N-hydroxy-3-methylbenzimidamide.



To a stirred solution of 3-methylbenzonitrile (1.0 g, 8.54 mmol, 1.02 mL) in ethanol (10 mL) and water (1 mL) was added hydroxylamine hydrochloride (1.19 g, 17.1 mmol) and triethylamine (1.73 g, 17.1 mmol, 2.37 mL). The mixture was heated at 75 °C for 16 h and then concentrated under reduced pressure to give a residue that was then diluted with dichloromethane. The organic phase was washed with saturated aqueous sodium chloride solution (5mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated to give N-hydroxy-3-methyl-benzimidine (1.05 g, solid) as a crude solid that was used directly in the next step without further purification. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.42 - 7.31 (m, 2H), 7.24 - 7.12 (m, 2H), 4.93 - 4.71 (s, 1H), 3.67 - 3.58 (m, 1H), 2.97 (q, J=7.3 Hz, 1H), 2.30 (s, 3H), 1.32 - 1.23 (m, 1H), 1.18 - 1.11 (m, 1H).


Step 2: Preparation of 1-(3,4-dimethylphenyl)-4-(4-[3-(m-tolyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl)pyrrolidin-2-one




To a stirred solution of 1-[1-(3,4-dimethylphenyl)-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (229 mg, 666 μmol) in N,N-dimethylformamide (1 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (253 mg, 666 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (258 mg, 2.00 mmol, 349 μL). The mixture was stirred at 25 °C for 5 mins then N-hydroxy-3-methyl-benzimidine (100 mg, 666 μmol) was added. After 16 h, the reaction mixture was diluted with water (1 mL) extracted with ethyl acetate (5 mL x 3). The organic layers were combined, washed with saturated aqueous sodium chloride solution (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude residue that was purified by prep-HPLC (Waters X bridge 150x25 5μm column, 41%-71% acetonitrile in an a 10 mM ammonium acetate solution in water, 12 min gradient) to give 1-(3,4-dimethylphenyl)-4-[4-[3-(m-tolyl)-1,2,4-oxadiazol-

5-yl]piperidine-1-carbonyl]pyrrolidin-2-one (118 mg, 266 μ mol, 38 %) as a yellow solid. ^1H NMR (400MHz, CHLOROFORM- d) δ = 7.93 - 7.83 (m, 1H), 7.40 – 7.30 (m, 3H), 7.16 - 7.07 (m, 1H), 4.58 - 4.45 (m, 1H), 4.29 – 4.25 (m, 1H), 4.00 - 3.90 (m, 2H), 3.59 – 3.55 (m, 1H), 3.43 - 3.24 (m, 2H), 3.19 - 3.01 (m, 1H), 3.01 - 2.89 (m, 1H), 2.87 - 2.74 (m, 1H), 2.43 (s, 3H), 2.27 – 2.22 (m, 8H), 2.07 - 1.90 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 459.3$.

Example 4. 6-(5-(1-(1-(3,4-Dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)-4-ethyl-2H-benzo[b][1,4]oxazin-3(4H)-one




Step 1: Preparation of 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile




To a stirred solution of 6-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one (3.0g, 13.2 mmol) in N,N-dimethylformamide (35 mL) was added zinc cyanide (1.24 g, 10.5 mmol, 668 μ L) and tetrakis(triphenylphosphine)palladium(0) (760 mg, 658 μ mol) under nitrogen. The mixture was then stirred at 80 $^{\circ}\text{C}$ for 16 h, cooled to room temperature, and extracted with ethyl acetate (60 mL x 4). The combined organic layers were washed with saturated aqueous sodium chloride solution (15 mL) and dried over anhydrous sodium sulfate. The combined organic layers were concentrated to dryness to give the crude product. The crude product was further purified by trituration in ethyl acetate and used in the next step without further purification. 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile (3.40 g) was obtained as a white solid. LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 175.0$.

Step 2: Preparation of 4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile




To a stirred solution of 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile (3.30 g, 19.0 mmol) in N,N-dimethylformamide (35 mL) was added sodium hydride (758 mg, 19 mmol, 60% dispersion in mineral oil) and iodoethane (3.84 g, 25 mmol, 1.97 mL) at 0 °C. The mixture was warmed to 20 °C. After 3 h, the mixture was cooled to 0 °C, quenched by addition of water (50 mL), and extracted with ethyl acetate (60 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50:1 to 5:1) to give 4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile (1.30 g, 6.43 mmol, 34 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.25 (dd, *J* = 1.8, 8.3 Hz, 1H), 7.17 (d, *J* = 1.8 Hz, 1H), 6.98 (d, *J* = 8.3 Hz, 1H), 4.62 (s, 2H), 3.93 (q, *J* = 7.2 Hz, 2H), 1.23 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z* = 203.1 [M+H]⁺.

Step 3: Preparation of 4-ethyl-N-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboximidamide



To a stirred solution of 4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile (1.20 g, 5.93 mmol) in ethanol (20 mL) was added hydroxylamine hydrochloride (825 mg, 11.9 mmol), triethylamine (1.20 g, 11.9 mmol, 1.64 mL) and water (2 mL), then the mixture was heated at 75 °C. After 5 h, the mixture was cooled to 20 °C and water (20 mL) added. The mixture was extracted with ethyl acetate (30 mL x 3), then the combined organic layers were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give 4-ethyl-N-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboximidamide (1.20 g, 5.10 mmol, 86 %) as a white solid that was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.61 (s, 1H), 7.44 (d, *J* = 1.6 Hz, 1H), 7.35 (dd, *J* = 1.8, 8.4 Hz, 1H), 7.00 (d, *J* = 8.4 Hz, 1H), 5.87 (s, 2H), 4.66 (s, 2H), 3.96 (q, *J* = 7.0 Hz, 2H), 1.18 (t, *J* = 7.0 Hz, 3H).


Step 4: Preparation of (E)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N-((4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)(hydroxyimino)methyl)piperidine-4-carboxamide



To a stirred solution of 4-ethyl-N-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboximidamide (150 mg, 638 μmol) in N,N-dimethylformamide (5 mL) was added 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (220 mg, 638 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (242 mg, 638 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (247 mg, 1.91 mmol, 334 μL). After 16 h at 20 °C, the reaction mixture was quenched with water (10 mL). The mixture was extracted with ethyl acetate (20 mL x 4), then the


combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give (E)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N-((4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)(hydroxyimino)methyl)piperidine-4-carboxamide (450 mg) as a yellow oil. This material was used directly without further purification. LCMS (ESI) m/z = 562.3 $[M+H]^+$.


Step 5: Preparation of 6-(5-(1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)-4-ethyl-2H-benzo[b][1,4]oxazin-3(4H)-one




(E)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N-((4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)(hydroxyimino)methyl)piperidine-4-carboxamide (450 mg, 801 μ mol) was heated in N,N-dimethylformamide (3 mL) at 120 °C for 3 h. The mixture was cooled and purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-65%, 12 min) to give 6-(5-(1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)-4-ethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (142 mg, 255 μ mol, 32 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.70-7.60 (m, 2H), 7.29 (s, 1H), 7.22-7.19 (m, 1H), 7.03 (dd, J = 8.3, 16.9 Hz, 2H), 4.60 (s, 2H), 4.56-4.40 (m, 1H), 4.21 (d, J = 7.3 Hz, 1H), 4.00 (d, J = 6.5 Hz, 2H), 3.96-3.78 (m, 2H), 3.49 (quin, J = 8.3 Hz, 1H), 3.37-3.19 (m, 2H), 3.09-2.82 (m, 2H), 2.81-2.69 (m, 1H), 2.18 (d, J = 12.8 Hz, 8H), 1.98-1.82 (m, 2H), 1.26 (t, J = 6.8 Hz, 3H); LCMS (ESI) $[M+H]^+$ = 544.2.

Example 5: Morpholino(1-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanone.




Step 1: Preparation of tert-butyl 4-(morpholine-4-carbonyl)piperidine-1-carboxylate


To a stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (300 mg, 1.31 mmol) in
 5 N,N-dimethylformamide (10 mL) was added morpholine (136 mg, 1.57 mmol, 138 μ L), (2-(1H-
 benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (496 mg, 1.31 mmol) and N-ethyl-N-
 (propan-2-yl)propan-2-amine (338 mg, 2.62 mmol, 457 μ L). The mixture was stirred at 20 °C for 16 h,
 then quenched with water (10 mL) and extracted with ethyl acetate (20 mL x 4). The combined organic
 phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous
 10 sodium sulfate, filtered and concentrated to give tert-butyl 4-(morpholine-4-carbonyl)piperidine-1-
 carboxylate (700 mg) as a yellow oil. This material was used directly without further purification. ¹H NMR
 (400 MHz, CDCl₃) δ 3.72-3.51 (m, 5H), 3.45 (br. s., 1H), 3.18-3.05 (m, 1H), 2.93-2.86 (m, 3H), 2.81 (s,
 3H), 2.75-2.71 (m, 2H), 2.59-2.48 (m, 1H), 1.39 (s, 9H).

Step 2: Preparation of morpholino(piperidin-4-yl)methanone


To a stirred solution of tert-butyl 4-(morpholine-4-carbonyl)piperidine-1-carboxylate (700 mg, 2.35
 mmol) in methanol (5 mL) was added 4N hydrochloric acid in methanol (15 mL). The mixture was stirred
 at 20 °C for 16 h then concentrated under reduced pressure to give morpholino(4-piperidinyl)methanone
 20 (300 mg) as a colorless oil that was used directly without further purification. LCMS (ESI) [M+H]⁺ = 199.1.

Step 3: Preparation of 3-phenyl-1,2,4-oxadiazol-5(4H)-one


To a stirred solution of N-hydroxybenzamidine (2.0 g, 14.69 mmol) in dioxane (10 mL) was added
 25 1,8-diazabicyclo[5.4.0]undec-7-ene (2.46 g, 16 mmol, 2.44 mL) and 1,1'-carbonyldiimidazole (3.57 g, 22
 mmol). The mixture was stirred at 110 °C for 16 h, then cooled and quenched with water (10 mL). The
 mixture was extracted with dichloromethane (50 mL x 4), then the combined organic phases were
 washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate,
 filtered, and concentrated to give crude product that was purified by chromatography (silica, petroleum
 ether : ethyl acetate = 1:1) to give 3-phenyl-1,2,4-oxadiazol-5(4H)-one (1.30 g, 8.02 mmol, 55 %) as a
 30 yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.83-7.75 (m, 2H), 7.66-7.52 (m, 3H); LCMS (ESI) m/z =
 163.2 [M+H]⁺.

Step 4: Preparation of 5-chloro-3-phenyl-1,2,4-oxadiazole


To a stirred solution of 3-phenyl-1,2,4-oxadiazol-5(4H)-one (500 mg, 3.08 mmol) equipped with calcium chloride tube was added N,N-dimethylformamide (1 mL). Phosphoryl chloride (10 mL) was added dropwise, and the resulting mixture was heated at 110 °C for 16 h. The reaction mixture was cooled to 20 °C and poured onto ice water (100 mL), and the resulting mixture was stirred for 30 min. The mixture was extracted with dichloromethane (20 mL x 5), then the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50:1) to give 5-chloro-3-phenyl-1,2,4-oxadiazole (180 mg, 997 μmol, 32 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.10-7.98 (m, 2H), 7.57-7.46 (m, 3H).

Step 5: Preparation of morpholino(1-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanone

To a stirred solution of morpholino(piperidin-4-yl)methanone (180 mg, 908 μmol) in N-methyl-2-pyrrolidone (5 mL) was added 5-chloro-3-phenyl-1,2,4-oxadiazole (163 mg, 908 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (234 mg, 1.82 mmol, 317 μL). The mixture was stirred at 120 °C for 16 h then cooled and purified directly by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water (10 mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give morpholino(1-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanone (130 mg, 380 μmol, 42 %) as a yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 8.00-7.94 (m, 2H), 7.55-7.45 (m, 3H), 4.26 (d, *J* = 13.3 Hz, 2H), 3.74-3.59 (m, 8H), 3.32-3.26 (m, 2H), 3.08-2.98 (m, 1H), 1.92-1.75 ppm (m, 4H); LCMS (ESI) [M+H]⁺ = 343.2.


Example 6: (1-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(piperidin-1-yl)methanone

Step 1: Preparation of tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate.




To a mixture of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (300 mg, 1.31 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (496 mg, 1.31 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (338 mg, 2.62 mmol, 457 μ L) in N,N-dimethylformamide (1 mL) was added piperidine (133 mg, 1.57 mmol, 155 μ L) at 0°C. The mixture was stirred at 25 °C for 2 h. The residue was poured into water (5 mL). The aqueous phase was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate (600 mg) as a yellow oil. This material was used directly without further purification. ¹H NMR (400MHz, CDCl₃) δ 3.73 (dd, J = 6.4, 9.9 Hz, 1H), 3.55 (br. s., 2H), 3.44 (br. s., 2H), 3.29-3.15 (m, 2H), 2.68-2.57 (m, 1H), 1.96-1.83 (m, 1H), 1.77-1.62 (m, 8H), 1.56 (br. s., 4H), 1.46 (s, 9H); LCMS (ESI) m/z = 297.3 [M+H]⁺.

Step 2: Preparation of piperidin-1-yl(piperidin-4-yl)methanone.




To a mixture of tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate (500 mg, 1.69 mmol) in methanol (5 mL) was added 4M methanolic hydrochloric acid (10 mL) at 0°C. The mixture was stirred at 25 °C for 2 h. The mixture was concentrated in vacuo to give piperidin-1-yl(piperidin-4-yl)methanone (300 mg) as a yellow oil which was used in the next step directly without further purification. LCMS (ESI) [M+H]⁺ = 197.3.

Step 3: Preparation of 3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5(4H)-one.




A mixture of N-hydroxy-3,4-dimethoxybenzimidamide (1.0 g, 5.10 mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (853 mg, 5.61 mmol, 845 μ L) and 1,1'-carbonyldiimidazole (1.24 g, 7.65 mmol) in dioxane (10 mL) was prepared at 15°C. The mixture was warmed to 110°C for 12 h. The mixture was cooled to 15°C and then poured into water (5 mL). The aqueous phase was extracted with dichloromethane (10 mL x 5), then the combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford 3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5(4H)-one (800 mg) as a yellow solid. ¹H NMR (400MHz, CDCl₃) δ 7.60-7.52 (m, 2H), 6.88 (d, J = 8.8 Hz, 1H), 3.91 (d, J = 6.1 Hz, 6H); LCMS (ESI) m/z = 223.2 [M+H]⁺.

Step 4: Preparation of 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole.




3-(3,4-Dimethoxyphenyl)-1,2,4-oxadiazol-5(4H)-one (500 mg, 2.25 mmol) was added to a mixture of phosphoryl chloride (13.2 g, 86.1 mmol, 8 mL) and N,N-dimethylformamide (1 mL). The mixture was equipped with a calcium chloride tube and heated at 100 °C for 16 h, at which time the mixture was cooled and concentrated in vacuo at 45°C. The residue was poured into ice-water (w/w = 10/1) (11mL) and stirred for 10 min. The mixture was extracted with dichloromethane (10 mL x 5), then the combined organic phases were washed with saturated aqueous sodium chloride solution (2 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by chromatography (silica, petroleum ether: ethyl acetate = 5:1 to 1:1 gradient) to afford 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole (200 mg, 0.83 mmol, 37 %) as a yellow solid. ¹H NMR (400MHz, CDCl₃) δ 7.67 (dd, *J* = 2.0, 8.4 Hz, 1H), 7.53 (d, *J* = 2.0 Hz, 1H), 6.97 (d, *J* = 8.4 Hz, 1H), 3.96 (d, *J* = 2.4 Hz, 6H); LCMS (ESI) *m/z* = 241.1 [M+H]⁺.

Step 5: Preparation of (1-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(piperidin-1-yl)methanone.




To a stirred solution of 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole (200 mg, 831 μmol) and triethylamine (252 mg, 2.49 mmol, 345 μL) in dichloromethane (2 mL) was added piperidin-1-yl(piperidin-4-yl)methanone (163 mg, 831 μmol) at 0 °C. The mixture was warmed to 15 °C and stirred for 2h, then concentrated in vacuo to afford crude product. The residue was purified by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10 mM ammonium carbonate)-acetonitrile]; B%: 20%-55%, 12 min) to give (1-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(piperidin-1-yl)methanone (36 mg, 89.7 μmol, 11 %) as a yellow solid. ¹H NMR (400MHz, CDCl₃) δ 7.61 (d, *J* = 8.4 Hz, 1H), 7.51 (s, 1H), 6.92 (d, *J* = 8.4 Hz, 1H), 4.28 (d, *J* = 13.2 Hz, 2H), 3.95 (d, *J* = 8.8 Hz, 6H), 3.65-3.41 (m, 4H), 3.30-3.15 (m, 2H), 2.85-2.69 (m, 1H), 2.01-1.89 (m, 2H), 1.88-1.79 (m, 2H), 1.68 (d, *J* = 4.9 Hz, 2H), 1.61 (br. s., 1H); LCMS (ESI) *m/z* = [M+H]⁺ : 401.2.

Example 7: *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid.



5
To a stirred solution of methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (5.0 g, 16.4 mmol) in tetrahydrofuran (50 mL) was added aqueous sodium hydroxide (2 M, 16.4 mL). The mixture was stirred at 20 °C for 2 h and then acidified by the addition of concentrated hydrochloric acid until pH 1. The mixture was extracted with dichloromethane (80 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (3.25 g, 11.2 mmol, 68 %) as a yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.87 (d, *J*=7.5 Hz, 2H), 7.59 - 7.42 (m, 3H), 4.39 - 4.20 (m, 3H), 3.92 (d, *J*=14.1 Hz, 1H), 3.24 (t, *J*=11.5 Hz, 1H), 2.98 - 2.88 (m, 1H), 2.62 (s, 1H), 2.08 - 1.89 (m, 2H), 1.81 - 1.53 (m, 2H).


Step 2: Preparation of *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




15
To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (2.0 g, 6.89 mmol) in N,N-dimethylformamide (30 mL) was added N-hydroxy-3,4-dimethoxybenzimidamide (1.62 g, 8.27 mmol), N-ethyl-N-(propan-2-yl)propan-2-amine (2.67 g, 20.67 mmol, 3.61 mL) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (2.62 g, 6.89 mmol). The mixture was stirred at 20 °C for 2 h and then warmed at 120 °C for 2 h. The reaction mixture was quenched by addition of water (40 mL), then the mixture was extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product that was purified by chromatography (silica, petroleum ether : ethyl acetate = 20 : 1 to 1 : 2) to give a yellow solid.

The yellow solid was washed with ethyl acetate (30 mL), then the mixture was filtered, and the filter cake was dried in vacuo to give N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (1.29 g, 2.86 mmol, 42 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.92 - 7.84 (m, 2H), 7.80 (s, 1H), 7.58 - 7.44 (m, 3H), 7.41 - 7.35 (m, 1H), 7.28 - 7.26 (m, 2H), 6.92 (d, *J*=8.9 Hz, 1H), 4.58 - 4.47 (m, 1H), 4.32 (d, *J*=3.9 Hz, 2H), 3.99 - 3.88 (m, 7H), 3.37 - 3.06 (m, 3H), 2.28 - 2.13 (m, 2H), 2.07 - 1.89 (m, 2H); LCMS (ESI) [M+H]⁺ = 451.3.

Example 8: (4-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(4-isopropylphenyl)methanone.




Step 1: Preparation of methyl 1-(4-isopropylbenzoyl)piperidine-4-carboxylate.




To a stirred solution of 4-isopropylbenzoic acid (250 mg, 1.52 mmol) in N,N-dimethylformamide (10 mL) was added methyl piperidine-4-carboxylate (261 mg, 1.82 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (576 mg, 1.52 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (392 mg, 3.04 mmol, 530 μL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with ethyl acetate (20 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product methyl 1-(4-isopropylbenzoyl)piperidine-4-carboxylate (900 mg) as a yellow oil. LCMS (ESI) *m/z*: 290.3 [M+H]⁺.

Step 2: Preparation of 1-(4-isopropylbenzoyl)piperidine-4-carboxylic acid.




To a stirred solution of methyl 1-(4-isopropylbenzoyl)piperidine-4-carboxylate (900 mg, 3.11 mmol) in tetrahydrofuran (10 mL) was added aqueous sodium hydroxide (2 M, 3.11 mL). The mixture was stirred at 20 °C for 16 h. The mixture was acidified to pH 1 by dropwise addition of concentrated hydrochloric acid. The mixture was extracted with dichloromethane (20 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product 1-(4-isopropylbenzoyl)piperidine-4-carboxylic acid (400 mg) as a yellow solid. LCMS (ESI) $[M+H]^+ = 276.2$.

Step 3: Preparation of 3-fluoro-N-hydroxybenzimidamide.



To a stirred solution of 3-fluorobenzonitrile (1.0 g, 8.26 mmol, 884 μ L) in ethanol (10 mL) were added hydroxylamine hydrochloride (1.15 g, 16.5 mmol), triethylamine (2.09 g, 20.7 mmol, 2.86 mL), and water (1 mL). Then the mixture was heated at 75 °C for 16 h. After cooling to 20 °C, water (10 mL) was added to the solution. The mixture was extracted with ethyl acetate (20 mL x 5). The combined organic layers were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 3-fluoro-N-hydroxybenzimidamide (2.0 g) as a green solid that was used directly in the next step without further purification. LCMS (ESI) m/z : 155.1 $[M+H]^+$.


Step 4: Preparation of (E)-N-((3-fluorophenyl)(hydroxyimino)methyl)-1-(4-isopropylbenzoyl)piperidine-4-carboxamide.



To a stirred solution of 1-(4-isopropylbenzoyl)piperidine-4-carboxylic acid (400 mg, 1.45 mmol) in N,N-dimethylformamide (10 mL) were added 3-fluoro-N-hydroxybenzimidamide (223 mg, 1.45 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (550 mg, 1.45 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (563 mg, 4.36 mmol, 761 μ L). The mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched with water (10 mL) and then extracted with ethyl acetate (20 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give (E)-N-((3-

fluorophenyl)(hydroxyimino)methyl)-1-(4-isopropylbenzoyl)piperidine-4-carboxamide (350 mg) as a yellow oil. LCMS (ESI) m/z : 412.3 $[M+H]^+$.


Step 5: Preparation of (4-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(4-isopropylphenyl)methanone.




(E)-N-((3-Fluorophenyl)(hydroxyimino)methyl)-1-(4-isopropylbenzoyl)piperidine-4-carboxamide (350 mg, 851 μ mol) was added to N,N-dimethylformamide (3 mL), and the mixture was stirred at 120 °C for 16 h. The reaction mixture was cooled and purified by direct injection and prep-HPLC (column:

Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 50%-80%, 12 min) to give (4-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(4-isopropylphenyl)methanone (82 mg, 210 μ mol, 25 %) as a yellow oil. ^1H NMR (400 MHz, Methanol- d_4) δ 7.92 (d, J = 7.8 Hz, 1H), 7.79 (d, J = 9.7 Hz, 1H), 7.57 (d, J = 5.6 Hz, 1H), 7.42-7.28 (m, 5H), 4.69-4.50 (m, 1H), 3.89 (br. s., 1H), 3.53-3.42 (m, 1H), 3.39-3.34 (m, 1H), 3.32-3.28 (m, 1H), 2.99 (td, J = 6.9, 13.8 Hz, 1H), 2.43-2.09 (m, 2H), 2.07-1.83 (m, 2H), 1.30 (s, 3H), 1.29 (s, 3H); LCMS (ESI) m/z $[M+H]^+$ = 394.2.

Example 9: N-(2-oxo-2-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide.



Step 1: Preparation of methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate.




To a stirred solution of 2-benzamidoacetic acid (3.0 g, 16.7 mmol) in N,N-dimethylformamide (30 mL) were added methyl piperidine-4-carboxylate (2.88 g, 20.09 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (6.35 g, 16.7 mmol), and N-ethyl-N-(propan-2-yl)propan-2-amine (6.49 g, 50.2 mmol, 8.77 mL). The mixture was stirred at 20 °C for 3 h and then quenched by

addition of water (40 mL). The mixture was extracted with ethyl acetate (80 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product that was purified by


chromatography (silica, petroleum ether : ethyl acetate = 5:1 to 1:1) to give methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (7.0 g, 23.0 mmol, quantitative), as a yellow oil. LCMS (ESI) $m/z = 305.1$ $[M+H]^+$.

Step 2: Preparation of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid.



To a stirred solution of methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (7.0 g, 23.0 mmol) in tetrahydrofuran (50 mL) was added aqueous sodium hydroxide (2 M, 23 mL). The mixture was then stirred at 20 °C for 16 h. The mixture was then acidified to pH 1 using concentrated hydrochloric acid and then extracted with dichloromethane (80 mL x 4). The organic phases were combined, washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (4.20 g, 14.47 mmol, 63 %) as a yellow solid. This was used directly in the next step without further purification. ^1H NMR (400 MHz, Methanol- d_4) δ 7.93-7.85 (m, 2H), 7.59-7.54 (m, 1H), 7.52-7.46 (m, 2H), 4.42-4.33 (m, 1H), 4.29 (s, 2H), 4.01-3.87 (m, 1H), 3.30-3.20 (m, 1H), 2.97-2.88 (m, 1H), 2.63-2.52 (m, 1H), 2.06-1.92 (m, 2H), 1.80-1.55 (m, 2H).


Step 3: Preparation of N-(2-oxo-2-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (200 mg, 689 μmol) in N,N-dimethylformamide (4 mL) were added *N*-hydroxybenzamidine (112 mg, 826 μmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (261 mg, 689 μmol), and N,N-diisopropylethylamine (267 mg, 2.07 mmol, 360.96 μL). The reaction mixture was then stirred at 20 °C for 2 h, quenched by addition of water (5 mL), and extracted with ethyl acetate (20 mL x 4). The organic extracts were combined, washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo to provide a crude residue. To the residue was added N,N-dimethylformamide (4 mL), and the resulting mixture was stirred at 120 °C for 2 h, concentrated under vacuum, and purified by prep-HPLC (column: Luna C8 100x30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-(2-oxo-2-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide (74 mg, 189 μmol , 27 %) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.13-8.08 (m, 2H), 7.88 (d, $J = 7.2$ Hz, 2H), 7.55-7.46 (m, 6H), 7.36 (br. s., 1H), 4.51 (d, J

= 13.7 Hz, 1H), 4.33 (d, J = 3.8 Hz, 2H), 3.94 (d, J = 13.3 Hz, 1H), 3.42-3.32 (m, 2H), 3.20 (t, J = 10.5 Hz, 1H), 2.28 (br. s., 2H), 2.11-1.96 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 391.1.

Example 10: *N*-(2-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of *N*-(2-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μ mol) and *N*-hydroxy-4-methoxybenzimidamide (82 mg, 496 μ mol) in *N,N*-dimethylformamide (2 mL) were added *N,N*-diisopropylamine (106 mg, 827 μ mol, 144 μ L) and (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol) at 15 °C, then the mixture was stirred for 15h. The mixture was heated to 110 °C and stirred for 5h. After cooling, the mixture was purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-65%, 12 min) to give *N*-(2-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (87 mg, 205 μ mol, 50 %) as a yellow solid. ¹H NMR (400 MHz, Methanol-*d*₄) δ 7.98 (d, J = 8.8 Hz, 2H), 7.88 (d, J = 7.5 Hz, 2H), 7.60 - 7.51 (m, 1H), 7.51 - 7.38 (m, 2H), 7.04 (d, J = 8.4 Hz, 2H), 4.46 (d, J = 13.2 Hz, 1H), 4.38 - 4.21 (m, 2H), 4.04 (d, J = 13.7 Hz, 1H), 3.86 (s, 3H), 3.47 - 3.34 (m, 2H), 3.07 (t, J = 11.9 Hz, 1H), 2.31 - 2.15 (m, 2H), 2.05 - 1.80 (m, 2H); LCMS (ESI) m/z $[M+H]^+$ = 421.1.

Example 11




Step 1: Preparation of *N*-hydroxy-3-methoxybenzimidamide.



To a stirred solution of 3-methoxybenzonitrile (2.0 g, 15.0 mmol, 1.83 mL) in ethanol (20 mL) was added hydroxylamine hydrochloride (2.09 g, 30.0 mmol), triethylamine (3.04 g, 30.0 mmol, 4.16 mL) and


water (2 mL). Then the mixture was heated at 75 °C for 5 h. After cooling to 20 °C, water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (40 mL x 4). The combined organic layers were washed with saturated aqueous sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate. The combined organic phases were concentrated in vacuo to give N-hydroxy-3-methoxybenzimidamide (2.60 g) as a white solid. This was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.67 (s, 1H), 7.37-7.24 (m, 3H), 7.10-6.88 (m, 1H), 5.84 (br. s., 2H), 3.82 (s, 3H).

Step 2: Preparation of N-(2-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (3 mL) were added N-hydroxy-3-methoxybenzimidamide (82 mg, 496 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol), and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture was cooled and purified directly by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-60%, 12 min) to give N-(2-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (83 mg, 198 μmol, 48 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.91-7.85 (m, 2H), 7.72-7.68 (m, 1H), 7.62 (dd, *J* = 1.5, 2.5 Hz, 1H), 7.57-7.52 (m, 1H), 7.51-7.45 (m, 2H), 7.42 (t, *J* = 8.0 Hz, 1H), 7.38-7.32 (m, 1H), 7.08 (ddd, *J* = 0.9, 2.6, 8.3 Hz, 1H), 4.52 (d, *J* = 13.6 Hz, 1H), 4.33 (d, *J* = 4.0 Hz, 2H), 3.95 (br. s., 1H), 3.91 (s, 3H), 3.42-3.32 (m, 2H), 3.25-3.13 (m, 1H), 2.33-2.22 (m, 2H), 2.11-1.94 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 421.2.

Example 12: N-(2-(4-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




Step 1: Preparation of N-hydroxy-2-methoxybenzimidamide.




To a stirred solution of 2-methoxybenzonitrile (2.0 g, 15.0 mmol, 1.83 mL) in ethanol (20 mL) were added hydroxylamine hydrochloride (2.09 g, 30.0 mmol), triethylamine (3.04 g, 30.0 mmol, 4.16 mL), and water (2 mL), then the mixture was heated to 70 °C for 15h. The mixture was cooled and quenched with water (20 mL), extracted with dichloromethane (30 mL x 3), and the combined organic phases were washed with water (20 mL), saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give N-hydroxy-2-methoxybenzimidamide (2.80 g) as a light green solid, which was used in next step directly. ¹H NMR (400 MHz, Methanol-d₄) δ 7.47 - 7.30 (m, 2H), 7.06 (d, J=8.4 Hz, 1H), 6.95 (t, J=7.5 Hz, 1H), 3.86 (s, 3H).

Step 2: Preparation of N-(2-(4-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) and N-hydroxy-2-methoxybenzimidamide (68 mg, 413 μmol) in N,N-dimethylformamide (2 mL) were added N-ethyl-N-(propan-2-yl)propan-2-amine (106 mg, 826 μmol, 144 μL) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol), and the mixture was stirred for 15 h at 15 °C. The mixture was then heated to 110 °C and stirred for 5h. After cooling, the mixture was purified directly by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-60%, 12 min) to give N-(2-(4-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (90 mg, 212 μmol, 51 %) as a yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.96 (d, J=7.5 Hz, 1H), 7.88 (d, J=7.9 Hz, 2H), 7.61 - 7.41 (m, 4H), 7.18 (d, J=8.8 Hz, 1H), 7.09 (t, J=7.5 Hz, 1H), 4.47 (d, J=13.2 Hz, 1H), 4.37 - 4.23 (m, 2H), 4.12 - 4.00 (m, 1H), 3.93 (s, 3H), 3.50 - 3.35 (m, 2H), 3.08 (t, J=11.5 Hz, 1H), 2.33 - 2.15 (m, 2H), 2.12 - 1.79 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 421.1.

Example 13: N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-4-methyl-benzamide.




Step 1: Preparation of *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-4-methylbenzamide.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μ mol) in N,N-dimethylformamide (2 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μ L) and 2-[(4-methylbenzoyl)amino]acetic acid (105 mg, 544 μ mol). The mixture was stirred at 20 °C for 5 h. The crude product was purified by prep-HPLC (column: Luna C8 100x30mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%:30%-60%,12 min) to give *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-4-methylbenzamide.

^1H NMR (400MHz, METHANOL- d_4) δ = 7.77 (d, J =7.5 Hz, 2H), 7.66 (d, J =8.2 Hz, 1H), 7.59 (s, 1H), 7.29 (d, J =7.7 Hz, 2H), 7.08 (d, J =8.4 Hz, 1H), 4.47 (d, J =12.8 Hz, 1H), 4.29 (m, J =6.0 Hz, 2H), 4.05 (d, J =14.1 Hz, 1H), 3.89 (s, 6H), 3.50 - 3.34 (m, 3H), 3.06 (t, J =12.0 Hz, 1H), 2.40 (s, 3H), 2.32 - 2.13 (t, 2H), 2.07 - 1.79 (m, 3H); LCMS (ESI) m/z : $[M+H]^+$ = 465.3.

Example 14: *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3-methylbenzamide.




Preparation of *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3-methylbenzamide




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (200 mg, 691 μ mol) in N,N-dimethylformamide (2 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (268 mg, 2.07 mmol, 362 μ L), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (262 mg, 691 μ mol) and 2-[(3-methylbenzoyl)amino]acetic acid (133 mg, 691 μ mol). The mixture was stirred at 20 °C for 16 h. The crude product was purified by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%,12 min) to give *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)-1-piperidyl)-2-oxo-ethyl)-3-methyl-benzamide (157 mg, 338 μ mol,

49 %) as a white solid. ¹H NMR (400MHz, DMSO-d₆) δ = 8.48 (t, J=5.5 Hz, 1H), 7.72 - 7.63 (m, 2H), 7.58 (dd, J=2.0, 8.4 Hz, 1H), 7.46 (d, J=1.8 Hz, 1H), 7.34 (d, J=4.9 Hz, 2H), 7.11 (d, J=8.4 Hz, 1H), 4.32 (br d, J=13.0 Hz, 1H), 4.15 (dd, J=2.3, 5.4 Hz, 2H), 3.96 (d, J=13.7 Hz, 1H), 3.87 - 3.77 (m, 6H), 3.51 - 3.39 (m, 1H), 3.24 (s, 1H), 2.90 (t, J=11.6 Hz, 1H), 2.35 (s, 3H), 2.20 - 2.04 (m, 2H), 1.89 - 1.75 (m, 1H), 1.72 - 1.54 (m, 1H); LCMS (ESI) m/z: [M+H]⁺ = 465.3.

Example 15: N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide




Preparation of N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide




To a stirred solution of 1-[2-[(3,4-dimethylbenzoyl)amino]acetyl]piperidine-4-carboxylic acid (200 mg, 628 μmol) and N-hydroxy-3,4-dimethoxy-benzamidinium (184 mg, 942 μmol) in N,N-dimethylformamide (1.50 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (238 mg, 628 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (243 mg, 1.88 mmol, 329 μL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. N,N-Dimethylformamide (2 mL) was added, then the mixture was heated to 120 °C and stirred for a further 4 h. The mixture was cooled to 25 °C, then water (5mL) was added, and the mixture extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. This residue was purified by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-65%, 12 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-3,4-dimethyl-benzamide (209 mg, 436 μmol, 69 %) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 8.40 (s, 1H), 7.66 (s, 1H), 7.59 (br d, J=7.9 Hz, 2H), 7.46 (s, 1H), 7.21 (br d, J=7.7 Hz, 1H), 7.11 (br d, J=8.4 Hz, 1H), 4.32 (br d, J=12.6 Hz, 1H), 4.14 (br s, 2H), 3.96 (br d, J=13.5 Hz, 1H), 3.89 - 3.72 (m, 6H), 3.43 (br t, J=10.8 Hz, 1H), 3.28 - 3.17 (m, 1H), 2.90 (br t, J=11.5 Hz, 1H), 2.26 (s, 6H), 2.20-2.10 (m, 2H), 1.80 (br d, J=10.4 Hz, 1H), 1.64 (br d, J=10.1 Hz, 1H). (ESI) m/z: [M+H]⁺ = 479.3.

Example 16: *N*-(2-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide



Step 1: Preparation of tert-butyl 2-(3,4-dimethylbenzamido)acetate.




5

To a stirred solution of 3,4-dimethylbenzoic acid (2.0 g, 13.3 mmol) and tert-butyl 2-aminoacetate (1.92 g, 14.7 mmol) in N,N-dimethylformamide (20 mL) were added N-ethyl-N-(propan-2-yl)propan-2-amine (3.44 g, 26.6 mmol, 4.65 mL) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (5.06 g, 13.3 mmol). After stirring at 15 °C for 3h, the mixture was treated with water (30 mL), extracted with ethyl acetate (30 mL x 3), and the combined organic phases were washed with water (20 mL), 1N hydrochloric acid (30 mL), saturated aqueous sodium hydrogen carbonate (30 mL), saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give tert-butyl 2-(3,4-dimethylbenzamido)acetate (4.0 g) as light brown oil, which was used in the next step directly without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, J=1.6 Hz, 1H), 7.46 (dd, J=1.9, 7.9 Hz, 1H), 7.11 (d, J=7.8 Hz, 1H), 4.08 - 4.04 (m, 2H), 2.23 (s, 6H), 1.44 (s, 9H).

10

15

Step 2: Preparation of 2-(3,4-dimethylbenzamido)acetic acid




20

A solution of tert-butyl 2-(3,4-dimethylbenzamido)acetate (4.0 g, 15.2 mmol) in TFA (20 mL) and dichloromethane (20 mL) was stirred for 20 h at 15 °C. The mixture was concentrated, and the residue was treated with water (10 mL) and extracted with dichloromethane/methanol (20/1, 20 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give 2-(3,4-dimethylbenzamido)acetic acid (3.20 g) as a yellow oil, which was used in next step directly without further purification.


25

Step 3: Preparation of methyl 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylate.




To a stirred solution of 2-(3,4-dimethylbenzamido)acetic acid (3.20 g, 15.4 mmol) and methyl
 5 piperidine-4-carboxylate (2.65 g, 18.5 mmol) in N,N-dimethylformamide (20 mL) were added N-ethyl-N-
 (propan-2-yl)propan-2-amine (3.99 g, 30.9 mmol, 5.39 mL) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-
 tetramethyluronium hexafluorophosphate) (5.86 g, 15.4 mmol) at 0 °C, then the mixture was warmed
 slowly to 15 °C and stirred for 15h. The mixture was treated with water (30 mL) at 0 °C, extracted with
 ethyl acetate (50 mL x 3). The combined organic phase was washed with water (20 mL), 1N hydrochloric
 10 acid (30 mL), saturated aqueous sodium hydrogen carbonate solution (30 mL), saturated aqueous
 sodium chloride solution (30 mL), and dried over anhydrous sodium sulfate, filtered, and concentrated to
 give a crude product. Purification by chromatography (silica, petroleum ether/ethyl acetate from 10:1 to
 1:2) gave methyl 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylate (3.50 g, 10.5 mmol, 68 %)
 as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.62 (s, 1H), 7.57 (d, *J*=7.9 Hz, 1H), 7.28 (m, 1H), 7.19 (d,
 15 *J*=7.5 Hz, 1H), 4.39 (d, *J*=13.2 Hz, 1H), 4.24 (d, *J*=3.5 Hz, 2H), 3.78 (d, *J*=13.7 Hz, 1H), 3.71 (s, 3H), 3.17
 (t, *J*=11.0 Hz, 1H), 3.02 - 2.91 (m, 1H), 2.67 - 2.54 (m, 1H), 2.30 (s, 6H), 1.98 (m, 2H), 1.80 - 1.64 (m,
 2H).

Step 4: Preparation of 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylic acid.




To a stirred solution of methyl 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylate (3.50
 g, 10.5 mmol) in tetrahydrofuran (20 mL) and methanol (20 mL) was added aqueous sodium hydroxide (2
 M, 7.90 mL), and the mixture was stirred at 15 °C for 5h. The mixture was concentrated to remove
 tetrahydrofuran and methanol, then the residue was acidified by 1N hydrochloric acid to pH = 2-3 at
 25 0 °C. The mixture was then extracted with dichloromethane (20 mL x 3), dried over anhydrous sodium
 sulfate, filtered, concentrated, and purified by prep-HPLC (column: Phenomenex luna C18 250x50mm 10
 μm; mobile phase: [water (0.1%TFA)-acetonitrile]; B%: 10%-40%, 20min) to give 1-(2-(3,4-
 dimethylbenzamido)acetyl)piperidine-4-carboxylic acid (1.80 g, 5.65 mmol, 54 %) as a white solid. ¹H
 NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 7.67 (s, 1H), 7.61 (d, *J*=7.7 Hz, 1H), 7.24 (d, *J*=7.7 Hz, 1H),
 30 4.21 (d, *J*=12.7 Hz, 1H), 4.12 (d, *J*=4.9 Hz, 2H), 3.85 (d, *J*=13.8 Hz, 1H), 3.14 (t, *J*=11.7 Hz, 1H), 2.79 (t,
J=11.5 Hz, 1H), 2.28 (s, 6H), 1.86 (m, 2H), 1.63 - 1.32 (m, 2H).

Step 5: Preparation of *N*-(2-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide.




To a stirred solution of 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylic acid (150 mg, 471 μ mol) and *N*-hydroxy-4-methoxybenzimidamide (93 mg, 565 μ mol) in *N,N*-dimethylformamide (2 mL) was added *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (121 mg, 942 μ mol, 164 μ L) and (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (178 mg, 471 μ mol) at 15 $^{\circ}$ C. After 15 h, the mixture was heated to 110 $^{\circ}$ C and stirred for 5 h. The mixture was cooled and directly purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give *N*-(2-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide (110 mg, 244 μ mol, 52 %) as a light yellow solid. ^{1} H NMR (400 MHz, Methanol-*d*₄) δ 7.98 (d, *J*=9.3 Hz, 2H), 7.66 (s, 1H), 7.60 (d, *J*=7.5 Hz, 1H), 7.23 (d, *J*=7.9 Hz, 1H), 7.05 (d, *J*=9.3 Hz, 2H), 4.46 (d, *J*=13.2 Hz, 1H), 4.34 - 4.23 (m, 2H), 4.04 (d, *J*=13.7 Hz, 1H), 3.86 (s, 3H), 3.47 - 3.36 (m, 2H), 3.07 (t, *J*=11.0 Hz, 1H), 2.42 - 2.26 (s, 6H), 2.21 (d, *J*=17.6 Hz, 2H), 2.04 - 1.82 (m, 2H); LCMS (ESI) *m/z*: [*M*+*H*]⁺ = 449.2.

Example 17: *N*-(2-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide.




Step 1: Preparation of *N*-(2-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide.




To a stirred solution of 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylic acid (150 mg, 471 μ mol) in *N,N*-dimethylformamide (3 mL) were added *N*-hydroxy-3-methoxybenzimidamide (93 mg, 565 μ mol), (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (178 mg, 471 μ mol) and *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (182 mg, 1.41 mmol, 246 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h and then heated at 120 $^{\circ}$ C for 2 h. The reaction mixture was cooled and then purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium

carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give N-(2-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide (119 mg, 263 μ mol, 56 %) as a white solid. ^1H NMR (400MHz, CDCl_3) δ 7.63-7.47 (m, 4H), 7.32 (t, J = 7.9 Hz, 1H), 7.23-7.20 (m, 1H), 7.15-7.10 (m, 1H), 6.98 (dd, J = 1.8, 8.3 Hz, 1H), 4.48-4.37 (m, 1H), 4.22 (d, J = 3.9 Hz, 2H), 3.88-3.82 (m, 1H), 3.81 (s, 3H), 3.31-3.22 (m, 2H), 3.13-3.04 (m, 1H), 2.24 (s, 6H), 2.22-2.12 (m, 2H), 2.00-1.87 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 449.3$.

Example 18: 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one




Step 1: Preparation of 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.



To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μ mol) in N,N-dimethylformamide (1.5 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μ L) and 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (111 mg, 544 μ mol). The mixture was stirred at 20 $^{\circ}\text{C}$ for 16 h. The mixture was filtered, and the filtrate was purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give 4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenylpyrrolidin-2-one (86 mg, 181 μ mol, 35 %) as a white solid. ^1H NMR (400MHz, $\text{METHANOL}-d_4$) δ = 7.69 - 7.56 (m, 4H), 7.38 (br t, J =7.2 Hz, 2H), 7.22 - 7.16 (m, 1H), 7.08 (br d, J =8.4 Hz, 1H), 4.56 - 4.42 (m, 1H), 4.19 - 4.04 (m, 3H), 3.89 (s, 6H), 3.86 - 3.81 (m, 1H), 3.50 - 3.37 (m, 2H), 3.14 - 3.00 (m, 1H), 2.94 - 2.78 (m, 2H), 2.31 - 2.16 (m, 2H), 2.01 - 1.81 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 477.3$.

Example 19: 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-(3,4-dimethylphenyl)pyrrolidin-2-one.


Step 1: Preparation of 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-(3,4-dimethylphenyl)pyrrolidin-2-one.




To a stirred solution of 1-[1-(3,4-dimethylphenyl)-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (200 mg, 581 μ mol) in N,N-dimethylformamide (1.5 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (220 mg, 581 μ mol), N-ethyl-N-(propan-2-

yl)propan-2-amine (225 mg, 1.74 mmol, 304 μ L), and N-hydroxy-3,4-dimethoxy-benzamidine (125 mg, 639 μ mol). The mixture was stirred at 20 °C for 12 h. The reaction mixture was diluted with water (5mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in N,N-dimethylformamide (2 mL) then heated at 120 °C for 5 h. The mixture was cooled to 25 °C then diluted with water (5mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue that was purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 12 min), to give 4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-(3,4-dimethylphenyl)pyrrolidin-2-one (7 mg, 15 μ mol, 3 %) as a pink solid. ¹H NMR (400MHz, METHANOL-d₄) δ = 7.66 (br d, J=8.2 Hz, 1H), 7.58 (s, 1H), 7.36 (s, 1H), 7.27 (br d, J=8.2 Hz, 1H), 7.16 - 7.04 (m, 2H), 4.49 (br d, J=8.4 Hz, 1H), 4.18 - 3.98 (m, 3H), 3.93 - 3.77 (m, 7H), 3.48 - 3.36 (m, 2H), 3.12 - 2.97 (m, 1H), 2.92 - 2.78 (m, 2H), 2.32 - 2.14 (m, 8H), 2.01 - 1.79 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 505.4.

Example 20: 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




Step 1: Preparation of N-hydroxy-4-methoxybenzimidamide.




To a stirred solution of 4-methoxybenzonitrile (2.0 g, 15.02 mmol) in ethanol (20 mL) was added hydroxylamine hydrochloride (2.09 g, 30.0mmol) and triethylamine (3.04 g, 30.0mmol, 4.16 mL) and water (2 mL), then the mixture was heated to 70 °C for 15h. The mixture was treated with water (20 mL) and extracted with dichloromethane (30 mL x 3). The combined organic phases were washed with water (20 mL), saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give crude N-hydroxy-4-methoxybenzimidamide (2.50 g) as a white solid, which was used in the next step directly. ¹H NMR (400 MHz, Methanol-d₄) δ 7.61 - 7.48 (m, 2H), 6.98 - 6.85 (m, 2H), 3.81 (s, 3H).

Step 2: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




To a stirred solution of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (250 mg, 726 μ mol) and N-hydroxy-4-methoxybenzimidamide (120 mg, 726 μ mol) in N,N-dimethylformamide (3 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (187 mg, 1.45 mmol, 253 μ L) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (275 mg, 726 μ mol),
 5 After 15h at 15 $^{\circ}$ C, the mixture was heated to 110 $^{\circ}$ C and stirred for 5 h. The reaction mixture was cooled and purified directly by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 36%-66%, 12 min) to give 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one (101 mg, 213 μ mol, 29 %) as a light yellow solid. ^{1} H NMR (400 MHz, Methanol- d_4) δ 7.98 (d, J =7.5 Hz, 2H), 7.36 (s, 1H), 7.27 (d, J =7.9 Hz, 1H), 7.13 (d, J =8.4 Hz, 1H), 7.04 (d, J =8.4 Hz, 2H), 4.47 (m., 1H), 4.19 - 3.96 (m, 3H), 3.86 (s, 3H),
 10 3.84 - 3.78 (m, 1H), 3.42 (m, 2H), 3.16 - 2.98 (m, 1H), 2.93 - 2.74 (m, 2H), 2.37 - 2.10 (m, 8H), 2.02 - 1.78 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 475.3.

Example 21: 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




Step 1: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




To a stirred solution of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (200 mg, 581 μ mol) in N,N-dimethylformamide (3 mL) was added N-hydroxy-3-methoxybenzimidamide (96 mg, 581 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (220 mg, 581 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (225 mg, 1.74 mmol, 304 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h, then heated at 120 $^{\circ}$ C for 2 h. The reaction mixture was purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-60%, 12 min) to give 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one (80 mg, 168 μ mol, 29 %) as a yellow solid. ^{1} H NMR (400MHz, $CDCl_3$) δ 7.72-7.67 (m, 1H), 7.62 (s, 1H), 7.45-7.37 (m, 2H), 7.30 (d, J = 2.3 Hz, 1H), 7.15 (d, J = 8.3 Hz, 1H), 7.11-7.06 (m, 1H), 4.61-4.47 (m, 1H), 4.30 (dd, J = 7.3, 9.5 Hz, 1H), 3.91 (s, 5H), 3.64-3.54 (m, 1H), 3.46-3.30 (m, 2H), 3.21-3.05 (m, 1H), 3.03-2.92 (m, 1H), 2.89-2.79 (m, 1H), 2.28 (d, J = 13.1 Hz, 8H), 2.10-1.90 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 475.3.

Example 22: N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-N-methylbenzamide.



5


Step 1: Preparation of N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-N-methylbenzamide.



To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidinyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in N,N-dimethylformamide (2 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL) and 2-[benzoyl(methyl)amino]acetic acid (105 mg, 544 μmol). The mixture was stirred at 20 °C for 5 h, then cooled and purified directly by prep-HPLC (column: Luna C8 100x30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-N-methyl-benzamide (133 mg, 282 μmol , 54 %) as a white solid. ^1H NMR (400MHz, DMSO- d_6) δ = 7.59 (dd, J =1.8, 8.4 Hz, 1H), 7.49 - 7.32 (m, 5H), 7.27 (br d, J =6.8 Hz, 1H), 7.16 - 7.08 (m, 1H), 4.44 - 4.24 (m, 2H), 4.21 - 4.03 (m, 1H), 4.02 - 3.88 (m, 1H), 3.88 - 3.74 (m, 6H), 3.56 (br d, J =13.7 Hz, 1H), 3.48 - 3.33 (m, 1H), 3.11 - 2.77 (m, 5H), 2.20 - 1.99 (m, 2H), 1.86 (br t, J =12.6 Hz, 1H), 1.74 - 1.48 (m, 2H), 1.43 - 1.26 (m, 1H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+$ = 465.3.


20

Example 23: N-(2-(4-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



25


Step 1: Preparation of 3,4-dichloro-N-hydroxybenzimidamide.



To a stirred solution of 3,4-dichlorobenzonitrile (1.0 g, 5.81 mmol) in ethanol (20 mL) was added hydroxylamine hydrochloride (807 mg, 11.6 mmol), triethylamine (1.18 g, 11.6 mmol, 1.61 mL) and water


(2 mL). The mixture was heated at 75 °C for 5 h, then cooled to 20 °C. Water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (40 mL x 4). The combined organic layers were washed with saturated aqueous sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated in vacuo to give 3,4-dichloro-N-hydroxybenzimidamide (1.20 g) as a white solid. This was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.86 (s, 1H), 7.87 (d, *J* = 1.8 Hz, 1H), 7.69-7.58 (m, 2H), 5.95 (s, 2H).

Step 2: Preparation of N-(2-(4-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (200 mg, 688.92 μmol) in N,N-dimethylformamide (4 mL) was added 3,4-dichloro-N-hydroxybenzimidamide (169 mg, 826 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (261 mg, 688.92 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (267 mg, 2.07 mmol, 360 μL). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture cooled then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give N-(2-(4-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (92 mg, 201 μmol, 29 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.14-8.09 (m, 1H), 7.85 (dd, *J* = 2.0, 8.2 Hz, 1H), 7.78 (d, *J* = 7.1 Hz, 2H), 7.39 (s, 4H), 7.25 (br. s., 1H), 4.43 (d, *J* = 13.7 Hz, 1H), 4.24 (d, *J* = 3.5 Hz, 2H), 3.84 (d, *J* = 14.1 Hz, 1H), 3.33-3.22 (m, 2H), 3.14-3.03 (m, 1H), 2.23-2.13 (m, 2H), 1.99-1.86 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.1.

Example 24: N-(2-(4-(3-(3,4-difluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



Step 1: Preparation of 3,4-difluoro-N-hydroxybenzimidamide.




To a stirred solution of 3,4-difluorobenzonitrile (1.0 g, 7.19 mmol) in ethanol (20 mL) were added hydroxylamine hydrochloride (999 mg, 14.4 mmol), triethylamine (1.46 g, 14.4 mmol, 1.99 mL), and water (2 mL). The mixture was heated at 75 °C for 2 h. After cooling to 20 °C, water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (30 mL x 4). The combined organic layers

were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, then filtered, and concentrated in vacuo to give 3,4-difluoro-N-hydroxybenzimidamide (1.24 g) as a white solid. This was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.79 (s, 1H), 7.68 (ddd, *J* = 2.0, 8.0, 12.2 Hz, 1H), 7.55 (br. s., 1H), 7.50-7.39 (m, 1H), 5.92 (br. s., 2H).

5


Step 2: Preparation of N-(2-(4-(3-(3,4-difluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (4 mL) were added 3,4-difluoro-N-hydroxybenzimidamide (85 mg, 496 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol), and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture was cooled then purified directly by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-60%, 12 min) to give N-(2-(4-(3-(3,4-difluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (50 mg, 118 μmol, 28 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 7.1 Hz, 4H), 7.44 (d, *J* = 7.1 Hz, 1H), 7.42-7.35 (m, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 4.43 (d, *J* = 13.7 Hz, 1H), 4.23 (d, *J* = 4.0 Hz, 2H), 3.84 (d, *J* = 13.7 Hz, 1H), 3.32-3.21 (m, 2H), 3.13-3.03 (m, 1H), 2.23-2.12 (m, 2H), 1.99-1.84 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 427.2.


20

Example 25: 2-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




25

Step 1: Preparation of tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (2.0 g, 6.91 mmol) in N,N-dimethylformamide (20 mL) was added 2-(tert-butoxycarbonylamino)acetic acid (1.21 g, 6.91 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (2.62 g, 6.91 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (2.68 g, 20.7 mmol, 3.62 mL). The mixture was stirred at 15 °C for 2 h. The reaction mixture was quenched by addition of water (20 mL), then the mixture was extracted with ethyl acetate (60 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude residue. Purification by chromatography (silica, petroleum ether : ethyl acetate = 5:1 to 1:1) gave tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (2.60 g, 5.82 mmol, 84 %) as a brown solid that was used directly without further purification. LCMS (ESI) m/z: [M+H]⁺ = 447.2.

Step 2: Preparation of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone.



To a stirred solution of tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (2.50 g, 5.60 mmol) in methanol (10 mL) was added methanolic hydrogen chloride solution (4M, 30 mL). The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated to give crude product. A part of crude product (0.1 g) was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (32 mg) for analysis. The remaining crude 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (1.90 g, 5.49 mmol, 98 %), obtained as a brown solid, was used directly. ¹H NMR (400 MHz, CDCl₃) δ 7.73-7.67 (m, 1H), 7.58 (d, J = 1.5 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.54 (d, J = 12.2 Hz, 1H), 3.98 (d, J = 7.2 Hz, 6H), 3.84 (d, J = 12.0 Hz, 1H), 3.54 (s, 2H), 3.34-3.21 (m, 2H), 3.08 (d, J = 12.3 Hz, 1H), 2.21 (d, J = 13.1 Hz, 2H), 1.98 (d, J = 9.4 Hz, 2H); LCMS (ESI) m/z: [M+H]⁺ = 347.1.


Step 3: Preparation of 2-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (185 mg, 537 μmol) in N,N-dimethylformamide (3 mL) was added 2-chlorobenzoic acid (70 mg, 447 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (169 mg, 447

μmol), and N-ethyl-N-(propan-2-yl)propan-2-amine (231 mg, 1.79 mmol, 312 μL). The mixture was stirred at 20 °C for 2 h, then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 26%-56%, 12 min) to give 2-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (124 mg, 256 μmol, 57 %) as a pink solid. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (ddd, *J* = 1.9, 6.3, 7.9 Hz, 2H), 7.59 (d, *J* = 1.9 Hz, 1H), 7.49-7.33 (m, 4H), 6.98 (d, *J* = 8.4 Hz, 1H), 4.52 (d, *J* = 13.6 Hz, 1H), 4.36 (d, *J* = 4.0 Hz, 2H), 3.99 (d, *J* = 7.8 Hz, 6H), 3.92 (d, *J* = 13.8 Hz, 1H), 3.41-3.30 (m, 2H), 3.16 (t, *J* = 10.9 Hz, 1H), 2.33-2.21 (m, 2H), 2.11-1.94 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 485.2.

Example 26: 3-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 3-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (185 mg, 537 μmol) in N,N-dimethylformamide (3 mL) were added 3-chlorobenzoic acid (70 mg, 447 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (169 mg, 447 μmol), and N-ethyl-N-(propan-2-yl)propan-2-amine (231 mg, 1.79 mmol, 312 μL). The mixture was stirred at 20 °C for 2 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 26%-56%, 12 min) to give 3-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (126 mg, 261 μmol, 58 %) as a white solid. ¹H NMR (400MHz, CDCl₃) δ 7.89-7.86 (m, 1H), 7.72 (d, *J* = 2.0 Hz, 2H), 7.59 (d, *J* = 1.9 Hz, 1H), 7.54-7.50 (m, 1H), 7.45-7.39 (m, 1H), 7.34 (br. s., 1H), 6.98 (d, *J* = 8.5 Hz, 1H), 4.53 (d, *J* = 14.3 Hz, 1H), 4.31 (d, *J* = 3.9 Hz, 2H), 3.98 (d, *J* = 7.4 Hz, 6H), 3.96-3.87 (m, 1H), 3.41-3.30 (m, 2H), 3.18 (t, *J* = 10.9 Hz, 1H), 2.33-2.22 (m, 2H), 2.10-1.94 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 485.3.

Example 27: 4-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




- 5 **Step 1: Preparation of 4-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.**




- To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (185 mg, 536.5 μ mol) in N,N-dimethylformamide (3 mL) were added 4-chlorobenzoic acid (70 mg, 447 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (169 mg, 447 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (231 mg, 1.79 mmol, 312 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give 4-chloro-N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (144 mg, 294 μ mol, 66 %) as a white solid. ^{1} H NMR (400MHz, CDCl_3) δ 7.82 (d, J = 8.5 Hz, 2H), 7.71 (dd, J = 1.9, 8.3 Hz, 1H), 7.59 (d, J = 1.8 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.33 (br. s., 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.52 (d, J = 14.2 Hz, 1H), 4.31 (d, J = 3.9 Hz, 2H), 3.98 (d, J = 7.3 Hz, 6H), 3.92 (d, J = 13.7 Hz, 1H), 3.41-3.30 (m, 2H), 3.17 (t, J = 10.7 Hz, 1H), 2.34-2.21 (m, 2H), 2.10-1.94 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 485.2.

Example 28: N-(1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-1-oxopropan-2-yl)benzamide.




Step 1: Preparation of *N*-(1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-1-oxopropan-2-yl)benzamide.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in *N,N*-dimethylformamide (2 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol), *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL), and 2-benzamidopropanoic acid (105 mg, 544 μmol). The mixture was stirred at 20 °C for 7 h, then the crude product was purified directly by prep-HPLC (column: Luna C8 100x30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile; B%: 35%-60%, 12 min] to give *N*-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide (52 mg, 112 μmol , 22 %) as a white solid. ^1H NMR (400MHz, $\text{DMSO}-d_6$) δ = 8.63 (br dd, J =7.3, 16.1 Hz, 1H), 7.88 (br d, J =7.3 Hz, 2H), 7.66 - 7.34 (m, 5H), 7.11 (br d, J =7.9 Hz, 1H), 4.97 (br d, J =6.0 Hz, 1H), 4.45 - 4.22 (m, 1H), 4.08 - 3.94 (m, 1H), 3.82 (s, 6H), 3.42 (br t, J =10.7 Hz, 1H), 3.29 - 3.21 (m, 1H), 3.00 - 2.80 (m, 1H), 2.09 (br d, J =11.9 Hz, 2H), 1.87 - 1.56 (m, 1H), 1.29 (s, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 465.3$.

Example 29: *N*-(1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-methyl-1-oxopropan-2-yl)benzamide.




Step 1: Preparation of *N*-(1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-methyl-1-oxopropan-2-yl)benzamide.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in *N,N*-dimethylformamide (2 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol), *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL) and 2-benzamido-2-methyl-propanoic acid (112 mg, 544 μmol). The mixture was stirred at 20 °C for 5 h. The crude product was purified directly by prep-HPLC (column: Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile; B%: 27%-57%, 12 min) to give *N*-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1,1-dimethyl-2-oxo-ethyl]benzamide (47 mg, 99 μmol , 19 %) as a pale yellow solid. ^1H NMR (400MHz, $\text{METHANOL}-d_4$) δ = 7.88 - 7.81 (m, 2H), 7.62

(dd, J=2.0, 8.4 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.49 - 7.42 (m, 2H), 7.06 (d, J=8.4 Hz, 1H), 4.61 - 4.45 (m, 2H), 3.88 (d, J=5.1 Hz, 6H), 3.13 (s, 3H), 2.08 (br s, 2H), 1.90 - 1.74 (m, 2H), 1.60 (s, 6H); LCMS (ESI) m/z: [M+H]⁺ = 477.1.

5 **Example 30: 2-(benzylamino)-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone.**




10 *Step 1: Preparation of 2-(benzylamino)-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone.*




15 To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidinyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in N,N-dimethylformamide (1.50 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol), N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL), and 2-(benzylamino)acetic acid (89 mg, 544 μmol). The mixture was stirred at 20 °C for 16 h and filtered, and the crude filtrate was purified directly by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give 2-(benzylamino)-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]ethanone (48 mg, 110 μmol, 21 %) as a yellow solid. ¹H NMR (400MHz, METHANOL-d₄) δ =

20 7.65 (dd, J=1.8, 8.2 Hz, 1H), 7.57 (d, J=1.8 Hz, 1H), 7.40 - 7.30 (m, 4H), 7.28 - 7.22 (m, 1H), 7.06 (d, J=8.4 Hz, 1H), 4.45 (br d, J=13.7 Hz, 1H), 3.94 - 3.83 (m, 7H), 3.78 (s, 2H), 3.57 - 3.44 (m, 2H), 3.40 - 3.33 (m, 1H), 3.27 - 3.20 (m, 1H), 3.01 (t, J=11.2 Hz, 1H), 2.17 (dd, J=2.8, 13.3 Hz, 2H), 1.93 - 1.73 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 437.3.

Example 31: 2-(benzyloxy)-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone.




- 5 **Step 1: Preparation of 2-(benzyloxy)-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone.**




- To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in N,N-dimethylformamide (2 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol), N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL), and 2-benzyloxyacetic acid (90 mg, 544 μmol , 77 μL). The mixture was stirred at 20 °C for 5 h. The crude product was purified directly by prep-HPLC (column: Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 32%-62%, 12 min) to give 2-benzyloxy-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone (68 mg, 157 μmol , 30 %) as a white solid. ^1H NMR (400MHz, DMSO- d_6) δ = 7.60 (dd, J =1.9, 8.3 Hz, 1H), 7.48 (d, J =1.9 Hz, 1H), 7.40 - 7.35 (m, 4H), 7.34 - 7.26 (m, 1H), 7.14 (d, J =8.4 Hz, 1H), 4.54 (s, 2H), 4.33 (br d, J =13.2 Hz, 1H), 4.25 (br d, J =7.8 Hz, 2H), 3.93 - 3.78 (m, 7H), 3.43 (tt, J =3.9, 11.0 Hz, 1H), 3.22 (br t, J =11.7 Hz, 1H), 2.90 (br t, J =11.7 Hz, 1H), 2.17 - 2.04 (m, 2H), 1.88 - 1.59 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 438.3.

- 20 **Example 32: N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethyl]benzamide**




Step 1: Preparation of tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)carbamate




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (750 mg, 2.59 mmol) in N,N-dimethylformamide (1 mL) were added cesium carbonate (844 mg, 2.59 mmol) and tert-butyl N-(2-bromoethyl)carbamate (871 mg, 3.89 mmol). The mixture was stirred at 50 °C for 16 h. The reaction mixture was cooled then extracted with ethyl acetate (5 mL x 2). The combined organic extracts were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethyl]carbamate (1.30 g) which was used directly without further purification. LCMS (ESI) m/z = 433.3 $[M+H]^+$.

Step 2: Preparation of 2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanamine




A solution of tert-butyl N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethyl]carbamate (1.0 g, 2.31 mmol) in hydrochloric acid/ethyl acetate (4M, 25 mL) was stirred at 25 °C for 30 mins. The reaction mixture was concentrated under reduced pressure to give 2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanamine (750 mg) which was used directly without further purification. LCMS (ESI) m/z = 333.1 $[M+H]^+$.

Step 3: Preparation of N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide




To a mixture of 2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanamine (200 mg, 602 μ mol) and benzoyl chloride (109 mg, 782 μ mol, 90 μ L) in dichloromethane (1 mL) was added triethylamine (182 mg, 1.81 mmol, 250 μ L) at 0 °C. The mixture was stirred at 20 °C for 5 h, then purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-50%, 12 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethyl]benzamide (25 mg, 56 μ mol, 9 %) as a white solid. ^1H NMR (400MHz, METHANOL- d_4) δ = 7.86 - 7.79 (m, 2H), 7.66 (dd, J =1.8, 8.4 Hz, 1H), 7.58 (d, J =1.8 Hz, 1H), 7.55 - 7.43 (m, 3H), 7.07 (d, J =8.6 Hz, 1H), 3.89 (s, 6H), 3.58 (t, J =6.8 Hz, 2H), 3.16 - 3.09 (m, 2H), 2.67 (t, J =6.8 Hz, 2H), 2.37 - 2.29 (m, 2H), 2.18 (br d, J =11.2 Hz, 2H), 2.07 - 1.91 (m, 3H); LCMS (ESI) m/z : $[M+H]^+$ = 437.3.

Example 33: (E)-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-4-phenylbut-2-ene-1,4-dione




5 **Step 1: Preparation of (E)-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-4-phenylbut-2-ene-1,4-dione**




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (250 mg, 864 μ mol) in N,N-dimethylformamide (4 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (327 mg, 864 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (335 mg, 2.59 mmol, 452 μ L) and (E)-4-oxo-4-phenylbut-2-enoic acid (152 mg, 864 μ mol). The mixture was stirred at 20 °C for 5 h, then the crude mixture was purified directly by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give (E)-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-4-phenylbut-2-ene-1,4-dione (118 mg, 251 μ mol, 29 %) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 8.03 (br d, J=7.3 Hz, 2H), 7.75 (d, J=15.4 Hz, 1H), 7.71 - 7.65 (m, 1H), 7.61 - 7.53 (m, 3H), 7.51 - 7.43 (m, 2H), 7.11 (d, J=8.4 Hz, 1H), 4.41 (br d, J=13.2 Hz, 1H), 4.11 - 3.99 (m, 1H), 3.88 - 3.77 (m, 6H), 3.54 - 3.34 (m, 2H), 3.02 (br t, J=11.2 Hz, 1H), 2.15 (br d, J=13.0 Hz, 2H), 1.88 - 1.67 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 448.2.

20 **Example 34: 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-((2,2,2-trifluoro-1-phenylethyl)amino)ethanone.**




Step 1: Preparation of 2,2,2-trifluoro-1-phenylethyl trifluoromethanesulfonate.



25 To a stirred solution of 2,2,2-trifluoro-1-phenylethanol (100 mg, 568 μ mol, 76 μ L) in dichloromethane (2 mL) were added 2,6-dimethylpyridine (121 mg, 1.14 mmol, 132 μ L) and trifluoromethanesulfonic anhydride (288 mg, 1.02 mmol, 168 μ L) at 0 °C. The mixture was stirred at 0 °C


for 0.5 h and then diluted with dichloromethane (5 mL) and water (5 mL), and the phases separated. The aqueous phase was extracted with dichloromethane (15 mL x 2), then the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give 2,2,2-trifluoro-1-phenylethyl trifluoromethanesulfonate (380 mg) as a brown oil. This material was used directly without further purification.


Step 2: Preparation of 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-((2,2,2-trifluoro-1-phenylethyl)amino)ethanone




To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (120 mg, 346 μ mol) in dichloromethane (2.5 mL) was added 2,2,2-trifluoro-1-phenylethyl trifluoromethanesulfonate (213 mg, 692.88 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (179 mg, 1.39 mmol, 242 μ L). The mixture was stirred at 40 °C for 16 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-((2,2,2-trifluoro-1-phenylethyl)amino)ethanone (52 mg, 101 μ mol, 29 %) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.63-7.56 (m, 1H), 7.51-7.37 (m, 6H), 7.14 (d, J = 8.4 Hz, 1H), 4.53-4.43 (m, 1H), 4.30 (br. s., 1H), 3.84 (s, 6H), 3.71 (d, J = 10.2 Hz, 1H), 3.44-3.36 (m, 2H), 3.18-3.07 (m, 1H), 2.99 (d, J = 5.5 Hz, 1H), 2.87 (br. s., 1H), 2.08 (d, J = 12.5 Hz, 2H), 1.75-1.56 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 505.3.

Example 35: N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




Step 1: Preparation of tert-butyl 4-(3-bromo-1,2,4-thiadiazol-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate

A mixture of 3-bromo-5-chloro-1,2,4-thiadiazole (500 mg, 2.51 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (931 mg, 3.01 mmol), cesium fluoride (762 mg, 5.02 mmol, 185 μ L) in dioxane (3.5 mL) was degassed and purged with nitrogen 3 times, then 4-ditert-butylphosphanyl-N,N-dimethyl-aniline;dichloropalladium (88 mg, 125.50 μ mol, 88 μ L, 0.05 eq) was added. The mixture was stirred at 80 $^{\circ}$ C for 2 h under an atmosphere of nitrogen. The mixture was cooled to 25 $^{\circ}$ C and concentrated in vacuo at 40 $^{\circ}$ C. The residue was poured into water (15 mL), the aqueous phase was extracted with dichloromethane (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford crude product. The crude product was purified by chromatography (silica, petroleum ether/ ethyl acetate (from 20/1 to 2/1) to give tert-butyl 4-(3-bromo-1,2,4-thiadiazol-5-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (260 mg, 750.92 μ mol, 30 %) as a yellow oil. LCMS (ESI) m/z: 368.3 [M+Na]⁺.

Step 2: Preparation of tert-butyl 4-(3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate


A mixture of tert-butyl 4-(3-bromo-1,2,4-thiadiazol-5-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (260 mg, 751 μ mol), (3,4-dimethoxyphenyl)boronic acid (163 mg, 901 μ mol), and sodium carbonate (103 mg, 976 μ mol) in water (400 μ L) and dimethoxyethane (1.2 mL) was degassed and purged with nitrogen 3 times, and then tetrakis(triphenylphosphine)palladium(0) (17 mg, 15 μ mol) was added. The mixture was stirred at 100 $^{\circ}$ C for 6 h under a nitrogen atmosphere. The mixture was cooled to 25 $^{\circ}$ C and concentrated in vacuo at 40 $^{\circ}$ C. The residue was poured into water (5 mL), and the aqueous phase was extracted with dichloromethane (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford crude product. The crude residue was purified by prep-TLC (silica, petroleum ether/ ethyl acetate=3:1) to give tert-butyl 4-[3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (122 mg, 303 μ mol, 40 %) as a yellow oil. LCMS (ESI) m/z: 404.1 [M+H]⁺.

Step 3: Preparation of tert-butyl 4-(3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl)piperidine-1-carboxylate

To a stirred solution of tert-butyl 4-[3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (100 mg, 248 μ mol) in methanol (10 mL) was added palladium(0) on carbon (10%,


150 mg) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen three times. The mixture was stirred under hydrogen (15 psi) at 20 °C for 48 h. The reaction mixture was filtered and concentrated under reduced pressure to give tert-butyl 4-[3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl]piperidine-1-carboxylate (79 mg) that was used into the next step without further purification. LCMS (ESI) m/z: 406.2 [M+H]⁺.

Step 4: Preparation of 3-(3,4-dimethoxyphenyl)-5-(piperidin-4-yl)-1,2,4-thiadiazole




A solution of tert-butyl 4-[3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl]piperidine-1-carboxylate (79 mg, 195 μmol) in hydrochloric acid/ethyl acetate (4M, 15 mL) was stirred at 20 °C for 3 h. The reaction mixture was concentrated in vacuo to give 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-thiadiazole (65 mg) that was used into the next step without further purification.

Step 5: Preparation of N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-thiadiazole (65 mg, 214 μmol) and 2-benzamidoacetic acid (46 mg, 257 μmol) in N,N-dimethylformamide (1 mL) were added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (81 mg, 214 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (69 mg, 536 μmol, 93 μL). After 2 h, the reaction mixture purified directly by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 26%-56%, 12 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-thiadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (10 mg, 22 μmol, 10 %) as a yellow solid. ¹H NMR (400MHz, METHANOL-d₄) δ = 7.92 - 7.82 (m, 4H), 7.59 - 7.52 (m, 1H), 7.51 - 7.44 (m, 2H), 7.06 (d, J=8.4 Hz, 1H), 4.61 (d, J=12.9 Hz, 1H), 4.41 - 4.24 (m, 2H), 4.11 (br d, J=14.9 Hz, 1H), 3.98 - 3.84 (m, 6H), 3.63 - 3.52 (m, 1H), 3.39 (br t, J=11.7 Hz, 1H), 2.99 (br t, J=11.6 Hz, 1H), 2.35 - 2.20 (m, 2H), 2.03 - 1.74 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 467.2.

Example 36: *N*-(2-(4-(5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl)piperidin-1-yl)-2-oxoethyl)benzamide




5 Step 1: Preparation of (Z)-tert-butyl 4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate



A mixture of tert-butyl 4-cyanopiperidine-1-carboxylate (2.0 g, 9.51 mmol), hydroxylamine hydrochloride (1.32 g, 19.0 mmol), and triethylamine (1.92 g, 19.0 mmol, 2.64 mL) in ethanol (20 mL) and water (2 mL) was heated at 75 °C for 16 h. The reaction mixture was cooled, diluted with water (10 mL), and extracted with ethyl acetate (15 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl 4-[(Z)-N'-hydroxycarbamimidoyl]piperidine-1-carboxylate (1.90 g) which was used directly without further purification. ¹H NMR (400MHz, METHANOL-d₄) δ = 4.15 (br d, J=13.3 Hz, 2H), 2.78 (br s, 2H), 2.27 (tt, J=3.6, 12.1 Hz, 1H), 1.84 - 1.70 (m, 2H), 1.62 (dq, J=4.3, 12.6 Hz, 2H), 1.53 - 1.39 (m, 9H).


Step 2: Preparation of tert-butyl 4-(5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carboxylate



To a stirred solution of tert-butyl 4-[(Z)-N'-hydroxycarbamimidoyl]piperidine-1-carboxylate (750 mg, 3.08 mmol) in N,N-dimethylformamide (5 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.17 g, 3.08 mmol), N-ethyl-N-(propan-2-yl)propan-2-amine (1.19 g, 9.24 mmol, 1.61 mL) and 3,4-dimethoxybenzoic acid (561 mg, 3.08 mmol). The mixture was stirred at 20 °C for 16 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (15 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. Tetrahydrofuran (500 μL) and tetrabutylammonium fluoride / tetrahydrofuran (1 M, 4.62 mL) were added to the residue, and the resulting mixture was heated at 50 °C for 16 h. The residue was purified by chromatography (silica, petroleum ether / ethyl acetate=5:1) to give


tert-butyl 4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]piperidine-1-carboxylate (970 mg, 2.49 mmol, 81 %) as a white solid. LCMS (ESI) m/z : 412.3 $[M+Na]^+ = 334.2$.

Step 3: Preparation of 5-(3,4-dimethoxyphenyl)-3-(piperidin-4-yl)-1,2,4-oxadiazole




A solution of tert-butyl 4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]piperidine-1-carboxylate (750 mg, 1.93 mmol) in hydrochloric acid / ethyl acetate (4M, 30 mL) was stirred at 20 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to give 5-(3,4-dimethoxyphenyl)-3-(4-piperidyl)-1,2,4-oxadiazole (683 mg) that was used directly without further purification.

Step 4: Preparation of N-(2-(4-(5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl)piperidin-1-yl)-2-oxoethyl)benzamide




To a stirred solution of 5-(3,4-dimethoxyphenyl)-3-(4-piperidyl)-1,2,4-oxadiazole (180 mg, 622 μ mol) in N,N-dimethylformamide (2 mL) were added 2-benzamidoacetic acid (111 mg, 622 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (235 mg, 622 μ mol), and N-ethyl-N-(propan-2-yl)propan-2-amine (241 mg, 1.87 mmol, 325 μ L). The mixture was stirred at 20 °C for 16 h. The crude product was purified by prep-HPLC (column: Waters Xbridge 150x25 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-[2-[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (169 mg, 376 μ mol, 60 %) as a white solid. ^1H NMR (400MHz, DMSO- d_6) δ = 8.55 (br t, J =5.4 Hz, 1H), 7.87 (br d, J =7.5 Hz, 2H), 7.70 (br d, J =8.4 Hz, 1H), 7.57 - 7.41 (m, 4H), 7.17 (br d, J =8.4 Hz, 1H), 4.34 (br d, J =12.3 Hz, 1H), 4.16 (br d, J =4.2 Hz, 2H), 3.97 (br d, J =13.0 Hz, 1H), 3.90 - 3.74 (m, 6H), 3.27 - 3.09 (m, 2H), 2.88 (br t, J =11.6 Hz, 1H), 2.03 (br t, J =11.8 Hz, 2H), 1.75 (br d, J =10.4 Hz, 1H), 1.59 (br d, J =9.9 Hz, 1H); LCMS (ESI) m/z : $[M+H]^+ = 451.2$.

Example 37: N-(2-(4-(4-(3,4-dimethoxyphenyl)oxazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 2-bromo-1-(3,4-dimethoxyphenyl)ethanone.




To a stirred solution of 1-(3,4-dimethoxyphenyl)ethanone (1.0 g, 5.55 mmol) in dichloromethane (6 mL) and methanol (3 mL) was added benzyltrimethylammonium tribromide (2.16 g, 5.55 mmol). After 16 h, the mixture was diluted with dichloromethane (80 mL) and water (40 mL), the organic layer was separated, and the water phase was extracted with dichloromethane (80 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give 2-bromo-1-(3,4-dimethoxyphenyl)ethanone (1.20 g, 4.63 mmol, 83 %) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.63 (s, 1H), 7.57 (d, *J*=2.1 Hz, 1H), 6.94 (d, *J*=8.4 Hz, 1H), 4.43 (s, 2H), 3.98 (d, *J*=8.4 Hz, 6H).

Step 2: Preparation of 2-(3,4-dimethoxyphenyl)-2-oxoethyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate.





To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (200 mg, 689 μmol) in acetonitrile (6 mL) was added 2-bromo-1-(3,4-dimethoxyphenyl)ethanone (214 mg, 826 μmol) and triethylamine (209 mg, 2.07 mmol, 286 μL) under nitrogen. The mixture was stirred at 20 °C for 2 h. The reaction mixture was concentrated in vacuo to give 2-(3,4-dimethoxyphenyl)-2-oxoethyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (233 mg, 497 μmol, 72 %) as a yellow solid. This was used directly without further purification. LCMS (ESI) *m/z*: [M+H]⁺ = 469.3.


Step 3: Preparation of N-(2-(4-(4-(3,4-dimethoxyphenyl)oxazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 2-(3,4-dimethoxyphenyl)-2-oxoethyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (180 mg, 384 μmol) in acetic acid (8 mL) was added ammonium acetate (148 mg, 1.92 mmol) under nitrogen, then the mixture was heated at 100 °C for 16 h. The reaction mixture was concentrated in vacuo to give crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-55%, 12 min) to give N-(2-(4-(4-(3,4-dimethoxyphenyl)oxazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide (55 mg, 120 μmol, 31 %) as a pink solid. ¹H NMR (400 MHz, CDCl₃) δ 7.92 - 7.84 (m, 2H), 7.80 (s, 1H), 7.58 - 7.44 (m, 3H), 7.41 - 7.35 (m, 1H), 7.28 - 7.26 (m, 2H), 6.92 (d, *J*=8.9 Hz, 1H), 4.58 - 4.47 (m, 1H), 4.32 (d, *J*=3.9 Hz, 2H), 3.99 - 3.88 (m, 7H), 3.37 - 3.06 (m, 3H), 2.28 - 2.13 (m, 2H), 2.07 - 1.89 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 450.3.

Example 38: N-(2-(4-(4-(3,4-dimethoxyphenyl)thiazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide.**5 Step 1: Preparation of tert-butyl 4-carbamothioylpiperidine-1-carboxylate.**

To a stirred solution of tert-butyl 4-carbamoylpiperidine-1-carboxylate (1.0 g, 4.38 mmol) in a mixture of dimethoxyethane (16 mL) and dichloromethane (8 mL) was added 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide (885 mg, 2.19 mmol). The mixture was stirred at 20 °C for 16 h, then concentrated in vacuo. The residue dissolved in ethyl acetate and washed with saturated aqueous potassium carbonate (10 mL x 2). The organic layer was separated, dried over sodium sulfate and concentrated in vacuo to give tert-butyl 4-carbamothioylpiperidine-1-carboxylate (1.0 g) as a yellow solid. This was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.45 (br. s., 1H), 9.17 (br. s., 1H), 4.14-3.98 (m, 2H), 3.91-3.79 (m, 1H), 2.80-2.66 (m, 2H), 1.74-1.55 (m, 4H), 1.46 (s, 9H).


15 Step 2: Preparation of tert-butyl 4-(4-(3,4-dimethoxyphenyl)thiazol-2-yl)piperidine-1-carboxylate.

To a stirred solution of tert-butyl 4-carbamothioylpiperidine-1-carboxylate (200 mg, 818.5 μmol) in N,N-dimethylformamide (5 mL) was added 2-bromo-1-(3,4-dimethoxyphenyl)ethanone (212 mg, 818.50 μmol) and potassium carbonate (124 mg, 900 μmol). The mixture was stirred at 110 °C for 16 h. The reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give tert-butyl 4-(4-(3,4-dimethoxyphenyl)thiazol-2-yl)piperidine-1-carboxylate (300 mg, 742 μmol, 91 %) as a yellow solid. This was used directly without further purification. LCMS (ESI) m/z: [M+H]⁺ = 405.3.


Step 3: Preparation of 4-(3,4-dimethoxyphenyl)-2-(piperidin-4-yl)thiazole.

To a stirred solution of tert-butyl 4-(4-(3,4-dimethoxyphenyl)thiazol-2-yl)piperidine-1-carboxylate (300 mg, 742 μ mol) in methanol (3 mL) was added methanolic hydrogen chloride solution (4M, 10 mL).


- 5 The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to provide 4-(3,4-dimethoxyphenyl)-2-(piperidin-4-yl)thiazole (260 mg) as a yellow solid. LCMS (ESI) m/z: [M+H]⁺ = 305.1.

Step 4: Preparation of N-(2-(4-(4-(3,4-dimethoxyphenyl)thiazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide.

- 10 To a stirred solution of 4-(3,4-dimethoxyphenyl)-2-(piperidin-4-yl)thiazole (203 mg, 670 μ mol) in N,N-dimethylformamide (4 mL) were added 2-benzamidoacetic acid (100 mg, 558 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (211 mg, 558 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (288 mg, 2.23 mmol, 389 μ L). The mixture was stirred at 20 °C for 16 h.
- 15 The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-(2-(4-(4-(3,4-dimethoxyphenyl)thiazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide (111 mg, 239 μ mol, 43 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.91-7.85 (m, 2H), 7.57-7.42 (m, 5H), 7.39 (br. s., 1H), 6.94 (d, J = 8.2 Hz, 1H), 4.70 (d, J = 13.6 Hz, 1H), 4.40-4.26 (m, 2H), 3.97 (d, J = 19.7 Hz, 7H), 3.43-3.26 (m, 2H),
- 20 3.05-2.95 (m, 1H), 2.37-2.23 (m, 2H), 1.98-1.83 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 466.3.


Example 39: N-(2-(4-(5-(3,4-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide.

Step 1: Ethyl 3,4-dimethoxybenzimidate.




To a stirred solution of 3,4-dimethoxybenzonitrile (2.0 g, 12.3 mmol) in dry ethanol (50 mL) was added dropwise acetyl chloride (7.70 g, 98.1 mmol, 7.0 mL) at 0 °C, after complete addition, the mixture was warmed to 15 °C and stirred for 30 h. The reaction was concentrated in vacuo, and then saturated hydrochloric acid in ethanol (50 mL) was added. After 5h, the mixture was concentrated in vacuo to give crude ethyl 3,4-dimethoxybenzenecarboximidate (2.50 g) as a light yellow solid, which was used in next step directly.

Step 2: methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate.



To a stirred solution of 2-benzamidoacetic acid (3.0 g, 16.7 mmol) and methyl piperidine-4-carboxylate (3.60 g, 25.1 mmol) in dry N,N-dimethylformamide (50 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (4.33 g, 33.5 mmol, 5.9 mL) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (7.0 g, 18.4 mmol) at 0 °C, then the mixture was warmed to 15 °C and stirred for 15h. The mixture was poured into ice water (100 mL) then extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with 1N hydrochloric acid (30 mL x 2), saturated aqueous sodium carbonate (30 mL), and saturated aqueous sodium chloride solution (30 mL), then dried over anhydrous sodium sulfate, filtered and concentrated to give a crude methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (5.30 g) as a brown oil, which was used in next step directly. ¹H NMR (400 MHz, Methanol-d₄) δ 7.87 (d, J=7.1 Hz, 2H), 7.58 - 7.51 (m, 1H), 7.49 - 7.40 (m, 2H), 4.39 - 4.29 (m, 1H), 4.28 - 4.17 (m, 2H), 3.96 - 3.84 (m, 1H), 3.68 (s, 3H), 3.28 - 3.17 (m, 1H), 2.96 - 2.86 (m, 1H), 2.69 - 2.62 (m, 1H), 2.00 - 1.88 (m, 2H), 1.78 - 1.51 (m, 2H).


Step 3: N-(2-(4-(hydrazinecarbonyl)piperidin-1-yl)-2-oxoethyl)benzamide.



A solution of methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (500 mg, 1.64 mmol) and hydrazine hydrate (328 mg, 6.56 mmol, 318 μL) in methanol (3 mL) was heated to 80 °C for 15 h. The mixture was concentrated in vacuo to give a crude residue that was washed with tert-butyl methyl ether (10 mL) to obtain N-[2-[4-(hydrazinecarbonyl)-1-piperidinyl]-2-oxo-ethyl]benzamide (500 mg) as a light yellow solid that was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.03 (s,


1H), 8.54 (t, J=5.6 Hz, 1H), 7.94 - 7.82 (m, 2H), 7.60 - 7.43 (m, 3H), 4.41 - 4.29 (m, 1H), 4.13 (d, J=5.6 Hz, 2H), 3.93 (d, J=12.9 Hz, 1H), 3.05 (t, J=11.9 Hz, 1H), 2.68 - 2.57 (m, 1H), 2.34 (tdd, J=3.9, 7.5, 11.2 Hz, 1H), 1.73 - 1.34 (m, 4H).

5 **Step 4: N-(2-(4-(5-(3,4-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)piperidin-1-yl)-2-oxoethyl)benzamide.**




A solution of N-[2-[4-(hydrazinecarbonyl)-1-piperidyl]-2-oxo-ethyl]benzamide (200 mg, 657 μ mol) and ethyl 3,4-dimethoxybenzenecarboximidate (151 mg, 723 μ mol) in ethanol (4 mL) was heated to 80 °C for 15h. The mixture was concentrated to give a crude product, which was purified by prep-HPLC
 10 (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-35%, 12 min) to give N-[2-[4-[5-(3,4-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (23 mg, 48 μ mol, 7 %) as a white solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.92 - 7.82 (m, 2H), 7.62 (dd, J=1.8, 8.4 Hz, 1H), 7.59 - 7.52 (m, 2H), 7.51 - 7.44 (m, 2H), 7.12 (d, J=8.4 Hz, 1H), 4.49 (d, J=13.2 Hz, 1H), 4.38 - 4.24 (m, 2H), 4.06 (d, J=13.7 Hz, 1H), 3.97 - 3.80 (m, 6H), 3.48 - 3.34 (m,
 15 2H), 3.06 (t, J=11.2 Hz, 1H), 2.33 - 2.15 (m, 2H), 2.06 - 1.94 (m, 1H), 1.92 - 1.75 (m, 1H); LCMS (ESI) m/z: [M+H]⁺ = 451.2.

Example 40: N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



20


Step 1: Preparation of 1,3-dimethyl-1H-indazole-6-carbonitrile.



To a stirred solution of 6-bromo-1,3-dimethyl-1H-indazole (400 mg, 1.78 mmol) in N,N-dimethylformamide (5 mL) was added zinc cyanide (209 mg, 1.78 mmol, 112 μ L) and
 25 tetrakis(triphenylphosphine)palladium(0) (205 mg, 178 μ mol, 0.10 eq) under nitrogen. The mixture was heated at 100 °C for 16 h, then cooled to 20 °C, water (10 mL) added, and the resulting mixture was


extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (15 mL) and dried over anhydrous sodium sulfate. The organic phase was filtered and concentrated in vacuo to give crude product. Petroleum ether (40 mL) was added to the crude product, then the mixture was filtered, and the filter cake dried in vacuo to give 1,3-dimethyl-1H-indazole-6-carbonitrile (250 mg, 1.46 mmol, 82 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 - 7.71 (m, 2H), 7.34 (dd, *J*=1.3, 8.3 Hz, 1H), 4.07 (s, 3H), 2.61 (s, 3H).

Step 2: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide.





To a stirred solution of 1,3-dimethyl-1H-indazole-6-carbonitrile (100 mg, 584 μmol) in ethanol (2 mL) was added hydroxylamine hydrochloride (81 mg, 1.17 mmol), triethylamine (118 mg, 1.17 mmol, 161 μL) and water (200 μL). The mixture was heated at 75 °C for 2 h. After cooling to 20 °C, water (5 mL) was added to the solution. The mixture was extracted with dichloromethane (30 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated in vacuo to give (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide (140 mg) as a white solid. LCMS (ESI) *m/z*: [M+H]⁺ = 205.1.


Step 3: Preparation of N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide (101 mg, 496 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture cooled then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-65%, 12 min) to give N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (46 mg, 101 μmol, 25 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (s, 1H), 7.81 - 7.73 (m, 3H), 7.66 (dd, *J*=0.6, 8.4 Hz, 1H), 7.48 - 7.42 (m, 1H), 7.42 - 7.35 (m, 2H), 7.26 (br. s., 1H), 4.46 (d, *J*=14.1 Hz, 1H), 4.24 (d, *J*=3.9 Hz, 2H), 4.01 (s, 3H), 3.86 (d, *J*=13.7 Hz, 1H), 3.29 (ddd, *J*=3.6, 10.5, 14.2 Hz, 2H), 3.13 - 3.04 (m, 1H), 2.53 (s, 3H), 2.26 - 2.15 (m, 2H), 2.04 - 1.89 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.3.

Example 41: N-(2-(4-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.**Step 1: Preparation of 4-fluoro-N-hydroxybenzimidamide.**


5 To a stirred solution of 4-fluorobenzonitrile (1.0 g, 8.26 mmol) in ethanol (10 mL) was added hydroxylamine hydrochloride (1.15 g, 16.5 mmol), triethylamine (1.67 g, 16.52 mmol, 2.29 mL) and water (1 mL). The mixture was heated at 75 °C for 2 h. After cooling to 20 °C, water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (40 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated in vacuo to give 4-fluoro-N-hydroxybenzimidamide (1.0 g, 6.49 mmol, 79 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.64 (s, 1H), 7.85-7.64 (m, 2H), 7.21 (t, *J* = 8.9 Hz, 2H), 5.84 (br. s., 2H).

Step 2: Preparation of N-(2-(4-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.


15 To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (3 mL) was added 4-fluoro-N-hydroxybenzimidamide (76 mg, 496 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture cooled then purified directly by prep-HPLC (column: Luna C18 150x2.5mm 5μm; mobile phase: [water (0.225%FA)-acetonitrile]; B%: 35%-65%, 12 min) to give N-(2-(4-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (56 mg, 135 μmol, 33 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.13-8.07 (m, 2H), 7.90-7.86 (m, 2H), 7.58-7.52 (m, 1H), 7.51-7.45 (m, 2H), 7.35 (br. s., 1H), 7.23-7.16 (m, 2H), 4.56-4.47 (m, 1H), 4.33 (d, *J* = 3.9 Hz, 2H),

3.93 (d, $J = 13.9$ Hz, 1H), 3.41-3.31 (m, 2H), 3.23-3.13 (m, 1H), 2.33-2.21 (m, 2H), 2.02 (ddq, $J = 4.1$, 10.5, 14.2 Hz, 2H); LCMS (ESI) m/z : $[M+H]^+ = 409.2$.

Example 42: *N*-(2-(4-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.





Step 1: Preparation of N-(2-(4-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



10 To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μ mol) in N,N-dimethylformamide (4 mL) was added 3-fluoro-N-hydroxybenzimidamide (76 mg, 496 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h, then heated at 120 $^{\circ}$ C for 2 h. The reaction mixture was cooled then purified directly by prep-HPLC (column: Luna C8 100*30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-60%, 12 min) to give N-(2-(4-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (59 mg, 145 μ mol, 35 %) as a yellow solid. ^{1} H NMR (400MHz, $CDCl_3$) δ 7.85-7.76 (m, 3H), 7.71 (d, $J=9.3$ Hz, 1H), 7.49-7.35 (m, 4H), 7.26 (br. s., 1H), 7.15 (s, 1H), 4.43 (d, $J=13.7$ Hz, 1H), 4.24 (d, $J=3.5$ Hz, 2H), 3.84 (d, $J=14.1$ Hz, 1H), 3.33-3.22 (m, 2H), 3.14-3.04 (m, 1H), 2.26-2.13 (m, 2H), 2.00-1.85 ppm (m, 2H);

15

20 LCMS (ESI) m/z : $[M+H]^+ = 409.2$.

Example 43: N-(2-(4-(3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.**Step 1: Preparation of 2-fluoro-N-hydroxybenzimidamide.**


5

To a stirred solution of 2-fluorobenzonitrile (1.0 g, 8.26 mmol, 877 μ L) in ethanol (10 mL) was added hydroxylamine hydrochloride (1.15 g, 16.5 mmol), triethylamine (1.67 g, 16.5 mmol, 2.29 mL) and water (1 mL). The mixture was heated at 75 $^{\circ}$ C for 2 h. After cooling to 20 $^{\circ}$ C, water (20 mL) was added. The mixture was extracted with dichloromethane (40 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated in vacuo to give 2-fluoro-N-hydroxybenzimidamide (1.20 g, 7.79 mmol, 94 %) as a white solid. LCMS (ESI) m/z: $[M+H]^+ = 155.1$.

10

Step 2: Preparation of N-(2-(4-(3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.

15




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (150 mg, 516.7 μ mol) in N,N-dimethylformamide (4 mL) was added 2-fluoro-N-hydroxybenzimidamide (95 mg, 620 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (195 mg, 516.7 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (200 mg, 1.55 mmol, 270 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h, then heated at 120 $^{\circ}$ C for 2 h. The reaction mixture was cooled then purified directly by prep-HPLC (column: Luna C8 100*30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-(2-(4-(3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (85 mg, 208.6 μ mol, 40 %) as a yellow solid. ^{1} H NMR (400 MHz, $CDCl_3$) δ 7.98 (s, 1H), 7.81-7.75 (m, 2H), 7.48-7.34 (m, 4H), 7.28-7.20 (m, 2H), 7.16 (d, $J = 8.5$ Hz, 1H), 4.42 (d, $J = 14.1$ Hz, 1H), 4.23 (d, $J = 3.9$ Hz,

20

25


2H), 3.84 (d, $J = 13.9$ Hz, 1H), 3.29 (dt, $J = 4.1, 10.4$ Hz, 2H), 3.14-3.04 (m, 1H), 2.25-2.13 (m, 2H), 2.02-1.86 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 409.2$.

Example 44: 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-phenylethanone.



5

Step 1: Preparation of 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-phenylethanone.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidinyl)-1,2,4-oxadiazole (150 mg, 518 μmol) in N,N-dimethylformamide (1.50 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol), N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL) and 2-phenylacetic acid (74 mg, 544 μmol , 68 μL). The mixture was stirred at 20 °C for 16 h. The crude product was purified directly by prep-HPLC (column: Luna C8 100x30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 12 min) to give 1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-phenyl-ethanone (24 mg, 59 μmol , 11 %) as a white solid. ^1H NMR (400MHz, METHANOL- d_4) δ = 7.63 (dd, $J=2.0, 8.4$ Hz, 1H), 7.55 (d, $J=1.8$ Hz, 1H), 7.39 - 7.20 (m, 5H), 7.05 (d, $J=8.4$ Hz, 1H), 4.49 (br d, $J=13.5$ Hz, 1H), 4.04 (br d, $J=13.2$ Hz, 1H), 3.88 (s, 6H), 3.82 (s, 2H), 3.34 (br d, $J=2.6$ Hz, 1H), 3.29 - 3.23 (m, 1H), 3.05 - 2.95 (m, 1H), 2.19 - 2.11 (m, 1H), 2.06 - 1.98 (m, 1H), 1.83 - 1.71 (m, 1H), 1.67 - 1.54 (m, 1H); LCMS (ESI) m/z : $[M+H]^+ = 408.3$.


15

20


Example 45: 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-(6-methylpyrazin-2-yl)ethanone.




25

Step 1: Preparation of diethyl 2-(6-methylpyrazin-2-yl)malonate.

To a stirred solution of 2-chloro-6-methylpyrazine (1.0 g, 7.78 mmol) in N,N-dimethylformamide (20 mL) was added diethyl malonate (3.12 g, 19.5 mmol, 2.94 mL) and potassium carbonate (2.69 g, 19.5 mmol), then the mixture was stirred at 110 °C for 16 h. The reaction mixture was cooled to 20 °C, quenched with water (20 mL), and then extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by chromatography (silica, petroleum ether : ethyl acetate = 50 : 1 to 10 : 1) gave diethyl 2-(6-methylpyrazin-2-yl)malonate (180 mg, 713.5 μmol, 9 %) as a green oil. ¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 1H), 8.44 (s, 1H), 4.91 (s, 1H), 4.20-4.15 (q, *J* = 7.2 Hz, 4H), 2.58 (s, 3H), 1.25-1.22 (t, *J* = 7.2 Hz, 6H); LCMS (ESI) *m/z*: 253.1 [M+H]⁺.

Step 2: Preparation of 2-(6-methylpyrazin-2-yl)acetic acid.


To a stirred solution of diethyl 2-(6-methylpyrazin-2-yl)malonate (180 mg, 713.5 μmol) in ethanol (10 mL) was added sodium hydroxide (2 M, 1.96 mL) and the mixture warmed at 60 °C for 2 h. The reaction was cooled to 20 °C, and acidified with 1 M hydrochloric acid (5 mL). The mixture was concentrated in vacuo to give 2-(6-methylpyrazin-2-yl)acetic acid (1.42 g) as a light yellow solid that was used directly without further purification.

Step 3: Preparation of 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-(6-methylpyrazin-2-yl)ethanone.


To a stirred solution of 2-(6-methylpyrazin-2-yl)acetic acid (1.05 g, 415 μmol, purity 6 %) in N,N-dimethylformamide (4 mL) was added 3-(3,4-dimethoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (120 mg, 415 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (157 mg, 415 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (214 mg, 1.66 mmol, 289 μL). The mixture was stirred at 20 °C for 4 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-50%, 12 min) to give 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-(6-methylpyrazin-2-yl)ethanone (26 mg, 62 μmol, 15 %) as a yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 8.41 (s, 2H), 7.68 (dd, *J*=1.9, 8.3 Hz, 1H), 7.61 (d, *J*=1.8 Hz, 1H), 7.10 (d, *J*=8.4 Hz, 1H), 4.51 (d, *J*=13.4 Hz, 1H), 4.22

(d, $J=13.9$ Hz, 1H), 4.12 - 3.93 (m, 2H), 3.92 (s, 6H), 3.52 - 3.38 (m, 2H), 3.12 - 3.02 (m, 1H), 2.57 (s, 3H), 2.28 - 2.17 (m, 2H), 2.04 - 1.80 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 424.2$.

Example 46: *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)acetamide.




Step 1: Preparation of N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)acetamide.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidin-1-yl)-1,2,4-oxadiazole (250 mg, 864 μ mol) in *N,N*-dimethylformamide (1.5 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (327 mg, 864 μ mol), *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (335 mg, 2.59 mmol, 452 μ L) and 2-acetamidoacetic acid (106 mg, 907 μ mol). The mixture was stirred at 20 °C for 16 h. The crude product was purified by prep-HPLC (column: Luna C8 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give *N*-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]acetamide (36 mg, 94 μ mol, 11 %) as a white solid. ¹H NMR (400MHz, METHANOL-*d*₄) δ = 7.69 (dd, $J=1.9$, 8.3 Hz, 1H), 7.61 (d, $J=1.9$ Hz, 1H), 7.10 (d, $J=8.4$ Hz, 1H), 4.47 (br d, $J=14.2$ Hz, 1H), 4.21 - 4.06 (m, 2H), 3.98 (br d, $J=13.1$ Hz, 1H), 3.92 (s, 6H), 3.47 - 3.38 (m, 2H), 3.13 - 3.00 (m, 1H), 2.31 - 2.16 (m, 2H), 2.05 (s, 3H), 2.00 - 1.79 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 389.2$.

Example 47: *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isobutyramide.




Step 1: Preparation of *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isobutyramide.




To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (150 mg, 433 μ mol) in dichloromethane (3 mL) was added isobutyryl chloride (55 mg, 520 μ mol, 54 μ L) and triethylamine (131 mg, 1.30 mmol, 180 μ L) at 0 $^{\circ}$ C. The mixture was warmed and stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was concentrated in vacuo to give crude product that was purified by HPLC prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 23%-53%, 12 min) to give *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isobutyramide (85 mg, 204 μ mol, 47 %) as a white solid. ^{1} H NMR (400MHz, CDCl_3) δ 7.74-7.68 (m, 1H), 7.58 (d, J = 1.9 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.63 (br. s., 1H), 4.49 (d, J = 13.3 Hz, 1H), 4.12 (d, J = 4.0 Hz, 2H), 3.98 (d, J = 7.3 Hz, 6H), 3.87 (d, J = 14.1 Hz, 1H), 3.36-3.26 (m, 2H), 3.13 (t, J = 10.9 Hz, 1H), 2.50 (td, J = 6.9, 13.8 Hz, 1H), 2.23 (br. s., 2H), 2.06-1.92 (m, 2H), 1.22 (d, J = 6.9 Hz, 6H); LCMS (ESI) m/z : $[M+H]^+$ = 417.3.

Example 48: *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)cyclohexanecarboxamide.



Step 1: Preparation of *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)cyclohexanecarboxamide.




To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (150 mg, 433 μ mol) in dichloromethane (3 mL) was added cyclohexanecarbonyl chloride (76 mg, 520 μ mol, 69 μ L) and triethylamine (131 mg, 1.30 mmol, 180 μ L) at 0 $^{\circ}$ C. The mixture was warmed and stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 23%-53%, 12 min) to give *N*-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)cyclohexanecarboxamide (78 mg, 171 μ mol, 39 %) as a white solid. ^{1} H NMR (400MHz, CDCl_3) δ 7.73-7.68 (m, 1H), 7.60-7.57 (m, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.64-6.59 (m, 1H), 4.53-4.45 (m, 1H), 4.11 (d, J = 4.0 Hz, 2H), 3.98 (d, J = 7.2 Hz, 6H), 3.86 (d, J = 13.3


Hz, 1H), 3.36-3.26 (m, 2H), 3.12 (t, $J = 10.7$ Hz, 1H), 2.28-2.18 (m, 3H), 2.05-1.89 (m, 4H), 1.82 (d, $J = 12.3$ Hz, 2H), 1.71 (d, $J = 10.9$ Hz, 1H), 1.54-1.42 (m, 2H), 1.37-1.22 (m, 3H); LCMS (ESI) m/z : $[M+H]^+ = 457.3$.

5

Example 49: 1-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-N-(2-phenylethyl)piperidine-4-carboxamide.




Step 1: Preparation of tert-butyl 4-(phenethylcarbamoyl)piperidine-1-carboxylate.




To a stirred solution of 1-tert-butoxycarbonyl-4-piperidinecarboxylic acid (1.0 g, 4.36 mmol) in dichloromethane (15 mL) was added 2-phenylethanamine (528 mg, 4.36 mmol, 544 μ L), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (835 mg, 4.36 mmol) and triethylamine (44 mg, 436 μ mol, 60 μ L). The mixture was stirred at 20 $^{\circ}$ C for 5 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by chromatography (silica, petroleum ether / ethyl acetate from 10/1 to 1/1) to give tert-butyl 4-(2-phenylethylcarbamoyl)piperidine-1-carboxylate (800 mg, 2.41 mmol, 55 %) as a white solid. LCMS (ESI) m/z : 355.2 $[M+Na]^+$.

Step 2: Preparation of N-phenethylpiperidine-4-carboxamide.



A solution of tert-butyl 4-(2-phenylethylcarbamoyl)piperidine-1-carboxylate (800 mg, 2.41 mmol) in 4N hydrochloric acid / ethyl acetate (10 mL) was stirred at 20 $^{\circ}$ C for 0.5 h. The reaction mixture was concentrated in vacuo to give N-(2-phenylethyl)piperidine-4-carboxamide (720 mg) as a hydrochloric acid salt and as a white solid.


Step 3: Preparation of 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole.



3-(3,4-dimethoxyphenyl)-4H-1,2,4-oxadiazol-5-one (900 mg, 4.05 mmol) was added to a mixture of N,N-dimethylformamide (2 mL) and phosphoryl chloride (24.8 g, 161.4 mmol, 15 mL). The mixture was


equipped with calcium chloride tube and the mixture was heated at 100 °C for 16 h. The mixture was cooled to 0 °C and concentrated under reduced pressure. The residue was poured into ice-water (20 mL) and stirred for 10 min, then the aqueous phase was extracted with dichloromethane (10 mL x 5). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by chromatography (silica, petroleum ether / ethyl acetate=5/1, 1/1) to give 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole (104 mg, 432 μmol, 11 %) as a white solid.

Step 4: Preparation of 1-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-phenethylpiperidine-4-carboxamide.




To a stirred solution of 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole (95 mg, 395 μmol) in N-methyl-2-pyrrolidone (2 mL) was added N-(2-phenylethyl)piperidine-4-carboxamide (110 mg, 474 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (102 mg, 790 μmol, 137 μL) at 20 °C. Then the mixture was heated to 120 °C and stirred for 5 h. The crude product was purified by prep-HPLC (column: Luna C8 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-65%, 12 min), Compound 1-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-N-(2-phenylethyl)piperidine-4-carboxamide (117 mg, 266 μmol, 67 %) as a white solid. ¹H NMR (400MHz, METHANOL-d₄) δ = 7.57 (dd, J=2.0, 8.4 Hz, 1H), 7.51 (d, J=1.9 Hz, 1H), 7.33 - 7.27 (m, 2H), 7.25 - 7.18 (m, 3H), 7.06 (d, J=8.4 Hz, 1H), 4.22 (br d, J=13.3 Hz, 2H), 3.90 (s, 6H), 3.44 (t, J=7.3 Hz, 2H), 3.27 - 3.17 (m, 2H), 2.82 (t, J=7.2 Hz, 2H), 2.51 - 2.40 (m, 1H), 1.92 - 1.67 (m, 4H); LCMS (ESI) m/z: [M+H]⁺ = 437.3.

Example 50: 1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




Step 1: Preparation of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carbonitrile.




To a stirred solution of 1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carboxylic acid (1.0 g, 4.29 mmol) in N,N-dimethylformamide (10 mL) was added piperidine-4-carbonitrile (567 mg, 5.15 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.63 g, 4.29 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (1.66 g, 12.87 mmol, 2.25 mL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with ethyl acetate (20 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to a yellow oil (1.6 g). A portion of the crude product (0.3 g) was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carbonitrile for analysis (144 mg). The remainder of the crude product was used directly without purification. ¹H NMR (400 MHz, Methanol-d₄) δ 7.37 (d, *J* = 2.5 Hz, 1H), 7.31-7.25 (m, 1H), 7.15 (d, *J* = 8.2 Hz, 1H), 4.08 (d, *J* = 7.0 Hz, 5H), 3.59-3.37 (m, 2H), 3.16-3.03 (m, 1H), 2.91-2.79 (m, 2H), 2.28 (d, *J* = 10.2 Hz, 6H), 2.10-1.72 (m, 4H); LCMS (ESI) *m/z*: [M+H]⁺ = 326.2.

Step 2: Preparation of (Z)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N'-hydroxypiperidine-4-carboximidamide.




To a stirred solution of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carbonitrile (1.30 g, 4.00 mmol) in ethanol (10 mL) was added hydroxylamine hydrochloride (555 mg, 8.00 mmol), triethylamine (809 mg, 8.00 mmol, 1.11 mL) and water (1 mL). The mixture was heated at 75 °C for 2 h. After cooling to 20 °C, water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (40 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a brown solid (1.4 g). A portion of crude product (0.3 g) was purified by prep-HPLC (column: Luna C18 150x2.5mm 5µm; mobile phase: [water (0.225% TFA)-acetonitrile]; B%: 15%-40%, 12 min) to give (Z)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N'-hydroxypiperidine-4-carboximidamide. The remainder was used directly in the next step. ¹H NMR (400 MHz, DMSO-d₆) δ 8.86-8.77 (m, 1H), 8.15 (s, 1H), 7.45-7.33 (m, 2H), 7.12 (dd, *J* = 8.2, 2.4 Hz, 1H), 5.36 (br. s., 2H), 4.47-4.32 (m, 1H), 4.06-3.86 (m, 3H), 3.75-3.60 (m, 1H), 3.07 (br. s., 1H), 2.80-2.57 (m, 3H), 2.36-2.24 (m, 1H), 2.21 (d, *J* = 11.8 Hz, 6H), 1.83-1.67 (m, 2H), 1.56 ppm (br. s., 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 359.3.

Step 3: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




To a stirred solution of (Z)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N'-hydroxypiperidine-4-carboximidamide (300 mg, 837 μ mol) in tetrahydrofuran (8 mL) was added 4-methylbenzoyl chloride (155 mg, 1.00 mmol, 132 μ L) and triethylamine (254 mg, 2.51 mmol, 348 μ L) at 0 $^{\circ}$ C, then the mixture was warmed at 20 $^{\circ}$ C. After 3 h, to the reaction mixture was added ethyl acetate and water and the organic phase was separated. The organic phase was washed with water and saturated aqueous sodium chloride solution and then dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. To the residue were added tetrahydrofuran (8 mL) and a tetrabutylammonium fluoride in tetrahydrofuran (1 M, 2.51 mL) solution, and the mixture warmed at 50 $^{\circ}$ C for 16 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Luna C18 100*30 5 μ m; mobile phase: [water (0.225%TFA)-acetonitrile]; B%: 45%-75%, 12 min) to give the racemic of 1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one (106 mg, 0.23 mmol, 28 %) as a white solid. ^{1} H NMR (400 MHz, CDCl₃) δ 8.06-7.99 (m, 2H), 7.41-7.33 (m, 3H), 7.31 (d, J = 2.0 Hz, 1H), 7.15 (d, J = 8.0 Hz, 1H), 4.60 (t, J = 13.2 Hz, 1H), 4.30 (dd, J = 7.4, 9.5 Hz, 1H), 4.04-3.88 (m, 2H), 3.60 (quin, J = 8.5 Hz, 1H), 3.42-3.31 (m, 1H), 3.25-3.14 (m, 1H), 3.11-2.94 (m, 2H), 2.88-2.78 (m, 1H), 2.47 (s, 3H), 2.32-2.12 (m, 8H), 2.03-1.86 (m, 2H); LCMS (ESI) m/z : [M+H]⁺ = 459.3.

Example 51: 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one.




Step 1: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one




To a stirred solution of (Z)-1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)-N'-hydroxypiperidine-4-carboximidamide (280 mg, 781 μ mol) in tetrahydrofuran (8 mL) was added 3-methylbenzoyl chloride (144 mg, 937 μ mol, 123 μ L) and triethylamine (237 mg, 2.34 mmol, 324 μ L) at 0 $^{\circ}$ C, the mixture was stirred at 20 $^{\circ}$ C for 3 h. To the reaction mixture was added ethyl acetate and water and the organic phase was separated. The organic phase was washed with water and saturated aqueous

sodium chloride solution, then dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. To the residue were added tetrahydrofuran (8 mL) and a tetrabutylammonium fluoride in tetrahydrofuran solution (1 M, 2.34 mL). The mixture was warmed to 50 °C and stirred for 16 h. The reaction mixture was cooled and concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Luna C8 100x30 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-75%, 12 min) to give the racemic of 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one (156 mg, 0.34 mmol, 44 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.99-7.91 (m, 2H), 7.43 (d, *J* = 1.0 Hz, 3H), 7.32-7.29 (m, 1H), 7.15 (d, *J* = 8.3 Hz, 1H), 4.60 (t, *J* = 14.1 Hz, 1H), 4.30 (dd, *J* = 7.3, 9.6 Hz, 1H), 4.04-3.88 (m, 2H), 3.65-3.54 (m, 1H), 3.37 (d, *J* = 7.0 Hz, 1H), 3.21 (d, *J* = 3.5 Hz, 1H), 3.11-2.94 (m, 2H), 2.88-2.78 (m, 1H), 2.48 (s, 3H), 2.32-2.13 (m, 8H), 1.93 (d, *J* = 12.2 Hz, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.3.

Example 52: (4-(5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl)piperidin-1-yl)(4-isopropylphenyl)methanone.




Step 1: Preparation of 1-(4-isopropylbenzoyl)piperidine-4-carbonitrile.




To a stirred solution of 4-isopropylbenzoic acid (1.0 g, 6.09 mmol) in N,N-dimethylformamide (10 mL) was added piperidine-4-carbonitrile (805 mg, 7.31 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (2.31 g, 6.09 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (2.36 g, 18.27 mmol, 3.19 mL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with ethyl acetate (40 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give yellow oil (1.8 g). A portion of crude product (0.2 g) was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-55%, 12 min) to give 1-(4-isopropylbenzoyl)piperidine-4-carbonitrile (115 mg) as a sample for analysis. The remainder was used directly. ¹H NMR (400 MHz, Methanol-d₄) δ 7.37 (s, 4H), 4.16-3.40 (m, 4H), 3.15-3.07 (m, 1H), 3.02-2.93 (m, 1H), 2.10-1.76 (m, 4H), 1.31-1.26 (m, 6H); LCMS (ESI) *m/z*: [M+H]⁺ = 257.2.

Step 2: Preparation of N-hydroxy-1-(4-isopropylbenzoyl)piperidine-4-carboximidamide.




To a stirred solution of 1-(4-isopropylbenzoyl)piperidine-4-carbonitrile (1.60 g, 6.24 mmol) in ethanol (15 mL) was added hydroxylamine hydrochloride (867 mg, 12.5 mmol), triethylamine (1.26 g, 12.48 mmol, 1.73 mL) and water (1.50 mL). The mixture was heated at 75 °C for 2 h. After cooling to 20 °C, water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (40 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated in vacuo to give N-hydroxy-1-(4-isopropylbenzoyl)piperidine-4-carboximidamide (1.60 g, 5.53 mmol, 89 %) as a white solid that was used directly without further purification. ¹H NMR (400 MHz, Methanol-d₄) δ 7.40-7.33 (m, 4H), 4.78-4.58 (m, 1H), 3.94-3.73 (m, 1H), 3.22 (d, *J* = 7.3 Hz, 2H), 3.02-2.95 (m, 1H), 2.50-2.35 (m, 1H), 1.96-1.67 (m, 4H), 1.31-1.27 (m, 6H).

Step 3: Preparation of (4-(5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl)piperidin-1-yl)(4-isopropylphenyl)methanone.




To a stirred solution of N-hydroxy-1-(4-isopropylbenzoyl)piperidine-4-carboximidamide (200 mg, 691 μmol) in tetrahydrofuran (5 mL) was added 3-fluorobenzoyl chloride (131 mg, 829 μmol, 99 μL) and triethylamine (209 mg, 2.07 mmol, 287 μL) at 0 °C. The mixture was warmed and then stirred at 20 °C for 16 h. To the reaction mixture was added ethyl acetate and water and the organic phase was separated. The organic phase was washed with water and saturated aqueous sodium chloride solution, then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. To the obtained residue were added tetrahydrofuran (5 mL) and a solution of tetrabutylammonium fluoride in tetrahydrofuran (1 M, 2.07 mL), then the mixture was warmed at 50 °C for 16 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 50%-80%, 12 min) to give (4-(5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl)piperidin-1-yl)(4-isopropylphenyl)methanone (76 mg, 193.5 μmol, 28 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 7.7 Hz, 1H), 7.78-7.72 (m, 1H), 7.45 (dt, *J* = 5.6, 8.0 Hz, 1H), 7.32-7.27 (m, 2H), 7.26-7.20 (m, 2H), 7.18 (s, 1H), 4.76-3.64 (m, 2H), 3.20-2.97 (m, 3H), 2.86 (td, *J* = 6.9, 13.8 Hz, 1H), 2.18-1.74 (m, 4H), 1.19 (d, *J* = 6.9 Hz, 6H); LCMS (ESI) *m/z*: [M+H]⁺ = 394.2.

Example 53: (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone.




Step 1: Preparation of 4-ethoxy-3-methoxybenzonitrile.




To a stirred solution of 4-hydroxy-3-methoxybenzonitrile (5.0 g, 33.5 mmol) in N,N-dimethylformamide (50 mL) was added iodoethane (6.27 g, 40.2 mmol, 3.22 mL) and potassium carbonate (9.27 g, 67.0 mmol) at 0 °C, then the reaction was warmed and stirred at 40 °C for 16 h. The reaction mixture was quenched by addition of water (50 mL) then the mixture was extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 4-ethoxy-3-methoxybenzonitrile (5.80 g, 32.7 mmol, 98 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.16 (m, 1H), 7.00 (d, *J* = 1.9 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 1H), 4.07 (q, *J* = 6.9 Hz, 2H), 3.82 (s, 3H), 1.45-1.39 (m, 3H).

Step 2: Preparation of (Z)-4-ethoxy-N'-hydroxy-3-methoxybenzimidamide.




To a stirred solution of 4-ethoxy-3-methoxybenzonitrile (5.80 g, 32.7 mmol) in ethanol (50 mL) was added hydroxylamine hydrochloride (4.55 g, 65.5 mmol), triethylamine (6.62 g, 65.46 mmol, 9.07 mL) and water (5 mL). The mixture was heated at 75 °C for 2 h. After cooling to 20 °C, the solvents were evaporated under vacuum, and water (20 mL) was added to the solution. The mixture was extracted with dichloromethane (60 mL x 3). The combined organic extracts were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and then filtered and concentrated in vacuo to give (Z)-4-ethoxy-N'-hydroxy-3-methoxybenzimidamide (5.96 g, 28.4 mmol, 87 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.44 (br. s., 1H), 7.28-7.14 (m, 2H), 6.90 (d, *J* = 8.4 Hz, 1H), 5.73 (s, 2H), 4.00 (q, *J* = 6.9 Hz, 2H), 3.75 (s, 3H), 1.31 (t, *J* = 7.1 Hz, 3H).

Step 3: Preparation of tert-butyl 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate.




To a stirred solution of (Z)-4-ethoxy-N'-hydroxy-3-methoxybenzimidamide (1.0 g, 4.76 mmol) in N,N-dimethylformamide (15 mL) was added 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1.09 g, 4.76 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.81 g, 4.76 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (1.85 g, 14.28 mmol, 2.49 mL). The mixture was stirred at 20 °C for 16 h then heated at 120 °C for 2 h. The reaction mixture was cooled then quenched by addition of water (40 mL), then the mixture was extracted with ethyl acetate (80 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give tert-butyl 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (2.56 g) as a yellow oil. LCMS (ESI) m/z: [M+H]⁺ = 404.3.

Step 4: Preparation of 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole.



To a stirred solution of tert-butyl 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (1.0 g, 2.48 mmol) in methanol (5 mL) was added 4 M methanolic hydrochloric acid (20 mL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced pressure to provide the crude 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (900 mg) as a yellow solid that was used directly without further purification. LCMS (ESI) m/z: [M+H]⁺ = 304.1


Step 5: Preparation of (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone




To a stirred solution of 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (200 mg, 659 μmol) in dichloromethane (3 mL) was added piperidine-1-carbonyl chloride (116 mg, 791 μmol, 98 μL) and triethylamine (200 mg, 1.98 mmol, 274 μL) at 0 °C. The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone (65 mg, 158 μmol, 24 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.71-7.66 (m, 1H), 7.59 (d, J = 1.9 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 3.98 (s, 3H), 3.75 (d, J = 13.6 Hz, 2H), 3.29-3.13 (m, 5H), 3.04-2.94 (m, 2H), 2.17 (dd, J = 3.1, 13.3 Hz,

2H), 2.05-1.93 (m, 2H), 1.60 (d, $J = 8.4$ Hz, 6H), 1.53 (t, $J = 7.0$ Hz, 3H); LCMS (ESI) m/z : $[M+H]^+ = 415.3$.

Example 54: (4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone.




Step 1: Preparation of (4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (100 mg, 346 μmol) in dichloromethane (3 mL) was added piperidine-1-carbonyl chloride (61 mg, 415 μmol , 51 μL) and triethylamine (104 mg, 1.04 mmol, 143 μL) at 0 $^{\circ}\text{C}$. The mixture was stirred at 20 $^{\circ}\text{C}$ for 1 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 12 min) to give (4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone (81 mg, 202 μmol , 58 %) as a white solid. ^1H NMR (400MHz, CDCl_3) δ 7.74-7.68 (m, 1H), 7.59 (d, $J = 1.9$ Hz, 1H), 6.98 (d, $J = 8.4$ Hz, 1H), 3.98 (d, $J = 8.4$ Hz, 6H), 3.76 (d, $J = 13.4$ Hz, 2H), 3.29-3.14 (m, 5H), 3.04-2.95 (m, 2H), 2.17 (dd, $J = 13.3, 3.4$ Hz, 2H), 2.05-1.94 (m, 2H), 1.60 ppm (d, $J = 8.5$ Hz, 6H); LCMS (ESI) m/z : $[M+H]^+ = 401.3$.

Example 55: 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-(isoquinolin-1-ylamino)ethanone.




Step 1: Preparation of 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-(isoquinolin-1-ylamino)ethanone.




5 To a stirred solution of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (150 mg, 433 μ mol) in toluene (2 mL) was added 1-chloroisoquinoline (70 mg, 433 μ mol), cesium carbonate (423 mg, 1.30 mmol), ($\pm$)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene (26 mg, 43 μ mol, 0.10 eq), and palladium(II) acetate (9 mg, 43 μ mol, 0.10 eq) under nitrogen. The mixture was stirred at 100 $^{\circ}$ C for 16 h. The reaction mixture was filtered through diatomaceous earth and the filtrate was
 10 concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Luna C8 100*30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give 1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-(isoquinolin-1-ylamino)ethanone (57 mg, 119 μ mol, 27 %) as a white solid. ^{1} H NMR (400MHz, CDCl_3) δ 8.04-7.96 (m, 2H), 7.75-7.50 (m, 5H), 7.03-6.95 (m, 2H), 6.66 (br. s., 1H), 4.60 (d, J = 13.7 Hz, 1H), 4.45 (br. s., 2H), 4.08 (d, J = 12.5 Hz, 1H), 3.98
 15 (d, J = 7.9 Hz, 6H), 3.46-3.30 (m, 2H), 3.24-3.13 (m, 1H), 2.28 (br. s., 2H), 2.13-1.97 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 474.3.

Example 56: N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)-2-oxoethyl)benzamide.



20

Step 1: Preparation of 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole.




25

To a mixture of N,N-dimethylformamide (1 mL) and phosphoryl chloride (8.25 g, 53.8 mmol, 5 mL) was added 3-(3,4-dimethoxyphenyl)-4H-1,2,4-oxadiazol-5-one (300 mg, 1.35 mmol) at 25 $^{\circ}$ C under calcium chloride tube. The mixture was heated to 100 $^{\circ}$ C and stirred for 16 h. The mixture was cooled to 25 $^{\circ}$ C and concentrated in vacuo carefully. The residue was poured into ice-water (20 mL) and stirred for 10 min. The aqueous phase was extracted with dichloromethane (10 mL x 5). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by chromatography


(petroleum ether / ethyl acetate=5/1 to 1/1) to afford 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole (99 mg, 414 μ mol, 31 %) as a white solid. LCMS (ESI) m/z : 241.1 $[M+H]^+$.

Step 2: Preparation of tert-butyl 4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxylate.




To a stirred solution of 5-chloro-3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazole (90 mg, 374 μ mol) and tert-butyl piperazine-1-carboxylate (83 mg, 448.80 μ mol) in N-methyl-2-pyrrolidone (1.50 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (96 mg, 748 μ mol, 130 μ L). The mixture was stirred at 120 $^{\circ}$ C for 2 h. The mixture was cooled to 25 $^{\circ}$ C and concentrated in vacuo at 40 $^{\circ}$ C. The residue was poured into water (10 mL) then the aqueous phase was extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford tert-butyl 4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperazine-1-carboxylate (900 mg) that was used directly without further purification.

Step 3: Preparation of 3-(3,4-dimethoxyphenyl)-5-(piperazin-1-yl)-1,2,4-oxadiazole.



A solution of tert-butyl 4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperazine-1-carboxylate (146 mg, 374 μ mol) in hydrochloric acid / ethyl acetate (4M, 10 mL) was stirred at 20 $^{\circ}$ C for 2 h. The reaction mixture was concentrated in vacuo to give 3-(3,4-dimethoxyphenyl)-5-piperazin-1-yl-1,2,4-oxadiazole hydrochloride (900 mg) which was used directly without further purification.


Step 4: Preparation of N-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-piperazin-1-yl-1,2,4-oxadiazole hydrochloride (667 mg, 306 μ mol) and 2-benzamidoacetic acid (137 mg, 765 μ mol) in N,N-dimethylformamide (2 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (174 mg, 459 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (118 mg, 918.51 μ mol, 160 μ L) at 20 $^{\circ}$ C. The mixture was stirred at 20 $^{\circ}$ C for 5 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-60%, 12 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl]-2-oxo-ethyl]benzamide (55 mg, 121 μ mol, 39 %) as a yellow solid. ^1H NMR (400MHz, DMSO- d_6) δ = 8.59 (br t, J =5.6 Hz, 1H),

7.93 - 7.83 (m, 2H), 7.60 - 7.44 (m, 4H), 7.39 (d, J=1.9 Hz, 1H), 7.08 (d, J=8.5 Hz, 1H), 4.20 (d, J=5.6 Hz, 2H), 3.81 (d, J=1.1 Hz, 6H), 3.73 - 3.58 (m, 8H); LCMS (ESI) m/z: [M+H]⁺ = 452.2.

Example 57: (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(piperidin-1-yl)methanone.




Step 1: Preparation of tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate.



To a stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1.0 g, 4.36 mmol) in N,N-dimethylformamide (15 mL) was added piperidine (445 mg, 5.23 mmol, 518 μ L), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (1.99 g, 5.23 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (1.69 g, 13.1 mmol, 2.29 mL). The mixture was stirred at 20 °C for 3 h. The reaction mixture was quenched by addition of water (20 mL) then the mixture was extracted with ethyl acetate (40 mL x 4), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate (1.90 g) as a yellow oil. This was used directly without further purification. LCMS (ESI) m/z: [M+H]⁺ = 297.2


Step 2: Preparation of piperidin-1-yl(piperidin-4-yl)methanone.



To a stirred solution of tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate (500 mg, 1.69 mmol) in methanol (5 mL) was added 4N methanolic hydrogen chloride solution (15 mL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced pressure to provide


piperidin-1-yl(piperidin-4-yl)methanone (400 mg) as a colorless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 3.51-3.36 (m, 4H), 3.28-3.18 (m, 2H), 2.90 (s, 4H), 1.82-1.68 (m, 4H), 1.64-1.37 (m, 6H).

Step 3: Preparation of 3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5(4H)-one.




To a stirred solution of 4-ethoxy-N-hydroxy-3-methoxybenzimidamide (800 mg, 3.81 mmol) in dioxane (8 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (638 mg, 4.19 mmol, 631 μL) and 1,1'-carbonyldiimidazole (926 mg, 5.72 mmol). The mixture was stirred at 110 °C for 16 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with dichloromethane (50 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Purification by chromatography (silica, dichloromethane : methanol = 50 : 1) gave 3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5(4H)-one (1.20 g, quant.) as a yellow oil. LCMS (ESI) m/z: [M+H]⁺ = 237.1.

Step 4: Preparation of 5-chloro-3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazole.



To a stirred mixture of 3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5(4H)-one (500 mg, 2.12 mmol) and N,N-dimethylformamide (1 mL) was equipped with calcium chloride tube and phosphoryl chloride (10 mL) was added dropwise. The mixture was heated at 110 °C for 16 h. The reaction mixture was cooled to 20 °C, then poured onto ice water (100 mL), and stirred for 30 min. The mixture was extracted with dichloromethane (20 mL x 5), then the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 5-chloro-3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazole (360 mg, 1.41 mmol, 67 %) as a brown solid. LCMS (ESI) m/z: [M+H]⁺ = 255.1

Step 5: Preparation of (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(piperidin-1-yl)methanone.




To a stirred solution of piperidin-1-yl(piperidin-4-yl)methanone (100 mg, 509 μmol) in N-methyl-2-pyrrolidone (4 mL) was added 5-chloro-3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazole (194 mg, 764 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (131 mg, 1.02 mmol, 177 μL). The mixture was stirred at 120 °C for 16 h. The reaction mixture was purified directly by prep-HPLC (column: Luna C8 100*30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 12 min) to give (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(piperidin-1-yl)methanone (61 mg,


147.6 μmol , 29 %) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.53-7.47 (m, 1H), 7.42 (d, J = 1.9 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 4.24-4.16 (m, 2H), 4.08 (q, J = 6.9 Hz, 2H), 3.87 (s, 3H), 3.50 (br. s., 2H), 3.40 (br. s., 2H), 3.19-3.09 (m, 2H), 2.69 (tt, J = 3.8, 10.7 Hz, 1H), 1.94-1.71 (m, 4H), 1.63-1.48 (m, 6H), 1.42 (t, J = 7.0 Hz, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 415.3$.

5

Example 58: N-(2-(4-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide.




10 **Step 1: N-(2-(4-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide.**



To a stirred solution of 1-(2-(3,4-dimethylbenzamido)acetyl)piperidine-4-carboxylic acid (150 mg, 471 μmol) and N-hydroxy-2-methoxybenzimidamide (78 mg, 471 μmol) in N,N-dimethylformamide (2 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (121 mg, 942 μmol , 164 μL) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (178 mg, 471 μmol) at 15 $^{\circ}\text{C}$. The mixture was stirred for 15 h, then the mixture was heated to 110 $^{\circ}\text{C}$ and stirred for 5 h. The mixture was cooled and then purified by prep-HPLC (column: Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 37%-67%, 12 min) to obtain N-(2-(4-(3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-3,4-dimethylbenzamide (110 mg, 244 μmol , 52 %) as yellow solid. ^1H NMR (400 MHz, Methanol- d_4) δ 7.96 (dd, J =1.5, 7.7 Hz, 1H), 7.66 (s, 1H), 7.60 (d, J =7.9 Hz, 1H), 7.56 - 7.49 (m, 1H), 7.23 (d, J =7.5 Hz, 1H), 7.18 (d, J =8.4 Hz, 1H), 7.09 (t, J =7.5 Hz, 1H), 4.47 (d, J =12.8 Hz, 1H), 4.35 - 4.23 (m, 2H), 4.04 (d, J =13.7 Hz, 1H), 3.92 (s, 3H), 3.49 - 3.35 (m, 2H), 3.07 (t, J =11.0 Hz, 1H), 2.32 (s, 6H), 2.27 - 2.10 (m, 2H), 2.06 - 1.83 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 449.3$.


25

Example 59: N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide, Enantiomer 1 and Example 60: N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide, Enantiomer 2



5

Step 1: Preparation of N-[(R)-2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide and N-[(S)-2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide.



10

To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (150 mg, 518 μmol) and 2-benzamidopropanoic acid (105 mg, 544 μmol) in N,N-dimethylformamide (2 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (196 mg, 518 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (201 mg, 1.56 mmol, 271 μL). The mixture was stirred at 20 $^{\circ}\text{C}$ for 5 h. The crude product was purified by prep-HPLC (column: Luna C18 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 12 min) to give rac-N-(1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-1-oxopropan-2-yl)benzamide then the product purified by SFC separation (column: AD(250x30mm, 5 μm); mobile phase: [Neu-IPA]; B%: 42%-42%, min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide, Enantiomer 1 (63 mg, 134.93 μmol , 26 %) as a white solid and N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide, Enantiomer 2 (56 mg, 120 μmol , 23% as a white solid).

20

N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide, Enantiomer 1:

25


^1H NMR (400MHz, DMSO- d_6) δ = 8.63 (br dd, J =7.3, 16.1 Hz, 1H), 7.88 (br d, J =7.5 Hz, 2H), 7.62 - 7.41 (m, 5H), 7.11 (br d, J =8.2 Hz, 1H), 4.97 (br d, J =6.4 Hz, 1H), 4.43 - 4.24 (m, 1H), 4.10 - 3.95 (m, 1H),

3.82 (s, 6H), 3.42 (br t, $J=10.8$ Hz, 1H), 3.30 - 3.21 (m, 1H), 2.99 - 2.83 (m, 1H), 2.09 (br d, $J=11.9$ Hz, 2H), 1.83 - 1.60 (m, 2H), 1.30 (br s, 3H); LCMS (ESI) m/z : $[M+H]^+ = 465.3$. ee = 100%.


N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]benzamide, Enantiomer 2:

^1H NMR (400MHz, DMSO- d_6) δ = 8.65 (br dd, $J=7.6, 16.1$ Hz, 1H), 7.98 - 7.86 (m, 2H), 7.70 - 7.41 (m, 5H), 7.13 (br d, $J=8.2$ Hz, 1H), 5.00 (br d, $J=5.5$ Hz, 1H), 4.49 - 4.24 (m, 1H), 4.12 - 3.96 (m, 1H), 3.85 (s, 6H), 3.45 (br t, $J=10.7$ Hz, 1H), 3.27 (br s, 1H), 3.05 - 2.83 (m, 1H), 2.12 (br d, $J=12.5$ Hz, 2H), 1.89 - 1.61 (m, 2H), 1.32 (br s, 3H); LCMS (ESI) m/z : $[M+H]^+ = 465.3$. ee = 99.6

Example 61: (2-methyl-4-(2-oxo-4-(4-(3-(*p*-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylum, Enantiomer 1 and Example 62: (2-methyl-4-(2-oxo-4-(4-(3-(*p*-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylum, Enantiomer 2



Step 1: Preparation of (2-methyl-4-(2-oxo-4-(4-(3-(*p*-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylum, Enantiomer 1 and (2-methyl-4-(2-oxo-4-(4-(3-(*p*-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylum, Enantiomer 2



To a stirred solution of N-hydroxy-4-methylbenzimidamide (300 mg, 2.0 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (834 mg, 2.20 mmol) and 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (688 mg, 2.00 mmol) in N,N-dimethylformamide (10 mL) were added N-ethyl-N-(propan-2-yl)propan-2-amine (516 mg, 4.00 mmol, 698 μL) at 0 $^{\circ}\text{C}$. Then the reaction was warmed to 25 $^{\circ}\text{C}$. After 17 h, the reaction was warmed to 90 $^{\circ}\text{C}$. After 3 h, the mixture was cooled, diluted with water (10 mL), and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by prep-HPLC (column: Phenomenex luna(2) C18 250x50 10 μm ; mobile phase: [water (0.1%TFA)-

acetonitrile]; B%: 40%-70%, 20 min) to give the racemic of 1-(3,4-dimethylphenyl)-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one (600 mg, 1.31 mmol, 65 %). This was purified by SFC (column: AS(250x30mm, 5 μ m); mobile phase: [CO₂ base-methanol]; B%: 40%-40%) to give (2-methyl-4-(2-oxo-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylmethylm, Enantiomer 1 (193 mg, 421 μ mol, 21%) as a white solid, and (2-methyl-4-(2-oxo-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylmethylm, Enantiomer 2 (199 mg, 433 μ mol, 22 %) as a white solid.


(2-methyl-4-(2-oxo-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylmethylm, Enantiomer 1:

¹H NMR (400MHz, DMSO-d₆) δ = 7.91 (br d, J=6.9 Hz, 2H), 7.43 (br s, 1H), 7.38 (br d, J=8.0 Hz, 3H), 7.12 (br d, J=6.3 Hz, 1H), 4.35 (br s, 1H), 4.09 - 3.98 (m, 2H), 3.92 (td, J=5.0, 10.0 Hz, 1H), 3.80 - 3.63 (m, 1H), 3.45 (br t, J=10.8 Hz, 1H), 3.36 (br s, 1H), 3.00 - 2.90 (m, 1H), 2.82 - 2.65 (m, 2H), 2.39 (s, 3H), 2.27 - 2.10 (m, 8H), 1.91 - 1.61 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 459.3; ee = 98.6


(2-methyl-4-(2-oxo-4-(4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)methylmethylm, Enantiomer 2:

¹H NMR (400MHz, DMSO-d₆) δ = 7.91 (br d, J=6.9 Hz, 2H), 7.43 (br s, 1H), 7.38 (br d, J=8.0 Hz, 3H), 7.12 (br d, J=6.4 Hz, 1H), 4.35 (br s, 1H), 4.11 - 3.97 (m, 2H), 3.92 (td, J=5.0, 9.9 Hz, 1H), 3.81 - 3.68 (m, 1H), 3.53 - 3.37 (m, 1H), 3.36 (br s, 1H), 3.02 - 2.90 (m, 1H), 2.82 - 2.65 (m, 2H), 2.39 (s, 3H), 2.25 - 2.09 (m, 8H), 1.89 - 1.62 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 459.3; ee = 99%.

Example 63: 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 and Example 64: 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2



Step 1: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 and 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2



To a stirred solution of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (350 mg, 1.02 mmol) and N-hydroxy-4-methoxybenzimidamide (168 mg, 1.02 mmol) in N,N-dimethylformamide (3 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (262 mg, 2.03 mmol, 354 μ L) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (385 mg, 1.02 mmol), then the mixture was stirred for 15 h at 15 $^{\circ}$ C. The mixture was then heated to 110 $^{\circ}$ C and stirred for 5 h. The mixture was cooled and purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 37%-67%, 12 min) to give racemic 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one (0.2 g) as a white solid. This was purified by SFC separation: (column: OJ(250x30mm,10 μ m); mobile phase: [CO₂ base-ethanol]; B%: 45%-45%) to give ((1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 (84 mg, 177 μ mol, 17 %) as a white solid and 1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2 (96 mg, 198 μ mol, 19 %) as a yellow solid

1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1:

¹H NMR (400 MHz, Methanol-d₄) δ 7.98 (dd, J=2.2, 8.8 Hz, 2H), 7.36 (s, 1H), 7.27 (d, J=7.9 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 7.04 (d, J=7.1 Hz, 2H), 4.53 - 4.43 (m, 1H), 4.18 - 3.99 (m, 3H), 3.95 - 3.73 (m, 4H), 3.49 - 3.36 (m, 2H), 3.14 - 3.01 (m, 1H), 2.93 - 2.77 (m, 2H), 2.47 - 2.04 (m, 8H), 2.01 - 1.80 (m, 2H);


LCMS (ESI) m/z: [M+H]⁺ = 475.3; ee = 100 %.

1-(3,4-dimethylphenyl)-4-(4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2:


¹H NMR (400 MHz, Methanol-d₄) δ 7.98 (dd, J=2.4, 9.0 Hz, 2H), 7.36 (s, 1H), 7.27 (d, J=8.4 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 7.04 (d, J=7.1 Hz, 2H), 4.48 (d, J=7.5 Hz, 1H), 4.16 - 4.00 (m, 3H), 3.92 - 3.74 (m, 4H), 3.49 - 3.37 (m, 2H), 3.13 - 3.03 (m, 1H), 2.91 - 2.80 (m, 2H), 2.34 - 2.11 (m, 8H), 1.98 - 1.83 (m, 2H);

LCMS (ESI) m/z: [M+H]⁺ = 475.3; ee = 100 %.

Example 65: (4S)-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one




5 Step 1: (4R)-4-benzyl-3-[(3S)-5-oxo-1-phenylpyrrolidine-3-carbonyl]oxazolidin-2-one



To a stirred solution of 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (20.0 g, 97.5 mmol) in chloroform (100 mL) was added (4R)-4-benzyl-2-oxazolidinone (20.72 g, 117 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (20.74 g, 108.2 mmol) and DMAP (6.43 g, 52.6 mmol) at 0 °C. After addition, the mixture was stirred for 15 min, then warmed and stirred at 20 °C for 18 h. The residue was purified by chromatography (silica, petroleum ether / ethyl acetate=1/1 to 1:9) to give (4R)-4-benzyl-3-[(3S)-5-oxo-1-phenylpyrrolidine-3-carbonyl]oxazolidin-2-one (10.0 g, 27.4 mmol, 28 %) and (4R)-4-benzyl-3-[(3R)-5-oxo-1-phenylpyrrolidine-3-carbonyl]oxazolidin-2-one (10.0 g, 27 mmol, 28 %) each as a white solid. LCMS (ESI) m/z: 365.1 [M+H]⁺.

15

Step 2: (3S)-5-oxo-1-phenylpyrrolidine-3-carboxylic acid




To a stirred solution of lithium hydroxide monohydrate (2.63 g, 62.8 mmol) in water (30 mL) was added dropwise hydrogen peroxide (15.5 g, 456.6 mmol, 13.2 mL) at 0 °C. The mixture was stirred for 30 min. To the mixture was then added tetrahydrofuran (80 mL), water (30 mL) followed by a solution of 3-[(3S)-5-oxo-1-phenylpyrrolidine-3-carbonyl]-4-phenyl-oxazolidin-2-one (10.0 g, 28.5 mmol) in

20


tetrahydrofuran (80 mL) dropwise. The mixture was stirred at 0 °C for 1h, quenched by addition of a sodium sulfate solution in water (10 mL) at 0 °C, and made basic (pH 11) by addition of an aqueous sodium carbonate solution. The mixture was extracted with ethyl acetate (100 mL), acidified to pH 2 using 1M HCl, and extracted again with ethyl acetate (100 mL). The organic layers were washed with a saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give (3S)-5-oxo-1-phenyl-pyrrolidine-3-carboxylic acid (4.80 g, 23.39 mmol, 82 %) as a white solid. ¹H NMR (400MHz, CHLOROFORM-d) δ 7.57 (dd, J=0.9, 8.6 Hz, 2H), 7.40 - 7.34 (m, 2H), 7.20 - 7.15 (m, 1H), 4.18 - 4.13 (m, 1H), 4.10 - 4.04 (m, 1H), 3.45 - 3.35 (m, 1H), 3.03 - 2.86 (m, 2H).

Step 3: methyl 1-[(3S)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylate



A mixture of (3S)-5-oxo-1-phenyl-pyrrolidine-3-carboxylic acid (4.50 g, 21.93 mmol), methyl piperidine-4-carboxylate (3.77 g, 26.32 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (27.91 g, 43.86 mmol, 26.08 mL, 50% purity), triethylamine (44.38 g, 438.60 mmol, 60 mL) in dichloromethane (60 mL) was degassed, purged with nitrogen 3 times, and then the mixture was stirred at 20 °C for 16 h under a nitrogen atmosphere. The reaction mixture was diluted with water (30 mL) and extracted with dichloromethane (50 mL). The organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over Na₂SO₄, filtered, concentrated under reduced pressure and purified by chromatography (silica, petroleum ether / ethyl acetate=1:1) to give methyl 1-[(3S)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylate (4.70 g, 14.2 mmol, 65 %) as a white solid. ¹H NMR (400MHz, CHLOROFORM-d) δ 7.56 (d, J=7.7 Hz, 2H), 7.35 (t, J=7.5 Hz, 2H), 7.16 - 7.11 (m, 1H), 4.47 - 4.34 (m, 1H), 4.24 (dd, J=7.3, 9.5 Hz, 1H), 3.91 - 3.81 (m, 2H), 3.69 (s, 3H), 3.52 (quin, J=8.5 Hz, 1H), 3.24 - 3.12 (m, 1H), 2.98 - 2.87 (m, 2H), 2.80 - 2.73 (m, 1H), 2.64 - 2.52 (m, 1H), 1.97 (br dd, J=4.3, 8.3 Hz, 2H), 1.73 - 1.63 (m, 2H).


Step 4: 1-[(3S)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid.



To a stirred solution of methyl 1-[(3S)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylate (3.00 g, 9.08 mmol) in tetrahydrofuran (60 mL) was added a solution of lithium hydroxide monohydrate (0.5 M, 21.79 mL) in water. The mixture was then stirred at 0 °C for 2 h. The mixture was acidified to pH 4-5 using 1M HCl, and then extracted with dichloromethane (60 mL; 30 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution 40 mL; 20 mL x


2), dried over sodium sulfate, filtered and concentrated under reduced pressure to give 1-[(3S)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (2.70 g, 8.53 mmol, 94 %) as a white solid.

Step 5: (4S)-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one




A mixture of N'-hydroxy-3,4-dimethoxy-benzamidine (1.04 g, 5.32 mmol), 1-[(3S)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (1.40 g, 4.43 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (2.18 g, 5.76 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (1.72 g, 13.29 mmol, 2.32 mL) in N,N-dimethylformamide (8.00 mL), was stirred at 20°C for 15h and at 110°C for 1h. The mixture was cooled to room temperature, concentrated under reduced pressure to give a residue purified by prep-HPLC [column: Phenomenex luna C18 250x50mmx10 μm; mobile phase: water / ammonium carbonate (10mM) / acetonitrile]; B%: 30%-60%, 30 min. The desired compound (4S)-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one was isolated as a light yellow solid (608 mg, 1.28 mmol, 29 %). ¹H NMR (400MHz, CHLOROFORM-d) δ 7.68 (br d, J=8.2 Hz, 1H), 7.61 - 7.53 (m, 3H), 7.40 - 7.33 (m, 2H), 7.18 - 7.12 (m, 1H), 6.95 (d, J=8.4 Hz, 1H), 4.61 - 4.46 (m, 1H), 4.30 (dd, J=7.2, 9.6 Hz, 1H), 4.01 - 3.92 (m, 8H), 3.57 (quin, J=8.4 Hz, 1H), 3.43 - 3.26 (m, 2H), 3.14 - 2.91 (m, 2H), 2.86 - 2.80 (m, 1H), 2.23 (br t, J=13.1 Hz, 2H), 2.02 - 1.93 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 477.3.

Example 66 [(4R)-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one]




Step 1: Preparation of (4R)-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.



To a stirred solution of 1-[(3R)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (115 mg, 363.52 μ mol) and N'-hydroxy-3,4-dimethoxy-benzamidine (71 mg, 363.52 μ mol) in N,N-dimethylformamide (500 μ L) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (137 mg, 363.52 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (93 mg, 727 μ mol, 126 μ L) at 25 °C. The mixture was then stirred at 25 °C for 2 h, and at 110 °C for 2h. The mixture was concentrated under reduced pressure and the resulting crude product was purified by chromatography (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: water / ammonium carbonate (10mM) / acetonitrile; B%: 25%-60%, 12 min to give (4R)-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one (32 mg, 67.45 μ mol, 19 %) as a yellow solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.68 (br d, J =8.2 Hz, 1H), 7.61 - 7.55 (t, 3H), 7.37 (t, J =7.8 Hz, 2H), 7.19 - 7.14 (t, 1H), 6.95 (d, J =8.4 Hz, 1H), 4.60 - 4.46 (m, 1H), 4.31 (dd, J =7.2, 9.6 Hz, 1H), 3.98 - 3.94 (m, 7H), 3.98 - 3.92 (m, 1H), 3.58 (quin, J =8.5 Hz, 1H), 3.43 - 3.26 (m, 2H), 3.16 - 2.91 (m, 2H), 2.88 - 2.79 (m, 1H), 2.24 (br t, J =13.3 Hz, 2H), 2.06 - 1.88 (m, 2H); LCMS (ESI) m/z : [M+H]⁺ = 477.3.


Examples 67: 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-(3,4-dimethylphenyl)pyrrolidin-2-one, Enantiomer 1 and Example 68: 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-(3,4-dimethylphenyl)pyrrolidin-2-one, Enantiomer 2.
Step 1: Preparation of 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-(3,4-dimethylphenyl)pyrrolidin-2-one




To a stirred solution of 1-[1-(3,4-dimethylphenyl)-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (351 mg, 1.02 mmol) in N,N-dimethylformamide (1.50 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (386 mg, 1.02 mmol), N-ethyl-N-(propan-2-yl)propan-2-amine (395 mg, 3.06 mmol, 534 μ L) and N-hydroxy-3,4-dimethoxy-benzamidine (200 mg, 1.02 mmol). The mixture was stirred at 20 °C for 12 h. The reaction mixture was then diluted with water (5mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. N,N-dimethylformamide (2 mL) was added to the residue and the resulting mixture was heated at 120 °C for 5 h. The mixture was cooled to 25 °C, diluted by addition of water (5mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue that was purified by prep-HPLC (column: Waters Xbridge 150x25 μ m; mobile phase: water / ammonium carbonate (10mM) / acetonitrile; B%: 33%-63%, 12 min) to give racemic 4-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-(3,4-dimethylphenyl)pyrrolidin-2-one. This was separated by chiral-SFC (column: AS(250x30mm, 10 μ m); mobile phase: [CO₂ base-methanol]; B%: 40%-40%, min) to give firstly 4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-(3,4-dimethylphenyl)pyrrolidin-2-one, Enantiomer 1 (51 mg, 102 μ mol, 10 %) as a white solid. ¹H NMR (400MHz, DMSO-d₆) δ = 7.61 (br d, J =8.4 Hz, 1H), 7.48 (s, 1H), 7.43 (br s, 1H), 7.38 (br d, J =7.5 Hz, 1H), 7.16 - 7.10 (m, 2H), 4.37 (br s,

1H), 4.08 - 3.99 (m, 2H), 3.96 - 3.88 (m, 1H), 3.85 (s, 6H), 3.79 - 3.67 (m, 1H), 3.45 (br t, J=10.8 Hz, 1H), 3.32 - 3.28 (m, 1H), 3.02 - 2.87 (m, 1H), 2.82 - 2.70 (m, 2H), 2.24 - 2.18 (m, 6H), 2.18 - 2.10 (m, 2H), 1.91 - 1.61 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 505.4 and secondly 4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-(3,4-dimethylphenyl)pyrrolidin-2-one, Enantiomer 2 (48 mg, 95 μmol, 9 %) also as a white solid. ¹H NMR (400MHz, DMSO-d₆) δ = 7.61 (br d, J=8.4 Hz, 1H), 7.48 (s, 1H), 7.43 (br s, 1H), 7.41 - 7.35 (m, 1H), 7.17 - 7.10 (m, 2H), 4.37 (br s, 1H), 4.09 - 3.99 (m, 2H), 3.98 - 3.89 (m, 1H), 3.85 (s, 6H), 3.78 - 3.68 (m, 1H), 3.50 - 3.39 (m, 1H), 3.35 (br s, 1H), 3.00 - 2.88 (m, 1H), 2.81 - 2.70 (m, 2H), 2.26 - 2.19 (m, 6H), 2.17 - 2.09 (m, 2H), 1.88 - 1.63 (m, 2H); LCMS (ESI) m/z: [M+H]⁺ = 505.4

Example 69 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 and Example 70 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2




Step 1: Preparation of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid



To a stirred solution of methyl 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylate (470 mg, 1.31 mmol) in tetrahydrofuran (5 mL) was added sodium hydroxide (2 M, 1.31 mL). The mixture was stirred at 20 °C for 16 h. The mixture was acidified with concentrated hydrochloric acid until pH = 1. The mixture was extracted with dichloromethane (20 mL x 4). The organic layers were combined and washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (300 mg) as a brown solid. LCMS (ESI) m/z: [M+H]⁺ = 345.2.

Step 2: Preparation of 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 and 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2



5

To a stirred solution of 1-(1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (300 mg, 871 μmol) in N,N-dimethylformamide (4 mL) was added N-hydroxy-3-methoxybenzamidinium (173 mg, 1.05 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (330 mg, 871 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (337 mg, 2.61 mmol, 456 μL). The mixture was stirred at 20 °C for 2 h and then at 120 °C for 2 h. The reaction mixture was cooled, concentrated under reduced pressure and purified directly by preparative HPLC (column: Luna C8 100*30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-65%, 12 min) to give (rac)- 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl) pyrrolidin-2-one that was purified by chiral-SFC (column: AD(250mm*30mm,5mm); mobile phase: [Base-isopropanol]; B%: 42%-42%,min) to give firstly 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl) pyrrolidin-2-one, Enantiomer 1 (75 mg, 158.7 μmol , 18 %, ee 100 %) as a white solid, then 1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2 (75 mg, 160 μmol , 18 %, ee 99.7 %) as a yellow solid.

20

1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl) pyrrolidin-2-one, Enantiomer 1.

^1H NMR (400 MHz, CDCl_3) δ 7.63-7.57 (m, 1H), 7.55-7.50 (m, 1H), 7.31 (d, J = 12.3 Hz, 2H), 7.22-7.19 (m, 1H), 7.05 (d, J = 8.2 Hz, 1H), 7.00 (d, J = 1.8 Hz, 1H), 4.53-4.37 (m, 1H), 4.21 (dd, J = 7.3, 9.6 Hz, 1H), 3.95-3.77 (m, 5H), 3.49 (td, J = 8.6, 16.9 Hz, 1H), 3.36-3.20 (m, 2H), 3.12-2.96 (m, 1H), 2.89 (td, J = 8.3, 16.9 Hz, 1H), 2.79-2.70 (m, 1H), 2.18 (d, J = 13.1 Hz, 8H), 1.99-1.83 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 475.1$.

25

1-(3,4-dimethylphenyl)-4-(4-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2.

^1H NMR (400 MHz, CDCl_3) δ 7.63-7.57 (m, 1H), 7.53 (s, 1H), 7.36-7.27 (m, 2H), 7.21 (d, J = 2.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 7.00 (d, J = 2.0 Hz, 1H), 4.53-4.37 (m, 1H), 4.21 (dd, J = 7.3, 9.5 Hz, 1H), 3.96-3.77 (m, 5H), 3.55-3.44 (m, 1H), 3.37-3.19 (m, 2H), 3.12-2.82 (m, 2H), 2.76 (d, J = 9.4 Hz, 1H), 2.18 (d, J = 13.1 Hz, 8H), 1.92 (br. s., 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 475.1$.

35

Example 71 (1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one), Enantiomer 1 and Example 72 (1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one), Enantiomer 2

Racemic 1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one (80 mg) was purified by SFC separation (column: AD (250x30mm,5μm); mobile phase: [CO₂ base-isopropanol]; B%: 50%-50%,min) to give firstly 1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 (26 mg, 59 μmol, 7 %) as a white solid and secondly 1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2 as a white solid (23 mg, 52 μmol, 6 %).

1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1.

¹H NMR (400 MHz, CDCl₃) δ 8.06-8.00 (m, 2H), 7.41-7.33 (m, 3H), 7.32-7.29 (m, 1H), 7.15 (d, *J* = 8.3 Hz, 1H), 4.66-4.54 (m, 1H), 4.30 (dd, *J* = 7.4, 9.5 Hz, 1H), 4.05-3.88 (m, 2H), 3.65-3.55 (m, 1H), 3.43-3.30 (m, 1H), 3.20 (d, *J* = 3.4 Hz, 1H), 3.12-2.94 (m, 2H), 2.85 (d, *J* = 9.7 Hz, 1H), 2.47 (s, 3H), 2.32-2.14 (m, 8H), 1.94 (br. s., 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.3.

1-(3,4-dimethylphenyl)-4-(4-(5-(p-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2.

¹H NMR (400 MHz, CDCl₃) δ 7.96-7.90 (m, 2H), 7.32-7.24 (m, 3H), 7.22-7.19 (m, 1H), 7.05 (d, *J* = 8.2 Hz, 1H), 4.58-4.43 (m, 1H), 4.20 (s, 1H), 3.94-3.79 (m, 2H), 3.50 (quin, *J* = 8.5 Hz, 1H), 3.28 (br. s., 1H), 3.10 (d, *J* = 3.9 Hz, 1H), 3.02-2.84 (m, 2H), 2.78-2.68 (m, 1H), 2.38 (s, 3H), 2.23-2.03 (m, 8H), 1.83 (d, *J* = 10.8 Hz, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.3.

Examples 73 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 and Example 74 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2

Racemic 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one (120 mg) was purified by SFC separation (column: OJ(250mmX30mm,5mm); mobile phase: [CO₂ base-ethanol]; B%: 30%-30%,min) to give firstly 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1 (39 mg, 86.7 μmol, 11 %) as a pink solid and secondly 1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2 (36 mg, 77.9 μmol, 10 %) as a pink solid.


1-(3,4-dimethylphenyl)-4-(4-(5-(m-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 1:

¹H NMR (400 MHz, CDCl₃) δ 7.94 (br. s., 2H), 7.39 (d, *J* = 15.0 Hz, 3H), 7.29 (br. s., 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 4.58 (t, *J* = 13.9 Hz, 1H), 4.28 (t, *J* = 8.6 Hz, 1H), 4.01-3.87 (m, 2H), 3.62-3.53 (m, 1H), 3.35 (br. s., 1H), 3.19 (br. s., 1H), 3.08-2.93 (m, 2H), 2.86-2.76 (m, 1H), 2.45 (s, 3H), 2.32-2.11 (m, 8H), 1.90 (d, *J* = 13.7 Hz, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.3.


1-(3,4-dimethylphenyl)-4-(4-(5-(*m*-tolyl)-1,2,4-oxadiazol-3-yl)piperidine-1-carbonyl)pyrrolidin-2-one, Enantiomer 2:

¹H NMR (400 MHz, Methanol-d₄) δ 8.00-7.90 (m, 2H), 7.53-7.45 (m, 2H), 7.41-7.37 (m, 1H), 7.32-7.27 (m, 1H), 7.19-7.13 (m, 1H), 4.53 (dd, *J*=3.5, 13.2 Hz, 1H), 4.19-4.03 (m, 3H), 3.90-3.80 (m, 1H), 3.49-3.39 (m, 1H), 3.30-3.20 (m, 1H), 3.12-3.00 (m, 1H), 2.94-2.82 (m, 2H), 2.47 (s, 3H), 2.35-2.11 (m, 8H), 1.99-1.77 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 459.3.

Example 75: (2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone).




Step 1: Preparation of tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate.



To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (2.0 g, 6.91 mmol) in N,N-dimethylformamide (20 mL) was added 2-(tert-butoxycarbonylamino)acetic acid (1.21 g, 6.91 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (2.62 g, 6.91 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (2.68 g, 20.7 mmol, 3.62 mL). The mixture was stirred at 15 °C for 2 h. The reaction mixture was quenched by addition of water (20 mL) then the mixture was extracted with ethyl acetate (60 mL x 4). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude material that was purified by chromatography (silica, petroleum ether : ethyl acetate = 5:1 to 1:1) to give tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (2.60 g, 5.82 mmol, 84 %) as a brown solid. LCMS (ESI) *m/z*: [M+H]⁺ = 447.2.


Step 2: Preparation of 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone




To a stirred solution of tert-butyl (2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (2.50 g, 5.60 mmol) in methanol (10 mL) was added methanolic hydrogen chloride solution (30 mL). The mixture was stirred at 20 °C for 1 h and then concentrated to give 2-amino-

1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (1.90 g, 5.49 mmol, 97.95 %), isolated as a brown solid and used for the next step without further purification. A small amount (0.1g) of the crude product was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give a pure sample for analysis: 2-amino-1-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone (32 mg). ¹H NMR (400 MHz, CDCl₃) δ 7.73-7.67 (m, 1H), 7.58 (d, J = 1.5 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.54 (d, J = 12.2 Hz, 1H), 3.98 (d, J = 7.2 Hz, 6H), 3.84 (d, J = 12.0 Hz, 1H), 3.54 (s, 2H), 3.34-3.21 (m, 2H), 3.08 (d, J = 12.3 Hz, 1H), 2.21 (d, J = 13.1 Hz, 2H), 1.98 (d, J = 9.4 Hz, 2H); LCMS (ESI) m/z: [M+H]⁺ = 347.1.

Example 76: (5-hydroxy-2,2-dimethyl-7-(2-oxo-2-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethoxy)chroman-4-one).




Step 1: Preparation of tert-butyl 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate




To a stirred solution of (Z)-N'-hydroxybenzimidamide (214 mg, 1.57 mmol) in N,N-dimethylformamide (5 mL) was added 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (300 mg, 1.31 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (496 mg, 1.31 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (507 mg, 3.93 mmol, 686 μ L). The mixture was stirred at 20 °C for 2 h, and then heated at 120 °C for 2 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude product was extracted with petroleum ether (30 mL x 2). The combined organic extracts were concentrated under reduced pressure to give tert-butyl 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (310 mg, 941 μ mol, 72 %) as a yellow oil. This product was used in the next step without further purification.

Step 2: Preparation of 3-phenyl-5-(piperidin-4-yl)-1,2,4-oxadiazole




To a stirred solution of tert-butyl 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (310 mg, 941 μ mol) in ethyl acetate (2 mL) was added an anhydrous solution of hydrochloric acid in ethyl acetate (20 mL). The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to provide the crude 3-phenyl-5-(piperidin-4-yl)-1,2,4-oxadiazole (233 mg) as a yellow solid that was used for the next step without further purification. LCMS (ESI) m/z : $[M+H]^+ = 230.2$.

Step 3: Preparation of 5-hydroxy-2,2-dimethyl-7-(2-oxo-2-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethoxy)choman-4-one




To a stirred solution of 2-((5-hydroxy-2,2-dimethyl-4-oxochoman-7-yl)oxy)acetic acid (150 mg, 563 μ mol) in N,N-dimethylformamide (2 mL) was added 3-phenyl-5-(piperidin-4-yl)-1,2,4-oxadiazole (142 mg, 620 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (213 mg, 563 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (291 mg, 2.25 mmol, 393 μ L). The mixture was stirred at 20 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the resulting residue purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-75%, 12 min) to give 5-hydroxy-2,2-dimethyl-7-(2-oxo-2-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethoxy)choman-4-one (120 mg, 250.6 μ mol, 44 %) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 12.00 (s, 1H), 8.12 - 8.07 (m, 2H), 7.56 - 7.48 (m, 3H), 6.07 (d, $J=2.4$ Hz, 1H), 6.04 (d, $J=2.3$ Hz, 1H), 4.74 (s, 2H), 4.46 (d, $J=13.8$ Hz, 1H), 3.98 (d, $J=13.1$ Hz, 1H), 3.42 - 3.28 (m, 2H), 3.13 (t, $J=11.1$ Hz, 1H), 2.71 (s, 2H), 2.23 (br. s., 2H), 2.07 - 1.92 (m, 2H), 1.49 - 1.46 (m, 6H); LCMS (ESI) m/z : $[M+H]^+ = 478.2$.

Example 77 (7-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethoxy)-5-hydroxy-2,2-dimethylchoman-4-one).




Step 1: Preparation of 7-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethoxy)-5-hydroxy-2,2-dimethylchoman-4-one.




To a stirred solution of 2-((5-hydroxy-2,2-dimethyl-4-oxochroman-7-yl)oxy)acetic acid (150 mg, 563 μmol) in N,N-dimethylformamide (2 mL) was added 3-(3,4-dimethoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (195 mg, 676 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (213 mg, 563 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (291 mg, 2.25 mmol, 393 μL). The mixture was stirred at 20 $^{\circ}\text{C}$ for 2 h. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give 7-(2-(4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethoxy)-5-hydroxy-2,2-dimethylchoman-4-one (133 mg, 245.66 μmol , 44 %) as a white solid. ^1H NMR (400MHz, CDCl_3) δ 12.00 (s, 1H), 7.71 (dd, $J=1.9, 8.3$ Hz, 1H), 7.58 (d, $J=1.9$ Hz, 1H), 6.98 (d, $J=8.4$ Hz, 1H), 6.06 (d, $J=2.4$ Hz, 1H), 6.03 (d, $J=2.4$ Hz, 1H), 4.74 (s, 2H), 4.47 (d, $J=14.2$ Hz, 1H), 4.01 - 3.94 (m, 7H), 3.41 - 3.26 (m, 2H), 3.11 (t, $J=11.0$ Hz, 1H), 2.71 (s, 2H), 2.22 (br. s., 2H), 2.06 - 1.93 (m, 2H), 1.47 (s, 6H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 538.3$.

Example 78: (N-(2-oxo-2-(4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide.




Step 1: Preparation of (Z)-N'-hydroxypicolinimidamide.




To a stirred solution of picolinonitrile (3.0 g, 28.8 mmol, 2.78 mL) in ethanol (30 mL) was added hydroxylamine hydrochloride (4.01 g, 57.6 mmol), triethylamine (5.83 g, 57.6 mmol, 8.0 mL) and water (5 mL). The mixture was heated at 75 $^{\circ}\text{C}$ for 5 h. The mixture was then concentrated to give a residue. The solid residue was triturated with water (30 mL), filtered, and dried under reduced pressure to give (Z)-N'-hydroxypicolinimidamide (2.0 g, 14.6 mmol, 51 %) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.93 (s, 1H), 8.57 (d, $J=4.5$ Hz, 1H), 7.92 - 7.75 (m, 2H), 7.47 - 7.35 (m, 1H), 5.85 (br. s., 2H).

Step 2: Preparation of N-(2-oxo-2-(4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxypicolinimidamide (56 mg, 413 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μ L) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol). The mixture was stirred at 20 $^{\circ}$ C for 2 h, then heated at 120 $^{\circ}$ C for 2 h. The reaction mixture was cooled, concentrated under reduced pressure and the resulting residue was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-55%, 12 min) to give N-(2-oxo-2-(4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide (75 mg, 192 μ mol, 47 %) as a yellow solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.84 (td, J =0.8, 4.0 Hz, 1H), 8.18 - 8.12 (m, 1H), 7.93 - 7.84 (m, 3H), 7.58 - 7.43 (m, 4H), 7.35 (br. s., 1H), 4.53 (d, J =13.6 Hz, 1H), 4.32 (t, J =3.5 Hz, 2H), 3.93 (d, J =14.1 Hz, 1H), 3.45 - 3.31 (m, 2H), 3.21 - 3.10 (m, 1H), 2.37 - 2.24 (m, 2H), 2.15 - 1.98 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 392.2$.

Example 79: N-(2-oxo-2-(4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide




Step 1: Preparation of (Z)-N'-hydroxyquinoline-2-carboximidamide.



To a stirred solution of quinoline-2-carbonitrile (900 mg, 5.84 mmol) in ethanol (10 mL) was added hydroxylamine hydrochloride (811 mg, 11.7 mmol), triethylamine (1.18 g, 11.7 mmol, 1.6 mL) and water (1 mL). The mixture was heated at 75 $^{\circ}$ C for 5 h. The reaction mixture was cooled and filtered, and the filter cake dried in vacuo to give (Z)-N'-hydroxyquinoline-2-carboximidamide (1.0 g, 5.34 mmol, 91 %) as a light yellow solid. This was used directly without further purification. ^{1} H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.23 (s, 1H), 8.34 (d, J =8.7 Hz, 1H), 8.10 - 7.93 (m, 3H), 7.80 (s, 1H), 7.67 - 7.59 (m, 1H), 6.02 (br. s., 2H).


Step 2: Preparation of N-(2-oxo-2-(4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxyquinoline-2-carboximidamide (77 mg, 413 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μ L) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol). The mixture was stirred at 20

°C for 2 h firstly, then heated at 120 °C for 2 h. The reaction mixture was cooled and purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%:30%-60%,12 min) to give N-(2-oxo-2-(4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethyl)benzamide (66 mg, 150 µmol, 36 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (dd, *J*=2.1, 8.5 Hz, 2H), 8.14 (d, *J*=8.5 Hz, 1H), 7.86 - 7.77 (m, 3H), 7.72 (dt, *J*=1.3, 7.7 Hz, 1H), 7.61 - 7.53 (m, 1H), 7.49 - 7.34 (m, 3H), 7.27 (br. s., 1H), 4.50 (d, *J*=13.8 Hz, 1H), 4.24 (d, *J*=3.6 Hz, 2H), 3.87 (d, *J*=13.8 Hz, 1H), 3.42 - 3.22 (m, 2H), 3.09 - 2.98 (m, 1H), 2.31 - 2.16 (m, 2H), 2.10 - 1.91 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 442.2.

Example 80: 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide




Step 1: (2-isocyanatocyclopropyl)benzene.



To a stirred solution of 2-phenylcyclopropanecarboxylic acid (1.0 g, 6.17 mmol) in toluene (10 mL) was added diphenylphosphoryl azide (2.04 g, 7.40 mmol, 1.60 mL) and triethylamine (935 mg, 9.25 mmol, 1.28 mL) under nitrogen. The mixture was stirred at 120 °C for 2 h. The reaction mixture was cooled then concentrated in vacuo to give (2-isocyanatocyclopropyl)benzene (2.0 g) as a yellow oil that was used directly without purification.


Step 2: Preparation of methyl 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylate.



To a stirred solution of methyl piperidine-4-carboxylate (800 mg, 5.59 mmol) in toluene (10 mL) was added (2-isocyanatocyclopropyl)benzene (2.0 g, 12.58 mmol, 2.25 eq) and N-ethyl-N-(propan-2-yl)propan-2-amine (722 mg, 5.59 mmol, 975 µL). After 16 h, the reaction mixture was quenched with water (10 mL). The mixture was extracted with ethyl acetate (50 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous


sodium sulfate, filtered and concentrated to a residue which was purified by chromatography (silica, petroleum ether : ethyl acetate = 50 : 1 to 2 : 1) to give methyl 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylate (820 mg, 2.71 mmol, 48 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.22 - 7.19 (m, 1H), 7.17 (s, 1H), 7.10 (d, *J*=7.4 Hz, 3H), 4.75 (br. s., 1H), 3.79 (d, *J*=13.3 Hz, 2H), 3.63 (s, 3H), 2.89 - 2.73 (m, 3H), 2.47 - 2.33 (m, 1H), 2.02 - 1.78 (m, 3H), 1.61 (dd, *J*=2.1, 13.1 Hz, 2H), 1.16 - 1.11 (m, 1H), 1.08 - 1.03 (m, 1H).

Step 3: Preparation of 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylic acid.




To a stirred solution of methyl 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylate (770 mg, 2.55 mmol) in tetrahydrofuran (10 mL) was added lithium hydroxide (1 M, 5.10 mL). After 2 h, the reaction was acidified with 1 M hydrochloric acid (8 mL). The mixture was extracted with dichloromethane (40 mL x 3). The organic phases were combined and washed with saturated aqueous sodium chloride solution (10 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated to give 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylic acid (660 mg, 2.29 mmol, 90 %) as a yellow solid that was used directly without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.22 (s, 1H), 7.33 - 7.01 (m, 5H), 6.78 (d, *J*=2.5 Hz, 1H), 3.85 (d, *J*=13.3 Hz, 2H), 2.81 - 2.66 (m, 3H), 2.40 (br. s., 1H), 1.95 - 1.69 (m, 3H), 1.39 (d, *J*=12.0 Hz, 2H), 1.21 - 1.13 (m, 1H), 1.10 - 1.04 (m, 1H).

Step 4: Preparation of 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide.




To a stirred solution of 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylic acid (100 mg, 347 μmol) in *N,N*-dimethylformamide (2 mL) was added (*Z*)-4-ethoxy-*N'*-hydroxy-3-methoxybenzimidamide (72 mg, 347 μmol), (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (131 mg, 347 μmol) and *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (134 mg, 1.04 mmol, 181 μL). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40 %-75 %, 12 min) to give 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-*N*-(2-phenylcyclopropyl)piperidine-1-carboxamide (81 mg, 173 μmol, 50 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.70 - 7.66 (m, 1H), 7.58 (d, *J*=1.9 Hz, 1H), 7.31 (s, 1H), 7.27 (s, 1H), 7.23 - 7.17 (m, 3H), 6.97 (d, *J*=8.5 Hz, 1H), 4.91 (s, 1H), 4.19 (q, *J*=7.0 Hz, 2H), 3.98 (s, 5H), 3.25 - 3.16 (m, 1H), 3.13 - 3.03 (m, 2H), 2.91 - 2.85 (m, 1H), 2.18 (dd, *J*=3.5, 13.4 Hz, 2H), 2.07 (ddd, *J*=3.3, 6.2, 9.5 Hz, 1H), 2.03 - 1.91 (m, 2H), 1.53 (t, *J*=7.0 Hz, 3H), 1.28 - 1.22 (m, 1H), 1.17 (td, *J*=5.0, 9.7 Hz, 1H); LCMS (ESI) *m/z*: [*M*+*H*]⁺ = 463.2.

Example 81: N-(2-phenylcyclopropyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide.


5

Step 1: Preparation of N-(2-phenylcyclopropyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide.




To a stirred solution of 1-((2-phenylcyclopropyl)carbamoyl)piperidine-4-carboxylic acid (130 mg, 451 μ mol) in N,N-dimethylformamide (1 mL) was added (Z)-N'-hydroxypicolinimidamide (74 mg, 541 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (170 mg, 451 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (174 mg, 1.35 mmol, 236 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h, then heated at 110 $^{\circ}$ C for 2 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-(2-phenylcyclopropyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide (47 mg, 121.6 μ mol, 27 %) as a yellow solid. ^{1} H NMR (400MHz, DMSO- d_6) δ 8.76 (d, J =4.0 Hz, 1H), 8.12 - 7.97 (m, 2H), 7.65 - 7.55 (m, 1H), 7.30 - 7.19 (m, 2H), 7.18 - 7.05 (m, 3H), 6.87 (br. s., 1H), 3.96 (d, J =13.2 Hz, 2H), 2.93 (t, J =11.7 Hz, 2H), 2.71 (d, J =3.1 Hz, 1H), 2.06 (d, J =11.5 Hz, 2H), 1.89 (br. s., 1H), 1.68 (d, J =11.9 Hz, 3H), 1.20 - 1.04 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 390.1.

20


Example 82: N-(2-phenylcyclopropyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide

Step 1: Preparation of N-(2-phenylcyclopropyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide.




To a stirred solution of 1-[(2-phenylcyclopropyl)carbamoyl]piperidine-4-carboxylic acid (130 mg, 451 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxyquinoline-2-carboximidamide (101 mg, 541 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (170 mg, 451 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (174 mg, 1.35 mmol, 236 μ L). The mixture was stirred at 20 °C for 2 h, and then heated at 120 °C for 2 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give N-(2-phenylcyclopropyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide (34 mg, 77 μ mol, 17 %) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 8.60 (s, 1H), 8.22 - 8.07 (m, 3H), 7.88 (br. s., 1H), 7.74 (d, *J*=7.5 Hz, 1H), 7.30 - 7.20 (m, 2H), 7.18 - 7.06 (m, 3H), 6.89 (br. s., 1H), 3.99 (d, *J*=13.7 Hz, 2H), 3.45 - 3.37 (m, 1H), 2.94 (t, *J*=11.7 Hz, 2H), 2.72 (d, *J*=3.5 Hz, 1H), 2.10 (d, *J*=11.0 Hz, 2H), 1.89 (br. s., 1H), 1.72 (d, *J*=11.5 Hz, 2H), 1.18 (td, *J*=4.6, 9.3 Hz, 1H), 1.11 - 1.05 (m, 1H); LCMS (ESI) *m/z*: [M+H]⁺ = 440.1.

Example 83: 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-phenethylpiperidine-1-carboxamide.




Step 1: Preparation of 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-phenethylpiperidine-1-carboxamide.




To a stirred solution of (2-isocyanatoethyl)benzene (72 mg, 494 μ mol, 68 μ L) in toluene (2 mL) was added 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (150 mg, 494 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (63 mg, 494 μ mol, 86 μ L). Then mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-60%, 12 min) to give 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-phenethylpiperidine-1-carboxamide (58 mg, 130 μ mol, 26 %) as a white solid. ¹H NMR (400MHz, CDCl₃) δ 7.59 (dd, *J*=2.0, 8.4 Hz, 1H), 7.49 (d, *J*=1.9 Hz, 1H), 7.28 - 7.22 (m, 2H), 7.18 - 7.12 (m, 3H), 6.87 (d, *J*=8.4 Hz, 1H), 4.40 (br. s., 1H), 4.10 (q, *J*=7.0 Hz, 2H), 3.88 (s, 3H), 3.86 - 3.80 (m, 2H), 3.48 - 3.41 (m, 2H), 3.14 - 3.05 (m, 1H), 2.97 - 2.88 (m, 2H), 2.78 (t, *J*=6.8 Hz, 2H), 2.04 (dd, *J*=3.2, 13.1 Hz, 2H), 1.89 - 1.77 (m, 2H), 1.43 (t, *J*=7.0 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 451.3.

Example 84: 4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, **Example 85:** (R)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, and **Example 86:** (S)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.



Step 1: Preparation of 4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, (S)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, and (R)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one



To a stirred solution of 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (200 mg, 975 μ mol) in N,N-dimethylformamide (4 mL) was added 3-(4-ethoxy-3-methoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (295 mg, 975 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (369 mg, 975 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (377 mg, 2.92 mmol, 510 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give racemic 4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (151 mg, 31 %). A portion of this racemic mixture (140 mg) underwent SFC separation (column: OJ(250x30mm, 5 μ m); mobile phase: [CO₂ base-isopropanol]; B%: 45%-45%, min]) to give (R)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (64 mg, 132 μ mol, 14 %, 99.7% purity) as a white solid then (S)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (65 mg, 133.9 μ mol, 14 %, 99.58% purity) also as a white solid.

4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one:
¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (d, *J*=8.0 Hz, 2H), 7.62 - 7.56 (m, 1H), 7.48 (s, 1H), 7.39 (t, *J*=6.7 Hz, 2H), 7.19 - 7.09 (m, 2H), 4.38 (d, *J*=13.8 Hz, 1H), 4.14 - 3.93 (m, 5H), 3.85 (s, 3H), 3.80 - 3.71 (m,

1H), 3.51 - 3.40 (m, 1H), 3.30 (br. s., 1H), 3.00 - 2.89 (m, 1H), 2.83 - 2.73 (m, 2H), 2.22 - 2.09 (m, 2H), 1.90 - 1.64 (m, 2H), 1.37 (t, $J=7.0$ Hz, 3H); LCMS (ESI) m/z : $[M+H]^+ = 491.2$.


(R)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one:

^1H NMR (400 MHz, DMSO- d_6) δ 7.68 (d, $J=7.9$ Hz, 2H), 7.62 - 7.56 (m, 1H), 7.51 - 7.46 (m, 1H), 7.39 (t, $J=6.7$ Hz, 2H), 7.19 - 7.09 (m, 2H), 4.38 (d, $J=13.4$ Hz, 1H), 4.13 - 3.95 (m, 5H), 3.85 (s, 3H), 3.80 - 3.71 (m, 1H), 3.44 (d, $J=10.0$ Hz, 2H), 2.94 (br. s., 1H), 2.81 - 2.74 (m, 2H), 2.16 (t, $J=13.6$ Hz, 2H), 1.91 - 1.64 (m, 2H), 1.37 (t, $J=6.9$ Hz, 3H); LCMS (ESI) m/z : $[M+H]^+ = 491.1$.


(S)-4-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.

^1H NMR (400 MHz, DMSO- d_6) δ 7.66 (d, $J=6.6$ Hz, 2H), 7.57 (d, $J=8.4$ Hz, 1H), 7.46 (s, 1H), 7.41 - 7.33 (m, 2H), 7.17 - 7.07 (m, 2H), 4.37 (d, $J=12.8$ Hz, 1H), 4.12 - 3.92 (m, 5H), 3.83 (s, 3H), 3.78 - 3.69 (m, 1H), 3.43 (t, $J=10.6$ Hz, 1H), 3.28 (br. s., 1H), 2.92 (t, $J=13.0$ Hz, 1H), 2.81 - 2.70 (m, 2H), 2.14 (t, $J=13.5$ Hz, 2H), 1.88 - 1.78 (m, 1H), 1.74 - 1.64 (m, 1H), 1.35 (t, $J=7.1$ Hz, 3H); LCMS (ESI) m/z : $C_{27}H_{30}N_4O_5$ $[M+H]^+ = 491.1$

Alternatively, Example 85: (4R)-4-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one can be prepared in an enantioselective fashion as follows:



Step 1: Preparation of (4R)-4-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.




To a stirred solution of 1-[(3R)-5-oxo-1-phenyl-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (100 mg, 316 μmol) and 4-ethoxy-N'-hydroxy-3-methoxy-benzamidine (66 mg, 316 μmol) in DMF (1.50 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (119 mg, 316 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (81 mg, 632 μmol , 110 μL) at 25 °C. After 12h, the mixture was heated and stirred at 110 °C for 1 h. The mixture was cooled then purified by prep_HPLC (Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-65%, 12 min) to give (4R)-4-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one (59 mg, 122 μmol , 39 %) as a pink solid. ^1H NMR (400MHz, CHLOROFORM- d) δ = 7.66 (br d, $J=8.2$ Hz, 1H), 7.61 - 7.54 (m, 3H), 7.37 (m, $J=7.9$ Hz, 2H), 7.19 - 7.14


(m, 1H), 6.94 (d, $J=8.4$ Hz, 1H), 4.59 - 4.46 (m, 1H), 4.31 (dd, $J=7.3, 9.7$ Hz, 1H), 4.17 (q, $J=7.0$ Hz, 2H), 3.99 - 3.90 (m, 5H), 3.58 (quin, $J=8.4$ Hz, 1H), 3.43 - 3.26 (m, 2H), 3.16 - 2.92 (m, 2H), 2.88 - 2.79 (m, 1H), 2.24 (br t, $J=12.9$ Hz, 2H), 2.05 - 1.89 (m, 2H), 1.50 (t, $J=6.9$ Hz, 3H); LCMS (ESI) m/z : $[M+H]^+ = 491.3$.

5

Example 87: *N*-(2-(4-(3-(3-chloro-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 3-chloro-4-ethoxybenzonitrile.



To a stirred solution of 3-chloro-4-hydroxybenzonitrile (2.0 g, 13.0 mmol) in N,N-dimethylformamide (20 mL) was added iodoethane (2.44 g, 15.6 mmol, 1.25 mL) and potassium carbonate (3.60 g, 26.1 mmol) at 0 °C. The reaction was warmed to 40 °C. After 16 h, the reaction mixture was quenched by addition of water (30 mL) then the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give crude 3-chloro-4-ethoxybenzonitrile (2.50 g) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.57 (d, $J=1.9$ Hz, 1H), 7.45 (dd, $J=2.0, 8.7$ Hz, 1H), 6.88 (d, $J=8.5$ Hz, 1H), 4.10 (q, $J=7.0$ Hz, 2H), 1.43 (t, $J=7.0$ Hz, 3H).

20


Step 2: Preparation of (Z)-3-chloro-4-ethoxy-N'-hydroxybenzimidamide.



To a stirred solution of 3-chloro-4-ethoxybenzonitrile (2.40 g, 13.2 mmol) in ethanol (30 mL) was added hydroxylamine hydrochloride (1.84 g, 26.4 mmol), triethylamine (2.67 g, 26.4 mmol, 3.66 mL) and water (3 mL). The mixture was heated at 80 °C for 2 h. The reaction mixture was filtered and the filter cake dried in vacuo to give (Z)-3-chloro-4-ethoxy-N'-hydroxybenzimidamide (700 mg, 3.62 mmol, 69 %) as a brown oil. ¹H NMR (400 MHz, DMSO-d₆) δ 9.59 (s, 1H), 7.72 (d, $J=2.0$ Hz, 2H), 7.14 (d, $J=8.8$ Hz, 1H), 5.83 (s, 2H), 4.14 (q, $J=6.9$ Hz, 2H), 1.45 - 1.30 (m, 3H).


25

Step 3: Preparation of *N*-(2-(4-(3-(3-chloro-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




5 To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-3-chloro-4-ethoxy-N'-hydroxybenzimidamide (97 mg, 455 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μ L). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 2 h. The reaction mixture was cooled then purified by prep-HPLC
 10 (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-80%, 12 min) to give *N*-(2-(4-(3-(3-chloro-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (104 mg, 223 μ mol, 54 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J*=2.0 Hz, 1H), 7.95 (dd, *J*=2.1, 8.6 Hz, 1H), 7.91 - 7.86 (m, 2H), 7.58 - 7.44 (m, 3H), 7.35 (br. s., 1H), 7.02 (d, *J*=8.7 Hz, 1H), 4.51 (d, *J*=13.7 Hz, 1H), 4.33 (d, *J*=3.9 Hz, 2H), 4.21 (q, *J*=7.0
 15 Hz, 2H), 3.93 (d, *J*=13.9 Hz, 1H), 3.41 - 3.29 (m, 2H), 3.18 (t, *J*=10.8 Hz, 1H), 2.33 - 2.20 (m, 2H), 2.09 - 1.93 (m, 2H), 1.53 (t, *J*=7.0 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 469.3.

Example 88: *N*-(2-(4-(3-(1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide



20


Step 1: Preparation of 1H-indazole-6-carbonitrile



To a stirred solution of 6-bromo-1H-indazole (1.0 g, 5.08 mmol) in N,N-dimethylformamide (12
 25 mL) was added zinc cyanide (595 mg, 5.08 mmol, 322 μ L) and tetrakis(triphenylphosphine)palladium(0) (586 mg, 508 μ mol), and the mixture was degassed with nitrogen three times. The mixture heated at 100 °C for 4 h under nitrogen. The reaction cooled to 20 °C, water (15 mL) was added, and the reaction


mixture was extracted with ethyl acetate (40 mL x 3). The combined organic extracts were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give crude product. This was triturated with petroleum ether (30 mL) and dichloromethane (5 mL), and the mixture filtered. The filter cake was dried in vacuo to give 1H-indazole-6-carbonitrile (880 mg) as a yellow solid that was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 13.65 (br. s., 1H), 8.33 - 8.12 (m, 2H), 7.99 (d, *J*=8.4 Hz, 1H), 7.88 - 7.80 (m, 1H).

Step 2: Preparation of (Z)-N'-hydroxy-1H-indazole-6-carboximidamide.




To a stirred solution of 1H-indazole-6-carbonitrile (800 mg, 5.59 mmol) in ethanol (1 mL) was added hydroxylamine hydrochloride (776 mg, 11.18 mmol), triethylamine (1.13 g, 11.18 mmol, 1.55 mL) and water (100 μL). The mixture was heated at 80 °C for 2 h. The reaction mixture was cooled, concentrated under reduced pressure, and then diluted with water (5 mL). The solid that formed was filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-1H-indazole-6-carboximidamide (500 mg, 2.84 mmol, 51 %) as a yellow solid that was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 13.22 - 13.10 (m, 1H), 9.68 (br. s., 1H), 8.04 (s, 1H), 7.78 (s, 1H), 7.70 - 7.66 (m, 1H), 7.47 - 7.42 (m, 1H), 5.87 (br. s., 2H).

Step 3: Preparation of N-(2-(4-(3-(1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxy-1H-indazole-6-carboximidamide (94 mg, 537 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Luna C18 100*30 5μm; mobile phase: [water (0.225%TFA)-acetonitrile]; B%: 30%-55%, 12 min) to give N-(2-(4-(3-(1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (21 mg, 44 μmol, 11 %) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.34 (br s, 1H), 8.55 (t, *J*=5.6 Hz, 1H), 8.18 - 8.16 (m, 1H), 7.94 - 7.89 (m, 1H), 7.88 - 7.83 (m, 2H), 7.72 (dd, *J*=1.1, 8.4 Hz, 1H), 7.54 - 7.41 (m, 3H), 4.36 - 4.27 (m, 1H), 4.16 (d, *J*=5.7 Hz, 2H), 3.97 (br d, *J*=14.1 Hz, 1H), 3.59 (br s, 1H), 3.47 (s, 1H), 3.34 - 3.24 (m, 1H), 2.98 - 2.88 (m, 1H), 2.20 - 2.08 (m, 2H), 1.89 - 1.77 (m, 1H), 1.66 (br d, *J*=11.5 Hz, 1H); LCMS (ESI) *m/z*: [M+H]⁺ = 431.1.

Example 89: 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, example 90: 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 1 and Example 91: (R)-4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 2.




Step 1: Preparation of 1,3-dimethyl-1H-indazole-6-carbonitrile.



To a stirred solution of 6-bromo-1,3-dimethyl-1H-indazole (480 mg, 2.13 mmol) in N,N-dimethylformamide (5 mL) was added zinc cyanide (250 mg, 2.13 mmol) and tetrakis(triphenylphosphine)palladium(0) (246 mg, 213 μmol) under nitrogen, then the mixture was heated to 100 °C. After 16 h, the reaction was cooled to 20 °C, water (10 mL) was added, and the reaction mixture extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered and then concentrated in vacuo to give crude product. The residue was triturated with petroleum ether (30 mL), then filtered and the filter cake dried in vacuo to give 1,3-dimethyl-1H-indazole-6-carbonitrile (300 mg, 1.75 mmol, 82 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 - 7.71 (m, 2H), 7.38 - 7.31 (m, 1H), 4.08 (s, 3H), 2.61 (s, 3H).


Step 2: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide.



To a stirred solution of 1,3-dimethyl-1H-indazole-6-carbonitrile (300 mg, 1.75 mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (243 mg, 3.50 mmol), triethylamine (354 mg, 3.50 mmol, 485 μL) and water (500 μL). The mixture was heated at 80 °C for 5 h, then cooled and filtered, and the filter cake was dried in vacuo to give (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide (290


mg, 1.42 mmol, 81 %) as a white solid that was used directly without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.71 (s, 1H), 7.86 (s, 1H), 7.65 (d, *J*=8.5 Hz, 1H), 7.49 (d, *J*=8.5 Hz, 1H), 5.90 (s, 2H), 3.97 (s, 3H), 2.47 (s, 3H).

5 *Step 3: Preparation of methyl 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylate.*




To a stirred solution of 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (500 mg, 2.44 mmol) in N,N-dimethylformamide (10 mL) was added methyl piperidine-4-carboxylate (349 mg, 2.44 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (925 mg, 2.44 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (946 mg, 7.32 mmol, 1.28 mL). The mixture was stirred at 20 °C for 2 h. The reaction mixture was quenched by addition of water (20 mL) then extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Purification by chromatography (silica, petroleum ether : ethyl acetate = 20 : 1 to 1 : 1) gave methyl 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylate (940 mg) as a yellow oil.

Step 4: Preparation of 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid



To a stirred solution of methyl 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylate (900 mg, 2.72 mmol) in tetrahydrofuran (10 mL) was added lithium hydroxide (2 M, 2.72 mL). After 2 h, the reaction mixture was acidified to pH 1 with 1 M hydrochloric acid (6 mL). The mixture was extracted with ethyl acetate (40 mL x 3). The organic extracts were combined and washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (600 mg, 1.90 mmol, 70 %) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 12.37 - 12.17 (m, 1H), 7.66 (dd, *J*=5.8, 7.2 Hz, 2H), 7.38 (t, *J*=7.9 Hz, 2H), 7.19 - 7.09 (m, 1H), 4.28 - 4.19 (m, 1H), 4.04 (s, 1H), 3.93 (br. s., 2H), 3.76 - 3.66 (m, 1H), 3.18 (br. s., 1H), 2.86 - 2.67 (m, 4H), 1.87 (t, *J*=13.2 Hz, 2H), 1.61 - 1.35 (m, 2H).

30 *Step 5: Preparation of 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 1 and 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 2.*



35 To a stirred solution of 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (150 mg, 474 μmol) in N,N-dimethylformamide (2 mL) was added N'-hydroxy-1,3-dimethyl-indazole-6-

carboxamidine (96 mg, 474 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (179 mg, 474 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (183 mg, 1.42 mmol, 248 μ L). The mixture was stirred at 20 °C for 2 h, then heated at 120 °C for 1 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-55%, 12 min) to give the racemic of 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (85 mg) as a white solid. A portion (25 mg, 53 μ mol, 11 %, 99.83% purity) was retained for analysis. The remainder (60 mg) was purified by SFC (column: OJ (250x30mm, 5 μ m); mobile phase: [CO₂ base-methanol]; B%: 45%-45%, min) to give 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 1 (27 mg, 56 μ mol, 12 %) as a brown solid then 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 2 (26 mg, 55 μ mol, 12 %) as a white solid.

4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one:

¹H NMR (400 MHz, CDCl₃) δ 8.13 - 8.07 (m, 1H), 7.83 (s, 1H), 7.78 - 7.72 (m, 1H), 7.61 (d, *J*=8.0 Hz, 2H), 7.39 (t, *J*=7.9 Hz, 2H), 7.18 (s, 1H), 4.65 - 4.50 (m, 1H), 4.34 (t, *J*=7.3 Hz, 1H), 4.09 (d, *J*=3.3 Hz, 3H), 4.05 - 3.92 (m, 2H), 3.60 (quin, *J*=8.4 Hz, 1H), 3.46 - 3.32 (m, 2H), 2.98 (d, *J*=6.7 Hz, 2H), 2.91 - 2.81 (m, 1H), 2.61 (s, 3H), 2.35 - 2.22 (m, 2H), 2.02 (d, *J*=6.1 Hz, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 485.2.


4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 1:

¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J*=4.1 Hz, 1H), 7.86 (br d, *J*=8.5 Hz, 1H), 7.80 - 7.74 (m, 1H), 7.63 (d, *J*=7.9 Hz, 2H), 7.41 (t, *J*=8.0 Hz, 2H), 7.23 - 7.18 (m, 1H), 4.67 - 4.52 (m, 1H), 4.36 (br t, *J*=7.0 Hz, 1H), 4.11 (d, *J*=3.4 Hz, 3H), 4.07 - 3.94 (m, 2H), 3.62 (quin, *J*=8.5 Hz, 1H), 3.49 - 3.35 (m, 2H), 3.22 - 2.96 (m, 2H), 2.93 - 2.81 (m, 1H), 2.63 (s, 3H), 2.37 - 2.25 (m, 2H), 2.11 - 1.97 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 485.3.


4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one, Enantiomer 2:

¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J*=3.9 Hz, 1H), 7.86 (d, *J*=8.4 Hz, 1H), 7.80 - 7.74 (m, 1H), 7.63 (d, *J*=8.3 Hz, 2H), 7.41 (t, *J*=8.0 Hz, 2H), 7.24 - 7.18 (m, 1H), 4.66 - 4.53 (m, 1H), 4.36 (br t, *J*=7.3 Hz, 1H), 4.11 (d, *J*=3.5 Hz, 3H), 4.07 - 3.94 (m, 2H), 3.62 (quin, *J*=8.5 Hz, 1H), 3.48 - 3.36 (m, 2H), 3.21 - 2.96 (m, 2H), 2.93 - 2.81 (m, 1H), 2.63 (s, 3H), 2.36 - 2.26 (m, 2H), 2.06 (br d, *J*=13.4 Hz, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 485.3.

Examples 90 and 91 can be synthesized in an enantiospecific fashion using appropriate enantiopure starting materials, following the representative procedure below:




Preparation of (4R)-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenylpyrrolidin-2-one.




To a stirred solution of 1-[(3R)-5-oxo-1-phenylpyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (115 mg, 363.52 μmol) and N'-hydroxy-1,3-dimethyl-indazole-6-carboxamide (74 mg, 364 μmol) in DMF (1.50 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (137 mg, 364 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (93 mg, 727 μmol , 126 μL) at 25 $^{\circ}\text{C}$. After 3 h, the mixture was warmed to 110 $^{\circ}\text{C}$. After 1 h, the mixture was purified by chromatography (Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-60%, 12 min) to give (4R)-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenylpyrrolidin-2-one (64 mg, 133 μmol , 37 %) as a pink solid. ^1H NMR (400MHz, CHLOROFORM-d) δ = 8.09 (d, J =4.0 Hz, 1H), 7.84 - 7.80 (d, 1H), 7.75 - 7.71 (d, 1H), 7.59 (d, J =7.9 Hz, 2H), 7.38 (t, J =7.9 Hz, 2H), 7.20 - 7.14 (t, 1H), 4.62 - 4.49 (m, 1H), 4.36 - 4.29 (m, 1H), 4.07 (d, J =3.3 Hz, 3H), 4.04 - 3.89 (m, 2H), 3.58 (quin, J =8.4 Hz, 1H), 3.45 - 3.30 (m, 2H), 3.18 - 2.92 (m, 2H), 2.90 - 2.80 (m, 1H), 2.59 (s, 3H), 2.27 (br t, J =13.2 Hz, 2H), 2.09 - 1.91 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 485.3$.

Example 92: (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(3-phenylisoxazol-5-yl)methanone.




Step 1: Preparation of 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole.




To a stirred solution of tert-butyl 4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (800 mg, 1.98 mmol) in ethyl acetate (5 mL) was added 4M hydrochloric acid / ethyl acetate (20 mL). The mixture was stirred at 20 °C for 0.5 h. The reaction mixture was filtered and the filter cake was dried in vacuo to give 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (450 mg, 1.48 mmol, 75 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.67 (dd, *J*=1.6, 8.3 Hz, 1H), 7.60 - 7.54 (m, 1H), 6.97 (d, *J*=8.4 Hz, 1H), 4.24 - 4.13 (m, 2H), 3.98 (s, 3H), 3.56 (br s, 2H), 3.39 (br s, 1H), 3.33 - 3.15 (m, 2H), 2.51 (br s, 2H), 2.48 - 2.33 (m, 2H), 2.19 - 1.83 (m, 1H), 1.53 (t, *J*=7.0 Hz, 3H).

Step 2: Preparation of (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(3-phenylisoxazol-5-yl)methanone.




To a stirred solution of 3-phenylisoxazole-5-carboxylic acid (75 mg, 396 μmol) in N,N-dimethylformamide (2 mL) was added 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (120 mg, 396 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (150 mg, 396 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (153 mg, 1.19 mmol, 207 μL). The mixture was stirred at 20 °C for 2 h. The reaction mixture was then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%:40%-70%, 12 min) to give (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(3-phenylisoxazol-5-yl)methanone (41 mg, 87 μmol, 22 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.87 (br s, 2H), 7.70 (br d, *J*=7.8 Hz, 1H), 7.60 (br s, 1H), 7.53 (br s, 3H), 7.14 (s, 1H), 6.99 (br d, *J*=7.5 Hz, 1H), 4.59 (br s, 1H), 4.36 (br d, *J*=12.5 Hz, 1H), 4.21 (br d, *J*=6.4 Hz, 2H), 4.00 (s, 3H), 3.55 (br s, 1H), 3.46 - 3.25 (m, 2H), 2.32 (br s, 2H), 2.15 (br s, 2H), 1.54 (br t, *J*=6.8 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 475.2.

Example 93: N-(2-(4-(3-(3-methyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




5

Step 1: Preparation of 3-methyl-1H-indazole-6-carbonitrile.




To a stirred solution of 6-bromo-3-methyl-1H-indazole (440 mg, 2.08 mmol) in N,N-dimethylformamide (5 mL) was added zinc cyanide (244 mg, 2.08 mmol) and tetrakis(triphenylphosphine)palladium(0) (240 mg, 208 μ mol), then the mixture was degassed with nitrogen three times. The mixture stirred at 100 °C for 4 h under nitrogen, then cooled to 20 °C, water (10 mL) added, and the reaction mixture was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give crude product. Petroleum ether (20 mL) was added to the crude product, then the mixture was filtered and the filter cake dried in vacuo to give 3-methyl-1H-indazole-6-carbonitrile (220 mg, 1.40 mmol, 67 %) as a brown solid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.29 - 13.09 (m, 1H), 8.09 - 8.05 (m, 1H), 7.96 - 7.90 (m, 1H), 7.41 (d, J =8.3 Hz, 1H), 2.54 (s, 3H).

Step 2: Preparation of (Z)-N'-hydroxy-3-methyl-1H-indazole-6-carboximidamide.




To a stirred solution of 3-methyl-1H-indazole-6-carbonitrile (200 mg, 1.27 mmol) in ethanol (1 mL) was added hydroxylamine hydrochloride (176 mg, 2.55 mmol), triethylamine (257 mg, 2.55 mmol, 352 μ L) and water (100 μ L). The mixture was stirred at 80 °C for 2 h. The reaction mixture was cooled and then concentrated under reduced pressure to remove ethanol. The residue was diluted with water (5 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-3-methyl-1H-indazole-6-carboximidamide (150 mg, 789 μ mol, 62 %) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 12.73 (s, 1H), 9.67 (s, 1H), 7.73 (s, 1H), 7.65 (d, J =8.5 Hz, 1H), 7.45 (d, J =8.5 Hz, 1H), 5.86 (s, 2H), 2.49 (s, 3H).

Step 3: Preparation of *N*-(2-(4-(3-(3-methyl-1*H*-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μ mol) in *N,N*-dimethylformamide (2 mL) was added (*Z*)-*N*'-hydroxy-3-methyl-1*H*-indazole-6-carboximidamide (78 mg, 413 μ mol), (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol) and *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μ L). The mixture was stirred at 20 °C for 2 h, then heated at 110 °C for 1 h. The reaction mixture was cooled then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-55%, 12 min) to give *N*-(2-(4-(3-(3-methyl-1*H*-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (93 mg, 209 μ mol, 51 %) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.92 (s, 1H), 8.59 - 8.53 (m, 1H), 8.08 (s, 1H), 7.86 (d, *J*=8.4 Hz, 3H), 7.71 - 7.65 (m, 1H), 7.55 - 7.42 (m, 3H), 4.30 (d, *J*=13.2 Hz, 1H), 4.16 (d, *J*=5.7 Hz, 2H), 3.97 (d, *J*=14.6 Hz, 1H), 3.49 - 3.43 (m, 1H), 3.29 - 3.24 (m, 1H), 2.92 (t, *J*=11.2 Hz, 1H), 2.50 (s, 3H), 2.14 (t, *J*=13.0 Hz, 2H), 1.88 - 1.78 (m, 1H), 1.66 (d, *J*=9.7 Hz, 1H); LCMS (ESI) *m/z*: [M+H]⁺ = 445.3.

Example 94: *N*-(2-(4-(3-(1-methyl-1*H*-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 1-methyl-1*H*-indazole-6-carbonitrile.



To a stirred solution of 6-bromo-1-methyl-1*H*-indazole (500 mg, 2.37 mmol) in *N,N*-dimethylformamide (8 mL) was added zinc cyanide (278 mg, 2.37 mmol) and tetrakis(triphenylphosphine)palladium(0) (273 mg, 236.90 μ mol), the mixture was degassed with nitrogen three times. The mixture was stirred at 100 °C for 4 h under nitrogen, then cooled to 20 °C, water (10 mL)


added, and the reaction mixture extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give crude product. The mixture was triturated with petroleum ether (20 mL) and dichloromethane (3 mL), then filtered and dried in vacuo to give 1-methyl-1H-indazole-6-carbonitrile (300 mg, 1.91 mmol, 81 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 7.88 - 7.83 (m, 1H), 7.82 (s, 1H), 7.39 (dd, *J*=1.1, 8.3 Hz, 1H), 4.16 (s, 3H).

Step 2: Preparation of (Z)-N'-hydroxy-1-methyl-1H-indazole-6-carboximidamide.




To a stirred solution of 1-methyl-1H-indazole-6-carbonitrile (250 mg, 1.59 mmol) in ethanol (1 mL) was added hydroxylamine hydrochloride (221 mg, 3.18 mmol), triethylamine (321 mg, 3.18 mmol, 440 μL) and water (100 μL). The mixture was heated at 80 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue then triturated with water (4 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-1-methyl-1H-indazole-6-carboximidamide (500 mg) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.65 (br. s., 2H), 9.65-9.84 (m, 1H), 7.98 (d, *J*=18.1 Hz, 2H), 7.67 (d, *J*=8.8 Hz, 1H), 7.46-7.52 (m, 1H), 4.03 ppm (s, 3H).

Step 3: Preparation of N-(2-(4-(3-(1-methyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxy-1-methyl-1H-indazole-6-carboximidamide (125 mg, 661 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 33%-63%, 12 min) to give N-(2-(4-(3-(1-methyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (29 mg, 64 μmol, 15 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, 1H), 8.06 (s, 1H), 7.92 - 7.82 (m, 4H), 7.58 - 7.45 (m, 3H), 7.36 (br. s., 1H), 4.56 (d, *J*=14.2 Hz, 1H), 4.34 (d, *J*=3.9 Hz, 2H), 4.19 (s, 3H), 4.00 - 3.92 (m, 1H), 3.44 - 3.34 (m, 2H), 3.19 (t, *J*=10.9 Hz, 1H), 2.36 - 2.26 (m, 2H), 2.14 - 1.98 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 445.2.

Example 95: *N*-(2-(4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




5 Step 1: Preparation of 1,3-dimethyl-1H-indazole-5-carbonitrile.




To a stirred solution of 5-bromo-1,3-dimethyl-1H-indazole (600 mg, 2.67 mmol) in N,N-dimethylformamide (10 mL) was added zinc cyanide (313 mg, 2.67 mmol, 169 μ L) and tetrakis(triphenylphosphine)palladium(0) (308 mg, 267 μ mol) under nitrogen. The mixture was stirred at 100 $^{\circ}$ C for 16 h, then cooled to 20 $^{\circ}$ C, and diluted with water (15 mL). The reaction mixture was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give crude product. This was triturated with petroleum ether (30 mL) and dichloromethane (5 mL), filtered and the filter cake dried in vacuo to give 1,3-dimethyl-1H-indazole-5-carbonitrile (340 mg, 1.99 mmol, 74 %) as a brown solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.02 (s, 1H), 7.54 (d, J =8.8 Hz, 1H), 7.37 (d, J =8.8 Hz, 1H), 4.02 (s, 3H), 2.57 (s, 3H).

Step 2: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-5-carboximidamide.




To a stirred solution of 1,3-dimethyl-1H-indazole-5-carbonitrile (340 mg, 1.99 mmol) in ethanol (6 mL) was added hydroxylamine hydrochloride (276 mg, 3.97 mmol), triethylamine (401 mg, 3.97 mmol, 550 μ L) and water (600 μ L). The mixture was stirred at 80 $^{\circ}$ C for 2 h. The reaction mixture was cooled and then concentrated under reduced pressure. The residue was triturated with water (4 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-5-carboximidamide (250 mg, 1.22 mmol, 62 %) as a white solid. ^{1} H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.50 (s, 1H), 7.99 (s, 1H), 7.72 (dd, J =1.5, 9.0 Hz, 1H), 7.48 (d, J =8.8 Hz, 1H), 5.82 (s, 2H), 3.92 (s, 3H), 2.46 (s, 3H).

Step 3: Preparation of N-(2-(4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (120 mg, 413 μmol) in N,N-dimethylformamide (2 mL) was added N'-hydroxy-1,3-dimethyl-indazole-5-carboxamide (84 mg, 413 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (160 mg, 1.24 mmol, 216 μL). The mixture was stirred at 20 °C for 2 h, and then heated at 110 °C for 2 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-64%, 12 min) to give N-(2-(4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (54 mg, 118 μmol , 29 %) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.55 (t, $J=5.5$ Hz, 1H), 8.34 (s, 1H), 7.96 (dd, $J=1.3$, 8.8 Hz, 1H), 7.86 (d, $J=7.1$ Hz, 2H), 7.70 (d, $J=8.8$ Hz, 1H), 7.55 - 7.42 (m, 3H), 4.31 (d, $J=13.2$ Hz, 1H), 4.16 (dd, $J=2.2$, 5.3 Hz, 2H), 4.03 - 3.92 (m, 4H), 3.49 - 3.40 (m, 1H), 3.34 - 3.30 (m, 1H), 2.92 (t, $J=11.5$ Hz, 1H), 2.52 (s, 3H), 2.14 (t, $J=13.0$ Hz, 2H), 1.83 (d, $J=10.1$ Hz, 1H), 1.71 - 1.62 (m, 1H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 459.3$.

Example 96: 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carbonyl)-1-phenylpyrrolidin-2-one.




Step 1: Preparation of 3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5(4H)-one.



To a stirred solution of (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide (180 mg, 881 μmol) in dioxane (3 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (147 mg, 970 μmol , 146 μL) and 1,1'-carbonyldiimidazole (214 mg, 1.32 mmol). The mixture was stirred at 110 °C for 16 h. The reaction mixture was concentrated in vacuo then purified by chromatography (silica, dichloromethane : methanol = 50 : 1) to give 3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5(4H)-one (220 mg) as a yellow solid. ^1H


NMR (400 MHz, Methanol-d₄) δ 7.97 - 7.93 (m, 1H), 7.82 - 7.77 (m, 1H), 7.62 (d, J =1.1 Hz, 1H), 4.05 (s, 3H), 2.57 (s, 3H).

Step 2: Preparation of 5-chloro-3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazole




A flask 3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5(4H)-one (220 mg, 956 μ mol) was charged with N,N-dimethylformamide (1 mL) then phosphoryl chloride (10 mL) was added dropwise. The mixture was heated at 110 °C for 16 h, then cooled and concentrated under reduced pressure, poured onto ice water (10 mL), and stirred for 10 min. The mixture was extracted with dichloromethane (20 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 5-chloro-3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazole (100 mg) as a brown solid.

Step 3: Preparation of tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxylate




To a stirred solution of 5-chloro-3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazole (100 mg, 402.1 μ mol) in N-methyl-2-pyrrolidone (3 mL) was added tert-butyl piperazine-1-carboxylate (74 mg, 402 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (103 mg, 804 μ mol, 140 μ L). The mixture was stirred at 120 °C for 16 h. The reaction mixture was cooled, quenched by addition of water (5 mL) then the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. Purification by prep-TLC (silica, petroleum ether : ethyl acetate = 1:1) gave tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxylate (65 mg, 163 μ mol, 41 %) as a brown solid.

Step 4: Preparation of 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole




To a stirred solution of tert-butyl 4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperazine-1-carboxylate (65 mg, 163 μ mol) in ethyl acetate (1 mL) was added hydrochloric acid / ethyl acetate (4M, 5 mL). The mixture was stirred at 20 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to give 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole (40 mg, 134 μ mol, 82 %) as a white solid. LCMS (ESI) m/z : $[M+H]^+$ = 299.1.

Step 5: Preparation of 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carbonyl)-1-phenylpyrrolidin-2-one




To a stirred solution of 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole (35 mg, 117 μ mol) in N,N-dimethylformamide (1 mL) was added 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (24 mg, 117 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (44 mg, 117 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (45 mg, 352 μ mol, 61 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give 4-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carbonyl)-1-phenylpyrrolidin-2-one (26 mg, 54.58 μ mol, 47 %) as a white solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.05 (s, 1H), 7.83 - 7.69 (m, 2H), 7.63 (br d, $J=7.5$ Hz, 2H), 7.42 (br t, $J=7.5$ Hz, 2H), 7.22 (br d, $J=7.9$ Hz, 1H), 4.37 (br t, $J=8.0$ Hz, 1H), 4.09 (s, 3H), 4.03 - 3.96 (m, 1H), 3.93 - 3.72 (m, 8H), 3.63 (br d, $J=9.7$ Hz, 1H), 3.04 - 2.85 (m, 2H), 2.62 (s, 3H); LCMS (ESI) m/z : $[M+H]^+ = 486.3$.

Example 97: N-(2-(4-(3-(4-ethoxy-3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




Step 1: Preparation of 4-ethoxy-3-fluorobenzonitrile



To a stirred solution of 3-fluoro-4-hydroxybenzonitrile (800 mg, 5.83 mmol) in N,N-dimethylformamide (10 mL) was added iodoethane (1.09 g, 7.00 mmol, 559 μ L) and potassium carbonate (1.61 g, 11.7 mmol) at 0 $^{\circ}$ C. The reaction was warmed at 40 $^{\circ}$ C for 16 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give crude 4-ethoxy-3-fluorobenzonitrile (750


mg, 4.54 mmol, 78 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.43 - 7.30 (m, 2H), 6.98 (t, *J*=8.3 Hz, 1H), 4.15 (q, *J*=7.0 Hz, 2H), 1.47 (tt, *J*=1.2, 7.0 Hz, 3H).

Step 2: Preparation of (Z)-4-ethoxy-3-fluoro-N'-hydroxybenzimidamide




To a stirred solution of 4-ethoxy-3-fluorobenzonitrile (400 mg, 2.42 mmol) in ethanol (6 mL) was added hydroxylamine hydrochloride (336 mg, 4.84 mmol), triethylamine (490 mg, 4.84 mmol, 671 μL) and water (600 μL). The mixture was stirred at 80 °C for 2 h. The reaction mixture was cooled then concentrated under reduced pressure. The residue was triturated with water (5 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-4-ethoxy-3-fluoro-N'-hydroxybenzimidamide (300 mg, 1.51 mmol, 63 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.57 (s, 1H), 7.47 - 7.39 (m, 2H), 7.12 (t, *J*=8.9 Hz, 1H), 5.80 (s, 2H), 4.13 - 4.06 (m, 2H), 1.34 - 1.29 (m, 3H).

Step 3: Preparation of N-(2-(4-(3-(4-ethoxy-3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (100 mg, 344 μmol) in N,N-dimethylformamide (2 mL) was added (Z)-4-ethoxy-3-fluoro-N'-hydroxybenzimidamide (68 mg, 344 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (130 mg, 344 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (133 mg, 1.03 mmol, 180 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give N-(2-(4-(3-(4-ethoxy-3-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (43 mg, 96 μmol, 28 %) as a pink solid. ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, *J*=7.0 Hz, 2H), 7.85 - 7.79 (m, 2H), 7.58 - 7.44 (m, 3H), 7.35 (br s, 1H), 7.05 (t, *J*=8.5 Hz, 1H), 4.51 (br d, *J*=13.6 Hz, 1H), 4.33 (d, *J*=3.8 Hz, 2H), 4.20 (q, *J*=7.0 Hz, 2H), 3.93 (br d, *J*=13.7 Hz, 1H), 3.41 - 3.29 (m, 2H), 3.23 - 3.13 (m, 1H), 2.32 - 2.20 (m, 2H), 2.08 - 1.93 (m, 2H), 1.51 (t, *J*=7.0 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 453.1.

Example 98: [4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-(2-phenyl-1H-imidazol-5-yl)methanone




5 **Step 1: Preparation of 2-phenyl-4H-oxazol-5-one**




A mixture of 2-benzamidoacetic acid (1.0 g, 5.58 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (953 mg, 6.14 mmol, 1.08 mL) in dichloromethane (25 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 20 °C for 6h under a nitrogen atmosphere. The mixture was concentrated in vacuum to get a crude product. The crude product, 2-phenyl-4H-oxazol-5-one (1.20 g) was used directly without further purification.

Step 2: Ethyl 2-phenyl-1H-imidazole-5-carboxylate




A mixture of 2-phenyl-4H-oxazol-5-one (1.0 g, 6.21 mmol), ethyl cyanofornate (676 mg, 6.83 mmol, 669 μ L) and tributylphosphine (753 mg, 3.72 mmol, 918 μ L) in dichloromethane (3 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 20 °C for 6h under a nitrogen atmosphere. The reaction mixture was quenched by addition of water (3 mL), then extracted with dichloromethane (10 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue that was purified by chromatography (silica, petroleum ether / ethyl acetate = 2:1) to give ethyl 2-phenyl-1H-imidazole-5-carboxylate (480 mg, 2.22 mmol, 36 %) as a white solid.

Step 3: 2-phenyl-1H-imidazole-5-carboxylic acid




A mixture of ethyl 2-phenyl-1H-imidazole-5-carboxylate (300 mg, 1.39 mmol) and sodium hydroxide (166 mg, 4.17 mmol) in tetrahydrofuran (3 mL) and water (1.50 mL) was stirred at 20 °C for 2 h. The reaction mixture was extracted with dichloromethane (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 2-phenyl-1H-imidazole-5-carboxylic acid (200 mg) that was used directly without further purification.

Step 4: [4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-(2-phenyl-1H-imidazol-5-yl)methanone




A mixture of 2-phenyl-1H-imidazole-5-carboxylic acid (62 mg, 330 μmol), 3-(4-ethoxy-3-methoxy-phenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (100 mg, 330 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (125 mg, 330 μmol) and diisopropylethylamine (85 mg, 659 μmol, 115 μL) in N,N-dimethylformamide (3 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 20 °C for 2 h under a nitrogen atmosphere. The mixture was purified by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-65%, 12 min) to give [4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-(2-phenyl-1H-imidazol-5-yl)methanone (25 mg, 105 μmol, 16 %) as a white solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.95 (br d, J=7.7 Hz, 2H), 7.65 (dd, J=1.8, 8.4 Hz, 1H), 7.54 (s, 2H), 7.47 - 7.32 (m, 3H), 6.92 (d, J=8.4 Hz, 1H), 5.56 - 5.27 (m, 1H), 4.77 - 4.46 (m, 1H), 4.14 (q, J=6.8 Hz, 2H), 3.99 - 3.88 (m, 3H), 3.66 - 3.09 (m, 3H), 2.24 (br d, J=9.7 Hz, 2H), 2.07 (br s, 1H), 1.84 (br s, 1H), 1.47 (t, J=6.8 Hz, 3H); LCMS(ESI) m/z: [M+H]⁺ = 474.3.

Example 99: N-(2-(4-(3-(3-bromo-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




Step 1: Preparation of *N*-(2-(4-(3-(3-bromo-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (100 mg, 344 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-3-bromo-4-ethoxy-N'-hydroxybenzimidamide (89 mg, 344 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (130 mg, 344 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (133 mg, 1.03 mmol, 180 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h, then heated at 110 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-75%, 12 min) to give *N*-(2-(4-(3-(3-bromo-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (43 mg, 83 μ mol, 24 %) as a yellow solid. ^{1} H NMR (400MHz, CDCl₃) δ 8.30 (d, J =2.1 Hz, 1H), 8.00 (dd, J =2.1, 8.6 Hz, 1H), 7.91 - 7.85 (m, 2H), 7.58 - 7.44 (m, 3H), 7.35 (br s, 1H), 6.98 (d, J =8.7 Hz, 1H), 4.50 (br d, J =14.1 Hz, 1H), 4.33 (d, J =3.9 Hz, 2H), 4.20 (q, J =6.9 Hz, 2H), 3.93 (br d, J =13.8 Hz, 1H), 3.41 - 3.29 (m, 2H), 3.18 (br t, J =10.6 Hz, 1H), 2.32 - 2.20 (m, 2H), 2.09 - 1.93 (m, 2H), 1.53 (t, J =7.0 Hz, 3H); LCMS (ESI) m/z : [M+H]⁺ = 513.2.

Example 100: (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(3-phenylpiperidin-1-yl)methanone.




Step 1: Preparation of 3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5(4H)-one



To a stirred solution of 4-ethoxy-N-hydroxy-3-methoxybenzimidamide (1.0 g, 4.76 mmol) in dioxane (10 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (796 mg, 5.24 mmol, 788 μ L) and 1,1'-carbonyldiimidazole (1.16 g, 7.14 mmol). The mixture was heated at 110 $^{\circ}$ C for 16 h. The reaction mixture was cooled, quenched with water (10 mL), and then extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with 1M aqueous hydrochloric acid (5 mL x 2), then with saturated aqueous sodium chloride solution (10 mL), filtered and dried over anhydrous sodium sulfate. The organic layer was concentrated to give 3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5(4H)-one


(1.02 g, 4.32 mmol, 91 %) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ 12.78 (br s, 1H), 7.38 - 7.28 (m, 2H), 7.08 (d, *J*=8.4 Hz, 1H), 4.05 (q, *J*=7.1 Hz, 2H), 3.77 (s, 3H), 1.30 (t, *J*=6.9 Hz, 3H).

Step 2: Preparation of 5-chloro-3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazole.




A flask 3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5(4H)-one (1.02 g, 4.32 mmol) was equipped with calcium chloride tube, then phosphoryl chloride (12 mL) and pyridine (170 mg, 2.16 mmol, 174 μL) were added dropwise and the mixture was heated at 110 °C for 16 h. The reaction mixture was cooled then concentrated under reduced pressure to remove phosphoryl chloride, and the residue added to ice water (20 mL) and stirred for 10 min. The mixture was extracted with dichloromethane (40 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give crude 5-chloro-3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazole (910 mg) as a yellow solid.

Step 3: Preparation of methyl 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylate.



To a stirred solution of 5-chloro-3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazole (600 mg, 2.36 mmol) in N-methyl-2-pyrrolidone (8 mL) was added methyl piperidine-4-carboxylate (337 mg, 2.36 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (610 mg, 4.72 mmol, 824 μL). The mixture was stirred at 120 °C for 16 h. The reaction mixture was quenched with water (10 mL), then the mixture was extracted with ethyl acetate (40 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50 : 1 to 10:1) to give methyl 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylate (510 mg, 1.41 mmol, 60 %) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.47 (dd, *J*=1.9, 8.3 Hz, 1H), 7.38 (d, *J*=2.0 Hz, 1H), 7.06 (d, *J*=8.4 Hz, 1H), 4.08 (q, *J*=7.0 Hz, 2H), 4.00 (td, *J*=3.5, 13.2 Hz, 2H), 3.82 (s, 3H), 3.64 (s, 3H), 3.31 - 3.24 (m, 2H), 2.68 (tt, *J*=3.9, 10.9 Hz, 1H), 1.98 (br dd, *J*=3.2, 13.5 Hz, 2H), 1.70 - 1.58 (m, 2H), 1.36 (t, *J*=7.0 Hz, 3H).


Step 4: Preparation of 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylic acid.



To a stirred solution of methyl 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylate (490 mg, 1.36 mmol) in tetrahydrofuran (10 mL) was added lithium hydroxide (2 M, 2.04 mL). The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced


pressure to remove tetrahydrofuran, then the mixture was acidified with concentrated hydrochloric acid until pH 1. The mixture was extracted with dichloromethane (40 mL x 3). The organic layer was washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give crude 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylic acid (400 mg, 1.15 mmol, 85 %) as a white solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.52 - 7.45 (m, 2H), 6.99 (d, *J*=8.4 Hz, 1H), 4.15 - 4.05 (m, 4H), 3.86 (s, 3H), 3.32 (br d, *J*=3.1 Hz, 1H), 3.28 - 3.25 (m, 1H), 2.61 (tt, *J*=3.8, 10.8 Hz, 1H), 2.07 - 1.98 (m, 2H), 1.80 - 1.68 (m, 2H), 1.41 (t, *J*=6.9 Hz, 3H).

Step 5: Preparation of (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(3-phenylpiperidin-1-yl)methanone.




To a stirred solution of 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylic acid (100 mg, 288 μmol) in N,N-dimethylformamide (500 μL) was added 3-phenylpiperidine (46 mg, 288 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (109 mg, 288 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (111 mg, 863.66 μmol, 150 μL). The mixture was stirred at 20 °C for 2 h. The reaction mixture was then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-60%, 12 min) to give (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(3-phenylpiperidin-1-yl)methanone (80 mg, 162 μmol, 56 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.45 - 7.40 (m, 1H), 7.36 - 7.16 (m, 6H), 7.02 (d, *J*=8.4 Hz, 1H), 4.49 - 4.36 (m, 1H), 4.09 - 3.92 (m, 5H), 3.78 (s, 3H), 3.28 - 2.92 (m, 4H), 2.70 - 2.50 (m, 2H), 1.89 (br d, *J*=11.7 Hz, 1H), 1.82 - 1.44 (m, 7H), 1.31 (t, *J*=6.9 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 491.3.

Example 101: N-(2-(4-(3-(3-cyano-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 3-bromo-4-ethoxybenzonitrile.



To a stirred solution of 3-bromo-4-hydroxybenzonitrile (1.0 g, 5.05 mmol) in N,N-dimethylformamide (10 mL) was added iodoethane (945 mg, 6.06 mmol, 484 μL) and potassium


carbonate (1.40 g, 10.1 mmol) at 0 °C. The reaction was warmed at 40 °C for 16 h. The reaction mixture was quenched by addition of water (15 mL), then the mixture was extracted with ethyl acetate (40 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 3-bromo-4-ethoxybenzonitrile (1.20 g) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J*=2.0 Hz, 1H), 7.55 (dd, *J*=2.0, 8.6 Hz, 1H), 6.89 (d, *J*=8.6 Hz, 1H), 4.14 (q, *J*=7.0 Hz, 2H), 1.49 (t, *J*=6.9 Hz, 3H).

Step 2: Preparation of (Z)-3-bromo-4-ethoxy-N'-hydroxybenzimidamide.




To a stirred solution of 3-bromo-4-ethoxybenzonitrile (1.15 g, 5.09 mmol) in ethanol (10 mL) was added hydroxylamine hydrochloride (706 mg, 10.2 mmol), triethylamine (1.03 g, 10.2 mmol, 1.41 mL) and water (1 mL). The mixture was heated at 80 °C for 1 h, then cooled and concentrated under reduced pressure to remove ethanol. The residue was triturated with water (5 mL) and filtered, and the filter cake was dried under reduced pressure to give (Z)-3-bromo-4-ethoxy-N'-hydroxybenzimidamide (1.31 g, 5.06 mmol, 99 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.55 (br s, 1H), 7.82 (d, *J*=2.2 Hz, 1H), 7.60 (dd, *J*=2.2, 8.6 Hz, 1H), 7.05 (d, *J*=8.8 Hz, 1H), 5.79 (s, 2H), 4.12 - 4.05 (m, 2H), 1.31 (t, *J*=7.1 Hz, 3H).

Step 3: Preparation of (Z)-3-cyano-4-ethoxy-N'-hydroxybenzimidamide.




To a stirred solution of zinc cyanide (226 mg, 1.93 mmol, 122 μL) in N,N-dimethylformamide (10 mL) was added (Z)-3-bromo-4-ethoxy-N'-hydroxybenzimidamide (500 mg, 1.93 mmol) and tetrakis(triphenylphosphine)palladium(0) (222 mg, 193 μmol), then the mixture was degassed with nitrogen three times. The mixture was heated at 110 °C for 16 h under nitrogen then cooled to 20 °C, water (10 mL) was added, and the reaction mixture extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 13%-43%, 12 min) to give (Z)-3-cyano-4-ethoxy-N'-hydroxybenzimidamide (60 mg, 292 μmol, 15 %) as a white solid.

Step 4: Preparation of N-(2-(4-(3-(3-cyano-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (70 mg, 241 μmol) in N,N-dimethylformamide (1 mL) was added (Z)-3-cyano-4-ethoxy-N'-hydroxybenzimidamide (49 mg, 241 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (91 mg, 241 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (93 mg, 723 μmol , 126 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-65%, 12 min) to give N-(2-(4-(3-(3-cyano-4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (20 mg, 43 μmol , 18 %) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.55 (t, $J=5.5$ Hz, 1H), 8.26 - 8.17 (m, 2H), 7.84 (dd, $J=1.2, 8.3$ Hz, 2H), 7.57 - 7.34 (m, 4H), 4.26 (q, $J=6.9$ Hz, 3H), 4.14 (br d, $J=5.5$ Hz, 2H), 3.94 (br d, $J=14.6$ Hz, 1H), 3.48 - 3.40 (m, 1H), 3.29 - 3.22 (m, 1H), 2.90 (br t, $J=11.4$ Hz, 1H), 2.10 (br t, $J=12.8$ Hz, 2H), 1.87 - 1.72 (m, 1H), 1.68 - 1.55 (m, 1H), 1.37 (t, $J=6.9$ Hz, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 460.2$.

Example 102: N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)-2-oxoethyl)benzamide




Step 1: Preparation of 1,3-dimethyl-1H-indazole-6-carbonitrile.




To a stirred solution of 6-bromo-1,3-dimethyl-1H-indazole (1.0 g, 4.44 mmol) in N,N-dimethylformamide (10 mL) was added zinc cyanide (521 mg, 4.44 mmol, 281 μL) and tetrakis(triphenylphosphine)palladium(0) (513 mg, 444 μmol), then the mixture was degassed with nitrogen three times. The mixture was stirred at 100 °C for 16 h under nitrogen, then cooled to 20 °C, water (10 mL) added, and the reaction mixture extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50 : 1 to 10:1) to give 1,3-dimethyl-1H-indazole-6-carbonitrile (660 mg, 3.86 mmol, 87 %) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.74 - 7.66 (m, 2H), 7.30 (d, $J=8.4$ Hz, 1H), 4.03 (s, 3H), 2.57 (s, 3H).

Step 2: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide.




To a stirred solution of 1,3-dimethyl-1H-indazole-6-carbonitrile (660 mg, 3.86 mmol) in ethanol (8 mL) was added hydroxylamine hydrochloride (536 mg, 7.72 mmol), triethylamine (781 mg, 7.72 mmol), 1.07 mL) and water (800 μ L). The mixture was heated at 80 $^{\circ}$ C for 2 h, then cooled and concentrated under reduced pressure. The residue was triturated with water (5 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide (650 mg, 3.18 mmol, 82 %) as a white solid. ^{1} H NMR (400 MHz, DMSO- d_6) δ 9.72 (br. s., 1H), 7.86 (s, 1H), 7.65 (d, J =8.5 Hz, 1H), 7.49 (dd, J =1.1, 8.5 Hz, 1H), 5.91 (s, 2H), 3.97 (s, 3H), 2.47 (s, 3H).

Step 3: Preparation of 3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5(4H)-one.



To a stirred solution of (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-6-carboximidamide (510 mg, 2.50 mmol) in dioxane (8 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (418 mg, 2.75 mmol, 414 μ L) and 1,1'-carbonyldiimidazole (608 mg, 3.75 mmol). The mixture was stirred at 110 $^{\circ}$ C for 16 h. The reaction mixture was cooled, quenched with water (10 mL), and then extracted with dichloromethane (50 mL x 3). The combined organic layers were washed with 1M hydrochloric acid (5 mL x 2), then washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5(4H)-one (430 mg, 1.87 mmol, 75 %) as a yellow solid. ^{1} H NMR (400 MHz, DMSO- d_6) δ 13.29 - 12.78 (m, 1H), 8.03 (s, 1H), 7.87 (d, J =8.4 Hz, 1H), 7.48 (dd, J =1.1, 8.4 Hz, 1H), 3.98 (s, 3H), 2.48 (br s, 3H).


Step 4: Preparation of 5-chloro-3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazole.



A flask 3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5(4H)-one (180 mg, 781.86 μ mol) was equipped with calcium chloride tube then pyridine (123 mg, 1.56 mmol, 126 μ L) and phosphoryl chloride (5 mL) were added dropwise. The mixture was heated at 110 $^{\circ}$ C for 16 h, then cooled and concentrated under reduced pressure to remove phosphoryl chloride, and then added to ice water (20 mL). The mixture was extracted with dichloromethane (40 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and


concentrated to give 5-chloro-3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazole (250 mg) as a brown solid.

Step 5: Preparation of tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxylate.




To a stirred solution of 5-chloro-3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazole (230 mg, 925 μ mol) in N-methyl-2-pyrrolidone (3 mL) was added tert-butyl piperazine-1-carboxylate (172 mg, 925 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (239 mg, 1.85 mmol, 323 μ L). The mixture was heated at 120 $^{\circ}$ C for 2 h. The reaction mixture was cooled, quenched by addition of water (5 mL), then the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Purification by prep-TLC (silica, petroleum ether : ethyl acetate = 1:1) gave tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxylate (150 mg, 376 μ mol, 41 %) as a pink solid.

Step 6: Preparation of 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole.



To a stirred solution of tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxylate (150 mg, 376 μ mol) in ethyl acetate (1 mL) was added hydrochloric acid / ethyl acetate (4M, 5 mL). The mixture was stirred at 20 $^{\circ}$ C for 2 h. The reaction mixture was concentrated under reduced pressure to give 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole (110 mg, 369 μ mol, 98 %) as a pink solid. LCMS (ESI) m/z: $[M+H]^+$ = 299.2.


Step 7: Preparation of N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole (50 mg, 168 μ mol) in N,N-dimethylformamide (1 mL) was added 2-benzamidoacetic acid (30 mg, 168 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (63 mg, 168 μ mol) and N-

ethyl-N-(propan-2-yl)propan-2-amine (64 mg, 503 μ mol, 87 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)-2-oxoethyl)benzamide (29 mg, 64 μ mol, 38 %) as a white solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.00 (s, 1H), 7.84 (d, J =7.7 Hz, 2H), 7.76 - 7.66 (m, 2H), 7.55 - 7.41 (m, 3H), 7.27 - 7.25 (m, 1H), 4.33 (d, J =3.7 Hz, 2H), 4.05 (s, 3H), 3.89 - 3.75 (m, 6H), 3.66 (br d, J =5.1 Hz, 2H), 2.57 (s, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 460.3$.

Example 103: (4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)(3-phenylisoxazol-5-yl)methanone.




Step 1: Preparation of (4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)(3-phenylisoxazol-5-yl)methanone.




To a stirred solution of 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperazin-1-yl)-1,2,4-oxadiazole (50 mg, 168 μ mol) in N,N-dimethylformamide (1 mL) was added 3-phenylisoxazole-5-carboxylic acid (31 mg, 168 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (63 mg, 168 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (64 mg, 502.8 μ mol, 87 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-75%, 12 min) to give (4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperazin-1-yl)(3-phenylisoxazol-5-yl)methanone (26 mg, 56.9 μ mol, 34 %) as a white solid. ^{1} H NMR (400MHz, CDCl_3) δ 8.01 (s, 1H), 7.83 (td, J =2.8, 4.1 Hz, 2H), 7.76 - 7.73 (m, 1H), 7.71 - 7.67 (m, 1H), 7.51 - 7.47 (m, 3H), 7.18 (s, 1H), 4.05 (s, 3H), 4.03 - 3.93 (m, 4H), 3.89 - 3.84 (m, 4H), 2.57 (s, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 470.3$.

Example 104: N-(2-(4-(3-(benzo[c][1,2,5]thiadiazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




5

Step 1: Preparation of benzo[c][1,2,5]thiadiazole-5-carbonitrile.



To a stirred solution of 5-bromobenzo[c][1,2,5]thiadiazole (200 mg, 930 μ mol) in N,N-dimethylformamide (2 mL) was added zinc cyanide (109 mg, 930 μ mol, 59 μ L) and tetrakis(triphenylphosphine)palladium(0) (107 mg, 93 μ mol), the mixture was degassed with nitrogen three times. The mixture was heated at 110 $^{\circ}$ C for 16 h under nitrogen. After cooling to 20 $^{\circ}$ C, water (5 mL) was added to the reaction, and the mixture extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give crude product. The mixture was triturated with petroleum ether (20 mL) and dichloromethane (2 mL), then the mixture was filtered, and the filter cake dried in vacuo to give benzo[c][1,2,5]thiadiazole-5-carbonitrile (100 mg, 620 μ mol, 67 %) as a red solid. LCMS (ESI) m/z: $[M+H]^+ = 162.0$.

Step 2: Preparation of (Z)-N'-hydroxybenzo[c][1,2,5]thiadiazole-5-carboximidamide.




20

To a stirred solution of benzo[c][1,2,5]thiadiazole-5-carbonitrile (100 mg, 620 μ mol) in ethanol (2 mL) was added hydroxylamine hydrochloride (86 mg, 1.24 mmol), triethylamine (125 mg, 1.24 mmol, 172 μ L) and water (200 μ L). The mixture was heated at 80 $^{\circ}$ C for 1 h. The reaction mixture was cooled and then concentrated under reduced pressure to remove ethanol. The residue was triturated with water (5 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxybenzo[c][1,2,5]thiadiazole-5-carboximidamide (70 mg, 360 μ mol, 58 %) as a brown solid. ^1H NMR


(400 MHz, DMSO-d₆) δ 10.13 (s, 1H), 8.35 (d, *J*=0.9 Hz, 1H), 8.10 (dd, *J*=1.5, 9.3 Hz, 1H), 8.01 - 7.96 (m, 1H), 6.08 (s, 2H).

Step 3: Preparation of N-(2-(4-(3-(benzo[c][1,2,5]thiadiazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (80 mg, 276 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxybenzo[c][1,2,5]thiadiazole-5-carboximidamide (53 mg, 276 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (104 mg, 276 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (106 mg, 827 μ mol, 144 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h, then heated at 110 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-65%, 12 min) to give N-(2-(4-(3-(benzo[c][1,2,5]thiadiazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (30 mg, 67 μ mol, 24 %) as a brown solid. ^{1} H NMR (400 MHz, DMSO- d_6) δ 8.66 (t, J =1.2 Hz, 1H), 8.55 (t, J =5.7 Hz, 1H), 8.28 - 8.22 (m, 2H), 7.87 - 7.83 (m, 2H), 7.54 - 7.42 (m, 3H), 4.31 (br d, J =13.0 Hz, 1H), 4.16 (dd, J =1.5, 5.7 Hz, 2H), 3.98 (br d, J =13.5 Hz, 1H), 3.54 - 3.51 (m, 1H), 3.29 (br t, J =11.5 Hz, 1H), 2.93 (br t, J =11.2 Hz, 1H), 2.16 (br t, J =13.2 Hz, 2H), 1.90 - 1.78 (m, 1H), 1.73 - 1.62 (m, 1H); LCMS (ESI) m/z : $[M+H]^+ = 449.2$.

Example 105: N-(2-(4-(3-(1,4-dimethylphthalazin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate.




To a stirred solution of 2-benzamidoacetic acid (5.0 g, 27.9 mmol) in N,N-dimethylformamide (50 mL) was added methyl piperidine-4-carboxylate (4.40 g, 30.7 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (10.6 g, 27.9 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (10.8 g, 83.7 mmol, 14.6 mL). The mixture was stirred at 20 °C for 2 h, then quenched by addition of water (50 mL). The mixture was extracted with ethyl acetate (100 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 5:1 to 1:1) to give methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (9.17 g) as a yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.88 - 7.83 (m, 2H), 7.55 - 7.49 (m, 1H), 7.48 - 7.41 (m, 2H), 4.35 - 4.28 (m, 1H), 4.24 (d, J=5.3 Hz, 2H), 3.88 (d, J=14.1 Hz, 1H), 3.66 (s, 3H), 3.20 (d, J=2.2 Hz, 1H), 2.92 - 2.84 (m, 1H), 2.65 (tt, J=4.0, 10.8 Hz, 1H), 1.99 - 1.87 (m, 2H), 1.74 - 1.64 (m, 1H), 1.62 - 1.51 (m, 1H).

Step 2: Preparation of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid.



To a stirred solution of methyl 1-(2-benzamidoacetyl)piperidine-4-carboxylate (9.17 g, 30.1 mmol) in tetrahydrofuran (90 mL) was added sodium hydroxide (2 M, 30.1 mL). The mixture was stirred at 20 °C for 2 h. The reaction mixture was concentrated under reduced pressure then acidified with concentrated hydrochloric acid until pH 1. The mixture was extracted with dichloromethane (80 mL x 4). The organic phases were combined and then washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue (8.85 g). A portion of crude product (2.5 g) was purified by prep-HPLC (column: Daiso 250*50mm, 10μm; mobile phase: [water (0.1%TFA)-acetonitrile]; B%: 1%-30%, 20 min) to provide 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (0.95 g). The remaining crude product was used directly without purification. ¹H NMR (400 MHz, Methanol-d₄) δ 7.87 - 7.83 (m, 2H), 7.55 - 7.50 (m, 1H), 7.48 - 7.42 (m, 2H), 4.36 (td, J=3.2, 13.2 Hz, 1H), 4.25 (d, J=3.3 Hz, 2H), 3.94 - 3.86 (m, 1H), 3.22 - 3.14 (m, 1H), 2.89 - 2.80 (m, 1H), 2.46 (tt, J=3.9, 11.0 Hz, 1H), 2.00 - 1.87 (m, 2H), 1.74 - 1.52 (m, 2H).


Step 3: Preparation of 2-acetyl-4-chlorophenyl trifluoromethanesulfonate.



Triflic anhydride (9.92 g, 35.2 mmol, 5.80 mL) was added dropwise at 0 °C to a stirred solution of 1-(5-chloro-2-hydroxy-phenyl)ethanone (5.0 g, 29.3 mmol) in pyridine (50 mL). The reaction was warmed slowly to 15 °C and stirred for 15 h. The reaction solution was diluted with dichloromethane (100 mL), then poured into 1N aqueous hydrochloric acid (100 mL) at 0 °C and the phases separated. The organic phase was washed with 1N hydrochloric acid (50 mL x 2), saturated aqueous sodium chloride solution


(50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by chromatography (silica, petroleum ether : ethyl acetate from 100/1 to 30/1) gave 2-acetyl-4-chlorophenyl trifluoromethanesulfonate (7.50 g, 24.8 mmol, 85 %) as a yellow liquid.

5 *Step 4: Preparation of 1,1'-(4-chloro-1,2-phenylene)diethanone.*




To a stirred solution of 2-acetyl-4-chlorophenyl trifluoromethanesulfonate (3.0 g, 9.91 mmol) in N,N-dimethylformamide (30 mL) was added 1-vinylxybutane (4.96 g, 49.6 mmol, 6.36 mL), palladium(II) acetate (111 mg, 495.5 μ mol), 3-diphenylphosphanylpropyl(diphenyl)phosphane (245 mg, 594.6 μ mol) and TEA (1.20 g, 11.9 mmol, 1.65 mL), then the mixture was degassed with nitrogen three times. The mixture was heated at 80 °C for 16 h under nitrogen. After cooling to 20 °C, 2M hydrochloric acid (20 mL) was added and the solution stirred at 20 °C for 2 h. Water (30 mL) was added and the mixture was extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50 : 1 to 10:1) to give 1,1'-(4-chloro-1,2-phenylene)diethanone (800 mg, 4.07 mmol, 41 %) as a red oil. ¹H NMR (400 MHz, CDCl₃) δ 7.58 - 7.54 (m, 1H), 7.51 - 7.47 (m, 1H), 7.43 (t, *J*=1.9 Hz, 1H), 2.52 (d, *J*=2.0 Hz, 3H), 2.50 (d, *J*=2.0 Hz, 3H).

20 *Step 5: Preparation of 6-chloro-1,4-dimethylphthalazine.*




1,1'-(4-chloro-1,2-phenylene)diethanone (800 mg, 4.07 mmol) in ethanol (15 mL) was added to hydrazine hydrate (224 mg, 4.48 mmol, 217 μ L) in ethanol (15 mL) at 0 °C over a period of 5 min under argon. The mixture was stirred at 20 °C for 18 h. The reaction mixture was concentrated under reduced pressure to ~15 mL, then extracted with dichloromethane (50 mL x 3). The combined organic phases were washed water (20 mL x 2), then the separated organic layer was washed saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 6-chloro-1,4-dimethylphthalazine (662 mg, 3.44 mmol, 84 %) as a red solid. ¹H NMR (400 MHz, CDCl₃) δ 7.98 - 7.93 (m, 2H), 7.75 (dd, *J*=2.1, 8.8 Hz, 1H), 2.88 (d, *J*=5.1 Hz, 6H).


30

Step 6: Preparation of 1,4-dimethylphthalazine-6-carbonitrile.

To a stirred solution of 6-chloro-1,4-dimethylphthalazine (640 mg, 3.32 mmol) in N,N-dimethylformamide (10 mL) was added zinc cyanide (390 mg, 3.32 mmol, 210 μ L) and tetrakis(triphenylphosphine)palladium(0) (383 mg, 332 μ mol) under nitrogen. The mixture was heated at 110 $^{\circ}$ C for 16 h, then cooled to 20 $^{\circ}$ C. Water (15 mL) was added then the reaction mixture was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude product. Trituration with petroleum ether (30 mL) and dichloromethane (5 mL) followed by filtration and drying the filter cake in vacuo gave 1,4-dimethylphthalazine-6-carbonitrile (400 mg, 2.18 mmol, 66 %) as a brown solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.47 (s, 1H), 8.21 (d, J =8.5 Hz, 1H), 8.09 (dd, J =1.4, 8.5 Hz, 1H), 3.04 (s, 6H).

Step 7: Preparation of (Z)-N'-hydroxy-1,4-dimethylphthalazine-6-carboximidamide.


To a stirred solution of 1,4-dimethylphthalazine-6-carbonitrile (380 mg, 2.07 mmol) in ethanol (1 mL) was added hydroxylamine hydrochloride (288 mg, 4.15 mmol), triethylamine (419 mg, 4.15 mmol, 575 μ L) and water (100 μ L). The mixture was heated at 80 $^{\circ}$ C for 1 h. The reaction mixture was cooled then concentrated under reduced pressure. The residue was triturated with water (5 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-1,4-dimethylphthalazine-6-carboximidamide (330 mg, 1.53 mmol, 74 %) as a brown solid. ^{1} H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.06 (s, 1H), 8.38 (d, J =1.3 Hz, 1H), 8.28 (dd, J =1.7, 8.7 Hz, 1H), 8.12 (d, J =8.8 Hz, 1H), 6.19 (s, 2H), 2.85 (d, J =17.0 Hz, 6H).

Step 8: Preparation of N-(2-(4-(3-(1,4-dimethylphthalazin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.


To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (100 mg, 344 μ mol) in N,N-dimethylformamide (2 mL) was added N'-hydroxy-1,4-dimethylphthalazine-6-carboximidine (74 mg, 344 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (130 mg, 344 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (133 mg, 1.03 mmol, 180 μ L). The mixture was stirred

at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled, then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-55%, 12 min) to give N-(2-(4-(3-(1,4-dimethylphthalazin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (37 mg, 77 µmol, 22 %) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.71 (d, *J*=1.5 Hz, 1H), 8.59 (t, *J*=5.6 Hz, 1H), 8.54 (dd, *J*=1.5, 8.6 Hz, 1H), 8.39 (d, *J*=8.6 Hz, 1H), 7.90 - 7.86 (m, 2H), 7.57 - 7.45 (m, 3H), 4.37 (br d, *J*=13.2 Hz, 1H), 4.25 - 4.13 (m, 2H), 4.02 (br d, *J*=13.5 Hz, 1H), 3.55 (tt, *J*=3.8, 11.1 Hz, 1H), 3.32 - 3.27 (m, 1H), 2.96 (s, 3H), 2.98 - 2.91 (m, 1H), 2.93 (s, 3H), 2.20 (br t, *J*=13.7 Hz, 2H), 1.95 - 1.82 (m, 1H), 1.77 - 1.65 (m, 1H); LCMS (ESI) *m/z*: [M+H]⁺ = 471.3.

Example 106: 2-(2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one.




Step 1: Preparation of 2-(2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one.




To a stirred solution of 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (50 mg, 165 µmol) in N,N-dimethylformamide (1 mL) was added 2-(1-oxoisoindolin-2-yl)acetic acid (31 mg, 165 µmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (62 mg, 165 µmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (63 mg, 494 µmol, 86 µL). The mixture was stirred at 20 °C for 1 h, then the reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give 2-(2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one (41 mg, 86 µmol, 52 %) as a gray solid. ¹H NMR (400MHz, CDCl₃) δ 7.88 (d, *J*=8.2 Hz, 1H), 7.66 (dd, *J*=1.9, 8.3 Hz, 1H), 7.59 - 7.54 (m, 2H), 7.48 (t, *J*=6.4 Hz, 2H), 6.95 (d, *J*=8.4 Hz, 1H), 4.59 (d, *J*=3.4 Hz, 2H), 4.53 - 4.40 (m, 3H), 4.18 (q, *J*=7.0 Hz, 2H), 4.08 (br d, *J*=13.7 Hz, 1H), 3.96 (s, 3H), 3.43 - 3.24 (m, 2H), 3.11 - 3.02 (m, 1H), 2.28 - 2.15 (m, 2H), 2.05 - 1.90 (m, 2H), 1.51 (t, *J*=7.0 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 477.3.

Example 107: N-[2-[4-[3-(5-ethoxy-6-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide.




5

Step 1: 2-bromo-6-iodo-pyridin-3-ol.



A mixture of 2-bromopyridin-3-ol (5.0 g, 28.7 mmol), iodine (8.02 g, 31.6 mmol, 6.37 mL), and potassium carbonate (7.94 g, 57.5 mmol) in water (66 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 20 °C for 16 h under a nitrogen atmosphere. Excess iodine was quenched by addition of solid sodium bisulfite. The pH of the solution was adjusted to 5-6 using glacial acetic acid, and the solid formed was collected by filtration and dried in vacuum to give 2-bromo-6-iodo-pyridin-3-ol (10.0 g) that was used directly without further purification.


Step 2: 2-bromo-3-ethoxy-6-iodo-pyridine.



To a stirred solution of 2-bromo-6-iodo-pyridin-3-ol (10.0 g, 33.4 mmol) in tetrahydrofuran (200 mL) was added potassium carbonate (6.91 g, 50.0 mmol) and the mixture was stirred for 10 min at 0 °C in an ice bath. Iodoethane (6.24 g, 40.0 mmol, 3.20 mL) was added dropwise, then the reaction mixture was warmed to 40 °C. After 16 h, the reaction mixture was quenched by addition of water (10 mL), and then extracted with ethyl acetate (10 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 2-bromo-3-ethoxy-6-iodo-pyridine (7.50 g, 22.9 mmol, 69 %) that was used directly without further purification.

25


Step 3: 3-ethoxy-6-iodo-2-methoxy-pyridine.



A mixture of 2-bromo-3-ethoxy-6-iodo-pyridine (7.0 g, 21.4 mmol) and sodium methoxide (1.73 g, 32.0 mmol) in N,N-dimethylformamide (3 mL) was degassed and purged with nitrogen 3 times, and then


the mixture was heated at 100 °C for 16 h under a nitrogen atmosphere. The reaction mixture was quenched by addition of water (20 mL), then extracted with ethyl acetate (20 mL x 3). The organic layer phases were combined and then washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 3-ethoxy-6-iodo-2-methoxy-pyridine (5.0 g, 17.9 mmol). This was used directly without further purification.

Step 4: 5-ethoxy-6-methoxy-pyridine-2-carbonitrile.




A mixture of 3-ethoxy-6-iodo-2-methoxy-pyridine (2.50 g, 8.96 mmol) and copper(I) cyanide (962 mg, 10.75 mmol, 2.35 mL) in N,N-dimethylformamide (10 mL) was degassed and purged with nitrogen 3 times, and then the mixture was heated at 100 °C for 16 h under a nitrogen atmosphere. The reaction mixture was quenched by addition of water (20 mL), then extracted with ethyl acetate (20 mL x 3). The organic extracts were combined, washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 5-ethoxy-6-methoxy-pyridine-2-carbonitrile (1.40 g). This was used directly without further purification.

Step 5: 5-ethoxy-6-methoxy-pyridine-2-carbonitrile.



A mixture of 5-ethoxy-6-methoxy-pyridine-2-carbonitrile (1.0 g, 5.61 mmol), hydroxylamine hydrochloride (857 mg, 12.34 mmol) and triethylamine (1.25 g, 12.34 mmol, 1.71 mL) in ethanol (10 mL) was heated at 75 °C for 16 h under a nitrogen atmosphere. The reaction mixture was cooled, diluted with water (10 mL), and filtered. The filter cake was dried in vacuo to give 5-ethoxy-N'-hydroxy-6-methoxy-pyridine-2-carboxamidine (950 mg, 4.50 mmol, 80 %) as a yellow solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.40 (d, J=8.2 Hz, 1H), 6.99 (d, J=8.2 Hz, 1H), 5.45 (br s, 2H), 4.05 (q, J=6.9 Hz, 2H), 3.98 (s, 3H), 1.41 (t, J=7.0 Hz, 3H).


Step 6: N-[2-[4-[3-(5-ethoxy-6-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxoethyl]benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (100 mg, 344 μmol) in N,N-dimethylformamide (2 mL) was added 5-ethoxy-N'-hydroxy-6-methoxy-pyridine-2-carboxamidine (72 mg, 344 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413

μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (133 mg, 1.03 mmol, 180 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The crude product was purified by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12 min) to give N-[2-[4-[3-(5-ethoxy-6-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (37 mg, 79.9 μmol, 23 %) as a yellow solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.91 - 7.85 (m, 2H), 7.70 (d, J=8.0 Hz, 1H), 7.57 - 7.52 (m, 1H), 7.51 - 7.44 (m, 2H), 7.36 (br s, 1H), 7.13 (d, J=8.2 Hz, 1H), 4.57 - 4.48 (m, 1H), 4.32 (d, J=3.9 Hz, 2H), 4.23 - 4.12 (m, 5H), 4.06 - 3.90 (m, 1H), 3.42 - 3.32 (m, 2H), 3.20 - 3.11 (m, 1H), 2.32 - 2.20 (m, 2H), 2.08 - 1.95 (m, 2H), 1.54 (t, J=7.0 Hz, 3H); LCMS(ESI) m/z: [M+H]⁺ = 466.3.


Example 108: 4-[4-[3-(5-ethoxy-6-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.



Step 1: 4-[4-[3-(5-ethoxy-6-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.




To a stirred solution of 5-ethoxy-N'-hydroxy-6-methoxy-pyridine-2-carboxamide (66 mg, 316 μmol) in N,N-dimethylformamide (2 mL) was added 1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (100 mg, 316 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (143 mg, 379 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (122 mg, 948 μmol, 165 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The mixture was cooled and the crude product was purified by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-70%, 12 min) to give 4-[4-[3-(5-ethoxy-6-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one (47 mg, 96 μmol, 3 %) as a yellow solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.71 (dd, J=4.6, 8.0 Hz, 1H), 7.62 (dd, J=1.1, 8.7 Hz, 2H), 7.43 - 7.38 (m, 2H), 7.22 - 7.17 (m, 1H), 7.13 (d, J=7.8 Hz, 1H), 4.63 - 4.48 (m, 1H), 4.34 (t, J=7.9 Hz, 1H), 4.22 - 4.15 (m, 5H), 4.03 - 3.93 (m, 2H), 3.60 (m, 1H), 3.46 - 3.33 (m, 2H), 3.15 - 2.95 (m, 2H), 2.91 - 2.82 (m, 1H), 2.27 (m, 2H), 2.08 - 1.94 (m, 2H), 1.54 (t, J=7.0 Hz, 3H); LCMS(ESI) m/z: [M+H]⁺ = 492.3.

Example 109: N-[2-[4-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide


5

Step 1: 2,2-difluoro-1,3-benzodioxole-5-carbonitrile.



A mixture of 5-bromo-2,2-difluoro-1,3-benzodioxole (500 mg, 2.11 mmol), zinc cyanide (247 mg, 2.11 mmol, 133 μ L) and tetrakis(triphenylphosphine)palladium(0) (243 mg, 211 μ mol) in N,N-dimethylformamide (4 mL) was degassed and purged with nitrogen 3 times, and then the mixture was heated at 100 $^{\circ}$ C for 16 h under a nitrogen atmosphere. The reaction mixture was cooled, diluted with water (5 mL), and extracted with ethyl acetate (10 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 2,2-difluoro-1,3-benzodioxole-5-carbonitrile (300 mg, 1.64 mmol, 78 %) as a solid. ^{1} H NMR (400MHz, CHLOROFORM- d) δ = 7.38 (dd, J =1.5, 8.3 Hz, 1H), 7.27 (d, J =1.5 Hz, 1H), 7.08 (d, J =8.3 Hz, 1H).


Step 2: 2,2-difluoro-N'-hydroxy-1,3-benzodioxole-5-carboxamidine.



A mixture of 2,2-difluoro-1,3-benzodioxole-5-carbonitrile (300 mg, 1.64 mmol), triethylamine (331 mg, 3.28 mmol, 454 μ L) and hydroxylamine hydrochloride (227 mg, 3.28 mmol) in water (500 μ L) and ethanol (5 mL) was heated at 70 $^{\circ}$ C for 16 h. The reaction mixture was cooled, diluted with water (10 mL) and filtered. The collected solid was dried in vacuo to give 2,2-difluoro-N'-hydroxy-1,3-benzodioxole-5-carboxamidine (210 mg) as a solid.


25

Step 3: *N*-[2-[4-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide,




A mixture of 2,2-difluoro-*N*'-hydroxy-1,3-benzodioxole-5-carboxamidine (74 mg, 344 μ mol), 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (100 mg, 344 μ mol), *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (133 mg, 1.03 mmol, 180 μ L) and (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (156 mg, 413 μ mol) in *N,N*-dimethylformamide (2 mL) was stirred at 20 °C for 1 h under a nitrogen atmosphere. The mixture was heated at 120 °C for 1 h, then cooled and purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12 min) to give *N*-[2-[4-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (58 mg, 124 μ mol, 36 %) as a white solid. ¹H NMR (400MHz, CHLOROFORM-*d*) δ = 7.85 - 7.76 (m, 3H), 7.72 (d, *J*=1.5 Hz, 1H), 7.48 - 7.42 (m, 1H), 7.41 - 7.35 (m, 2H), 7.26 (br s, 1H), 7.10 (d, *J*=8.4 Hz, 1H), 4.53 - 4.37 (m, 1H), 4.23 (d, *J*=4.0 Hz, 2H), 3.84 (br d, *J*=13.9 Hz, 1H), 3.35 - 3.21 (m, 2H), 3.12 - 3.02 (m, 1H), 2.26 - 2.10 (m, 2H), 1.98 - 1.85 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺:471.2.

Example 110: *N*-(2-(4-(3-(4-ethyl-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-7-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



Step 1: Preparation of 7-bromo-4-ethyl-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine




To a stirred solution of 7-bromo-4-ethyl-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-one (900 mg, 3.51 mmol) in tetrahydrofuran (10 mL) was added a solution of borane in tetrahydrofuran (1 M, 12.28 mL), and the mixture was stirred 20 °C for 1 h, then heated at 80 °C for 2 h. The reaction mixture was cooled then quenched by addition of methanol (15 mL). The mixture was concentrated under reduced pressure, then diluted with water (20 mL), extracted with ethyl acetate (60 mL x 2), and the combined organic phases

washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 7-bromo-4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (750 mg, 3.10 mmol, 88 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 6.86 - 6.80 (m, 2H), 6.45 (d, *J*=8.3 Hz, 1H), 4.19 - 4.13 (m, 2H), 3.28 - 3.18 (m, 4H), 1.06 (t, *J*=7.1 Hz, 3H).


5

Step 2: Preparation of 4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbonitrile.



To a stirred solution of 7-bromo-4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (80 mg, 330 μmol) in N,N-dimethylformamide (1 mL) was added zinc cyanide (38 mg, 330 μmol) and tetrakis(triphenylphosphine)palladium(0) (38 mg, 33 μmol), then the mixture was degassed with nitrogen three times. The mixture was heated at 110 °C for 16 h under nitrogen, then cooled to 20 °C, and water (3 mL) added. The reaction mixture was extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and then concentrated in vacuo to give a crude residue that was purified by prep-TLC (petroleum ether : ethyl acetate=2:1) to give 4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbonitrile (60 mg, 319 μmol, 96 %) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.10 (td, *J*=1.4, 8.5 Hz, 1H), 7.00 - 6.92 (m, 1H), 6.59 (d, *J*=8.4 Hz, 1H), 4.20 (dt, *J*=0.9, 4.5 Hz, 2H), 3.42 - 3.33 (m, 4H), 1.16 (dt, *J*=0.9, 7.2 Hz, 3H).


Step 3: Preparation of (Z)-4-ethyl-N'-hydroxy-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboximidamide.



To a stirred solution of 4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbonitrile (60 mg, 319 μmol) in ethanol (1 mL) was added hydroxylamine hydrochloride (44 mg, 638 μmol), triethylamine (64 mg, 638 μmol, 88 μL) and water (100 μL). The mixture was stirred at 80 °C for 5 h. The reaction mixture was cooled, concentrated under reduced pressure, and then diluted with water (5 mL). The mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give crude (Z)-4-ethyl-N'-hydroxy-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboximidamide (60 mg, 271 μmol, 85 %) as a white solid.


30

Step 4: Preparation of N-(2-(4-(3-(4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (60 mg, 207 μ mol) in N,N-dimethylformamide (1 mL) was added (Z)-4-ethyl-N'-hydroxy-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboximidamide (45 mg, 207 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (78 mg, 207 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (80 mg, 620 μ mol, 108 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h, then heated at 110 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Luna C18 150x2.5mm 5 μ m; mobile phase: [water (0.225% TFA)-acetonitrile]; B%: 40%-65%, 16 min) to give N-(2-(4-(3-(4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (17 mg, 35.8 μ mol, 17 %) as a brown solid. ^{1} H NMR (400 MHz, CDCl_3) δ 7.89 - 7.84 (m, 2H), 7.58 - 7.43 (m, 5H), 7.35 (br s, 1H), 6.72 (d, J =8.5 Hz, 1H), 4.45 (br d, J =13.8 Hz, 1H), 4.33 - 4.24 (m, 4H), 3.89 (br d, J =14.1 Hz, 1H), 3.45 - 3.25 (m, 6H), 3.18 (br t, J =10.4 Hz, 1H), 2.28 - 2.18 (m, 2H), 2.07 - 1.92 (m, 2H), 1.20 (t, J =7.2 Hz, 3H); LCMS (ESI) m/z : $[M+H]^+$ = 476.3.

Example 111: N-(2-(4-(3-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 7-bromo-4-ethyl-2H-benzo[b][1,4]oxazin-3(4H)-one.




To a stirred solution of 7-bromo-4H-1,4-benzoxazin-3-one (2.0 g, 8.77 mmol) in N,N-dimethylformamide (20 mL) was added iodoethane (1.64 g, 10.52 mmol, 841 μ L) and potassium carbonate (3.64 g, 26.3 mmol) at 0 $^{\circ}$ C. The reaction was warmed at 40 $^{\circ}$ C for 2 h. The reaction mixture was cooled then quenched by addition of water (30 mL), and then the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 7-bromo-4-ethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (2.06 g, 8.04 mmol, 92 %) as a yellow solid. ^{1} H NMR (400 MHz, CDCl_3) δ 7.11 - 7.05 (m, 2H), 6.78 (d, J =8.9 Hz, 1H), 4.52 (s, 2H), 3.89 (q, J =7.2 Hz, 2H), 1.20 (t, J =7.2 Hz, 3H).

Step 2: Preparation of 4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbonitrile.




To a stirred solution of 7-bromo-4-ethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (800 mg, 3.12 mmol) in N,N-dimethylformamide (10 mL) was added copper(I) cyanide (559 mg, 6.25 mmol, 1.36 mL) and tetrakis(triphenylphosphine)palladium(0) (360 mg, 312 μ mol). The mixture was degassed with nitrogen, then heated at 110 °C for 16 h under nitrogen. The reaction mixture was cooled to 20 °C, then water (15 mL) was added and the reaction mixture extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 5:1) to give 4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbonitrile (70 mg, 346 μ mol, 11 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.38 (dd, *J*=1.9, 8.4 Hz, 1H), 7.30 - 7.29 (m, 1H), 7.08 (d, *J*=8.3 Hz, 1H), 4.68 (s, 2H), 4.04 (q, *J*=7.2 Hz, 2H), 1.32 (t, *J*=7.2 Hz, 3H).

Step 3: Preparation of (Z)-4-ethyl-N'-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboximidamide.



To a stirred solution of 4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbonitrile (70 mg, 346 μ mol) in ethanol (1 mL) was added hydroxylamine hydrochloride (48 mg, 692 μ mol), triethylamine (70 mg, 692 μ mol, 95 μ L) and water (100 μ L). The mixture was heated at 80 °C for 5 h. The reaction mixture was cooled then concentrated under reduced pressure. The residue was diluted with water (5 mL), then the reaction mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (Z)-4-ethyl-N'-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboximidamide (60 mg, 255 μ mol, 74 %) as a white solid.


Step 4: Preparation of N-(2-(4-(3-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-(benzamidoacetyl)piperidine-4-carboxylic acid (60 mg, 206.7 μ mol) in N,N-dimethylformamide (1 mL) was added (Z)-4-ethyl-N'-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboximidamide (48 mg, 206.7 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate) (78 mg, 206.7 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (80 mg, 620 μ mol, 108 μ L). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled then purified by prep-HPLC (column: Luna C18 100x30 5 μ m; mobile phase: [water (0.1%TFA)-methanol]; B%: 38%-68%,12 min) to give N-(2-(4-(3-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (6 mg, 13 μ mol, 6 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J*=7.2 Hz, 2H), 7.77 (dd, *J*=1.8, 8.5 Hz, 1H), 7.71 (d, *J*=1.8 Hz, 1H), 7.56 - 7.43 (m, 3H), 7.34 (br s, 1H), 7.10 (d, *J*=8.4 Hz, 1H), 4.66 (s, 2H), 4.50 (br d, *J*=13.7 Hz, 1H), 4.31 (d, *J*=3.8 Hz, 2H), 4.04 (q, *J*=7.1 Hz, 2H), 3.92 (br d, *J*=14.7 Hz, 1H), 3.40 - 3.29 (m, 2H), 3.17 (br t, *J*=10.7 Hz, 1H), 2.31 - 2.19 (m, 2H), 2.00 (br t, *J*=13.4 Hz, 2H), 1.32 (t, *J*=7.2 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 490.2.

Example 112: (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(2-phenylmorpholino)methanone.




Step 1: Preparation of (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(2-phenylmorpholino)methanone.




To a stirred solution of 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylic acid (80 mg, 230 μ mol) in N,N-dimethylformamide (1 mL) was added 2-phenylmorpholine (37 mg, 230 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (87 mg, 230 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (89 mg, 690.93 μ mol, 120 μ L). The mixture was stirred at 20 °C for 1 h. The reaction mixture was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-70%,12 min) to give (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(2-phenylmorpholino)methanone (94 mg, 191.6 μ mol, 83 %) as a yellow oil. ¹H NMR (400MHz, Methanol-d₄) δ 7.55 - 7.41 (m, 3H), 7.40 - 7.26 (m, 4H), 6.99 (d, *J*=8.4 Hz, 1H), 4.51 - 4.36 (m, 2H), 4.26 - 4.13 (m, 2H), 4.12 - 3.98 (m, 4H), 3.86 (s, 3H), 3.75 - 3.58 (m, 1H), 3.46 - 3.30 (m, 1H), 3.28 - 3.17 (m, 2H), 3.04 (br s, 1H), 2.95 - 2.64 (m, 1H), 1.93 - 1.68 (m, 4H), 1.40 (t, *J*=6.9 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 493.3.

Example 113: (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(4-methyl-3-phenylpiperazin-1-yl)methanone.





- 5 **Step 1: Preparation of (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(4-methyl-3-phenylpiperazin-1-yl)methanone.**




- To a stirred solution of 1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylic acid (70 mg, 201.5 μ mol) in N,N-dimethylformamide (1 mL) was added 1-methyl-2-phenylpiperazine dihydrochloride (50 mg, 201.5 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (76 mg, 201.5 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (78 mg, 604.6 μ mol, 105 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h. The reaction mixture was purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 38%-68%, 12 min) to give (1-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)(4-methyl-3-phenylpiperazin-1-yl)methanone (60 mg, 117 μ mol, 58 %) as a yellow solid. ^{1} H NMR (400MHz, CDCl_3) δ 7.57 (br d, $J=7.9$ Hz, 1H), 7.50 (br s, 1H), 7.45 - 7.29 (m, 5H), 6.91 (d, $J=8.3$ Hz, 1H), 4.68 - 4.48 (m, 1H), 4.35 - 4.11 (m, 4H), 3.94 (s, 3H), 3.92 - 3.69 (m, 1H), 3.52 - 3.10 (m, 3H), 3.09 - 2.60 (m, 4H), 2.33 - 2.17 (m, 1H), 2.07 (br d, $J=4.9$ Hz, 3H), 2.04 - 1.73 (m, 4H), 1.49 (t, $J=7.0$ Hz, 3H); LCMS (ESI) m/z : $[M+H]^+ = 506.4$.

- 20 **Example 114: N-(2-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.**




Step 1: Preparation of 4,6-dichloro-N-methoxy-N-methylnicotinamide.

To a stirred solution of 4,6-dichloronicotinic acid (1.0 g, 5.21 mmol) in N,N-dimethylformamide (15 mL) was added N,O-dimethylhydroxylamine (1.02 g, 10.42 mmol), hydroxybenzotriazole (1.41 g, 10.4 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (2.0 g, 10.4 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (2.02 g, 15.6 mmol, 2.73 mL). The mixture was stirred at 20 °C for 48 h. The reaction mixture was quenched by addition of water (20 mL) then the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50 : 1 to 5:1 to give 4,6-dichloro-N-methoxy-N-methylnicotinamide (660 mg, 2.81 mmol, 54 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 7.45 (s, 1H), 3.51 (br s, 3H), 3.40 (br s, 3H).


Step 2: Preparation of 1-(4,6-dichloropyridin-3-yl)ethanone.

To a stirred solution of 4,6-dichloro-N-methoxy-N-methylnicotinamide (600 mg, 2.55 mmol) in tetrahydrofuran (10 mL) was added methylmagnesium bromide (3 M, 2.16 mL) at 0 °C, then the mixture was stirred at 0 °C for 2 h. After addition of saturated aqueous ammonium chloride (20 mL), the mixture was concentrated to ~20 mL and the residue that remained was extracted with dichloromethane (40 mL x 3). The combined organic layers were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1-(4,6-dichloropyridin-3-yl)ethanone (430 mg, 2.26 mmol, 89 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 1H), 7.48 (s, 1H), 2.70 (s, 3H).

Step 3: Preparation of 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine.


1-(4,6-dichloropyridin-3-yl)ethanone (430 mg, 2.26 mmol) in hydrazine hydrate (10 mL) was stirred at 20 °C for 4 h. The reaction mixture was diluted with water (10 mL), then the mixture was extracted with dichloromethane (40 mL x 3). The combined organic phases were washed with water (10 mL x 2), then saturated aqueous sodium chloride solution (20 mL), then dried over anhydrous sodium sulfate, filtered and concentrated to give crude 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (370 mg, 2.21 mmol, 98 %) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.23 (br s, 1H), 8.95 (br s, 1H), 7.59 (s, 1H), 2.61 (br s, 3H).

Step 4: Preparation of 6-chloro-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine.




To a stirred solution of 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (330 mg, 1.97 mmol) in N,N-dimethylformamide (5 mL) was added iodomethane (558 mg, 3.94 mmol, 245 μ L) and potassium carbonate (816 mg, 5.91 mmol) at 0 $^{\circ}$ C. The reaction was heated at 60 $^{\circ}$ C for 2 h. The reaction mixture was cooled then quenched with water (10 mL), and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by prep-TLC (Petroleum ether : ethyl acetate=1:1) to give 6-chloro-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine (120 mg, 661 μ mol, 34 %) as a yellow solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.77 (s, 1H), 7.29 - 7.27 (m, 1H), 3.98 (s, 3H), 2.63 (s, 3H).

Step 5: Preparation of 1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile.



To a stirred solution of 6-chloro-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine (100 mg, 551 μ mol) in N,N-dimethylformamide (2 mL) was added zinc cyanide (64 mg, 551 μ mol) and tetrakis(triphenylphosphine)palladium(0) (63 mg, 55 μ mol), then the mixture was degassed with nitrogen three times. The mixture was stirred at 110 $^{\circ}$ C for 16 h under nitrogen. The reaction was cooled to 20 $^{\circ}$ C, then water (3 mL) was added and the mixture was extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue that was purified by prep-TLC (silica, petroleum ether : ethyl acetate = 1:1). 1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile (50 mg, 290 μ mol, 53 %) as a white solid. LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 173.1$.

Step 6: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carboximidamide.




To a stirred solution of 1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile (50 mg, 290 μ mol) in ethanol (1 mL) was added hydroxylamine hydrochloride (40 mg, 580.76 μ mol), triethylamine (58 mg, 580.76 μ mol, 80 μ L) and water (100 μ L). The mixture was stirred at 80 $^{\circ}$ C for 2 h. The reaction mixture was concentrated under reduced pressure then diluted with water (5 mL). The reaction mixture was

extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give crude (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carboximidamide (60 mg) as a white solid. LCMS (ESI) m/z : $[M+H]^+ = 206.2$.

5


Step 7: Preparation of N-(2-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (35 mg, 120.6 μmol) in N,N-dimethylformamide (1 mL) was added (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carboximidamide (24 mg, 120.6 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (45 mg, 120.6 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (46 mg, 361.7 μmol , 63 μL). The mixture was stirred at 20 $^{\circ}\text{C}$ for 1 h, then heated at 110 $^{\circ}\text{C}$ for 1 h. The reaction mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give N-(2-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (5 mg, 11 μmol , 9 %) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 9.13 (d, $J=1.1$ Hz, 1H), 8.12 (d, $J=1.0$ Hz, 1H), 7.89 - 7.84 (m, 2H), 7.56 - 7.43 (m, 3H), 7.34 (br s, 1H), 4.55 (br d, $J=13.7$ Hz, 1H), 4.32 (d, $J=3.9$ Hz, 2H), 4.09 (s, 3H), 3.94 (br d, $J=13.8$ Hz, 1H), 3.44 - 3.32 (m, 2H), 3.14 (br t, $J=10.9$ Hz, 1H), 2.68 (s, 3H), 2.37 - 2.24 (m, 2H), 2.16 - 1.96 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 460.1$.


20

Example 115: N-[2-[4-[3-(1,3-dimethylpyrazolo[3,4-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide.



25


Step 1: 2,6-difluoro-N-methoxy-N-methylpyridine-3-carboxamide.



A mixture of 2,6-difluoropyridine-3-carboxylic acid (3.0 g, 18.9 mmol), N-methoxymethanamine hydrochloride (12.9 g, 132.0 mmol) hydroxybenzotriazole (10.2 g, 75.4 mmol), diisopropylethylamine


(3.70 g, 28.7 mmol, 5.01 mL) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (7.20 g, 37.5 mmol) in N,N-dimethylformamide (50 mL) was stirred at 20 °C for 16 h under a nitrogen atmosphere. The reaction mixture was diluted with water (30 mL) and extracted with dichloromethane (20 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 2,6-difluoro-N-methoxy-N-methyl-pyridine-3-carboxamide (2.80 g, 13.9 mmol, 73 %) as a solid.

Step 2: 1-(2,6-difluoro-3-pyridyl)ethanone.




To a stirred solution of 2,6-difluoro-N-methoxy-N-methyl-pyridine-3-carboxamide (3.0 g, 14.8 mmol) in tetrahydrofuran (60 mL) was added dropwise methylmagnesium bromide (1.77 g, 14.84 mmol) at 0 °C. The resulting mixture was stirred at 0 °C for 2 h, and then quenched by water at 0 °C. The mixture was diluted with ethyl acetate (60 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (25 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. Purification by chromatography (silica, petroleum ether / ethyl acetate=2:1) gave 1-(2,6-difluoro-3-pyridyl)ethanone (2.20 g, 14.0 mmol, 94 %) as a white solid.

Step 3: 3-ethoxy-6-iodo-2-methoxy-pyridine.




A solution of 1-(2,6-difluoro-3-pyridyl)ethanone (1.50 g, 9.55 mmol) in dichloromethane (55 mL) was treated with titanium(IV) isopropoxide (10.37 g, 36.48 mmol, 10.80 mL) at room temperature. The resulting mixture was stirred for 15 min, then hydrazine hydrate (2.06 g, 41.16 mmol, 2 mL) was added. Stirring continued for an additional 1.5 h, then water (5 mL) was added, and the resulting thick mixture was stirred vigorously for 20 min. The reaction mixture was filtered, and the solids were washed with dichloromethane (10 mL). The filtrate was concentrated in vacuo to provide the crude hydrazone intermediate as an oil. The crude hydrazone was dissolved in ethanol (15 mL), and the solution was heated at 80 °C for 24 h. The reaction mixture was quenched by addition of water (10 mL) at 20 °C, and then extracted with dichloromethane (10 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 6-fluoro-3-methyl-1H-pyrazolo[3,4-b]pyridine (1.20 g) which was used directly without further purification.

Step 4: 6-fluoro-1,3-dimethyl-pyrazolo[3,4-b]pyridine.




A mixture of 6-fluoro-3-methyl-1H-pyrazolo[3,4-b]pyridine (1.20 g, 7.94 mmol), dimethylsulfate (1.20 g, 9.53 mmol, 903 μ L), sodium hydroxide (952 mg, 23.82 mmol) in water (30 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 70 $^{\circ}$ C for 2 h under a nitrogen atmosphere. The reaction mixture was cooled, extracted with ethyl acetate (50 mL x 2), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by chromatography (silica, petroleum ether / ethyl acetate=2:1) to give 6-fluoro-1,3-dimethyl-pyrazolo[3,4-b]pyridine (400 mg, 2.42 mmol, 3 %) as a yellow solid.

Step 5: 1,3-dimethylpyrazolo[3,4-b]pyridine-6-carbonitrile.




A mixture of 6-fluoro-1,3-dimethyl-pyrazolo[3,4-b]pyridine (350 mg, 2.12 mmol), tetra-n-butylammonium bromide (1.37 g, 4.24 mmol) and sodium cyanide (727 mg, 14.84 mmol) in dimethylsulfoxide (10 mL) was degassed and purged with nitrogen 3 times, and then the mixture was heated at 150 $^{\circ}$ C for 2 h under a nitrogen atmosphere. The reaction mixture was cooled then extracted with ethyl acetate (5 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, then filtered and concentrated under reduced pressure to give a residue. The residue was purified by chromatography (silica, petroleum ether / ethyl acetate=2:1) to give 1,3-dimethylpyrazolo[3,4-b]pyridine-6-carbonitrile (150 mg, 871 μ mol, 41 %) as a yellow solid.

Step 6: N'-hydroxy-1,3-dimethyl-pyrazolo[3,4-b]pyridine-6-carboxamidine




A mixture of 1,3-dimethylpyrazolo[3,4-b]pyridine-6-carbonitrile (150 mg, 871 μ mol), hydroxylamine hydrochloride (121 mg, 1.74 mmol) and triethylamine (176 mg, 1.74 mmol, 241 μ L) in ethanol (3 mL) and water (300 μ L) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 70 $^{\circ}$ C for 5 h under a nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give N'-hydroxy-1,3-dimethyl-pyrazolo[3,4-b]pyridine-6-carboxamidine (120 mg, 584.7 μ mol, 67 %) as a yellow solid.

Step 7: *N*-[2-[4-[3-(1,3-dimethylpyrazolo[3,4-*b*]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide



5 A mixture of *N*'-hydroxy-1,3-dimethyl-pyrazolo[3,4-*b*]pyridine-6-carboxamide (50 mg, 243.6 μ mol), 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (84 mg, 292 μ mol), (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (110 mg, 292 μ mol) and *N*-ethyl-*N*-(propan-2-yl)propan-2-amine (94 mg, 730.92 μ mol, 127 μ L) in *N,N*-dimethylformamide (1 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 20 °C for 1 h under a nitrogen
10 atmosphere. The mixture was stirred at 120 °C for 1h. The mixture was cooled then purified via Prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12 min) to give *N*-[2-[4-[3-(1,3-dimethylpyrazolo[3,4-*b*]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (14 mg, 31.71 μ mol, 13 %) as a brown solid. ¹H NMR (400MHz, CHLOROFORM-*d*) δ 8.17 – 8.15 (d, *J*=8.3 Hz, 1H), 7.96 – 7.94 (d, *J*=8.2 Hz, 1H), 7.90 - 7.86 (m, 2H), 7.57 - 7.52 (m, 1H), 7.51 - 7.46 (m, 2H), 7.36 (br s, 1H), 4.60 – 4.56 (br d, *J*=13.9 Hz, 1H), 4.34 – 4.33 (d, *J*=4.0 Hz, 2H), 4.20 (s, 3H), 3.98- 3.95 (br d, *J*=13.3 Hz, 1H), 3.49 - 3.33 (m, 2H), 3.22 - 3.10 (m, 1H), 2.64 (s, 3H), 2.38 - 2.26 (m, 2H), 2.15 - 1.99 (m, 2H); LCMS(ESI) *m/z*: [*M*+*H*]⁺ = 460.3.


Example 116: 4-[4-[3-(1,3-dimethylpyrazolo[3,4-*b*]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.




Prepared using a similar experimental procedure as for example 115.

4-[4-[3-(1,3-dimethylpyrazolo[3,4-*b*]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one (4.06 mg, 8.36 μ mol, 3.43% yield) was obtained as a white solid. ¹H NMR (400MHz, CHLOROFORM-*d*) δ 8.15-8.17 (d, *J*=8.4 Hz, 1H), 7.96-7.93 (dd, *J*=3.2, 8.2 Hz, 1H), 7.61-7.63 (d, *J*=7.7 Hz, 2H), 7.42-7.40 (t, *J*=8.0 Hz, 2H), 7.23 - 7.17 (m, 1H), 4.65-4.62 (br t, *J*=14.0 Hz, 1H), 4.36-4.32 (dd, *J*=7.3, 9.6 Hz, 1H), 4.21 (s, 3H), 4.07 - 3.94 (m, 2H), 3.69 - 3.58 (m, 1H), 3.50 - 3.37 (m, 2H), 3.16 - 2.96 (m, 2H), 2.91 - 2.84 (m, 1H), 2.64 (s, 3H), 2.33 (br t, *J*=13.9 Hz, 2H), 2.13 - 1.97 (m, 2H); LCMS(ESI) *m/z*: [*M*+*H*]⁺ = 486.3.

Example 117: (4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone.




5 **Step 1: Preparation of tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate.**



To a stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (150 mg, 654 μ mol) in N,N-dimethylformamide (2 mL) was added (Z)-N'-hydroxy-1,3-dimethyl-1H-indazole-5-carboximidamide (133 mg, 654 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (248 mg, 654 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (253 mg, 1.96 mmol, 342 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h, then heated at 120 $^{\circ}$ C for 1 h. The reaction mixture was quenched by addition of water (5 mL) then the mixture was extracted with ethyl acetate (20 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by prep-TLC (silica, petroleum ether : ethyl acetate = 1:1) to furnish tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (190 mg, 478 μ mol, 73 %) as a white solid.

Step 2: Preparation of 3-(1,3-dimethyl-1H-indazol-5-yl)-5-(piperidin-4-yl)-1,2,4-oxadiazole.




To a stirred solution of tert-butyl 4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (190 mg, 478 μ mol) in methanol (3 mL) was added methanolic hydrogen chloride solution (4M, 10 mL). The mixture was stirred at 20 $^{\circ}$ C for 0.5 h. The reaction mixture was concentrated under reduced pressure to provide 3-(1,3-dimethyl-1H-indazol-5-yl)-5-(piperidin-4-yl)-1,2,4-

oxadiazole (140 mg, 471 μ mol, 98 %) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.04 (br s, 1H), 8.33 (d, $J=0.7$ Hz, 1H), 7.96 (dd, $J=1.3, 8.8$ Hz, 1H), 7.71 (d, $J=8.8$ Hz, 1H), 3.98 (s, 3H), 3.53 - 3.43 (m, 1H), 3.34 (br d, $J=12.6$ Hz, 2H), 3.11 - 3.00 (m, 2H), 2.52 (s, 3H), 2.26 (br d, $J=10.8$ Hz, 2H), 2.08 - 1.95 (m, 2H).


5

Step 3: Preparation of (4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone.




To a stirred solution of 3-(1,3-dimethyl-1H-indazol-5-yl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (130 mg, 437 μ mol) in dichloromethane (500 μ L) was added piperidine-1-carbonyl chloride (77 mg, 524.6 μ mol, 65 μ L) and triethylamine (132 mg, 1.31 mmol, 181 μ L) at 0 $^\circ\text{C}$. The mixture was warmed and then stirred at 20 $^\circ\text{C}$ for 1 h. The reaction mixture was concentrated in vacuo to give a crude product that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-70%, 12 min) to give (4-(3-(1,3-dimethyl-1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone (68 mg, 166.6 μ mol, 38 %) as a pale yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.42 (s, 1H), 8.08 (dd, $J=1.4, 8.8$ Hz, 1H), 7.40 (d, $J=8.8$ Hz, 1H), 4.03 (s, 3H), 3.80 - 3.70 (m, 2H), 3.28 - 3.14 (m, 5H), 3.05 - 2.93 (m, 2H), 2.62 (s, 3H), 2.18 (br dd, $J=3.3, 13.6$ Hz, 2H), 2.07 - 1.93 (m, 2H), 1.60 (br s, 6H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 409.1$.

Example 118: 4-(4-(3-(5-ethoxy-4-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.



Step 1: Preparation of 2-chloro-5-ethoxypyridine.




25

To a stirred solution of 6-chloropyridin-3-ol (3.0 g, 23.2 mmol) in N,N-dimethylformamide (30 mL) was added iodoethane (4.33 g, 27.8 mmol, 2.22 mL), and potassium carbonate (9.60 g, 69.6 mmol) at 0 $^\circ\text{C}$. The reaction was warmed and stirred at 40 $^\circ\text{C}$ for 2 h. The reaction mixture was quenched by addition of water (30 mL) then the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 2-chloro-5-ethoxypyridine (3.30 g, 20.9 mmol, 90 %) as a

30


yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.97 (d, $J=2.9$ Hz, 1H), 7.17 - 7.07 (m, 2H), 3.99 (q, $J=7.0$ Hz, 2H), 1.36 (t, $J=7.0$ Hz, 3H).

Step 2: Preparation of 2-chloro-5-ethoxypyridine 1-oxide.




Hydrogen peroxide-urea adduct (3.82 g, 40.61 mmol) was added in one portion to a solution of 2-chloro-5-ethoxypyridine (3.20 g, 20.3 mmol) in dichloromethane (30 mL) at 0 °C, trifluoroacetic anhydride (7.68 g, 36.6 mmol, 5.08 mL) was added dropwise. The mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched by addition of saturated aqueous sodium thiosulfate (30 mL). The mixture was extracted with dichloromethane (60 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 2-chloro-5-ethoxypyridine 1-oxide (4.0 g) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.35 - 8.28 (m, 1H), 7.44 (dt, $J=3.0, 6.0$ Hz, 1H), 7.13 - 7.04 (m, 1H), 4.13 - 4.00 (m, 2H), 1.50 - 1.40 (m, 3H).

Step 3: Preparation of 2-chloro-5-ethoxy-4-nitropyridine.



To a stirred solution of 2-chloro-5-ethoxypyridine 1-oxide (1.80 g, 10.37 mmol) in concentrated sulfuric acid (12 mL) was added concentrated nitric acid (6.50 mL) at 0 °C, the mixture was stirred at 25 °C for 1 hrs, then heated to 110 °C and stirred for 16 hrs. After cooling to 20 °C, the mixture was poured onto ice, and then aqueous sodium hydroxide solution (40 wt.%) was added carefully to adjust the pH to 14. The mixture was extracted with dichloromethane (80 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 2-chloro-5-ethoxy-4-nitropyridine (810 mg, 4.00 mmol, 39 %) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 7.64 (s, 1H), 4.30 (q, $J=6.9$ Hz, 2H), 1.51 (t, $J=7.0$ Hz, 3H).


Step 4: Preparation of 2-chloro-5-ethoxy-4-methoxypyridine.



To a stirred solution of 2-chloro-5-ethoxy-4-nitropyridine (770 mg, 3.80 mmol) in methanol (8 mL) was added potassium tert-butoxide (644 mg, 4.18 mmol) at 0 °C, then the mixture was warmed and stirred at 20 °C for 2 h. The reaction mixture was concentrated under reduced pressure then diluted with water (10 mL) of water. The mixture was extracted with dichloromethane (60 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 2-chloro-5-ethoxy-4-methoxypyridine (660


mg, 3.52 mmol, 93 %) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.85 (s, 1H), 6.80 (s, 1H), 4.13 (q, $J=7.0$ Hz, 2H), 3.95 - 3.88 (m, 3H), 1.47 (t, $J=7.0$ Hz, 3H).

Step 5: Preparation of 5-ethoxy-4-methoxypicolinonitrile.




To a stirred solution of zinc cyanide (368 mg, 3.14 mmol) in *N,N*-dimethylformamide (8 mL) was added 2-chloro-5-ethoxy-4-methoxypyridine (590 mg, 3.14 mmol) and tetrakis(triphenylphosphine)palladium(0) (362 mg, 314 μmol) under nitrogen. The mixture was heated at 120 $^\circ\text{C}$ for 16 h. The reaction was cooled to 20 $^\circ\text{C}$, water (20 mL) was added to the reaction, and then the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 5:1) to give 5-ethoxy-4-methoxypicolinonitrile (320 mg, 1.80 mmol, 57 %) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.19 (s, 1H), 7.18 (s, 1H), 4.25 (q, $J=6.9$ Hz, 2H), 3.96 (s, 3H), 1.52 (t, $J=7.0$ Hz, 3H).

*Step 6: Preparation of (Z)-5-ethoxy-*N'*-hydroxy-4-methoxypicolinimidamide.*



To a stirred solution of 5-ethoxy-4-methoxypicolinonitrile (320 mg, 1.80 mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (250 mg, 3.60 mmol), triethylamine (364 mg, 3.60 mmol, 499 μL) and water (0.50 mL). The mixture was stirred at 80 $^\circ\text{C}$ for 2 h. The reaction mixture was concentrated under reduced pressure then diluted with water (10 mL). The mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL) then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (Z)-5-ethoxy-*N'*-hydroxy-4-methoxypicolinimidamide (330 mg, 1.56 mmol, 87 %) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.71 (s, 1H), 8.10 (s, 1H), 7.39 (s, 1H), 5.75 (br s, 2H), 4.17 - 4.06 (m, 2H), 3.84 (s, 3H), 1.34 (t, $J=6.9$ Hz, 3H).


Step 7: Preparation of 4-(4-(3-(5-ethoxy-4-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.




To a stirred solution of 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (90 mg, 285 μmol) in *N,N*-dimethylformamide (2 mL) was added (Z)-5-ethoxy-*N'*-hydroxy-4-methoxypicolinimidamide (60 mg, 285 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate) (107 mg, 285 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (110 mg, 854 μ mol, 149 μ L). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled and then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-55%, 12 min) to give 4-(4-(3-(5-ethoxy-4-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (34 mg, 70 μ mol, 24 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 1H), 7.68 - 7.57 (m, 3H), 7.44 - 7.33 (m, 2H), 7.22 - 7.13 (m, 1H), 4.63 - 4.50 (m, 1H), 4.36 - 4.22 (m, 3H), 4.04 - 3.90 (m, 5H), 3.59 (td, J =8.6, 16.7 Hz, 1H), 3.43 - 3.30 (m, 2H), 3.12 - 2.93 (m, 2H), 2.88 - 2.79 (m, 1H), 2.33 - 2.20 (m, 2H), 2.13 - 1.93 (m, 2H), 1.52 (t, J =7.0 Hz, 3H); LCMS (ESI) m/z : [M+H]⁺ = 492.1.

Example 119: (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)((2S,5R)-5-phenylpyrrolidin-2-yl)methanone.




Step 1: Preparation of methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-phenylpentanoate.




To a stirred solution of O1-tert-butyl O2-methyl 5-oxopyrrolidine-1,2-dicarboxylate (1.0 g, 4.11 mmol) in tetrahydrofuran (10 mL) was added phenylmagnesium bromide (1 M in THF, 4.93 mL) at -30 °C. The reaction mixture was slowly warmed to 20 °C and stirred for 16 h. The reaction mixture was quenched by addition of saturated aqueous ammonium chloride (10 mL), and then extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 20:1) to give methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-phenylpentanoate (900 mg, 2.80 mmol, 68 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, J =8.0 Hz, 2H), 7.60 - 7.53 (m, 1H), 7.50 - 7.43 (m, 2H), 5.17 (br s, 1H), 4.40 (brs, 1H), 3.75 (s, 3H), 3.19 - 2.99 (m, 2H), 2.37 - 2.26 (m, 1H), 2.15 - 2.02 (m, 1H), 1.42 (s, 9H).

Step 2: Preparation of (2S/R,5R/S)-1-tert-butyl 2-methyl 5-phenylpyrrolidine-1,2-dicarboxylate.




To a stirred solution of methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-phenylpentanoate (800 mg, 2.49 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (5.68 g, 49.8 mmol, 3.69 mL) at 20 °C. After 16 h, the solvent was removed under reduced pressure, then the residue was dissolved in methanol (10 mL) and cooled to 0 °C. Sodium borohydride (188 mg, 4.98 mmol) was slowly added, then the mixture was warmed and stirred at 20 °C for 16 h. The mixture was concentrated in vacuo and the resulting orange oil was diluted with methanol (20 mL) and concentrated again a total of four times. The residue was suspended in dichloromethane (10 mL), then di-tert-butyl dicarbonate (815 mg, 3.74 mmol, 858 µL), triethylamine (377 mg, 3.74 mmol, 517 µL), 4-dimethylaminopyridine (3 mg, 24.90 µmol) were added and stirred at 20 °C for 16 h. Sat. aq. ammonium chloride (20 mL) was added and the layers were separated. The aqueous layer was extracted with dichloromethane (50 mL x 3) and the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 36%-66%, 12min)] to give (2S/R,5R/S)-1-tert-butyl 2-methyl 5-phenylpyrrolidine-1,2-dicarboxylate (230 mg, 753 µmol, 30 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (br d, J=7.5 Hz, 2H), 7.33 (t, J=7.5 Hz, 2H), 7.26 - 7.19 (m, 1H), 5.00 (br d, J=3.4 Hz, 0.4H), 4.75 (br t, J=7.0 Hz, 0.6H), 4.50 (br dd, J=4.7, 8.0 Hz, 0.6H), 4.36 (br t, J=7.4 Hz, 0.4H), 3.82 (s, 3H), 2.38 - 2.28 (m, 1H), 2.20 (ddd, J=6.5, 7.8, 12.5 Hz, 1H), 2.12 - 1.91 (m, 2H), 1.42 (s, 3.6H), 1.15 (s, 5.4H).

Step 3: Preparation of (2S/R,5R/S)-1-(tert-butoxycarbonyl)-5-phenylpyrrolidine-2-carboxylic acid.




To a stirred solution of (2S/R,5R/S)-1-tert-butyl 2-methyl 5-phenylpyrrolidine-1,2-dicarboxylate (180 mg, 589 µmol) in tetrahydrofuran (2 mL) was added lithium hydroxide (2 M, 589 µL). The mixture was stirred at 20 °C for 16 h. The mixture was acidified to pH 1 by dropwise addition of concentrated hydrochloric acid. The mixture was extracted with ethyl acetate (40 mL x 3). The organic layer was washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give (2S/R,5R/S)-1-(tert-butoxycarbonyl)-5-phenylpyrrolidine-2-carboxylic acid (300 mg) as a white solid.

Step 4: Preparation of (2S/R,5R/S)-tert-butyl 2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-5-phenylpyrrolidine-1-carboxylate.




To a stirred solution of (2S,5R)-1-(tert-butoxycarbonyl)-5-phenylpyrrolidine-2-carboxylic acid (270 mg, 927 μ mol) in N,N-dimethylformamide (3 mL) was added 3-(4-ethoxy-3-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (281 mg, 927 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (351 mg, 927 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (359 mg, 2.78 mmol, 485 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h. Water (15 mL) was added to the reaction, then the reaction mixture was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (2S/R,5R/S)-tert-butyl 2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-5-phenylpyrrolidine-1-carboxylate (500 mg) as a yellow oil. This material was used directly without purification.

Step 5: Preparation of (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)((2S/R,5R/S)-5-phenylpyrrolidin-2-yl)methanone.




To a stirred solution of (2S/R,5R/S)-tert-butyl 2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-5-phenylpyrrolidine-1-carboxylate (500 mg, 867 μ mol) in ethyl acetate (5 mL) was added 4N hydrochloric acid in ethyl acetate (20 mL). The mixture was stirred at 20 $^{\circ}$ C for 0.5 h. The reaction mixture was concentrated under reduced pressure to provide the crude product. The crude product was purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-65%, 12 min) to give (4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)((2S/R,5R/S)-5-phenylpyrrolidin-2-yl)methanone (78 mg, 161.6 μ mol, 19 %) as a yellow solid. ^{1} H NMR (400 MHz, Methanol-d₄) δ 7.66 (ddd, J =2.0, 3.5, 8.3 Hz, 1H), 7.61 (br d, J =2.5 Hz, 1H), 7.48 (br d, J =7.8 Hz, 2H), 7.39 (t, J =7.4 Hz, 2H), 7.35 - 7.28 (m, 1H), 7.11 - 7.04 (m, 1H), 4.53 (br t, J =12.5 Hz, 1H), 4.24 - 4.05 (m, 5H), 3.92 (d, J =1.8 Hz, 3H), 3.49 - 3.38 (m, 2H), 3.18 - 3.06 (m, 1H), 2.45 - 2.20 (m, 4H), 2.04 - 1.66 (m, 4H), 1.45 (t, J =7.0 Hz, 3H); LCMS (ESI) m/z : [M+H]⁺ = 477.1.

Example 120: 4-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.




5 Step 1: Preparation of 4,6-dichloro-N-methoxy-N-methylnicotinamide.




A solution of 4,6-dichloropyridine-3-carboxylic acid (13.5 g, 70.3 mmol) and 1,1'-carbonyldiimidazole (17.10 g, 105.5 mmol) in tetrahydrofuran (200 mL) was stirred for 0.5 h at 25 °C. N-ethyl-N-(propan-2-yl)propan-2-amine (18.17 g, 140.62 mmol, 24.55 mL) and N,O-dimethylhydroxylamine hydrochloride (8.23 g, 84.4 mmol) were added and the resulting solution was stirred at 25 °C for 16 h. The reaction mixture was diluted with water (200 mL), then the mixture was extracted with ethyl acetate (200 mL x 3). The combined organic layer was washed with water (50 mL x 3) then saturated aqueous sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 4,6-dichloro-N-methoxy-N-methylnicotinamide (19.0 g) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H), 7.44 (d, J=0.6 Hz, 1H), 3.49 (br s, 3H), 3.38 (br s, 3H).

Step 2: Preparation of 1-(4,6-dichloropyridin-3-yl)ethanone.




To a stirred solution of 4,6-dichloro-N-methoxy-N-methylnicotinamide (16.0 g, 68.1 mmol) in tetrahydrofuran (200 mL) was added a solution of methylmagnesium bromide in tetrahydrofuran (3 M, 57.6 mL) at 0 °C, the mixture was stirred at 0 °C for 2 h. After addition of saturated aqueous ammonium chloride (100 mL), the mixture was concentrated to ~ 200 mL and the residue was extracted with dichloromethane (200 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (60 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1-(4,6-dichloropyridin-3-yl)ethanone (8.95 g, 47.1 mmol, 69 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.62 (s, 1H), 7.46 (s, 1H), 2.68 (s, 3H).

Step 3: Preparation of 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine.




1-(4,6-dichloropyridin-3-yl)ethanone (8.40 g, 44.2 mmol) in hydrazine hydrate (60 mL) was stirred at 20 °C for 1 h. The reaction mixture was diluted with water (100 mL), then the mixture was extracted with dichloromethane (150 mL x 3). The separated organic layer was washed with water (40 mL x 3) and saturated aqueous sodium chloride solution (50 mL), then dried over anhydrous sodium sulfate, filtered and concentrated to give 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (6.10 g, 36.4 mmol, 82 %) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (br s, 1H), 8.88 (s, 1H), 7.53 (s, 1H), 2.55 (s, 3H).

Step 4: Preparation of 6-chloro-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine.



To a stirred solution of 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine (5.90 g, 35.2 mmol) in N,N-dimethylformamide (80 mL) was added iodomethane (9.99 g, 70.4 mmol, 4.38 mL), and potassium hydroxide (7.90 g, 140.8 mmol) at 0 °C. The reaction was stirred at 60 °C for 2 h. The reaction mixture was cooled then quenched by addition of water (100 mL). The mixture was extracted with ethyl acetate (150 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 5:1) to give 6-chloro-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine (2.73 g, 15.0 mmol, 43 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 7.22 (s, 1H), 3.93 (s, 3H), 2.58 (s, 3H).


Step 5: Preparation of 1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile.



To a stirred solution of 6-chloro-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine (1.70 g, 9.36 mmol) in N,N-dimethylformamide (20 mL) was added zinc cyanide (1.10 g, 9.36 mmol, 594 μL) and tetrakis(triphenylphosphine)palladium(0) (1.08 g, 936 μmol) under nitrogen. The mixture was stirred at 110 °C for 16 h. The reaction was cooled to 20 °C, water (30 mL) was added to the reaction, and then the reaction mixture was extracted with ethyl acetate (80 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 50:1 to 1:1) to give 1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile

(1.06 g, 6.16 mmol, 66 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 9.03 (d, *J*=1.0 Hz, 1H), 7.73 (d, *J*=1.0 Hz, 1H), 4.07 (s, 3H), 2.67 (s, 3H).


Step 6: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carboximidamide.



5

To a stirred solution of 1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carbonitrile (1.06 g, 6.16 mmol) in ethanol (15 mL) was added hydroxylamine hydrochloride (855 mg, 12.3 mmol), triethylamine (1.25 g, 12.3 mmol, 1.71 mL) and water (1.50 mL). The mixture was heated at 80 °C for 2 h. The reaction mixture was concentrated under reduced pressure then the residue was triturated with water (5 mL), filtered and
 10 the filter cake was dried under reduced pressure to give (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carboximidamide (1.0 g, 4.87 mmol, 79 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.73 (s, 1H), 9.02 (s, 1H), 7.91 (s, 1H), 5.91 (br s, 2H), 3.98 (s, 3H), 2.56 (s, 3H).


Step 7: Preparation of methyl 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylate.



15

To a stirred solution of 5-oxo-1-phenylpyrrolidine-3-carboxylic acid (3.0 g, 14.6 mmol) in dichloromethane (30 mL) was added methyl piperidine-4-carboxylate (2.09 g, 14.6 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (9.30 g, 14.6 mmol, 8.69 mL, 50% purity in ethyl acetate) and triethylamine (1.48 g, 14.6 mmol, 2.03 mL). The mixture was stirred at 25 °C for 16 h. The reaction
 20 mixture was diluted by addition of water (20 mL) then extracted with dichloromethane (60 mL x 3). The combined organic layer was washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give methyl 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylate (4.02 g, 12.2 mmol, 83 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J*=7.7 Hz, 2H), 7.38 (t, *J*=7.3 Hz, 2H), 7.21 - 7.12 (m, 1H), 4.43 (m, 1H), 4.29 (dd, *J*=7.3, 9.6 Hz,
 25 1H), 3.97 - 3.81 (m, 2H), 3.72 (s, 3H), 3.55 (m, 1H), 3.28 - 3.17 (m, 1H), 3.01 - 2.75 (m, 3H), 2.62 (dt, *J*=6.3, 10.4 Hz, 1H), 2.08 - 1.94 (m, 2H), 1.80 - 1.64 (m, 2H).


Step 8: Preparation of 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid.



To a stirred solution of methyl 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylate (4.0 g, 12.11 mmol) in tetrahydrofuran (30 mL) was added aqueous lithium hydroxide (2 M, 12.11 mL).


5 After 1 h, the reaction mixture was cooled to 0 °C then acidified with 2 M hydrochloric acid (6 mL). The mixture was extracted with ethyl acetate (80 mL x 3). The combined organic extracts were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (3.60 g, 11.38 mmol, 94 %) as a yellow solid. ¹H NMR (400 MHz, Methanol-d₄) δ 7.59 (dd, *J*=4.0, 7.7 Hz, 2H), 7.38 (t, *J*=7.6 Hz, 2H), 7.23 - 7.15 (m, 1H), 4.41 - 4.30 (m, 1H), 4.15 - 3.96 (m, 3H), 3.85 - 3.75 (m, 1H), 3.30 - 3.22 (m, 1H), 2.99 - 2.77 (m, 3H), 2.63 (m, 1H), 2.06 - 1.93 (m, 2H), 1.74 - 1.53 (m, 2H).

Step 9: Preparation of 4-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.




15 To a stirred solution of (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-c]pyridine-6-carboximidamide (84 mg, 410.9 μmol) in N,N-dimethylformamide (2 mL) was added 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (130 mg, 410.9 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (155 mg, 410.9 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (159 mg, 1.23 mmol, 215 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-40%, 12 min) to give 4-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (78 mg, 155 μmol, 38 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 9.13 (d, *J*=1.0 Hz, 1H), 8.12 (br d, *J*=3.9 Hz, 1H), 7.60 (br d, *J*=7.8 Hz, 2H), 7.39 (br t, *J*=8.0 Hz, 2H), 7.18 (br t, *J*=7.4 Hz, 1H), 4.59 (br t, *J*=13.8 Hz, 1H), 4.36 - 4.27 (m, 1H), 4.09 (d, *J*=3.8 Hz, 3H), 4.03 - 3.92 (m, 2H), 3.60 (m, 1H), 3.39 (br s, 2H), 3.14 - 2.94 (m, 2H), 2.90 - 2.80 (m, 1H), 2.68 (s, 3H), 2.37 - 2.23 (m, 2H), 2.12 - 1.96 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 486.1.

Example 121: N-(2-(4-(3-(5-ethoxy-4-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




5 Step 1: Preparation of 2-chloro-5-ethoxypyridine.



To a stirred solution of 6-chloropyridin-3-ol (21.0 g, 162.1 mmol) in N,N-dimethylformamide (200 mL) was added iodoethane (30.34 g, 194.5 mmol, 15.6 mL) and potassium carbonate (67.2 g, 486.3 mmol) at 0 °C, then the reaction was warmed and stirred at 40 °C for 2 h. The reaction mixture was quenched by addition of water (200 mL), then the mixture was extracted with ethyl acetate (300 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 2-chloro-5-ethoxypyridine (26.0 g) as a yellow oil. This was used directly without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, J=2.9 Hz, 1H), 7.15 - 7.06 (m, 2H), 3.98 (q, J=7.0 Hz, 2H), 1.35 (t, J=7.0 Hz, 3H).

15


Step 2: Preparation of 2-chloro-5-ethoxypyridine 1-oxide.



Hydrogen peroxide-urea complex (31.04 g, 330 mmol) was added in one portion to a solution of 2-chloro-5-ethoxypyridine (26.0 g, 165 mmol) in dichloromethane (250 mL) at 0 °C, then trifluoroacetic anhydride (62.4 g, 297 mmol, 41.3 mL) was added dropwise. The mixture was stirred at 20 °C for 16 h. The reaction mixture was quenched by addition of saturated aqueous sodium thiosulfate (150 mL). The mixture was extracted with dichloromethane (200 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 1:2) to give 2-chloro-5-ethoxypyridine 1-oxide (22.0 g, 126.7 mmol, 77 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, J=2.6 Hz, 1H), 7.29 (d, J=9.0 Hz, 1H), 6.81 (dd, J=2.6, 9.1 Hz, 1H), 3.97 (q, J=6.9 Hz, 2H), 1.37 (t, J=7.0 Hz, 3H).

25


Step 3: Preparation of 2-chloro-5-ethoxy-4-nitropyridine.



30


To a stirred solution of 2-chloro-5-ethoxypyridine 1-oxide (5.0 g, 28.8 mmol) in concentrated sulfuric acid (30 mL) was added dropwise concentrated nitric acid (15 mL) at 0 °C, then the mixture was warmed, stirred at 25 °C for 1 h, and then heated to 110 °C for 16 h. After cooling to 20 °C, the mixture was poured onto ice, and then aqueous sodium hydroxide solution (40 wt.%) was added carefully to adjust the pH to 14. The mixture was extracted with dichloromethane (100 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 2-chloro-5-ethoxy-4-nitropyridine (3.10 g, 15.3 mmol, 53 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.32 (s, 1H), 7.64 (s, 1H), 4.30 (q, *J*=7.0 Hz, 2H), 1.50 (t, *J*=7.0 Hz, 3H).

Step 4: Preparation of 2-chloro-5-ethoxy-4-methoxypyridine.




To a stirred solution of 2-chloro-5-ethoxy-4-nitropyridine (3.10 g, 15.3 mmol) in methanol (32 mL) was added potassium tert-butoxide (2.60 g, 16.8 mmol) at 0 °C, the mixture was warmed and stirred at 20 °C for 2 h. The reaction was concentrated under reduced pressure then diluted with water (20 mL). The mixture was extracted with dichloromethane (60 mL x 3), then the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 2-chloro-5-ethoxy-4-methoxypyridine (2.68 g, 14.28 mmol, 93 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.88 - 7.81 (m, 1H), 6.83 - 6.76 (m, 1H), 4.18 - 4.07 (m, 2H), 3.91 (dd, *J*=2.1, 2.8 Hz, 3H), 1.46 (m, 3H).

Step 5: Preparation of 5-ethoxy-4-methoxypicolinonitrile.




To a stirred solution of zinc cyanide (1.31 g, 11.2 mmol) in N,N-dimethylformamide (25 mL) was added 2-chloro-5-ethoxy-4-methoxypyridine (2.10 g, 11.2 mmol) and tetrakis(triphenylphosphine)palladium(0) (1.29 g, 1.12 mmol) under nitrogen. The mixture was heated at 110 °C for 16 h. The reaction was cooled to 20 °C, then water (40 mL) was added and the reaction mixture extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with saturated aqueous sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue that was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 5:1) to give 5-ethoxy-4-methoxypicolinonitrile (1.20 g, 6.73 mmol, 60 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1H), 7.18 (s, 1H), 4.24 (q, *J*=7.0 Hz, 2H), 3.96 (s, 3H), 1.51 (t, *J*=7.0 Hz, 3H).

Step 6: Preparation of (Z)-5-ethoxy-N'-hydroxy-4-methoxypicolinimidamide.




To a stirred solution of 5-ethoxy-4-methoxypicolinonitrile (1.20 g, 6.73 mmol) in ethanol (15 mL) was added hydroxylamine hydrochloride (935 mg, 13.5 mmol), triethylamine (1.36 g, 13.5 mmol, 1.87 mL) and water (1.50 mL). The mixture was heated at 80 °C for 2 h. The reaction mixture was cooled and then concentrated under reduced pressure. The residue was triturated with water (5 mL), filtered and the filter cake was dried under reduced pressure to give (Z)-5-ethoxy-N'-hydroxy-4-methoxypicolinimidamide (1.30 g, 6.15 mmol, 91 %) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.70 (s, 1H), 8.10 (s, 1H), 7.38 (s, 1H), 5.72 (s, 2H), 4.12 (q, J=7.0 Hz, 2H), 3.84 (s, 3H), 1.34 (t, J=6.9 Hz, 3H).

Step 7: Preparation of N-(2-(4-(3-(5-ethoxy-4-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (150 mg, 516.7 μmol) in N,N-dimethylformamide (2 mL) was added (Z)-5-ethoxy-N'-hydroxy-4-methoxypicolinimidamide (109 mg, 516.7 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (195 mg, 516.7 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (200 mg, 1.55 mmol, 270 μL). The mixture was stirred at 20 °C for 1 h, then heated at 110 °C for 1 h. The reaction mixture was cooled and then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-40%, 12 min) to give N-(2-(4-(3-(5-ethoxy-4-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (32 mg, 67 μmol, 13 %) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 1H), 7.90 - 7.82 (m, 2H), 7.64 (s, 1H), 7.56 - 7.42 (m, 3H), 7.34 (br s, 1H), 4.52 (br d, J=13.6 Hz, 1H), 4.34 - 4.21 (m, 4H), 4.02 (s, 3H), 3.91 (br d, J=14.1 Hz, 1H), 3.41 - 3.28 (m, 2H), 3.12 (br t, J=11.0 Hz, 1H), 2.33 - 2.21 (m, 2H), 2.13 - 1.95 (m, 2H), 1.52 (t, J=7.0 Hz, 3H); LCMS (ESI) m/z: [M+H]⁺ = 466.3.

Example 122: N-[2-[4-[3-(1,3-dimethyl-2-oxo-benzimidazol-5-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide:




5 Step 1: Preparation of 3,4-diaminobenzonitrile.




To a stirred solution of 4-amino-3-nitro-benzonitrile (2.00 g, 12.3 mmol) in methanol (20 mL) was added Pd/C (500 mg, 10% purity), then the flask was degassed and filled with hydrogen three times, and the reaction mixture stirred vigorously under hydrogen (balloon) for 18 h at 25 °C. The mixture was evacuated and backfilled with nitrogen three times, then filtered through a pad of celite, and the filtrate concentrated in vacuo to give 3,4-diaminobenzonitrile (1.47 g, 11.04 mmol, 90 %) as a green oil that was used in next step directly.

Step 2: Preparation of 2-oxo-1,3-dihydrobenzimidazole-5-carbonitrile



To a stirred solution of 3,4-diaminobenzonitrile (1.40 g, 10.5 mmol) in tetrahydrofuran (70 mL) at 0 °C was added 1,1'-carbonyldiimidazole (2.22 g, 13.7 mmol), then the mixture was warmed to 25 °C and stirred for 18 h. The mixture was treated with ethyl acetate (100 mL), washed with 1N HCl (20 mL x 2) and saturated aqueous sodium chloride solution (30 mL), then dried over anhydrous sodium sulfate, filtered and concentrated to give 2-oxo-1,3-dihydrobenzimidazole-5-carbonitrile (1.50 g) as a pale yellow solid, which was used in next step directly.


Step 3: Preparation of 1,3-dimethyl-2-oxo-benzimidazole-5-carbonitrile.



To a stirred suspension of sodium hydride (1.13 g, 28.29 mmol, 47.15 mL, 60% dispersion in mineral oil) in N,N-dimethylformamide (5 mL) was added 2-oxo-1,3-dihydrobenzimidazole-5-carbonitrile


(1.50 g, 9.43 mmol) in N,N-dimethylformamide (5 mL) at 25 °C. After 15 min, the mixture was cooled to 5 °C then methyl iodide (4.70 g, 33.1 mmol, 2.06 mL) was added dropwise. The reaction mixture was warmed to 25 °C and stirred for 1 h. The mixture was poured into ice-water (100 mL), filtered and the residue dissolved in dichloromethane (10 mL). The phases were separated and the organic phase was washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 1,3-dimethyl-2-oxo-benzimidazole-5-carbonitrile (1.26 g, 6.73 mmol, 71 %) as pale yellow solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.37 (dd, *J*=1.4, 8.2 Hz, 1H), 7.15 (s, 1H), 6.95 (d, *J*=8.2 Hz, 1H), 3.38 (d, *J*=3.3 Hz, 6H).

Step 4: Preparation of N'-hydroxy-1,3-dimethyl-2-oxo-benzimidazole-5-carboxamide.




A mixture of 1,3-dimethyl-2-oxo-benzimidazole-5-carbonitrile (1.25 g, 6.68 mmol), hydroxylamine hydrochloride (928 mg, 13.4 mmol) and triethylamine (1.35 g, 13.4 mmol, 1.85 mL) in ethanol (15 mL) and water (1.50 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 70 °C for 5 h under a nitrogen atmosphere. The resulting suspension was filtered then the filter cake was dissolved in ethyl acetate (20 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo to give N'-hydroxy-1,3-dimethyl-2-oxo-benzimidazole-5-carboxamide (1.25 g, 5.68 mmol, 85 %) as a white solid.

Step 5: Preparation of N-[2-[4-[3-(1,3-dimethyl-2-oxo-benzimidazol-5-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide.




To a stirred solution of N'-hydroxy-1,3-dimethyl-2-oxo-benzimidazole-5-carboxamide (80 mg, 363 μmol) and 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (105 mg, 363 μmol) in N,N-dimethylformamide (1 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (137 mg, 363 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (93 mg, 726.5 μmol, 126 μL) at 25 °C. After stirring at 25 °C for 1h, the mixture was warmed to 110 °C and stirred for 1 h. The mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x25 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-40%, 12 min) to give N-[2-[4-[3-(1,3-dimethyl-2-oxo-benzimidazol-5-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (38 mg, 78.7 μmol, 22 %) as pale yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 8.55 (t, *J*=5.7 Hz, 1H), 7.89 - 7.83 (m, 2H), 7.75 (dd, *J*=1.5, 8.2 Hz, 1H), 7.67 (d, *J*=1.3 Hz, 1H), 7.55 - 7.42 (m, 3H), 7.29 (d, *J*=8.2 Hz, 1H), 4.31 (br d, *J*=13.0 Hz, 1H), 4.16 (dd, *J*=3.6, 5.4 Hz, 2H), 3.97 (br d, *J*=13.9 Hz, 1H), 3.48 - 3.40 (m, 1H), 3.37 (d, *J*=10.4 Hz, 6H), 3.29 - 3.22 (m, 1H), 2.91 (br t, *J*=11.2 Hz, 1H), 2.13 (br t, *J*=12.9 Hz, 2H), 1.89 - 1.58 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 475.3.

Example 123: 1,3-dimethyl-5-[5-[1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)-4-piperidyl]-1,2,4-oxadiazol-3-yl]benzimidazol-2-one.




5

Step 1: Preparation of 1,3-dimethyl-5-[5-[1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)-4-piperidyl]-1,2,4-oxadiazol-3-yl]benzimidazol-2-one.




To a stirred solution of N'-hydroxy-1,3-dimethyl-2-oxo-benzimidazole-5-carboxamide (120 mg, 544.9 μ mol) and 1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (206 mg, 653.9 μ mol) in N,N-dimethylformamide (2 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (206 mg, 544.9 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (140 mg, 1.09 mmol, 190 μ L) at 25 °C. After stirring at 25 °C for 2h, the mixture was heated at 120 °C for 1 h. The mixture was cooled then purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-55%, 12 min) to give 1,3-dimethyl-5-[5-[1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)-4-piperidyl]-1,2,4-oxadiazol-3-yl]benzimidazol-2-one (57 mg, 110.5 μ mol, 20 %) as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ = 7.75 (td, J =1.5, 8.2 Hz, 1H), 7.69 - 7.62 (m, 3H), 7.38 - 7.32 (m, 2H), 7.29 (d, J =8.4 Hz, 1H), 7.15 - 7.08 (m, 1H), 4.35 (br d, J =12.8 Hz, 1H), 4.07 - 3.91 (m, 3H), 3.77 - 3.68 (m, 1H), 3.47 - 3.39 (m, 1H), 3.39 - 3.34 (m, 6H), 3.34 - 3.32 (m, 1H), 3.28 (s, 1H), 2.98 - 2.88 (m, 1H), 2.82 - 2.67 (m, 2H), 2.14 (br t, J =13.8 Hz, 2H), 1.90 - 1.63 (m, 2H). LCMS (ESI) m/z : [M+H]⁺ = 501.3.

Example 124: 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one




5

Step 1: Preparation of 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid




To a stirred solution of methyl 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylate (200 mg, 494 μ mol) in tetrahydrofuran (2 mL) was added aqueous lithium hydroxide (2 M, 494 μ L). The mixture was stirred at 20 $^{\circ}$ C for 2 h, then the mixture was acidified with 2N hydrochloric acid to pH 1. The mixture was extracted with ethyl acetate (20 mL x 3), then the organic extracts were combined and washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (160 mg, 409.8 μ mol, 83 %) as a yellow solid.

Step 2: Preparation of 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one.




To a stirred solution of N'-hydroxy-1,3-dimethyl-indazole-6-carboxamide (78 mg, 384 μ mol) in N,N-dimethylformamide (2 mL) was added 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (150 mg, 384 μ mol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (145 mg, 384 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (148 mg, 1.15 mmol, 201 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h, then heated at 110 $^{\circ}$ C for 1 h. The reaction mixture was cooled then purified directly by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-50%, 12 min) to give 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one (35 mg, 64 μ mol, 17 %) as a pink solid. ^{1} H NMR (400 MHz, CDCl₃) δ 8.09 (d, J =4.1 Hz, 1H), 7.85 - 7.80 (m, 1H), 7.77 - 7.71 (m, 1H), 7.17 (d, J =8.7 Hz, 1H), 6.49 - 6.43 (m, 2H), 4.59 - 4.38 (m, 3H), 4.08 (d, J =1.8 Hz, 3H), 3.98 - 3.86 (m, 1H), 3.84 - 3.77 (m, 6H), 3.71 - 3.62 (m, 1H), 3.46 - 3.24 (m, 4H), 3.13 - 2.96 (m, 1H), 2.85 - 2.75 (m, 1H), 2.67 (m, 1H), 2.60 (s, 3H), 2.21 (br s, 2H), 2.04 - 1.87 (m, 2H); LCMS (ESI) m/z : [M+H]⁺ = 559.3.

Example 125: 1-cyclohexyl-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one




Step 1: Preparation of 1-cyclohexyl-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (100 mg, 345.6 μ mol) and 1-cyclohexyl-5-oxo-pyrrolidine-3-carboxylic acid (73 mg, 345.6 μ mol) in N,N-dimethylformamide (1.00 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (131 mg, 345.63 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (89 mg, 691 μ mol, 120 μ L) at 25 $^{\circ}$ C. The mixture was then stirred for an additional 2h at 25 $^{\circ}$ C. The reaction mixture

was concentrated under reduced pressure to give a residue further purified by chromatography [Waters Xbridge 150x25 5µm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-50%, 12 min]. The title product, 1-cyclohexyl-4-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one, was isolated as a white solid (97 mg, 201.6 µmol, 58 %). ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.69 (dd, *J*=1.7, 8.3 Hz, 1H), 7.57 (d, *J*=1.8 Hz, 1H), 6.97 (d, *J*=8.4 Hz, 1H), 4.60 - 4.44 (dd, 1H), 3.97 (d, *J*=7.9 Hz, 6H), 3.77 (br t, *J*=7.0 Hz, 1H), 3.51 - 3.21 (m, 4H), 3.14 - 2.97 (m, 1H), 2.77 - 2.61 (m, 2H), 2.28 - 2.17 (m, 2H), 2.03 - 1.89 (m, 2H), 1.88 - 1.64 (m, 7H), 1.48 - 1.32 (m, 4H), 1.23 - 1.04 (m, 1H); LCMS (ESI) *m/z*: [M+H]⁺ = 483.3.

Example 126: 4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one.




Step 1: Preparation of 1,3-dimethylindazole-6-carbonitrile.




To a stirred solution of 6-bromo-1,3-dimethyl-indazole (3.0 g, 13.33 mmol) in N,N-dimethylformamide (30 mL) was added, under a nitrogen atmosphere, zinc cyanide (1.57 g, 13.33 mmol, 846 µL) and tetrakis(triphenylphosphine)palladium(0) (1.54 g, 1.33 mmol). The mixture was then stirred at 110 °C for 16 h and then cooled to 20 °C. Water (50 mL) was added to the reaction mixture which was extracted with ethyl acetate (80 mL x 3). The organic extracts were combined, washed with saturated aqueous sodium chloride (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product further purified by chromatography (silica, petroleum ether: ethyl acetate = 50 : 1 to 10:1). The title compound, 1,3-dimethylindazole-6-carbonitrile was isolated as a white solid (1.92 g, 11.21 mmol, 84 %) ¹H NMR (400 MHz, CDCl₃) δ 7.78 - 7.67 (m, 2H), 7.33 (dd, *J*=1.0, 8.3 Hz, 1H), 4.05 (s, 3H), 2.59 (s, 3H)

Step 2: Preparation of *N'*-hydroxy-1,3-dimethyl-indazole-6-carboxamide.




To a stirred solution of 1,3-dimethylindazole-6-carbonitrile (2.50 g, 14.60 mmol) in ethanol (30 mL) was added hydroxylamine hydrochloride (2.03 g, 29.20 mmol), triethylamine (2.95 g, 29.20 mmol, 4.05 mL) and water (3 mL). The mixture was stirred at 80 °C for 2 h, and then concentrated under reduced pressure. Water (5mL) was added to the residue, the resulting solid was collected by filtration and used for the next step without further purification. The title compound, *N'*-hydroxy-1,3-dimethyl-indazole-6-carboxamide, was isolated as a white solid (2.86 g, 14.00 mmol, 96 %); ¹H NMR (400 MHz, DMSO-d₆) δ 9.70 (s, 1H), 7.85 (s, 1H), 7.63 (d, *J*=8.4 Hz, 1H), 7.47 (dd, *J*=1.2, 8.5 Hz, 1H), 5.89 (s, 2H), 3.96 (s, 3H), 2.46 (s, 3H).

Step 3: Preparation of methyl 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylate.




To a stirred solution of 1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carboxylic acid (1.0 g, 3.58 mmol) in dichloromethane (15 mL) was added methyl piperidine-4-carboxylate (512 mg, 3.58 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (2.51 g, 3.94 mmol, 2.34 mL, 50% purity), triethylamine (724 mg, 7.16 mmol, 992 μL), and the reaction mixture was stirred at 20 °C for 2 h. Water (30 mL) was added to the mixture which was extracted with dichloromethane (50 mL x 3). The organic extracts were combined, washed with saturated aqueous sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give methyl 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylate isolated as a yellow oil (1.37 g, 3.39 mmol, 95 %) and used for the next step without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.15 (br d, *J*=8.5 Hz, 1H), 6.51 - 6.39 (m, 2H), 4.50 - 4.33 (m, 3H), 3.80 (s, 6H), 3.75 (br d, *J*=5.0 Hz, 1H), 3.70 (s, 3H), 3.65 - 3.55 (m, 1H), 3.42 - 3.29 (m, 2H), 3.19 - 3.05 (m, 1H), 2.94 - 2.71 (m, 2H), 2.64 - 2.49 (m, 2H), 1.94 (br dd, *J*=3.3, 13.3 Hz, 2H), 1.62 (br s, 2H).

Step 4: Preparation of 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid.



To a stirred solution of methyl 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylate (1.17 g, 2.89 mmol) in tetrahydrofuran (15 mL) was added lithium hydroxide (2 M solution in tetrahydrofuran, 2.89 mL). The reaction mixture was stirred at 20 °C for 1 h, and then acidified until pH 1 using a 2M aqueous solution of hydrochloric acid. The resulting mixture was extracted with ethyl acetate (80 mL x 3). The organic extracts were combined, washed with saturated aqueous sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid isolated as a white solid (1.0 g, 2.56 mmol, 89 %) and used for the next step without further purification. ¹H NMR (400 MHz, Methanol-d₄) δ 7.09 (dd, *J*=2.9, 8.4 Hz, 1H), 6.52 (d, *J*=2.2 Hz, 1H), 6.47 (dd, *J*=2.3, 8.3 Hz, 1H), 4.46 - 4.25 (m, 3H), 3.92 - 3.83 (m, 1H), 3.80 (d, *J*=1.3 Hz, 3H), 3.78 - 3.75 (m, 3H), 3.65 - 3.36 (m, 3H), 3.25 - 3.11 (m, 1H), 2.92 - 2.80 (m, 1H), 2.71 - 2.52 (m, 3H), 1.97 - 1.87 (m, 2H), 1.68 - 1.42 (m, 2H).


Step 5: Preparation of 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one.



To a stirred solution of N'-hydroxy-1,3-dimethyl-indazole-6-carboxamide (261 mg, 1.28 mmol) in N,N-dimethylformamide (6 mL) was added 1-[1-[(2,4-dimethoxyphenyl)methyl]-5-oxo-pyrrolidine-3-carbonyl]piperidine-4-carboxylic acid (500 mg, 1.28 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (485 mg, 1.28 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (496 mg, 3.84 mmol, 670 μL). The reaction mixture was stirred at 20 °C for 1 h, at 110 °C for 1 h, and then cooled to 20 °C. Water (10 mL) was added to the mixture, which was extracted with ethyl acetate (40 mL x 3). The organic extracts were combined, washed with saturated aqueous sodium chloride (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide the crude product further purified by chromatography (Dichloromethane : Methanol = 1:0 to 10:1). The title compound, 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one was isolated as a yellow solid (500 mg, 895 μmol, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J*=5.0 Hz, 1H), 7.84 (d, *J*=8.5 Hz, 1H), 7.79 - 7.73 (m, 1H),


7.17 (d, $J=8.9$ Hz, 1H), 6.50 - 6.44 (m, 2H), 4.58 - 4.41 (m, 3H), 4.10 (s, 3H), 3.97 - 3.88 (m, 1H), 3.84 - 3.79 (m, 6H), 3.69 (br d, $J=6.7$ Hz, 1H), 3.47 - 3.27 (m, 4H), 3.16 (q, $J=7.5$ Hz, 1H), 2.83 - 2.76 (m, 1H), 2.71 - 2.64 (m, 1H), 2.62 (s, 3H), 2.25 (br s, 2H), 2.03 - 1.88 (m, 2H)

5 **Step 6: Preparation of 4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one.**




A mixture of 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one (150 mg, 268.51 μ mol), anisole (58 mg, 537 μ mol, 58 μ L) in trifluoro acetic acid (2 mL) was degassed, purged with nitrogen three times, and then stirred at 80 $^{\circ}$ C for 2 h under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give the crude product further purified by chromatography (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 15%-35%, 12min). The title compound, 4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one, was isolated as a white solid (50 mg, 122.8 μ mol, 46 %) ^{1} H NMR (400 MHz, $CDCl_3$) δ 8.10 (br s, 1H), 7.86 - 7.80 (m, 1H), 7.77 - 7.72 (m, 1H), 5.74 (br s, 1H), 4.55 (br t, $J=14.1$ Hz, 1H), 4.08 (s, 3H), 3.95 (br d, $J=9.0$ Hz, 1H), 3.82 - 3.75 (m, 1H), 3.66 - 3.53 (m, 2H), 3.43 - 3.29 (m, 2H), 3.15 - 3.02 (m, 1H), 2.77 - 2.67 (m, 1H), 2.60 (s, 3H), 2.59 - 2.52 (m, 1H), 2.33 - 2.18 (m, 2H), 2.08 - 1.92 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 409.3.

20 **Example 127: [4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-(4-isopropylphenyl)methanone.**




25 **Step 1: Preparation of [4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-(4-isopropylphenyl)methanone.**




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (80 mg, 276.50 μ mol) and 4-isopropylbenzoic acid (54 mg, 331.80 μ mol) in N,N-dimethylformamide (1.00 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (125 mg, 331.80 μ mol) and N-

ethyl-N-(propan-2-yl)propan-2-amine (71 mg, 553 μ mol, 96 μ L) at 25 $^{\circ}$ C. The mixture was stirred at 25 $^{\circ}$ C for 2h and then concentrated under reduced pressure to provide a residue purified by chromatography (Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12min). The title compound, [4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-(4-isopropylphenyl)methanone was isolated as a yellow solid (83 mg, 191.6 μ mol, 69 %). ^{1} H NMR (400MHz, CHLOROFORM- d) δ = 7.71 (dd, J =1.9, 8.3 Hz, 1H), 7.59 (d, J =1.9 Hz, 1H), 7.40 - 7.36 (dd, 2H), 7.31 - 7.26 (t, 2H), 6.97 (d, J =8.4 Hz, 1H), 4.65 (br s, 1H), 3.97 (d, J =8.5 Hz, 6H), 3.36 - 3.15 (m, 3H), 2.95 (spt, J =6.9 Hz, 1H), 2.33 - 1.62 (m, 4H), 2.36 - 1.62 (m, 1H), 1.28 (d, J =6.9 Hz, 6H); LCMS (ESI) m/z : $[M+H]^+$ = 436.3.

Example 128: 2-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-(hydroxymethyl)-2-oxo-ethyl]isoindolin-1-one.




Step 1: Preparation of 2-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-(hydroxymethyl)-2-oxo-ethyl]isoindolin-1-one.




To a stirred solution of 3-hydroxy-2-(1-oxoisoindolin-2-yl)propanoic acid (120 mg, 542 μ mol) in N,N-dimethylformamide (2 mL) was added 3-(4-ethoxy-3-methoxy-phenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (153 mg, 452 μ mol, 1.00 eq, hydrochloric acid), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (205 mg, 542 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (175 mg, 1.36 mmol, 236 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h, and then purified directly by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-60%, 12min). The title compound, 2-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-(hydroxymethyl)-2-oxo-ethyl]isoindolin-1-one was isolated as a white solid (139 mg, 274.8 μ mol, 61 %). ^{1} H NMR (400 MHz, $CDCl_3$) δ 7.88 (t, J =6.8 Hz, 1H), 7.68 - 7.44 (m, 5H), 6.92 (dd, J =8.4, 17.7 Hz, 1H), 5.38 (t, J =4.6 Hz, 1H), 4.84 (br d, J =17.2 Hz, 1H), 4.48 - 4.35 (m, 2H), 4.21 - 3.98 (m, 5H), 3.94 (d, J =17.1 Hz, 3H), 3.77 - 3.41 (m, 1H), 3.39 - 3.04 (m, 3H), 2.26 - 1.78 (m, 4H), 1.50 (q, J =6.8 Hz, 3H); LCMS (ESI) m/z : $[M+H]^+$ = 507.3.

Example 129: 2-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-(hydroxymethyl)-2-oxo-ethyl]isoindolin-1-one.



5


Step 1: Preparation of 2-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-(hydroxymethyl)-2-oxo-ethyl]isoindolin-1-one.



To a stirred solution of 3-hydroxy-2-(1-oxoisoindolin-2-yl)propanoic acid (120 mg, 542 μmol) in N,N-dimethylformamide (2 mL) was added 3-(1,3-dimethylindazol-6-yl)-5-(4-piperidyl)-1,2,4-oxadiazole, hydrochloride (150 mg, 452 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (205 mg, 542 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (175 mg, 1.36 mmol, 236 μL). The reaction mixture was stirred at 20 $^{\circ}\text{C}$ for 1 h and then purified directly by prep-HPLC (column: Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-55%, 12min). The title compound, 2-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-(hydroxymethyl)-2-oxo-ethyl]isoindolin-1-one was isolated as a white solid (68 mg, 137 μmol , 30 %). ^1H NMR (400 MHz, CDCl_3) δ 8.10 - 7.97 (m, 1H), 7.91 - 7.65 (m, 3H), 7.62 - 7.44 (m, 3H), 5.40 (t, $J=4.9$ Hz, 1H), 4.82 (dd, $J=3.0, 17.3$ Hz, 1H), 4.51 - 4.37 (m, 2H), 4.16 - 3.99 (m, 6H), 3.65 (br s, 1H), 3.43 - 3.04 (m, 3H), 2.58 (d, $J=6.7$ Hz, 3H), 2.27 - 1.93 (m, 3.6H), 1.62 - 1.50 (m, 0.4H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 501.3$.


20

Example 130: 4-[4-[3-(6-ethoxy-5-methoxy-3-pyridyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenylpyrrolidin-2-one.




25

Step 1: Preparation of 4-[4-[3-(6-ethoxy-5-methoxy-3-pyridyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.




5 A solution of (Z)-6-ethoxy-N'-hydroxy-5-methoxynicotinimidamide (100 mg, 474 μ mol) in N,N-dimethylformamide (2.00 mL) was added 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (150 mg, 474 μ mol) N-ethyl-N-(propan-2-yl)propan-2-amine (183 mg, 1.42 mmol, 248 μ L), and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (197 mg, 521.58 μ mol). The mixture was stirred at 25 $^{\circ}$ C for 12 h, and then at 110 $^{\circ}$ C for 1 h. The residue was purified directly by pre-HPLC (column: Waters Xbridge 150x2.5mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-50%, 12min) to give 4-[4-[3-(6-ethoxy-5-methoxy-3-pyridyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one (96 mg, 194.7 μ mol, 41 %), isolated as a yellow solid. ^{1} H NMR (400MHz, CHLOROFORM-d) δ = 8.44 (s, 1H), 7.64 - 7.57 (m, 3H), 7.41 - 7.34 (m, 2H), 7.21 - 7.14 (m, 1H), 4.61 - 4.46 (m, 3H), 4.37 - 4.28 (m, 1H), 4.02 - 3.90 (m, 5H), 3.58 (td, J=8.4, 16.6 Hz, 1H), 3.44 - 3.26 (m, 2H), 3.17 - 2.91 (m, 2H), 2.89 - 2.78 (m, 1H), 2.31 - 2.17 (m, 2H), 2.06 - 1.87 (m, 2H), 1.47 (t, J=7.2 Hz, 3H); LCMS (ESI) m/z: [M+H] $^{+}$ = 492.1.

Example 131: 2-(2-(4-(3-(6-ethoxy-5-methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one.




Step 1: Preparation of 2-(2-(4-(3-(6-ethoxy-5-methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one.




25 A solution of 6-ethoxy-N'-hydroxy-5-methoxy-pyridine-3-carboxamide (104 mg, 496 μ mol) in N,N-dimethylformamide (2 mL) was added 1-[2-(1-oxoisoindolin-2-yl)acetyl]piperidine-4-carboxylic acid (150 mg, 496 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (192 mg, 1.49 mmol, 259 μ L) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (206 mg, 545.77 μ mol). The mixture was stirred at 25 $^{\circ}$ C for 12 h, and then at 110 $^{\circ}$ C for 1 h. The mixture was purified by pre-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-

50%, 12 min) to give 2-[2-[4-[3-(6-ethoxy-5-methoxy-3-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxoethyl]isoindolin-1-one (82 mg, 171 μ mol, 34 %), isolated as a pink solid. ^1H NMR (400 MHz, CHLOROFORM- d) δ = 8.46 (d, J =1.8 Hz, 1H), 7.89 (d, J =7.8 Hz, 1H), 7.65 (d, J =1.5 Hz, 1H), 7.62 - 7.56 (m, 1H), 7.50 (t, J =6.7 Hz, 2H), 4.64 - 4.44 (m, 7H), 4.11 (br d, J =13.7 Hz, 1H), 3.98 (s, 3H), 3.46 - 3.26 (m, 2H), 3.08 (br t, J =10.9 Hz, 1H), 2.24 (br t, J =14.0 Hz, 2H), 2.09 - 1.89 (m, 2H), 1.50 (t, J =7.1 Hz, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 478.1$.

Example 132: N-(2-(4-(3-(6-ethoxy-5-methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 5-bromo-2-ethoxy-3-methoxypyridine.




A solution of sodium (465 mg, 20.23 mmol, 479 μ L) in ethanol (5 mL) was stirred at 20 $^{\circ}\text{C}$ for 2 h. 5-Bromo-2-chloro-3-methoxypyridine (1.50 g, 6.74 mmol) was then added to the mixture which was stirred at 100 $^{\circ}\text{C}$ for 12 h. The reaction mixture was concentrated under reduced pressure. Water (50 mL) was then added to the residue. The mixture was extracted with dichloromethane (60 mL x 3). The organic extracts were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide 5-bromo-2-ethoxy-3-methoxypyridine, isolated as a white solid (1.70 g, crude), and used for the next step without further purification. ^1H NMR (400 MHz, METHANOL- d_4) δ = 7.70 (d, J =2.0 Hz, 1H), 7.34 (d, J =2.2 Hz, 1H), 4.34 (q, J =7.1 Hz, 2H), 3.83 (s, 3H), 1.36 (t, J =7.1 Hz, 3H).

Step 2: Preparation of 6-ethoxy-5-methoxynicotinonitrile.




To a stirred solution of 5-bromo-2-ethoxy-3-methoxy-pyridine (1.70 g, 7.33 mmol) in N,N-dimethylformamide (10 mL) was added zinc cyanide (860 mg, 7.33 mmol, 464 μ L), and tetrakis(triphenylphosphine)palladium(0) (847 mg, 733 μ mol, 0.10 eq), the mixture was degassed with nitrogen for three times. The resulting mixture was stirred at 110 °C for 12 h under nitrogen atmosphere and then poured into water (30 mL). The mixture was then extracted with dichloromethane (50 mL x 3). The organic extracts were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide the crude product purified by chromatography (silica, petroleum ether : ethyl acetate = 50:1 R_f = 0.6). The title compound, 6-ethoxy-5-methoxy-pyridine-3-carbonitrile was isolated as a white solid (820 mg, 4.60 mmol, 63 %) ^1H NMR (400MHz, METHANOL- d_4) δ = 8.08 (d, J=1.8 Hz, 1H), 7.49 (d, J=1.8 Hz, 1H), 4.48 (q, J=7.1 Hz, 2H), 3.92 - 3.88 (m, 3H), 1.42 (t, J=7.1 Hz, 3H).

Step 3: Preparation of (Z)-6-ethoxy-N'-hydroxy-5-methoxynicotinimidamide.



To a stirred solution of 6-ethoxy-5-methoxynicotinonitrile (820 mg, 4.60 mmol) in ethanol (20 mL) and water (2 mL) was added hydroxylamine hydrochloride (639 mg, 9.20 mmol) and triethylamine (931 mg, 9.20 mmol, 1.28 mL). The mixture was stirred at 80 °C for 2 h, cooled to room temperature, concentrated under reduced pressure and poured into water (5 mL). The resulting mixture was extracted with ethyl acetate (10 mL x 3). The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure to give (Z)-6-ethoxy-N'-hydroxy-5-methoxynicotinimidamide (1.0 g, crude) as a white solid. ^1H NMR (400MHz, METHANOL- d_4) δ = 7.94 (d, J=2.0 Hz, 1H), 7.44 (d, J=2.0 Hz, 1H), 4.43 - 4.36 (m, 2H), 3.86 (s, 3H), 1.38 (t, J=7.1 Hz, 3H).


Step 4: Preparation of N-(2-(4-(3-(6-ethoxy-5-methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.



To a stirred solution of (Z)-6-ethoxy-N'-hydroxy-5-methoxynicotinimidamide (109 mg, 516.69 μ mol) in N,N-dimethylformamide (2 mL) was added 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (150 mg, 516.69 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (200 mg, 1.55 mmol, 270 μ L) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (215 mg, 568 μ mol). The mixture was stirred at 25 °C for 12 h, and at 110 °C for 1 h. The residue was purified directly by chromatography (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-50%, 12min) to give N-(2-(4-(3-(6-ethoxy-5-methoxypyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (83 mg, 177.7 μ mol, 34 %) as a yellow solid. ^1H NMR (400MHz, CHLOROFORM- d) δ = 8.44 (d, J=1.8 Hz, 1H), 7.88 - 7.82 (m, 2H), 7.62 (d, J=2.0 Hz, 1H), 7.55 - 7.49 (m, 1H), 7.48 - 7.42 (m, 2H), 7.32 (br s, 1H), 4.58 - 4.47 (m, 3H), 4.30 (d, J=4.0 Hz, 2H), 3.95 (s,

3H), 3.39 - 3.28 (m, 2H), 3.18 - 3.09 (m, 1H), 2.30 - 2.19 (m, 2H), 2.07 - 1.91 (m, 2H), 1.47 (t, J=7.1 Hz, 3H); LCMS (ESI) m/z: [M+H]⁺ = 466.1.


Example 133: 3-methyl-5-[5-[1-[2-(1-oxoisindolin-2-yl)acetyl]-4-piperidyl]-1,2,4-oxadiazol-3-yl]-1H-benzimidazol-2-one.



Step 1: 3-methyl-5-[5-[1-[2-(1-oxoisindolin-2-yl)acetyl]-4-piperidyl]-1,2,4-oxadiazol-3-yl]-1H-benzimidazol-2-one.

A mixture of N'-hydroxy-3-methyl-2-oxo-1H-benzimidazole-5-carboxamide (81.85 mg, 396.94 μ mol, 1.20 eq), 1-[2-(1-oxoisindolin-2-yl)acetyl]piperidine-4-carboxylic acid (100.00 mg, 330.78 μ mol, 1.00 eq), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (188.16 mg, 496.16 μ mol, 1.50 eq), N-ethyl-N-(propan-2-yl)propan-2-amine (128.25 mg, 992.33 μ mol, 173.31 μ L, 3.00 eq) in N,N-dimethylformamide (2.00 mL) then the mixture was stirred at 20 °C for 15h then the mixture was stirred at 110 °C for 1 h. The product was purified by column: Waters Xbridge 150x25 μ m; mobile phase: [water (10 mM NH₄HCO₃)-acetonitrile]; B%: 20%-45%, 12min to obtain compound 3-methyl-5-[5-[1-[2-(1-oxoisindolin-2-yl)acetyl]-4-piperidyl]-1,2,4-oxadiazol-3-yl]-1H-benzimidazol-2-one (53.58 mg, 113.40 μ mol, 34.28 %) as a pink solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 9.60 (br s, 1H), 7.79 (t, J=9.0 Hz, 2H), 7.61 (s, 1H), 7.51 - 7.46 (m, 1H), 7.42 - 7.37 (m, 2H), 7.10 (d, J=8.2 Hz, 1H), 4.52 (s, 2H), 4.45 - 4.37 (m, 3H), 4.02 (br d, J=13.6 Hz, 1H), 3.42 (s, 3H), 3.37 - 3.19 (m, 2H), 3.00 (br t, J=11.0 Hz, 1H), 2.21 - 2.10 (m, 2H), 1.99 - 1.85 (m, 2H); LCMS (ESI) m/z [M+H]⁺ = 473.3.

Example 134: 3-methyl-5-[5-[1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)-4-piperidyl]-1,2,4-oxadiazol-3-yl]-1H-benzimidazol-2-one.




Step 1: Preparation of 3-methyl-5-[5-[1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)-4-piperidyl]-1,2,4-oxadiazol-3-yl]-1H-benzimidazol-2-one.


Example 134 was synthesized according to the synthetic procedure reported for the preparation of Example 133. ¹H NMR (400MHz, CHLOROFORM-d) δ = 9.82 (br s, 1H), 7.79 (br d, J=8.2 Hz, 1H), 7.62 (br s, 1H), 7.52 (d, J=8.2 Hz, 2H), 7.34 - 7.29 (m, 2H), 7.14 - 7.08 (m, 2H), 4.57 - 4.40 (m, 1H), 4.26 (br t, J=7.3 Hz, 1H), 3.97 - 3.84 (m, 2H), 3.52 (quin, J=8.4 Hz, 1H), 3.42 (d, J=1.6 Hz, 3H), 3.37 - 3.23 (m,

2H), 3.13 - 2.86 (m, 2H), 2.83 - 2.76 (m, 1H), 2.19 (br t, $J=12.5$ Hz, 2H), 2.00 - 1.82 (m, 2H). LCMS (ESI) m/z : $[M+H]^+ = 487.3$.

Example 135: N-[2-[4-[3-(3-methyl-1,2-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide




Step 1: Preparation of 1-(4-bromo-2-hydroxy-phenyl)ethanone oxime



To a stirred solution of 1-(4-bromo-2-hydroxy-phenyl)ethanone (10.00 g, 46.50 mmol) and pyridine (49.66 g, 627.75 mmol, 50.67 mL) in ethanol (100 mL) was added hydroxylamine hydrochloride (16.16 g, 232.50 mmol) at 25 °C. The mixture was heated to 90 °C for 4 h and was poured into a 2M aqueous solution of hydrochloric acid (250 mL). The mixture was then extracted with ethyl acetate (100 mL x 4), washed with saturated aqueous sodium chloride solution (25 mL x 1), dried with anhydrous Na_2SO_4 , filtered and concentrated under vacuum to give 1-(4-bromo-2-hydroxy-phenyl)ethanone oxime (12.49 g, crude), isolated as pale yellow solid, and used for the next step without further purification. (^1H NMR (400MHz, CHLOROFORM-d) δ = 11.47 (br s, 1H), 8.65 (br d, $J=4.3$ Hz, 1H), 7.94 (br s, 1H), 7.31 - 7.28 (d, 1H), 7.17 (d, $J=1.9$ Hz, 1H), 7.06 (dd, $J=2.0, 8.5$ Hz, 1H), 2.37 (s, 3H)


Step 2: Preparation of [(E)-1-(4-bromo-2-hydroxy-phenyl)ethylideneamino] acetate.



Acetic anhydride (25.50 mL) was added to 1-(4-bromo-2-hydroxy-phenyl)ethanone oxime (12.49 g, 54.29 mmol, 1.00 eq) one portion at 25 °C, then the mixture was stirred at 25 °C for 30 mins. Water (100 mL) was then added to the suspension (a solid precipitated from the reaction mixture after 30 min stirring at room temperature), further stirred for 30 min at 25 °C. The suspension was filtered and the resulting solid was washed with water (10 mL x 3) and dissolved in ethyl acetate (20 mL). The organic solution was then dried with anhydrous Na_2SO_4 , filtered and concentrated under vacuum to give [(E)-1-(4-bromo-2-hydroxy-phenyl)ethylideneamino] acetate (12.18 g, 44.8 mmol, 82 %) as pale white solid. ^1H


NMR (400MHz, CHLOROFORM-d) δ = 11.48 (s, 1H), 7.34 (d, J =8.7 Hz, 1H), 7.24 (d, J =1.9 Hz, 1H), 7.07 (dd, J =1.9, 8.6 Hz, 1H), 2.45 (s, 3H), 2.28 (s, 3H).

Step 3: Preparation of 6-bromo-3-methyl-1,2-benzoxazole




[(E)-1-(4-bromo-2-hydroxy-phenyl)ethylideneamino] acetate (11.00 g, 40.4 mmol) was added in one portion to pyridine (100 mL) and the resulting solution was refluxed at 130 °C for 15 h. The mixture was cooled to room temperature and poured into a 2M aqueous solution of hydrochloric acid (500 mL). The resulting mixture was extracted with methyl tert-butyl ether (200 mL x 3). The organic extracts were washed with saturated aqueous sodium chloride solution (20 mL x 1), dried with anhydrous Na₂SO₄, filtered and concentrated under vacuum to give the crude product further purified by chromatography (silica, petroleum ether / ethyl acetate=200/1 to 100/1). The desired compound (6-bromo-3-methyl-1,2-benzoxazole) was obtained as a yellow solid (7.50 g). ¹H NMR (400MHz, DMSO-d₆) δ = 8.05 (s, 1H), 8.08 - 8.03 (d, 1H), 8.08 - 8.03 (, 1H), 7.82 (d, J =8.4 Hz, 1H), 7.56 (dd, J =1.1, 8.3 Hz, 1H), 2.56 (s, 3H).

Step 4: Preparation of 3-methyl-1,2-benzoxazole-6-carbonitrile.



To a stirred solution of 6-bromo-3-methyl-1,2-benzoxazole (2.50 g, 11.8 mmol) and zinc cyanide (1.38 g, 11.8 mmol, 748 μ L) in N,N-dimethylformamide (12 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.36 g, 1.18 mmol) at 25 °C, the mixture was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 110 °C for 24 hrs under a nitrogen atmosphere. The suspension was filtered through a pad of Celite. The filtrate was then poured into water (50 mL), extracted with ethyl acetate (50 mL x 3) and the organic layer was washed with saturated aqueous sodium chloride solution (20 mL x 1), dried with anhydrous Na₂SO₄, and concentrated in vacuo. The residue was purified by chromatography (silica, petroleum ether / ethyl acetate=100/1 to 50:1) to give 3-methyl-1,2-benzoxazole-6-carbonitrile (240 mg, 1.52 mmol, 13 %), isolated as a white solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 7.89 (t, J =1.0 Hz, 1H), 7.76 (dd, J =0.7, 8.2 Hz, 1H), 7.60 - 7.57 (m, 1H), 2.63 (s, 3H).


Step 5: Preparation of N'-hydroxy-3-methyl-1,2-benzoxazole-6-carboxamide



To a stirred solution of 3-methyl-1,2-benzoxazole-6-carbonitrile (240 mg, 1.52 mmol) in ethanol (4.00 mL) and water (400 μ L) was added hydroxylamine hydrochloride (210 mg, 3.03 mmol) and triethylamine (307 mg, 3.03 mmol, 420 μ L) at 25 °C. The mixture was then stirred at 70 °C for 5 h and


concentrated in vacuo to give N'-hydroxy-3-methyl-1,2-benzoxazole-6-carboxamide (265 mg, 1.39 mmol, 91.60 %) isolated as a white solid, and used for the next step without further purification.

Step 6: Preparation of N-[2-[4-[3-(3-methyl-1,2-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide.




To a stirred solution of N'-hydroxy-3-methyl-1,2-benzoxazole-6-carboxamide (85 mg, 447.80 μ mol) and 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (130 mg, 447.80 μ mol) in N,N-dimethylformamide (2.00 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (169 mg, 447.80 μ mol) and N-ethyl-N-(propan-2-yl)propan-2-amine (115 mg, 895.60 μ mol, 156 μ L) at 25 $^{\circ}$ C. The mixture was then stirred at 25 $^{\circ}$ C for 4 h and warmed to 110 $^{\circ}$ C for 1 h. The mixture was concentrated in vacuo and the resulting residue was purified by chromatography (Boston Green ODS 150x30mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 26%-56%, 11.5 min) to give N-[2-[4-[3-(3-methyl-1,2-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (48 mg, 107.82 μ mol, 24%, 99% purity), isolated as a pale yellow solid. ^{1} H NMR (400MHz, CHLOROFORM-d) δ = 8.28 (s, 1H), 8.05 (d, J =8.3 Hz, 1H), 7.85 (d, J =7.5 Hz, 2H), 7.74 (d, J =7.9 Hz, 1H), 7.55 - 7.42 (m, 3H), 7.34 (br s, 1H), 4.51 (br d, J =13.6 Hz, 1H), 4.31 (d, J =3.9 Hz, 2H), 3.93 (br d, J =14.0 Hz, 1H), 3.41 - 3.32 (m, 2H), 3.16 (br t, J =10.7 Hz, 1H), 2.63 (s, 3H), 2.33 - 2.22 (m, 2H), 2.09 - 1.93 (m, 2H); LCMS (ESI) m/z : [M+H] $^{+}$:446.2.

Example 136: 4-[4-[3-(3-methyl-1,2-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.




Step 1: Preparation of 4-[4-[3-(3-methyl-1,2-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-1-phenyl-pyrrolidin-2-one.




To a stirred solution of N'-hydroxy-3-methyl-1,2-benzoxazole-6-carboxamide (78 mg, 410.94 μ mol) and 1-(5-oxo-1-phenyl-pyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (130 mg, 410.94 μ mol) in N,N-dimethylformamide (2.00 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate) (155 mg, 410.94 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (106 mg, 821.88 μmol , 143 μL) at 25 $^{\circ}\text{C}$. The mixture was then stirred at 25 $^{\circ}\text{C}$ for 4 h and warmed to 110 $^{\circ}\text{C}$ for 1 h. The mixture was concentrated in vacuo and the resulting residue was purified by chromatography (Boston Green ODS 150x30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 11.5 min) to give 4-[4-[3-(3-methyl-1,2-benzoxazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-carbonyl]-1-phenyl-pyrrolidin-2-one (42 mg, 89.8 μmol , 22 %) isolated as a yellow solid. ^1H NMR (400MHz, CHLOROFORM-d) δ = 8.28 (s, 1H), 8.06 (d, J =8.3 Hz, 1H), 7.74 (d, J =8.3 Hz, 1H), 7.60 (d, J =7.9 Hz, 2H), 7.38 (t, J =7.9 Hz, 2H), 7.20 - 7.14 (t, 1H), 4.61 - 4.48 (t, 1H), 4.35 - 4.29 (t, 1H), 4.04 - 3.92 (dd, 2H), 3.59 (quin, J =8.4 Hz, 1H), 3.46 - 3.31 (m, 2H), 3.20 - 3.05 (m, 1H), 3.03 - 2.92 (m, 1H), 2.89 - 2.80 (m, 1H), 2.63 (s, 3H), 2.28 (br t, J =12.3 Hz, 2H), 2.08 - 1.91 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 472.2$.


Example 137: N-(2-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




Step 1: Preparation of 1-(5-bromo-3-fluoropyridin-2-yl)ethanone.




A 3M solution of ethylmagnesium bromide in tetrahydrofuran (4.97 mL) was added at 0 $^{\circ}\text{C}$ to a stirred solution of 5-bromo-3-fluoropyridin-2-yl ethanone (2.0 g, 9.95 mmol) in tetrahydrofuran (20 mL). The mixture was then stirred at 25 $^{\circ}\text{C}$ for 1 h, and quenched by addition of an aqueous solution of ammonium hydroxide ammonium chloride solution (20 mL). The resulting mixture was extracted with ethyl acetate (2 X 20 mL). The combined organic extracts were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give the crude product further purified by chromatography (silica, petroleum ether : ethyl acetate = 20:1 to 1:1). The desired compound (1-(5-bromo-3-fluoropyridin-2-yl)ethanone) was isolated as a yellow solid (580 mg, 1.49 mmol, 15 %). ^1H NMR (400MHz, CHLOROFORM-d) δ 8.56 (s, 1H), 7.74 (dd, J =1.8, 9.8 Hz, 1H), 2.68 (s, 3H).

Step 2 preparation of 6-bromo-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine

To a stirred solution of 1-(5-bromo-3-fluoropyridin-2-yl)ethanone (570 mg, 1.46 mmol) in ethanol (5 mL), was added methylhydrazine (1.68 g, 14.60 mmol, 1.91 mL), and the resulting mixture was heated at 80 °C for 2 h. The reaction mixture was then quenched with water (5 mL) and extracted with ethyl acetate (2X5 mL). The combined organic extracts were washed with saturated aqueous sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give the crude product further purified by prep-TLC (silica, petroleum ether : ethyl acetate = 3:1). The title compound (6-bromo-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine) was isolated as a yellow solid (280 mg, 1.23 mmol, 84 %) ¹H NMR (400MHz, CHLOROFORM-d) δ 8.54 (d, *J*=1.9 Hz, 1H), 7.86 (d, *J*=1.9 Hz, 1H), 3.99 (s, 3H), 2.64 (s, 3H).

Step 3 preparation of 1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile.

A solution of 6-bromo-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine (280 mg, 1.24 mmol), tetrakis(triphenylphosphine)palladium(0) (214 mg, 186 μmol), and zinc cyanide (87 mg, 744 μmol, 47 μL) in N,N-dimethylformamide (2 mL) under nitrogen was heated to 100 °C and stirred for 12 h at 100 °C. The reaction mixture was cooled to room temperature, filtered and the filtrate was concentrated to give a residue poured into water (3 mL). The aqueous phase was extracted with ethyl acetate (3 mL x 3). The combined organic extracts were then washed with saturated aqueous sodium chloride solution (5 mL x 1), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-TLC (silica, petroleum ether : ethyl acetate = 1:1) to give 1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile (190 mg, 805.5 μmol, 65 %) as a light yellow solid. ¹H NMR (400MHz, CHLOROFORM-d) δ 8.72 (d, *J*=1.5 Hz, 1H), 8.04 (d, *J*=1.5 Hz, 1H), 4.09 (s, 3H), 2.69 (s, 3H).


Step 4: Preparation of (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carboximidamide.

To a stirred solution of 1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile (170 mg, 987 μmol) in ethanol (2 mL) was added hydroxylamine hydrochloride (137 mg, 1.97 mmol), triethylamine (199 mg, 1.97 mmol, 273 μL) and water (200 μL). The reaction mixture was then stirred at 80 °C for 2 h. and concentrated under reduced pressure. The residue was diluted with water (5 mL). The resulting solid

was filtered to give (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carboximidamide (160 mg, 779.7 μ mol, 79 %) isolated as a light yellow solid, and used for the next step without further purification. ^1H NMR (400MHz, DMSO- d_6) δ 9.93 (s, 1H), 8.82 (d, $J=1.8$ Hz, 1H), 8.29 (d, $J=2.0$ Hz, 1H), 6.07 (br s, 2H), 4.00 (s, 3H), 2.51 (s, 3H).

5


Step 5: Preparation of N-(2-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




To a stirred solution of 1-(2-benzamidoacetyl)piperidine-4-carboxylic acid (150 mg, 516.69 μ mol) in N,N-dimethylformamide (1.50 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (215 mg, 568 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (200 mg, 1.55 mmol, 270 μ L) and (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carboximidamide (106 mg, 516.69 μ mol). The reaction mixture was stirred at 25 $^{\circ}\text{C}$ for 1 h, and then warmed to 110 $^{\circ}\text{C}$ for 1 h. The reaction mixture was concentrated under vacuum and the resulting residue was purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-45%, 12min) to give N-(2-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide (116 mg, 252.7 μ mol, 49 %) isolated as a brown solid. ^1H NMR (400MHz, DMSO- d_6) δ 9.05 (d, $J=1.8$ Hz, 1H), 8.64 (d, $J=1.8$ Hz, 1H), 8.61 - 8.54 (m, 1H), 7.88 (br d, $J=7.1$ Hz, 2H), 7.57 - 7.45 (m, 3H), 4.35 (br d, $J=13.0$ Hz, 1H), 4.19 (br t, $J=5.6$ Hz, 2H), 4.10 (s, 3H), 4.01 (br d, $J=13.2$ Hz, 1H), 3.53 (br t, $J=10.9$ Hz, 1H), 3.58 - 3.48 (m, 1H), 3.32 - 3.24 (m, 1H), 2.96 (br t, $J=11.8$ Hz, 1H), 2.56 (s, 3H), 2.18 (br t, $J=13.7$ Hz, 2H), 1.88 (br d, $J=10.1$ Hz, 1H), 1.81 - 1.57 (m, 1H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 460.3$.

Example 138: 4-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.

25




Step 1: Preparation of 4-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one.




To a stirred solution of 1-(5-oxo-1-phenylpyrrolidine-3-carbonyl)piperidine-4-carboxylic acid (150 mg, 474 μ mol) in N,N-dimethylformamide (1.50 mL) was added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (197 mg, 521.58 μ mol), N-ethyl-N-(propan-2-yl)propan-2-amine (183 mg, 1.42 mmol, 248 μ L) and (Z)-N'-hydroxy-1,3-dimethyl-1H-pyrazolo[4,3-b]pyridine-6-carboximidamide (97 mg, 474 μ mol). The reaction mixture was stirred at 25 °C for 1 h and then warmed to 110 °C for 1 h. The reaction mixture was concentrated under vacuum and the resulting residue was purified by prep-HPLC (column: Waters Xbridge 150x25 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-50%, 12min) to give 4-(4-(3-(1,3-dimethyl-1H-pyrazolo[4,3-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-1-phenylpyrrolidin-2-one (121 mg, 249 μ mol, 52 %) isolated as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 9.05 (s, 1H), 8.64 (br s, 1H), 7.66 (br d, *J*=8.2 Hz, 2H), 7.41 - 7.34 (m, 2H), 7.17 - 7.11 (m, 1H), 4.39 (br d, *J*=13.5 Hz, 1H), 4.10 (s, 3H), 4.06 (br d, *J*=9.0 Hz, 2H), 4.00 - 3.93 (m, 1H), 3.80 - 3.71 (m, 1H), 3.52 (br t, *J*=10.9 Hz, 1H), 3.40 - 3.34 (m, 1H), 3.03 - 2.92 (m, 1H), 2.85 - 2.71 (m, 2H), 2.56 (s, 3H), 2.19 (t, *J*=14.3 Hz, 2H), 1.95 - 1.82 (m, 1H), 1.80-1.70 (m, 1H); LCMS (ESI) *m/z*: [M+H]⁺ = 486.3.

Example 139: 4-[4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]benzonitrile.




Step 1: Preparation of 4-[4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one.



A mixture of 1-[(2,4-dimethoxyphenyl)methyl]-4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one (350 mg, 626.53 μ mol), anisole (135 mg, 1.25 mmol, 135 μ L) in trifluoroacetic acid (5 mL) was degassed and purged with nitrogen three times. The reaction mixture was stirred at 80 °C for 2 h under a nitrogen atmosphere and then concentrated under reduced pressure to to


provide the crude product (500 mg) isolated as a yellow oil and used for the next step without further purification.

Step 2: Preparation of 4-[4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]benzonitrile.




A mixture of 4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]pyrrolidin-2-one (200 mg, 489.66 μmol), 4-iodobenzonitrile (112 mg, 489.66 μmol), potassium phosphate tribasic (187 mg, 881 μmol), copper iodide (18 mg, 97.93 μmol) and (1S,2S)-cyclohexane-1,2-diamine (55 mg, 489.66 μmol , 60 μL) in dioxane (1 mL) and N,N-dimethylformamide (1 mL) was degassed and purged with nitrogen three times. The mixture was stirred at 110 $^{\circ}\text{C}$ for 16 h under a nitrogen atmosphere. After the reaction cooled to 20 $^{\circ}\text{C}$, water (10 mL) was added to the mixture which was extracted with ethyl acetate (30 mL x 3). The combined organic extracts were washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give the crude product further purified by prep-HPLC (column: Waters Xbridge 150x2.5mm 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 15%-40%, 12min). The title compound (4-[4-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]benzonitrile) was isolated as a pale yellow solid (17 mg, 34 μmol , 7 %). ^1H NMR (400 MHz, CDCl_3) δ 8.10 (br s, 1H), 7.87 - 7.72 (m, 4H), 7.67 (d, $J=8.8$ Hz, 2H), 4.63 - 4.47 (m, 1H), 4.36 (dd, $J=7.1$, 9.5 Hz, 1H), 4.09 (s, 3H), 4.03 - 3.93 (m, 2H), 3.62 (m, 1H), 3.48 - 3.32 (m, 2H), 3.20 - 3.04 (m, 1H), 3.02 - 2.88 (m, 2H), 2.61 (s, 3H), 2.30 (br t, $J=14.4$ Hz, 2H), 2.10 - 1.96 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 510.3$.

Example 140: 2-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]isoindolin-1-one.




Step 1: Preparation of 2-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]isoindolin-1-one.




To a stirred solution of 3-(4-ethoxy-3-methoxy-phenyl)-5-(4-piperidyl)-1,2,4-oxadiazole (130 mg, 382.56 μmol , 1.00 eq, hydrochloric acid) in N,N-dimethylformamide (2 mL) was added 2-(1-oxoisoindolin-2-yl)propanoic acid (78 mg, 382.56 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (174 mg, 459 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (148 mg, 1.15 mmol, 200 μL). The mixture was stirred at 20 $^{\circ}\text{C}$ for 1 h. The reaction mixture was concentrated under vacuum and the residue was purified by prep-HPLC (column: Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12min) to give 2-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]isoindolin-1-one (132 mg, 266 μmol , 70 %), isolated as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.86 (br t, $J=6.2$ Hz, 1H), 7.69 - 7.43 (m, 5H), 6.93 (dd, $J=8.4, 15.4$ Hz, 1H), 5.55 (q, $J=6.8$ Hz, 1H), 4.57 - 4.36 (m, 3H), 4.29 - 4.11 (m, 3H), 3.95 (d, $J=13.5$ Hz, 3H), 3.42 - 3.19 (m, 2H), 3.14 - 3.00 (m, 1H), 2.16 (br dd, $J=4.4, 8.8$ Hz, 2H), 2.06 - 1.67 (m, 2H), 1.54 - 1.47 (m, 6H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 491.1$.

Example 141: 2-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]isoindolin-1-one




Step 1: Preparation of 2-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]isoindolin-1-one



To a stirred solution of 2-(1-oxoisoindolin-2-yl)propanoic acid (79 mg, 389 μmol) in N,N-dimethylformamide (2 mL) was added 3-(1,3-dimethylindazol-6-yl)-5-(4-piperidyl)-1,2,4-oxadiazole (130

mg, 389 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (177 mg, 467 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (150 mg, 1.17 mmol, 204 μL). The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under vacuum and the residue was purified by prep-HPLC (column: Waters Xbridge 150x25 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 40%-70%, 12min) to give 2-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-1-methyl-2-oxo-ethyl]isoindolin-1-one (118 mg, 243.5 μmol , 63 %) isolated as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.12 - 8.01 (m, 1H), 7.90 - 7.67 (m, 3H), 7.60 - 7.44 (m, 3H), 5.56 (q, $J=6.6$ Hz, 1H), 4.58 - 4.40 (m, 3H), 4.27 (br t, $J=13.7$ Hz, 1H), 4.07 (d, $J=9.9$ Hz, 3H), 3.45 - 3.24 (m, 2H), 3.14 - 3.03 (m, 1H), 2.59 (d, $J=6.6$ Hz, 3H), 2.21 (br d, $J=12.8$ Hz, 2H), 2.10 - 1.70 (m, 2H), 1.52 (br dd, $J=4.3$, 6.3 Hz, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 485.1$.


Example 142: 2-(2-(4-(3-(5-ethoxy-6-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one




Step 1: 2-(2-(4-(3-(5-ethoxy-6-methoxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)isoindolin-1-one.

Example 142 was synthesized according to the synthetic procedure reported for the preparation of Example 147. ^1H NMR (400MHz, CHLOROFORM-d) δ = 7.87 (d, $J=7.5$ Hz, 1H), 7.67 (d, $J=8.3$ Hz, 1H), 7.58 - 7.53 (m, 1H), 7.47 (t, $J=6.8$ Hz, 2H), 7.10 (d, $J=7.9$ Hz, 1H), 4.58 (d, $J=5.7$ Hz, 2H), 4.52 (s, 1H), 4.48 - 4.41 (m, 2H), 4.19 - 4.12 (m, 5H), 4.04 (s, 1H), 3.44 - 3.26 (m, 2H), 3.05 (br t, $J=11.0$ Hz, 1H), 2.26 - 2.13 (m, 2H), 1.96 (br dd, $J=10.1$, 19.7 Hz, 2H), 1.52 (t, $J=7.0$ Hz, 3H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ : 478.1$.

Example 143: N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxoethyl]piperidine-1-carboxamide




Step 1: Preparation of tert-butyl N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]carbamate.




To a stirred solution of 3-(3,4-dimethoxyphenyl)-5-(4-piperidyl)-1,2,4-oxadiazole hydrochloride (1.00 g, 3.07 mmol, 1.00 eq) and 2-(tert-butoxycarbonylamino) acetic acid (537 mg, 3.07 mmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.16 g, 3.07 mmol) in N,N-dimethylformamide (10.00 mL) was added N-ethyl-N-(propan-2-yl)propan-2-amine (793 mg, 6.14 mmol, 1.07 mL) at 25 °C. The mixture was then stirred at 25 °C for 1h. The mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic extracts were washed with saturated aqueous sodium chloride solution (20 mL), dried with anhydrous Na₂SO₄, filtered and concentrated under vacuum to provide the crude product further purified by chromatography (silica, petroleum ether / ethyl acetate=100/1 to 50:1 to 1:1). The title compound (tert-butyl N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]carbamate) was isolated as a pale yellow oil (1.70 g, crude) (contained some residual ethyl acetate and dimethylformamide, and was used without further purification).

Step 2: 2-amino-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone.




To a stirred solution of tert-butyl N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]carbamate (800 mg, 1.79 mmol) in ethyl acetate (5.00 mL) was added a 4M hydrochloric acid in ethyl acetate (15.00 mL). The mixture was then stirred at 25 °C for 1 h, and then concentrated under vacuum to give 2-amino-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone hydrochloride (660 mg, crude), isolated as a white solid and used for the next step without further purification.

Step 3: Preparation of N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]piperidine-1-carboxamide.




To a stirred solution of 2-amino-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone (200 mg, 522 μ mol) and piperidine-1-carbonyl chloride (77 mg, 522 μ mol, 65 μ L) in dichloromethane (3.00 mL) was added triethylamine (158 mg, 1.57 mmol, 217 μ L) at 25 $^{\circ}$ C. The mixture was then stirred at 25 $^{\circ}$ C for 5 h. The reaction mixture was poured into 5mL water and extracted with dichloromethane (5 mL x 3). The combined organic extracts were concentrated under vacuum, dissolved in N,N-dimethylformamide (3 mL) and purified by chromatography (Boston Green ODS 150x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 30%-70%, 11.5min to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]piperidine-1-carboxamide (113 mg, 248 μ mol, 48 %) isolated as a white solid. ^{1} H NMR (400MHz, CHLOROFORM-d) δ = 7.68 (dd, J =1.8, 8.3 Hz, 1H), 7.56 (d, J =1.8 Hz, 1H), 6.95 (d, J =8.8 Hz, 1H), 5.57 (br s, 1H), 4.46 (br d, J =13.6 Hz, 1H), 4.10 (d, J =3.5 Hz, 2H), 3.95 (d, J =7.5 Hz, 6H), 3.86 (br d, J =14.0 Hz, 1H), 3.40 - 3.35 (m, 4H), 3.32 - 3.23 (m, 2H), 3.08 (br t, J =11.0 Hz, 1H), 2.25 - 2.15 (m, 2H), 2.03 - 1.88 (m, 2H), 1.62 - 1.51 (m, 6H); LCMS (ESI) m/z : [M+H] $^+$ = 458.1.

Example 144: N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-2-methoxy-benzamide.




Step 1: Preparation of N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-2-methoxy-benzamide.




To a stirred solution of 2-amino-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone hydrochloride (200 mg, 522 μ mol) and 2-methoxybenzoic acid (79 mg, 522 μ mol) in dichloromethane (3.00 mL) was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (661.8 mg, 1.04 mmol, 681.51 μ L, 50% purity) and triethylamine (158 mg, 1.57 mmol, 217 μ L) at 25 $^{\circ}$ C. The mixture was then stirred at 25 $^{\circ}$ C for 5 h. The reaction mixture was poured into water (5mL) and extracted with dichloromethane (5 mL x 3). The combined organic extracts were concentrated under vacuum. The resulting residue, dissolved in dimethylsulphoxide (3mL), was purified by chromatography (Boston Green ODS 150*30mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 42%-72%, 11.5 min) to give N-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-2-methoxy-benzamide (83 mg, 169.3 μ mol, 32 %) isolated as a white solid. ^{1} H NMR (400MHz, CHLOROFORM-d) δ = 9.01 (br s, 1H), 8.21 (dd, J =1.8, 7.9 Hz, 1H), 7.68

(dd, $J=2.2, 8.3$ Hz, 1H), 7.56 (d, $J=1.8$ Hz, 1H), 7.49 - 7.43 (m, 1H), 7.11 - 6.93 (m, 3H), 4.51 (br d, $J=13.6$ Hz, 1H), 4.36 (d, $J=3.9$ Hz, 2H), 4.04 (s, 3H), 3.95 (t, $J=7.9$ Hz, 7H), 3.38 - 3.26 (m, 2H), 3.13 (br t, $J=11.0$ Hz, 1H), 2.28 - 2.17 (d, 2H), 2.07 - 1.91 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 481.1$.

5 **Example 145: *N*-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]pyridine-2-carboxamide.**




10 *Step 1: Preparation of N*-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]pyridine-2-carboxamide.



To a stirred solution of 2-amino-1-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone (200 mg, 522 μ mol, 1.00 eq, HCl) and pyridine-2-carboxylic acid (64 mg, 522 μ mol) in dichloromethane (3.00 mL) was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (661.81 mg, 1.04 mmol, 681.51 μ L, 50% purity, 2eq) and triethylamine (158 mg, 1.57 mmol, 217 μ L) at 25 °C, then the mixture was stirred at 25 °C for 5 h. The reaction mixture was poured into water (5mL) and extracted with dichloromethane (5 mL x 3). The combined organic extracts were concentrated under vacuum. The resulting residue, dissolved in dimethylsulphoxide (3mL), was purified by prep-HPLC (Boston Green ODS 150x30mm 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 35%-65%, 11.5 min) to give *N*-[2-[4-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]pyridine-2-carboxamide (85 mg, 182.18 μ mol, 35 %) isolated as a white solid. ^1H NMR (400MHz, CHLOROFORM- d) δ = 8.91 (br s, 1H), 8.61 (d, $J=3.9$ Hz, 1H), 8.17 (d, $J=7.9$ Hz, 1H), 7.84 (dt, $J=1.8, 7.7$ Hz, 1H), 7.68 (dd, $J=1.8, 8.3$ Hz, 1H), 7.56 (d, $J=1.8$ Hz, 1H), 7.46 - 7.40 (dd, 1H), 6.95 (d, $J=8.3$ Hz, 1H), 4.53 (br d, $J=13.6$ Hz, 1H), 4.33 (d, $J=4.4$ Hz, 2H), 3.95 (d, $J=7.9$ Hz, 6H), 3.91 (br s, 1H), 3.39 - 3.26 (m, 2H), 3.12 (br t, $J=11.0$ Hz, 1H), 2.29 - 2.18 (t, 2H), 2.07 - 1.91 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 452.1$.

Example 146: 2-[2-[4-[3-(1,3-dimethylpyrazolo[3,4-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]isoindolin-1-one.




5

Step 1: 2-[2-[4-[3-(1,3-dimethylpyrazolo[3,4-b]pyridin-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]isoindolin-1-one.


Example 146 was synthesized according to the synthetic procedure reported for the preparation of Example 147. ¹H NMR (400MHz, CHLOROFORM-d) δ = 8.11 (d, J=8.4 Hz, 1H), 7.89 (d, J=8.2 Hz, 1H), 7.85 (d, J=8.2 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.47 - 7.41 (m, 2H), 4.60 - 4.41 (m, 5H), 4.16 (s, 3H), 4.12 - 4.05 (m, 1H), 3.41 - 3.31 (m, 2H), 3.06 - 2.98 (m, 1H), 2.62 - 2.57 (m, 3H), 2.25 (br t, J=14.6 Hz, 2H), 2.05 - 1.94 (m, 2H); LCMS(ESI) m/z: [M+H]⁺:472.3.

15

Example 147: 2-[2-[4-[3-(5-ethoxy-4-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]isoindolin-1-one.



Step 1: methyl 1-[2-(1-oxoisoindolin-2-yl)acetyl]piperidine-4-carboxylate.




20

A mixture of 2-(1-oxoisoindolin-2-yl)acetic acid (3.0 g, 15.69 mmol), methyl piperidine-4-carboxylate (2.47 g, 17.26 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (12.98 g, 20.40 mmol, 12.13 mL, 50% purity) and triethylamine (31.76 g, 313.80 mmol, 43.51 mL) in dichloromethane (60 mL), was stirred at 20 °C for 16 h. The reaction mixture was then diluted with water (20 mL) and extracted with dichloromethane (60 mL). The organic layers were combined, washed with saturated aqueous sodium chloride solution (30 mL x 2), dried over anhydrous sodium sulfate filtered and concentrated under reduced pressure to give the crude product further purified by chromatography (silica, petroleum ether / ethyl acetate=1:2). The title compound methyl 1-[2-(1-oxoisoindolin-2-yl)acetyl]piperidine-4-carboxylate was isolated as a yellow solid (4.30 g, 13.6 mmol, 87 %).


25

Step 2: Preparation of 1-[2-(1-oxoisindolin-2-yl)acetyl]piperidine-4-carboxylic acid.




A mixture of methyl 1-[2-(1-oxoisindolin-2-yl)acetyl]piperidine-4-carboxylate (4.30 g, 13.59 mmol), Lithium hydroxide monohydrate (1 M, 13.59 mL) in tetrahydrofuran (50 mL) was stirred at 20 °C for 1 h, and then acidified to pH 3 by addition of a 1M aqueous hydrochloric acid solution. The mixture was extracted with dichloromethane 20 mL. The organic layers were combined, washed with saturated aqueous sodium chloride solution (25 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1-[2-(1-oxoisindolin-2-yl)acetyl]piperidine-4-carboxylic acid (2.50 g, 8.27 mmol, 60.85 %) isolated as a white solid, and used for the next step without further purification.

Step 3: 2-[2-[4-[3-(5-ethoxy-4-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]isindolin-1-one.




A mixture of 1-[2-(1-oxoisindolin-2-yl)acetyl]piperidine-4-carboxylic acid (150 mg, 496 μmol), 5-ethoxy-N'-hydroxy-4-methoxy-pyridine-2-carboxamide (125 mg, 595 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (282 mg, 744 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (192 mg, 1.49 mmol, 259 μL) in N,N-dimethylformamide (2 mL) was stirred at 20 °C for 5 h, and at 110 °C for 1 h. The mixture was then cooled to room temperature and concentrated under vacuum to give a residue purified by chromatography (Boston Green ODS 150x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-45%, 11.5min). The title compound 2-[2-[4-[3-(5-ethoxy-4-methoxy-2-pyridyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]isindolin-1-one was isolated as a white solid (76 mg, 160 μmol, 32 %) as a white solid. ¹H NMR (400MHz, CHLOROFORM-d) δ = 8.26 (s, 1H), 7.88 - 7.82 (m, 1H), 7.62 (s, 1H), 7.56 - 7.52 (m, 1H), 7.48 - 7.43 (m, 2H), 4.56 (d, J=9.3 Hz, 2H), 4.52 - 4.40 (m, 3H), 4.24 (q, J=7.1 Hz, 2H), 4.07 (br d, J=13.7 Hz, 1H), 4.00 (s, 3H), 3.40 - 3.26 (m, 2H), 3.05 - 2.97 (m, 1H), 2.27 - 2.16 (m, 2H), 2.07 - 1.93 (m, 2H), 1.50 (t, J=6.9 Hz, 3H); LCMS (ESI) m/z: [M+H]⁺ = 478.3.

Example 148: (R)-5-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-3-phenyloxazolidin-2-one.





- 5 **Step 1: Preparation of (R)-5-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-3-phenyloxazolidin-2-one.**




To a stirred solution of (R)-2-oxo-3-phenyloxazolidine-5-carboxylic acid (100 mg, 482.67 μ mol) in dichloromethane (2 mL) was added 1-ethyl-3-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl hydrochloride (164 mg, 482.67 μ mol). The reaction mixture was stirred at 25 $^{\circ}$ C for 12 h and then concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Boston Green ODS 150x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 45%-75%, 11.5min) to give (R)-5-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-3-phenyloxazolidin-2-one (139 mg, 280 μ mol, 58 %) as a pale yellow solid. ^{1} H NMR (400MHz, CHLOROFORM-d) δ 7.67 (d, J =8.3 Hz, 1H), 7.59 - 7.55 (m, 3H), 7.40 (t, J =7.7 Hz, 2H), 7.17 (t, J =6.9 Hz, 1H), 6.95 (dd, J =1.1, 8.6 Hz, 1H), 5.25 (ddd, J =3.1, 6.2, 9.1 Hz, 1H), 4.81 (dd, J =6.8, 8.6 Hz, 1H), 4.58 (br d, J =14.0 Hz, 0.5H), 4.37 - 4.21 (m, 1H), 4.17 (q, J =7.0 Hz, 2H), 4.07 (dt, J =2.6, 9.0 Hz, 1.5H), 3.96 (d, J =2.2 Hz, 3H), 3.59 (ddd, J =3.3, 10.3, 14.0 Hz, 0.5H), 3.41 - 3.17 (m, 2H), 3.09 - 3.00 (m, 0.5H), 2.34 - 1.95 (m, 4H), 1.54 - 1.47 (m, 3H); LCMS (ESI) m/z : $[M+H]^+$ = 493.3.

Example 149: (S)-5-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-3-phenyloxazolidin-2-one.




Step 1: Preparation of benzyl phenylcarbamate.

To a stirred solution of aniline (5.0 g, 53.69 mmol, 4.90 mL) in tetrahydrofuran (100 mL) at 0 °C was added saturated aqueous sodium hydrogen carbonate (4.96 g, 59.06 mmol, 2.30 mL) followed by benzyl chloroformate (10.07 g, 59.06 mmol, 8.39 mL). The reaction mixture was stirred for 0.25h at 0 °C, warmed to 25 °C and stirring was continued for 0.75 h at 25 °C. The reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (3 X 50 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide benzyl phenylcarbamate (12.98 g, 53.7 mmol, 100 %) isolated as a white solid, and used for the next step without further purification ¹H NMR (400MHz, DMSO-d₆) δ 9.76 (s, 1H), 7.53 - 7.23 (m, 9H), 6.99 (t, *J*=7.1 Hz, 1H), 5.15 (s, 2H).


Step 2 preparation of (S)-5-(hydroxymethyl)-3-phenyloxazolidin-2-one.

A solution of benzyl phenylcarbamate (3.0 g, 13.20 mmol) in dry tetrahydrofuran (30 mL) was cooled to -78 °C under dry nitrogen atmosphere. A solution of *n*-butyl lithium in tetrahydrofuran (2.5 M, 7.92 mL) was slowly added to the reaction mixture which was stirred for 0.75h at -78 °C. A solution of (S)-oxiran-2-ylmethyl butyrate (2.28 g, 15.84 mmol) in dry tetrahydrofuran (10 mL) was slowly added to the mixture which was stirred at -78 °C for 2 h and then slowly warmed to 25 °C. Stirring was continued for 12h at room temperature and the reaction mixture was quenched by the addition of saturated aqueous ammonium chloride (30 mL). Ethyl acetate (30 mL) and water (30 mL) were added to the mixture and the layers were separated. The aqueous layer was further extracted with ethyl acetate (3 X 30 mL). The combined organic extracts were washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to give the crude product purified by chromatography (silica, petroleum ether : ethyl acetate = 1:1). The title compound (S)-5-(hydroxymethyl)-3-phenyloxazolidin-2-one was isolated as a white solid (1.70 g, 8.80 mmol, 67 %). ¹H NMR (400MHz, METHANOL-d₄) δ 7.57 (d, *J*=7.8 Hz, 2H), 7.43 - 7.31 (m, 2H), 7.14 (t, *J*=7.2 Hz, 1H), 4.78 - 4.71 (m, 1H), 4.13 (t, *J*=9.0 Hz, 1H), 3.94 (dd, *J*=6.6, 8.8 Hz, 1H), 3.85 (dd, *J*=3.4, 12.5 Hz, 1H), 3.70 (dd, *J*=4.2, 12.6 Hz, 1H).

Step 3 preparation of (S)-2-oxo-3-phenyloxazolidine-5-carboxylic acid.


To an ice-cooled solution of NaIO_4 (3.88 g, 18.13 mmol, 1.01 mL) in water (30 mL) was added a solution of (S)-5-(hydroxymethyl)-3-phenyloxazolidin-2-one (1.0 g, 5.18 mmol) in a mixture of acetonitrile (20 mL) and carbon tetrachloride (20 mL). Solid $\text{RuCl}_3 \cdot \text{H}_2\text{O}$ (58 mg, 259 μmol) was added to the reaction mixture which was stirred at 0 °C for 0.5 h, warmed to 25 °C and then stirred at 25 °C for an additional 12 h. The suspension was then filtered and the filtered solid was washed thoroughly with dichloromethane (50 mL). The filtrate was concentrated under reduced pressure to provide a residue further dissolved in ethyl acetate (50 mL). The organic solution was washed with saturated aqueous sodium carbonate (2 X 20 mL). The organic layer was discarded. The aqueous layer was acidified with concentrated hydrochloric acid and extracted with ethyl acetate (3 X 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product (850 mg) crude. 500 mg of this crude product was purified by prep-HPLC (column: Luna C18 150x25mm 5 μm ; mobile phase: [water (0.225%FA)-acetonitrile]; B%: 30%-50%, 12min) to give 150 mg of (S)-2-oxo-3-phenyloxazolidine-5-carboxylic acid as an off-white solid. ^1H NMR (400MHz, CHLOROFORM-d) δ 7.57 - 7.45 (m, 2H), 7.44 - 7.34 (m, 2H), 7.24 - 7.10 (m, 1H), 5.12 (dd, $J=5.3, 9.8$ Hz, 1H), 4.37 (t, $J=9.6$ Hz, 1H), 4.19 (dd, $J=5.3, 9.4$ Hz, 1H).

Step 4: Preparation of (S)-5-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-3-phenyloxazolidin-2-one.




To a stirred solution of (S)-2-oxo-3-phenyloxazolidine-5-carboxylic acid (80 mg, 386 μmol) in hydroxybenzotriazole (62 mg, 463 μmol), triethylamine (117 mg, 1.16 mmol, 160 μL) and 3-(1,3-dimethyl-1H-indazol-6-yl)-5-(piperidin-4-yl)-1,2,4-oxadiazole, hydrochloride (128 mg, 386 μmol , hydrochloric acid). The reaction mixture was stirred at 25 °C for 12 h and was then concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Boston Green ODS 150x30 5 μm ; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 43%-73%, 11.5min) to give (S)-5-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carbonyl)-3-phenyloxazolidin-2-one (82 mg, 168.7 μmol , 44 %) isolated as a white solid. ^1H NMR (400MHz, CHLOROFORM-d) δ 8.11 (d, $J=7.9$ Hz, 1H), 7.84 (d, $J=8.8$ Hz, 1H), 7.74 (dd, $J=3.5, 8.3$ Hz, 1H), 7.58 (d, $J=8.3$ Hz, 2H), 7.41 (t, $J=7.7$ Hz, 2H), 7.20 - 7.16 (m, 1H), 5.26 (dd, $J=7.5, 8.3$ Hz, 1H), 4.83 (dd, $J=6.4, 9.0$ Hz, 1H), 4.66 - 4.57 (m, 0.5H), 4.38 - 4.27 (m, 1H), 4.09 (d, $J=3.1$ Hz, 4.5H), 3.66 - 3.59 (m, 0.5H), 3.45 - 3.32 (m, 2H), 3.08 (br t, $J=11.2$ Hz, 0.5H), 2.60 (s, 3H), 2.39 - 2.25 (m, 2H), 2.24 - 1.97 (m, 2H); LCMS (ESI) m/z : $[\text{M}+\text{H}]^+ = 487.3$.

Example 150: N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-4-methoxy-pyridine-2-carboxamide.




- 5 **Step 1: Preparation of N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-4-methoxy-pyridine-2-carboxamide.**



To a stirred solution of 2-amino-1-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone (130 mg, 366.81 μ mol) in dichloromethane (3 mL) was added 4-methoxypyridine-2-carboxylic acid (56 mg, 366.81 μ mol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (256 mg, 403 μ mol, 239 μ L, 50% purity) and triethylamine (111 mg, 1.10 mmol, 152 μ L). The mixture was stirred at 20 $^{\circ}$ C for 1 h and then concentrated under reduced pressure. The resulting residue was purified by chromatography (column: Luna C18 100x30 5 μ m; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 20%-60%, 10min) to give N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-4-methoxy-pyridine-2-carboxamide (18 mg, 35 μ mol, 10 %) as a white solid. ^{1} H NMR (400 MHz, CDCl_3) δ 8.93 (br s, 1H), 8.41 (d, J =5.5 Hz, 1H), 8.10 (s, 1H), 7.86 - 7.80 (m, 1H), 7.77 - 7.69 (m, 2H), 6.93 (dd, J =2.4, 5.5 Hz, 1H), 4.56 (br d, J =14.1 Hz, 1H), 4.34 (d, J =4.4 Hz, 2H), 4.08 (s, 3H), 3.96 (br d, J =13.9 Hz, 1H), 3.92 (s, 3H), 3.41 - 3.31 (m, 2H), 3.14 (br t, J =11.6 Hz, 1H), 2.60 (s, 3H), 2.33 - 2.22 (m, 2H), 2.11 - 1.95 (m, 2H); LCMS (ESI) m/z : $[M+H]^+$ = 490.2.

20


Example 151: N-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-5-methoxypicolinamide.



25 Example 151 was synthesized according to a procedure similar to the one described in Example 154. ^{1} H NMR (400 MHz, CDCl_3) δ 8.72 (br s, 1H), 8.27 (d, J =2.6 Hz, 1H), 8.13 (d, J =8.6 Hz, 1H), 8.09 (s, 1H), 7.85 - 7.79 (m, 1H), 7.77 - 7.68 (m, 1H), 7.29 (d, J =2.6 Hz, 1H), 4.55 (br d, J =13.7 Hz, 1H), 4.33 (d, J =4.2 Hz, 2H), 4.08 (s, 3H), 3.96 (br d, J =13.9 Hz, 1H), 3.91 (s, 3H), 3.40 - 3.30 (m, 2H), 3.13 (br t,


$J=10.9$ Hz, 1H), 2.60 (s, 3H), 2.27 (br t, $J=11.8$ Hz, 2H), 2.09 - 1.95 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 490.2$.

Example 152: *N*-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)-2-methoxybenzamide.




Example 152 was synthesized according to a procedure similar to the one described in Example 154. ^1H NMR (400 MHz, CDCl_3) δ 9.03 (br s, 1H), 8.22 (dd, $J=1.4, 7.8$ Hz, 1H), 8.10 (s, 1H), 7.87 - 7.80 (m, 1H), 7.77 - 7.71 (m, 1H), 7.51 - 7.43 (m, 1H), 7.09 (t, $J=7.6$ Hz, 1H), 7.01 (d, $J=8.2$ Hz, 1H), 4.55 (br d, $J=13.9$ Hz, 1H), 4.38 (d, $J=4.0$ Hz, 2H), 4.08 (s, 3H), 4.05 (s, 3H), 3.96 (br d, $J=14.1$ Hz, 1H), 3.41 - 3.31 (m, 2H), 3.15 (br t, $J=11.4$ Hz, 1H), 2.60 (s, 3H), 2.28 (br t, $J=10.6$ Hz, 2H), 2.10 - 1.96 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 489.3$.

Example 153: *N*-(2-(4-(3-(1,3-dimethyl-1H-indazol-6-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)picolinamide.




Example 153 was synthesized according to a procedure similar to the one described in Example 154. ^1H NMR (400 MHz, CDCl_3) δ 8.93 (br s, 1H), 8.63 (d, $J=4.0$ Hz, 1H), 8.19 (d, $J=7.7$ Hz, 1H), 8.10 (s, 1H), 7.89 - 7.80 (m, 2H), 7.76 - 7.71 (m, 1H), 7.47 - 7.41 (m, 1H), 4.56 (br d, $J=13.7$ Hz, 1H), 4.35 (d, $J=4.4$ Hz, 2H), 4.09 (s, 3H), 3.96 (br d, $J=13.9$ Hz, 1H), 3.44 - 3.31 (m, 2H), 3.15 (br t, $J=10.7$ Hz, 1H), 2.60 (s, 3H), 2.34 - 2.23 (m, 2H), 2.11 - 1.95 (m, 2H); LCMS (ESI) m/z : $[M+H]^+ = 460.2$.

Example 154: N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-6-methoxy-pyridine-2-carboxamide.




- 5 **Step 1: Preparation of tert-butyl N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]carbamate.**




- To a stirred solution of 3-(1,3-dimethylindazol-6-yl)-5-(4-piperidyl)-1,2,4-oxadiazole (1.0 g, 3.00 mmol, 1.00 eq, hydrochloric acid salt) in dichloromethane (20 mL) was added 2-(tert-butoxycarbonylamino)acetic acid (525 mg, 3.00 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (2.86 g, 4.50 mmol, 2.68 mL, 50% purity) and triethylamine (1.82 g, 18.00 mmol, 2.49 mL, 6.00 eq). The mixture was stirred at 20 °C for 16 h. Water (30 mL) was then added to the reaction mixture which was extracted with dichloromethane (60 mL x 3). The combined organic extracts were washed with saturated aqueous sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide the crude product further purified by chromatography (silica, petroleum ether : ethyl acetate = 20:1 to 1:4). The title compound (tert-butyl N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]carbamate) was isolated as a white solid (1.0 g, 2.20 mmol, 73 %). ¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 7.86 - 7.80 (m, 1H), 7.77 - 7.72 (m, 1H), 5.53 (br s, 1H), 4.50 (br d, J=12.3 Hz, 1H), 4.09 (s, 3H), 4.02 (br d, J=3.5 Hz, 2H), 3.83 (br d, J=12.7 Hz, 1H), 3.38 - 3.23 (m, 2H), 3.10 (br t, J=11.6 Hz, 1H), 2.60 (s, 3H), 2.23 (br s, 2H), 2.06 - 1.94 (m, 2H), 1.47 (s, 9H).

Step 2: Preparation of 2-amino-1-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone.




To a stirred solution of tert-butyl N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]carbamate (980 mg, 2.16 mmol) in ethyl acetate (5 mL) was added a 4M solution of hydrochloric acid in ethyl acetate (50 mL). The mixture was stirred at 20 °C for 0.5 h and then concentrated under reduced pressure to give 2-amino-1-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone, hydrochloride (940 mg, crude) isolated as a white solid and used for the next step without further purification. ¹H NMR (400 MHz, Methanol-d₄) δ 8.19 (s, 1H), 7.83 (d, *J*=0.9 Hz, 2H), 4.48 (br d, *J*=13.9 Hz, 1H), 4.06 (s, 3H), 4.04 - 3.95 (m, 2H), 3.86 (br d, *J*=13.9 Hz, 1H), 3.53 - 3.43 (m, 1H), 3.38 (br t, *J*=11.5 Hz, 1H), 3.13 (br t, *J*=11.2 Hz, 1H), 2.58 (s, 3H), 2.28 (br t, *J*=9.3 Hz, 2H), 2.01 - 1.84 (m, 2H).

Step 3: Preparation of N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-6-methoxy-pyridine-2-carboxamide.




To a stirred solution of 2-amino-1-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]ethanone (130 mg, 366.81 μmol) in N,N-dimethylformamide (2 mL) was added 6-methoxypyridine-2-carboxylic acid (56 mg, 366.81 μmol), (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (166 mg, 440 μmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (142 mg, 1.10 mmol, 192 μL). The mixture was stirred at 20 °C for 1 h and concentrated under reduced pressure. The resulting residue was purified by chromatography (column: Luna C18 100x30 5μm; mobile phase: [water (10mM ammonium carbonate)-acetonitrile]; B%: 25%-65%, 10min) to give N-[2-[4-[3-(1,3-dimethylindazol-6-yl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]-6-methoxy-pyridine-2-carboxamide (92 mg, 187.6 μmol, 51 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.82 (br s, 1H), 8.10 (s, 1H), 7.86 - 7.69 (m, 4H), 6.92 (d, *J*=8.2 Hz, 1H), 4.55 (br d, *J*=13.9 Hz, 1H), 4.34 (d, *J*=4.2 Hz, 2H), 4.08 (s, 3H), 4.05 (s, 3H), 4.01 - 3.92 (m, 1H), 3.43 - 3.32 (m, 2H), 3.17 (br t, *J*=11.1 Hz, 1H), 2.60 (s, 3H), 2.34 - 2.23 (m, 2H), 2.12 - 1.97 (m, 2H); LCMS (ESI) *m/z*: [M+H]⁺ = 490.3.

Example 155: N-(2-(4-(3-(4-ethoxy-3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-2-oxoethyl)benzamide.




5

Step 1: Preparation of 4-ethoxy-3-methoxy-benzonitrile.




To a 0 °C stirred solution of 4-hydroxy-3-methoxy-benzonitrile (20g, 134.09 mmol) in N,N-dimethylformamide (200 mL) was added iodoethane (25.10 g, 160.91 mmol, 12.87 mL), potassium carbonate (37.07 g, 268.18 mmol). The reaction mixture was stirred at 40 °C for 16 h and then quenched by addition of water (300 mL). The mixture was extracted with ethyl acetate (200mL x 3) and the combined organic extracts were washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 4-ethoxy-3-methoxy-benzonitrile (25.0 g, crude), isolated as a yellow solid and used for the next step without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.30 - 7.20 (m, 1H), 7.07 (d, *J*=1.8 Hz, 1H), 6.88 (d, *J*=8.4 Hz, 1H), 4.14 (q, *J*=7.0 Hz, 2H), 3.88 (s, 3H), 1.49 (t, *J*=7.0 Hz, 3H).

Step 2: Preparation of 4-ethoxy-N'-hydroxy-3-methoxy-benzamidine.




To a stirred solution of 4-ethoxy-3-methoxy-benzonitrile (25.0 g, 141.08 mmol) in ethanol (200 mL) was added hydroxylamine hydrochloride (19.61 g, 282.17 mmol), triethylamine (28.55 g, 282.17 mmol, 39.11 mL) and water (20 mL). The mixture was stirred at 80 °C for 2 h and then concentrated under reduced pressure. The resulting residue was diluted with water (30 mL) and filtered to provide 4-ethoxy-N'-hydroxy-3-methoxy-benzamidine isolated as a white solid (24.0 g, 114.2 mmol, 81 %) and used for the next step without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.47 (br s, 1H), 7.25 (d, *J*=2.0 Hz, 1H), 7.20 (dd, *J*=2.0, 8.4 Hz, 1H), 6.92 (d, *J*=8.4 Hz, 1H), 5.75 (br s, 2H), 4.01 (q, *J*=7.0 Hz, 2H), 3.76 (s, 3H), 1.32 (t, *J*=7.0 Hz, 3H).

Step 3: Preparation of tert-butyl 4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate.




To a stirred solution of 4-ethoxy-N'-hydroxy-3-methoxy-benzamidine (10.0 g, 47.57 mmol) in N,N-dimethylformamide (100 mL) was added 1-tert-butoxycarbonylpiperidine-4-carboxylic acid (10.91 g, 47.57 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (18.04 g, 47.57 mmol) and N-ethyl-N-(propan-2-yl)propan-2-amine (18.44 g, 142.71 mmol, 24.92 mL). The mixture was stirred at 20 °C for 16 h and at 110 °C for 1 h. The reaction mixture was then cooled to room temperature, quenched by addition of water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with saturated aqueous sodium chloride (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product further was purified by chromatography (silica, petroleum ether : ethyl acetate = 1:0 to 10:1). The title compound, tert-butyl 4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate, was isolated as a yellow solid (13.30 g, 33.0 mmol, 69 %).

Step 4: Preparation of 3-(4-ethoxy-3-methoxy-phenyl)-5-(4-piperidyl)-1,2,4-oxadiazole.



To a stirred solution of tert-butyl 4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate (13.30 g, 32.96 mmol) in ethyl acetate (300 mL) was added a 4M solution of hydrochloric acid in methanol (30 mL). The mixture was stirred at 20 °C for 2 h and filtered to give 3-(4-ethoxy-3-methoxy-phenyl)-5-(4-piperidyl)-1,2,4-oxadiazole hydrochloride (10.0 g, 29.4 mmol, 89 %), isolated as a white solid and used for the next step without further purification.

Step 5: Preparation of N-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide.




To a stirred solution of 2-benzamidoacetic acid (1.16 g, 6.48 mmol) in dichloromethane (20 mL) was added 3-(4-ethoxy-3-methoxy-phenyl)-5-(4-piperidyl)-1,2,4-oxadiazole hydrochloride (2.0 g, 5.89 mmol), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in ethyl acetate (4.87 g, 7.65 mmol, 4.55 mL, 50% in ethyl acetate) and triethylamine (2.38 g, 23.5 mmol, 3.26 mL). The mixture was stirred at 20 °C for 16 h. Water (20 mL) was then added to the mixture which was extracted with dichloromethane


(80 mL x 2). The combined organic extracts were washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated to give a residue dissolved in with ethyl acetate (40 mL). The organic solution was washed with 1N aqueous hydrochloric acid solution (15 mL x 2), saturated sodium carbonate (15 mL x 2), saturated aqueous sodium chloride solution (15 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. To a solution of the crude product in methyl tert-butyl ether (20 mL) was added petroleum ether (2 mL). The precipitate, formed after 2 h stirring at room temperature, was collected by filtration, washed with methyl tert-butyl ether (5 mL x 2) and dried under reduced pressure to give N-[2-[4-[3-(4-ethoxy-3-methoxy-phenyl)-1,2,4-oxadiazol-5-yl]-1-piperidyl]-2-oxo-ethyl]benzamide (1.68 g, 3.60 mmol, 61 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.89 - 7.83 (m, 2H), 7.66 (dd, *J*=1.9, 8.3 Hz, 1H), 7.58 - 7.42 (m, 4H), 7.35 (br s, 1H), 6.95 (d, *J*=8.4 Hz, 1H), 4.50 (td, *J*=3.8, 13.6 Hz, 1H), 4.30 (d, *J*=4.0 Hz, 2H), 4.17 (q, *J*=7.0 Hz, 2H), 3.96 (s, 3H), 3.94 - 3.87 (m, 1H), 3.38 - 3.27 (m, 2H), 3.19 - 3.08 (m, 1H), 2.24 (m, 2H), 2.07 - 1.91 (m, 2H), 1.50 (t, *J*=7.0 Hz, 3H); LCMS (ESI) *m/z*: [M+H]⁺ = 465.2.

Example 156. Characterization Data of Compounds of the Invention


The following compounds were synthesized by methods similar to those described above.




¹H NMR (400 MHz, DMSO-*d*₆) δ 8.10-7.71 (m, 5H), 7.65-7.30 (m, 7H), 4.87 (br s, 2H), 4.26 (s, 2H), 3.69 (br s, 2H), 1.23 (br s, 3H); LCMS (ESI) [M+H]⁺: 372.1.



¹H NMR (400 MHz, DMSO-*d*₆) δ 8.07-8.00 (m, 1H), 7.99-7.91 (m, 1H), 7.86 (d, *J* = 6.2 Hz, 1H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.58-7.52 (m, 3H), 7.49 (br s, 2H), 7.20 (d, *J* = 8.4 Hz, 1H), 4.92 (br s, 2H), 4.32 (s, 2H), 3.91 (d, *J* = 6.2 Hz, 6H), 3.74 (br s, 2H), 1.28 (br s, 3H); LCMS (ESI) [M+H]⁺: 432.1.




¹H NMR (400 MHz, DMSO-d₆) δ 7.71-7.59 (m, 1H), 7.33 (br d, J = 8.6 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.89 (br d, J = 8.6 Hz, 2H), 4.76 (s, 2H), 4.06-3.91 (m, 2H), 3.74 (s, 3H), 1.60-1.49 (m, 2H), 1.34 (br d, J = 2.2 Hz, 2H), 1.16 (br t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 392.2.



5


¹H NMR (400 MHz, DMSO-d₆) δ 7.73-7.63 (m, 2H), 7.44-7.39 (m, 2H), 7.37-7.25 (m, 3H), 7.21-7.15 (m, 1H), 4.84-4.69 (s, 2H), 4.05-3.91 (m, 2H), 1.62-1.54 (m, 2H), 1.43-1.36 (m, 2H), 1.16 (s, 3H); LCMS (ESI) [M+H]⁺: 362.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.71 (dd, J = 1.8, 8.3 Hz, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.37-7.31 (m, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.22-7.16 (m, 2H), 7.00 (d, J = 8.3 Hz, 1H), 4.60 (s, 2H), 4.28 (q, J = 7.2 Hz, 1H), 3.99 (q, J = 7.1 Hz, 2H), 1.69 (d, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H); LCMS (ESI) [M+H]⁺: 350.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09-8.11 (m, 2H), 7.51-7.53 (m, 5H), 7.25-7.40 (m, 3H), 1.72-1.74 (t, 2H), 1.43-1.46 (t, 2H); LCMS (ESI) [M+H]⁺: 263.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 9.06 (br s, 1H), 7.88-7.80 (m, 3H), 7.69 (s, 1H), 7.53-7.44 (m, 3H), 7.40-7.30 (m, 1H), 7.18-7.16 (d, J = 8.4 Hz, 1H), 4.54-4.50 (m, 1H), 4.33-4.32 (d, J = 4.0 Hz, 2H), 3.95-3.91 (m, 1H), 3.49 (s, 3H), 3.39-3.13 (m, 1H), 2.30-2.23 (m, 2H), 2.05-1.98 (m, 2H); LCMS (ESI) [M+H]⁺: 461.1.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.64 (t, J = 1.1 Hz, 1H), 8.11 (dd, J = 1.2, 9.4 Hz, 1H), 7.96 (dd, J = 1.0, 9.4 Hz, 1H), 7.87-7.81 (m, 2H), 7.54-7.48 (m, 1H), 7.47-7.41 (m, 2H), 7.31 (br s, 1H), 4.57-4.48 (m, 1H), 4.30 (d, J = 3.7 Hz, 2H), 3.92 (br d, J = 14.1 Hz, 1H), 3.41-3.31 (m, 2H), 3.20-3.09 (m, 1H), 2.27 (dt, J = 3.7, 13.2 Hz, 2H), 2.00 (ddq, J = 4.1, 10.6, 14.4 Hz, 2H); LCMS (ESI) [M+H]⁺: 433.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.63 (s, 1H), 8.10 (d, J = 9.3 Hz, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.57 (d, J = 7.9 Hz, 2H), 7.35 (t, J = 7.8 Hz, 2H), 7.18-7.12 (m, 1H), 4.63-4.43 (m, 1H), 4.30 (br t, J = 7.9 Hz, 1H), 4.06-3.87 (m, 2H), 3.57 (quin, J = 8.6 Hz, 1H), 3.45-3.28 (m, 2H), 3.17-2.75 (m, 3H), 2.36-2.20 (m, 2H), 2.07-1.89 (m, 2H); LCMS (ESI) [M+H]⁺: 459.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.14 (s, 1H), 7.77-7.70 (m, 3H), 7.62-7.47 (m, 2H), 7.51-7.46 (m, 1H), 4.64-4.42 (m, 5H), 4.09-4.01 (m, 1H), 4.01 (s, 3H), 3.48-3.37 (m, 2H), 3.06 (br t, J = 11.0 Hz, 1H), 2.53 (s, 3H), 2.32-2.18 (m, 2H), 2.07-1.84 (m, 2H); LCMS (ESI) [M+H]⁺: 471.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (s, 1H), 7.85 (d, J = 7.0 Hz, 2H), 7.54-7.42 (m, 3H), 7.32 (br s, 1H), 4.51 (br d, J = 13.6 Hz, 1H), 4.29 (t, J = 4.8 Hz, 2H), 4.26-4.17 (m, 5H), 3.90 (br d, J = 14.0 Hz, 1H), 3.42-3.28 (m, 2H), 3.10 (br t, J = 11.0 Hz, 1H), 2.33-2.22 (m, 2H), 2.13-1.95 (m, 2H), 1.52 (t, J = 7.0 Hz, 3H); LCMS (ESI) [M+H]⁺: 467.3.




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.68 (dd, J = 1.8, 8.3 Hz, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.36-7.27 (m, 3H), 7.24-7.20 (m, 1H), 6.95 (d, J = 8.3 Hz, 1H), 4.76-4.53 (m, 1H), 3.86-3.93 (m, 1H), 3.94-3.96 (d, J = 8.3 Hz, 6H), 3.34-3.14 (m, 2H), 3.34-3.11 (m, 1H), 2.93 (quin, J = 7.0 Hz, 1H), 2.97-2.89 (m, 1H), 2.34-1.88 (m, 4H), 1.26 (d, J = 7.0 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 436.2.



10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.10 (d, J = 3.1 Hz, 1H), 8.01-7.88 (m, 2H), 7.87-7.80 (m, 1H), 7.78-7.71 (m, 1H), 7.53-7.42 (m, 2H), 4.63-4.49 (m, 1H), 4.34 (dd, J = 7.1, 8.8 Hz, 1H), 4.09 (d, J = 2.6 Hz, 3H), 4.04-3.92 (m, 2H), 3.63 (quin, J = 8.2 Hz, 1H), 3.48-3.34 (m, 2H), 3.21-2.85 (m, 3H), 2.61 (s, 3H), 2.30 (br t, J = 14.3 Hz, 2H), 2.11-1.94 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 510.0.




15
20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.69 (br s, 1H), 8.32 (dd, J = 1.5, 4.2 Hz, 1H), 8.10 (s, 1H), 7.86-7.80 (m, 1H), 7.77-7.71 (m, 1H), 7.45-7.36 (m, 2H), 4.54 (br d, J = 13.9 Hz, 1H), 4.37 (br d, J = 3.5 Hz, 2H), 4.09 (s, 3H), 4.00 (s, 3H), 3.96 (br s, 1H), 3.41-3.31 (m, 2H), 3.14 (br t, J = 11.1 Hz, 1H), 2.60 (s, 3H), 2.33-2.22 (m, 2H), 2.11-1.94 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 490.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (br d, J = 7.1 Hz, 1H), 7.87-7.79 (m, 1H), 7.78-7.63 (m, 3H), 7.56-7.48 (m, 1H), 7.46-7.38 (m, 1H), 4.56 (br t, J = 13.6 Hz, 1H), 4.32-4.22 (m, 1H), 4.17-3.96 (m, 5H), 3.74 (quin, J = 8.2 Hz, 1H), 3.48-3.31 (m, 2H), 3.20-3.04 (m, 1H), 3.01-2.84 (m, 2H), 2.60 (s, 3H), 2.36-2.21 (m, 2H), 2.10-1.93 (m, 2H); LCMS (ESI) [M+H]⁺: 510.3.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.05 (s, 1H), 7.87-7.78 (m, 4H), 7.54-7.42 (m, 2H), 7.35 (br s, 1H), 5.00-4.91 (spt, J = 6.8 Hz, 1H), 4.52-4.50 (br d, J = 13.7 Hz, 1H), 4.35-4.27 (d, J = 3.7 Hz, 2H), 3.94-3.91 (br d, J = 13.9 Hz, 1H), 3.38-3.32 (m, 2H), 3.18-3.12 (br t, J = 11.0 Hz, 1H), 2.35-2.21 (m, 2H), 2.09-1.96 (m, 2H), 1.63-1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 473.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.67 (br d, J = 8.2 Hz, 1H), 7.60-7.55 (m, 3H), 7.40 (t, J = 7.7 Hz, 2H), 7.18 (t, J = 6.9 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 5.28-5.22 (m, 1H), 4.84-4.79 (m, 1H), 4.59 (br d, J = 13.5 Hz, 0.5H), 4.36-4.22 (m, 1H), 4.18 (q, J = 7.1 Hz, 2H), 4.13-4.03 (m, 1.5H), 3.97 (d, J = 2.2 Hz, 3H), 3.64-3.54 (m, 0.5H), 3.41-3.27 (m, 2H), 3.09-3.01 (m, 0.5H), 2.35-2.15 (m, 2.5H), 2.11-1.93 (m, 1.5H), 1.51 (t, J = 6.8 Hz, 3H); LCMS (ESI) [M+H]⁺: 492.8.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (d, J = 7.5 Hz, 1H), 7.84 (dd, J = 1.3, 8.3 Hz, 1H), 7.74 (dd, J = 3.9, 8.3 Hz, 1H), 7.58 (d, J = 7.9 Hz, 2H), 7.40 (t, J = 7.7 Hz, 2H), 7.18 (t, J = 7.3 Hz, 1H), 5.26 (t, J = 7.7 Hz, 1H), 4.83 (dd, J = 6.6, 8.8 Hz, 1H), 4.62 (d, J = 13.6 Hz, 0.5H), 4.38-4.26 (m, 1H), 4.13-4.05 (m, 4.5H), 3.66-3.58 (m, 0.5H), 3.45-3.31 (m, 2H), 3.11-3.04 (m, 0.5H), 2.60 (s, 3H), 2.40-2.25 (m, 2H), 2.24-1.96 (m, 2H); LCMS (ESI) [M+H]⁺: 487.3.


25




¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 8.17 (s, 1H), 7.92-7.90 (d, J = 8.4 Hz, 1H), 7.75-7.73 (d, J = 8.4 Hz, 1H), 7.66-7.64 (br d, J = 8.2 Hz, 2H), 7.38-7.33 (dt, J = 3.7, 7.8 Hz, 2H), 7.13-7.11 (m, 1H), 5.15-5.11 (dt, J = 3.5, 6.5 Hz, 1H), 4.39-4.35 (br d, J = 13.2 Hz, 1H), 4.06-3.93 (m, 3H), 3.78-3.70 (m, 1H), 3.50-3.45 (br t, J = 10.7 Hz, 1H), 3.36-3.33 (m, 1H), 2.98-2.93 (m, 1H), 2.81-2.71 (m, 2H), 2.20-2.13 (br t, J = 14.0 Hz, 2H), 1.89-1.65 (m, 2H), 1.49-1.48 (d, J = 6.4 Hz, 6H); LCMS (ESI) [M+H]⁺: 499.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.69-7.62 (m, 2H), 7.55 (d, J = 1.8 Hz, 1H), 7.45 (dt, J = 4.6, 7.7 Hz, 1H), 7.27-7.24 (m, 1H), 7.27-7.19 (m, 1H), 6.94 (d, J = 8.6 Hz, 1H), 4.63 (d, J = 2.9 Hz, 2H), 4.55-4.39 (m, 3H), 4.16 (q, J = 6.9 Hz, 2H), 4.02 (br d, J = 13.7 Hz, 1H), 3.95 (s, 3H), 3.43-3.23 (m, 2H), 3.06 (br t, J = 10.9 Hz, 1H), 2.29-2.15 (m, 2H), 2.08-1.88 (m, 2H), 1.50 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 495.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.85 (dd, J = 5.3, 8.4 Hz, 1H), 7.65 (dd, J = 1.8, 8.4 Hz, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.20-7.13 (m, 2H), 6.95 (d, J = 8.4 Hz, 1H), 4.57 (d, J = 3.7 Hz, 2H), 4.51-4.41 (m, 3H), 4.18 (q, J = 7.0 Hz, 2H), 4.05 (br d, J = 13.9 Hz, 1H), 3.96 (s, 3H), 3.42-3.24 (m, 2H), 3.07 (br t, J = 10.9 Hz, 1H), 2.29-2.15 (m, 2H), 2.07-1.89 (m, 2H), 1.51 (t, J = 6.9 Hz, 3H); LCMS (ESI) [M+H]⁺: 495.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.53 (dd, J = 2.0, 8.4 Hz, 1H), 7.46-7.39 (m, 2H), 7.30 (dd, J = 4.4, 8.2 Hz, 1H), 7.18-7.10 (m, 1H), 6.83 (d, J = 8.4 Hz, 1H), 4.52-4.27 (m, 5H), 4.05 (q, J = 7.0 Hz, 2H), 3.92 (br d, J = 13.7 Hz, 1H), 3.84 (s, 3H), 3.32-3.10 (m, 2H), 2.94 (br t, J = 10.8 Hz, 1H), 2.10 (br t, J = 15.0 Hz, 2H), 1.95-1.76 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 495.1.

5



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.66 (dd, J = 2.0, 8.4 Hz, 1H), 7.58-7.49 (m, 2H), 7.24 (d, J = 7.5 Hz, 1H), 7.10 (t, J = 8.8 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 4.59 (d, J = 5.1 Hz, 2H), 4.53-4.38 (m, 3H), 4.17 (q, J = 6.9 Hz, 2H), 4.07 (br d, J = 13.9 Hz, 1H), 3.96 (s, 3H), 3.45-3.22 (m, 2H), 3.12-3.02 (m, 1H), 2.22 (br dd, J = 14.2, 18.2 Hz, 2H), 2.09-1.88 (m, 2H), 1.51 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 495.3.


10



15


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.56 (dd, J = 2.3, 7.2 Hz, 1H), 8.13-8.02 (m, 2H), 7.86-7.79 (m, 1H), 7.77-7.71 (m, 1H), 7.17 (d, J = 8.6 Hz, 1H), 4.64-4.47 (m, 1H), 4.32 (ddd, J = 3.3, 6.6, 9.5 Hz, 1H), 4.08 (d, J = 2.2 Hz, 3H), 4.04-3.91 (m, 2H), 3.63 (quin, J = 8.3 Hz, 1H), 3.46-3.32 (m, 2H), 3.19-3.04 (m, 1H), 3.01-2.81 (m, 2H), 2.60 (s, 3H), 2.54 (s, 3H), 2.28 (br t, J = 13.3 Hz, 2H), 2.11-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 500.3.

20




25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 7.98 (s, 1H), 7.73 (s, 2H), 7.59-7.57 (br d, J = 8.2 Hz, 2H), 7.38-7.34 (t, J = 7.9 Hz, 2H), 7.17-7.13 (m, 1H), 4.85-4.77 (m, 1H), 4.50-4.42 (br t, J = 14.9 Hz, 1H), 4.33-4.23 (m, 1H), 4.01-3.89 (m, 2H), 3.62-3.54 (quin, J = 8.5 Hz, 1H), 3.45-3.27 (m, 2H), 3.22-2.90 (m, 2H), 2.87-2.75 (m, 1H), 2.31-2.17 (m, 2H), 2.07-1.91 (m, 2H), 1.67-1.66 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 499.3.




¹H NMR (400 MHz, DMSO-d₆) δ 8.57-8.52 (m, 2H), 8.27 (s, 1H), 7.88-7.84 (t, J = 7.6 Hz, 3H), 7.62-7.60 (dd, J = 1.2, 8.7 Hz, 1H), 7.55-7.43 (m, 3H), 4.92-4.82 (spt, J = 6.7 Hz, 1H), 4.34-4.31 (br d, J = 13.5 Hz, 1H), 4.18-4.16 (d, J = 5.5 Hz, 2H), 4.00-3.96 (br d, J = 13.9 Hz, 1H), 3.50-3.43 (m, 1H), 3.29-3.25 (m, 1H), 2.95-2.90 (br t, J = 11.2 Hz, 1H), 2.18-2.12 (br t, J = 12.3 Hz, 2H), 1.88-1.80 (q, J = 10.6 Hz, 1H), 1.73-1.63 (m, 1H), 1.60-1.55 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 473.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.63 (t, J = 1.1 Hz, 1H), 8.11 (dd, J = 1.3, 9.3 Hz, 1H), 7.96 (dd, J = 1.0, 9.4 Hz, 1H), 7.88-7.83 (m, 1H), 7.59-7.53 (m, 1H), 7.50-7.43 (m, 2H), 4.58 (s, 2H), 4.53-4.43 (m, 3H), 4.11 (br d, J = 14.1 Hz, 1H), 3.45-3.28 (m, 2H), 3.12-3.01 (m, 1H), 2.25 (br t, J = 14.1 Hz, 2H), 2.07-1.87 (m, 2H); LCMS (ESI) [M+H]⁺: 445.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.44 (br d, J = 5.5 Hz, 1H), 8.09 (s, 1H), 7.87-7.80 (m, 1H), 7.78-7.71 (m, 1H), 7.50 (br s, 1H), 7.40 (br d, J = 5.3 Hz, 1H), 4.64-4.48 (m, 1H), 4.29 (dd, J = 6.9, 9.6 Hz, 1H), 4.08 (s, 3H), 4.04-3.90 (m, 2H), 3.61 (quin, J = 8.4 Hz, 1H), 3.40 (br d, J = 10.8 Hz, 2H), 3.21-3.04 (m, 1H), 3.02-2.82 (m, 2H), 2.60 (s, 3H), 2.56 (s, 3H), 2.29 (br t, J = 14.7 Hz, 2H), 2.11-1.96 (m, 2H); LCMS (ESI) [M+H]⁺: 500.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.27 (br dd, J = 4.7, 8.3 Hz, 1H), 8.15 (br s, 1H), 8.10 (br s, 1H), 7.86-7.79 (m, 1H), 7.78-7.71 (m, 1H), 7.52 (br d, J = 8.4 Hz, 1H), 4.57 (br t, J = 12.7 Hz, 1H), 4.41 (dd, J = 9.0, 10.8 Hz, 1H), 4.22-4.14 (m, 1H), 4.09 (s, 3H), 4.04 (br d, J = 14.1 Hz, 1H), 3.57 (quin, J = 8.2 Hz, 1H), 3.47-3.32 (m, 2H), 3.25 (br dd, J = 7.7, 17.2 Hz, 1H), 3.16-3.04 (m, 1H), 2.86-2.76 (m, 1H), 2.60 (s, 3H), 2.36-2.21 (m, 5H), 2.12-1.93 (m, 2H); LCMS (ESI) [M+H]⁺: 500.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.85-7.80 (m, 2H), 7.66 (br t, J = 8.8 Hz, 1H), 7.58-7.49 (m, 3H), 7.47-7.41 (m, 2H), 6.94 (t, J = 7.9 Hz, 1H), 5.18 (br d, J = 2.6 Hz, 1H), 4.54-4.38 (m, 1H), 4.18 (br t, J = 14.0 Hz, 1H), 3.97-3.92 (m, 7H), 3.89-3.83 (m, 1H), 3.46-3.36 (m, 1H), 3.34-3.23 (m, 1H), 3.19-3.03 (m, 1H), 2.23 (br s, 2H), 2.11-1.92 (m, 2H); LCMS (ESI) [M+H]⁺: 481.3.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.14 (br d, J = 11.0 Hz, 1H), 7.89-7.84 (m, 2H), 7.77 (br d, J = 7.0 Hz, 2H), 7.55-7.43 (m, 3H), 5.23 (t, J = 6.1 Hz, 1H), 4.58-4.45 (m, 1H), 4.28 (br t, J = 14.9 Hz, 1H), 4.02 (br d, J = 5.3 Hz, 3H), 3.93-3.82 (m, 2H), 3.54-3.40 (m, 2H), 3.16-3.03 (m, 1H), 2.54 (s, 3H), 2.34-2.18 (m, 2H), 2.08-1.86 (m, 2H); LCMS (ESI) [M+H]⁺: 489.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.86 (d, J = 7.1 Hz, 2H), 7.58-7.42 (m, 3H), 7.35 (br s, 1H), 7.23 (d, J = 2.2 Hz, 2H), 6.61 (t, J = 2.2 Hz, 1H), 4.50 (br d, J = 13.7 Hz, 1H), 4.31 (d, J = 4.0 Hz, 2H), 3.91 (br d, J = 14.3 Hz, 1H), 3.86 (s, 6H), 3.39-3.29 (m, 2H), 3.15 (br t, J = 10.7 Hz, 1H), 2.30-2.20 (m, 2H), 2.08-1.93 (m, 2H); LCMS (ESI) [M+H]⁺: 451.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (d, J = 4.9 Hz, 1H), 7.87-7.80 (m, 1H), 7.79-7.72 (m, 1H), 7.57 (br dd, J = 4.6, 8.6 Hz, 2H), 7.08 (t, J = 8.6 Hz, 2H), 4.65-4.48 (m, 1H), 4.36-4.29 (m, 1H), 4.09 (d, J = 3.3 Hz, 3H), 4.05-3.87 (m, 2H), 3.60 (quin, J = 8.3 Hz, 1H), 3.48-3.32 (m, 2H), 3.20-3.03 (m, 1H), 3.01-2.82 (m, 2H), 2.61 (s, 3H), 2.29 (br t, J = 13.7 Hz, 2H), 2.10-1.94 (m, 2H); LCMS (ESI) [M+H]⁺: 503.3.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.34 (d, J = 0.9 Hz, 1H), 7.93 (d, J = 1.1 Hz, 1H), 7.83-7.75 (m, 4H), 7.49-7.35 (m, 3H), 7.27 (br s, 1H), 4.52-4.43 (m, 1H), 4.25 (dd, J = 2.4, 3.7 Hz, 2H), 4.02 (br d, J = 6.4 Hz, 2H), 3.91-3.81 (m, 2H), 3.34-3.24 (m, 2H), 3.11-3.02 (m, 1H), 2.21 (dt, J = 3.4, 13.2 Hz, 2H), 2.05-1.87 (m, 2H), 1.69 (s, 6H); LCMS (ESI) [M+H]⁺: 503.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.83-7.78 (m, 2H), 7.67 (br t, J = 8.6 Hz, 1H), 7.58-7.47 (m, 2H), 7.46-7.40 (m, 2H), 7.16 (br d, J = 6.6 Hz, 1H), 6.97-6.90 (m, 1H), 5.09-4.96 (m, 1H), 4.59-4.38 (m, 1H), 4.23-4.06 (m, 1H), 3.99-3.91 (m, 6H), 3.49-3.25 (m, 2H), 3.21-3.04 (m, 1H), 2.34-2.13 (m, 2H), 2.10-1.90 (m, 2H), 1.25 (br d, J = 5.7 Hz, 1H), 0.74-0.43 (m, 4H); LCMS (ESI) [M+H]⁺: 491.0.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08 (br d, J = 6.6 Hz, 1H), 7.85-7.77 (m, 3H), 7.75-7.67 (m, 1H), 7.53-7.46 (m, 1H), 7.45-7.40 (m, 2H), 7.18 (br s, 1H), 5.09-4.96 (m, 1H), 4.59-4.43 (m, 1H), 4.23-4.10 (m, 1H), 4.06 (br d, J = 5.3 Hz, 3H), 3.52-3.30 (m, 2H), 3.21-3.05 (m, 1H), 2.58 (d, J = 2.2 Hz, 3H),


2.37-2.19 (m, 2H), 2.13-1.97 (m, 1H), 2.13-1.97 (m, 1H), 1.27 (br s, 1H), 0.63-0.43 (m, 4H); LCMS (ESI) [M+H]⁺: 499.3.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.04 (d, J = 5.7 Hz, 2H), 7.88-7.78 (m, 4H), 7.55-7.40 (m, 3H), 7.33 (br s, 1H), 4.51 (br d, J = 13.7 Hz, 1H), 4.30 (d, J = 3.7 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.90 (br d, J = 14.1 Hz, 1H), 3.39-3.28 (m, 2H), 3.12 (br t, J = 11.1 Hz, 1H), 2.32-2.17 (m, 2H), 1.99 (s, 8H), 1.15 (t, J = 7.2 Hz, 3H); LCMS (ESI) [M+H]⁺: 545.2.

10



15


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.53 (s, 1H), 8.12 (s, 1H), 7.76-7.71 (m, 2H), 7.58 (br d, J = 7.9 Hz, 2H), 7.36 (t, J = 7.9 Hz, 2H), 7.15 (t, J = 7.3 Hz, 1H), 4.51-4.37 (m, 1H), 4.28 (q, J = 8.3 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 4.01-3.89 (m, 2H), 3.57 (quin, J = 8.4 Hz, 1H), 3.45-3.28 (m, 2H), 3.23-3.09 (m, 1H), 3.02-2.91 (m, 1H), 2.86-2.76 (m, 1H), 2.31-2.16 (m, 2H), 2.00 (s, 8H), 1.17 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 571.2.




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.55 (s, 1H), 8.15 (s, 1H), 7.86 (d, J = 7.1 Hz, 2H), 7.76 (s, 2H), 7.56-7.42 (m, 3H), 7.36 (br s, 1H), 4.45 (br d, J = 13.7 Hz, 1H), 4.32 (br s, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.91 (br d, J = 14.1 Hz, 1H), 3.42-3.29 (m, 2H), 3.22 (br t, J = 10.6 Hz, 1H), 2.26 (br t, J = 10.8 Hz, 2H), 2.10-1.94 (m, 8H), 1.20 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 545.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.44-8.31 (m, 2H), 8.11 (s, 1H), 7.87-7.81 (m, 1H), 7.78-7.66 (m, 2H), 7.06 (br s, 1H), 4.64-4.52 (m, 1H), 4.44 (dd, J = 9.0, 11.0 Hz, 1H), 4.25-4.17 (m, 1H), 4.09 (s, 3H), 4.04 (br d, J = 13.0 Hz, 1H), 3.58 (quin, J = 8.2 Hz, 1H), 3.48-3.32 (m, 2H), 3.27 (dd, J = 7.7, 17.4 Hz, 1H), 3.17-3.05 (m, 1H), 2.88-2.78 (m, 1H), 2.61 (s, 3H), 2.36-2.22 (m, 2H), 2.14-1.94 (m, 2H); LCMS (ESI) [M+H]⁺: 486.3.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08-8.02 (m, 2H), 7.88-7.79 (m, 2H), 7.58 (d, J = 7.9 Hz, 2H), 7.36 (t, J = 7.9 Hz, 2H), 7.19-7.12 (m, 1H), 4.60-4.47 (m, 1H), 4.36-4.26 (m, 1H), 4.20 (br dd, J = 3.4, 6.9 Hz, 2H), 3.94 (q, J = 9.3 Hz, 2H), 3.58 (quin, J = 8.4 Hz, 1H), 3.43-3.27 (m, 2H), 3.16-2.89 (m, 2H), 2.88-2.79 (m, 1H), 2.25 (br t, J = 12.8 Hz, 2H), 1.99 (s, 8H), 1.18-1.10 (m, 3H); LCMS (ESI) [M+H]⁺: 571.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 9.09 (d, J = 1.6 Hz, 1H), 8.76 (dd, J = 1.6, 4.9 Hz, 1H), 8.16 (td, J = 2.0, 8.0 Hz, 1H), 8.10 (s, 1H), 7.87-7.80 (m, 1H), 7.78-7.71 (m, 1H), 7.46-7.37 (m, 2H), 4.58-4.48 (m, 1H), 4.33 (d, J = 3.9 Hz, 2H), 4.08 (s, 3H), 3.93 (br d, J = 13.8 Hz, 1H), 3.44-3.33 (m, 2H), 3.23-3.13 (m, 1H), 2.60 (s, 3H), 2.36-2.24 (m, 2H), 2.13-1.97 (m, 2H); LCMS (ESI) [M+H]⁺: 460.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.81-8.76 (m, 2H), 8.09 (s, 1H), 7.86-7.80 (m, 1H), 7.77-7.67 (m, 3H), 7.48 (br s, 1H), 4.58-4.48 (m, 1H), 4.31 (d, J = 3.9 Hz, 2H), 4.08 (s, 3H), 3.92 (br d, J = 14.1 Hz, 1H), 3.38 (ddd, J = 3.4, 10.6, 14.0 Hz, 2H), 3.23-3.13 (m, 1H), 2.60 (s, 3H), 2.36-2.24 (m, 2H), 2.12-1.96 (m, 2H); LCMS (ESI) [M+H]⁺: 460.3.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.89-7.83 (m, 2H), 7.67 (dd, J = 1.9, 8.3 Hz, 1H), 7.60-7.42 (m, 4H), 7.35 (br s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.55-4.46 (m, 1H), 4.31 (d, J = 3.9 Hz, 2H), 4.20 (q, J = 7.0 Hz, 2H), 3.94 (s, 3H), 3.93-3.87 (m, 1H), 3.40-3.27 (m, 2H), 3.20-3.09 (m, 1H), 2.25 (dt, J = 3.9, 12.8 Hz, 2H), 2.08-1.92 (m, 2H), 1.51 (t, J = 7.0 Hz, 3H); LCMS (ESI) [M+H]⁺: 465.3.

10




15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 9.16 (br d, J = 1.8 Hz, 1H), 8.33 (d, J = 1.5 Hz, 1H), 7.82 (br d, J = 7.5 Hz, 1H), 7.55-7.48 (m, 1H), 7.45-7.39 (m, 2H), 4.54 (s, 2H), 4.49-4.41 (m, 3H), 4.05 (s, 4H), 3.41-3.24 (m, 2H), 3.03 (br t, J = 11.8 Hz, 1H), 2.65 (s, 3H), 2.22 (br t, J = 15.8 Hz, 2H), 2.07-1.86 (m, 4H); LCMS (ESI) [M+H]⁺: 472.1.

20




25 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.48 (s, 1H), 8.08 (s, 1H), 7.74 (s, 2H), 7.58 (d, J = 7.7 Hz, 2H), 7.36 (t, J = 7.9 Hz, 2H), 7.18-7.11 (m, 1H), 4.53-4.40 (m, 1H), 4.33-4.24 (m, 1H), 4.00-3.89 (m, 4H), 3.57 (quin, J = 8.4 Hz, 1H), 3.44-3.28 (m, 2H), 3.20-3.06 (m, 1H), 3.03-2.90 (m, 1H), 2.86-2.77 (m, 1H), 2.30-2.18 (m, 2H), 2.07-1.88 (m, 3H), 1.71 (s, 6H); LCMS (ESI) [M+H]⁺: 529.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.50 (d, J = 0.9 Hz, 1H), 8.10 (d, J = 0.7 Hz, 1H), 7.86 (d, J = 7.3 Hz, 2H), 7.77 (s, 2H), 7.56-7.50 (m, 1H), 7.49-7.43 (m, 2H), 7.36 (br s, 1H), 4.47 (br d, J = 13.5 Hz, 1H), 4.31 (d, J = 2.6 Hz, 2H), 4.06 (br s, 1H), 3.99-3.87 (m, 3H), 3.43-3.31 (m, 2H), 3.21 (br t, J = 10.7 Hz, 1H), 2.33-2.21 (m, 2H), 2.11-1.94 (m, 2H), 1.73 (s, 6H); LCMS (ESI) [M+H]⁺: 503.3.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.39 (s, 1H), 7.99 (s, 1H), 7.88-7.79 (m, 1H), 7.88-7.79 (m, 1H), 7.58 (d, J = 7.9 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.19-7.12 (m, 1H), 4.64-4.49 (m, 1H), 4.36-4.27 (m, 1H), 4.07 (br s, 2H), 4.02-3.85 (m, 3H), 3.57 (quin, J = 8.5 Hz, 1H), 3.43-3.29 (m, 2H), 3.16-2.89 (m, 2H), 2.88-2.78 (m, 1H), 2.34-2.19 (m, 2H), 2.05-1.96 (m, 2H), 1.74 (d, J = 2.0 Hz, 6H); LCMS (ESI) [M+H]⁺: 529.3.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 8.01 (s, 1H), 7.87-7.78 (m, 2H), 7.35 (d, J = 8.2 Hz, 2H), 7.24 (s, 1H), 4.64 (br s, 1H), 4.14 (s, 3H), 4.09-3.71 (m, 1H), 3.37-3.27 (m, 1H), 3.20 (br s, 2H), 2.97-2.87 (m, 1H), 2.28-1.96 (m, 4H), 1.24 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 430.0.


15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 8.01 (d, J = 0.7 Hz, 1H), 7.87-7.78 (m, 2H), 7.34-7.26 (m, 3H), 7.21 (br d, J = 7.3 Hz, 1H), 4.66 (br s, 1H), 4.14 (s, 3H), 3.97-3.78 (m, 1H), 3.36-3.12 (m, 3H), 2.96-2.87 (m, 1H), 2.32-1.90 (m, 4H), 1.25 (d, J = 7.1 Hz, 6H); LCMS (ESI) [M+H]⁺: 430.0.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (br d, J = 4.9 Hz, 1H), 7.86-7.81 (m, 1H), 7.77-7.72 (m, 1H), 7.49 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 4.64-4.51 (m, 1H), 4.30 (br s, 1H), 4.09 (d, J = 3.5 Hz, 3H), 3.99 (br s, 1H), 3.91 (br t, J = 8.8 Hz, 1H), 3.81 (s, 3H), 3.59 (quin, J = 8.2 Hz, 1H), 3.47-3.31 (m, 2H), 3.19-3.03 (m, 1H), 3.00-2.79 (m, 2H), 2.61 (s, 3H), 2.34-2.23 (m, 2H), 2.01 (br d, J = 10.8 Hz, 2H); LCMS (ESI) [M+H]⁺: 515.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.84 (d, J = 7.1 Hz, 2H), 7.79-7.66 (m, 2H), 7.55-7.41 (m, 3H), 7.22 (br s, 1H), 4.29-4.13 (m, 2H), 4.06 (s, 3H), 4.04-3.96 (m, 2H), 3.96-3.84 (m, 2H), 3.69-3.56 (m, 3H), 3.50 (dd, J = 5.1, 10.8 Hz, 1H), 3.31-3.22 (m, 1H), 3.20-3.11 (m, 1H), 2.59 (s, 3H); LCMS (ESI) [M+H]⁺: 486.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.79 (d, J = 4.8 Hz, 1H), 8.16 (s, 1H), 8.05-7.99 (m, 3H), 7.87-7.80 (m, 2H), 7.75 (s, 1H), 7.52-7.44 (m, 3H), 7.25 (d, J = 4.8 Hz, 1H), 4.67 (br d, J = 11.4 Hz, 1H), 4.16 (s, 3H), 3.83 (br d, J = 14.0 Hz, 1H), 3.41-3.21 (m, 3H), 2.34 (br s, 1H), 2.22-1.97 (m, 3H); LCMS (ESI) [M+H]⁺: 465.0.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12-8.08 (m, 1H), 7.89-7.80 (m, 3H), 7.77-7.72 (m, 1H), 7.56-7.42 (m, 3H), 7.25 (br d, J = 3.1 Hz, 1H), 4.33-4.24 (m, 2H), 4.17-3.99 (m, 5H), 3.97-3.68 (m, 3H), 2.68-2.38 (m, 5H); LCMS (ESI) [M+H]⁺: 445.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.79-7.74 (m, 1H), 7.73-7.67 (m, 1H), 7.46-7.30 (m, 5H), 4.71-4.51 (m, 1H), 4.44 (br d, J = 10.4 Hz, 1H), 4.39-4.25 (m, 2H), 4.15 (br d, J = 11.7 Hz, 1H),
 5 4.07 (s, 3H), 3.90-3.65 (m, 2H), 3.51-3.17 (m, 3H), 2.98-2.70 (m, 2H), 2.59 (s, 3H), 2.11-1.79 (m, 4H);
 LCMS (ESI) [M+H]⁺: 487.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.79-7.73 (m, 1H), 7.72-7.65 (m, 1H), 7.47-7.30 (m, 5H), 4.71-4.51 (m, 1H), 4.44 (br d, J = 10.4 Hz, 1H), 4.39-4.25 (m, 2H), 4.15 (br d, J = 11.7 Hz, 1H),
 10 4.06 (s, 3H), 3.90-3.66 (m, 2H), 3.51-3.17 (m, 3H), 2.98-2.71 (m, 2H), 2.59 (s, 3H), 2.11-1.79 (m, 4H);
 LCMS (ESI) [M+H]⁺: 487.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.01 (t, J = 1.0 Hz, 1H), 7.89-7.80 (m, 2H), 7.72 (dq, J = 1.0, 8.6 Hz, 2H), 7.60-7.50 (m, 1H), 7.50-7.43 (m, 2H), 6.98 (br s, 1H), 4.52 (s, 4H), 4.49 (s, 2H), 4.34 (s, 2H),
 15 4.08 (d, J = 4.6 Hz, 2H), 4.07 (s, 3H), 2.59 (s, 3H); LCMS (ESI) [M+H]⁺: 472.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.00 (s, 1H), 7.91 (d, J = 0.9 Hz, 1H), 7.59 (dd, J = 8.5, 12.0 Hz, 3H), 7.43-7.32 (m, 2H), 7.22-7.13 (m, 1H), 6.85 (td, J = 1.5, 8.6 Hz, 1H), 4.71-4.53 (m, 1H),
 25 4.27 (ddd, J = 6.8, 9.6, 18.8 Hz, 1H), 4.03 (s, 3H), 4.00-3.91 (m, 2H), 3.57 (quin, J = 8.3 Hz, 1H), 3.25-3.11 (m, 1H), 3.04-2.90 (m, 1H), 2.87-2.76 (m, 2H), 2.57 (dt, J = 4.1, 10.9 Hz, 1H), 2.08-1.94 (m, 2H),
 1.89-1.80 (m, 1H), 1.89-1.79 (m, 1H); LCMS (ESI) [M+H]⁺: 446.1.




5 ^1H NMR (400 MHz, METHANOL- d_4) δ 7.93-7.70 (m, 4H), 7.55-7.35 (m, 3H), 7.25-7.10 (m, 1H), 5.23-5.19 (t, J = 6.0 Hz, 1H), 4.60-4.40 (m, 1H), 4.30-4.15 (m, 1H), 3.90-3.75 (m, 2H), 3.55-3.35 (m, 8H), 3.20-2.95 (m, 1H), 2.30-2.10 (m, 2H), 2.10-1.95 (m, 1H), 1.95-1.75 (m, 1H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 505.2.



10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.47 (s, 1H), 7.84 (d, J = 7.3 Hz, 2H), 7.54-7.41 (m, 4H), 7.38 (s, 1H), 7.26-7.22 (t, 2H), 4.53 (br d, J = 13.9 Hz, 1H), 4.30 (t, J = 3.7 Hz, 2H), 3.91 (br d, J = 13.7 Hz, 1H), 3.38-3.27 (m, 2H), 3.11 (br t, J = 11.1 Hz, 1H), 2.73 (s, 3H), 2.31-2.19 (t, 2H), 2.07-1.90 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 445.2.




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.42 (br d, J = 4.4 Hz, 1H), 7.53 (br d, J = 8.2 Hz, 2H), 7.43 (d, J = 9.5 Hz, 1H), 7.36-7.28 (dd, 3H), 7.20 (m, 1H), 7.14-7.07 (t, 1H), 4.59-4.43 (dd, 1H), 4.31-4.23 (m, 1H), 3.98-3.82 (m, 2H), 3.52 (quin, J = 8.4 Hz, 1H), 3.39-3.21 (m, 2H), 3.15-2.73 (m, 3H), 2.68 (d, J = 5.7 Hz, 3H), 2.27-2.13 (t, 2H), 1.99-1.81 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 471.3.



25 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.57 (br d, J = 8.3 Hz, 1H), 7.49 (s, 1H), 7.43-7.31 (m, 5H), 6.90 (d, J = 8.3 Hz, 1H), 4.65 (br d, J = 13.6 Hz, 1H), 4.53 (br d, J = 12.7 Hz, 1H), 4.42 (br d, J = 10.5 Hz, 1H), 4.34-4.21 (m, 2H), 4.14 (q, J = 7.0 Hz, 3H), 3.93 (s, 3H), 3.86-3.64 (m, 2H), 3.43 (br t, J = 11.4 Hz, 1H),


3.27-3.16 (m, 2H), 2.91 (br t, J = 11.4 Hz, 1H), 2.81-2.67 (m, 2H), 2.07-1.77 (m, 4H), 1.48 (t, J = 7.0 Hz, 3H); LCMS (ESI) [M+H]⁺: 493.0.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.57 (br d, J = 8.3 Hz, 1H), 7.49 (s, 1H), 7.43-7.32 (m, 5H), 6.90 (d, J = 8.3 Hz, 1H), 4.66 (br d, J = 13.6 Hz, 0.5H), 4.54 (br d, J = 13.6 Hz, 0.5H), 4.42 (br d, J = 10.1 Hz, 1H), 4.34-4.22 (m, 2H), 4.15 (q, J = 7.0 Hz, 3H), 3.93 (s, 3H), 3.87-3.65 (m, 2H), 3.44 (br t, J = 11.6 Hz, 0.5H), 3.27-3.17 (m, 2H), 2.91 (br t, J = 11.8 Hz, 0.5H), 2.81-2.69 (m, 2H), 2.06-1.78 (m, 4H), 1.48 (t, J = 7.0 Hz, 3H); LCMS (ESI) [M+H]⁺: 493.0.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.01 (s, 1H), 7.88 (d, J = 7.5 Hz, 1H), 7.78-7.67 (m, 2H), 7.61-7.55 (m, 1H), 7.52-7.46 (m, 2H), 4.59 (s, 2H), 4.52 (s, 2H), 4.06 (s, 3H), 3.83-3.73 (m, 8H), 2.59 (s, 3H); LCMS (ESI) [M+H]⁺: 472.0.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.00 (br d, J = 7.5 Hz, 1H), 7.95 (br s, 1H), 7.59 (d, J = 7.9 Hz, 2H), 7.41-7.33 (m, 3H), 7.19-7.14 (m, 1H), 5.16 (s, 4H), 4.58-4.47 (m, 1H), 4.31 (dd, J = 7.2, 9.4 Hz, 1H), 4.00-3.89 (m, 2H), 3.62-3.55 (m, 1H), 3.44-3.28 (m, 2H), 3.18-2.92 (m, 2H), 2.87-2.80 (m, 1H), 2.32-2.18 (m, 2H), 2.06-1.90 (m, 2H); LCMS (ESI) [M+H]⁺: 459.2.


20



25

¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (d, J = 5.3 Hz, 1H), 8.57 (br t, J = 5.7 Hz, 1H), 8.06-8.00 (m, 1H), 7.96 (s, 1H), 7.89 (d, J = 7.0 Hz, 2H), 7.58-7.52 (m, 1H), 7.52-7.44 (m, 2H), 7.29 (d, J = 5.3 Hz, 1H), 7.09


(d, $J = 8.8$ Hz, 1H), 4.51 (br d, $J = 12.3$ Hz, 1H), 4.27-4.12 (m, 2H), 4.06 (br d, $J = 13.6$ Hz, 1H), 3.84 (d, $J = 4.4$ Hz, 6H), 3.23 (br t, $J = 12.1$ Hz, 1H), 3.04 (br t, $J = 11.8$ Hz, 1H), 2.79 (br t, $J = 12.1$ Hz, 1H), 2.00 (br t, $J = 12.1$ Hz, 2H), 1.86-1.73 (m, 1H), 1.70-1.56 (m, 1H); LCMS (ESI) $[M+H]^+$: 461.3.




5

^1H NMR (400 MHz, CHLOROFORM- d) δ 8.10 (s, 1H), 7.95 (dd, $J = 1.2, 2.8$ Hz, 1H), 7.86-7.80 (m, 1H), 7.78-7.72 (m, 1H), 7.46 (dd, $J = 1.1, 5.1$ Hz, 1H), 7.36 (dd, $J = 3.1, 5.1$ Hz, 1H), 7.15 (br s, 1H), 4.53 (br d, $J = 13.7$ Hz, 1H), 4.29 (d, $J = 4.0$ Hz, 2H), 4.09 (s, 3H), 3.93 (br d, $J = 14.3$ Hz, 1H), 3.42-3.32 (m, 2H), 3.16 (br t, $J = 10.8$ Hz, 1H), 2.60 (s, 3H), 2.29 (br t, $J = 10.9$ Hz, 2H), 2.11-1.95 (m, 2H); LCMS (ESI) $[M+H]^+$: 465.2.

10




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.99 (d, $J = 7.9$ Hz, 1H), 7.94 (s, 1H), 7.86 (d, $J = 8.3$ Hz, 1H), 7.57-7.52 (m, 1H), 7.49-7.43 (m, 2H), 7.34 (d, $J = 7.9$ Hz, 1H), 5.16 (s, 4H), 4.60-4.39 (m, 5H), 4.07 (br d, $J = 14.0$ Hz, 1H), 3.43-3.24 (m, 2H), 3.07 (br t, $J = 11.2$ Hz, 1H), 2.21 (br t, $J = 13.8$ Hz, 2H), 2.03-1.88 (m, 2H); LCMS (ESI) $[M+H]^+$: 445.2.




20

^1H NMR (400 MHz, CHLOROFORM- d) δ 7.99 (d, $J = 7.9$ Hz, 1H), 7.94 (s, 1H), 7.85 (d, $J = 7.0$ Hz, 2H), 7.54-7.48 (m, 1H), 7.48-7.42 (m, 2H), 7.35 (br d, $J = 7.9$ Hz, 2H), 5.16 (s, 4H), 4.49 (br d, $J = 14.0$ Hz, 1H), 4.30 (d, $J = 3.9$ Hz, 2H), 3.90 (br d, $J = 14.0$ Hz, 1H), 3.40-3.26 (m, 2H), 3.21-3.13 (m, 1H), 2.32-2.18 (m, 2H), 2.07-1.91 (m, 2H); LCMS (ESI) $[M+H]^+$: 433.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.87 (d, J = 7.5 Hz, 1H), 7.59-7.54 (m, 2H), 7.51-7.45 (m, 3H), 6.91 (d, J = 8.4 Hz, 1H), 4.58 (s, 2H), 4.51 (s, 2H), 4.15 (q, J = 6.9 Hz, 2H), 3.94 (s, 3H), 3.79-3.68 (m, 8H), 1.49 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 478.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.70 (d, J = 4.6 Hz, 1H), 8.23 (br s, 1H), 8.10 (s, 1H), 7.89-7.80 (m, 2H), 7.77-7.70 (m, 1H), 4.55 (br d, J = 14.1 Hz, 1H), 4.32 (d, J = 4.4 Hz, 2H), 4.09 (s, 3H), 3.93 (br d, J = 13.5 Hz, 1H), 3.41-3.32 (m, 2H), 3.15 (br t, J = 11.4 Hz, 1H), 2.60 (s, 3H), 2.34-2.22 (m, 2H), 2.12-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 466.2.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.88-7.81 (m, 3H), 7.78-7.72 (m, 1H), 7.55-7.50 (m, 1H), 7.49-7.43 (m, 2H), 7.35 (br s, 1H), 4.42-4.31 (m, 2H), 4.28-4.19 (m, 1H), 4.10 (s, 3H), 3.76 (br d, J = 14.3 Hz, 1H), 3.46-3.36 (m, 1H), 3.21-3.11 (m, 1H), 2.61 (s, 3H), 2.58-2.45 (m, 2H), 1.84-1.74 (m, 2H), 1.61 (s, 3H); LCMS (ESI) [M+H]⁺: 473.3.


15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.49 (s, 1H), 8.11-8.04 (m, 2H), 7.87-7.83 (m, 2H), 7.54-7.49 (m, 2H), 7.47-7.42 (m, 2H), 7.35 (br s, 1H), 4.88 (td, J = 6.7, 13.3 Hz, 1H), 4.53-4.46 (m, 1H), 4.31 (d, J = 3.7 Hz, 2H), 3.96-3.88 (m, 1H), 3.40-3.28 (m, 2H), 3.22-3.12 (m, 1H), 2.26 (dt, J = 3.6, 13.0 Hz, 2H), 2.09-1.93 (m, 2H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 473.3.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.45 (s, 1H), 8.06 (s, 1H), 7.95 (dd, J = 1.3, 9.0 Hz, 1H), 7.85 (d, J = 7.3 Hz, 2H), 7.79 (d, J = 9.0 Hz, 1H), 7.54-7.49 (m, 1H), 7.47-7.42 (m, 2H), 7.35 (br s, 1H), 4.82 (quin, J = 6.7 Hz, 1H), 4.49 (td, J = 4.0, 13.7 Hz, 1H), 4.30 (d, J = 4.0 Hz, 2H), 3.95-3.87 (m, 1H), 3.38-3.27 (m, 2H), 3.21-3.13 (m, 1H), 2.25 (dt, J = 3.7, 12.9 Hz, 2H), 2.07-1.95 (m, 2H), 1.68 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 473.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.93 (br s, 1H), 8.64 (br d, J = 4.3 Hz, 1H), 8.20 (d, J = 7.9 Hz, 1H), 7.94-7.84 (m, 2H), 7.70 (s, 1H), 7.49-7.41 (m, 1H), 7.07 (d, J = 8.2 Hz, 1H), 4.56 (br d, J = 13.6 Hz, 1H), 4.36 (br d, J = 4.4 Hz, 2H), 3.97 (br d, J = 14.3 Hz, 1H), 3.50 (d, J = 8.3 Hz, 6H), 3.43-3.32 (m, 2H), 3.16 (br t, J = 11.2 Hz, 1H), 2.27 (br t, J = 12.1 Hz, 2H), 2.11-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 476.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.60-7.54 (m, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.19-7.10 (m, 1H), 4.81 (s, 4H), 4.52-4.39 (m, 1H), 4.27 (dd, J = 7.3, 9.7 Hz, 1H), 4.20 (s, 4H), 3.95-3.84 (m, 2H), 3.53 (quin, J = 8.4 Hz, 1H), 3.34-3.23 (m, 1H), 3.15-2.87 (m, 3H), 2.84-2.75 (m, 1H), 2.16-2.04 (m, 2H), 1.90-1.75 (m, 2H); LCMS (ESI) [M+H]⁺: 438.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.94 (br s, 1H), 8.63 (br s, 1H), 8.36-8.27 (m, 1H), 8.19 (br d, J = 7.3 Hz, 1H), 8.08 (br d, J = 7.9 Hz, 1H), 7.90-7.81 (m, 1H), 7.73 (br d, J = 7.7 Hz, 1H), 7.52-7.40 (m, 1H), 4.75 (br d, J = 12.1 Hz, 1H), 4.36 (br s, 2H), 4.10 (br s, 3H), 4.02 (br d, J = 12.6 Hz, 1H), 3.51 (br s, 1H), 3.36 (br t, J = 11.2 Hz, 1H), 3.08-2.94 (m, 1H), 2.61 (br s, 3H), 2.32 (br d, J = 14.8 Hz, 2H), 1.96 (br d, J = 10.8 Hz, 2H); LCMS (ESI) [M+H]⁺: 476.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 9.10 (dd, J = 0.7, 2.3 Hz, 1H), 8.77 (dd, J = 1.7, 4.9 Hz, 1H), 8.17 (td, J = 2.0, 7.9 Hz, 1H), 7.89 (dd, J = 1.5, 8.2 Hz, 1H), 7.69 (d, J = 1.3 Hz, 1H), 7.42 (ddd, J = 0.8, 4.9, 7.9 Hz, 2H), 7.07 (d, J = 8.2 Hz, 1H), 4.53 (td, J = 3.8, 13.8 Hz, 1H), 4.33 (d, J = 3.9 Hz, 2H), 3.96-3.89 (m, 1H), 3.49 (d, J = 7.6 Hz, 6H), 3.42-3.32 (m, 2H), 3.18 (ddd, J = 3.1, 10.9, 13.6 Hz, 1H), 2.29 (dt, J = 3.8, 13.8 Hz, 2H), 2.12-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 476.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.67-7.58 (m, 1H), 7.55-7.46 (m, 3H), 7.42-7.32 (m, 3H), 6.91 (br d, J = 8.4 Hz, 1H), 4.57-4.39 (m, 1H), 4.13 (q, J = 7.1 Hz, 2H), 4.05-3.97 (m, 1H), 3.96-3.91 (m, 3H), 3.90-3.61 (m, 3H), 3.58-3.42 (m, 1H), 3.39-3.18 (m, 3H), 3.08-2.91 (m, 1H), 2.34-1.82 (m, 6H), 1.47 (t, J = 6.9 Hz, 3H); LCMS (ESI) [M+H]⁺: 505.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.63 (br s, 1H), 7.54 (br s, 1H), 7.45-7.39 (m, 2H), 7.38-7.34 (m, 2H), 7.32-7.27 (m, 1H), 6.93 (br d, J = 8.4 Hz, 1H), 4.67 (br s, 1H), 4.45-4.39 (m, 1H), 4.26 (br dd, J = 8.5, 12.7 Hz, 1H), 4.15 (q, J = 6.6 Hz, 2H), 3.94 (br s, 3H), 3.77 (br d, J = 12.8 Hz, 1H), 3.47 (br t, J = 11.5 Hz, 0.5H), 3.35-3.15 (m, 2H), 2.97 (br t, J = 12.1 Hz, 0.5H), 2.23 (br s, 2H), 2.12-1.87 (m, 2H), 1.49 (br t, J = 6.9 Hz, 3H); LCMS (ESI) [M+H]⁺: 507.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (br d, J = 8.6 Hz, 1H), 7.82 (br s, 1H), 7.77-7.70 (m, 1H), 7.65 (d, J = 7.1 Hz, 2H), 7.51-7.38 (m, 3H), 4.75 (br s, 1H), 4.63-4.27 (m, 4H), 4.08 (br d, J = 4.6 Hz, 3H), 3.70-3.59 (m, 2H), 3.39-2.99 (m, 3H), 2.60 (s, 3H), 2.24 (br d, J = 11.0 Hz, 2H), 2.05-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 485.3.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.65 (br d, J = 7.1 Hz, 3H), 7.56 (br s, 1H), 7.51-7.39 (m, 3H), 6.95 (br d, J = 8.2 Hz, 1H), 4.74 (br t, J = 7.1 Hz, 1H), 4.59-4.25 (m, 4H), 4.17 (q, J = 7.1 Hz, 2H), 3.97 (br s, 3H), 3.68-3.57 (m, 2H), 3.35-2.97 (m, 3H), 2.20 (br d, J = 12.1 Hz, 2H), 2.03-1.87 (m, 2H), 1.51 (t, J = 6.9 Hz, 3H); LCMS (ESI) [M+H]⁺: 491.3.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.80-8.74 (m, 2H), 7.87 (dd, J = 1.5, 8.2 Hz, 1H), 7.70-7.66 (m, 3H), 7.46 (br s, 1H), 7.07-7.02 (m, 1H), 7.05 (d, J = 8.2 Hz, 1H), 4.51 (td, J = 3.7, 13.7 Hz, 1H), 4.30 (d, J = 3.7 Hz, 2H), 3.93-3.86 (m, 1H), 3.47 (d, J = 7.1 Hz, 6H), 3.40-3.29 (m, 2H), 3.21-3.13 (m, 1H), 2.27 (dt, J = 3.5, 13.3 Hz, 2H), 2.09-1.94 (m, 2H); LCMS (ESI) [M+H]⁺: 476.2.


15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11-8.04 (m, 1H), 7.84-7.76 (m, 1H), 7.74-7.70 (m, 1H), 7.56-7.48 (m, 2H), 7.43-7.35 (m, 3H), 4.62-4.46 (m, 1H), 4.10-4.02 (m, 4H), 4.00-3.67 (m, 3H), 3.62-3.45 (m, 1H), 3.41-3.20 (m, 3H), 3.12-2.94 (m, 1H), 2.58 (s, 3H), 2.38-1.86 (m, 6H); LCMS (ESI) [M+H]⁺: 499.3.


25




¹H NMR (400 MHz, DMSO-d₆) δ 8.22-8.17 (m, 1H), 7.91-7.86 (m, 1H), 7.76-7.64 (m, 3H), 7.41-7.34 (m, 2H), 7.18-7.11 (m, 1H), 4.99-4.34 (m, 1H), 4.13-3.86 (m, 6H), 3.77-3.64 (m, 1H), 3.49 (br s, 1H), 2.90-2.62 (m, 3H), 2.52-2.52 (m, 3H), 2.38-2.03 (m, 4H), 1.42-0.87 (m, 3H); LCMS (ESI) [M+H]⁺: 499.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (br s, 1H), 7.85 (br d, J = 8.4 Hz, 1H), 7.80-7.71 (m, 1H), 7.60 (br d, J = 7.0 Hz, 2H), 7.47-7.33 (m, 2H), 7.19 (br d, J = 5.1 Hz, 1H), 4.76-4.16 (m, 3H), 4.09 (br s, 3H), 4.03-3.39 (m, 5H), 3.08-2.80 (m, 2H), 2.61 (s, 3H), 2.52-2.23 (m, 2H); LCMS (ESI) [M+H]⁺: 521.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.59 (d, J = 8.2 Hz, 2H), 7.38 (t, J = 7.8 Hz, 2H), 7.21-7.14 (m, 1H), 4.56-4.42 (m, 1H), 4.33-4.23 (m, 3H), 3.97-3.83 (m, 4H), 3.56 (quin, J = 8.5 Hz, 1H), 3.37-3.27 (m, 1H), 3.19-2.90 (m, 4H), 2.87-2.78 (m, 1H), 2.75 (d, J = 7.1 Hz, 2H), 2.14 (br t, J = 12.5 Hz, 2H), 1.93-1.78 (m, 2H); LCMS (ESI) [M+H]⁺: 435.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.59 (d, J = 8.2 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.32 (s, 1H), 7.22-7.13 (m, 1H), 4.55-4.41 (m, 3H), 4.31 (br t, J = 8.3 Hz, 1H), 3.96-3.79 (m, 4H), 3.76 (s, 3H), 3.56 (quin, J = 8.5 Hz, 1H), 3.38-3.27 (m, 1H), 3.18-2.90 (m, 3H), 2.89-2.74 (m, 3H), 2.14 (br t, J = 13.0 Hz, 2H), 1.94-1.79 (m, 2H); LCMS (ESI) [M+H]⁺: 476.2.




- 5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.11 (s, 1H), 7.85 (t, J = 7.3 Hz, 3H), 7.78-7.73 (m, 1H), 7.58-7.51 (m, 1H), 7.50-7.43 (m, 2H), 7.22 (br s, 1H), 4.65-4.49 (m, 0.5H), 4.44-4.18 (m, 3H), 4.09 (s, 3H), 4.07-4.01 (m, 0.5H), 3.94-3.70 (m, 2H), 3.67-3.50 (m, 1H), 2.61 (s, 3H), 2.47-2.31 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 495.3.



- 10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.88-7.80 (d, J = 2, 1H), 7.60 (dd, J = 1.1, 8.4 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 4.40-4.26 (m, 1H), 3.88-3.84 (s, 3H), 3.80-3.64 (m, 2H), 3.40 (t, J = 9.2 Hz, 1H), 3.25 (td, J = 8.4, 16.6 Hz, 1H), 3.18-3.08 (m, 2H), 3.03-2.78 (m, 3H), 2.57-2.41 (m, 2H), 2.38 (s, 3H), 2.11-1.96 (m, 15 2H), 1.85-1.67 (m, 2H), 0.76-0.66 (m, 1H), 0.36-0.29 (m, 2H), 0.02 (q, J = 4.8 Hz, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 463.2.




- 20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 9.13 (d, J = 1.8 Hz, 1H), 8.28 (d, J = 1.8 Hz, 1H), 7.61-7.55 (m, 2H), 7.37 (t, J = 7.9 Hz, 2H), 7.19-7.14 (m, 1H), 4.32 (dd, J = 7.2, 9.4 Hz, 1H), 4.07 (s, 3H), 3.95 (t, J = 9.2 Hz, 1H), 3.86-3.67 (m, 8H), 3.63-3.54 (m, 1H), 2.97-2.81 (m, 2H), 2.68 (s, 3H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 487.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.75 (br s, 1H), 7.64 (d, J = 3.7 Hz, 1H), 7.58 (d, J = 7.9 Hz, 2H), 7.37 (t, J = 7.9 Hz, 2H), 7.20-7.13 (m, 1H), 4.61-4.46 (m, 1H), 4.30 (br t, J = 8.4 Hz, 1H), 4.01-3.88 (m, 2H), 3.56 (quin, J = 8.4 Hz, 1H), 3.43-3.25 (m, 2H), 3.12-2.88 (m, 2H), 2.87-2.79 (m, 1H), 2.23 (br t, J = 12.8 Hz, 2H), 2.01-1.86 (m, 2H); LCMS (ESI) [M+H]⁺: 448.1.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.54-7.43 (m, 3H), 7.34-7.26 (m, 2H), 7.12-7.03 (m, 2H), 4.44 (br t, J = 15.5 Hz, 1H), 4.22 (br d, J = 2.3 Hz, 1H), 3.94-3.83 (m, 2H), 3.55-3.45 (m, 1H), 3.35-3.15 (m, 2H), 3.05-2.83 (m, 2H), 2.81-2.71 (m, 1H), 2.15 (br t, J = 13.6 Hz, 2H), 1.95-1.78 (m, 2H); LCMS (ESI) [M+H]⁺: 501.1.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.93-7.82 (m, 2H), 7.69 (dd, J = 1.9, 8.4 Hz, 1H), 7.61-7.42 (m, 4H), 7.38-7.31 (m, 2H), 4.57-4.45 (m, 1H), 4.31 (d, J = 3.8 Hz, 2H), 3.94 (s, 3H), 3.93-3.86 (m, 1H), 3.85-3.78 (m, 1H), 3.41-3.26 (m, 2H), 3.22-3.09 (m, 1H), 2.34-2.18 (m, 2H), 2.10-1.92 (m, 2H), 0.95-0.81 (m, 4H); LCMS (ESI) [M+H]⁺: 477.2.


15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 7.3 Hz, 2H), 7.73 (d, J = 8.4 Hz, 1H), 7.56-7.50 (m, 1H), 7.49-7.44 (m, 2H), 7.36 (br s, 1H), 4.72 (br d, J = 13.4 Hz, 1H), 4.40-4.27 (m, 2H), 4.10 (s, 3H), 4.00 (br d, J = 13.9 Hz, 1H), 3.52 (tt, J = 3.7, 11.0 Hz, 1H), 3.41-3.31 (m, 1H), 3.04 (br t, J = 11.3 Hz, 1H), 2.61 (s, 3H), 2.35 (br t, J = 15.7 Hz, 2H), 1.95 (dq, J = 3.9, 12.1 Hz, 2H); LCMS (ESI) [M+H]⁺: 475.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 7.8 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.22-7.15 (m, 1H), 4.75 (br t, J = 14.6 Hz, 1H), 4.35 (q, J = 8.1 Hz, 1H), 4.10 (d, J = 2.2 Hz, 3H), 4.04 (br s, 1H), 3.96 (dt, J = 3.1, 9.0 Hz, 1H), 3.60 (quin, J = 8.5 Hz, 1H), 3.51 (dt, J = 4.0, 11.0 Hz, 1H), 3.46-3.33 (m, 1H), 3.07-2.92 (m, 2H), 2.91-2.82 (m, 1H), 2.61 (s, 3H), 2.43-2.28 (m, 2H), 2.01-1.87 (m, 2H); LCMS (ESI) [M+H]⁺: 501.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 9.24 (s, 1H), 8.53 (br d, J = 8.1 Hz, 1H), 8.35 (d, J = 8.1 Hz, 1H), 8.07 (br s, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.40 (t, J = 7.9 Hz, 2H), 7.22-7.17 (m, 1H), 4.64-4.50 (m, 1H), 4.37-4.30 (m, 1H), 4.05-3.94 (m, 2H), 3.61 (quin, J = 8.4 Hz, 1H), 3.47-3.33 (m, 2H), 3.09 (d, J = 5.1 Hz, 4H), 3.04-2.94 (m, 1H), 2.91-2.82 (m, 1H), 2.35-2.22 (m, 2H), 2.07-1.92 (m, 2H); LCMS (ESI) [M+H]⁺: 475.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.89-7.83 (m, 2H), 7.73-7.67 (m, 2H), 7.57-7.50 (m, 1H), 7.50-7.43 (m, 2H), 7.38-7.31 (m, 2H), 4.53 (br d, J = 14.6 Hz, 1H), 4.32 (d, J = 3.3 Hz, 2H), 3.98 (s, 3H), 3.92 (br d, J = 13.5 Hz, 1H), 3.40-3.30 (m, 2H), 3.19-3.09 (m, 1H), 2.32-2.20 (m, 2H), 2.08-1.93 (m, 2H); LCMS (ESI) [M+H]⁺: 505.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.60 (d, J = 8.2 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.21-7.14 (m, 1H), 4.49 (br t, J = 14.6 Hz, 1H), 4.30 (dd, J = 7.3, 9.7 Hz, 1H), 4.21-4.13 (m, 2H), 4.05-3.98 (m, 2H), 3.93 (br t, J = 8.7 Hz, 2H), 3.57 (quin, J = 8.5 Hz, 1H), 3.39-3.27 (m, 1H), 3.18-2.92 (m, 3H), 2.88-2.79 (m, 2H), 2.20-2.08 (m, 2H), 1.88 (br d, J = 12.1 Hz, 2H), 1.35 (s, 6H); LCMS (ESI) [M+H]⁺: 463.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (d, J = 4.4 Hz, 1H), 7.86-7.79 (m, 1H), 7.77-7.71 (m, 1H), 4.87-4.78 (m, 2H), 4.61-4.45 (m, 3H), 4.09 (d, J = 2.6 Hz, 3H), 3.92 (br d, J = 8.4 Hz, 1H), 3.87-3.79 (m, 1H), 3.77-3.69 (m, 1H), 3.63-3.56 (m, 1H), 3.50-3.42 (m, 2H), 3.41-3.23 (m, 3H), 3.15-3.00 (m, 1H), 2.79-2.63 (m, 2H), 2.61 (s, 3H), 2.26 (br s, 2H), 2.06-1.90 (m, 2H); LCMS (ESI) [M+H]⁺: 479.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.35-8.25 (m, 2H), 7.82 (br d, J = 8.2 Hz, 1H), 7.66-7.59 (m, 2H), 7.02-6.95 (m, 2H), 4.52-4.42 (m, 1H), 4.35 (dd, J = 8.9, 11.0 Hz, 1H), 4.18-4.08 (m, 1H), 3.95 (br d, J = 13.6 Hz, 1H), 3.54-3.47 (m, 1H), 3.41 (d, J = 8.8 Hz, 6H), 3.36-3.23 (m, 2H), 3.18 (dd, J = 7.8, 17.2 Hz, 1H), 3.10-2.97 (m, 1H), 2.81-2.69 (m, 1H), 2.22-2.15 (m, 2H), 2.07-1.84 (m, 2H); LCMS (ESI) [M+H]⁺: 502.3.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.87-7.80 (m, 1H), 7.78-7.71 (m, 1H), 7.43-7.29 (m, 5H), 4.63 (s, 2H), 4.51 (br d, J = 13.0 Hz, 1H), 4.23 (d, J = 2.8 Hz, 2H), 4.08 (s, 3H), 4.02 (br d, J = 13.6 Hz, 1H), 3.36-3.23 (m, 2H), 3.04 (br t, J = 11.8 Hz, 1H), 2.61 (s, 3H), 2.21 (br s, 2H), 2.04-1.92 (m, 2H); LCMS (ESI) [M+H]⁺: 446.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.87-7.80 (m, 1H), 7.78-7.66 (m, 1H), 4.43 (br d, J = 13.8 Hz, 2H), 4.08 (s, 3H), 3.36-3.26 (m, 1H), 3.16 (br t, J = 11.8 Hz, 2H), 2.60 (s, 3H), 2.26-2.18 (m, 2H), 2.03-1.92 (m, 2H), 1.33 (s, 9H); LCMS (ESI) [M+H]⁺: 382.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.00 (s, 1H), 7.77-7.70 (m, 1H), 7.67-7.62 (m, 1H), 7.30-7.23 (m, 2H), 7.23-7.16 (m, 3H), 4.48 (br d, J = 13.4 Hz, 1H), 4.00 (s, 3H), 3.87 (br d, J = 13.7 Hz, 1H), 3.72 (s, 2H), 3.22-3.12 (m, 2H), 2.97 (br t, J = 11.1 Hz, 1H), 2.52 (s, 3H), 2.12 (br d, J = 10.8 Hz, 1H), 1.97 (br d, J = 10.8 Hz, 1H), 1.91-1.80 (m, 1H), 1.71-1.60 (m, 1H); LCMS (ESI) [M+H]⁺: 416.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.87-7.80 (m, 1H), 7.77-7.70 (m, 1H), 4.55 (br s, 1H), 4.31 (br s, 1H), 4.08 (s, 3H), 3.49-3.27 (m, 2H), 3.01 (br s, 1H), 2.60 (s, 3H), 2.24 (br s, 2H), 2.01 (br s, 2H), 1.85-1.75 (m, 1H), 1.02 (br s, 2H), 0.80 (br dd, J = 2.8, 7.6 Hz, 2H); LCMS (ESI) [M+H]⁺: 366.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.04 (s, 1H), 7.80-7.70 (m, 2H), 7.53-7.45 (m, 5H), 4.08 (s, 3H), 3.96-3.65 (m, 8H), 2.61 (s, 3H); LCMS (ESI) [M+H]⁺: 403.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.03 (s, 1H), 7.81-7.67 (m, 2H), 7.52-7.32 (m, 4H), 4.19-4.06 (m, 4H), 3.94-3.70 (m, 5H), 3.55-3.35 (m, 2H), 2.61 (s, 3H); LCMS (ESI) [M+H]⁺: 437.0.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.78-7.70 (m, 1H), 4.62 (br d, J = 13.1 Hz, 1H), 4.08 (s, 3H), 4.05 (br d, J = 15.3 Hz, 1H), 3.36-3.25 (m, 2H), 2.97 (br t, J = 11.7 Hz, 1H), 2.60 (s, 3H), 2.32 (s, 2H), 2.22 (br d, J = 12.2 Hz, 2H), 2.05-1.88 (m, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 396.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.87-7.79 (m, 1H), 7.77-7.69 (m, 1H), 4.59 (br d, J = 13.1 Hz, 1H), 4.08 (s, 3H), 4.02-3.90 (m, 1H), 3.38-3.23 (m, 2H), 3.00 (br t, J = 11.5 Hz, 1H), 2.60 (s, 3H), 2.34 (d, J = 6.8 Hz, 2H), 2.23 (br d, J = 13.1 Hz, 2H), 2.06-1.89 (m, 2H), 1.15-1.02 (m, 1H), 0.66-0.53 (m, 2H), 0.25-0.18 (m, 2H); LCMS (ESI) [M+H]⁺: 380.2.

15



20


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.90-7.77 (m, 2H), 5.10-4.88 (m, 1H), 4.30-4.01 (m, 2H), 3.32-3.15 (m, 1H), 3.02 (t, J = 12.0 Hz, 2H), 2.29-2.06 (m, 2H), 2.04 -1.87 (m, 2H), 1.63 (d, J = 6.8 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 412.1.



25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.87-7.80 (m, 1H), 7.78-7.69 (m, 1H), 7.32 (t, J = 7.7 Hz, 2H), 7.05-6.94 (m, 3H), 4.74 (s, 2H), 4.49 (br d, J = 13.3 Hz, 1H), 4.14 (br s, 1H), 4.08 (s, 3H),


3.46-3.25 (m, 2H), 3.10 (br t, $J = 11.4$ Hz, 1H), 2.60 (s, 3H), 2.22 (br s, 2H), 2.10-1.91 (m, 2H); LCMS (ESI) $[M+H]^+$: 432.2.



5


^1H NMR (400 MHz, CHLOROFORM- d) δ 8.11 (s, 1H), 7.98 (d, $J = 8.2$ Hz, 2H), 7.87-7.83 (m, 1H), 7.81-7.74 (m, 3H), 7.42 (br s, 1H), 4.54 (br d, $J = 13.6$ Hz, 1H), 4.33 (d, $J = 3.7$ Hz, 2H), 4.10 (s, 3H), 3.93 (br d, $J = 14.1$ Hz, 1H), 3.40 (br t, $J = 10.7$ Hz, 2H), 3.27-3.16 (m, 1H), 2.62 (s, 3H), 2.37-2.25 (m, 2H), 2.14-2.00 (m, 2H); LCMS (ESI) $[M+H]^+$: 484.2.

10




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.19 (s, 1H), 8.12-8.06 (m, 2H), 7.86-7.81 (m, 2H), 7.74 (s, 1H), 7.64-7.58 (m, 1H), 7.43 (br s, 1H), 4.58-4.50 (m, 1H), 4.33 (d, $J = 3.8$ Hz, 2H), 4.10 (s, 3H), 3.98-3.89 (m, 1H), 3.46-3.33 (m, 2H), 3.28-3.15 (m, 1H), 2.62 (s, 3H), 2.31 (dt, $J = 3.3, 13.3$ Hz, 2H), 2.14-1.98 (m, 2H); LCMS (ESI) $[M+H]^+$: 484.2.

15




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.11 (s, 1H), 7.88-7.79 (m, 3H), 7.78-7.74 (m, 1H), 7.45 (d, $J = 8.3$ Hz, 2H), 7.33 (br s, 1H), 4.54 (br d, $J = 13.4$ Hz, 1H), 4.32 (d, $J = 3.5$ Hz, 2H), 4.10 (s, 3H), 3.94 (br d, $J = 14.1$ Hz, 1H), 3.39 (br t, $J = 10.6$ Hz, 2H), 3.19 (br t, $J = 10.8$ Hz, 1H), 2.62 (s, 3H), 2.35-2.23 (m, 2H), 2.13-1.99 (m, 2H); LCMS (ESI) $[M+H]^+$: 493.1.

20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.94 (s, 1H), 7.70-7.60 (m, 2H), 7.41-7.32 (m, 1H), 7.17-7.07 (m, 3H), 3.98 (s, 3H), 3.89-3.55 (m, 8H), 2.51 (s, 3H); LCMS (ESI) [M+H]⁺: 421.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.81-7.72 (m, 2H), 7.66-7.55 (m, 3H), 7.03 (br s, 1H), 4.52 (br d, J = 13.4 Hz, 1H), 4.34 (d, J = 3.9 Hz, 2H), 4.13 (s, 3H), 3.92 (br d, J = 13.7 Hz, 1H), 3.38 (br t, J = 10.6 Hz, 2H), 3.17 (br t, J = 11.0 Hz, 1H), 2.65 (s, 3H), 2.30 (br t, J = 13.9 Hz, 2H), 2.14-1.99 (m, 2H); LCMS (ESI) [M+H]⁺: 527.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 7.85 (dd, J = 1.0, 8.4 Hz, 1H), 7.78-7.71 (m, 1H), 7.43-7.34 (m, 2H), 7.25-7.19 (m, 1H), 7.14 (d, J = 7.7 Hz, 2H), 4.43-4.25 (m, 2H), 4.09 (s, 3H), 3.32 (tt, J = 3.9, 10.7 Hz, 2H), 3.20 (br s, 1H), 2.61 (s, 3H), 2.28 (br dd, J = 3.3, 13.4 Hz, 2H), 2.09 (br d, J = 10.8 Hz, 2H); LCMS (ESI) [M+H]⁺: 418.1.

15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.78-7.69 (m, 1H), 4.20 (br s, 2H), 4.08 (s, 3H), 3.74 (s, 3H), 3.29-3.19 (m, 1H), 3.10 (br t, J = 11.6 Hz, 2H), 2.60 (s, 3H), 2.18 (br d, J = 11.0 Hz, 2H), 2.03-1.90 (m, 2H); LCMS (ESI) [M+H]⁺: 356.2.




25


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.86 (d, J = 7.2 Hz, 2H), 7.67 (dd, J = 1.8, 8.3 Hz, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.56-7.50 (m, 1H), 7.49-7.43 (m, 2H), 7.34 (br s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.66 (spt, J = 6.1 Hz, 1H), 4.55-4.45 (m, 1H), 4.31 (d, J = 3.9 Hz, 2H), 3.92 (s, 3H), 3.90 (br d, J = 3.7 Hz, 1H), 3.39-3.27 (m, 2H), 3.21-3.10 (m, 1H), 2.24 (dt, J = 3.5, 12.9 Hz, 2H), 2.08-1.92 (m, 2H), 1.41 (d, J = 6.0 Hz, 6H); LCMS (ESI) [M+H]⁺: 479.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.45-8.39 (m, 1H), 8.18 (br s, 1H), 8.09 (s, 1H), 7.86-7.80 (m, 1H), 7.76-7.72 (m, 1H), 7.44 (br t, J = 8.3 Hz, 1H), 4.61-4.51 (m, 1H), 4.41-4.34 (m, 1H), 4.20 (td, J = 5.9, 11.3 Hz, 1H), 4.08 (s, 3H), 4.02 (br d, J = 14.3 Hz, 1H), 3.57 (quin, J = 8.0 Hz, 1H), 3.47-3.31 (m, 2H), 3.22 (dd, J = 7.6, 17.3 Hz, 1H), 3.16-3.04 (m, 1H), 2.88-2.78 (m, 1H), 2.60 (s, 3H), 2.37-2.21 (m, 2H), 2.12-1.92 (m, 2H); LCMS (ESI) [M+H]⁺: 504.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (dd, J = 4.9, 7.9 Hz, 1H), 8.10 (s, 1H), 7.85-7.80 (m, 1H), 7.76-7.72 (m, 1H), 7.57 (t, J = 7.9 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 4.64-4.49 (m, 1H), 4.47-4.39 (m, 1H), 4.20 (dd, J = 7.1, 11.2 Hz, 1H), 4.08 (s, 3H), 4.03 (br s, 1H), 3.55 (quin, J = 8.3 Hz, 1H), 3.47-3.31 (m, 2H), 3.26-3.01 (m, 2H), 2.85-2.76 (m, 1H), 2.60 (s, 3H), 2.46 (d, J = 2.2 Hz, 3H), 2.26 (br d, J = 14.1 Hz, 2H), 2.12-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 500.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.53 (s, 1H), 8.00 (s, 1H), 7.79-7.70 (m, 2H), 4.91-4.77 (m, 1H), 4.22-4.05 (m, 2H), 3.26-3.14 (m, 1H), 3.03 (br t, J = 11.2 Hz, 2H), 2.22-2.08 (m, 2H), 1.98-1.85 (m, 2H), 1.69 (d, J = 6.8 Hz, 6H), 1.94 (s, 9H); LCMS (ESI) [M+H]⁺: 412.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.94 (s, 1H), 7.70-7.60 (m, 2H), 7.35 (dd, J = 4.8, 8.8 Hz, 1H), 7.06-6.96 (m, 2H), 4.07-3.96 (m, 4H), 3.88-3.60 (m, 5H), 3.45-3.28 (m, 2H), 2.51 (s, 3H); LCMS (ESI)

5 [M+H]⁺: 455.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.78-7.69 (m, 1H), 4.09 (s, 3H), 3.89 (br d, J = 13.1 Hz, 2H), 3.28-3.14 (m, 4H), 2.60 (s, 3H), 2.26 (br dd, J = 2.9, 13.4 Hz, 2H), 2.17-2.05 (m, 2H), 1.38 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 404.1.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.90-7.81 (m, 1H), 7.78-7.70 (m, 1H), 7.44 (s, 5H), 4.82-4.37 (m, 1H), 4.09 (s, 3H), 3.91 (br s, 1H), 3.40-3.30 (m, 1H), 3.30-3.17 (m, 2H), 2.61 (s, 3H), 2.37-1.96 (m, 4H); LCMS (ESI) [M+H]⁺: 402.1.


15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 7.89-7.84 (m, 2H), 7.83-7.78 (m, 1H), 7.75-7.70 (m, 1H), 7.55-7.49 (m, 1H), 7.49-7.42 (m, 2H), 7.33 (br s, 1H), 4.88 (m, 1H), 4.53 (m, J = 3.7, 13.5 Hz, 1H), 4.32 (d, J = 3.9 Hz, 2H), 3.99-3.87 (m, 1H), 3.43-3.29 (m, 2H), 3.23-3.09 (m, 1H), 2.61 (s, 3H), 2.28 (m, 2H), 2.13-1.92 (m, 2H), 1.60 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 487.2.

20


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.77-7.70 (m, 1H), 4.35 (br s, 1H), 4.08 (s, 3H), 3.96 (br d, J = 13.4 Hz, 2H), 3.26-3.16 (m, 1H), 3.08-2.99 (m, 2H), 2.60 (s, 3H),
 5 2.19 (br d, J = 10.3 Hz, 2H), 2.04-1.92 (m, 2H), 1.38 (s, 9H); LCMS (ESI) [M+H]⁺: 397.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.88-7.80 (m, 1H), 7.74 (br d, J = 7.9 Hz, 2H),
 10 7.68-7.60 (m, 1H), 7.59-7.52 (m, 1H), 7.38 (dd, J = 7.5, 17.2 Hz, 1H), 4.78-4.63 (m, 1H), 4.09 (s, 3H), 3.58-3.46 (m, 1H), 3.39-3.14 (m, 3H), 2.61 (s, 3H), 2.38-2.30 (m, 1H), 2.16-1.86 (m, 3H); LCMS (ESI) [M+H]⁺: 470.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.84 (dd, J = 1.0, 8.4 Hz, 1H), 7.79-7.70 (m, 1H),
 15 7.48-7.37 (m, 1H), 7.22 (d, J = 7.6 Hz, 1H), 7.19-7.10 (m, 2H), 4.65 (br s, 1H), 4.09 (s, 3H), 3.91 (br s, 1H), 3.45-3.16 (m, 3H), 2.61 (s, 3H), 2.42-1.91 (m, 4H); LCMS (ESI) [M+H]⁺: 420.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.67 (s, 1H), 8.10 (s, 1H), 7.54 (s, 1H), 7.38-7.33 (m, 2H), 7.29-
 20 7.26 (m, 2H), 4.62 (br s, 1H), 4.10 (s, 1H), 3.93 (s, 3H), 3.34 (tt, J = 4.0, 10.8 Hz, 1H), 3.19 (br s, 2H), 2.94 (spt, J = 6.9 Hz, 1H), 2.18 (br d, J = 4.6 Hz, 2H), 1.98 (br d, J = 9.5 Hz, 2H), 1.27 (d, J = 6.8 Hz, 6H);
 25 LCMS (ESI) [M+H]⁺: 423.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.27 (s, 1H), 7.89-7.82 (m, 3H), 7.72 (d, J = 8.6 Hz, 1H), 7.56-7.50 (m, 1H), 7.49-7.43 (m, 2H), 7.35 (br s, 1H), 4.59-4.49 (m, 1H), 4.32 (d, J = 3.7 Hz, 2H), 3.94 (br d, J = 13.9 Hz, 1H), 3.58 (tt, J = 3.6, 6.9 Hz, 1H), 3.44-3.30 (m, 2H), 3.23-3.10 (m, 1H), 2.58 (s, 3H), 2.29 (dt, J = 3.2, 13.1 Hz, 2H), 2.15-1.95 (m, 2H), 1.28-1.17 (m, 4H); LCMS (ESI) [M+H]⁺: 485.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.52 (s, 1H), 7.49 (d, J = 1.8 Hz, 1H), 7.38-7.34 (m, 2H), 7.28 (d, J = 7.7 Hz, 2H), 6.43 (d, J = 1.8 Hz, 1H), 4.84-4.39 (m, 1H), 4.35-3.91 (m, 1H), 3.85 (s, 3H), 3.37 (tt, J = 4.0, 10.9 Hz, 1H), 3.28-3.10 (m, 2H), 2.95 (spt, J = 6.9 Hz, 1H), 2.19 (br d, J = 9.9 Hz, 2H), 2.08-1.87 (m, 2H), 1.27 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 423.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (d, J = 2.6 Hz, 1H), 7.87-7.80 (m, 1H), 7.78-7.70 (m, 1H), 7.43 (br d, J = 5.4 Hz, 1H), 7.40-7.28 (m, 3H), 4.80-4.63 (m, 1H), 4.08 (s, 3H), 3.67-3.53 (m, 1H), 3.41-3.12 (m, 3H), 2.60 (s, 3H), 2.34 (br d, J = 13.1 Hz, 1H), 2.20-1.87 (m, 3H); LCMS (ESI) [M+H]⁺: 436.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.50 (s, 1H), 7.85 (br d, J = 7.3 Hz, 2H), 7.66 (m, 2H), 7.55-7.41 (m, 3H), 7.35 (br s, 1H), 4.78 (td, J = 6.7, 13.3 Hz, 1H), 4.44 (br d, J = 13.2 Hz, 1H), 4.30 (m, 2H), 3.90 (br d, J = 13.5 Hz, 1H), 3.43-3.28 (m, 2H), 3.22 (br t, J = 11.4 Hz, 1H), 2.72-2.56 (s, 3H), 2.33-2.17 (m, 2H), 2.13-1.91 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 487.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.79-7.67 (m, 1H), 7.39 (d, J = 7.6 Hz, 2H), 7.29 (d, J = 7.8 Hz, 2H), 4.63 (br s, 1H), 4.10 (s, 3H), 3.92 (br s, 1H), 3.45-3.13 (m, 3H), 2.96 (quind, J = 6.8, 13.8 Hz, 1H), 2.62 (s, 3H), 2.38-1.94 (m, 4H), 1.28 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 444.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.88-7.81 (m, 1H), 7.78-7.71 (m, 1H), 7.46-7.37 (m, 4H), 4.60 (br s, 1H), 4.09 (s, 3H), 3.91 (br s, 1H), 3.44-3.13 (m, 3H), 2.61 (s, 3H), 2.40-1.88 (m, 4H); LCMS (ESI) [M+H]⁺: 436.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.88-7.80 (m, 1H), 7.78-7.69 (m, 2H), 7.27-7.20 (m, 1H), 7.09 (br dd, J = 7.9, 16.6 Hz, 1H), 4.78-4.55 (m, 1H), 4.09 (s, 3H), 3.58-3.46 (m, 1H), 3.41-3.16 (m, 3H), 2.61 (s, 3H), 2.43-2.26 (m, 1H), 2.19-1.90 (m, 3H); LCMS (ESI) [M+H]⁺: 488.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.93 (s, 1H), 7.72-7.60 (m, 3H), 7.21 (br d, J = 2.3 Hz, 1H), 7.17 (d, J = 2.2 Hz, 1H), 7.02 (dd, J = 2.4, 7.9 Hz, 1H), 4.05-3.96 (m, 4H), 3.86-3.69 (m, 3H), 3.65-3.55 (m, 2H), 3.30 (t, J = 5.2 Hz, 2H), 2.51 (s, 3H); LCMS (ESI) [M+H]⁺: 489.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09-8.00 (m, 2H), 7.95 (d, J = 7.8 Hz, 1H), 7.78-7.65 (m, 3H), 7.56-7.50 (m, 1H), 7.32 (br s, 1H), 4.49-4.41 (m, 1H), 4.25 (d, J = 3.9 Hz, 2H), 4.01 (s, 3H), 3.89-3.81 (m, 1H), 3.34-3.26 (m, 2H), 3.16-3.07 (m, 1H), 2.52 (s, 3H), 2.22 (dt, J = 3.5, 13.5 Hz, 2H), 2.04-1.90 (m, 2H); LCMS (ESI) [M+H]⁺: 527.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.82-7.69 (m, 3H), 7.69-7.57 (m, 2H), 7.39 (d, J = 7.5 Hz, 1H), 4.15-4.06 (m, 4H), 3.96-3.79 (m, 3H), 3.71-3.61 (m, 2H), 3.40-3.33 (m, 2H), 2.60 (s, 3H); LCMS (ESI) [M+H]⁺: 471.1.

15



¹H NMR (400 MHz, CHLOROFORM-d) 8.02-7.83 (m, 2H), 7.66 (br d, J = 8.4 Hz, 1H), 7.58 (s, 1H), 7.51-7.40 (m, 2H), 6.95 (d, J = 8.6 Hz, 1H), 4.67-4.62 (m, 1H), 4.58-4.44 (m, 1H), 4.37-4.27 (m, 1H), 4.01-3.93 (m, 2H), 3.91 (s, 3H), 3.64-3.56 (m, 1H), 3.45-3.24 (m, 2H), 3.19-3.02 (m, 1H), 3.01-2.83 (m, 2H), 2.24 (br t, J = 14.4 Hz, 2H), 2.09-1.88 (m, 2H), 1.40 (br d, J = 5.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 530.2.


20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.41 (s, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.44-7.33 (m, 3H), 7.27 (d, J = 7.9 Hz, 2H), 4.63 (br s, 1H), 4.03 (s, 4H), 3.32 (br t, J = 10.7 Hz, 1H), 3.21 (br s, 2H), 2.97-2.90 (m, 1H), 2.62 (s, 3H), 2.36-1.87 (m, 4H), 1.26 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 444.1.

5



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.86 (d, J = 7.1 Hz, 2H), 7.75 (dd, J = 1.5, 8.4 Hz, 1H), 7.65 (d, J = 1.3 Hz, 1H), 7.57-7.50 (m, 1H), 7.49-7.43 (m, 2H), 7.35 (br s, 1H), 6.76 (d, J = 8.4 Hz, 1H), 4.52 (br d, J = 13.7 Hz, 1H), 4.31 (d, J = 3.7 Hz, 2H), 4.17-4.05 (m, 2H), 3.92 (br d, J = 14.1 Hz, 1H), 3.85 (s, 2H), 3.42-3.28 (m, 2H), 3.19-3.07 (m, 1H), 2.92 (s, 3H), 2.33-2.19 (m, 2H), 2.10-1.91 (m, 2H), 1.32 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 503.2.


10



15


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.42 (s, 1H), 8.07 (dd, J = 0.9, 8.8 Hz, 1H), 7.87 (d, J = 7.3 Hz, 2H), 7.56-7.51 (m, 1H), 7.45 (dd, J = 8.4, 17.2 Hz, 3H), 7.35 (br s, 1H), 4.53 (br d, J = 13.7 Hz, 1H), 4.43-4.37 (m, 2H), 4.32 (d, J = 3.7 Hz, 2H), 3.94 (br d, J = 13.9 Hz, 1H), 3.41-3.32 (m, 1H), 3.36 (dt, J = 4.1, 10.3 Hz, 1H), 3.17 (br t, J = 10.9 Hz, 1H), 2.63 (s, 3H), 2.35-2.22 (m, 2H), 2.12-1.96 (m, 2H), 1.52 (t, J = 7.3 Hz, 3H); LCMS (ESI) [M+H]⁺: 473.2.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 4.26 (br s, 2H), 4.09 (s, 3H), 3.41-3.31 (m, 1H), 2.98 (br t, J = 12.0 Hz, 2H), 2.60 (s, 3H), 2.23 (br d, J = 12.0 Hz, 2H), 1.85 (dq, J = 4.0, 12.0 Hz, 2H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 414.1.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.34 (s, 1H), 7.99 (dd, J = 1.2, 8.7 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 4.31 (q, J = 7.3 Hz, 2H), 4.08 (br d, J = 10.1 Hz, 2H), 3.15-3.08 (m, 1H), 2.94 (br t, J = 11.7 Hz, 2H), 2.55 (s, 3H), 2.07 (br dd, J = 2.9, 13.2 Hz, 2H), 1.93-1.82 (m, 2H), 1.46-1.43 (m, 3H), 1.41 (s, 9H); LCMS (ESI) [M+H]⁺: 412.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28-8.24 (m, 1H), 8.14 (br s, 1H), 8.09 (d, J = 3.5 Hz, 1H), 7.85-7.80 (m, 1H), 7.74-7.72 (m, 1H), 7.51 (br d, J = 8.8 Hz, 1H), 4.56 (br t, J = 13.4 Hz, 1H), 4.40 (dd, J = 9.2, 11.0 Hz, 1H), 4.21-4.12 (m, 1H), 4.08 (s, 3H), 4.03 (br d, J = 13.6 Hz, 1H), 3.62-3.51 (m, 1H), 3.46-3.30 (m, 2H), 3.25 (dd, J = 7.9, 17.1 Hz, 1H), 3.15-3.01 (m, 1H), 2.86-2.74 (m, 1H), 2.59 (s, 3H), 2.35-2.20 (m, 5H), 2.12-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 500.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28-8.24 (m, 1H), 8.14 (br s, 1H), 8.09 (d, J = 3.5 Hz, 1H), 7.85-7.80 (m, 1H), 7.76-7.71 (m, 1H), 7.51 (br d, J = 8.3 Hz, 1H), 4.56 (br t, J = 12.7 Hz, 1H), 4.40-4.37 (m, 1H), 4.21-4.13 (m, 1H), 4.08 (s, 3H), 4.03 (br d, J = 13.2 Hz, 1H), 3.62-3.51 (m, 1H), 3.46-3.30 (m, 2H), 3.25 (dd, J = 7.7, 17.3 Hz, 1H), 3.15-3.01 (m, 1H), 2.86-2.75 (m, 1H), 2.59 (s, 3H), 2.35-2.20 (m, 5H), 2.11-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 500.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.75 (dd, J = 0.9, 8.4 Hz, 1H), 7.69-7.62 (m, 2H), 7.22 (dd, J = 2.4, 8.1 Hz, 1H), 7.19-7.14 (m, 1H), 6.97 (br s, 1H), 4.46-4.36 (m, 1H), 4.23 (d, J = 4.0 Hz, 2H), 4.01 (s, 3H), 3.81 (br d, J = 13.9 Hz, 1H), 3.34-3.24 (m, 2H), 3.13-3.04 (m, 1H), 2.53 (s, 3H), 2.27-2.15 (m, 2H), 2.05-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 545.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (d, J = 2.3 Hz, 1H), 8.02-7.89 (m, 2H), 7.87-7.82 (m, 1H),
 5 7.79-7.73 (m, 1H), 7.54-7.43 (m, 2H), 4.66-4.48 (m, 1H), 4.35 (dd, J = 6.6, 9.4 Hz, 1H), 4.10 (d, J = 2.1 Hz, 3H), 4.06-3.92 (m, 2H), 3.64 (m, 1H), 3.52-3.33 (m, 2H), 3.25-3.07 (m, 1H), 3.06-2.86 (m, 2H), 2.62 (s, 3H), 2.39-2.23 (m, 2H), 2.15-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 510.2.




10 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (d, J = 2.3 Hz, 1H), 8.00-7.87 (m, 2H), 7.86-7.80 (m, 1H), 7.77-7.70 (m, 1H), 7.53-7.40 (m, 2H), 4.62-4.47 (m, 1H), 4.33 (dd, J = 6.7, 9.4 Hz, 1H), 4.08 (d, J = 2.3 Hz, 3H), 4.03-3.90 (m, 2H), 3.61 (td, J = 8.3, 16.1 Hz, 1H), 3.51-3.31 (m, 2H), 3.13 (m, 1H), 3.02-2.83 (m, 2H), 2.60 (s, 3H), 2.38-2.20 (m, 2H), 2.12-1.92 (m, 2H); LCMS (ESI) [M+H]⁺: 510.2.

15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.85-7.71 (m, 4H), 7.66 (d, J = 8.8 Hz, 2H), 4.62-4.47 (m, 1H), 4.35 (dd, J = 6.8, 9.6 Hz, 1H), 4.08 (s, 3H), 4.03-3.91 (m, 2H), 3.61 (m, 1H), 3.48-3.30 (m, 2H), 3.22-3.05 (m, 1H), 3.03-2.84 (m, 2H), 2.60 (s, 3H), 2.29 (br t, J = 13.2 Hz, 2H), 2.12-1.92 (m, 2H);
 20 LCMS (ESI) [M+H]⁺: 510.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.85-7.72 (m, 4H), 7.66 (d, J = 8.8 Hz, 2H), 4.65-4.47 (m, 1H), 4.35 (dd, J = 6.8, 9.6 Hz, 1H), 4.08 (s, 3H), 4.03-3.89 (m, 2H), 3.61 (m, 1H), 3.48-3.31 (m, 2H), 3.22-3.05 (m, 1H), 3.03-2.85 (m, 2H), 2.60 (s, 3H), 2.29 (br t, J = 13.3 Hz, 2H), 2.14-1.92 (m, 2H);

5 LCMS (ESI) [M+H]⁺: 510.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.90-7.77 (m, 4H), 7.57-7.45 (m, 3H), 7.36 (br s, 1H), 4.59-4.50 (m, 1H), 4.33 (d, J = 3.8 Hz, 2H), 4.10 (s, 3H), 3.95 (br d, J = 14.1 Hz, 1H), 3.38 (ddd, J = 3.3, 10.6, 14.0 Hz, 2H), 3.22-3.12 (m, 1H), 3.07-3.00 (m, 1H), 3.04 (q, J = 7.6 Hz, 1H), 2.30 (dt, J = 3.3, 13.0 Hz, 2H), 2.11-1.97 (m, 2H), 1.44 (t, J = 7.6 Hz, 3H); LCMS (ESI) [M+H]⁺: 473.2.



15


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.86 (br d, J = 6.8 Hz, 2H), 7.60 (dd, J = 1.6, 8.4 Hz, 1H), 7.53 (t, J = 7.2 Hz, 1H), 7.46 (t, J = 7.2 Hz, 1H), 7.38 (d, J = 1.2 Hz, 1H), 7.37-7.31 (m, 1H), 7.05 (d, J = 8.4 Hz, 1H), 4.52 (td, J = 3.6, 13.6 Hz, 1H), 4.31 (d, J = 8.0 Hz, 2H), 4.05 (q, J = 7.2 Hz, 2H), 3.92 (d, J = 13.6 Hz, 1H), 3.42-3.27 (m, 2H), 3.20-3.07 (m, 1H), 2.93 (s, 3H), 2.34-2.17 (m, 2H), 2.08-1.90 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H); LCMS (ESI) [M+H]⁺: 503.3.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.87-7.79 (m, 1H), 7.78-7.66 (m, 1H), 4.08 (s, 3H), 3.79 (br d, J = 13.4 Hz, 2H), 3.74-3.64 (m, 4H), 3.37-3.28 (m, 4H), 3.28-3.18 (m, 1H), 3.04 (br t, J = 11.6 Hz, 2H), 2.60 (s, 3H), 2.20 (br d, J = 10.9 Hz, 2H), 2.09-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 411.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.87-7.80 (m, 1H), 7.78-7.70 (m, 1H), 7.45-7.32 (m, 1H), 7.16-6.98 (m, 2H), 4.76-4.60 (m, 1H), 4.09 (s, 3H), 3.59 (br t, J = 12.8 Hz, 1H), 3.41-3.16 (m, 3H), 2.60 (s, 3H), 2.34 (br d, J = 11.1 Hz, 1H), 2.24-1.87 (m, 3H); LCMS (ESI) [M+H]⁺: 454.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.77-7.68 (m, 1H), 4.08 (s, 3H), 3.75 (br d, J = 13.4 Hz, 2H), 3.30-3.15 (m, 5H), 2.99 (br t, J = 11.8 Hz, 2H), 2.60 (s, 3H), 2.18 (br d, J = 10.9 Hz, 2H), 2.08-1.95 (m, 2H), 1.60 (br s, 6H); LCMS (ESI) [M+H]⁺: 409.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.79 (br s, 1H), 8.55 (s, 1H), 8.14-8.07 (m, 2H), 7.81 (br d, J = 8.4 Hz, 2H), 7.75-7.70 (m, 1H), 4.54 (br d, J = 13.7 Hz, 1H), 4.32 (br d, J = 4.2 Hz, 2H), 4.07 (s, 3H), 3.93 (br d, J = 13.7 Hz, 1H), 3.41-3.30 (m, 2H), 3.13 (br t, J = 11.6 Hz, 1H), 2.59 (s, 3H), 2.32-2.19 (m, 2H), 2.10-1.93 (m, 2H); LCMS (ESI) [M+H]⁺: 494.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.59 (br d, J = 7.7 Hz, 2H), 7.38 (br t, J = 7.4 Hz, 2H), 7.22-7.13 (m, 1H), 4.83 (s, 4H), 4.49 (br t, J = 15.0 Hz, 1H), 4.33-4.27 (m, 1H), 4.22 (s, 4H), 3.97-3.87 (m, 2H), 3.61-3.50 (m, 1H), 3.31 (br d, J = 8.2 Hz, 1H), 3.16-2.90 (m, 3H), 2.87-2.77 (m, 1H), 2.19-2.07 (m, 2H), 1.86 (br d, J = 10.4 Hz, 2H); LCMS (ESI) [M+H]⁺: 438.2.




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.59 (br d, J = 7.5 Hz, 2H), 7.38 (br t, J = 7.2 Hz, 2H), 7.22-7.13 (m, 1H), 4.83 (br s, 4H), 4.49 (br t, J = 15.0 Hz, 1H), 4.30 (br t, J = 8.2 Hz, 1H), 4.22 (br s, 4H), 3.97-3.87 (m, 2H), 3.61-3.51 (m, 1H), 3.31 (br d, J = 6.8 Hz, 1H), 3.17-2.90 (m, 3H), 2.87-2.77 (m, 1H), 2.19-2.07 (m, 2H), 1.86 (br d, J = 10.6 Hz, 2H); LCMS (ESI) $[M+H]^+$: 438.2.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.11 (s, 1H), 7.99 (d, J = 8.1 Hz, 2H), 7.84 (dd, J = 0.9, 8.4 Hz, 1H), 7.75 (dd, J = 5.0, 8.1 Hz, 3H), 7.43 (br s, 1H), 4.60-4.50 (m, 1H), 4.34 (d, J = 3.8 Hz, 2H), 4.10 (s, 3H), 3.94 (br d, J = 14.1 Hz, 1H), 3.45-3.33 (m, 2H), 3.25-3.14 (m, 1H), 2.62 (s, 3H), 2.37-2.25 (m, 2H), 2.14-1.99 (m, 2H); LCMS (ESI) $[M+H]^+$: 527.1.




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.29 (s, 1H), 7.86 (dd, J = 1.5, 9.0 Hz, 1H), 7.61 (d, J = 9.0 Hz, 1H), 7.29 (d, J = 8.0, 2H), 7.20 (d, J = 7.6 Hz, 2H), 4.54 (br s, 1H), 4.05 (s, 4H), 4.26-3.24 (m, 1H), 3.15 (br t, J = 11.4 Hz, 2H), 2.90-2.81 (m, 1H), 2.60 (s, 3H), 2.22-1.86 (m, 4H), 1.19 (d, J = 7.0 Hz, 6H); LCMS (ESI) $[M+H]^+$: 444.2.




25 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.15 (s, 1H), 7.86-7.83 (m, 1H), 7.79-7.76 (m, 1H), 4.16 (br s, 2H), 4.09 (s, 3H), 3.10-2.91 (m, 3H), 2.61 (s, 3H), 2.08 (br d, J = 10.6 Hz, 2H), 1.94-1.82 (m, 2H), 1.48 (s, 9H); LCMS (ESI) $[M+H]^+$: 398.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.38 (s, 1H), 7.95 (br d, J = 9.2 Hz, 1H), 7.88 (br d, J = 7.6 Hz, 2H), 7.72 (d, J = 8.9 Hz, 1H), 7.57-7.44 (m, 3H), 7.36 (br s, 1H), 4.58-4.40 (m, 3H), 4.33 (br d, J = 3.5 Hz, 2H), 3.94 (br d, J = 13.6 Hz, 1H), 3.43-3.32 (m, 2H), 3.19 (br t, J = 11.1 Hz, 1H), 2.70 (s, 3H), 2.33-2.23 (m, 2H), 2.13-1.99 (m, 2H), 1.60 (t, J = 7.2 Hz, 3H); LCMS (ESI) [M+H]⁺: 473.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.43 (s, 1H), 7.88 (br d, J = 7.7 Hz, 2H), 7.71 (s, 2H), 7.57-7.51 (m, 1H), 7.51-7.45 (m, 2H), 7.36 (br s, 1H), 4.51 (br d, J = 13.8 Hz, 1H), 4.33 (br d, J = 2.3 Hz, 2H), 4.18 (s, 3H), 3.94 (br d, J = 13.9 Hz, 1H), 3.42-3.33 (m, 2H), 3.21 (br t, J = 10.7 Hz, 1H), 3.13-3.07 (m, 2H), 2.34-2.24 (m, 2H), 2.12-2.00 (m, 2H), 1.40 (t, J = 7.6 Hz, 3H); LCMS (ESI) [M+H]⁺: 473.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.18 (s, 1H), 8.11-8.00 (m, 2H), 7.81 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.42 (br s, 1H), 4.90 (br d, J = 13.2 Hz, 1H), 4.43-4.22 (m, 2H), 4.10 (s, 3H), 3.97 (d, J = 14.0 Hz, 1H), 3.60-3.46 (m, 1H), 3.37 (t, J = 12.0 Hz, 1H), 3.06 (t, J = 11.6 Hz, 1H), 2.61 (s, 3H), 2.37 (t, J = 11.6 Hz, 2H), 2.05-1.86 (m, 2H); LCMS (ESI) [M+H]⁺: 500.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.67 (br s, 1H), 7.53 (br t, J = 6.0 Hz, 1H), 7.30 (t, J = 8.2 Hz, 1H), 7.15 (br d, J = 7.9 Hz, 1H), 4.56-4.38 (m, 1H), 4.28 (dd, J = 7.1, 9.5 Hz, 1H), 4.01-3.86 (m, 2H), 3.84-

3.76 (m, 4H), 3.60-3.52 (m, 1H), 3.44 (br t, J = 4.3 Hz, 4H), 3.39-3.28 (m, 1H), 3.20-2.90 (m, 3H), 2.89-2.78 (m, 1H), 2.23-2.08 (m, 2H), 1.96-1.77 (m, 2H); LCMS (ESI) [M+H]⁺: 460.2.




5 ¹H NMR (400 MHz, CHLOROFORM-d) δ 7.67 (s, 1H), 7.56-7.49 (m, 1H), 7.30 (t, J = 8.2 Hz, 1H), 7.15 (d, J = 8.2 Hz, 1H), 4.56-4.41 (m, 1H), 4.28 (dd, J = 7.1, 9.5 Hz, 1H), 4.19-4.03 (m, 2H), 3.91 (br t, J = 7.9 Hz, 2H), 3.63-3.46 (m, 3H), 3.40-3.27 (m, 1H), 3.21-2.90 (m, 5H), 2.89-2.76 (m, 1H), 2.15 (br t, J = 13.2 Hz, 2H), 1.96-1.77 (m, 2H), 1.27 (d, J = 6.4 Hz, 6H); LCMS (ESI) [M+H]⁺: 488.1.


10



15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 7.67 (br s, 1H), 7.53 (br d, J = 6.0 Hz, 1H), 7.30 (t, J = 8.2 Hz, 1H), 7.15 (br d, J = 7.1 Hz, 1H), 4.48 (s, 5H), 4.28 (dd, J = 7.1, 9.5 Hz, 1H), 3.91 (br t, J = 7.9 Hz, 2H), 3.56 (quin, J = 8.3 Hz, 1H), 3.43-3.28 (m, 5H), 3.18-2.89 (m, 3H), 2.87-2.77 (m, 1H), 2.20-2.07 (m, 2H), 1.98-1.92 (m, 4H), 1.91-1.76 (m, 2H); LCMS (ESI) [M+H]⁺: 500.2.




20 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 7.89-7.82 (m, 3H), 7.80-7.75 (m, 1H), 7.55-7.49 (m, 1H), 7.48-7.42 (m, 2H), 7.36 (br s, 1H), 4.57 (br d, J = 13.8 Hz, 1H), 4.31 (d, J = 3.8 Hz, 2H), 4.09 (s, 3H), 3.92 (br d, J = 13.9 Hz, 1H), 3.37-3.28 (m, 1H), 3.26-3.17 (m, 1H), 3.13-3.04 (m, 1H), 2.60 (s, 3H), 2.26-2.15 (m, 2H), 2.05-1.90 (m, 2H); LCMS (ESI) [M+H]⁺: 459.1.



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.89-7.84 (m, 1H), 7.79-7.75 (m, 1H), 4.20 (s, 3H), 3.81-3.73 (m, 4H), 3.44-3.36 (m, 4H), 3.27 (br s, 4H), 2.71 (s, 3H); LCMS (ESI) [M+H]⁺: 410.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.70-7.65 (m, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.54-7.42 (m, 2H), 6.97 (br s, 1H), 4.42 (br d, J = 13.6 Hz, 1H), 4.23 (d, J = 3.9 Hz, 2H), 4.01 (s, 3H), 3.81 (br d, J = 14.2 Hz, 1H), 3.34-3.23 (m, 2H), 3.09 (br t, J = 11.1 Hz, 1H), 2.53 (s, 3H), 2.21 (br t, J = 13.4 Hz, 2H), 2.05-1.91 (m, 2H); LCMS (ESI) [M+H]⁺: 561.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.17-7.97 (m, 1H), 7.87-7.77 (m, 1H), 7.75-7.66 (m, 1H), 7.24 (br d, J = 6.6 Hz, 2H), 7.20-7.12 (m, 3H), 4.89 (s, 1H), 4.06 (s, 3H), 3.99 (br d, J = 13.5 Hz, 2H), 3.21 (br t, J = 10.8 Hz, 1H), 3.06 (br t, J = 11.5 Hz, 2H), 2.85 (br s, 1H), 2.58 (s, 3H), 2.18 (br d, J = 11.5 Hz, 2H), 2.09-1.87 (m, 3H), 1.25-1.20 (m, 1H), 1.17-1.10 (m, 1H); LCMS (ESI) [M+H]⁺: 457.2.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 4.26 (br s, 2H), 4.09 (s, 3H), 3.41-3.31 (m, 1H), 2.98 (br t, J = 12.0 Hz, 2H), 2.60 (s, 3H), 2.23 (br d, J = 12.0 Hz, 2H), 1.85 (dq, J = 4.0, 12.0 Hz, 2H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 414.1.


20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (d, J = 4.3 Hz, 1H), 8.00 (br d, J = 4.6 Hz, 1H), 7.94 (br t, J = 7.6 Hz, 1H), 7.89-7.84 (d, 1H), 7.83-7.77 (d, 1H), 7.54-7.43 (m, 2H), 4.61 (m, 1H), 4.35 (m, 1H), 4.12 (d, J = 1.7 Hz, 3H), 4.05-3.92 (m, 2H), 3.65 (m, 1H), 3.47-3.34 (m, 1H), 3.31-3.19 (m, 1H), 3.16-2.86 (m, 3H), 2.63 (s, 3H), 2.31-2.16 (m, 2H), 2.09-1.89 (m, 2H); LCMS (ESI) [M+H]⁺: 510.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.96 (br d, J = 10.6 Hz, 1H), 7.90 (br t, J = 9.0 Hz, 1H), 7.52-7.41 (m, 2H), 4.83 (s, 4H), 4.47 (br t, J = 14.4 Hz, 1H), 4.35-4.27 (m, 1H), 4.22 (s, 4H), 3.99-3.84 (m, 2H), 3.58 (quin, J = 8.2 Hz, 1H), 3.40-3.26 (m, 1H), 3.19-2.82 (m, 4H), 2.14 (br t, J = 14.0 Hz, 2H), 1.96-1.72 (m, 2H); LCMS (ESI) [M+H]⁺: 463.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (dd, J = 3.9, 8.3 Hz, 1H), 8.13 (s, 1H), 7.50 (dd, J = 1.8, 8.3 Hz, 1H), 4.82 (s, 4H), 4.52-4.41 (m, 1H), 4.36 (t, J = 9.9 Hz, 1H), 4.21 (s, 4H), 4.13 (br t, J = 7.7 Hz, 1H), 3.93 (br d, J = 13.2 Hz, 1H), 3.51 (quin, J = 8.1 Hz, 1H), 3.32 (br t, J = 11.2 Hz, 1H), 3.21 (br dd, J = 7.5, 17.1 Hz, 1H), 3.14-2.93 (m, 2H), 2.77 (br dd, J = 9.2, 18.9 Hz, 1H), 2.29 (s, 3H), 2.18-2.05 (m, 2H), 1.94-1.74 (m, 2H); LCMS (ESI) [M+H]⁺: 453.2.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.48-7.36 (m, 5H), 4.83 (s, 4H), 4.74-4.45 (m, 1H), 4.22 (s, 4H), 3.81 (br d, J = 15.4 Hz, 1H), 3.27-3.00 (m, 3H), 2.30-1.94 (m, 2H), 1.87 (br s, 2H); LCMS (ESI) [M+H]⁺: 355.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.49-7.35 (m, 5H), 4.59 (br s, 1H), 4.13 (d, J = 8.6 Hz, 2H), 4.01 (d, J = 8.6 Hz, 2H), 3.87 (t, J = 6.8 Hz, 2H), 3.84-3.67 (m, 1H), 3.26-3.02 (m, 3H), 2.25-2.11 (m, 3H),
 5 2.02-1.73 (m, 5H); LCMS (ESI) [M+H]⁺: 369.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 7.39-7.29 (m, 4H), 4.52 (br s, 1H), 4.08-3.97 (m, 4H), 3.86 (t, J =
 10 6.8 Hz, 3H), 3.23 (tt, J = 4.0, 10.8 Hz, 3H), 2.96 (td, J = 6.9, 13.8 Hz, 1H), 2.25-2.02 (m, 4H), 1.95 (quin, J = 7.1 Hz, 2H), 1.81 (br s, 2H), 1.27 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 411.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.38-7.31 (m, 2H), 7.27-7.24 (m, 2H), 4.83 (s, 4H), 4.71-4.40 (m, 1H), 4.22 (s, 4H), 4.09-3.68 (m, 1H), 3.31-3.03 (m, 3H), 2.94 (spt, J = 6.9 Hz, 1H), 2.06 (br d, J = 7.1 Hz, 2H), 1.88 (br s, 2H), 1.26 (d, J = 7.1 Hz, 6H); LCMS (ESI) [M+H]⁺: 397.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.05-7.92 (m, 2H), 7.71-7.60 (m, 1H), 7.50 (br t, J = 7.4 Hz, 1H),
 20 7.28 (t, J = 8.2 Hz, 1H), 7.13 (dd, J = 1.0, 8.0 Hz, 1H), 4.64-4.40 (m, 2H), 4.26 (dd, J = 7.1, 9.3 Hz, 1H),
 4.00-3.85 (m, 2H), 3.60-3.51 (m, 1H), 3.41-3.20 (m, 2H), 3.15-2.99 (m, 1H), 2.99-2.77 (m, 2H), 2.21 (br t,
 25 J = 13.6 Hz, 2H), 2.02-1.84 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 483.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.68-7.64 (m, 1H), 7.52 (br t, J = 6.2 Hz, 1H), 7.30 (t, J = 8.2 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 4.84 (s, 4H), 4.56-4.39 (m, 1H), 4.30-4.24 (m, 1H), 4.22 (s, 4H), 3.90 (dt, J = 3.5, 8.9 Hz, 2H), 3.60-3.51 (m, 1H), 3.40-3.25 (m, 1H), 3.18-2.97 (m, 2H), 2.97-2.88 (m, 1H), 2.87-2.78 (m, 1H), 2.13 (t, J = 12 Hz, 2H), 1.96-1.72 (m, 2H); LCMS (ESI) [M+H]⁺: 472.2.




¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (d, J = 2.0 Hz, 1H), 8.06 (s, 1H), 7.86-7.80 (m, 1H), 7.55 (br d, J = 8.2 Hz, 1H), 7.37 (dt, J = 2.3, 8.1 Hz, 1H), 7.17 (br d, J = 8.2 Hz, 1H), 5.68-5.61 (m, 1H), 4.96-4.83 (m, 4H), 4.31 (br d, J = 12.6 Hz, 1H), 4.08-4.01 (m, 1H), 3.97 (br d, J = 13.9 Hz, 1H), 3.91 (dd, J = 5.7, 9.7 Hz, 1H), 3.76-3.65 (m, 1H), 3.44-3.34 (m, 1H), 3.29-3.21 (m, 1H), 2.90 (br t, J = 13.8 Hz, 1H), 2.79-2.68 (m, 2H), 2.09 (br t, J = 14.0 Hz, 2H), 1.87-1.56 (m, 2H); LCMS (ESI) [M+H]⁺: 497.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (t, 1H), 7.79 (m, 2H), 4.38 (m, 2H), 4.09 (s, 3H), 3.59 (m, 1H), 2.61 (s, 3H), 2.06 (m, 5H), 1.81 (d, J = 8 Hz, 2H), 1.51 (s, 9H); LCMS (ESI) [M+H]⁺: 424.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.29 (s, 1H), 7.86 (dd, J = 1.5, 9.0 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 4.35 (q, J = 7.3 Hz, 2H), 4.06 (br s, 2H), 3.11 (tt, J = 3.6, 10.8 Hz, 1H), 2.93 (br t, J = 11.7 Hz, 2H), 2.60 (s, 3H), 2.06 (br dd, J = 2.7, 13.1 Hz, 2H), 1.90-1.81 (m, 2H), 1.50 (t, J = 7.3 Hz, 3H), 1.41 (s, 9H); LCMS (ESI) [M+H]⁺: 412.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 7.84-7.78 (m, 1H), 7.75-7.69 (m, 1H), 4.88 (m, 1H), 4.16 (br s, 2H), 3.25-3.15 (m, 1H), 3.07-2.94 (m, 2H), 2.60 (s, 3H), 2.20-2.10 (m, 2H), 2.00-1.87 (m, 2H), 1.59 (d, J = 6.6 Hz, 6H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 426.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.30 (s, 1H), 8.07 (s, 1H), 7.95-7.78 (m, 2H), 7.49-7.36 (m, 1H), 7.25-7.20 (m, 1H), 7.19-7.10 (m, 2H), 5.06-4.89 (m, 1H), 4.86-4.50 (m, 1H), 4.05-3.72 (m, 1H), 3.46-3.32 (m, 1H), 3.30-3.15 (m, 2H), 2.46-1.92 (m, 4H), 1.64 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 434.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.90-7.74 (m, 2H), 7.49-7.27 (m, 4H), 5.09-4.98 (m, 1H), 4.82-4.68 (m, 1H), 3.70-3.52 (m, 1H), 3.44-3.10 (m, 3H), 2.43-2.27 (m, 1H), 2.22-1.81 (m, 3H), 1.64 (d, J = 6.4 Hz, 6H); LCMS (ESI) [M+H]⁺: 450.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.84 (q, J = 8.4 Hz, 2H), 7.45 (s, 5H), 5.06-4.90 (m, 1H), 4.77-4.54 (m, 1H), 4.10-3.77 (m, 1H), 3.45-3.30 (m, 1H), 3.30-3.07 (m, 2H), 2.45-1.93 (m, 4H), 1.64 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 416.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 11.23-10.26 (m, 1H), 8.16 (s, 2H), 7.72-7.63 (m, 1H), 7.53 (br t, J = 7.3 Hz, 1H), 7.31 (t, J = 8.1 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 4.66-4.44 (m, 1H), 4.35-4.23 (m, 1H), 4.02-3.89 (m, 2H), 3.63-3.54 (m, 1H), 3.44-3.26 (m, 2H), 3.21-2.77 (m, 3H), 2.24 (br t, J = 13.5 Hz, 2H), 2.06-1.87 (m, 2H); LCMS (ESI) [M+H]⁺: 441.1.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.67 (br d, J = 10.1 Hz, 1H), 7.52 (br t, J = 8.7 Hz, 1H), 7.30 (t, J = 8.2 Hz, 1H), 7.15 (br d, J = 7.9 Hz, 1H), 4.50 (br dd, J = 14.2, 18.4 Hz, 1H), 4.34-4.18 (m, 1H), 4.04-3.85 (m, 2H), 3.60-3.52 (m, 1H), 3.44-3.22 (m, 2H), 3.16-3.00 (m, 1H), 3.00-2.77 (m, 2H), 2.31-2.13 (m, 2H), 2.03-1.79 (m, 2H); LCMS (ESI) [M+H]⁺: 409.0.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.03 (s, 1H), 7.77 (s, 2H), 4.94 (spt, J = 6.6 Hz, 1H), 3.70 (br d, J = 5.1 Hz, 4H), , 3.62-3.55 (m, 4H), 1.61 (d, J = 6.8 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 413.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.03-7.94 (m, 1H), 7.89 (br dd, J = 8.2, 19.2 Hz, 1H), 7.54-7.41 (m, 2H), 4.50 (br t, J = 14.3 Hz, 1H), 4.36-4.24 (m, 1H), 4.02-3.87 (m, 2H), 3.60 (s, J = 8.2 Hz, 1H), 3.46-3.24 (m, 2H), 3.18-3.01 (m, 1H), 3.00-2.82 (m, 2H), 2.22 (br t, J = 14.0 Hz, 2H), 2.03-1.79 (m, 2H); LCMS (ESI) [M+H]⁺: 400.1.

20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.49-7.34 (m, 5H), 4.61 (br s, 1H), 3.86 (br s, 1H), 3.31-3.10 (m, 3H), 2.27 -1.92 (m, 4H); LCMS (ESI) [M+H]⁺: 292.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.38-7.32 (m, 2H), 7.29-7.25 (m, 2H), 4.60 (br s, 1H), 3.94 (br s, 1H), 3.35-3.08 (m, 3H), 2.94 (spt, J = 6.8 Hz, 1H), 2.15 (br s, 2H), 1.93 (br s, 2H), 1.26 (d, J = 7.1 Hz, 6H); LCMS (ESI) [M+H]⁺: 334.2.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.26 (t, J = 8.6 Hz, 1H), 8.14 (br s, 1H), 7.51 (br d, J = 7.9 Hz, 1H), 4.50 (br s, 1H), 4.38 (br t, J = 10.1 Hz, 1H), 4.13 (dd, J = 7.2, 11.2 Hz, 1H), 3.98 (br d, J = 13.6 Hz, 1H), 3.57-3.48 (m, 1H), 3.37 (br t, J = 11.8 Hz, 1H), 3.31-3.17 (m, 2H), 3.09-2.98 (m, 1H), 2.78 (dd, J = 9.2, 17.1 Hz, 1H), 2.30 (s, 3H), 2.18 (br d, J = 14.0 Hz, 2H), 1.99-1.83 (m, 2H); LCMS (ESI) [M+H]⁺: 390.3.


15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 7.86-7.82 (d, J = 1.2 Hz, 1H), 7.78-7.74 (d, J = 8.4 Hz, 1H), 7.34-7.27 (m, 5H), 4.86 (d, J = 14.7 Hz, 1H), 4.52 (d, J = 14.7 Hz, 1H), 4.10 (s, 3H), 3.63 (tdd, J = 3.6, 7.3, 13.5 Hz, 1H), 3.40-3.34 (m, 2H), 3.05 (d, J = 7.5 Hz, 2H), 2.62 (s, 3H), 2.45-2.36 (m, 1H), 2.29-2.19 (m, 1H); LCMS (ESI) [M+H]⁺: 402.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.05 (s, 1H), 7.90-7.75 (m, 2H), 4.95 (spt, J = 6.6 Hz, 1H), 4.18 (br s, 2H), 3.72 (s, 3H), 3.22 (tt, J = 3.9, 10.7 Hz, 1H), 3.08 (br t, J = 11.7 Hz, 2H), 2.16 (br d, J = 11.0 Hz, 2H), 2.03-1.86 (m, 2H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 370.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.03 (s, 1H), 7.77 (s, 2H), 4.94 (spt, J = 6.6 Hz, 1H), 3.76 (s, 3H), 3.72 (br s, 4H), 3.65 (br s, 4H), 1.61 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 371.2.



10


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.83 (q, J = 8.4 Hz, 2H), 5.07-4.87 (m, 2H), 4.20 (br s, 2H), 3.23 (tt, J = 4.0, 10.8 Hz, 1H), 3.06 (br t, J = 11.6 Hz, 2H), 2.25-2.09 (m, 2H), 2.05-1.87 (m, 2H), 1.64 (d, J = 6.8 Hz, 6H), 1.28 (d, J = 6.0 Hz, 6H); LCMS (ESI) [M+H]⁺: 398.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.93-7.77 (m, 2H), 7.32 (br t, J = 7.2 Hz, 2H), 7.09-6.92 (m, 3H), 5.09-4.90 (m, 1H), 4.74 (s, 2H), 4.49 (br d, J = 13.6 Hz, 1H), 4.13 (br d, J = 13.6 Hz, 1H), 3.57-3.25 (m, 2H), 3.10 (br t, J = 11.6 Hz, 1H), 2.35-2.17 (m, 2H), 2.12-1.87 (m, 2H), 1.64 (d, J = 5.6 Hz, J = 6H); LCMS (ESI) [M+H]⁺: 446.2.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (s, 1H), 8.04 (s, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 4.26-4.08 (m, 5H), 3.27-3.16 (m, 1H), 3.03 (br t, J = 11.6 Hz, 2H), 2.16 (br d, J = 10.0 Hz, 2H), 2.03-1.87 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 384.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.34 (s, 1H), 7.98 (s, 1H), 7.92-7.84 (m, 1H), 7.83-7.75 (m, 1H), 4.24-4.07 (m, 2H), 3.72-3.62 (m, 1H), 3.27-3.15 (m, 1H), 3.09-2.93 (m, 2H), 2.16 (br d, J = 11.0 Hz, 2H),
5 2.01-1.87 (m, 2H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 410.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.05 (s, 1H), 7.82 (q, J = 8.5 Hz, 2H), 4.96 (spt, J =
10 6.7 Hz, 1H), 4.16 (q, J = 7.2 Hz, 4H), 3.22 (tt, J = 3.9, 10.8 Hz, 1H), 3.07 (br t, J = 11.7 Hz, 2H), 2.22-2.11 (m, 2H), 2.02-1.89 (m, 2H), 1.62 (d, J = 6.6 Hz, 6H), 1.28 (t, J = 7.2 Hz, 3H); LCMS (ESI) [M+H]⁺: 384.2.



¹H NMR (400 MHz, DMSO-d₆) δ 8.17 (s, 1H), 8.12 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.67 (dd, J = 1.0, 8.5
15 Hz, 1H), 7.53-7.41 (m, 4H), 5.06 (quin, J = 6.5 Hz, 1H), 3.78-3.62 (m, 8H), 1.53 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 417.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.09 (s, 1H), 7.91-7.81 (m, 2H), 7.47-7.39 (m, 4H),
20 5.07-4.92 (m, 1H), 4.65 (br s, 1H), 3.89 (br s, 1H), 3.44-3.15 (m, 3H), 2.40-1.94 (m, 4H), 1.65 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 450.2.




25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 8.04 (s, 1H), 7.77 (s, 2H), 7.47-7.30 (m, 4H), 5.01-4.86 (m, 1H), 4.16-4.07 (m, 1H), 3.95-3.64 (m, 5H), 3.52-3.31 (m, 2H), 1.61 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 451.0.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 7.89-7.81 (d, J = 8.4 Hz, 1H), 7.78-7.69 (d, J = 8.4 Hz, 1H), 4.48-4.33 (m, 4H), 4.15-4.02 (m, 4H), 2.61 (s, 3H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 370.1.



10


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.19 (s, 1H), 8.05 (s, 1H), 7.87 (d, J = 7.2 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 4.52 (q, J = 7.2 Hz, 2H), 4.30-4.12 (m, 2H), 3.24-3.18 (m, 1H), 3.01 (t, J = 5.6 Hz, 2H), 2.18-2.14 (m, 2H), 1.98-1.92 (m, 2H), 1.57 (t, J = 7.2 Hz, 3H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 398.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.17 (s, 1H), 8.04 (s, 1H), 7.92-7.85 (d, J = 8.4 Hz, 1H), 7.84-7.78 (d, J = 8.4 Hz, 1H), 5.36-5.26 (m, 1H), 4.36-4.06 (m, 5H), 4.00-3.82 (m, 4H), 3.29-3.18 (m, 1H), 3.16-3.00 (m, 2H), 2.30-2.17 (m, 3H), 2.11-1.88 (m, 3H); LCMS (ESI) [M+H]⁺: 398.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.86-7.80 (d, J = 8.4 Hz, 1H), 7.78-7.72 (d, J = 8.4 Hz, 1H), 4.08 (s, 3H), 3.98-3.46 (m, 5H), 2.60 (s, 3H), 2.50-2.35 (m, 2H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 384.2.


25




¹H NMR (400 MHz, DMSO-d₆) δ 8.23 (s, 1H), 8.11 (s, 1H), 7.90 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.39 (s, 0.2H), 7.25-7.22 (d, J = 8.4 Hz, 2H), 7.22-7.20 (s, 0.6H), 7.03 (s, 0.2H), 4.14-3.93 (m, 5H), 3.54-3.43 (m, 1H), 3.23 (br t, J = 11.2 Hz, 2H), 2.17 (br dd, J = 2.5, 13.1 Hz, 2H), 1.93-1.82 (m, 2H); LCMS (ESI) [M+H]⁺: 454.2.




10 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.50 (s, 1H), 7.97 (s, 1H), 7.79-7.71 (m, 2H), 4.51 (q, J = 7.6 Hz, 2H), 4.13 (br d, J = 8.8 Hz, 2H), 3.19 (tt, J = 4.0, 10.8 Hz, 1H), 3.01 (br t, J = 11.6 Hz, 2H), 2.14 (br dd, J = 2.8, 13.2 Hz, 2H), 2.00-1.86 (m, 2H), 1.66 (t, J = 7.6 Hz, 3H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 342.2, LCMS (ESI) [M+23]⁺: 420.2.




15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.85-7.80 (d, J = 8.4 Hz, 1H), 7.76-7.71 (d, J = 8.4 Hz, 1H), 4.51 (br d, J = 13.0 Hz, 1H), 4.19 (d, J = 6.8 Hz, 2H), 4.08 (s, 4H), 3.64-3.56 (m, 2H), 3.37-3.25 (m, 2H), 3.03 (br t, J = 11.5 Hz, 1H), 2.60 (s, 3H), 2.24 (br d, J = 12.3 Hz, 2H), 2.07-1.91 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 384.2.




25 ¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (s, 1H), 7.85-7.81 (d, J = 8.4 Hz, 1H), 7.77-7.72 (d, J = 8.4 Hz, 1H), 4.55 (br d, J = 13.5 Hz, 1H), 4.09 (s, 3H), 3.91 (br d, J = 14.3 Hz, 1H), 3.46-3.25 (m, 4H), 3.20-3.07 (m, 1H), 2.61 (s, 3H), 2.33-2.21 (m, 2H), 2.11-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 408.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 2H), 8.10 (s, 1H), 7.83 (dd, J = 1.1, 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 4.76 (td, J = 3.5, 13.5 Hz, 2H), 4.07 (s, 3H), 3.32 (tt, J = 4.0, 11.0 Hz, 1H), 3.25-3.15 (m, 2H), 2.59 (s, 3H), 2.49 (q, J = 7.5 Hz, 2H), 2.25 (br dd, J = 3.0, 13.6 Hz, 2H), 2.07-1.95 (m, 2H), 1.21 (t, J = 7.6 Hz, 3H); LCMS (ESI) [M+H]⁺: 404.2.




¹H NMR (400 MHz, DMSO-d₆) δ 8.18 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 1.3 Hz, 1H), 6.59 (d, J = 1.3 Hz, 1H), 4.04 (s, 3H), 3.45 (s, 3H), 3.38-3.32 (m, 1H), 3.27-3.24 (m, 2H), 2.92 (br t, J = 10.7 Hz, 2H), 2.21-2.12 (m, 2H), 2.08-1.96 (m, 2H); LCMS (ESI) [M+H]⁺: 378.3.




¹H NMR (400 MHz, DMSO-d₆) δ 8.18 (s, 1H), 7.88-7.86 (d, J = 8 Hz, 1H), 4.71-4.73 (d, J = 8 Hz, 1H), 4.05 (s, 3H), 3.95-9.32 (m, 2H), 3.49-3.53 (m, 1H), 3.32-3.48 (m, 1H), 2.25-2.22 (m, 2H), 1.99-1.96 (m, 2H); LCMS (ESI) [M+H]⁺: 380.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.05 (s, 1H), 7.82 (q, J = 8.5 Hz, 2H), 5.05-4.90 (m, 1H), 4.62 (br d, J = 13.7 Hz, 1H), 4.03 (br d, J = 13.2 Hz, 1H), 3.36-3.22 (m, 2H), 2.95 (br t, J = 11.1 Hz, 1H), 2.31 (s, 2H), 2.21 (br d, J = 10.8 Hz, 2H), 2.07-1.86 (m, 2H), 1.62 (d, J = 6.6 Hz, 6H), 1.08 (s, 9H); LCMS (ESI) [M+H]⁺: 410.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.06 (s, 1H), 7.98 (s, 1H), 7.70 (s, 2H), 4.88 (spt, J = 6.6 Hz, 1H), 3.75 (br d, J = 4.8 Hz, 2H), 3.67 (br d, J = 4.9 Hz, 4H), 3.62 (br d, J = 5.3 Hz, 2H), 2.26 (s, 2H), 1.55 (d, J = 6.7 Hz, 6H), 1.02 (s, 9H); LCMS (ESI) [M+H]⁺: 411.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 7.87-7.81 (d, J = 8.4 Hz, 1H), 7.78-7.72 (d, J = 8.4 Hz, 1H), 4.65-4.40 (m, 4H), 4.17-4.11 (m, 1H), 4.09 (s, 3H), 2.61 (s, 3H), 2.06 (s, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 368.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.19 (s, 1H), 8.07 (s, 1H), 7.83 (q, J = 8.4 Hz, 2H), 4.72-4.62 (m, 1H), 4.16 (br s, 2H), 3.25-3.16 (m, 1H), 3.01 (br t, J = 11.7 Hz, 2H), 2.20-2.08 (m, 3H), 2.00-1.87 (m, 3H), 1.60 (d, J = 6.6 Hz, 3H), 1.48 (s, 9H), 0.80 (t, J = 7.4 Hz, 3H); LCMS (ESI) [M+H]⁺: 426.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.53 (s, 1H), 7.96 (s, 1H), 7.77-7.70 (m, 2H), 4.54 (qd, J = 6.9, 14.0 Hz, 1H), 4.10 (br s, 2H), 3.22-3.13 (m, 1H), 3.02 (br t, J = 11.4 Hz, 2H), 2.17-2.04 (m, 3H), 2.00-1.85 (m, 3H), 1.66 (d, J = 6.8 Hz, 3H), 1.48 (s, 9H), 0.84 (t, J = 7.4 Hz, 3H); LCMS (ESI) [M+H]⁺: 426.2, LCMS (ESI) [M-55]⁺: 370.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 8.15 (s, 1H), 8.04 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.66 (s, 0.2H), 7.51 (s, 0.5H), 7.36 (s, 0.3H), 4.15 (br s, 2H), 3.26-3.16 (m, 1H), 3.01 (br t, J = 12.8 Hz, 2H), 2.15 (br d, J = 10.4 Hz, 2H), 1.99-1.87 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 420.2, LCMS (ESI) [M+23]⁺: 442.1, LCMS (ESI) [M-100+23]⁺: 342.0.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08 (s, 1H), 7.82-7.80 (d, J = 8.4 Hz, 1H), 7.76-7.69 (d, J = 8.4 Hz, 1H), 4.57-4.37 (m, 1H), 4.07 (s, 3H), 3.65-3.47 (m, 1H), 3.04-2.87 (m, 1H), 2.59 (s, 3H), 2.36-2.14 (m, 4H), 1.82 (dq, J = 2.9, 12.9 Hz, 2H), 1.46 (s, 9H), 1.29 (dq, J = 3.0, 12.5 Hz, 2H); LCMS (ESI) [M+H]⁺: 412.2.




10 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.53 (s, 1H), 8.39 (s, 1H), 7.87-7.78 (m, 2H), 7.65 (s, 0.2H), 7.49 (s, 0.5H), 7.34 (s, 0.3H), 4.13 (br s, 2H), 3.24-3.15 (m, 1H), 3.07-2.96 (m, 2H), 2.15 (br d, J = 10.8 Hz, 2H), 1.98-1.86 (m, 2H), 1.48 (s, 9H); LCMS (ESI) [M+23]⁺: 442.1, LCMS (ESI) [M-100]⁺: 320.0, LCMS (ESI) [M-55]⁺: 364.0.




15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.42 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.04 (s, 1H), 7.80 (d, J = 8.4 Hz, 1H), 4.99 (td, J = 6.7, 13.3 Hz, 1H), 4.35-4.14 (m, 2H), 3.43-3.29 (m, 1H), 2.97 (br t, J = 12.0 Hz, 2H), 2.22 (br d, J = 11.7 Hz, 2H), 1.85 (m, 2H), 1.63 (d, J = 6.6 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 428.2.




25 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.85-7.79 (m, 1H), 7.77-7.70 (m, 1H), 4.08 (d, J = 1.8 Hz, 3H), 4.06-3.92 (m, 2H), 3.88-3.73 (m, 2H), 3.71-3.62 (m, 1H), 2.60 (s, 3H), 2.56-2.35 (m, 2H), 2.30-2.20 (m, 2H), 1.10 (d, J = 1.8 Hz, 9H); LCMS (ESI) [M+H]⁺: 382.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12-8.08 (m, 1H), 7.83 (dd, J = 1.1, 8.6 Hz, 1H), 7.76-7.72 (m, 1H), 4.09 (s, 3H), 3.99-3.49 (m, 5H), 2.60 (s, 3H), 2.50-2.34 (m, 2H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 384.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.87-7.81 (m, 1H), 7.74 (d, J = 8.3 Hz, 1H), 4.64-4.62 (m, 1H), 4.09 (s, 3H), 3.77-3.74 (m, 1H), 3.23-3.20 (m, 1H), 2.61 (s, 3H), 2.15 (br s, 2H), 2.01 (dt, J = 4.2, 8.9 Hz, 2H), 1.85 (br d, J = 4.4 Hz, 2H), 1.73 (br s, 2H), 1.46 (s, 9H); LCMS (ESI) [M+H]⁺: 412.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.16 (s, 1H), 7.85-7.74 (m, 2H), 4.04 (s, 3H), 3.27-3.06 (m, 2H), 2.56 (s, 3H), 2.44-2.30 (m, 2H), 2.21 (br d, J = 10.6 Hz, 2H), 1.83 (m, 2H), 1.70-1.51 (m, 2H); LCMS (ESI) [M+H]⁺: 312.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.94-7.78 (m, 2H), 4.97 (td, J = 6.7, 13.3 Hz, 1H), 4.59 (br d, J = 13.7 Hz, 1H), 3.95 (br d, J = 13.9 Hz, 1H), 3.39-3.21 (m, 2H), 3.00 (br t, J = 11.4 Hz, 1H), 2.34 (d, J = 6.8 Hz, 2H), 2.28-2.13 (m, 2H), 2.07-1.88 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.14-1.00 (m, 1H), 0.67-0.52 (m, 2H), 0.21 (q, J = 4.9 Hz, 2H); LCMS (ESI) [M+H]⁺: 394.3.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.24 (s, 1H), 7.86 (s, 2H), 4.08 (s, 3H), 3.47 (br t, J = 4.3 Hz, 1H), 3.36-3.32 (m, 1H), 2.60 (s, 3H), 2.49-2.39 (m, 2H), 2.12-1.98 (m, 4H), 1.84-1.68 (m, 2H); LCMS (ESI) [M+H]⁺: 312.2.




5

¹H NMR (400 MHz, METHANOL-d₄) δ 8.40 (br s, 1H), 8.22 (s, 1H), 7.83 (s, 2H), 4.63-4.45 (m, 5H), 4.05 (s, 3H), 2.57 (s, 3H); LCMS (ESI) [M+H]⁺: 270.1.



10


¹H NMR (400 MHz, METHANOL-d₄) δ 8.25 (s, 1H), 7.87 (s, 2H), 4.15 (quin, J = 7.2 Hz, 1H), 4.09 (s, 3H), 3.91-3.80 (m, 2H), 3.63-3.50 (m, 2H), 2.72-2.62 (m, 1H), 2.61 (s, 3H), 2.50 (qd, J = 6.9, 13.8 Hz, 1H); LCMS (ESI) [M+H]⁺: 284.2.



15


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.06 (s, 1H), 7.87-7.79 (m, 2H), 4.96 (quind, J = 6.7, 13.3 Hz, 1H), 4.52 (dq, J = 2.0, 8.5 Hz, 2H), 4.19 (br t, J = 17.3 Hz, 2H), 3.33-3.08 (m, 3H), 2.21 (br d, J = 11.5 Hz, 2H), 2.07-1.92 (m, 2H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 438.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.05 (s, 1H), 7.90-7.75 (m, 2H), 4.95 (spt, J = 6.6 Hz, 1H), 4.18 (br s, 2H), 3.72 (s, 3H), 3.22 (tt, J = 3.9, 10.7 Hz, 1H), 3.08 (br t, J = 11.7 Hz, 2H), 2.16 (br d, J = 11.0 Hz, 2H), 2.03-1.86 (m, 2H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 370.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.08 (s, 1H), 7.91-7.79 (m, 2H), 4.99 (td, J = 6.7, 13.3 Hz, 1H), 4.62 (br t, J = 12.5 Hz, 2H), 4.31-4.08 (m, 2H), 3.36-3.09 (m, 4H), 2.23 (br s, 2H), 2.02 (br s, 2H), 1.65 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 488.0.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.08 (s, 1H), 7.91-7.80 (m, 2H), 5.81 (spt, J = 6.1 Hz, 1H), 4.99 (spt, J = 6.6 Hz, 1H), 4.34-4.07 (m, 2H), 3.42-3.14 (m, 3H), 2.26 (br d, J = 3.5 Hz, 2H), 2.13-1.94 (m, 2H), 1.65 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 506.0.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.72 (d, J = 6.0 Hz, 2H), 8.20 (s, 1H), 8.06 (s, 1H), 7.91-7.77 (m, 2H), 7.32 (d, J = 6.0 Hz, 2H), 4.96 (spt, J = 6.6 Hz, 1H), 4.64 (br d, J = 11.2 Hz, 1H), 3.76 (br d, J = 11.9 Hz, 1H), 3.44-3.32 (m, 1H), 3.26 (br d, J = 10.8 Hz, 2H), 2.32 (br s, 1H), 2.23-1.88 (m, 3H), 1.63 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 417.1.




¹H NMR (400 MHz, DMSO-d₆) δ 8.27 (s, 1H), 8.15 (s, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 5.11 (spt, J = 6.7 Hz, 1H), 4.14-4.00 (m, 1H), 3.94 (br d, J = 13.5 Hz, 2H), 3.49-3.36 (m, 1H), 3.49-3.36 (m, 1H), 3.13-3.08 (m, 2H), 2.13 (br dd, J = 3.3, 13.2 Hz, 2H), 1.86-1.70 (m, 2H), 1.53 (d, J = 6.4 Hz, 6H), 0.72-0.60 (m, 4H); LCMS (ESI) [M+H]⁺: 396.2.




¹H NMR (400 MHz, DMSO-d₆) δ 8.68-8.63 (m, 2H), 8.28 (s, 1H), 8.16 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.48 (dd, J = 4.9, 7.7 Hz, 1H), 5.11 (spt, J = 6.6 Hz, 1H), 4.06 (br s, 2H), 3.59-3.46 (m, 1H), 3.29 (br t, J = 11.2 Hz, 2H), 2.25-2.15 (m, 2H), 1.98-1.83 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 417.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.60 (br d, J = 4.4 Hz, 1H), 8.21 (s, 1H), 8.05 (s, 1H), 7.88-7.78 (m, 3H), 7.67 (br d, J = 7.7 Hz, 1H), 7.40-7.33 (m, 1H), 4.96 (td, J = 6.6, 13.2 Hz, 1H), 4.68 (br d, J = 13.2 Hz, 1H), 4.11 (br d, J = 13.2 Hz, 1H), 3.36 (br t, J = 10.5 Hz, 2H), 3.24 (br t, J = 11.5 Hz, 1H), 2.32 (br d, J = 11.7 Hz, 1H), 2.24-2.01 (m, 3H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 417.1.




¹H NMR (400 MHz, DMSO-d₆) δ 8.26 (s, 1H), 8.13 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.32 (q, J = 8.2 Hz, 4H), 5.09 (spt, J = 6.5 Hz, 1H), 4.06 (br s, 2H), 3.58-3.42 (m, 1H), 3.27-3.11 (m, 2H), 2.94 (spt, J = 6.8 Hz, 1H), 2.16 (br dd, J = 2.9, 13.0 Hz, 2H), 1.93-1.77 (m, 2H), 1.52 (d, J = 6.6 Hz, 6H), 1.23 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 458.3.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.09-8.06 (m, 1H), 7.90-7.76 (m, 2H), 5.52 (br s, 1H), 4.96 (dq, J = 4.2, 6.5 Hz, 1H), 4.49 (br d, J = 13.2 Hz, 1H), 4.01 (br s, 2H), 3.82 (br d, J = 13.5 Hz,


1H), 3.39-3.22 (m, 2H), 3.08 (br t, J = 12.0 Hz, 1H), 2.21 (br s, 2H), 2.06-1.89 (m, 2H), 1.63 (dd, J = 2.6, 6.6 Hz, 6H), 1.46 (d, J = 2.0 Hz, 9H); LCMS (ESI) [M+H]⁺: 349.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.49 (d, J = 1.7 Hz, 1H), 8.20 (s, 1H), 8.05 (s, 1H), 7.91-7.82 (m, 2H), 7.70-7.62 (m, 2H), 4.71 (br d, J = 13.4 Hz, 1H), 4.18 (s, 4H), 3.45-3.33 (m, 2H), 3.25 (br t, J = 11.1 Hz, 1H), 3.02 (spt, J = 6.9 Hz, 1H), 2.34 (br d, J = 10.9 Hz, 1H), 2.23-2.11 (m, 3H), 1.33 (d, J = 7.0 Hz, 6H); LCMS (ESI) [M+H]⁺: 431.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.06 (s, 1H), 7.89-7.81 (m, 2H), 4.35 (d, J = 6.8 Hz, 2H), 4.25-4.11 (m, 2H), 3.25-3.18 (m, 1H), 3.09-2.97 (m, 2H), 2.21-2.12 (m, 2H), 2.01-1.89 (m, 2H), 1.50 (s, 9H), 1.41 (br d, J = 4.9 Hz, 1H), 0.65-0.59 (m, 2H), 0.49-0.44 (m, 2H); LCMS (ESI) [M+H]⁺: 424.1.

15




20 ¹H NMR (400 MHz, DMSO-d₆) δ 8.30 (s, 1H), 8.19 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 1.1, 8.4 Hz, 1H), 5.14 (quin, J = 6.6 Hz, 1H), 3.93 (br d, J = 7.3 Hz, 1H), 3.78 (br d, J = 8.2 Hz, 1H), 3.68-3.60 (m, 1H), 3.52-3.44 (m, 1H), 3.40 (br d, J = 7.5 Hz, 1H), 2.40 (br s, 1H), 2.24 (br d, J = 6.8 Hz, 1H), 1.50 (d, J = 6.4 Hz, 6H), 1.42 (s, 9H); LCMS (ESI) [M+H]⁺: 398.2.

25



¹H NMR (400 MHz, DMSO-d₆) δ 9.05 (br s, 2H), 7.85 (d, J = 1.3 Hz, 1H), 7.80 (dd, J = 1.5, 8.4 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 4.58 (spt, J = 6.9 Hz, 1H), 3.52 (tt, J = 3.8, 10.9 Hz, 1H), 3.38-3.33 (m, 2H), 3.07


(br t, J = 11.2 Hz, 2H), 2.27 (br dd, J = 2.9, 14.1 Hz, 2H), 2.10-1.98 (m, 2H), 1.49 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 329.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08 (s, 1H), 7.85-7.79 (d, J = 8.4 Hz 1H), 7.75-7.68 (d, J = 8.4 Hz 1H), 7.42-7.29 (m, 5H), 5.11 (s, 2H), 4.68 (br d, J = 5.5 Hz, 1H), 4.07 (s, 3H), 3.73-3.55 (m, 1H), 3.05-2.90 (m, 1H), 2.59 (s, 3H), 2.36-2.16 (m, 4H), 1.94-1.75 (m, 2H), 1.43-1.24 (m, 2H); LCMS (ESI) [M+H]⁺: 446.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.52 (s, 2H), 8.10 (s, 1H), 7.86-7.81 (d, J = 8.4 Hz, 1H), 7.76-7.72 (d, J = 8.4 Hz, 1H), 4.85 (td, J = 3.7, 13.6 Hz, 2H), 4.08 (s, 3H), 3.45-3.25 (m, 3H), 2.60 (s, 3H), 2.29 (br dd, J = 3.3, 13.6 Hz, 2H), 2.11-1.94 (m, 2H); LCMS (ESI) [M+H]⁺: 444.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08 (s, 1H), 7.82-7.80 (d, J = 8.0 Hz, 1H), 7.73-7.70 (d, J = 8.0 Hz, 1H), 5.40-5.30 (m, 1H), 4.07 (s, 3H), 3.89 (m, 1H), 2.97 (tt, J = 3.5, 12.2 Hz, 1H), 2.59 (s, 3H), 2.34-2.15 (m, 4H), 1.99 (s, 3H), 1.86 (m, 2H), 1.39-1.20 (m, 2H); LCMS (ESI) [M+H]⁺: 354.2.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.78-7.70 (m, 1H), 5.50-5.47 (br s, 1H), 4.09 (s, 3H), 4.08-3.99 (m, 1H), 3.31-3.23 (m, 1H), 2.61 (s, 3H), 2.27-2.16 (m, 2H), 2.08-2.00 (m, 2H), 1.99 (s, 3H), 1.95-1.84 (m, 2H), 1.73-1.64 (m, 2H); LCMS (ESI) [M+H]⁺: 354.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.79-7.71 (m, 3H), 7.54-7.40 (m, 3H), 6.10 (br d, J = 7.1 Hz, 1H), 4.26 (tt, J = 4.1, 7.9 Hz, 1H), 4.09 (s, 3H), 3.32 (quin, J = 5.2 Hz, 1H), 2.61 (s, 3H), 2.35-2.23 (m, 2H), 2.15-1.98 (m, 4H), 1.86-1.73 (m, 2H); LCMS (ESI) [M+H]⁺: 416.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.07 (s, 1H), 7.85 (q, J = 8.4 Hz, 2H), 4.98 (quin, J = 6.7 Hz, 1H), 4.48-4.32 (m, 4H), 4.16-4.02 (m, 1H), 1.64 (d, J = 6.8 Hz, 6H), 1.50-1.45 (m, 9H); LCMS (ESI) [M+H]⁺: 384.2.




¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 8.14 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 4.41 (d, J = 6.8 Hz, 2H), 3.93 (br d, J = 13.5 Hz, 2H), 3.45-3.32 (m, 1H), 3.04-2.95 (m, 2H), 2.11 (br dd, J = 3.2, 13.8 Hz, 2H), 1.84-1.67 (m, 2H), 1.51 (s, 3H), 1.39-1.26 (m, 1H), 0.89-0.77 (m, 2H), 0.64-0.59 (m, 2H), 0.56-0.50 (m, 2H), 0.44-0.38 (m, 2H); LCMS (ESI) [M+H]⁺: 422.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.86-7.82 (m, 1H), 7.80-7.71 (m, 3H), 7.55-7.42 (m, 3H), 5.99 (br d, J = 7.8 Hz, 1H), 4.20-4.03 (m, 4H), 3.03 (tt, J = 3.2, 12.2 Hz, 1H), 2.60 (s, 3H), 2.41-2.28 (m, 4H), 2.03-1.84 (m, 2H), 1.52-1.36 (m, 2H); LCMS (ESI) [M+H]⁺: 416.3.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.86-7.81 (m, 1H), 7.77-7.70 (m, 1H), 4.08 (s, 3H), 3.96-3.49 (m, 5H), 2.60 (s, 3H), 2.51-2.32 (m, 2H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 384.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.83 (dd, J = 1.0, 8.4 Hz, 1H), 7.76-7.72 (d, J = 8.4 Hz, 1H), 4.61 (t, J = 12.7 Hz, 2H), 4.27-4.10 (m, 2H), 4.08 (s, 3H), 3.32-3.10 (m, 3H), 2.60 (s, 3H), 2.24-2.15 (m, 2H), 2.00 (br d, J = 4.9 Hz, 2H); LCMS (ESI) [M+H]⁺: 474.1.



10


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.86-7.81 (m, 1H), 7.77-7.71 (m, 1H), 5.79 (spt, J = 6.2 Hz, 1H), 4.25-4.15 (m, 2H), 4.09 (s, 3H), 3.37-3.20 (m, 3H), 2.61 (s, 3H), 2.32-2.21 (m, 2H), 2.12-1.97 (m, 2H); LCMS (ESI) [M+H]⁺: 492.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.27 (s, 1H), 8.07 (s, 1H), 7.92-7.86 (m, 1H), 7.85-7.80 (m, 1H), 5.01-4.91 (m, 1H), 4.80 (s, 2H), 3.60 (s, 3H), 1.63 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 273.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.29 (s, 1H), 8.06 (s, 1H), 7.93-7.86 (m, 1H), 7.83-7.77 (m, 1H), 4.96 (spt, J = 6.8 Hz, 1H), 4.83 (dd, J = 2.8, 10.7 Hz, 1H), 4.24 (br d, J = 11.7 Hz, 1H), 3.84-3.62 (m, 1H), 2.22-2.11 (m, 1H), 2.09-1.91 (m, 2H), 1.86-1.74 (m, 2H), 1.73-1.65 (m, 1H), 1.62 (dd, J = 1.1, 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 313.1.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.06 (s, 1H), 7.91-7.85 (m, 1H), 7.84-7.78 (m, 1H), 5.29 (dd, J = 5.4, 7.8 Hz, 1H), 4.97 (spt, J = 6.7 Hz, 1H), 4.27-4.14 (m, 1H), 4.11-3.99 (m, 1H), 2.55-2.42 (m, 1H), 2.40-2.31 (m, 1H), 2.28-2.04 (m, 2H), 1.63 (dd, J = 1.1, 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 299.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.16 (s, 1H), 8.02 (s, 1H), 7.88-7.79 (m, 2H), 4.80 (d, J = 7.0 Hz, 2H), 4.50 (d, J = 7.0 Hz, 2H), 4.21-4.08 (m, 5H), 3.29-3.20 (m, 1H), 3.21-3.09 (m, 2H), 2.18 (br d, J = 13.6 Hz, 2H), 2.02-1.92 (m, 2H), 1.75 (s, 3H); LCMS (ESI) [M+H]⁺: 398.1.




¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (d, J = 0.9 Hz, 1H), 8.17 (d, J = 0.9 Hz, 1H), 7.94 (dd, J = 0.6, 8.4 Hz, 1H), 7.77 (dd, J = 1.2, 8.4 Hz, 1H), 7.69-7.64 (m, 2H), 7.60-7.56 (m, 2H), 7.24-6.96 (t, J = 55.6 Hz, 1H), 4.55-4.45 (m, 1H), 4.15 (s, 3H), 3.67-3.48 (m, 2H), 3.29-3.08 (m, 2H), 2.33-2.00 (m, 2H), 1.91-1.75 (m, 2H); LCMS (ESI) [M+H]⁺: 438.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.16 (s, 1H), 8.02 (s, 1H), 7.87-7.78 (m, 2H), 4.31-3.96 (m, 5H), 3.26-3.16 (m, 1H), 3.03 (br t, J = 11.1 Hz, 2H), 2.15 (br d, J = 11.5 Hz, 2H), 1.92 (br d, J = 9.3 Hz, 2H), 1.56 (s, 3H), 0.91-0.84 (m, 2H), 0.67-0.55 (m, 2H); LCMS (ESI) [M+H]⁺: 382.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.76-7.69 (d, J = 8.4 Hz, 1H), 7.42-7.32 (m, 2H), 7.25-7.08 (m, 3H), 4.96 (br d, J = 7.6 Hz, 1H), 4.07 (s, 3H), 3.70 (br dd, J = 4.1, 7.4 Hz, 1H), 3.01 (br t, J = 12.2 Hz, 1H), 2.59 (s, 3H), 2.40-2.25 (m, 4H), 1.95-1.81 (m, 2H), 1.49-1.36 (m, 2H); LCMS (ESI) [M+H]⁺: 432.2.




10 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 8.15 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.66-7.36 (t, J = 59.2 Hz, 1H), 4.62 (br d, J = 13.6 Hz, 1H), 4.04 (br d, J = 13.9 Hz, 1H), 3.35-3.24 (m, 2H), 3.01-2.90 (m, 1H), 2.31 (s, 2H), 2.22 (br d, J = 12.7 Hz, 2H), 2.04-1.86 (m, 2H), 1.08 (s, 9H); LCMS (ESI) [M+H]⁺: 418.




15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 8.15 (s, 1H), 8.07-8.01 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.67-7.37 (t, J = 59.6 Hz, 1H), 7.45-7.40 (m, 1H), 7.36-7.27 (m, 3H), 4.78-4.63 (m, 1H), 3.64-3.53 (m, 1H), 3.40-3.13 (m, 3H), 2.34 (br dd, J = 3.3, 13.6 Hz, 1H), 2.20-1.85 (m, 3H); LCMS (ESI) [M+H]⁺: 458.0.




25 ¹H NMR (400 MHz, CHLOROFORM-d) δ 7.97 (br s, 1H), 7.82 (br d, J = 6.4 Hz, 1H), 7.66-7.50 (m, 2H), 4.78-4.64 (m, 1H), 3.87-3.34 (m, 5H), 2.35-2.09 (m, 2H), 2.06-1.93 (m, 2H), 1.45-1.31 (m, 6H), 0.95-0.75 (m, 9H); LCMS (ESI) [M+H]⁺: 396.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31-8.21 (m, 1H), 8.15-8.04 (m, 1H), 7.91-7.77 (m, 2H), 4.99 (quind, J = 6.6, 13.3 Hz, 1H), 4.69-4.39 (m, 4H), 4.14 (tt, J = 6.0, 8.9 Hz, 1H), 2.14-2.00 (m, 2H), 1.65 (d, J = 6.6 Hz, 6H), 1.15-1.03 (m, 9H); LCMS (ESI) [M+H]⁺: 382.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.80 (br s, 1H), 8.57 (s, 1H), 8.21 (s, 1H), 8.14 (br d, J = 8.4 Hz, 1H), 8.07 (s, 1H), 7.90-7.76 (m, 3H), 4.97 (td, J = 6.6, 13.1 Hz, 1H), 4.56 (br d, J = 13.0 Hz, 1H), 4.33 (br s, 2H), 3.94 (br d, J = 14.1 Hz, 1H), 3.44-3.26 (m, 2H), 3.15 (br t, J = 11.5 Hz, 1H), 2.28 (br t, J = 12.5 Hz, 2H), 2.14-1.94 (m, 2H), 1.63 (br d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 508.2.



¹H NMR (400 MHz, DMSO-d₆) δ 8.26 (s, 1H), 8.14 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.79-7.71 (m, 1H), 7.08 (d, J = 5.1 Hz, 1H), 5.09 (spt, J = 6.7 Hz, 1H), 4.03 (br d, J = 10.8 Hz, 2H), 3.56-3.45 (m, 1H), 3.36-3.22 (m, 2H), 2.21 (br dd, J = 3.1, 13.2 Hz, 2H), 1.96-1.78 (m, 2H), 1.52 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 456.1.




¹H NMR (400 MHz, DMSO-d₆) δ 8.30 (s, 1H), 8.20 (br s, 2H), 8.14-8.08 (m, 1H), 7.94 (br d, J = 8.3 Hz, 1H), 7.75 (br d, J = 8.3 Hz, 1H), 5.14 (td, J = 6.3, 12.8 Hz, 1H), 4.36 (br d, J = 12.8 Hz, 1H), 4.02-3.74 (m, 3H), 3.63-3.47 (m, 1H), 3.30-3.21 (m, 1H), 3.01 (br t, J = 11.7 Hz, 1H), 2.18 (br d, J = 12.1 Hz, 2H), 2.00-1.83 (m, 1H), 1.78-1.61 (m, 1H), 1.51 (br d, J = 6.4 Hz, 6H); LCMS (ESI) [M+H]⁺: 369.1.




¹H NMR (300 MHz, CHLOROFORM-d) δ 8.74 (s, 1H), 8.46 (s, 2H), 8.12 (s, 1H), 7.91-7.80 (m, 1H), 7.76 (d, J = 8.5 Hz, 1H), 4.10 (s, 3H), 3.83 (d, J = 12.8 Hz, 2H), 3.12 (t, J = 10.3 Hz, 2H), 2.61 (s, 3H), 2.37 (d, J = 12.7 Hz, 2H), 2.29-2.16 (m, 2H); LCMS (ESI) [M+H]⁺: 376.1.

5




¹H NMR (300 MHz, CHLOROFORM-d) δ 8.21 (d, J = 14.0 Hz, 2H), 7.96-7.82 (m, 2H), 5.91 (t, J = 7.1 Hz, 1H), 5.35 (t, J = 6.5 Hz, 2H), 5.17 (t, J = 7.2 Hz, 2H), 4.16 (s, 2H), 3.02 (t, J = 12.0 Hz, 2H), 2.17 (d, J = 13.4 Hz, 2H), 2.07-1.77 (m, 2H), 1.50 (s, 8H); LCMS (ESI) [M+H]⁺: 426.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.16 (s, 1H), 7.86 (dd, J = 1.3, 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 4.80 (s, 2H), 4.08 (s, 3H), 3.60 (s, 3H), 2.60 (s, 3H); LCMS (ESI) [M+H]⁺: 259.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (s, 1H), 7.87 (dd, J = 1.1, 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 4.83 (dd, J = 2.6, 10.5 Hz, 1H), 4.24 (br d, J = 11.8 Hz, 1H), 4.07 (s, 3H), 3.75-3.67 (m, 1H), 2.60 (s, 3H), 2.16 (br d, J = 15.8 Hz, 1H), 2.08-1.91 (m, 2H), 1.84-1.64 (m, 3H); LCMS (ESI) [M+H]⁺: 299.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 7.85 (dd, J = 1.3, 8.3 Hz, 1H), 7.76-7.70 (m, 1H), 5.29 (dd, J = 5.3, 7.9 Hz, 1H), 4.24-4.15 (m, 1H), 4.08 (s, 3H), 4.07-4.02 (m, 1H), 2.60 (s, 3H), 2.54-2.43 (m, 1H), 2.41-2.32 (m, 1H), 2.26-2.06 (m, 2H); LCMS (ESI) [M+H]⁺: 285.1.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.40 (s, 1H), 8.30 (dd, J = 1.5, 8.8 Hz, 1H), 7.69-7.61 (m, 1H), 4.20-4.05 (m, 2H), 3.20 (tt, J = 3.9, 10.9 Hz, 1H), 3.02 (br t, J = 11.3 Hz, 2H), 2.66 (s, 3H), 2.15 (br d, J = 10.8 Hz, 2H), 1.98-1.88 (m, 2H), 1.49 (s, 9H); LCMS (ESI) $[M+H]^+$: 385.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.86-7.78 (m, 1H), 7.71 (s, 1H), 7.44-7.28 (m, 3H), 7.25-7.19 (m, 2H), 4.70-4.57 (m, 1H), 4.52 (td, J = 7.0, 13.9 Hz, 1H), 3.51 (br t, J = 13.9 Hz, 1H), 3.28-3.19 (m, 2H), 3.16-3.05 (m, 1H), 2.25 (br d, J = 13.4 Hz, 1H), 2.08-1.99 (m, 2H), 1.90-1.74 (m, 1H), 1.53 (d, J = 6.8 Hz, 6H); LCMS (ESI) $[M+H]^+$: 467.0.



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.88 (d, J = 8.4 Hz, 1H), 7.78 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 4.59 (spt, J = 6.9 Hz, 1H), 4.32-3.96 (m, 2H), 3.25-3.13 (m, 1H), 3.05-3.00 (m, 2H), 2.18-2.10 (m, 2H), 1.95-1.89 (m, 2H), 1.64-1.56 (m, 9H), 0.92-0.86 (m, 2H), 0.69-0.61 (m, 2H); LCMS (ESI) $[M+H]^+$: 427.1.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.32 (s, 1H), 8.10 (s, 1H), 7.96-7.78 (m, 2H), 4.39 (d, J = 6.8 Hz, 2H), 3.60-3.50 (m, 3H), 3.29-3.21 (m, 2H), 2.47 (br dd, J = 3.3, 14.5 Hz, 2H), 2.29-2.10 (m, 2H), 1.44-1.28 (m, 1H), 0.64-0.53 (m, 2H), 0.46 (m, 2H); LCMS (ESI) $[M+H]^+$: 324.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.06 (s, 1H), 7.92-7.78 (m, 2H), 4.61 (br d, J = 14.1 Hz, 1H), 4.36 (d, J = 6.8 Hz, 2H), 3.98 (br d, J = 13.4 Hz, 1H), 3.37-3.22 (m, 2H), 3.05-2.90 (m, 1H), 2.40 (d, J = 4.0 Hz, 2H), 2.23 (br d, J = 13.3 Hz, 2H), 2.06-1.86 (m, 2H), 1.40 (br d, J = 7.2 Hz, 1H), 1.18 (s, 3H), 0.67-0.55 (m, 2H), 0.49-0.40 (m, 6H); LCMS (ESI) [M+H]⁺: 420.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.85 (dd, J = 1.2, 8.4 Hz, 1H), 7.75 (s, 1H), 7.36-7.30 (m, 2H), 7.24 (m, 3H), 4.60-4.50 (m, 2H), 3.98-3.94 (m, 1H), 3.33-3.08 (m, 3H), 2.91 (td, J = 6.9, 13.8 Hz, 1H), 2.30-1.90 (m, 4H), 1.56 (d, J = 7.0 Hz, 6H), 1.23 (d, J = 7.0 Hz, 6H); LCMS (ESI) [M+H]⁺: 475.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.81 (dd, J = 1.1, 8.3 Hz, 1H), 7.71 (s, 1H), 7.22 (d, J = 8.3 Hz, 1H), 4.59-4.48 (m, 2H), 3.96 (br d, J = 13.8 Hz, 1H), 3.28-3.15 (m, 2H), 2.87 (br t, J = 11.2 Hz, 1H), 2.24 (d, J = 1.7 Hz, 2H), 2.12 (br d, J = 13.2 Hz, 2H), 1.94-1.79 (m, 2H), 1.52 (d, J = 7.0 Hz, 6H), 1.00 (s, 9H); LCMS (ESI) [M+H]⁺: 427.1.

15



20


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.06 (s, 1H), 7.87-7.80 (m, 2H), 4.96 (spt, J = 6.7 Hz, 1H), 4.57 (br d, J = 13.6 Hz, 1H), 3.93 (br d, J = 14.5 Hz, 1H), 3.66-3.51 (m, 1H), 3.30-3.22 (m, 1H), 2.43-2.21 (m, 6H), 1.62 (d, J = 7.0 Hz, 6H), 1.08 (s, 9H); LCMS (ESI) [M+H]⁺: 428.2.




25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.08 (s, 1H), 7.90-7.82 (m, 2H), 5.02-4.95 (m, 1H), 4.08-4.00 (m, 2H), 3.40 (br d, J = 9.8 Hz, 2H), 2.40-2.24 (m, 4H), 1.65 (d, J = 6.7 Hz, 6H), 1.51 (s, 9H); LCMS (ESI) [M+H]⁺: 430.2.


30




- 5 ^1H NMR (400 MHz, DMSO- d_6) δ 8.47 (s, 1H), 8.45 (s, 1H), 8.36-8.07 (t, J = 58.8, 1H), 8.09-8.05 (m, 1H), 7.99-7.95 (m, 1H), 7.36-7.28 (m, 4H), 4.05 (br d, J = 4.6 Hz, 2H), 3.54-3.41 (m, 1H), 3.26-3.17 (m, 2H), 2.98-2.88 (m, 1H), 2.17 (br dd, J = 3.2, 13.3 Hz, 2H), 1.91-1.80 (m, 2H), 1.23 (d, J = 6.8 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 466.0.



- 10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.16 (s, 1H), 8.05 (s, 1H), 7.84-7.77 (m, 2H), 4.94 (m, 1H), 3.92-3.72 (m, 2H), 3.61-3.48 (m, 2H), 2.40 (m, 2H), 2.17 (t, J = 3.1 Hz, 1H), 1.62 (d, J = 7.0 Hz, 6H), 1.47 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 410.2.




- 15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.44 (s, 1H), 8.12 (d, J = 8.4 Hz, 1H), 8.04 (s, 1H), 7.80 (d, J = 8.4 Hz, 1H), 6.89 (br s, 1H), 4.99 (td, J = 6.7, 13.3 Hz, 1H), 4.21 (m, 2H), 3.71 (br t, J = 5.5 Hz, 2H), 2.77 (br s, J = 1.6 Hz, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.51 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 426.2.



- 20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.27 (s, 1H), 8.08 (s, 1H), 7.86 (m, 2H), 4.97 (td, J = 6.6, 13.2 Hz, 1H), 4.20-4.12 (m, 2H), 3.12-2.87 (m, 3H), 2.08 (br d, J = 11.2 Hz, 2H), 1.95-1.79 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.48 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 412.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.36 (s, 1H), 8.13 (s, 1H), 7.97-7.82 (m, 2H), 5.08 (td, J = 6.6, 13.2 Hz, 1H), 4.25-4.12 (m, 1H), 3.92-3.80 (m, 2H), 3.70-3.49 (m, 2H), 2.79-2.64 (m, 1H), 2.52 (qd, J = 6.9, 13.6 Hz, 1H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 298.1.



5


¹H NMR (400 MHz, DMSO-d₆) δ 9.33 (br s, 2H), 8.34 (s, 1H), 8.21 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 5.14 (td, J = 6.6, 13.0 Hz, 1H), 4.64-4.45 (m, 1H), 4.41-4.28 (m, 4H), 1.51 (d, J = 6.5 Hz, 6H); LCMS (ESI) [M+H]⁺: 284.1.

10




¹H NMR (400 MHz, DMSO-d₆) δ 9.04 (br s, 2H), 8.56 (s, 1H), 8.50-8.21 (t, J = 58 Hz, 1H), 8.47 (s, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 3.60-3.51 (m, 1H), 3.36 (br d, J = 12.8 Hz, 2H), 3.09 (br t, J = 11.0 Hz, 2H), 2.30 (br d, J = 14.3 Hz, 2H), 2.14-2.01 (m, 2H); LCMS (ESI) [M+H]⁺: 320.1.

15




¹H NMR (400 MHz, DMSO-d₆) δ 9.31-8.98 (m, 2H), 8.36 (s, 1H), 7.94 (br d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 4.08 (s, 3H), 3.62-3.58 (m, 1H), 3.39-3.24 (m, 3H), 3.15-3.01 (m, 2H), 2.52 (s, 3H), 2.25-2.15 (m, 2H), 2.09-1.95 (m, 2H); LCMS (ESI) [M+H]⁺: 298.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 7.86-7.82 (m, 1H), 7.79-7.75 (m, 1H), 4.66 (br d, J = 13.8 Hz, 1H), 4.09 (s, 3H), 4.04 (br d, J = 15.0 Hz, 1H), 3.26 (br t, J = 11.7 Hz, 1H), 3.18-3.08 (m, 1H), 2.89 (br t, J = 11.8 Hz, 1H), 2.60 (s, 3H), 2.31 (s, 2H), 2.14 (br dd, J = 3.1, 13.6 Hz, 2H), 1.99-1.80 (m, 2H), 1.08 (s, 9H); LCMS (ESI) [M+H]⁺: 396.2.


25




¹H NMR (400 MHz, DMSO-d₆) δ 8.55 (s, 1H), 8.49-8.21 (t, J = 58 Hz, 1H), 8.48 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 7.99 (dd, J = 1.2, 8.4 Hz, 1H), 4.05-3.80 (m, 2H), 3.41 (tt, J = 3.9, 11.0 Hz, 1H), 3.02 (br t, J = 10.8 Hz, 2H), 2.16-2.07 (m, 2H), 1.79-1.66 (m, 2H), 1.49 (s, 3H), 0.83-0.78 (m, 2H), 0.67-0.57 (m, 2H); LCMS (ESI) [M+H]⁺: 418.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28 (s, 1H), 8.10 (s, 1H), 7.87 (m, 2H), 4.98 (td, J = 6.7, 13.3 Hz, 1H), 4.67 (br d, J = 13.5 Hz, 1H), 4.06-4.00 (m, 1H), 3.27 (br t, J = 11.6 Hz, 1H), 3.18-3.07 (m, 1H), 2.90 (br t, J = 11.4 Hz, 1H), 2.33 (d, J = 1.1 Hz, 2H), 2.16 (br dd, J = 3.1, 13.2 Hz, 2H), 2.02-1.78 (m, 2H), 1.65 (d, J = 6.8 Hz, 6H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 410.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 7.85 (dd, J = 1.2, 8.4 Hz, 1H), 7.78-7.72 (d, J = 8.4 Hz, 1H), 7.41-7.32 (m, 2H), 7.24-7.17 (m, 1H), 7.14 (d, J = 7.7 Hz, 2H), 5.11 (br d, J = 6.5 Hz, 1H), 4.09 (s, 3H), 3.95-3.83 (m, 1H), 3.31-3.21 (m, 1H), 2.61 (s, 3H), 2.29-2.18 (m, 2H), 2.11-1.92 (m, 4H), 1.89-1.78 (m, 2H); LCMS (ESI) [M+H]⁺: 432.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.27 (s, 1H), 7.98-7.83 (m, 2H), 4.42-4.25 (m, 1H), 4.11 (s, 3H), 3.99 (td, J = 8.6, 13.6 Hz, 1H), 3.88-3.74 (m, 1H), 3.69 (br d, J = 13.6 Hz, 1H), 3.46-3.35 (m, 1H), 2.72-2.56 (m, 5H); LCMS (ESI) [M+H]⁺: 334.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.84 (dd, J = 1.2, 8.4 Hz, 1H), 7.73 (dd, J = 0.6, 8.4 Hz, 1H), 7.42-7.30 (m, 5H), 5.11 (s, 2H), 4.86-4.82 (m, 1H), 4.08 (s, 3H), 3.86-3.82 (m, 1H), 3.27-3.18 (m, 1H), 2.60 (s, 3H), 2.22-2.10 (m, 2H), 2.07-1.97 (m, 2H), 1.91-1.87 (m, 2H), 1.81-1.69 (m, 2H); LCMS (ESI) [M+H]⁺: 446.2.




10 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (d, J = 0.7 Hz, 1H), 7.99 (s, 1H), 7.82-7.77 (m, 1H), 7.76-7.72 (m, 1H), 4.89 (spt, J = 6.7 Hz, 1H), 4.40-3.98 (m, 2H), 3.75-3.58 (m, 1H), 3.51-3.36 (m, 1H), 3.31-3.13 (m, 1H), 2.39-2.12 (m, 2H), 1.56 (d, J = 6.6 Hz, 6H), 1.48-1.32 (m, 9H); LCMS (ESI) [M+H]⁺: 448.2.




15 ¹H NMR (300 MHz, CHLOROFORM-d) δ 8.39 (s, 1H), 8.12 (s, 2H), 7.85 (dd, J = 8.4, 1.3 Hz, 1H), 7.75 (dd, J = 8.4, 0.9 Hz, 1H), 7.26-7.14 (m, 1H), 4.09 (s, 3H), 3.80 (d, J = 12.7 Hz, 2H), 3.25 (m, 1H), 3.07 (d, J = 14.2 Hz, 2H), 2.61 (s, 3H), 2.32 (s, 2H), 2.26-2.16 (m, 1H); LCMS (ESI) [M+H]⁺: 375.1.



20 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.88-7.80 (m, 2H), 4.98 (td, J = 6.6, 13.4 Hz, 1H), 4.65-4.50 (m, 1H), 3.80-3.70 (m, 1H), 3.21 (br d, J = 4.0 Hz, 1H), 2.16 (br d, J = 7.9 Hz, 2H), 2.05-1.97 (m, 2H), 1.85 (br d, J = 4.4 Hz, 2H), 1.75-1.70 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.46 (s, 9H); LCMS (ESI) [M+H]⁺: 426.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.04 (s, 1H), 7.79-7.76 (m, 1H), 7.73-7.70 (m, 1H), 4.08 (s, 3H), 3.76-3.70 (m, 4H), 3.65-3.59 (m, 4H), 2.61 (s, 3H), 1.52 (s, 9H); LCMS (ESI) [M+H]⁺: 399.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.20 (s, 1H), 8.06 (s, 1H), 7.88-7.78 (m, 2H), 5.50-5.35 (m, 1H), 4.96 (spt, J = 6.7 Hz, 1H), 4.04 (td, J = 3.9, 8.2 Hz, 1H), 3.30-3.22 (m, 1H), 2.25-2.16 (m, 2H), 2.03 (qd, J = 4.6, 9.2 Hz, 2H), 1.98 (s, 3H), 1.93-1.84 (m, 2H), 1.70-1.60 (m, 8H); LCMS (ESI) [M+H]⁺: 368.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (d, J = 8.4 Hz, 1H), 8.09 (s, 1H), 7.95 (d, J = 8.2 Hz, 1H), 5.52 (spt, J = 6.7 Hz, 1H), 4.20-4.10 (m, 2H), 3.26 (tt, J = 3.8, 11.1 Hz, 1H), 2.99 (br t, J = 12.0 Hz, 2H), 2.16 (br d, J = 10.4 Hz, 2H), 2.00-1.89 (m, 2H), 1.59 (d, J = 6.6 Hz, 6H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 413.2.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 2H), 8.10 (s, 1H), 7.83 (dd, J = 1.2, 8.4 Hz, 1H), 7.73 (dd, J = 0.6, 8.4 Hz, 1H), 4.74 (td, J = 3.5, 13.6 Hz, 2H), 4.07 (s, 3H), 3.32 (tt, J = 4.0, 11.0 Hz, 1H), 3.20 (ddd, J = 2.8, 11.3, 13.7 Hz, 2H), 2.60 (s, 3H), 2.24 (br dd, J = 3.2, 13.5 Hz, 2H), 2.07-1.92 (m, 2H), 1.73 (tt, J = 5.1, 8.5 Hz, 1H), 0.97-0.86 (m, 2H), 0.63-0.57 (m, 2H); LCMS (ESI) [M+H]⁺: 416.1.


20




25

¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (s, 1H), 8.19 (s, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.75 (dd, J = 1.0, 8.4 Hz, 1H), 5.14 (spt, J = 6.5 Hz, 1H), 3.93 (br d, J = 6.7 Hz, 1H), 3.78 (br d, J = 7.2 Hz, 1H), 3.68-3.61 (m, 1H), 3.51-3.44 (m, 1H), 3.40 (br d, J = 6.6 Hz, 1H), 2.46-2.33 (m, 1H), 2.24 (br d, J = 7.1 Hz, 1H), 1.50 (d, J = 6.6 Hz, 6H), 1.42 (s, 9H); LCMS (ESI) [M+H]⁺: 398.2.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.08 (s, 1H), 7.92-7.81 (m, 2H), 4.98 (quind, J = 6.7, 13.3 Hz, 1H), 4.83 (d, J = 7.1 Hz, 2H), 4.53 (d, J = 7.5 Hz, 2H), 4.17 (br s, 2H), 3.35-3.20 (m, 1H),
 5 3.13 (br s, 2H), 2.22 (br d, J = 11.1 Hz, 2H), 2.06-1.92 (m, 2H), 1.78 (s, 3H), 1.65 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 426.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.86-7.81 (m, 1H), 7.77-7.72 (m, 1H), 4.53 (dq, J = 2.2, 8.4 Hz, 2H), 4.20 (br t, J = 16.1 Hz, 2H), 4.08 (s, 3H), 3.32-3.23 (m, 1H), 3.22-3.10 (m, 2H), 2.60 (s, 3H), 2.22 (br d, J = 11.9 Hz, 2H), 2.07-1.94 (m, 2H); LCMS (ESI) [M+H]⁺: 424.1.




15 ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.84 (dd, J = 1.2, 8.4 Hz, 1H), 7.73 (dd, J = 0.7, 8.4 Hz, 1H), 4.08 (s, 3H), 3.60 (t, J = 5.9 Hz, 2H), 3.54 (q, J = 7.0 Hz, 2H), 3.10-2.99 (m, 3H), 2.65 (t, J = 6.0 Hz, 2H), 2.60 (s, 3H), 2.27 (dt, J = 2.3, 11.3 Hz, 2H), 2.21-2.03 (m, 4H), 1.23 (t, J = 7.0 Hz, 3H); LCMS (ESI) [M+H]⁺: 370.2.




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.89-7.78 (m, 2H), 4.97 (td, J = 6.6, 13.4 Hz, 1H), 4.02-3.43 (m, 5H), 2.52-2.32 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 398.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28 (s, 1H), 8.10 (s, 1H), 7.91-7.81 (m, 2H), 7.47-7.40 (m, 1H), 7.39-7.28 (m, 3H), 4.98 (td, J = 6.6, 13.5 Hz, 1H), 4.76 (br t, J = 12.5 Hz, 1H), 3.65-3.52 (m, 1H), 3.36-3.10 (m, 3H), 2.28 (br dd, J = 3.5, 13.6 Hz, 1H), 2.15-1.95 (m, 2.5H), 1.94-1.79 (m, 0.5H), 1.65 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 450.1.




¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.49 (s, 1H), 8.25 (s, 1H), 7.99 (d, J = 8.3 Hz, 1H), 7.80 (dd, J = 1.1, 8.6 Hz, 1H), 5.22 (spt, J = 6.4 Hz, 1H), 3.39-3.35 (m, 1H), 3.33-3.24 (m, 2H), 3.14-3.00 (m, 2H), 2.20 (br d, J = 11.8 Hz, 2H), 2.08-1.92 (m, 2H), 1.50 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 312.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.16 (s, 1H), 8.12 (s, 1H), 7.94-7.89 (m, 1H), 7.87-7.82 (m, 1H), 5.46 (q, J = 7.2 Hz, 1H), 4.20-4.05 (m, 2H), 3.72 (s, 3H), 3.21 (tt, J = 3.9, 10.8 Hz, 1H), 3.02 (br t, J = 11.9 Hz, 2H), 2.15 (br d, J = 10.5 Hz, 2H), 1.98 (d, J = 7.2 Hz, 3H), 1.97-1.87 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 456.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.04 (s, 1H), 7.77 (m, 2H), 4.95 (m, 1H), 3.99-3.87 (m, 2H), 3.74-3.56 (m, 4H), 3.47-3.24 (m, 2H), 3.07 (br s, 2H), 1.61 (d, J = 7.0 Hz, 6H), 1.47 (s, 9H) LCMS (ESI) [M+H]⁺: 439.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.22 (s, 1H), 8.09 (s, 1H), 7.84 (dd, J = 1.2, 8.4 Hz, 1H), 7.73 (dd, J = 0.7, 8.4 Hz, 1H), 5.03 (m, 1H), 3.93 (br dd, J = 7.4, 11.2 Hz, 2H), 3.75 (dd, J = 3.1, 11.2 Hz, 2H), 3.65 (br dd, J = 6.8, 11.6 Hz, 2H), 3.41-3.32 (m, 3H), 3.29 (m, 1H), 1.59 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 339.1.




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.92-7.84 (m, 3H), 7.79 (d, J = 1.1 Hz, 1H), 7.56-7.51 (m, 1H), 7.49-7.43 (m, 2H), 7.36-7.28 (m, 2H), 4.64-4.49 (m, 2H), 4.32 (t, J = 3.2 Hz, 2H), 3.93 (br d, J = 13.7 Hz, 1H), 3.40-3.30 (m, 2H), 3.14 (br t, J = 11.0 Hz, 1H), 2.33-2.21 (m, 2H), 2.09-1.94 (m, 2H), 1.60 (d, J = 6.8 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 490.2.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.29 (s, 1H), 8.04 (dd, J = 1.2, 8.3 Hz, 1H), 7.81 (dd, J = 0.6, 8.2 Hz, 1H), 4.20-4.05 (m, 2H), 3.46 (spt, J = 7.0 Hz, 1H), 3.21 (tt, J = 3.9, 10.9 Hz, 1H), 3.02 (br t, J = 11.6 Hz, 2H), 2.15 (br dd, J = 3.0, 13.3 Hz, 2H), 1.92 (dtd, J = 4.2, 11.1, 13.5 Hz, 2H), 1.53 (d, J = 7.0 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 413.2.



15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.28 (s, 1H), 8.05 (dd, J = 1.1, 8.2 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 4.20-4.05 (m, 2H), 3.20 (tt, J = 3.9, 10.9 Hz, 1H), 3.01 (br t, J = 11.9 Hz, 2H), 2.63 (s, 3H), 2.14 (br dd, J = 3.0, 13.3 Hz, 2H), 1.97-1.85 (m, 2H), 1.48 (s, 9H); LCMS (ESI) $[\text{M}-55]^+$: 329.1.




20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.20 (s, 1H), 8.08 (s, 1H), 7.91-7.87 (m, 1H), 7.86-7.81 (m, 1H), 4.95-4.83 (m, 1H), 4.27-4.02 (m, 4H), 3.21 (tt, J = 3.9, 10.9 Hz, 1H), 3.02 (br t, J = 11.6 Hz, 2H), 2.82-2.78 (m, 1H), 2.16 (br dd, J = 2.6, 13.3 Hz, 2H), 2.00-1.87 (m, 2H), 1.60 (d, J = 6.7 Hz, 3H), 1.49 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 428.2.




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.24 (s, 1H), 8.06 (s, 1H), 7.88-7.78 (m, 2H), 5.01-4.93 (m, 1H), 3.19-2.99 (m, 4H), 2.37-2.24 (m, 4H), 1.63 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 330.1.

5




^1H NMR (400 MHz, CHLOROFORM- d) δ 7.69 (s, 1H), 7.45-7.41 (m, 1H), 7.36-7.32 (m, 1H), 4.20 (br d, J = 13.5 Hz, 1H), 3.68 (s, 3H), 3.57 (br d, J = 14.1 Hz, 1H), 2.92-2.84 (m, 2H), 2.58 (br t, J = 11.8 Hz, 1H), 2.20 (s, 3H), 2.00 (d, J = 3.1 Hz, 2H), 1.83 (br d, J = 13.2 Hz, 2H), 1.62-1.50 (m, 2H), 0.78 (s, 3H), 0.08-0.03 (m, 4H); LCMS (ESI) $[M+H]^+$: 394.2.

10



^1H NMR (300 MHz, CHLOROFORM- d) δ 8.11 (s, J = 1.0 Hz, 1H), 7.85 (dd, J = 8.4, 1.3 Hz, 1H), 7.75 (dd, J = 8.4, 0.8 Hz, 1H), 7.22 (d, J = 3.6 Hz, 1H), 6.62 (d, J = 3.6 Hz, 1H), 4.14 (m, 2H), 4.09 (s, 3H), 3.32 (td, J = 12.9, 11.9, 3.1 Hz, 2H), 2.61 (s, 3H), 2.38-2.25 (m, 2H), 2.25-2.10 (m, 2H); LCMS (ESI) $[M+H]^+$: 381.1.


15




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.13 (s, 1H), 8.05 (s, 1H), 7.78 (s, 2H), 4.95 (td, J = 6.6, 13.3 Hz, 1H), 3.93-3.57 (m, 8H), 2.41 (s, 2H), 1.63 (d, J = 6.7 Hz, 6H), 1.18 (s, 3H), 0.58-0.37 (m, 4H); LCMS (ESI) $[M+H]^+$: 409.2.

20

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.05 (s, 1H), 7.78 (d, J = 0.9 Hz, 2H), 5.03-4.86 (m, 1H), 3.84-3.49 (m, 8H), 1.62 (d, J = 6.7 Hz, 6H), 1.59 (s, 3H), 0.95-0.88 (m, 2H), 0.72-0.64 (m, 2H); LCMS (ESI) [M+H]⁺: 411.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.04 (s, 1H), 7.79-7.75 (m, 2H), 5.01-4.90 (m, 1H), 3.96 (td, J = 7.9, 10.8 Hz, 2H), 3.88-3.77 (m, 2H), 3.68-3.50 (m, 3H), 3.45 (dd, J = 5.3, 10.7 Hz, 1H), 3.23-3.03 (m, 2H), 2.19 (s, 2H), 1.61 (d, J = 6.6 Hz, 6H), 1.06 (s, 9H); LCMS (ESI) [M+H]⁺: 437.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.04 (s, 1H), 7.86-7.74 (m, 2H), 5.02-4.89 (m, 1H), 4.02 (d, J = 11.5 Hz, 1H), 3.81 (d, J = 11.5 Hz, 1H), 3.50 (dt, J = 2.8, 11.9 Hz, 2H), 2.32-2.16 (m, 3H), 1.61 (dd, J = 6.7, 11.7 Hz, 6H), 1.19 (s, 9H); LCMS (ESI) [M+H]⁺: 410.2.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.62 (d, J = 4.2 Hz, 1H), 8.29 (d, J = 0.9 Hz, 1H), 8.10 (s, 1H), 7.87 (s, 2H), 7.82 (dt, J = 1.8, 7.7 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.36 (ddd, J = 1.1, 4.9, 7.7 Hz, 1H), 4.99 (td, J = 6.6, 13.4 Hz, 1H), 4.74 (br d, J = 13.9 Hz, 1H), 4.08 (br d, J = 12.6 Hz, 1H), 3.40-3.27 (m, 1H), 3.26-3.10 (m, 2H), 2.26 (br d, J = 10.6 Hz, 1H), 2.16-1.95 (m, 3H), 1.65 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 417.1.


20




25

¹H NMR (400 MHz, METHANOL-d₄) δ 8.27 (s, 1H), 8.08 (s, 1H), 7.90-7.83 (m, 2H), 4.14 (s, 3H), 3.59-3.50 (m, 3H), 3.28-3.21 (m, 2H), 2.46 (br dd, J = 3.6, 14.9 Hz, 2H), 2.24-2.13 (m, 2H); LCMS (ESI) [M+H]⁺: 284.1.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.63 (d, J = 1.8 Hz, 1H), 8.10 (d, J = 0.6 Hz, 1H), 7.96 (d, J = 0.7 Hz, 1H), 7.81-7.73 (m, 3H), 7.59 (d, J = 8.2 Hz, 1H), 5.42 (s, 1H), 5.19 (s, 1H), 4.62 (br d, J = 13.4 Hz, 1H), 4.09 (s, 4H), 3.36-3.27 (m, 2H), 3.22-3.11 (m, 1H), 2.30-2.20 (m, 1H), 2.14-2.03 (m, 6H); LCMS (ESI) [M+H]⁺: 429.2.




10 ¹H NMR (400 MHz, METHANOL-d₄) δ 8.25-8.12 (m, 1H), 7.83 (br s, 2H), 4.47 (br d, J = 13.4 Hz, 1H), 4.14-4.01 (m, 6H), 3.63 (br s, 2H), 3.47-3.35 (m, 2H), 3.07-2.90 (m, 2H), 2.83 (br d, J = 5.7 Hz, 2H), 2.59 (s, 3H), 2.34-2.18 (m, 2H), 2.03-1.83 (m, 2H), 1.45 (s, 9H); LCMS (ESI) [M+H]⁺: 495.3.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.11 (s, 1H), 7.92-7.86 (m, 1H), 7.86-7.79 (m, 1H), 5.17-5.02 (m, 1H), 4.91 (dd, J = 8.0, 9.2 Hz, 0.5H), 4.84-4.74 (m, 1H), 4.67 (dd, J = 4.9, 9.3 Hz, 0.5H), 4.16 (br s, 2H), 3.21 (tt, J = 3.9, 10.9 Hz, 1H), 3.02 (br t, J = 11.7 Hz, 2H), 2.22-2.09 (m, 2H), 2.02-1.87 (m, 2H), 1.66 (dd, J = 1.6, 6.8 Hz, 3H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 430.1.




¹H NMR (400 MHz, CHLOROFORM-*d*) δ 8.14 (s, 1H), 7.89 (dd, *J* = 0.9, 8.4 Hz, 1H), 7.77 (d, *J* = 8.4 Hz, 1H), 4.31 (br s, 1H), 4.22-4.14 (m, 1H), 4.13 (s, 3H), 3.79-3.66 (m, 1H), 3.48 (br d, *J* = 14.5 Hz, 1H), 3.27 (br t, *J* = 10.6 Hz, 1H), 2.65 (s, 3H), 2.42-2.30 (m, 1H), 2.30-2.20 (m, 1H), 1.51 (s, 9H); LCMS (ESI) [M+H]⁺: 434.2.




¹H NMR (400 MHz, DMSO-d₆) δ 8.44 (s, 1H), 8.21 (s, 1H), 7.98 (m, J = 8.4 Hz, 1H), 7.80 (dd, J = 0.9, 8.4 Hz, 1H), 7.53-7.48 (m, 2H), 7.47-7.42 (m, 2H), 5.18 (spt, J = 6.7 Hz, 1H), 4.00-4.2 (m, 2H), 3.35-3.16 (m, 3H), 2.10 (br d, J = 10.8 Hz, 2H), 1.90-1.71 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 450.1.

5




¹H NMR (400 MHz, DMSO-d₆) δ 8.44 (s, 1H), 8.21 (s, 1H), 7.98 (m, J = 8.6 Hz, 1H), 7.81 (dd, J = 1.0, 8.5 Hz, 1H), 7.51 (dt, J = 5.7, 7.9 Hz, 1H), 7.32-7.20 (m, 3H), 5.18 (spt, J = 6.6 Hz, 1H), 4.00-4.20 (m, 2H), 3.36-3.16 (m, 3H), 2.11 (br d, J = 10.6 Hz, 2H), 1.89-1.75 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 434.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.89 (dd, J = 1.5, 8.4 Hz, 1H), 7.79 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 4.96 (spt, J = 6.2 Hz, 1H), 4.64-4.53 (m, 1H), 4.19 (br d, J = 11.9 Hz, 2H), 3.20 (tt, J = 3.9, 10.9 Hz, 1H), 3.11-2.99 (m, 2H), 2.15 (br dd, J = 3.1, 13.2 Hz, 2H), 1.99-1.87 (m, 2H), 1.60 (d, J = 6.8 Hz, 6H), 1.27 (d, J = 6.2 Hz, 6H); LCMS (ESI) [M+H]⁺: 415.2.

15




¹H NMR (400 MHz, METHANOL-d₄) δ 8.35 (s, 1H), 8.12 (s, 1H), 7.93-7.84 (m, 2H), 5.13-5.02 (m, 1H), 4.36-4.21 (m, 1H), 3.99 (td, J = 8.5, 13.4 Hz, 1H), 3.86-3.63 (m, 2H), 3.43-3.34 (m, 1H), 2.68-2.56 (m, 2H), 1.60 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 348.1.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 7.99 (s, 1H), 7.80-7.72 (m, 2H), 7.03 (br d, J = 10.3 Hz, 1H), 4.95-4.84 (m, 1H), 4.11 (q, J = 5.0 Hz, 1H), 3.98-3.78 (m, 1H), 3.52-3.35 (m, 1H), 2.35-2.14 (m, 2H), 1.56 (d, J = 6.6 Hz, 6H), 1.45 (s, 9H); LCMS (ESI) [M+H]⁺: 428.2.


25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31-8.23 (m, 1H), 8.09 (s, 1H), 7.94-7.89 (m, 1H), 7.86-7.80 (m, 1H), 5.08-4.93 (m, 1H), 4.28 (br s, 2H), 3.69 (br d, J = 5.0 Hz, 2H), 2.85 (br s, 2H), 1.65 (dd, J = 1.3, 6.7 Hz, 6H), 1.53 (d, J = 1.3 Hz, 9H); LCMS (ESI) [M+H]⁺: 428.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.84 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 6.40 (dd, J = 8.8, 2.0 Hz, 1H), 6.22 (s, 1H), 4.79-4.61 (m, 1H), 3.71 (s, 4H), 3.43 (t, J = 5.6 Hz, 4H), 1.81 (br t, J = 5.2 Hz, 4H), 1.56 (d, J = 6.8 Hz, 6H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 385.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.29 (s, 1H), 7.97-7.85 (m, 2H), 4.80 (td, J = 9.1, 13.6 Hz, 0.7H), 4.63 (br d, J = 14.2 Hz, 0.4H), 4.34-4.16 (m, 2.4H), 4.13 (s, 3H), 4.10-3.98 (m, 1.5H), 3.96-3.79 (m, 0.6H), 3.66-3.48 (m, 1H), 3.33-3.25 (m, 0.4H), 2.64 (s, 3H), 2.56-2.26 (m, 2H); LCMS (ESI) [M+H]⁺: 391.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (d, J = 0.9 Hz, 1H), 8.03 (s, 1H), 7.81-7.74 (m, 2H), 5.03-4.87 (m, 1H), 4.03-3.90 (m, 2H), 3.84-3.67 (m, 2H), 3.43-3.32 (m, 2H), 3.13 (t, J = 10.3 Hz, 2H), 2.41 (m, 2H), 1.61 (d, J = 6.7 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 439.2.




¹H NMR (300 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.85 (dd, J = 8.4, 1.3 Hz, 1H), 7.75 (dd, J = 8.5, 0.8 Hz, 1H), 7.39 (s, 1H), 7.21 (d, J = 1.2 Hz, 1H), 7.15-7.04 (m, 1H), 4.45-4.32 (m, 2H), 4.09 (s, 3H), 3.53-3.30 (m, 3H), 2.61 (s, 3H), 2.43-2.28 (m, 2H), 2.28-2.12 (m, 2H); LCMS (ESI) [M+H]⁺: 415.3.



5


¹H NMR (300 MHz, CHLOROFORM-d) δ 7.98 (t, J = 0.7 Hz, 1H), 7.88-7.77 (m, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 8.8, 1H), 4.90-4.76 (m, 1H), 3.95 (ms, 2H), 3.88 (s, 2H), 3.38 (t, J = 12.4 Hz, 2H), 2.02 (m, 2H), 1.84 (m, 2H), 1.60 (d, J = 6.7 Hz, 6H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 415.3.

10




¹H NMR (300 MHz, DMSO-d₆) δ 8.31 (s, 1H), 8.19 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 8.4, 1.2 Hz, 1H), 5.16 (p, J = 6.5 Hz, 1H), 3.71 (dt, J = 13.2, 3.8 Hz, 2H), 3.39 (tt, J = 10.9, 3.8 Hz, 1H), 3.13 (td, J = 12.4, 12.0, 2.7 Hz, 3H), 2.19 (dd, J = 13.7, 3.6 Hz, 2H), 2.01 (t, J = 11.9 Hz, 2H), 1.92-1.72 (m, 4H), 1.62 (d, J = 12.6 Hz, 1H), 1.50 (d, J = 6.5 Hz, 6H), 1.45-1.21 (m, 5H); LCMS (ESI) [M+H]⁺: 458.4.

15



¹H NMR (300 MHz, DMSO-d₆) δ 8.31 (s, 1H), 8.19 (d, J = 0.8 Hz, 1H), 7.93 (dd, J = 8.4, 0.8 Hz, 1H), 7.75 (dd, J = 8.5, 1.3 Hz, 1H), 5.15 (p, J = 6.5 Hz, 1H), 3.71 (d, J = 12.7 Hz, 3H), 3.47-3.35 (m, 2H), 3.21 (s, 2H), 3.13 (t, J = 11.4 Hz, 2H), 2.19 (dd, J = 13.9, 2.4 Hz, 3H), 1.95 (d, J = 13.7 Hz, 2H), 1.88-1.60 (m, 7H), 1.50 (d, J = 6.5 Hz, 6H), 1.44 (d, J = 2.9 Hz, 1H); LCMS (ESI) [M+H]⁺: 488.4..


20




25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.85-7.81 (m, 1H), 7.76-7.72 (m, 1H), 4.54 (br d, J = 13.9 Hz, 1H), 4.08 (s, 3H), 3.99-3.89 (m, 1H), 3.39-3.28 (m, 2H), 3.10-2.99 (m, 1H), 2.66-2.61 (m, 2H), 2.60 (s, 3H), 2.59-2.50 (m, 2H), 2.31-2.17 (m, 2H), 2.09-1.90 (m, 2H); LCMS (ESI) [M+H]⁺: 422.1.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 8.00 (s, 1H), 7.83-7.72 (m, 4H), 7.50-7.43 (m, 1H), 7.42-7.34 (m, 2H), 7.14 (br s, 1H), 4.90 (td, J = 6.6, 13.3 Hz, 1H), 4.51 (dt, J = 6.7, 14.7 Hz, 0.5H), 4.38-4.08 (m, 3H), 3.96 (br s, 0.5H), 3.86-3.63 (m, 2H), 3.61-3.41 (m, 1H), 2.40-2.18 (m, 2H), 1.56 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 509.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, 1H), 8.10 (s, 1H), 7.94-7.83 (m, 4H), 7.31-7.23 (m, 1H), 7.15 (br t, J = 8.6 Hz, 2H), 5.07-4.93 (m, 1H), 4.70-4.50 (m, 0.5H), 4.45-4.16 (m, 3H), 4.06 (br d, J = 13.4 Hz, 0.5H), 3.95-3.69 (m, 2H), 3.67-3.49 (m, 1H), 2.51-2.26 (m, 2H), 1.66 (br d, J = 6.5 Hz, 6H); LCMS (ESI) [M+H]⁺: 527.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28-8.22 (m, 1H), 8.13 (br s, 1H), 7.95-7.79 (m, 4H), 7.49 (br d, J = 8.2 Hz, 2H), 7.35-7.18 (m, 1H), 5.02 (br d, J = 6.7 Hz, 1H), 4.62 (br s, 0.5H), 4.46-4.18 (m, 3H), 4.07 (br s, 0.5H), 3.99-3.50 (m, 3H), 2.56-2.28 (m, 2H), 1.69 (br d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 543.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 8.00 (s, 1H), 7.86-7.71 (m, 3H), 7.64 (br d, J = 7.6 Hz, 1H), 7.43 (br d, J = 7.7 Hz, 1H), 7.37-7.28 (m, 1H), 4.98-4.80 (m, 1H), 4.50 (dt, J = 6.2, 14.5 Hz, 0.5H), 4.37-4.22 (m, 2.5H), 4.22-4.08 (m, 0.5H), 3.96 (br d, J = 13.6 Hz, 0.5H), 3.87-3.62 (m, 2H), 3.60-3.38 (m, 1H), 2.42-2.18 (m, 2H); LCMS (ESI) [M+H]⁺: 543.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 8.09 (br d, J = 4.6 Hz, 1H), 8.02-7.95 (m, 2H), 7.83-7.68 (m, 3H), 7.52 (br t, J = 7.7 Hz, 1H), 7.38-7.21 (m, 1H), 4.90 (td, J = 6.6, 13.2 Hz, 1H), 4.60-4.41 (m, 0.5H), 4.37-4.21 (m, 2.5H), 4.20-4.08 (m, 0.5H), 3.97 (br d, J = 13.4 Hz, 0.5H), 3.89-3.62 (m, 2H), 3.61-3.42 (m, 1H), 2.42-2.22 (m, 2H), 1.56 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 534.2.




¹H NMR (400 MHz, DMSO-d₆) δ 8.50 (s, 1H), 8.25 (s, 1H), 7.99 (m, J = 8.4 Hz, 1H), 7.81 (dd, J = 1.2, 8.5 Hz, 1H), 5.23 (spt, J = 6.6 Hz, 1H), 3.78-3.66 (m, 2H), 3.60-3.52 (m, 1H), 3.52-3.43 (m, 1H), 3.38 (br t, J = 8.4 Hz, 1H), 2.33 (br s, 1H), 2.25-2.07 (m, 1H), 1.50 (d, J = 6.6 Hz, 6H), 1.42 (s, 9H); LCMS (ESI) [M+H]⁺: 398.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.88-7.79 (m, 2H), 5.51-5.37 (m, 1H), 4.97 (td, J = 6.6, 13.2 Hz, 1H), 4.60-4.48 (m, 0.5H), 4.30 (m, 0.5H), 4.20-4.01 (m, 2.5H), 3.93 (m, 0.5H), 3.89-3.59 (m, 2H), 3.56-3.37 (m, 1H), 2.46-2.21 (m, 2H), 1.63 (d, J = 6.6 Hz, 6H), 1.46 (s, 9H); LCMS (ESI) [M-55]⁺: 449.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.02 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.68-7.63 (m, 1H), 4.00 (s, 3H), 3.69 (br t, J = 10.3 Hz, 1H), 2.93 (tt, J = 3.7, 11.8 Hz, 1H), 2.52 (s, 3H), 2.26-2.18 (m, 2H), 2.10 (br dd, J = 3.3, 13.0 Hz, 2H), 1.79-1.69 (m, 2H), 1.45-1.34 (m, 2H); LCMS (ESI) [M+H]⁺: 313.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.86-7.81 (m, 1H), 7.77-7.70 (m, 1H), 5.55-5.39 (m, 1H), 4.55 (dt, J = 6.6, 14.4 Hz, 0.5H), 4.35-4.26 (m, 0.5H), 4.22-4.10 (m, 1H), 4.08 (s, 3H), 4.07-3.90 (m, 2H), 3.89-3.60 (m, 2H), 3.58-3.39 (m, 1H), 2.60 (s, 3H), 2.43-2.25 (m, 2H), 1.47 (s, 9H); LCMS (ESI) [M+H]⁺: 435.1.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (br s, 1H), 8.09 (s, 1H), 8.02-7.82 (m, 4H), 7.54-7.44 (m, 2H), 5.05-4.92 (m, 1H), 4.66-4.51 (m, 1H), 4.36 (dd, J = 6.6, 9.5 Hz, 1H), 4.06-3.93 (m, 2H), 3.69-3.60 (m, 1H), 3.49-3.35 (m, 2H), 3.23-3.07 (m, 1H), 3.02-2.90 (m, 2H), 2.31 (br t, J = 14.1 Hz, 2H), 2.13-1.96 (m, 2H), 1.65 (dd, J = 1.2, 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 524.2.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (br s, 1H), 7.99 (s, 1H), 7.93-7.73 (m, 4H), 7.43-7.34 (m, 2H), 4.89 (qd, J = 6.6, 13.3 Hz, 1H), 4.55-4.41 (m, 1H), 4.26 (dd, J = 7.0, 8.9 Hz, 1H), 3.96-3.84 (m, 2H), 3.55 (td, J = 8.3, 16.0 Hz, 1H), 3.40-3.26 (m, 2H), 3.13-2.97 (m, 1H), 2.94-2.81 (m, 2H), 2.22 (br t, J = 14.3 Hz, 2H), 2.03-1.89 (m, 2H), 1.56 (br d, J = 5.9 Hz, 6H); LCMS (ESI) [M+H]⁺: 524.2.


15



20


¹H NMR (400 MHz, METHANOL-d₄) δ 8.23 (s, 1H), 8.11 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 5.12-4.98 (m, 1H), 4.07-3.96 (m, 2H), 3.63 (br dd, J = 5.9, 10.5 Hz, 2H), 3.51 (br t, J = 9.7 Hz, 2H), 3.17 (br t, J = 10.8 Hz, 2H), 2.81-2.65 (m, 2H), 1.61 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 339.1.

25




30

¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (s, 1H), 8.25 (s, 1H), 8.01 (m, J = 8.4 Hz, 1H), 7.82 (dd, J = 1.1, 8.6 Hz, 1H), 5.20 (spt, J = 6.5 Hz, 1H), 3.86 (quin, J = 7.6 Hz, 1H), 3.68 (dd, J = 8.2, 11.7 Hz, 1H), 3.46 (dd, J = 7.5, 11.7 Hz, 1H), 3.41-3.26 (m, 2H), 2.47-2.37 (m, 1H), 2.29-2.15 (m, 1H), 1.50 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 298.1.




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.88-7.79 (m, 2H), 7.47-7.39 (m, 2H), 7.26-7.22 (m, 1H), 7.16-7.10 (m, 1H), 4.98 (td, J = 6.7, 13.3 Hz, 1H), 4.71 (br d, J = 12.8 Hz, 1H), 3.72 (br d, J = 13.6 Hz, 1H), 3.42-3.17 (m, 3H), 2.33 (br dd, J = 3.3, 13.6 Hz, 1H), 2.23-2.03 (m, 3H), 1.64 (d, J = 6.7 Hz, 5H), 1.66-1.62 (m, 1H).; LCMS (ESI) $[M+H]^+$: 434.2.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.88-7.80 (m, 2H), 7.41-7.36 (m, 1H), 7.25 (dd, J = 1.8, 8.3 Hz, 1H), 7.18 (dd, J = 1.9, 9.2 Hz, 1H), 4.97 (spt, J = 6.7 Hz, 1H), 4.67 (br d, J = 13.4 Hz, 1H), 3.70 (br d, J = 13.8 Hz, 1H), 3.42-3.18 (m, 3H), 2.33 (br dd, J = 3.4, 13.6 Hz, 1H), 2.24-1.95 (m, 3H), 1.66-1.62 (m, 1H), 1.64 (d, J = 6.7 Hz, 5H); LCMS (ESI) $[M+H]^+$: 468.1.


15




20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.85 (s, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.46-7.40 (m, 1H), 7.38-7.28 (m, 3H), 6.40 (dd, J = 1.6, 8.7 Hz, 1H), 6.23 (s, 1H), 4.70 (spt, J = 6.6 Hz, 1H), 3.92-3.70 (m, 6H), 3.38-3.17 (m, 2H), 2.06-1.87 (m, 3H), 1.82-1.73 (m, 1H), 1.56 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 423.2.




25 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.13 (s, 1H), 7.98 (s, 1H), 7.80-7.71 (m, 2H), 5.27 (br d, J = 7.9 Hz, 1H), 4.94-4.84 (m, 1H), 3.90-3.78 (m, 1H), 2.91 (tt, J = 3.5, 12.2 Hz, 1H), 2.25-2.11 (m, 4H), 1.93 (s, 3H), 1.79 (dq, J = 3.2, 13.0 Hz, 2H), 1.56 (d, J = 6.7 Hz, 6H), 1.24 (dq, J = 3.3, 12.5 Hz, 2H); LCMS (ESI) $[M+H]^+$: 368.1.




¹H NMR (400 MHz, DMSO-d₆) δ 8.30 (s, 1H), 8.19 (s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.77 (dd, J = 1.1, 8.4 Hz, 1H), 5.17-5.07 (m, 1H), 3.43 (br t, J = 4.5 Hz, 1H), 3.25-3.16 (m, 1H), 2.25 (br dd, J = 4.6, 9.2 Hz, 2H), 1.97-1.88 (m, 4H), 1.66-1.57 (m, 2H), 1.50 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 326.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.89-7.81 (m, 2H), 4.99 (td, J = 6.7, 13.3 Hz, 1H), 4.48 (br s, 1H), 3.57 (br s, 1H), 2.99 (tt, J = 3.4, 12.2 Hz, 1H), 2.33-2.20 (m, 4H), 1.85 (dq, J = 3.0, 13.0 Hz, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.48 (s, 9H), 1.38-1.26 (m, 2H); LCMS (ESI) [M+H]⁺: 426.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.84 (s, 1H), 7.52 (d, J = 8.8 Hz, 1H), 6.40 (dd, J = 8.8, 2.0 Hz, 1H), 6.22 (s, 1H), 4.79-4.61 (m, 1H), 3.69 (s, 4H), 3.10-2.66 (m, 5H), 1.83 (br t, J = 5.2 Hz, 4H), 1.56 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 285.1.




¹H NMR (300 MHz, DMSO-d₆) δ 8.27 (d, J = 1.2 Hz, 1H), 8.19 (s, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.79 (dd, J = 8.7, 2.3 Hz, 1H), 7.72 (dd, J = 8.5, 1.3 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 5.14 (p, J = 6.6 Hz, 1H), 3.96 (s, 3H), 3.69 (d, J = 11.9 Hz, 3H), 2.22 (d, J = 12.9 Hz, 3H), 1.87 (q, J = 10.5, 9.9 Hz, 2H), 1.50 (d, J = 6.5 Hz, 6H); LCMS (ESI) [M+H]⁺: 560.2, 562.1.




¹H NMR (300 MHz, DMSO-d₆) δ 8.29 (d, J = 1.1 Hz, 1H), 8.19 (s, 1H), 8.02 (dd, J = 7.7, 1.6 Hz, 1H), 7.92 (dd, J = 8.5, 0.8 Hz, 1H), 7.76-7.66 (m, 3H), 7.59 (ddd, J = 7.9, 6.8, 1.9 Hz, 1H), 5.15 (p, J = 6.5 Hz, 1H),

3.78 (d, J = 12.8 Hz, 2H), 3.39 (d, J = 15.0 Hz, 1H), 3.09-2.93 (m, 2H), 2.21 (dd, J = 13.4, 3.5 Hz, 2H), 1.93-1.74 (m, 1H), 1.50 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 486.3, 488.2.




5 ¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 8.15 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.48 (dd, J = 1.9, 9.6 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 5.10 (td, J = 6.6, 13.2 Hz, 1H), 4.03 (br s, 1H), 4.20-3.86 (m, 1H), 3.58-3.43 (m, 1H), 3.25 (br t, J = 11.2 Hz, 2H), 2.19 (br d, J = 9.9 Hz, 2H), 1.99-1.81 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 468.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.29 (s, 1H), 8.11 (d, J = 3.4 Hz, 1H), 7.88 (d, J = 5.4 Hz, 2H), 5.07-4.90 (m, 1H), 4.09-3.95 (m, 1H), 3.94-3.77 (m, 2H), 3.76-3.57 (m, 2H), 2.55-2.31 (m, 2H), 2.29-2.24 (m, 2H), 1.66 (d, J = 6.6 Hz, 6H), 1.11 (d, J = 1.8 Hz, 9H); LCMS (ESI) [M+H]⁺: 396.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08 (d, J = 2.9 Hz, 1H), 7.82 (br dd, J = 2.6, 8.4 Hz, 1H), 7.72 (dd, J = 3.4, 8.3 Hz, 1H), 4.24-4.13 (m, 2H), 4.07 (d, J = 3.7 Hz, 3H), 3.44-3.25 (m, 3H), 2.59-2.57 (m, 3H), 2.29-2.27 (m, 2H), 2.23 (d, J = 4.0 Hz, 3H), 2.16-2.04 (m, 2H); LCMS (ESI) [M+H]⁺: 380.2.

20




25 ¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 8.16 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 1.0, 8.5 Hz, 1H), 7.55-7.47 (m, 2H), 7.30-7.22 (m, 2H), 5.11 (quin, J = 6.6 Hz, 1H), 4.06 (br s, 2H), 3.57-3.45 (m, 1H), 3.32-3.18 (m, 2H), 2.19 (br dd, J = 3.4, 13.1 Hz, 2H), 1.97-1.81 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 434.2.




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.09 (d, J = 0.9 Hz, 1H), 8.01 (d, J = 0.9 Hz, 1H), 7.79-7.77 (m, 2H), 4.14 (s, 3H), 3.74-3.68 (m, 4H), 3.62-3.56 (m, 4H), 1.50 (s, 9H); LCMS (ESI) $[M+H]^+$: 385.2.

5




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.28 (s, J = 0.7 Hz, 1H), 8.10 (s, 1H), 7.91-7.82 (m, 2H), 4.98 (spt, J = 6.6 Hz, 1H), 4.64 (br d, J = 13.6 Hz, 1H), 3.98 (br d, J = 13.6 Hz, 1H), 3.32-3.20 (m, 1H), 3.15 (tt, J = 3.9, 10.9 Hz, 1H), 2.91 (br t, J = 11.2 Hz, 1H), 2.40 (d, J = 4.2 Hz, 2H), 2.16 (br d, J = 11.1 Hz, 2H), 1.99-1.80 (m, 2H), 1.65 (d, J = 6.7 Hz, 6H), 1.18 (s, 3H), 0.55-0.31 (m, 4H); LCMS (ESI) $[M+H]^+$: 408.2.

10




^1H NMR (400 MHz, DMSO- d_6) δ 8.17 (d, J = 10.8 Hz, 2H), 7.87 (d, J = 8.4 Hz, 1H), 7.67 (dd, J = 1.1, 8.4 Hz, 1H), 7.61-7.49 (m, 1H), 7.41-7.24 (m, 3H), 5.10 (td, J = 6.6, 13.1 Hz, 1H), 3.94-3.43 (m, 8H), 1.50 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 435.2.

15



^1H NMR (400 MHz, CHLOROFORM- d) δ 8.22 (s, 1H), 8.09 (s, 1H), 7.84 (d, J = 0.7 Hz, 2H), 4.97 (quin, J = 6.7 Hz, 1H), 3.57 (br d, J = 5.5 Hz, 8H), 1.65 (d, J = 6.6 Hz, 6H), 1.51 (s, 9H); LCMS (ESI) $[M+H]^+$: 413.2.


20




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.22 (s, 1H), 8.06 (s, 1H), 7.92 (d, J = 3.1 Hz, 1H), 7.88-7.77 (m, 2H), 7.57 (d, J = 3.3 Hz, 1H), 5.43 (br d, J = 13.7 Hz, 1H), 4.97 (spt, J = 6.7 Hz, 1H), 4.67 (br d, J = 12.6 Hz, 1H), 3.80-3.60 (m, 1H), 3.48-3.36 (m, 1H), 3.34-3.18 (m, 1H), 2.31 (br s, 2H), 2.15 (br s, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 423.1.

25


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.84 (dd, J = 1.2, 8.4 Hz, 1H), 7.77-7.71 (m, 1H), 4.76 (br s, 1H), 4.09 (s, 3H), 3.81 (br s, 1H), 3.68 (s, 3H), 3.28-3.16 (m, 1H), 2.61 (s, 3H), 2.25-2.12 (m, 2H), 2.07-1.97 (m, 2H), 1.88 (dt, J = 4.0, 8.7 Hz, 2H), 1.79-1.69 (m, 2H); LCMS (ESI) [M+H]⁺: 370.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (br s, 1H), 8.06 (br s, 1H), 7.91-7.77 (m, 2H), 7.65-7.55 (m, 2H), 7.43 (br d, J = 5.7 Hz, 1H), 7.33-7.15 (m, 2H), 5.04-4.91 (m, 0.8H), 4.57 (br s, 0.4H), 4.44-4.31 (m, 2H), 4.28-4.14 (m, 0.5H), 4.02 (br s, 0.5H), 3.93-3.68 (m, 2H), 3.68-3.46 (m, 1H), 2.50-2.25 (m, 2H), 1.63 (br d, J = 6.4 Hz, 6H); LCMS (ESI) [M+H]⁺: 527.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.96-7.94 (d, J = 8.0 Hz, 2H), 7.87-7.81 (m, 2H), 7.80-7.60 (d, J = 8.0 Hz, 2H), 7.33-7.25 (m, 1H), 5.00-4.93 (m, 1H), 4.65-4.50 (m, 0.5H), 4.45-4.25 (m, 2.6H), 4.25-4.15 (m, 0.5 h), 4.08-3.98 (m, 0.5H), 3.95-3.80 (m, 1.5H), 3.80 -3.05 (m, 0.5H), 3.65-3.50 (m, 1H), 2.50-2.33 (m, 2H), 1.64-1.62 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 534.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.73 (br d, J = 15.2 Hz, 1H), 8.57 (d, J = 2.3 Hz, 1H), 8.20-8.11 (m, 2H), 7.92 (d, J = 8.6 Hz, 1H), 7.87-7.78 (m, 2H), 4.64 (dt, J = 6.8, 14.3 Hz, 0.5H), 4.39 (br t, J = 5.4 Hz, 2.4H), 4.30-4.22 (m, 0.6H), 4.18 (s, 3H), 4.06 (br d, J = 14.4 Hz, 0.6H), 3.93-3.70 (m, 2H), 3.62-3.49 (m, 1H), 2.69 (s, 3H), 2.50-2.29 (m, 2H); LCMS (ESI) [M+H]⁺: 530.1.



5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.17 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.48-7.39 (m, 2H), 7.28-7.19 (m, 1H), 4.64 (dt, J = 7.3, 14.2 Hz, 0.5H), 4.48-4.32 (m, 2.3H), 4.26 (br s, 0.6H), 4.22 (s, 3H), 4.06 (br d, J = 8.8 Hz, 0.7H), 3.95-3.69 (m, 2H), 3.61-3.47 (m, 1H), 2.73 (s, 3H), 2.50-2.30 (m, 2H); LCMS (ESI) $[M+H]^+$: 529.1.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.12 (d, J = 0.8 Hz, 1H), 8.04 (s, 1H), 7.77 (d, J = 0.8 Hz, 2H), 5.05-4.85 (m, 1H), 4.06 (s, 4H), 3.42 (t, J = 5.6 Hz, 4H), 1.85 (t, J = 5.6 Hz, 4H), 1.61 (d, J = 6.4 Hz, 6H), 1.48 (s, 9H); LCMS (ESI) $[M+H]^+$: 453.2.




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.19 (s, 1H), 8.16 (s, 1H), 8.08-8.04 (m, 2H), 7.87-7.78 (m, 3H), 7.59 (t, J = 7.8 Hz, 1H), 7.41-7.35 (m, 1H), 4.96 (quin, J = 6.7 Hz, 1H), 4.52 (br d, J = 13.7 Hz, 1H), 4.31 (d, J = 3.7 Hz, 2H), 3.91 (br d, J = 13.9 Hz, 1H), 3.37 (ddd, J = 3.3, 10.5, 13.9 Hz, 2H), 3.25-3.11 (m, 1H), 2.37-2.21 (m, 2H), 2.13-1.94 (m, 2H), 1.63 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 498.2.


20




25 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.11 (s, 1H), 7.93-7.81 (m, 3H), 7.79-7.72 (m, 1H), 7.25-7.10 (m, 3H), 4.59 (dt, J = 6.7, 14.9 Hz, 0.5H), 4.43-4.30 (m, 2.5H), 4.24 (dt, J = 6.3, 14.6 Hz, 0.5H), 4.10 (s, 3H), 4.05 (br d, J = 13.9 Hz, 0.5H), 3.95-3.70 (m, 2H), 3.68-3.50 (m, 1H), 2.61 (s, 3H), 2.49-2.31 (m, 2H); LCMS (ESI) $[M+H]^+$: 513.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.06-7.90 (m, 2H), 7.75-7.57 (m, 2H), 5.76-5.60 (m, 1H), 5.12 (t, J = 6.5 Hz, 2H), 4.95 (t, J = 7.3 Hz, 2H), 4.38 (m, 1H), 3.74 (m, 1H), 3.17-2.98 (m, 2H), 2.86-2.69 (m, 1H), 2.12 (d, J = 6.8 Hz, 2H), 2.07-1.95 (m, 2H), 1.84-1.66 (m, 2H), 0.93-0.80 (m, 1H), 0.44-0.33 (m, 2H), 0.05-0.05 (m, 2H); LCMS (ESI) [M+H]⁺: 408.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (d, J = 0.7 Hz, 1H), 8.17 (s, 1H), 7.93-7.81 (m, 2H), 5.96-5.83 (m, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.16 (t, J = 7.3 Hz, 2H), 4.60 (br d, J = 13.4 Hz, 1H), 3.97 (br d, J = 13.9 Hz, 1H), 3.36-3.20 (m, 2H), 2.96 (br t, J = 11.2 Hz, 1H), 2.39 (m, 2H), 2.22 (br d, J = 13.4 Hz, 2H), 2.05-1.85 (m, 2H), 1.17 (s, 3H), 0.55-0.32 (m, 4H); LCMS (ESI) [M+H]⁺: 422.2.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.85-7.80 (m, 1H), 7.73 (d, J = 8.3 Hz, 1H), 4.32 (br d, J = 13.2 Hz, 2H), 4.08 (s, 3H), 3.36-3.27 (m, 1H), 3.23-3.11 (m, 2H), 2.72 (q, J = 7.7 Hz, 2H), 2.60 (s, 3H), 2.34-2.25 (m, 2H), 2.15-2.03 (m, 2H), 1.28 (t, J = 7.7 Hz, 3H); LCMS (ESI) [M+H]⁺: 404.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 8.15 (d, J = 0.7 Hz, 1H), 8.04 (dd, J = 1.1, 8.4 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.68-7.35 (t, J = 59.2 Hz, 1H), 4.19 (br s, 2H), 3.73 (s, 3H), 3.23 (tt, J = 3.9, 10.9 Hz, 1H), 3.08 (br t, J = 11.6 Hz, 2H), 2.17 (br d, J = 10.9 Hz, 2H), 2.01-1.89 (m, 2H); LCMS (ESI) [M+H]⁺: 378.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 8.10 (s, 1H), 7.85-7.82 (m, 1H), 7.80-7.75 (m, 1H), 7.40-7.33 (m, 1H), 7.32-7.20 (m, 3H), 5.92-5.74 (m, 1H), 5.26 (t, J = 6.6 Hz, 2H), 5.09 (t, J = 7.0 Hz, 2H),

4.76-4.55 (m, 1H), 3.61-3.44 (m, 1H), 3.36-3.01 (m, 3H), 2.27 (m, 1H), 2.15-1.93 (m, 2H), 1.93-1.77 (m, 1H); LCMS (ESI) [M+H]⁺: 464.1.




5
¹H NMR (400 MHz, DMSO-d₆) δ 8.25 (s, 1H), 8.14 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 5.11-5.05 (m, 1H), 4.07-3.99 (m, 1H), 3.66-3.56 (m, 1H), 3.49 (br dd, J = 9.2, 13.3 Hz, 1H), 3.32-3.15 (m, 2H), 2.22-2.13 (m, 1H), 1.98-1.93 (m, 1H), 1.84-1.75 (m, 1H), 1.60-1.45 (m, 7H), 1.38 (s, 9H); LCMS (ESI) [M+H]⁺: 412.2.


10



15
¹H NMR (400 MHz, CHLOROFORM-d) δ 8.29-8.16 (m, 2H), 7.97-7.84 (m, 2H), 7.46 (m, 5H), 5.99-5.85 (m, 1H), 5.36 (t, J = 6.7 Hz, 2H), 5.18 (t, J = 7.3 Hz, 2H), 4.86-4.54 (m, 1H), 3.94 (m, 1H), 3.46-3.31 (m, 1H), 3.25 (br s, 2H), 2.39-1.82 (m, 4H); LCMS (ESI) [M+H]⁺: 430.1.




20
¹H NMR (300 MHz, DMSO-d₆) δ 8.31 (d, J = 1.1 Hz, 1H), 8.19 (s, 0H), 7.93 (dd, J = 8.4, 0.8 Hz, 1H), 7.75 (dd, J = 8.5, 1.3 Hz, 1H), 5.16 (h, J = 6.6 Hz, 1H), 3.65 (dt, J = 11.7, 3.3 Hz, 3H), 3.43-3.27 (m, 1H), 3.02 (td, J = 12.6, 2.7 Hz, 3H), 2.95 (d, J = 6.6 Hz, 2H), 2.23 (dd, J = 13.6, 3.7 Hz, 2H), 2.12 (dq, J = 13.3, 6.7 Hz, 1H), 1.97-1.78 (m, 2H), 1.50 (d, J = 6.6 Hz, 6H), 1.05 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 432.3.




25
¹H NMR (400 MHz, CHLOROFORM-d) δ 7.77 (dd, J = 1.1, 7.7 Hz, 1H), 7.67 (s, 1H), 7.35 (d, J = 7.7 Hz, 1H), 4.68 (spt, J = 7.0 Hz, 1H), 4.14 (m, 2H), 3.56 (s, 2H), 3.19 (tt, J = 4.0, 10.9 Hz, 1H), 3.01 (br t, J = 11.6 Hz, 2H), 2.14 (br dd, J = 2.8, 13.3 Hz, 2H), 1.98-1.84 (m, 2H), 1.54 (d, J = 7.1 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 427.2.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.86-7.81 (m, 1H), 7.74 (d, J = 8.4 Hz, 1H), 4.42 (dd, J = 7.2, 9.2 Hz, 1H), 4.16 (dd, J = 5.3, 9.3 Hz, 1H), 4.08 (s, 3H), 3.09-2.89 (m, 3H), 2.87-2.76 (m, 1H), 2.68-2.61 (m, 1H), 2.60 (s, 3H), 2.45 (d, J = 7.9 Hz, 2H), 2.37 (dd, J = 5.7, 17.6 Hz, 1H), 2.31-2.13 (m, 4H), 2.11-1.98 (m, 2H)




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (d, J = 0.7 Hz, 1H), 8.04 (s, 1H), 7.77 (m, 2H), 4.95 (m, 1H), 3.99 (m, 2H), 3.84 (dd, J = 6.3, 9.8 Hz, 1H), 3.80-3.71 (m, 4H), 3.39 (m, 2H), 3.17 (q, J = 10.4 Hz, 2H), 2.53-2.34 (m, 2H), 1.61 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 397.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (d, J = 0.9 Hz, 1H), 8.04 (s, 1H), 7.81-7.73 (m, 2H), 4.95 (m, 1H), 4.07-3.93 (m, 3H), 3.84 (dd, J = 6.6, 8.9 Hz, 1H), 3.45-3.36 (m, 2H), 3.30 (dd, J = 9.2, 10.8 Hz, 1H), 3.16 (t, J = 11.0 Hz, 1H), 2.57-2.32 (m, 2H), 2.26-2.15 (m, 2H), 1.61 (d, J = 6.6 Hz, 6H), 1.12-1.04 (m, 9H); LCMS (ESI) [M+H]⁺: 437.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.04 (s, 1H), 7.77 (s, 2H), 5.00-4.88 (m, 1H), 4.07 (s, 4H), 3.71 (s, 3H), 3.47 (t, J = 4.8 Hz, 4H), 1.86 (t, J = 5.6 Hz, 4H), 1.61 (d, J = 6.8 Hz, 6H); LCMS (ESI) [M+H]⁺: 411.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.05 (s, 1H), 7.76 (s, 2H), 5.01-4.90 (m, 1H), 4.15-4.04 (m, 4H), 3.61 (t, J = 5.2 Hz, 2H), 3.45 (t, J = 5.6 Hz, 2H), 2.13 (s, 3H), 1.89 (dt, J = 16.6, 4.4 Hz, 4H), 1.61 (d, J = 6.4 Hz, 6H); LCMS (ESI) [M+H]⁺: 395.1.




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.83 (s, 1H), 7.71 (dd, J = 1.2, 7.6 Hz, 1H), 7.28 (d, J = 7.6 Hz, 1H), 4.73 (spt, J = 6.9 Hz, 1H), 4.25-4.00 (m, 2H), 3.18 (tt, J = 3.9, 10.9 Hz, 1H), 3.00 (br t, J = 11.7 Hz, 2H), 2.91-2.85 (m, 2H), 2.60 (dd, J = 5.8, 8.3 Hz, 2H), 2.13 (br dd, J = 2.8, 13.1 Hz, 2H), 1.96-1.85 (m, 2H), 1.58 (d, J = 7.1 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) $[M-55]^+$: 385.1.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.82 (d, J = 2.2 Hz, 1H), 8.22 (s, 1H), 8.06 (s, 1H), 8.03 (d, J = 2.2 Hz, 1H), 7.92-7.77 (m, 2H), 4.97 (spt, J = 6.7 Hz, 1H), 4.63 (br d, J = 7.3 Hz, 2H), 3.47 (br s, 1H), 3.38 (tt, J = 4.2, 10.5 Hz, 1H), 3.24 (br s, 1H), 2.29 (br s, 2H), 2.19-2.07 (m, 2H), 1.63 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 423.1.




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.90-7.79 (m, 2H), 7.48 (dd, J = 1.0, 5.0 Hz, 1H), 7.34 (dd, J = 1.0, 3.6 Hz, 1H), 7.08 (dd, J = 3.7, 4.9 Hz, 1H), 4.98 (td, J = 6.6, 13.2 Hz, 1H), 4.47 (br d, J = 12.8 Hz, 2H), 3.45-3.27 (m, 3H), 2.28 (br dd, J = 3.4, 13.6 Hz, 2H), 2.15-2.01 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 422.1.




20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.89-7.79 (m, 2H), 7.18 (d, J = 5.7 Hz, 1H), 6.99 (d, J = 5.7 Hz, 1H), 4.97 (td, J = 6.6, 13.4 Hz, 1H), 4.66 (br d, J = 12.8 Hz, 1H), 3.80 (br d, J = 13.5 Hz, 1H), 3.43-3.16 (m, 3H), 2.40-2.17 (m, 2H), 2.17-1.93 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[M+H]^+$: 456.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (d, J = 0.6 Hz, 1H), 8.16 (s, 1H), 7.93-7.87 (m, 1H), 7.86-7.81 (m, 1H), 5.89 (quin, J = 7.0 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.15 (t, J = 7.3 Hz, 2H), 4.32-3.96 (m, 2H), 3.20 (m, 1H), 3.08-2.96 (m, 2H), 2.15 (br d, J = 12.5 Hz, 2H), 1.99-1.83 (m, 2H), 1.59 (br s, 1H), 1.57 (s, 3H), 0.93-0.83 (m, 2H), 0.72-0.59 (m, 2H); LCMS (ESI) [M+H]⁺: 424.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.92-7.81 (m, 3H), 7.79-7.72 (m, 1H), 7.57-7.52 (m, 1H), 7.51-7.43 (m, 2H), 7.26-7.17 (m, 1H), 4.65-4.50 (m, 0.5H), 4.44-4.32 (m, 2.5H), 4.25 (dt, J = 5.7, 14.8 Hz, 0.5H), 4.09 (s, 3H), 4.04 (br d, J = 4.9 Hz, 0.5H), 3.96-3.69 (m, 2H), 3.68-3.50 (m, 1H), 2.61 (s, 3H), 2.50-2.23 (m, 2H); LCMS (ESI) [M+H]⁺: 495.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.90-7.81 (m, 3H), 7.78-7.73 (m, 1H), 7.58-7.51 (m, 1H), 7.50-7.43 (m, 2H), 7.30-7.19 (m, 1H), 4.65-4.49 (m, 0.5H), 4.45-4.31 (m, 2.5H), 4.25 (dt, J = 5.6, 14.8 Hz, 0.5H), 4.09 (s, 3H), 4.08-4.00 (m, 0.5H), 3.98-3.70 (m, 2H), 3.66-3.51 (m, 1H), 2.61 (s, 3H), 2.50-2.31 (m, 2H); LCMS (ESI) [M+H]⁺: 495.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.10 (s, 1H), 7.91-7.83 (m, 2H), 6.77-6.62 (m, 1H), 5.00 (td, J = 6.6, 13.2 Hz, 1H), 4.58 (dt, J = 6.8, 14.5 Hz, 0.5H), 4.34 (br d, J = 13.9 Hz, 0.5H), 4.28-4.14 (m, 2.5H), 4.00 (br d, J = 13.6 Hz, 0.5H), 3.94-3.45 (m, 3H), 2.36 (br d, J = 16.4 Hz, 2H), 1.66 (d, J = 6.7 Hz, 6H), 1.57-1.49 (m, 1H), 1.06-0.99 (m, 2H), 0.82 (td, J = 3.6, 7.4 Hz, 2H); LCMS (ESI) [M+H]⁺: 473.2.




- 5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.22 (s, 1H), 8.09 (s, 1H), 7.87-7.79 (m, 2H), 7.48-7.43 (m, 1H), 7.42-7.30 (m, 3H), 4.97 (td, J = 6.8, 13.2 Hz, 1H), 4.13-4.00 (m, 1H), 3.97-3.84 (m, 1H), 3.72 (br s, 2H), 3.66-3.57 (m, 1H), 3.56-3.41 (m, 2H), 3.38 (br d, J = 7.1 Hz, 1H), 1.64 (br d, J = 6.6 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 451.1.




- 10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.07 (s, 1H), 7.83-7.78 (m, 1H), 7.74-7.69 (m, 1H), 4.19 (td, J = 3.8, 13.6 Hz, 2H), 4.06 (s, 3H), 3.40-3.23 (m, 3H), 2.94-2.84 (m, 1H), 2.58 (s, 3H), 2.27 (br dd, J = 3.3, 13.7 Hz, 2H), 2.15-2.02 (m, 2H), 1.28 (d, J = 6.8 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 408.2.




- 15 ^1H NMR (400 MHz, DMSO- d_6) δ 8.37 (s, 1H), 8.19 (s, 1H), 7.95 (m, J = 8.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.54-7.37 (m, 5H), 5.15 (spt, J = 6.6 Hz, 1H), 3.66 (br s, 4H), 3.58-3.50 (m, 4H), 1.53 (d, J = 6.6 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 417.2.




- 20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.23 (s, 1H), 8.11 (s, 1H), 7.91-7.86 (m, 1H), 7.85-7.81 (m, 1H), 5.16-5.03 (m, 1H), 4.91 (dd, J = 7.9, 9.3 Hz, 0.5H), 4.82-4.76 (m, 1H), 4.67 (dd, J = 4.9, 9.4 Hz, 0.5H), 4.61 (br s, 1H), 4.04 (br d, J = 13.7 Hz, 1H), 3.36-3.24 (m, 2H), 2.97 (br t, J = 12.1 Hz, 1H), 2.32 (s, 2H), 2.27-2.17 (m, 2H), 2.05-1.89 (m, 2H), 1.66 (dd, J = 1.6, 6.8 Hz, 3H), 1.09 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 428.2.




5




10



15




25



30


= 13.9 Hz, 1H), 3.53-3.44 (m, 1H), 3.44-3.35 (m, 1H), 3.32-3.17 (m, 1H), 2.38-2.21 (m, 2H), 2.21-2.07 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 423.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.89-7.80 (m, 2H), 7.68 (s, 1H), 5.41 (br d, J = 12.3 Hz, 1H), 4.97 (td, J = 6.6, 13.4 Hz, 1H), 4.60 (br d, J = 11.5 Hz, 1H), 3.75-3.62 (m, 1H), 3.49-3.35 (m, 1H), 3.33-3.19 (m, 1H), 2.30 (br s, 2H), 2.14 (br s, 2H), 1.64 (d, J = 6.6 Hz, 5H), 1.66-1.61 (m, 1H); LCMS (ESI) [M+H]⁺: 457.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.27 (s, 1H), 8.05 (dd, J = 1.1, 8.2 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 4.16 (br s, 2H), 3.20 (tt, J = 3.9, 10.8 Hz, 1H), 3.09-2.97 (m, 2H), 2.62 (s, 3H), 2.14 (br d, J = 11.4 Hz, 2H), 1.98-1.84 (m, 2H), 1.56 (s, 3H), 0.91-0.85 (m, 2H), 0.67-0.61 (m, 2H); LCMS (ESI) [M+H]⁺: 383.1.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28 (s, 1H), 8.05 (dd, J = 1.1, 8.2 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 4.58 (br d, J = 13.7 Hz, 1H), 3.96 (br d, J = 13.5 Hz, 1H), 3.34-3.22 (m, 2H), 2.97 (br t, J = 11.2 Hz, 1H), 2.63 (s, 3H), 2.39 (s, 2H), 2.21 (br d, J = 13.2 Hz, 2H), 2.03-1.85 (m, 2H), 1.16 (s, 3H), 0.48-0.38 (m, 4H); LCMS (ESI) [M+H]⁺: 381.1.


20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.88-7.81 (m, 1H), 7.79-7.70 (m, 1H), 4.94 (t, J = 7.0 Hz, 2H), 4.52 (br d, J = 13.7 Hz, 1H), 4.43 (t, J = 5.6 Hz, 2H), 4.09 (s, 3H), 3.98 (br d, J = 13.6 Hz, 1H), 3.50-3.39 (m, 1H), 3.33 (br s, 2H), 3.00 (br s, 1H), 2.83 (d, J = 7.7 Hz, 2H), 2.61 (s, 3H), 2.25 (br t, J = 14.4 Hz, 2H), 2.09-1.89 (m, 2H); LCMS (ESI) [M+H]⁺: 396.2.

30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (d, J = 0.7 Hz, 1H), 8.05 (s, 1H), 7.78 (d, J = 0.9 Hz, 2H), 4.95 (spt, J = 6.6 Hz, 1H), 4.56 (q, J = 8.4 Hz, 2H), 3.78 (br s, 4H), 3.74-3.68 (m, 4H), 1.63 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 439.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.84 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 8.39 (dd, J = 8.4, 1.6 Hz, 1H), 6.22 (s, 1H), 4.75-4.64 (m, 1H), 4.13-4.05 (m, 1H), 3.71 (s, 4H), 3.55-3.30 (m, 4H), 1.93-1.72 (m, 4H), 1.56 (d, J = 6.8 Hz, 6H), 0.75-0.62 (m, 4H); LCMS (ESI) [M+H]⁺: 369.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (d, J = 0.9 Hz, 1H), 8.05 (s, 1H), 7.78 (d, J = 1.0 Hz, 2H), 4.95 (td, J = 6.7, 13.3 Hz, 1H), 4.17 (s, 2H), 3.84-3.68 (m, 8H), 3.51-3.42 (m, 1H), 3.46 (s, 2H), 1.63 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 485.1.

15



¹H NMR (400 MHz, DMSO-d₆) δ 8.26 (s, 1H), 8.18 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.73 (dd, J = 1.1, 8.4 Hz, 1H), 5.09 (spt, J = 6.6 Hz, 1H), 3.16-3.05 (m, 2H), 2.24 (br d, J = 11.4 Hz, 2H), 2.10 (br d, J = 10.0 Hz, 2H), 1.76-1.65 (m, 2H), 1.54 (br dd, J = 2.8, 12.6 Hz, 2H), 1.49 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 326.1.


20



¹H NMR (300 MHz, CHLOROFORM-d) δ 8.19 (dd, J = 14.6, 1.0 Hz, 2H), 7.95-7.80 (m, 2H), 5.89 (p, J = 7.1 Hz, 1H), 5.33 (t, J = 6.9, 6.2 Hz, 2H), 5.16 (t, J = 7.2 Hz, 2H), 4.51 (q, J = 6.7 Hz, 2H), 3.83 (s, 1H), 3.37 (d, J = 10.6 Hz, 1H), 3.32 (s, 1H), 3.19-3.05 (m, 1H), 2.80 (s, 1H), 2.25 (s, 1H), 1.64 (d, J = 7.0 Hz,

25


1H), 1.57-1.42 (m, 1H), 1.38 (dd, J = 8.8, 6.1 Hz, 3H), 1.25 (s, 1H), 1.06 (s, 1H); LCMS (ESI) [M+H]⁺: 398.3.



5


¹H NMR (300 MHz, CHLOROFORM-d) δ 8.26-8.14 (m, 2H), 7.96-7.80 (m, 4H), 7.59-7.40 (m, 3H), 7.33 (s, 1H), 5.88 (q, J = 6.8 Hz, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.16 (t, J = 7.3 Hz, 2H), 4.54 (d, J = 14.0 Hz, 1H), 4.32 (d, J = 4.0 Hz, 2H), 3.93 (d, J = 13.8 Hz, 1H), 3.43-3.28 (m, 2H), 3.15 (t, J = 12.1 Hz, 1H), 2.02 (dd, J = 14.6, 10.7 Hz, 2H), 1.47 (s, 1H), 1.25 (s, 2H); LCMS (ESI) [M+H]⁺: 487.3.

10




¹H NMR (300 MHz, CHLOROFORM-d) δ 8.27-8.14 (m, 2H), 8.01-7.81 (m, 4H), 7.55-7.40 (m, 2H), 5.90 (s, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.16 (t, J = 7.2 Hz, 2H), 4.57 (t, J = 15.7 Hz, 1H), 4.34 (dd, J = 9.5, 6.6 Hz, 1H), 3.95 (t, J = 8.1 Hz, 2H), 3.62 (p, J = 8.2 Hz, 1H), 3.40 (d, J = 8.2 Hz, 1H), 3.37 (s, 1H), 3.21-2.87 (m, 3H), 2.28 (d, J = 13.1 Hz, 2H), 2.06 (s, 1H), 1.25 (s, 1H); LCMS (ESI) [M+H]⁺: 538.3.

15



¹H NMR (300 MHz, CHLOROFORM-d) δ 8.27-8.14 (m, 2H), 8.01-7.81 (m, 4H), 7.55-7.40 (m, 2H), 5.89 (s, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.17 (t, J = 7.1 Hz, 2H), 4.57 (s, 1H), 4.34 (dd, J = 9.5, 6.6 Hz, 1H), 3.96 (t, J = 8.5 Hz, 2H), 3.68-3.56 (m, 1H), 3.39 (s, 1H), 3.12 (s, 1H), 3.06-2.89 (m, 2H), 2.29 (s, 1H), 2.06 (s, 1H), 1.25 (s, 1H); LCMS (ESI) [M+H]⁺: 538.3.


20



25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.09 (s, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.83 (dd, J = 0.7, 8.4 Hz, 1H), 7.79-7.71 (m, 3H), 7.42-7.29 (m, 1H), 4.58 (dt, J = 6.5, 14.7 Hz, 0.5H), 4.44-4.30 (m, 2.5H), 4.29-


4.16 (m, 0.5H), 4.08 (s, 3H), 4.06-3.99 (m, 0.5H), 3.96-3.69 (m, 2H), 3.67-3.50 (m, 1H), 2.60 (s, 3H), 2.49-2.29 (m, 2H); LCMS (ESI) [M+H]⁺: 520.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.03 (s, 1H), 7.76 (dd, J = 1.1, 8.4 Hz, 1H), 7.70-7.64 (m, 1H), 7.57-7.46 (m, 2H), 7.36 (dt, J = 5.6, 7.9 Hz, 1H), 7.21-7.11 (m, 2H), 4.57-4.42 (m, 0.5H), 4.34-4.22 (m, 2.6H), 4.21-4.10 (m, 0.6H), 4.01 (s, 3H), 3.99-3.90 (m, 0.5H), 3.87-3.62 (m, 2H), 3.60-3.42 (m, 1H), 2.53 (s, 3H), 2.41-2.22 (m, 2H); LCMS (ESI) [M+H]⁺: 513.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 7.91-7.85 (m, 2H), 7.81-7.76 (m, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.46-7.40 (m, 1H), 7.23 (br d, J = 19.8 Hz, 1H), 4.60 (dt, J = 6.4, 14.7 Hz, 0.5H), 4.44-4.32 (m, 2.5H), 4.25 (dt, J = 5.3, 14.7 Hz, 0.5H), 4.13 (s, 3H), 4.06 (br d, J = 13.4 Hz, 0.5H), 3.97-3.71 (m, 2H), 3.69-3.52 (m, 1H), 2.65 (s, 3H), 2.48-2.33 (m, 2H); LCMS (ESI) [M+H]⁺: 529.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.17 (br d, J = 5.3 Hz, 1H), 8.11 (s, 1H), 8.07 (br d, J = 7.9 Hz, 1H), 7.87-7.80 (m, 2H), 7.76 (dd, J = 0.7, 8.4 Hz, 1H), 7.64-7.59 (m, 1H), 7.35-7.26 (m, 1H), 4.58 (dt, J = 6.3, 14.9 Hz, 0.5H), 4.44-4.30 (m, 2.5H), 4.24 (dt, J = 5.6, 15.1 Hz, 0.5H), 4.09 (s, 3H), 4.04 (br d, J = 14.5 Hz, 0.5H), 3.96-3.84 (m, 1.5H), 3.82-3.70 (m, 0.5H), 3.70-3.49 (m, 1H), 2.61 (s, 3H), 2.47-2.31 (m, 2H); LCMS (ESI) [M+H]⁺: 520.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.32 (s, 1H), 8.11 (s, 1H), 7.95-7.79 (m, 2H), 5.00 (spt, J = 6.6 Hz, 1H), 4.42-4.24 (m, 4H), 4.01 (tt, J = 6.1, 8.8 Hz, 1H), 1.66 (d, J = 6.6 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M-55]⁺: 328.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.31 (s, 1H), 8.11 (s, 1H), 7.88 (m, 2H), 4.99 (spt, J = 6.7 Hz, 1H), 4.59-4.49 (m, 2H), 4.48-4.41 (m, 1H), 4.39-4.32 (m, 1H), 4.04 (tt, J = 6.0, 8.8 Hz, 1H), 2.14-2.02 (m, 2H), 1.66 (d, J = 6.6 Hz, 6H), 1.10 (s, 9H); LCMS (ESI) [M+H]⁺: 382.2.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.11 (s, 1H), 7.91-7.86 (m, 1H), 7.85-7.80 (m, 1H), 5.16-5.03 (m, 1H), 4.90 (t, J = 8.6 Hz, 0.5H), 4.82-4.74 (m, 1H), 4.67 (dd, J = 5.0, 9.4 Hz, 0.5H), 4.34-3.93 (br s, 2H), 3.21 (tt, J = 3.9, 10.8 Hz, 1H), 3.11-2.97 (m, 2H), 2.16 (br d, J = 12.0 Hz, 2H), 1.94 (br d, J = 9.7 Hz, 2H), 1.66 (dd, J = 1.5, 6.9 Hz, 3H), 1.58 (s, 3H), 0.95-0.84 (m, 2H), 0.69-0.60 (m, 2H); LCMS (ESI) [M+H]⁺: 428.1.


15



20


¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (s, 1H), 8.19 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 6.95 (br d, J = 4.5 Hz, 1H), 5.14 (spt, J = 6.5 Hz, 1H), 4.65-4.43 (m, 1H), 3.20-3.12 (m, 1H), 2.58 (d, J = 4.5 Hz, 3H), 2.21 (br d, J = 11.4 Hz, 2H), 2.04 (br dd, J = 3.1, 12.5 Hz, 2H), 1.82-1.71 (m, 2H), 1.57-1.44 (m, 8H); LCMS (ESI) [M+H]⁺: 384.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.83 (dd, J = 1.0, 8.4 Hz, 1H), 7.76-7.70 (m, 1H), 4.80-4.54 (m, 2H), 4.08 (s, 3H), 3.06-2.96 (m, 1H), 2.82 (d, J = 4.8 Hz, 3H), 2.60 (s, 3H), 2.34-2.16 (m, 4H), 1.94-1.82 (m, 2H), 1.60-1.46 (m, 2H); LCMS (ESI) [M+H]⁺: 370.1.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.77 (d, J = 7.7 Hz, 1H), 7.66 (s, 1H), 7.35 (d, J = 7.6 Hz, 1H), 4.72-4.65 (m, 1H), 4.25-4.00 (m, 2H), 3.56 (s, 2H), 3.24-3.15 (m, 1H), 3.03 (br t, J = 11.1 Hz, 2H), 2.14 (br d, J = 11.9 Hz, 2H), 1.92 (br d, J = 9.5 Hz, 2H), 1.57 (s, 3H), 1.54 (d, J = 7.0 Hz, 6H), 0.92-0.87 (m, 2H), 0.68-0.63 (m, 2H); LCMS (ESI) [M+H]⁺: 425.2.




10 ¹H NMR (400 MHz, CHLOROFORM-d) δ 7.77 (d, J = 7.7 Hz, 1H), 7.66 (s, 1H), 7.35 (d, J = 7.7 Hz, 1H), 4.72-4.65 (m, 1H), 4.62 (br d, J = 14.1 Hz, 1H), 4.03 (br d, J = 14.1 Hz, 1H), 3.56 (s, 2H), 3.34-3.22 (m, 2H), 2.95 (br t, J = 11.5 Hz, 1H), 2.32 (s, 2H), 2.20 (br d, J = 11.5 Hz, 2H), 2.03-1.84 (m, 2H), 1.54 (d, J = 6.8 Hz, 6H), 1.08 (s, 9H); LCMS (ESI) [M+H]⁺: 425.2.




15 ¹H NMR (400 MHz, METHANOL-d₄) δ 7.80 (d, J = 7.7 Hz, 1H), 7.75 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.49-7.35 (m, 4H), 4.70-4.63 (m, 2H), 3.60-3.53 (m, 1H), 3.44-3.39 (m, 1H), 3.52-3.37 (m, 1H), 3.32-3.22 (m, 2H), 2.35 (br d, J = 11.9 Hz, 1H), 2.17 (br d, J = 13.0 Hz, 1H), 2.10-1.96 (m, 2H), 1.95-1.81 (m, 1H), 20 1.55 (d, J = 7.1 Hz, 6H). LCMS (ESI) [M+H]⁺: 465.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.94 (s, 1H), 7.70-7.61 (m, 2H), 3.99 (s, 3H), 3.67-3.49 (m, 8H), 25 2.51 (s, 3H), 1.51 (s, 3H), 0.88-0.79 (m, 2H), 0.64-0.56 (m, 2H); LCMS (ESI) [M+H]⁺: 397.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.03 (s, 1H), 7.81-7.73 (m, 2H), 4.95 (m, 1H), 4.30 (m, 2H), 3.49 (q, J = 7.1 Hz, 2H), 3.32 (d, J = 6.0 Hz, 2H), 3.15 (dt, J = 2.3, 12.8 Hz, 2H), 1.96-1.80 (m, 3H), 1.61 (d, J = 6.6 Hz, 6H), 1.46-1.29 (m, 2H), 1.21 (t, J = 6.9 Hz, 3H); LCMS (ESI) [M+H]⁺: 370.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.90-7.78 (m, 3H), 7.28 (s, 1H), 5.09-4.91 (m, 2H), 4.65 (br d, J = 13.2 Hz, 1H), 3.70-3.58 (m, 1H), 3.47-3.36 (m, 1H), 3.34-3.23 (m, 1H), 2.30 (br d, J = 3.5 Hz, 2H), 2.23-2.05 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 407.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.08 (s, 1H), 7.91-7.79 (m, 2H), 4.98 (td, J = 6.6, 13.3 Hz, 1H), 4.74-4.49 (m, 1H), 4.25-4.03 (m, 1H), 3.53-3.29 (m, 3H), 3.23-2.97 (m, 2H), 2.77 (s, 3H), 2.48 (br dd, J = 7.6, 17.0 Hz, 1H), 2.38-2.21 (m, 2H), 2.11-1.92 (m, 2H), 1.65 (d, J = 6.6 Hz, 6H), 1.43 (s, 3H), 1.17 (d, J = 5.0 Hz, 3H); LCMS (ESI) [M+H]⁺: 465.2.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.17 (s, 1H), 7.94-7.89 (m, 1H), 7.88-7.83 (m, 1H), 5.90 (quin, J = 7.0 Hz, 1H), 5.34 (t, J = 6.6 Hz, 2H), 5.16 (t, J = 7.3 Hz, 2H), 4.63 (br d, J = 13.4 Hz, 1H), 4.05 (br d, J = 13.4 Hz, 1H), 3.37-3.23 (m, 2H), 2.96 (br t, J = 11.2 Hz, 1H), 2.32 (s, 2H), 2.22 (br d, J = 12.8 Hz, 2H), 2.03-1.88 (m, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 424.2.


20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.17 (s, 1H), 7.94-7.88 (m, 1H), 7.88-7.82 (m, 1H), 5.90 (quin, J = 7.0 Hz, 1H), 5.34 (t, J = 6.5 Hz, 2H), 5.16 (t, J = 7.3 Hz, 2H), 4.39-3.91 (m, 3H), 3.23 (tt, J = 3.9, 10.9 Hz, 1H), 3.07 (ddd, J = 2.9, 11.2, 13.8 Hz, 2H), 2.25-2.08 (m, 2H), 2.03-1.85 (m, 2H), 0.76-0.66 (m, 4H); LCMS (ESI) [M+H]⁺: 410.1.

30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (br d, J = 2.9 Hz, 2H), 7.86-7.78 (m, 2H), 5.93-5.84 (m, 1H), 5.33 (m, 2H), 5.19-5.11 (m, 2H), 3.85-3.67 (m, 8H), 2.33 (d, J = 2.4 Hz, 2H), 1.09 (d, J = 2.4 Hz, 9H);

5 LCMS (ESI) [M+H]⁺: 425.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (d, J = 7.1 Hz, 2H), 7.84-7.78 (m, 2H), 5.88 (quin, J = 7.1 Hz, 1H), 5.32 (t, J = 6.6 Hz, 2H), 5.14 (t, J = 7.3 Hz, 2H), 3.74-3.56 (m, 8H), 1.58 (s, 3H), 0.93-0.88 (t, J = 6.4 Hz, 2H), 0.70-0.65 (t, J = 6.4 Hz, 2H); LCMS (ESI) [M+H]⁺: 425.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.46 (s, 1H), 8.21-8.14 (m, 2H), 7.85 (d, J = 8.4 Hz, 1H), 5.94 (m, 1H), 5.37 (t, J = 6.6 Hz, 2H), 5.18 (t, J = 7.3 Hz, 2H), 4.26 (m, 2H), 3.38 (m, 1H), 3.00 (m, 2H), 2.25 (m, 2H), 1.87 (m, 2H), 1.52 (s, 9H); LCMS (ESI) [M+H]⁺: 442.1.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.07 (s, 1H), 7.89-7.80 (m, 2H), 5.02-4.93 (m, 1H), 4.10 (br s, 2H), 3.75 (s, 3H), 3.42 (br t, J = 10.6 Hz, 2H), 2.41-2.23 (m, 4H), 1.63 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 388.1.


20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.09 (s, 1H), 7.90-7.83 (m, 2H), 5.03-4.96 (m, 1H), 4.56 (br d, J = 13.4 Hz, 1H), 3.89 (br d, J = 13.9 Hz, 1H), 3.62 (br t, J = 11.4 Hz, 1H), 3.29 (br t, J = 11.2 Hz, 1H), 2.48-2.24 (m, 6H), 1.65 (d, J = 6.6 Hz, 6H), 1.20 (s, 3H), 0.52-0.40 (m, 4H); LCMS (ESI) [M+H]⁺: 426.2.

25


30



5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.15 (s, 1H), 7.99 (s, 1H), 7.80-7.73 (m, 2H), 4.95-4.84 (m, 1H), 4.19-3.78 (m, 3H), 3.39-3.24 (m, 2H), 2.34-2.11 (m, 4H), 1.55 (d, J = 6.7 Hz, 6H), 0.67-0.61 (m, 4H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 414.1.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.24 (s, 1H), 8.08 (s, 1H), 7.89-7.82 (m, 2H), 4.98 (spt, J = 6.6 Hz, 1H), 4.22-3.89 (m, 2H), 3.46-3.32 (m, 2H), 2.40-2.23 (m, 4H), 1.65 (d, J = 6.6 Hz, 6H), 1.59 (s, 3H), 1.05-0.86 (m, 2H), 0.71-0.65 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 428.1.




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.77 (d, J = 7.7 Hz, 1H), 7.66 (s, 1H), 7.35 (d, J = 7.5 Hz, 1H), 4.72-4.65 (m, 1H), 4.59 (br d, J = 13.5 Hz, 1H), 3.96 (br d, J = 13.7 Hz, 1H), 3.56 (s, 2H), 3.33-3.23 (m, 2H), 2.97 (br t, J = 11.4 Hz, 1H), 2.39 (d, J = 4.4 Hz, 2H), 2.21 (br d, J = 13.2 Hz, 2H), 2.01-1.87 (m, 2H), 1.54 (d, J = 7.1 Hz, 6H), 1.17 (s, 3H), 0.48-0.38 (m, 4H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 423.2.


20



25 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.77 (dd, J = 1.0, 7.6 Hz, 1H), 7.66 (s, 1H), 7.35 (d, J = 7.7 Hz, 1H), 4.68 (spt, J = 7.0 Hz, 1H), 4.30-4.00 (m, 2H), 3.73 (s, 3H), 3.55 (s, 2H), 3.22 (tt, J = 4.0, 10.8 Hz, 1H), 3.08 (br t, J = 11.7 Hz, 2H), 2.16 (br d, J = 10.8 Hz, 2H), 2.03-1.84 (m, 2H), 1.54 (d, J = 7.1 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 385.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.27 (s, 1H), 8.10 (s, 1H), 7.87 (m, 2H), 5.06-4.92 (m, 1H), 4.37-3.97 (m, 2H), 3.14-2.90 (m, 3H), 2.09 (br d, J = 10.8 Hz, 2H), 1.88 (br d, J = 9.9 Hz, 2H), 1.65 (d, J = 6.6 Hz, 6H), 1.58 (s, 3H), 0.97-0.83 (m, 2H), 0.70-0.59 (m, 2H); LCMS (ESI) [M+H]⁺: 410.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28 (s, J = 0.6 Hz, 1H), 8.10 (s, 1H), 7.92-7.82 (m, 2H), 4.98 (spt, J = 6.7 Hz, 1H), 4.22 (br s, 2H), 3.74 (s, 3H), 3.16-2.97 (m, 3H), 2.11 (m, J = 11.7 Hz, 2H), 1.99-1.82 (m, 2H), 1.65 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 370.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.09 (s, 1H), 7.84 (m, 2H), 4.97 (spt, J = 6.6 Hz, 1H), 3.76 (s, 3H), 3.69-3.44 (m, 8H), 1.64 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 371.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.03-7.82 (m, 3H), 7.78-7.73 (m, 1H), 7.53-7.43 (m, 2H), 4.65 (m, 0.4H), 4.48 (m, 0.5H), 4.41-4.24 (m, 2H), 4.10 (br d, J = 2.4 Hz, 3H), 4.00 (t, J = 9.0 Hz, 1H), 3.95-3.75 (m, 2H), 3.73-3.45 (m, 2H), 3.07-2.89 (m, 2H), 2.62 (s, 3H), 2.49-2.32 (m, 2H); LCMS (ESI) [M+H]⁺: 546.2.

20




25


¹H NMR (400 MHz, CHLOROFORM-d) δ 7.85 (s, 1H), 7.54 (d, J = 8.7 Hz, 1H), 6.40 (dd, J = 1.6, 8.7 Hz, 1H), 6.23 (s, 1H), 4.83-4.60 (m, 1H), 3.73 (s, 4H), 3.69-3.44 (m, 4H), 2.30 (s, 2H), 1.85 (br dd, J = 5.4, 8.8 Hz, 4H), 1.57 (d, J = 6.6 Hz, 6H), 1.08 (s, 9H); LCMS (ESI) [M+H]⁺: 383.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.38 (s, 1H), 8.14-8.04 (m, 2H), 7.76 (d, J = 8.4 Hz, 1H), 6.83 (br s, 1H), 5.85 (t, J = 6.9 Hz, 1H), 5.28 (t, J = 6.5 Hz, 2H), 5.09 (t, J = 7.3 Hz, 2H), 4.15 (d, J = 2.4 Hz, 2H), 3.64 (t, J = 5.4 Hz, 2H), 2.70 (m, 2H), 1.44 (s, 9H) LCMS (ESI) [M+H]⁺: 440.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.08 (s, 1H), 7.89-7.81 (m, 2H), 5.04-4.93 (m, 1H), 3.84-3.73 (m, 1H), 3.03 (tt, J = 3.7, 11.9 Hz, 1H), 2.33-2.26 (m, 2H), 2.24-2.15 (m, 2H), 1.88-1.77 (m, 2H), 1.64 (d, J = 6.7 Hz, 6H), 1.55-1.44 (m, 2H); LCMS (ESI) [M+H]⁺: 327.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.17 (s, 1H), 7.94-7.88 (m, 1H), 7.87-7.81 (m, 1H), 5.90 (quin, J = 7.0 Hz, 1H), 5.34 (t, J = 6.5 Hz, 2H), 5.16 (t, J = 7.3 Hz, 2H), 4.31-4.08 (m, 2H), 3.74 (s, 3H), 3.23 (tt, J = 3.9, 10.9 Hz, 1H), 3.09 (br t, J = 11.5 Hz, 2H), 2.18 (br dd, J = 2.8, 13.3 Hz, 2H), 2.02-1.89 (m, 2H); LCMS (ESI) [M+H]⁺: 384.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (d, J = 4.5 Hz, 2H), 7.81-7.81 (m, 2H), 5.87 (quin, J = 7.0 Hz, 1H), 5.32 (t, J = 6.5 Hz, 2H), 5.14 (t, J = 7.3 Hz, 2H), 3.76 (s, 3H), 3.72 (m, 4H), 3.65 (m, 4H); LCMS (ESI) [M+H]⁺: 385.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.12 (s, 1H), 8.03 (s, 1H), 7.81-7.73 (m, 2H), 4.95 (m, 1H), 4.33 (m, 2H), 3.57 (d, J = 6.2 Hz, 2H), 3.16 (dt, J = 2.8, 13.0 Hz, 2H), 1.90 (br d, J = 12.6 Hz, 2H), 1.84-1.73 (m, 1H), 1.61 (d, J = 6.6 Hz, 6H), 1.45-1.33 (m, 2H); LCMS (ESI) [M+H]⁺: 342.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.08 (s, 1H), 7.84-7.79 (m, 1H), 7.75-7.71 (m, 1H), 4.50 (br dd, J = 10.0, 13.3 Hz, 1H), 4.37 (t, J = 8.5 Hz, 1H), 4.19 (t, J = 9.3 Hz, 1H), 4.07 (s, 3H), 3.92 (br d, J = 13.5 Hz, 1H), 3.79 (dd, J = 5.6, 8.5 Hz, 1H), 3.67 (br dd, J = 5.7, 9.5 Hz, 1H), 3.31 (br t, J = 10.9 Hz, 2H), 3.06-2.96 (m, 2H), 2.80-2.62 (m, 2H), 2.59 (s, 3H), 2.29-2.18 (m, 2H), 2.05-1.91 (m, 2H), 1.85 (s, 3H); LCMS (ESI) [M+H]⁺: 437.5.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.45 (s, 1H), 8.28 (d, J = 8.7 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 4.16 (br s, 2H), 3.48 (td, J = 7.0, 14.0 Hz, 1H), 3.28-3.13 (m, 1H), 3.02 (br t, J = 11.6 Hz, 2H), 2.15 (br d, J = 10.4 Hz, 2H), 2.03-1.86 (m, 2H), 1.54 (d, J = 7.0 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 413.1.




¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (s, 1H), 8.20 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.74 (dd, J = 1.2, 8.5 Hz, 1H), 4.46-4.29 (m, 1H), 3.98 (br d, J = 13.2 Hz, 2H), 3.48-3.35 (m, 1H), 2.99 (br s, 2H), 2.10 (br dd, J = 3.1, 13.2 Hz, 2H), 1.80-1.64 (m, 2H), 1.59 (d, J = 6.6 Hz, 3H), 1.47-1.36 (m, 10H), 0.64-0.55 (m, 1H), 0.44 (qd, J = 4.8, 9.5 Hz, 1H), 0.38-0.30 (m, 1H), 0.25 (qd, J = 4.9, 9.6 Hz, 1H); LCMS (ESI) [M+H]⁺: 438.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.07 (s, 1H), 7.88-7.84 (d, J = 12 Hz, 1H), 7.83-7.79 (d, J = 12 Hz, 1H), 5.15-5.01 (m, 1H), 4.16-4.13 (m, 2H), 3.64-3.62 (m, 1H), 3.45-3.34 (m, 1H), 3.21-3.18 (m, 1H), 2.98-3.02 (m, 2H), 2.39-2.36 (m, 1H), 2.24-2.09 (m, 3H), 1.99-1.86 (m, 3H), 1.63 (d, J = 6.6 Hz, 3H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 442.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (d, J = 6.1 Hz, 2H), 7.84-7.78 (m, 2H), 5.88 (quin, J = 7.1 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.14 (t, J = 7.3 Hz, 2H), 4.16-4.10 (m, 1H), 3.79-3.56 (m, 8H), 0.78-0.67 (m, 4H); LCMS (ESI) [M+H]⁺: 411.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.30 (s, 1H), 8.21 (s, 1H), 7.98-7.83 (m, 2H), 5.91 (m, J = 7.0 Hz, 1H), 5.40-5.30 (m, 2H), 5.24-5.11 (m, 2H), 4.29-4.06 (m, 2H), 3.06 (tt, J = 3.7, 11.2 Hz, 1H), 2.97 (br t, J = 11.9 Hz, 2H), 2.16-2.01 (m, 2H), 1.97-1.79 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M-55]⁺: 370.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (d, J = 8.4 Hz, 2H), 8.00-7.94 (m, 1H), 7.92-7.83 (m, 1H), 5.90-5.75 (m, 1H), 5.16 (s, 2H), 4.25-4.10 (m, 2H), 3.29-2.96 (m, 3H), 2.80 (d, J = 4.8 Hz, 3H), 2.18 (br d, J = 11.1 Hz, 2H), 2.05-1.85 (m, 2H), 1.51 (s, 9H); LCMS (ESI) [M-100+H]⁺: 341.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.32 (s, 1H), 8.08 (s, 1H), 7.91-7.88 (m, 1H), 7.85-7.81 (m, 1H), 5.61 (br s, 1H), 4.92 (dd, J = 4.3, 14.4 Hz, 1H), 4.63 (dd, J = 8.5, 14.4 Hz, 1H), 4.17 (m, 2H), 3.39-3.16 (m, 3H), 3.14-2.95 (m, 3H), 2.31-2.07 (m, 4H), 2.02-1.89 (m, 2H); LCMS (ESI) [M+H]⁺: 367.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.45 (s, 1H), 8.28 (dd, J = 1.6, 8.8 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 4.19 (br s, 2H), 3.74 (s, 3H), 3.48 (td, J = 6.9, 14.0 Hz, 1H), 3.29-3.18 (m, 1H), 3.09 (br t, J = 12.5

Hz, 2H), 2.17 (br d, J = 13.6 Hz, 2H), 2.02-1.88 (m, 2H), 1.55 (s, 3H), 1.54 (s, 3H); LCMS (ESI) [M+H]⁺: 371.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.06 (s, 1H), 7.89-7.80 (m, 2H), 5.04-4.93 (m, 2H), 4.65 (br s, 1H), 3.18-3.09 (m, 1H), 2.82 (d, J = 4.9 Hz, 3H), 2.23-1.97 (m, 6H), 1.77 (br d, J = 11.1 Hz, 2H), 1.63 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 384.1.



10


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 8.01-7.83 (m, 3H), 7.79-7.73 (m, 1H), 7.52-7.43 (m, 2H), 4.64 (dt, J = 6.5, 14.2 Hz, 1H), 4.47 (br d, J = 13.3 Hz, 1H), 4.41-4.25 (m, 2H), 4.10 (br d, J = 2.8 Hz, 3H), 3.99 (t, J = 9.0 Hz, 1H), 3.94-3.75 (m, 2H), 3.71-3.43 (m, 2H), 3.05-2.87 (m, 2H), 2.61 (s, 3H), 2.48-2.30 (m, 2H); LCMS (ESI) [M+H]⁺: 546.2.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 5.55-5.48 (m, 1H), 5.24-5.21 (m, 2H), 5.15-5.11 (m, 2H), 4.22-4.05 (m, 2H), 3.19 (tt, J = 3.8, 11.0 Hz, 1H), 3.00 (br t, J = 11.8 Hz, 2H), 2.14 (br d, J = 10.6 Hz, 2H), 1.98-1.85 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M-55]⁺: 387.1.


20




25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, 1H), 8.08 (s, 1H), 7.93-7.87 (m, 1H), 7.86-7.79 (m, 1H), 5.43-5.33 (m, 1H), 4.34-4.12 (m, 5H), 4.05 (q, J = 7.3 Hz, 1H), 3.21 (br t, J = 10.9 Hz, 1H), 3.02 (br t, J = 11.7 Hz, 2H), 2.55 (q, J = 6.7 Hz, 2H), 2.16 (br d, J = 13.0 Hz, 2H), 2.01-1.86 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 440.5.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28 (s, 1H), 8.07 (s, 1H), 7.88-7.84 (d, J = 8.4 Hz, 1H), 7.82-7.77 (d, J = 8.4 Hz, 1H), 5.35-5.23 (m, 1H), 4.18-4.16 (m, 2H), 4.05-3.96 (m, 2H), 3.25-3.14 (m, 2H), 3.03 (br t, J = 11.9 Hz, 2H), 2.93 (dd, J = 6.1, 16.0 Hz, 1H), 2.16 (br d, J = 10.8 Hz, 2H), 2.01-1.89 (m, 2H), 1.64 (d, J = 6.6 Hz, 3H), 1.50 (s, 9H), 1.10 (t, J = 7.2 Hz, 3H); LCMS (ESI) [M+H]⁺: 484.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.17 (s, 1H), 8.14 (s, 1H), 7.93-7.87 (m, 1H), 7.86-7.80 (m, 1H), 5.54-5.42 (m, 1H), 4.60-4.52 (m, 2H), 4.51-4.43 (m, 2H), 4.22-4.07 (m, 2H), 3.20 (tt, J = 3.9, 10.9 Hz, 1H), 3.01 (br t, J = 12.0 Hz, 2H), 2.15 (br dd, J = 2.6, 13.2 Hz, 2H), 2.00-1.83 (m, 2H), 1.49 (d, J = 2.6 Hz, 18H); LCMS (ESI) [M-100+H]⁺: 425.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.93-7.85 (m, 1H), 7.07 (dd, J = 11.5, 18.0 Hz, 1H), 6.09 (d, J = 18.1 Hz, 1H), 5.63-5.46 (m, 1H), 5.05-4.85 (m, 1H), 4.16 (br s, 2H), 3.21 (ddd, J = 4.2, 6.9, 10.8 Hz, 1H), 3.02 (br t, J = 11.6 Hz, 2H), 2.16 (br d, J = 11.1 Hz, 2H), 2.00-1.88 (m, 2H), 1.63 (d, J = 6.7 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 438.5.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.06 (s, 1H), 7.90-7.80 (m, 2H), 4.98 (spt, J = 6.6 Hz, 1H), 4.05 (br d, J = 2.9 Hz, 1H), 3.19-3.03 (m, 1H), 2.32-2.21 (m, 2H), 1.98 (qd, J = 4.5, 13.7 Hz, 2H), 1.91-1.77 (m, 4H), 1.64 (d, J = 6.6 Hz, 6H), 1.43 (d, J = 3.4 Hz, 1H); LCMS (ESI) [M+H]⁺: 327.1




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 8.07 (s, 1H), 7.80-7.76 (m, 1H), 7.75-7.72 (m, 1H), 5.36-5.26 (m, 1H), 4.32-4.08 (m, 5H), 4.06-3.99 (m, 1H), 3.24-3.14 (m, 1H), 3.03 (br t, J = 11.8 Hz, 2H), 2.69-2.58 (m, 1H), 2.54-2.44 (m, 1H), 2.15 (br d, J = 11.4 Hz, 2H), 1.99-1.87 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 440.5.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.53 (d, J = 0.7 Hz, 1H), 8.10 (s, 1H), 7.82-7.77 (m, 1H), 7.76-7.71 (m, 1H), 5.35 (m, 1H), 4.55-4.45 (m, 4H), 4.21-4.04 (m, 2H), 3.25-3.12 (m, 1H), 3.02 (br t, J = 11.7 Hz, 2H), 2.14 (br dd, J = 2.9, 13.2 Hz, 2H), 2.00-1.83 (m, 2H), 1.48 (d, J = 1.5 Hz, 18H); LCMS (ESI) [M+23]⁺: 547.2, LCMS (ESI) [M-100+H]⁺: 425.2, LCMS (ESI) [M-100-55+H]⁺: 369.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 8.07 (s, 1H), 7.79 (m, 2H), 5.04-4.88 (m, 1H), 3.85 (m, 8H), 2.28 (s, 3H), 1.64 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 395.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 7.98-7.90 (m, 2H), 7.46-7.36 (m, 2H), 4.22-4.05 (m, 4H), 3.94 (q, J = 7.9 Hz, 1H), 3.80-3.73 (m, 1H), 3.48 (quin, J = 7.8 Hz, 1H), 3.17 (m, 1H), 2.99 (br t, J = 11.4 Hz, 2H), 2.41 (m, 1H), 2.18-1.99 (m, 3H), 1.97-1.83 (m, 2H), 1.48 (s, 9H); LCMS (ESI) [M-100+H]⁺: 300.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (d, J = 3.4 Hz, 2H), 7.85-7.78 (m, 2H), 5.88 (quin, J = 7.1 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.14 (t, J = 7.3 Hz, 2H), 3.83-3.62 (m, 8H), 2.35 (d, J = 6.7 Hz, 2H), 1.12-1.02 (m, 1H), 0.65-0.58 (m, 2H), 0.25-0.18 (m, 2H); LCMS (ESI) [M+H]⁺: 409.2.




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.43 (s, 1H), 8.13 (s, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.68-7.34 (t, J = 59.6 Hz, 1H), 3.70 (m, 4H), 3.62-3.57 (m, 4H), 1.50 (s, 9H); LCMS (ESI) $[M-55]^+$: 365.1.




10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.20 (s, 1H), 8.04 (d, J = 0.7 Hz, 1H), 7.91-7.86 (m, 1H), 7.84-7.80 (m, 1H), 4.85 (dd, J = 6.5, 7.5 Hz, 2H), 4.76 (d, J = 7.5 Hz, 2H), 4.62 (t, J = 6.1 Hz, 2H), 4.26-4.05 (m, 2H), 3.72-3.60 (m, 1H), 3.21 (tt, J = 3.9, 11.0 Hz, 1H), 3.02 (br t, J = 11.6 Hz, 1H), 3.08-2.96 (m, 1H), 2.16 (br dd, J = 2.4, 13.6 Hz, 2H), 2.01-1.87 (m, 2H), 1.49 (s, 9H); LCMS (ESI) $[M+H]^+$: 440.2.




15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 7.76 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.05 (s, 1H), 5.22-5.09 (m, 1H), 5.02 (t, J = 7.1 Hz, 2H), 4.70 (t, J = 7.3 Hz, 2H), 4.21-4.08 (m, 2H), 3.17 (tt, J = 3.8, 10.9 Hz, 1H), 3.06-2.94 (m, 4H), 2.62 (t, J = 7.2 Hz, 2H), 2.12 (br d, J = 11.0 Hz, 2H), 1.97-1.83 (m, 2H), 1.49 (s, 9H); LCMS (ESI) $[M+H]^+$: 455.2.



25 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.34 (s, 1H), 8.24 (s, 1H), 8.00-7.89 (m, 2H), 5.93 (quin, J = 6.9 Hz, 1H), 5.35 (t, J = 6.5 Hz, 2H), 5.20 (t, J = 7.2 Hz, 2H), 4.53-4.04 (m, 2H), 3.69-3.38 (m, 2H), 3.35-3.22 (m, 1H), 2.41-2.14 (m, 2H), 1.53 (s, 9H); LCMS (ESI) $[M+H]^+$: 462.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.14 (d, J = 4.4 Hz, 2H), 7.85-7.78 (m, 2H), 5.88(quin, J = 7.1 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.14 (t, J = 7.3 Hz, 2H), 3.75-3.67 (m, 4H), 3.63-3.57(m, 4H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 427.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, 1H), 8.02 (d, J = 7.7 Hz, 1H), 7.64 (br d, J = 8.1 Hz, 1H), 7.40-7.33 (m, 1H), 4.14 (br s, 2H), 3.18 (tt, J = 3.8, 10.9 Hz, 1H), 3.01 (br t, J = 11.6 Hz, 2H), 2.13 (br d, J = 10.9 Hz, 2H), 1.98-1.82 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M-55]⁺: 352.0.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.84 (q, J = 8.4 Hz, 1H), 7.90-7.80 (m, 1H), 4.98 (td, J = 6.7, 13.4 Hz, 1H), 4.86 (t, J = 6.8 Hz, 1H), 3.93 (br t, J = 12.8 Hz, 2H), 3.59-3.41 (m, 2H), 3.34-3.22 (m, 1H), 3.20-3.03 (m, 2H), 2.38-2.28 (m, 1H), 2.36-1.92 (m, 7H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 434.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.07 (s, 1H), 7.90-7.79 (m, 2H), 4.98 (td, J = 6.7, 13.3 Hz, 1H), 3.68 (br d, J = 13.4 Hz, 2H), 3.50 (t, J = 6.6 Hz, 2H), 3.19 (tt, J = 4.0, 11.1 Hz, 1H), 2.99-2.82 (m, 2H), 2.26-2.13 (m, 2H), 2.06-1.94 (m, 2H), 1.91-1.82 (m, 2H), 1.80-1.74 (m, 2H), 1.64 (d, J = 6.7 Hz, 6H), 1.46 (s, 6H); LCMS (ESI) [M+H]⁺: 437.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.05 (s, 1H), 7.78 (s, 2H), 4.96 (td, J = 6.6, 13.3 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.79-3.61 (m, 8H), 1.63 (d, J = 6.7 Hz, 6H), 1.31 (t, J = 7.1 Hz, 3H); LCMS (ESI) [M+H]⁺: 385.1.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.05 (s, 1H), 7.78 (s, 2H), 4.95 (td, J = 6.6, 13.3 Hz, 1H), 3.92-3.68 (m, 8H), 3.18 (s, 2H), 2.31 (s, 6H), 1.63 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 398.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.45 (s, 1H), 8.28 (dd, J = 1.4, 8.7 Hz, 1H), 7.66 (d, J = 8.7 Hz, 1H), 4.60 (br d, J = 13.3 Hz, 1H), 3.97 (br d, J = 13.6 Hz, 1H), 3.48 (td, J = 6.9, 14.0 Hz, 1H), 3.37-3.22 (m, 2H), 2.97 (br t, J = 11.1 Hz, 1H), 2.40 (d, J = 4.0 Hz, 2H), 2.22 (br d, J = 12.6 Hz, 2H), 2.04-1.86 (m, 2H), 1.55 (s, 6H), 1.18 (s, 3H), 0.49-0.40 (m, 4H); LCMS (ESI) [M+H]⁺: 409.2.




¹H NMR (400 MHz, CHLOROFORM-d) δ 9.20 (s, 1H), 8.24 (s, 1H), 8.09 (m, J = 8.2 Hz, 1H), 7.85 (br d, J = 8.2 Hz, 1H), 4.58 (br d, J = 14.1 Hz, 1H), 4.03 (br d, J = 13.7 Hz, 1H), 3.28 (br d, J = 11.7 Hz, 3H), 2.98 (br t, J = 11.8 Hz, 1H), 2.32 (s, 2H), 2.21 (br d, J = 12.6 Hz, 2H), 2.05-1.80 (m, 2H), 1.37 (m, 2H), 1.18 (m, J = 4.0 Hz, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 436.20.



¹H NMR (400 MHz, CHLOROFORM-d) δ 7.71 (d, J = 7.7 Hz, 1H), 7.43-7.35 (m, 2H), 6.89 (dd, J = 2.5, 8.3 Hz, 1H), 5.32-5.26 (m, 1H), 5.02 (t, J = 6.8 Hz, 2H), 4.79 (dd, J = 5.3, 7.2 Hz, 2H), 4.13 (br d, J = 9.9 Hz, 2H), 3.17 (tt, J = 3.9, 10.9 Hz, 1H), 3.00 (br t, J = 11.8 Hz, 2H), 2.12 (br dd, J = 2.8, 13.3 Hz, 2H), 1.94-1.83 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M-55]⁺: 346.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.18 (s, 1H), 8.04 (s, 1H), 7.79 (s, 2H), 5.01-4.90 (m, 1H), 4.24 (br s, 2H), 3.12-3.04 (m, 1H), 2.99-2.88 (m, 2H), 2.15-2.06 (m, 2H), 1.89-1.80 (m, 2H), 1.61 (d, J = 6.6 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 411.2.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.79 (s, 1H), 8.54 (s, 1H), 7.79 (m, 2H), 4.60 (m, J = 13.0 Hz, 1H), 4.04 (m, J = 13.5 Hz, 1H), 3.47 (s, 1H), 3.39-3.22 (m, 2H), 3.00 (t, J = 11.7 Hz, 1H), 2.33 (m, 2H), 2.22 (m, J = 13.5 Hz, 2H), 2.07-1.82 (m, 2H), 1.44 (m, 2H), 1.32 (m, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 436.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.30 (s, 1H), 8.21 (s, 1H), 8.01-7.82 (m, 2H), 5.91 (quin, J = 7.0 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.19 (t, J = 7.2 Hz, 2H), 4.27 (m, 1H), 4.16-3.98 (m, 2H), 3.18-2.93 (m, 3H), 2.08 (m, 2H), 1.90 (m, 2H), 0.78-0.65 (m, 4H); LCMS (ESI) [M+H]⁺: 410.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.30 (s, 1H), 8.21 (s, 1H), 7.98-7.86 (m, 2H), 5.97-5.81 (m, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.18 (t, J = 7.2 Hz, 2H), 4.21 (m, 2H), 3.74 (s, 3H), 3.20-2.92 (m, 3H), 2.11 (m, J = 11.8 Hz, 2H), 1.96-1.79 (m, 2H); LCMS (ESI) [M+H]⁺: 384.1.

20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.10 (s, 1H), 7.97 (s, 1H), 7.73-7.66 (m, 2H), 4.94-4.78 (m, 1H), 4.19 (br s, 2H), 3.66 (s, 3H), 3.09-2.86 (m, 3H), 2.06 (br d, J = 10.9 Hz, 2H), 1.87-1.71 (m, 2H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 369.1.



30


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.54 (s, 1H), 8.08 (s, 1H), 7.91-7.71 (m, 2H), 6.65 (br s, 1H), 5.15 (s, 2H), 4.25-4.07 (m, 2H), 3.22 (br t, J = 10.8 Hz, 1H), 3.12-2.97 (m, 2H), 2.83 (d, J = 4.9 Hz, 3H), 2.17 (br d, J = 11.1 Hz, 2H), 2.04-1.87 (m, 2H), 1.51 (s, 9H); LCMS (ESI) [M+H]⁺: 441.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (s, 1H), 7.94 (s, 1H), 7.73-7.62 (m, 2H), 7.37-7.25 (m, 5H), 4.84-4.64 (m, 2H), 3.87-3.67 (m, 1H), 3.16-2.88 (m, 3H), 2.12-1.74 (m, 4H), 1.47 (br d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 415.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.56 (br s, 1H), 8.02 (s, 1H), 7.77-7.72 (m, 1H), 7.68-7.63 (m, 1H), 4.38 (br d, J = 13.4 Hz, 1H), 4.20-4.07 (m, 2H), 4.01 (s, 3H), 3.85 (br d, J = 14.4 Hz, 1H), 3.66 (br s, 2H), 3.30-3.10 (m, 3H), 2.93 (br t, J = 10.5 Hz, 1H), 2.84-2.73 (m, 2H), 2.52 (s, 3H), 2.21-2.08 (m, 2H), 1.96-1.81 (m, 2H); LCMS (ESI) [M+H]⁺: 395.2.

15




20

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.35 (s, 1H), 8.21 (s, 1H), 7.98-7.90 (m, 1H), 7.89-7.81 (m, 1H), 5.99-5.86 (m, 1H), 5.35 (t, J = 6.6 Hz, 2H), 5.24-5.12 (m, 2H); LCMS (ESI) [M+H]⁺: 219.0.




25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.08 (s, 1H), 7.82 (m, 2H), 5.08-4.88 (m, 1H), 3.55 (m, 8H), 1.63 (d, J = 6.6 Hz, 6H), 1.57 (s, 3H), 0.96-0.85 (m, 2H), 0.68-0.60 (m, 2H); LCMS (ESI) [M+H]⁺: 411.1.




- 5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.23 (d, J = 0.9 Hz, 1H), 8.18 (s, 1H), 7.94-7.90 (m, 1H), 7.87-7.84 (m, 1H), 5.92 (quin, J = 7.1 Hz, 1H), 5.35 (t, J = 6.7 Hz, 2H), 5.17 (t, J = 7.4 Hz, 2H), 4.61 (br s, 1H), 3.76 (br s, 1H), 3.26-3.16 (m, 1H), 2.21-2.10 (m, 2H), 2.06-1.96 (m, 2H), 1.92-1.81 (m, 2H), 1.77-1.66 (m, 2H), 1.46 (s, 9H); LCMS (ESI) $[M+H]^+$: 440.2.




- 10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.22 (s, 1H), 8.06 (s, 1H), 7.88-7.80 (m, 2H), 4.97 (quin, J = 6.6 Hz, 1H), 3.99-3.90 (m, 4H), 3.22 (tt, J = 3.9, 10.9 Hz, 1H), 3.01-2.92 (m, 2H), 2.16 (br dd, J = 3.2, 13.4 Hz, 2H), 2.05-1.95 (m, 4H), 1.64 (d, J = 6.6 Hz, 6H), 1.53 (s, 6H); LCMS (ESI) $[M+H]^+$: 423.2.



- 15 ^1H NMR (400 MHz, DMSO- d_6) δ 8.49 (s, 1H), 8.37 (s, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.50-7.39 (m, 5H), 6.28-6.15 (m, 1H), 5.08 (d, J = 6.8 Hz, 4H), 4.07 (br s, 2H), 3.32-3.15 (m, 3H), 2.11 (br d, J = 11.5 Hz, 2H), 1.89-1.74 (m, 2H); LCMS (ESI) $[M+H]^+$: 430.1.




- 20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.84 (q, J = 8.4 Hz, 2H), 4.97 (td, J = 6.5, 13.4 Hz, 1H), 4.54 (br d, J = 12.7 Hz, 1H), 4.22 (br d, J = 13.8 Hz, 1H), 3.31 (br t, J = 10.5 Hz, 2H), 3.25-3.10 (m, 2H), 3.01 (br t, J = 11.0 Hz, 1H), 2.33 (s, 6H), 2.23 (br d, J = 13.6 Hz, 2H), 2.07-1.89 (m, 2H), 1.64 (d, J = 6.7 Hz, 6H); LCMS (ESI) $[M+H]^+$: 397.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.22 (s, 1H), 8.06 (s, 1H), 7.89-7.78 (m, 2H), 5.66 (dd, J = 1.7, 9.5 Hz, 1H), 4.97 (td, J = 6.6, 13.3 Hz, 1H), 3.80-3.67 (m, 3H), 3.63-3.45 (m, 3H), 3.23 (tt, J = 4.1, 10.9 Hz, 1H), 3.07-2.90 (m, 2H), 2.22 (br t, J = 10.7 Hz, 2H), 2.13-1.91 (m, 2H), 1.90-1.73 (m, 4H), 1.63 (d, J = 6.6 Hz, 6H), 1.43 (s, 3H); LCMS (ESI) [M+H]⁺: 453.2.

5




¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 8.15 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 5.11 (td, J = 6.7, 13.1 Hz, 1H), 4.26 (br d, J = 13.9 Hz, 2H), 3.62-3.47 (m, 1H), 3.39-3.26 (m, 2H), 2.29-2.20 (m, 2H), 1.89 (q, J = 10.4 Hz, 2H), 1.62-1.56 (m, 2H), 1.53 (m, 8H); LCMS (ESI) [M+H]⁺: 405.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.05 (s, 1H), 7.78 (d, J = 0.7 Hz, 2H), 4.95 (td, J = 6.7, 13.3 Hz, 1H), 4.21-4.05 (m, 1H), 3.80-3.52 (m, 8H), 1.62 (d, J = 6.6 Hz, 6H), 0.79-0.67 (m, 4H); LCMS (ESI) [M+H]⁺: 397.1.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (d, J = 4.5 Hz, 2H), 7.91-7.85 (m, 1H), 7.81-7.77 (m, 1H), 5.53-5.42 (m, 1H), 4.93-4.83 (m, 2H), 4.66-4.56 (m, 2H), 4.08 (br s, 2H), 3.14 (tt, J = 3.8, 10.9 Hz, 1H), 2.95 (br t, J = 11.6 Hz, 2H), 2.14-2.03 (m, 2H), 1.93-1.80 (m, 2H), 1.42 (s, 9H); LCMS (ESI) [M+H]⁺: 418.1.


20




25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.05 (s, 1H), 7.87-7.76 (m, 2H), 4.96 (td, J = 6.6, 13.2 Hz, 1H), 4.76 (br d, J = 13.3 Hz, 1H), 4.03 (br d, J = 13.6 Hz, 1H), 3.30-3.13 (m, 2H), 2.85 (br t, J = 11.7 Hz, 1H), 2.51-2.35 (m, 2H), 2.28-2.10 (m, 2H), 2.02-1.84 (m, 2H), 1.61 (d, J = 6.6 Hz, 6H), 1.19 (s, 2H), 1.20-1.17 (m, 1H), 0.50-0.38 (m, 4H); LCMS (ESI) [M+H]⁺: 407.2.

30




5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.55 (dd, J = 1.0, 4.7 Hz, 1H), 8.29 (s, 1H), 8.09 (s, 1H), 7.86 (s, 2H), 7.78 (dd, J = 1.0, 8.2 Hz, 1H), 7.32 (dd, J = 4.6, 8.2 Hz, 1H), 4.99 (td, J = 6.7, 13.3 Hz, 1H), 4.78-4.71 (m, 1H), 3.55-3.46 (m, 1H), 3.30-3.14 (m, 3H), 2.28 (br dd, J = 3.5, 13.6 Hz, 1H), 2.14-2.02 (m, 3H), 1.65 (d, J = 6.7 Hz, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 451.1.




10 ^1H NMR (400 MHz, DMSO- d_6) δ 8.53 (s, 1H), 8.41 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.84 (dd, J = 1.2, 8.5 Hz, 1H), 7.55-7.47 (m, 1H), 7.44 (br t, J = 6.7 Hz, 1H), 7.35-7.27 (m, 2H), 6.29 (quin, J = 6.9 Hz, 1H), 5.04 (d, J = 7.1 Hz, 4H), 4.53 (br d, J = 13.2 Hz, 1H), 3.49 (br d, J = 13.7 Hz, 1H), 3.31-3.23 (m, 2H), 3.15-3.06 (m, 1H), 2.16 (br d, J = 11.5 Hz, 1H), 2.02 (br d, J = 12.1 Hz, 1H), 1.82-1.65 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 448.1.


15




20 ^1H NMR (400 MHz, DMSO- d_6) δ 8.53 (s, 1H), 8.42 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.55 (br d, J = 6.8 Hz, 1H), 7.49-7.36 (m, 3H), 6.34-6.23 (m, 1H), 5.04 (d, J = 6.8 Hz, 4H), 4.54 (br d, J = 12.1 Hz, 1H), 3.37 (br d, J = 2.4 Hz, 1H), 3.32-3.16 (m, 2H), 3.16-3.05 (m, 1H), 2.20-2.09 (m, 1H), 2.07-1.95 (m, 1H), 1.85-1.72 (m, 2H), 1.72-1.61 (m, 1H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 464.1.




25 ^1H NMR (400 MHz, DMSO- d_6) δ 8.48 (s, 1H), 8.37 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 5.3 Hz, 1H), 7.10 (d, J = 5.3 Hz, 1H), 6.21 (m, 1H), 5.08 (d, J = 6.8 Hz, 4H), 4.15-3.95 (m, 2H), 3.35-3.23 (m, 3H), 2.14 (br dd, J = 3.2, 13.3 Hz, 2H), 1.89-1.75 (m, 2H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 470.0.




- 5 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.17 (s, 1H), 7.90-7.81 (m, 1H), 7.79-7.67 (m, 1H), 4.91 (td, J = 6.6, 13.3 Hz, 1H), 4.16 (br s, 2H), 4.09 (q, J = 5.9 Hz, 2H), 3.28-3.18 (m, 3H), 3.11 (t, J = 6.3 Hz, 1H), 3.02 (br t, J = 11.7 Hz, 2H), 2.16 (br d, J = 11.5 Hz, 2H), 2.02-1.87 (m, 2H), 1.60 (d, J = 6.6 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) $[M+H]^+$: 456.2.




- 10 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.25 (s, 1H), 8.17 (s, 1H), 7.94-7.89 (m, 1H), 7.88-7.82 (m, 1H), 5.96-5.85 (m, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.17 (t, J = 7.3 Hz, 2H), 4.47-4.32 (m, 4H), 4.14-4.04 (m, 1H), 1.48 (s, 9H); LCMS (ESI) $[M+H]^+$: 398.1.



- 15 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.46 (d, J = 0.9 Hz, 1H), 8.18-8.11 (m, 1H), 7.72 (m, 2H), 5.79-5.71 (m, 1H), 5.25-5.16 (m, 4H), 3.72-3.67 (m, 4H), 3.62-3.56 (m, 4H), 1.50 (s, 9H); LCMS (ESI) $[M+H]^+$: 427.1.




- 20 ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.14 (s, 1H), 7.81 (s, 2H), 4.90 (quin, J = 6.7 Hz, 1H), 4.15 (br s, 2H), 3.88-3.75 (m, 2H), 3.40 (s, 3H), 3.29 (t, J = 7.1 Hz, 2H), 3.24-3.14 (m, 1H), 3.02 (br t, J = 11.1 Hz, 2H), 2.15 (br d, J = 13.3 Hz, 2H), 2.01-1.88 (m, 2H), 1.63-1.57 (m, 6H), 1.49 (s, 9H); LCMS (ESI) $[M+H]^+$: 470.2.
- 25




¹H NMR (400 MHz, DMSO-d₆) δ 8.27 (s, 1H), 8.15 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 5.11 (td, J = 6.6, 13.2 Hz, 1H), 4.56-4.37 (m, 2H), 3.97-3.85 (m, 1H), 3.75 (q, J = 7.4 Hz, 1H), 3.53-3.41 (m, 1H), 3.24-3.11 (m, 2H), 2.72-2.63 (m, 1H), 2.16 (br s, 2H), 1.91-1.71 (m, 4H), 1.64-1.56 (m, 1H), 1.53 (d, J = 6.6 Hz, 6H), 1.42 (s, 3H); LCMS (ESI) [M+H]⁺: 424.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.06 (s, 1H), 7.90-7.78 (m, 2H), 4.97 (td, J = 6.7, 13.3 Hz, 1H), 4.06 (td, J = 3.8, 13.4 Hz, 2H), 3.36-3.22 (m, 3H), 2.42 (s, 3H), 2.29 (br dd, J = 3.4, 13.7 Hz, 2H), 2.20-2.05 (m, 2H), 1.65-1.62 (m, 6H); LCMS (ESI) [M+H]⁺: 394.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.89-7.78 (m, 2H), 5.03-4.90 (m, 1H), 4.51 (br d, J = 13.2 Hz, 1H), 4.27 (br d, J = 13.4 Hz, 1H), 3.40-3.24 (m, 2H), 3.03-2.90 (m, 1H), 2.53 (s, 1H), 2.27-2.15 (m, 8H), 2.03-1.89 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 406.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.92-7.77 (m, 2H), 4.97 (td, J = 6.6, 13.2 Hz, 1H), 4.74-4.49 (m, 1H), 4.40-4.16 (m, 1H), 3.31 (br s, 2H), 3.23-2.91 (m, 3H), 2.38 (s, 3H), 2.30-2.13 (m, 4H), 2.04-1.76 (m, 5H), 1.64 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 423.2.

20




25

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (d, J = 0.7 Hz, 1H), 8.17 (s, 1H), 7.94-7.82 (m, 2H), 5.95-5.83 (m, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.17 (t, J = 7.3 Hz, 2H), 4.66-4.36 (m, 4H), 4.18-4.07 (m, 1H), 2.05 (s, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 369.2.



30


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.56 (s, 1H), 8.17 (s, 1H), 7.84-7.73 (m, 2H), 5.76 (m, 1H), 5.28-5.14 (m, 4H), 4.45-4.30 (m, 4H), 4.14-4.03 (m, 1H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 398.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (d, J = 0.7 Hz, 1H), 8.17 (s, 1H), 7.94-7.90 (m, 1H), 7.88-7.83 (m, 1H), 5.96-5.85 (m, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.21-5.11 (t, J = 7.3 Hz, 2H), 4.53-4.40 (m, 4H), 4.15 (m, 1H), 3.80 (s, 2H), 0.96 (s, 9H); LCMS (ESI) [M+H]⁺: 412.2.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.53 (s, 1H), 8.07 (s, 1H), 7.82-7.77 (m, 1H), 7.77-7.71 (m, 1H), 5.40 (m, 1H), 4.79 (dd, J = 5.3, 8.8 Hz, 1H), 4.73-4.65 (m, 1H), 4.63-4.55 (m, 2H), 4.13 (br d, J = 8.2 Hz, 2H), 3.25-3.13 (m, 1H), 3.02 (br t, J = 11.5 Hz, 2H), 2.14 (br d, J = 11.2 Hz, 2H), 1.99 (s, 3H), 1.97-1.85 (m, 2H), 1.48 (s, 9H); LCMS (ESI) [M-100+H]⁺: 367.1.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.16 (s, 2H), 7.95-7.89 (m, 1H), 7.87-7.82 (m, 1H), 5.54 (m, 1H), 4.80 (dd, J = 5.4, 8.7 Hz, 1H), 4.72-4.63 (m, 1H), 4.62-4.51 (m, 2H), 4.23-4.07 (m, 2H), 3.26-3.14 (m, 1H), 3.02 (br t, J = 11.5 Hz, 2H), 2.15 (m, 2H), 1.99 (s, 3H), 1.98-1.86 (m, 2H), 1.48 (s, 9H); LCMS (ESI) [M-100+H]⁺: 367.1.


20



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.20 (s, 1H), 7.88 (m, 2H), 7.46 (s, 5H), 5.90 (quin, J = 6.9 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.18 (t, J = 7.3 Hz, 2H), 3.61 (m, 8H); LCMS (ESI) [M+H]⁺: 431.1.

30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, 1H), 8.19 (s, 1H), 7.94-7.82 (m, 2H), 5.90 (quin, J = 7.0 Hz, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.18 (t, J = 7.2 Hz, 2H), 3.76 (s, 3H), 3.69-3.41 (m, 8H); LCMS (ESI)

5 [M+H]⁺: 385.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.49 (d, J = 4.6 Hz, 1H), 8.29 (s, 1H), 8.10 (s, 1H), 7.87 (s, 2H), 7.55-7.49 (m, 1H), 7.40 (td, J = 4.4, 8.6 Hz, 1H), 4.99 (spt, J = 6.7 Hz, 1H), 4.78-4.68 (m, 1H), 3.67 (br d, J = 13.8 Hz, 1H), 3.32-3.17 (m, 3H), 2.27 (br dd, J = 3.5, 13.6 Hz, 1H), 2.15-2.01 (m, 3H), 1.65 (d, J = 6.7 Hz, 6H); LCMS (ESI) [M+H]⁺: 435.2.

10



¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (s, 1H), 8.19 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.81-7.75 (m, 2H), 7.08 (d, J = 5.3 Hz, 1H), 5.22-5.10 (m, 1H), 4.02 (br s, 2H), 3.33-3.20 (m, 3H), 2.13 (m, 2H), 1.86-1.75 (m, 2H), 1.52 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 456.1.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.85 (d, J = 5.0 Hz, 2H), 8.30 (s, 1H), 8.09 (s, 1H), 7.86 (d, J = 0.9 Hz, 2H), 7.37 (t, J = 5.0 Hz, 1H), 4.99 (spt, J = 6.6 Hz, 1H), 4.78-4.68 (m, 1H), 3.73-3.65 (m, 1H), 3.33-3.17 (m, 3H), 2.29-2.21 (m, 1H), 2.16-2.04 (m, 3H), 1.65 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺:

20


418.2.

25




¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 8.16 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 5.12 (quin, J = 6.6 Hz, 1H), 4.31 (br d, J = 14.1 Hz, 2H), 3.62-3.49 (m, 1H), 3.33 (br t, J = 12.1 Hz, 2H), 2.25 (br d, J = 10.4 Hz, 2H), 1.98-1.82 (m, 2H), 1.59 (s, 6H), 1.54 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 407.1.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.23 (s, 1H), 8.18 (s, 1H), 7.94-7.89 (m, 1H), 7.88-7.83 (m, 1H), 7.41 (d, J = 5.3 Hz, 1H), 6.95 (d, J = 5.3 Hz, 1H), 5.90 (quin, J = 7.1 Hz, 1H), 5.34 (t, J = 6.5 Hz, 2H), 5.20-5.14 (m, 2H), 4.77-3.73 (m, 2H), 3.50-3.16 (m, 3H), 2.28 (br d, J = 11.6 Hz, 2H), 2.18-2.03 (m, 2H); LCMS (ESI) [M+H]⁺: 470.1.

10



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.51 (s, 1H), 8.14 (s, 1H), 7.79-7.73 (m, 2H), 4.69-4.61 (m, 1H), 4.23 (dd, J = 4.0, 11.4 Hz, 1H), 4.14 (br d, J = 6.2 Hz, 2H), 4.03-3.91 (m, 2H), 3.72-3.63 (m, 1H), 3.19 (tt, J = 3.9, 10.8 Hz, 1H), 3.03 (br t, J = 11.4 Hz, 2H), 2.41-2.32 (m, 2H), 2.15 (br d, J = 10.3 Hz, 2H), 1.98-1.79 (m, 4H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 454.2.


15



20


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, 1H), 8.06 (s, 1H), 7.91-7.86 (m, 1H), 7.84-7.79 (m, 1H), 4.79-4.68 (m, 1H), 4.24-4.02 (m, 4H), 3.85 (t, J = 10.7 Hz, 1H), 3.60-3.50 (m, 1H), 3.22 (tt, J = 3.9, 10.9 Hz, 1H), 3.03 (br t, J = 11.6 Hz, 2H), 2.48-2.35 (m, 1H), 2.27 (br d, J = 12.5 Hz, 1H), 2.17 (br d, J = 10.6 Hz, 2H), 2.02-1.89 (m, 4H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 454.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.11 (d, J = 0.9 Hz, 1H), 8.06 (s, 1H), 7.79-7.74 (m, 2H), 5.16 (quin, J = 8.3 Hz, 1H), 3.77-3.65 (m, 4H), 3.63-3.53 (m, 4H), 2.89-2.75 (m, 2H), 2.61-2.50 (m, 2H), 2.06-1.86 (m, 2H), 1.50 (s, 9H); LCMS (ESI) [M+H]⁺: 425.2.


30




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.28 (br d, J = 2.6 Hz, 1H), 8.10 (br d, J = 3.4 Hz, 1H), 7.86 (br d, J = 4.2 Hz, 2H), 5.06-4.91 (m, 1H), 4.60 (br d, J = 12.2 Hz, 2H), 3.36-3.03 (m, 3H), 2.27-2.13 (m, 2H),
 5 2.05-1.90 (m, 2H), 1.70-1.62 (m, 6H), 1.17-1.08 (m, 2H), 0.99 (br s, 2H); LCMS (ESI) [M+H]⁺: 396.2.




¹H NMR (400 MHz, METHANOL-d₄) δ 8.53 (s, 1H), 8.35-8.27 (m, 1H), 7.75 (d, J = 8.8 Hz, 1H), 3.60-3.45
 10 (m, 4H), 3.30-3.21 (m, 2H), 2.47 (br dd, J = 3.2, 14.4 Hz, 2H), 2.25-2.11 (m, 2H), 1.51 (d, J = 7.1 Hz, 6H);
 LCMS (ESI) [M+H]⁺: 313.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, 1H), 8.17 (s, 1H), 7.94-7.89 (m, 1H), 7.88-7.83 (m, 1H),
 15 5.90 (quin, J = 7.0 Hz, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.17 (t, J = 7.3 Hz, 2H), 4.50-4.31 (m, 4H), 4.18-4.03
 (m, 1H), 1.57 (s, 3H), 0.96-0.85 (m, 2H), 0.68-0.61 (m, 2H); LCMS (ESI) [M+H]⁺: 396.1.




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, J = 0.9 Hz, 1H), 8.20 (s, 1H), 7.88 (m, J = 0.9 Hz, 2H),
 20 7.50-7.40 (m, 2H), 7.28 (d, J = 0.9 Hz, 0.3H), 7.26-7.22 (m, 0.7H), 7.14 (t, J = 9.2 Hz, 1H), 5.96-5.81 (m,
 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.18 (t, J = 7.5 Hz, 2H), 3.98 (br s, 2H), 3.71 (br t, J = 4.8 Hz, 2H), 3.62-3.41
 (m, 4H); LCMS (ESI) [M+H]⁺: 449.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.20 (s, 1H), 7.88 (m, 2H), 7.48-7.42 (m, 1H), 7.41-
 25 7.31 (m, 3H), 5.89 (quin, J = 7.0 Hz, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.23-5.14 (m, 2H), 4.13-4.02 (m, 1H),


3.98-3.85 (m, 1H), 3.78-3.69 (m, 2H), 3.68-3.57 (m, 1H), 3.57-3.41 (m, 2H), 3.40-3.32 (m, 1H); LCMS (ESI) [M+H]⁺: 465.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 9.23 (s, 1H), 8.19 (d, J = 0.9 Hz, 1H), 8.13 (dd, J = 1.3, 8.3 Hz, 1H), 7.86 (dd, J = 0.7, 8.3 Hz, 1H), 6.22 (dd, J = 6.8, 9.0 Hz, 1H), 4.93-4.76 (m, 2H), 4.57 (br d, J = 13.2 Hz, 1H), 4.05 (br d, J = 12.2 Hz, 1H), 3.41-3.19 (m, 3H), 3.10-2.87 (m, 2H), 2.35 (s, 2H), 2.24 (br dd, J = 3.5, 13.4 Hz, 2H), 2.03 (m, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 452.2.

10




¹H NMR (400 MHz, METHANOL-d₄) δ 8.54 (br d, J = 4.3 Hz, 1H), 8.36 (s, 1H), 8.33 (s, 1H), 7.97-7.89 (m, 2H), 5.98 (quin, J = 7.2 Hz, 1H), 4.72-4.57 (m, 4H), 4.14 (m, 2H), 3.42-3.34 (m, 1H), 3.20-3.01 (m, 2H), 2.19 (m, 2H), 1.94-1.79 (m, 2H), 1.56-1.46 (s, 9H); LCMS (ESI) [M+H]⁺: 425.2.

15




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.43 (d, J = 1.0 Hz, 1H), 7.98 (s, 1H), 7.68 (d, J = 0.9 Hz, 2H), 5.07 (quin, J = 8.4 Hz, 1H), 3.71-3.64 (m, 4H), 3.62-3.54 (m, 4H), 2.83-2.67 (m, 2H), 2.66-2.51 (m, 2H), 2.06-1.89 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 425.2.

20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.19 (s, 1H), 8.07 (s, 1H), 7.88-7.74 (m, 2H), 5.17 (quin, J = 8.3 Hz, 1H), 4.15 (br s, 2H), 3.20 (tt, J = 3.9, 11.0 Hz, 1H), 3.01 (br t, J = 12.0 Hz, 2H), 2.91-2.76 (m, 2H), 2.63-2.50 (m, 2H), 2.15 (br d, J = 10.8 Hz, 2H), 2.06-1.84 (m, 4H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 424.2.

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.52 (d, J = 1.1 Hz, 1H), 8.00 (s, 1H), 7.77-7.70 (m, 2H), 5.08 (quin, J = 8.3 Hz, 1H), 4.20-4.07 (m, 2H), 3.21-3.12 (m, 1H), 3.02 (br t, J = 11.5 Hz, 2H), 2.82-2.58 (m, 4H), 2.14 (br d, J = 9.9 Hz, 2H), 2.06-1.85 (m, 4H), 1.48 (s, 9H); LCMS (ESI) [M+H]⁺: 424.2.

5




¹H NMR (400 MHz, CHLOROFORM-d) δ 10.59 (br s, 1H), 8.29 (s, J = 0.9 Hz, 1H), 8.15 (s, J = 0.9 Hz, 1H), 7.89 (m, J = 1.0, 8.5 Hz, 2H), 4.62 (br d, J = 13.7 Hz, 1H), 4.04 (br d, J = 13.9 Hz, 1H), 3.45-3.20 (m, 2H), 2.99 (br t, J = 11.0 Hz, 1H), 2.33 (m, 2H), 2.22 (m, J = 13.5 Hz, 2H), 2.00-1.85 (m, 2H), 1.09 (s, 9H); LCMS (ESI) [M+H]⁺: 368.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.41 (br s, 1H), 8.07 (s, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.71 (dd, J = 1.1, 8.6 Hz, 1H), 7.47 (br d, J = 8.8 Hz, 1H), 4.99 (spt, J = 6.7 Hz, 1H), 4.05-3.90 (m, 1H), 3.86-3.60 (m, 3H), 3.58-3.45 (m, 1H), 2.51-2.22 (m, 2H), 1.64 (d, J = 6.6 Hz, 6H), 1.49 (s, 9H); LCMS (ESI) [M+H]⁺: 408.2.

15



20


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.55 (d, J = 5.1 Hz, 1H), 8.00 (s, 1H), 7.88 (dd, J = 1.3, 5.1 Hz, 1H), 4.18 (br s, 2H), 3.73 (s, 3H), 3.23 (tt, J = 3.9, 10.9 Hz, 1H), 3.08 (br t, J = 11.7 Hz, 2H), 2.20-2.12 (m, 2H), 1.99-1.86 (m, 2H); LCMS (ESI) [M+H]⁺: 323.0.



25


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.24 (s, J = 0.7 Hz, 1H), 8.20 (s, 1H), 7.88 (m, 2H), 5.90 (quin, J = 7.0 Hz, 1H), 5.33 (t, J = 6.5 Hz, 2H), 5.22-5.11 (m, 2H), 3.56 (br s, 8H), 1.58 (s, 3H), 0.95-0.85 (m, 2H), 0.72-0.61 (m, 2H); LCMS (ESI) [M+H]⁺: 425.1.

30




^1H NMR (400 MHz, DMSO- d_6) δ 8.46 (d, J = 0.9 Hz, 1H), 8.15 (d, J = 0.9 Hz, 1H), 7.97-7.88 (m, 1H), 7.73 (dd, J = 1.2, 8.4 Hz, 1H), 5.07 (t, J = 5.7 Hz, 1H), 3.98 (br d, J = 13.0 Hz, 2H), 3.81 (d, J = 5.7 Hz, 2H), 3.43-3.36 (m, 1H), 2.98 (br s, 2H), 2.11 (br dd, J = 2.9, 13.3 Hz, 2H), 1.79-1.63 (m, 8H), 1.42 (s, 9H);

5 LCMS (ESI) $[\text{M}+\text{H}]^+$: 442.1.




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.16-8.12 (m, 2H), 7.85-7.78 (m, 2H), 5.92-5.84 (m, 1H), 5.33 (t, J = 6.7 Hz, 2H), 5.14 (t, J = 7.3 Hz, 2H), 3.84-3.71 (m, 8H), 3.17 (s, 2H), 2.30 (s, 6H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 412.2.

10



^1H NMR (400 MHz, CHLOROFORM- d) δ 8.31 (s, 1H), 8.20 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 13.7 Hz, 1H), 6.85-6.73 (m, 1H), 4.78 (dd, J = 2.9, 17.0 Hz, 1H), 4.67-4.52 (m, 1H), 4.16 (br s, 2H), 3.21 (tt, J = 3.8, 10.9 Hz, 1H), 3.01 (br t, J = 11.4 Hz, 2H), 2.16 (br d, J = 11.2 Hz, 2H), 2.00-1.86 (m, 2H), 1.48 (s, 9H); LCMS (ESI) $[\text{M}+\text{H}]^+$: 440.2.


15




^1H NMR (400 MHz, CHLOROFORM- d) δ 8.48 (s, 1H), 8.07 (s, 1H), 7.79-7.70 (m, 2H), 7.51 (d, J = 13.7 Hz, 1H), 7.14-7.02 (m, 1H), 4.92 (dd, J = 2.9, 16.3 Hz, 1H), 4.81-4.66 (d, J = 48 Hz, 1H), 4.13 (br s, 2H), 3.25-3.14 (m, 1H), 3.02 (br t, J = 11.7 Hz, 2H), 2.14 (br d, J = 11.0 Hz, 2H), 1.98-1.85 (m, 2H), 1.48 (s, 9H); LCMS (ESI) $[\text{M}-55]^+$: 384.1.

20

25




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.15 (s, 2H), 7.93 (d, J = 3.2 Hz, 1H), 7.86-7.79 (m, 2H), 7.60 (d, J = 3.2 Hz, 1H), 5.93-5.84 (m, 1H), 5.33 (t, J = 6.6 Hz, 2H), 5.15 (t, J = 7.3 Hz, 2H), 4.66 (m, 2H), 3.98 (m, 2H), 3.87 (br t, J = 4.9 Hz, 4H); LCMS (ESI) [M+H]⁺: 438.1.



5


¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (t, J = 1.5 Hz, 1H), 8.09 (td, J = 1.4, 7.8 Hz, 1H), 7.73 (td, J = 1.4, 7.8 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 4.34-4.14 (m, 4H), 4.05 (br d, J = 9.0 Hz, 2H), 3.14-3.06 (m, 1H), 2.94 (br t, J = 11.7 Hz, 2H), 2.35-2.23 (m, 2H), 2.05 (br dd, J = 3.2, 13.3 Hz, 2H), 1.88-1.74 (m, 2H), 1.41 (s, 9H); LCMS (ESI) [M-100+1]⁺: 313.1, LCMS (ESI) [M+23]⁺: 435.1.

10




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.17 (s, 1H), 8.11 (s, 1H), 7.92-7.88 (dd, J = 8.8, 1H), 7.85-7.81 (d, J = 8.8, 1H), 5.19-5.05 (m, 1H), 4.14 (m, 2H), 3.51-3.35 (m, 2H), 3.28-3.15 (m, 3H), 3.02 (br t, J = 11.6 Hz, 2H), 2.15 (br dd, J = 2.6, 13.4 Hz, 2H), 2.00-1.87 (m, 2H), 1.49 (s, 9H); LCMS (ESI) [M-55]⁺: 404.1.

15



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.04 (s, 1H), 7.81-7.74 (m, 2H), 4.95 (td, J = 6.6, 13.4 Hz, 1H), 4.81 (dd, J = 6.2, 7.7 Hz, 2H), 4.51 (t, J = 6.3 Hz, 2H), 4.33 (br d, J = 13.2 Hz, 2H), 3.17 (dt, J = 2.6, 12.9 Hz, 2H), 2.86-2.74 (m, 1H), 2.03-1.91 (m, 1H), 1.77 (br d, J = 11.9 Hz, 2H), 1.62 (d, J = 6.6 Hz, 6H), 1.25 (dq, J = 4.4, 12.5 Hz, 2H); LCMS (ESI) [M+H]⁺: 368.2.


20




¹H NMR (400 MHz, CHLOROFORM-d) δ 8.13 (s, 1H), 8.04 (s, 1H), 7.80-7.75 (m, 2H), 4.95 (quin, J = 6.7 Hz, 1H), 4.60 (t, J = 7.7 Hz, 2H), 3.85 (td, J = 4.9, 13.6 Hz, 2H), 3.68 (ddd, J = 3.3, 9.8, 13.3 Hz, 2H), 2.47 (t, J = 7.8 Hz, 2H), 2.13 (td, J = 4.2, 13.3 Hz, 2H), 1.92 (ddd, J = 4.4, 9.6, 13.6 Hz, 2H), 1.62 (d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 354.2.

25

30



¹H NMR (400 MHz, DMSO-d₆) δ 9.44 (br s, 1H), 8.25 (s, 1H), 7.92 (br d, J = 8.3 Hz, 1H), 7.76 (br d, J = 8.3 Hz, 1H), 4.05 (s, 3H), 2.85 (br d, J = 3.5 Hz, 3H), 2.52 (br s, 3H); LCMS (ESI) [M+H]⁺: 272.1.



¹H NMR (400 MHz, CHLOROFORM-d) δ 8.25 (s, 1H), 8.06 (s, 1H), 7.90-7.78 (m, 2H), 7.19 (br s, 1H), 5.03-4.87 (m, 1H), 3.21-3.06 (m, 3H), 1.63 (br d, J = 6.6 Hz, 6H); LCMS (ESI) [M+H]⁺: 286.1.

Example 157. Description of yeast models

α-synuclein and ApoE4 yeast strains were previously engineered to express the human α-synuclein or ApoE4 genes under control of the yeast galactose-regulated promoter, *GAL1*, as described in International Patent Publication No. WO2016/040794 and U.S. Patent Nos. 7,452,670 and 7,045,290, the procedures for the production of such strains of which are herein incorporated by reference. The induced expression of α-synuclein and ApoE4 confers cytotoxicity, thus enabling the identification of compounds that can restore cell viability. This instantaneous/synchronous induction of α-synuclein and ApoE4 can be achieved due to the following expression control. In glucose-containing media, gene expression from the *GAL1* promoter is 'off' and actively repressed by additional epigenetic factors. In raffinose, expression is 'off', but the promoter not actively repressed. Upon transition to galactose-containing media, the promoter is instantaneously turned 'on' to achieve robust and synchronous induction of α-synuclein or ApoE4 expression. This highly regulated induction provides a robust window for the determination of both efficacy (amplitude of protective effect) and potency (concentration of protective effect) of cytoprotective compounds.

Compound Profiling

Fresh powders (~5 mg) of newly synthesized compounds were dissolved to 10 mM in 100% DMSO using a Janus (Perkin Elmer) robotic workstation. Re-suspended compound stocks were subsequently arrayed into 384 well compound plates using automated pipetting. All other wells not receiving stock compound were filled with 10 μL of 100% DMSO using an automated plate filler (Multidrop Combi). An 11 point, 2-fold serial dilution was then performed using the robotic platform. Compound assay plates were covered with foil and stored at -20°C until use.

Each strain was handled according to standard protocols and cultured in media composed of CSM (complete synthetic media), YNB (yeast nitrogenous base), and a 2% (w/v) carbon source (either glucose, raffinose, or galactose). Single use frozen aliquots of each strain were generated by growing

cells in CSM/glucose media to an OD₆₀₀ of 0.6-0.8, concentrating the yeast to 12.5 OD₆₀₀ units per 30 µL of CSM/glucose media supplemented with 20% glycerol, and freezing 30 µL aliquots at -80°C.

In a standard yeast assay, a single-use aliquot of cells was thawed on ice and diluted into CSM/glucose (5 mL). Cultures were grown for 8 hours at 30°C. This pre-growth enables the yeast to exit the thaw and begin to grow without expressing aSyn or ApoE4. After 8 hours, cell density (OD₆₀₀) was determined and cultures diluted to an OD₆₀₀ of 0.01 in CSM/raffinose for an overnight culture phase at 30°C. During this period, the active glucose repression of the *GAL1* promoter was relieved; however, expression of the α-Syn/ApoE4 genes were not yet induced. After ~16 hours of growth, cultures attain an OD₆₀₀ of 0.4-0.8 and were ready to apply to assay plates containing compound.

Compound profiling assays were executed in clear-bottom 384 well plates. First, compound plates were thawed at room temperature for 45', centrifuged at 1,000xg for 1 minute, and the foil removed. Clear 384 well assay plates were then filled with 15 µL of CSM/galactose. Both compound and media-containing plates were arranged on the Janus workstation and a compound pin tool (384 x 100 nL slotted pins) used to deliver 100 nL of compounds to each well according to the well map of the compound plate. Based on the previous serial dilution, the final concentration of compound ranged from 33.3 µL to 12.5 nM. The pin tool was washed iteratively with both 50% DMSO and 100% ethanol between each assay plate. After delivering compound to each assay plate, the overnight CSM/raffinose aSyn or ApoE4 cultures were added at a 2X cell density (0.04 for aSyn and 0.08 for ApoE4) in CSM/galactose to achieve a final assay OD₆₀₀ of 0.02 and 0.04 for aSyn and ApoE, respectively. The cultures (15 µL per well) were then dispensed to the compound-containing 384 well assay plates using an automated plate filler. Plates were incubated in a humidified 30°C incubator for 40 or 24 hours for aSyn and ApoE4, respectively. The OD₆₀₀ of each assay plate was then read with a microplate reader (e.g., Perkin Elmer Envision).

The efficacy and potency of compounds were calculated according to the following. Raw data (OD₆₀₀ values) were first background corrected to account for OD₆₀₀ contributed by the plate and media itself. The efficacy (percent above DMSO, herein referred to as "E_{max}") was calculated according to the equation: (Experimental well – DMSO control well)/(DMSO control well)*100. For each individual compound with positive activity (>30% above DMSO – or 3 standard deviations from the DMSO negative control wells), the dose-response data were normalized to a scale of 0 – 100% to enable potency (herein referred to as "EC₅₀") determination. Normalized dose-response data was fit with a logistic regression curve using Spotfire (TIBCO), or similar curve-fitting software package. EC₅₀ values were then reported along with E_{max} to provide both efficacy and potency measures for each analog and enable further compound design. As shown in Table 3, compounds of the invention are able to reduce the toxicity of the expressed alpha-synuclein and/or ApoE4 proteins.

Table 3: Yeast rescue data for examples 1-155 showing that compounds of the invention were able to reduce toxicity in yeast strains expressing the human proteins α-synuclein and/or ApoE4.

Compound #	α-Syn EC ₅₀ (nM)	α-Syn E _{max} (%)	ApoE4 EC ₅₀ (nM)	ApoE4 E _{max} (%)
1	n/a	155	n/a	320

Compound #	α -Syn EC50 (nM)	α -Syn Emax (%)	ApoE4 EC50 (nM)	ApoE4 Emax (%)
2	8569	80		
3	17843	307	n/a	200
4	8428	59	11756	76
6	10194	460	15110	815
7	40	594	176	782
8	13764	188	n/a	111
9	12113	167	n/a	301
10	4870	392	4614	736
11	5892	309	n/a	600
12	16197	43		
13	58	712	368	837
14	1164	463	1830	771
15	1711	628	3627	866
16	17823	249	21200	418
17	17395	330	n/a	246
18	266	452	1512	826
19	2425	574	5627	891
20	15131	181	16216	529
21	n/a	276	n/a	447
22	8423	334	n/a	372
23	7680	182	6513	466
24	5126	76	13342	301
25	751	619	1855	889
26	42	608	377	811
27	59	589	390	761
28	66	576	1594	836
29	13928	38		
31	7506	438	9813	721
32	9883	41		
33	111	260	717	281
34	11112	562	n/a	596
35	52	626	1122	911
36	1757	629	2154	908
37	2205	608	6530	849
38	3296	336	6014	750
39	18143	216		
40	86	443		
41	10899	211	n/a	400

Compound #	α -Syn EC50 (nM)	α -Syn Emax (%)	ApoE4 EC50 (nM)	ApoE4 Emax (%)
42	12462	255	n/a	399
43	14607	222	17730	517
44	10870	579	13312	676
45	26019	121	29268	19
46	10930	35		
47	16513	88		
48	1471	615	2944	874
49	1469	636	4336	942
50	7857	85	n/a	133
51	10924	137	n/a	286
52	9059	82	14485	154
53	6603	81	16643	296
54	9095	95	17308	240
55	23816	47	7902	29
56	1665	549	8325	793
57	9005	503	12060	797
58	7943	23		
59	15667	82	n/a	47
60	32	605	119	795
61	19706	229	19380	465
62	21699	204	21427	430
63	17170	68	13385	250
64	13746	228	15275	330
65	36	643	987	779
66	11067	350	21212	790
67	7377	255	17364	420
68	1864	652	3123	775
69	n/a	294	n/a	387
70	n/a	605	n/a	580
71	8093	151	8969	235
72	12665	35		
73	15760	151	n/a	303
74	17866	155	n/a	411
76	9921	76	14827	162
77	n/a	345	n/a	436
78	14604	38		
79	9907	627	18845	631
80	3322	188	6014	262

Compound #	α -Syn EC50 (nM)	α -Syn Emax (%)	ApoE4 EC50 (nM)	ApoE4 Emax (%)
82			16773	40
83	9309	151	n/a	567
84	60	463	956	866
85	12610	486	17049	602
86	18	772	64	633
87	1929	579		
88	9037	130		
89	165	580		
90	1646	281		
91	107	452		
92	2499	187		
93	1800	626		
94	40	1083		
95	91	827		
96	26	343	228	840
97	707	132	3884	704
98	8009	386	9747	650
99	1032	209	2749	663
100	1191	385	2106	651
101	1175	122		
102	284	411		
103	2023	75		
104	1872	253		
105	3180	391		
106	100	415		
107	2899	312		
108	11149	316		
109	3041	35		
110	4493	374		
111	339	289		
112	320	258		
113	15628	55		
114	17316	373		
115	887	326		
116	9038	345		
117	7502	124		
118	15667	65		
119	20897	61		

Compound #	α -Syn EC50 (nM)	α -Syn Emax (%)	ApoE4 EC50 (nM)	ApoE4 Emax (%)
120	19502	139		
121	15527	388		
122	139	414		
123	69	343		
124	17661	395		
125	16712	200		
127	7416	349		
128	252	306		
129	47	360		
130	1443	328		
131	167	352		
132	1006	253		
133	6381	281		
134	13976	357		
135	593	144		
136	4080	67		
137	1052	376		
138	1280	353		
139	21	437		
140	49	322		
141	19	259		
142	7644	319		
143	16891	73		
144	521	537		
145	100	432		
146	1941	516		
147	17902	453		
148	13652	258		
149	60	458		
150	99	473		
151	45	405		
152	134	474		
153	20	271		
154	57	410		
155	11	556	2159	865

Example 158: U2OS transient overexpression induced cytotoxicity assay

U2OS (Sigma-Aldrich), a human bone osteosarcoma epithelial cell line, is regularly maintained in

McCoy's 5A medium (ATCC) supplemented with 10% FBS (ThermoFisher) between passage 11-21 and sub-cultured twice a week for the assay.

On the day of experiment, cells are about 80% confluence and trypsinized using 0.25% trypsin-EDTA (ThermoFisher Inc.) for 5 minutes at 37°C. Based on a ratio of 2 µg DNA/2e5 cells, required cells are spun down at 800 rpm for 5 minutes at room temperature. Cells are then re-suspended in SE solution (Lonza Inc.) at a density of 2e4 cells/µl. Nucleofection is performed using 4D-Nucleofector™ System (Lonza Inc.) under program code CM130. Cells are allowed to recover in the cuvette at room temperature for 10-15 minutes before further handling. Pre-warmed medium is added and cells suspension is thoroughly but gently mixed before plating. Cells are seeded at 2e4 cells/100 µl/well into 96 well PLD-coated white plate (Corning) using customized Viaflow program (Integra Biosciences). Serial dilution of drugs is carried out in DMSO. Drug solution is prepared at 6x fold, 20 µl of which is added to cells 4 hours after transfection. The final DMSO concentration is 0.3%. Microclimate lid (Labcyte) is strongly recommended to reduce evaporation and variation. Seventy-two hours post transfection, cells are lysed using CellTiter-Glow (Promega) and ATP content is determined using a luminescence plate reader (Perkin Elmer).

%Maximum fold rescue at each concentration is calculated as follows:

$$\% \text{ Fold} = \frac{(RLU^{\alpha\text{Syn}}_{\text{drug}}) * 100}{RLU^{\alpha\text{Syn}}_{\text{DMSO}}}$$

FK506 (tacrolimus), a macrolide calcineurin inhibitor, is used as reference compound in the assay. FK506 has been shown to rescue αSyn toxicity in yeast models, and this activity has translated to rodent in vivo models of neurodegeneration.

% Rescue (normalized by max fold rescue of FK506) = (%Fold^{αSyn} drug - 100) * 100 / (%Max fold^{αSyn} FK506 - 100).

As shown in Table 4, the compounds of the invention were able to rescue human bone osteosarcoma epithelial U2OS cells that were transiently overexpressing the toxic alpha-synuclein protein, reducing the level of induced cytotoxicity:

Table 4.

% Rescue (normalized by FK506 max rescue)

Example #	1 (µM)	0.3 (µM)	0.1 (µM)	0.01 (µM)
40	77	105	137	107
155	10	44	83	-23

Example 159: Stearoyl-CoA desaturase (SCD) is the target of 1,2,4-oxadiazoles

A. Materials and Methods

Strain Construction and OLE1 Replacement with SCD1 or SCD5

Strain GMYF was constructed from the ABC16/Green monster strain described in Suzuki et al. *Nat. Methods* 8(2):159-164, 2011. In this strain, *YAP1* was deleted using a HIS3-MX6 cassette, and *FLR1* was deleted using a NAT-MX6 cassette using standard methods. The knockout cassettes were PCR-amplified from plasmid templates (see, e.g., Bahler et al. *Yeast* 14(10):943-951, 1998; Longtine et al. *Yeast* 14(10):953-961, 1998) and transformed into yeast using lithium acetate-based transformation

(Gietz et al. *Methods Mol. Biol.* 1205:1-12, 2014). The *yap1::his3* deletion strain was selected on media lacking histidine and *flr1::NAT* on plates containing 100 µg/mL nourseothricin. All strains were confirmed by diagnostic PCR. Strain W303 *pdr1Δ pdr3Δ* was constructed from W303-1A (American Type Culture Collection (ATCC) 208352) by deleting *PDR1* and *PDR3* with kan-MX6 cassettes separately in MATa and MATα W303a isolates, mating, sporulating, and identifying double deletion haploids by tetrad dissection and identification of non-parental ditype tetrads. Strain W-*erg3* was derived from W303 *pdr1Δ pdr3Δ* by deleting *SNQ2* with NAT-MX6, *YAP1* with HIS3-MX6, and *ERG3* with BleMX.

Strain ApoE-*mga2Δ* was generated by amplifying 1000 base pairs (bp) upstream and downstream of the *MGA2* ORF in a strain in which *MGA2* was deleted using a G418 (GENETICIN®) resistance cassette (kanMX) (Piotrowski et al. *Proc. Natl. Acad. Sci. USA* 112(12):E1490-1497, 2015) and transforming the resulting deletion cassette into the ApoE4 strain in the BY4741 (ATCC 201388) genetic background. The ApoE strain is described, for example, in International Patent Application Publication No. WO 2016/040794, which is incorporated herein by reference in its entirety.

The alpha-synuclein expression strain was made in the same manner as described in Su et al. *Dis. Model Mech.* 3(3-4):194-208, 2010, except that the alpha-synuclein construct lacked the green fluorescent protein (GFP) tag.

Strain *ole1Δ* (yeast *ole1* deletion mutant) was constructed by deleting *OLE1* with NAT-MX6 in BY4741, amplifying the deletion cassette from the genomic DNA of the resulting strain with primers flanking the ORF by 1000 bp upstream and downstream, transforming the resulting deletion cassette into W303 *pdr1Δ pdr3Δ*, and plating transformants on YPD media containing G418 (200 µg/mL) and nourseothricin (100 µg/mL) with 0.01% TWEEN®-20 and 0.5 mM oleic and palmitoleic acids.

To generate yeast strains expressing SCD1 or SCD5 as the sole desaturase, the human SCD1 and SCD5 genes were cloned from cDNAs (Harvard PlasmID database Clone ID HsCD00340237 for SCD1 and HsCD00342695 for SCD5) into yeast plasmid pRS316 (ATCC 77145) between the yeast *TDH3* promoter and the *CYC1* terminator. The coding sequence of yeast *OLE1* was also cloned into this plasmid. These clones were then transformed into the *ole1Δ* strain and plated on CSM-Ura media (CSM lacking uracil) with 2% glucose (w/v) and independent colonies were isolated and amplified.

Compound Profiling Methods

All compound profiling experiments were performed using the same basic protocol. Different genetic backgrounds (e.g., gene deletions) or conditions (e.g., addition of oleic and palmitoleic acid) were replaced as indicated below.

Yeast were cultured using standard techniques in complete synthetic media (CSM) and yeast nitrogen base supplemented with 2% (w/v) carbon source (glucose, raffinose, or galactose) to regulate the expression of the toxic disease protein. An initial starter culture was inoculated in 3 mL CSM-Glucose media and incubated overnight in a 30°C shaker incubator (225 rpm). Saturated morning cultures were then diluted 1:20 in fresh CSM-Raffinose media and grown for 6 h to an OD₆₀₀ (optical density) of ~0.4-0.8 at 30°C with shaking.

Compound stocks (10 mM in 100% DMSO) were arrayed into 384 round well, v-bottom polypropylene plates and diluted according to indicated dilution factors. Compound administration was performed in two separate steps. First, 15 µL of CSM-Galactose (induces expression of toxic protein)

was dispensed into clear 384 well assay plates using a MULTIDROP™ Combi reagent dispenser. The diluted compound stock plates were then applied to the assay plates using an automated workstation (Perkin Elmer JANUS™) outfitted with a 384 pin tool containing slotted pins that deliver 100 nL of compound. The cultures described above were then diluted to a 2x concentration (0.03 and 0.08 for alpha-synuclein and ApoE, final OD₆₀₀ of 0.015 and 0.04) in CSM-Galactose. For wild-type and Ole1/SCD1/SCD5 plasmid-containing strains, the 2x cell density was 0.02. In all experiments, 15 µL culture was then dispensed into the pinned assay plate to achieve 30 µL of the 1x OD₆₀₀ culture and a top drug concentration of 33.3 µM. For 96-well assays (Figs. 1A and 1B), compound dilutions in DMSO were generated in 96 well plates and 1 µL was manually pipetted into 96 well clear bottom assay plates.

For experiments with oleic and palmitoleic acid supplementation (Figs. 2A, 2B, 4, and 5), TWEEN®-20 was first added to culture media at a concentration of 0.01%. Oleic and palmitoleic acid were both then added at the indicated concentrations (0.08 to 0.5 mM) and mixed thoroughly prior to compound pinning or the addition of yeast.

For experiments using a plasmid-borne copy of Ole1, SCD1, or SCD5 (Figs. 3B, 6, and 7), media lacking uracil (SX-Ura, where X is glucose, raffinose, or galactose), was used for all steps of the compound profiling protocol to ensure its maintenance throughout the assay.

After yeast delivery, assay plates were incubated under humidified conditions at 30°C for 24 to 40 h. ApoE4 rescue experiments were stopped at 24 h, aSyn experiments at 40 h, Ole1 at 24 h, and SCD1/SCD5 at 40 h. The growth of yeast was monitored by reading the OD₆₀₀ of each well using a microplate reader (Perkin Elmer EnVision™). Data were analyzed as follows. For model rescue experiments, raw data were processed by background subtracting and calculating a fold-change relative to DMSO control $[(EXP-0.035)/(DMSO-0.035) - \text{where } 0.035 \text{ is the OD}_{600} \text{ contributed by an empty well containing } 30 \mu\text{L of media alone}]$. For growth inhibition of wild-type cells, raw data were processed by background subtracting and converting values to a percent of the nontreated condition for that strain $[(EXP-0.035)/(DMSO-0.035) \times 100\%]$.

Compound Sources

Compounds were sourced as follows: cycloheximide (Sigma Aldrich), A939572 (Abcam), CAY10566 (Abcam), MF-438 (Calbiochem), MK-8245 (Selleckchem), oleic acid (Sigma Aldrich), palmitoleic acid (Acros organics), mycophenolic acid (Sigma Aldrich), and tunicamycin (Cayman Chemical).

Drug Resistant Mutant Selection

Strains GMYF and W-erg3 were grown to saturation in CSM-glucose, centrifuged, resuspended in phosphate-buffered Saline (PBS), and plated at a density of 10⁷ cells/plate on solid 15cm petri dishes containing CSM with 2% galactose (w/v), 2% (w/v) agar, and 10 µM Compound 155, and incubated at 30°C. Resistant colonies were isolated after 5-7 days, re-streaked on the same media, and resistance reconfirmed. Cultures of validated strains were then inoculated for genomic DNA isolation using a YeaStar™ yeast genomic DNA kit (Zymo Research).

Libraries were prepared for sequencing using the Illumina NEXTERA™ library prep kit and sequenced via Illumina HiSeq™ 2500 1X50 bp (single end reads). Sequences were aligned to the *S.*

cerevisiae reference genome (S288CCR64-1-1, Saccharomyces Genome Database (SGD)) using Burrows-Wheeler Aligner (BWA, see, e.g., Li et al. *Bioinformatics* 25:1754-1760, 2009; Li et al. *Bioinformatics* 2010, Epub (PMID 20080505)). The BWA output SAI files were converted to SAM files using BWA. The SAM files were sorted using SAMtools 1.3.1 (Li et al. *Bioinformatics* 25:2079-2079, 2009). Variants (single-nucleotide polymorphisms (SNPs), indels) were identified using Freebayes (see, e.g., arXiv:1207.3907). Variant locations were summarized using snpEFF (Cingolani et al. *Fly (Austin)* 6(2):80-92, 2012).

Quantitative Lipid Profiling

Overnight cultures of yeast strain W303 *pdr1Δ pdr3Δ* were diluted into CSM media with 2% (w/v) raffinose, OD₆₀₀ 0.25, and grown for 4 h before resuspending at an OD₆₀₀ of 0.2 in CSM media with 2% (w/v) galactose and adding Compound 95 or DMSO at the indicated concentrations. Cells were grown for the indicated timepoints before centrifugation, washing once in PBS, and freezing pellets. Lipids were extracted from pellets by resuspending the pellets in 600 μL methanol, 300 μL water, and 400 μL chloroform, followed by cell lysis by vortexing with glass beads for 1 min. Samples were then centrifuged at 10,000 x g for 10 min, and the bottom layer that formed (organic/lipids) was moved into a new tube and evaporated. Samples were then analyzed by LC/MS/MS using a Thermo Scientific Q Exactive™ Orbitrap™ coupled to a Dionex UltiMate® 3000 ultra-high performance liquid chromatography system, following the method described in Tafesse et al. *PLoS Pathog.* 11(10): e1005188, 2015.

B. Results

The effect of 1,2,4-oxadiazoles on cell growth was assessed in a control condition and in a yeast model for ApoE4 toxicity (see International Patent Application Publication No. WO 2016/040794). The control condition was growth of the ApoE4 strain under non-inducing conditions using raffinose as the carbon source. The 1,2,4-oxadiazoles exhibited a bell-shaped rescue curve in the ApoE4 model (Fig. 1A, top panel). At higher concentrations, these compounds inhibited the growth in the control condition (Fig. 1B, bottom panel). The potency of model rescue correlated well with the potency of growth inhibition across the entire series of 1,2,4-oxadiazoles tested (Fig. 1B). These relationships indicate that the growth inhibition arises from an “on-target” activity, i.e., over activation or inhibition of a target that results in slowed growth.

Drug-resistant mutants can be used to identify the target of the compounds, for example, by preventing or reducing drug binding, and therefore allowing growth under inhibitory doses of 1,2,4-oxadiazole concentrations. Twenty drug-resistant mutants were isolated, and the mutants were subjected to whole-genome sequencing in order to identify genetic lesions associated with the drug resistance. Surprisingly, all mutations identified in the drug resistant mutants localized to OLE1 (YGL055W), the sole stearyl-CoA desaturase (SCD; also referred to as Δ⁹-desaturase) in yeast (Fig. 9). The drug resistant mutants specifically conferred resistance to 1,2,4-oxadiazoles, but were not cross-resistant to other toxic compounds. The *ole1* mutations identified included indels and substitution mutations, including A305V, L118Δ, S190T, A305T, I301N, A91T, S190T, P123T, and E118Q. These mutations are relative to the wild-type OLE1 sequence provided below.

MPTSGTTIELIDDQFPKDDSSASSGIVDEVLDLTEANILATGLNKKAPRIVNGFGSLMGSKE

MVSVEFDKKGNEKKSNDRLLEKDNQEKEEAKTKIHISEQPWTLNNWHQHNLNLMVLVC
 GMPMIGWYFALSGKVPLHLNVFLFSVFYAVGGVSITAGYHRLWSHRSYSAHWPLRLFYA
 IFGCASVEGSAKWWGHSRHRYTDTLRDPYDARRGLWYSHMGWMLLKPNPKYKARADI
 TDMTDDWTIRFQHRHYILLMLLTAFVIPTLICGYFFNDYMGGLIYAGFIRVFVIQQATFC
 5 INSLAHYIGTQPFDDRRTPRDNWITAIVTFGEGYHNFHHEFPTDYRNAIKWYQYDPTKVI
 IYLTSLVGLAYDLKKFSQNAIEEALIQQEQQKINKKKAKINWGPVLTDLPMWDKQTFLAK
 SKENKGLVIISGIVHDVSGYISEHPGGETLIKALGKDATKAFSGGVYRHSNAAQNVLAD
 MRVAVIKESKNSAIRMASKRGEIYETGKFF (SEQ ID NO: 1)

10 These data strongly suggest that Ole1 is the target of 1,2,4-oxadiazoles. Additionally, addition of exogenous oleic acid reversed both growth inhibition of wild-type cells and rescue of toxicity in a yeast disease model of alpha-synuclein toxicity (Figs. 2A and 2B, respectively). Likewise, these effects were specific for 1,2,4-oxadiazoles, but not other toxic compounds.

Drug-resistant Ole1 mutations reduced 1,2,4-oxadiazole-induced growth inhibition in control
 15 conditions (Fig. 3A). The same mutations also increased the EC₅₀ (concentration that gives half-maximal response) in the context of the alpha-synuclein model, which is consistent with reduced binding to the target. These shifts in dose response were specific for 1,2,4-oxadiazoles. These data further support that Ole1/SCD is the target for both growth inhibition and rescue of toxicity in disease models.

The *OLE1* gene is essential in *Saccharomyces cerevisiae*. However, strains deleted for *OLE1*
 20 (*ole1Δ*) are viable if their growth media is supplemented with oleic/palmitoleic acid. The *ole1Δ* strain supplemented with exogenous fatty acids was fully resistant to 1,2,4-oxadiazoles (Fig. 4). In other words, in the absence of the target, Ole1, the 1,2,4-oxadiazoles do not have growth inhibition activity. Independently, a chemical genetics approach identified *MGA2*, the transcription factor that regulates Ole1. Genetic deletion of *MGA2* (*mga2Δ*) phenocopied the effects of 1,2,4-oxadiazoles (Fig. 5). *mga2Δ*
 25 cells have reduced Ole1 levels, which itself rescues toxicity in the yeast disease models (e.g., the ApoE4 model). Supplementation of the growth media with oleic acid reversed this effect, similar to the results described above. Consistent with these data, treatment of yeast cells with the 1,2,4-oxadiazole Compound 95 inhibited lipid desaturation (Figs. 8A-8D). Overall, these data provide still further evidence that Ole1/SCD is the target of 1,2,4-oxadiazoles.

30 Humanized yeast strains expressing the human SCD proteins SCD1 or SCD5 were generated by genetic deletion of *OLE1* and expressing human SCD1 or SCD5 on a plasmid. Yeast expressing *OLE1* were resistant to known SCD1/SCD5 inhibitors such as A939572, CAY10566, MF-438, and MK-8245 (Fig. 6), suggesting that they do not target the yeast enzyme. In marked contrast, in the SCD1 and SCD5 humanized strains, the known SCD1/SCD5 inhibitors were extremely potent, with low nanomolar half-maximal inhibitory concentration (IC₅₀) values (Fig. 6).
 35

The effect of 1,2,4-oxadiazoles was also evaluated in both of the humanized SCD1 and SCD5 models. 1,2,4-oxadiazoles inhibited the growth of the SCD1 and/or SCD5 yeast strains, and differences in the structure-activity relationship (SAR) between the three SCD proteins was observed (Fig. 7). Some compounds inhibited the growth of both the SCD1 and the SCD5 strains. Other compounds appeared to
 40 target only the yeast enzyme. Out of a total of 250 1,2,4-oxadiazoles tested, approximately 50%

exhibited activity against the human enzymes. The divergent SAR provides additional strong evidence for SCD being the target of 1,2,4-oxadiazoles.

Finally, treatment of yeast cells with the 1,2,4-oxadiazole Compound 95 inhibited lipid desaturation (Figs. 8A-8D), providing additional confirmatory evidence that SCD is the target of 1,2,4-oxadiazoles.

Taken together, these data demonstrate that Ole1/SCD is the target of 1,2,4-oxadiazoles, and that these compounds inhibit Ole1/SCD.

Example 160. Inhibition of Ole1, SCD1, and SCD5 by Compounds of the Invention

Using the methods described above, the inhibition of Ole1, SCD1, and SCD5 was tested for compounds of the invention. The results are shown in Table 5.

Table 5. Inhibition of Ole1, SCD1, and SCD5 by Compounds of the Invention

Compound #	OLE1 % Max Inhibition	OLE1 IC50	SCD1 % Max Inhibition	SCD1 IC50 (μM)	SCD5 % Max Inhibition	SCD5 IC50 (μM)
156	63.63	37.08	72.58	>45	22.37	>45
157	91.55	>45	80.54	>45	72.54	>45
158	89.93	>45	78.34	>45	91.96	>45
159	46.92	>45	70.17	38.85	10.25	13.86
160	71.55	36.23	63.44	40.70	28.51	24.31
1	77.42	40.32	13.31	>45	6.34	>45
2	89.46	>45	39.07	>45	6.07	>45
3	82.44	38.49	22.77	>45	18.19	>45
4	97.53	>45	82.28	>45	5.61	>45
494	92.28	>45	79.67	>45	73.76	>45
5	4.18	>45	72.44	>45	38.42	24.45
6	64.04	39.15	72.55	>45	77.35	41.10
7	3.03	>45	50.66	39.16	8.11	>45
8	16.92	>45	1.03	>45	2.16	>45
493	91.16	>45	68.84	>45	60.28	30.20
9	104.24	>45	115.64	>45	62.24	>45
10	18.99	>45	18.39	>45	6.06	>45
11	78.50	>45	74.99	>45	35.13	>45
12	98.37	>45	70.29	>45	77.40	>45
13	5.69	>45	70.42	>45	25.88	>45
14	14.56	>45	90.98	>45	51.85	27.53
15	9.81	>45	21.78	>45	0.80	>45
16	82.88	>45	66.57	37.11	3.55	>45
17	94.17	>45	71.38	>45	23.21	>45
18	5.70	>45	74.70	41.00	22.66	>45
19	12.81	>45	28.21	>45	4.13	>45
20	112.10	>45	38.25	>45	6.14	>45
21	105.47	>45	87.64	39.94	12.90	>45

22	51.46	40.47	64.47	41.00	74.04	30.02
23	92.36	>45	61.05	33.58	40.64	>45
24	99.70	>45	66.31	>45	67.98	30.03
25	3.45	>45	70.78	>45	51.67	39.44
26	23.82	>45	82.66	>45	50.25	24.46
27	1.78	>45	0.90	>45	-0.86	>45
27	2.82	>45	13.09	>45	3.95	>45
28	4.80	>45	98.15	>45	79.98	>45
29	91.00	>45	69.52	>45	74.10	>45
30	100.46	>45	80.58	>45	74.17	>45
31	79.60	>45	81.19	>45	24.26	25.37
32	108.22	>45	84.16	>45	80.17	>45
33	1.55	>45	8.14	>45	24.10	>45
34	76.89	>45	42.55	>45	5.37	>45
35	3.66	>45	79.23	>45	68.57	>45
36	17.70	>45	64.67	30.02	63.86	>45
37	9.99	>45	81.44	>45	74.18	>45
38	20.26	>45	72.81	>45	64.24	41.03
39	110.89	>45	77.01	>45	79.10	>45
40	1.26	>45	41.70	>45	0.43	>45
40	0.80	>45	47.19	>45	4.73	>45
40	4.9	>45	57.7	>45	13.7	>45
41	85.45	>45	55.28	38.72	43.51	>45
42	95.43	>45	90.77	>45	47.40	>45
43	107.35	>45	76.52	>45	65.66	>45
492	106.45	>45	83.92	>45	75.64	>45
44	93.69	>45	17.96	>45	10.99	>45
46	87.95	>45	70.27	>45	72.35	>45
47	109.20	>45	73.30	>45	74.25	>45
48	8.16	>45	63.58	39.27	75.26	>45
49	34.89	>45	61.29	>45	63.18	>45
491	107.15	>45	118.81	>45	83.61	>45
50	98.10	>45	67.05	41.00	46.80	>45
51	102.56	>45	76.83	>45	6.59	>45
52	11.78	>45	1.65	>45	-1.01	>45
53	98.51	>45	79.96	>45	2.94	>45
54	85.34	>45	82.41	>45	47.60	>45
55	114.12	>45	74.99	33.67	74.78	>45
56	10.04	>45	59.58	>45	70.33	30.00
57	82.47	>45	80.82	>45	63.17	41.10
490	96.38	>45	63.84	38.76	50.39	35.13
58	92.35	>45	101.47	>45	66.93	>45
489	94.30	>45	68.84	41.00	61.11	41.10
488	90.53	>45	75.87	>45	72.82	>45
59	105.25	>45	79.13	>45	59.32	>45

60	2.91	>45	72.03	>45	57.19	41.10
61	71.50	40.87	2.37	>45	13.18	>45
62	86.77	>45	28.73	>45	5.75	>45
63	101.06	>45	62.04	33.67	9.39	>45
64	115.95	>45	32.39	>45	42.05	>45
65	4.02	>45	83.43	>45	73.43	>45
66	99.71	>45	94.04	>45	19.53	>45
67	85.79	>45	54.45	40.71	4.32	>45
68	9.74	>45	22.28	>45	3.75	>45
69	105.31	>45	60.59	>45	8.06	>45
70	74.02	>45	39.36	>45	22.44	>45
71	97.50	>45	67.35	>45	46.73	>45
72	85.17	>45	41.97	27.27	52.89	32.98
73	83.83	>45	61.02	33.67	5.84	>45
74	85.96	>45	51.32	31.26	5.68	>45
75	91.51	>45	80.18	>45	63.65	30.05
487	103.20	>45	83.76	>45	70.73	40.19
486	103.51	>45	76.95	>45	72.76	>45
485	75.19	>45	62.60	>45	65.42	30.03
484	92.09	>45	75.84	>45	81.46	>45
78	87.89	38.34	86.39	>45	86.12	>45
79	104.92	>45	81.83	>45	76.87	>45
80	46.71	>45	98.34	>45	15.53	>45
81	13.12	>45	13.86	>45	3.39	>45
82	107.01	>45	83.67	>45	75.72	>45
83	3.73	>45	7.65	>45	1.65	>45
85	64.87	>45	88.05	>45	16.38	>45
86	2.85	>45	84.44	>45	66.85	33.33
88	16.29	>45	63.82	33.46	5.70	>45
89	119.71	>45	106.83	>45	87.41	>45
90	23.20	>45	107.22	>45	3.66	>45
91	3.64	>45	97.20	>45	32.20	>45
92	107.87	>45	80.31	>45	83.38	>45
93	5.46	>45	97.21	>45	8.16	>45
94	29.00	>45	90.84	>45	61.78	39.28
95	5.72	>45	58.05	39.20	7.46	>45
96	3.94	>45	12.37	>45	1.38	>45
97	10.45	>45	81.79	>45	78.75	30.01
98	92.44	>45	74.79	>45	52.40	41.10
99	64.73	>45	13.74	>45	8.85	>45
100	23.98	>45	54.37	32.84	6.56	>45
101	12.74	>45	29.81	>45	29.09	>45
102	24.90	>45	60.33	>45	6.56	>45
103	5.27	>45	93.33	>45	68.60	>45
104	110.40	>45	76.89	>45	77.11	>45

105	34.19	>45	41.38	>45	13.93	>45
106	35.35	>45	78.19	>45	71.22	>45
107	4.55	>45	73.32	>45	74.80	>45
108	72.04	>45	72.79	>45	64.66	>45
109	87.87	>45	84.36	>45	89.75	>45
110	96.31	>45	66.85	>45	65.07	>45
111	38.26	>45	76.39	>45	32.73	>45
112	3.16	>45	66.76	>45	21.21	>45
113	5.55	>45	55.33	40.72	27.28	>45
114	90.17	>45	74.54	>45	77.66	>45
115	101.68	>45	77.36	>45	77.85	>45
116	12.75	>45	71.12	>45	8.35	>45
117	92.97	>45	95.94	>45	54.63	36.14
118	87.29	>45	93.37	>45	32.21	27.53
119	111.86	>45	86.22	>45	93.93	>45
120	119.08	>45	99.80	>45	96.39	>45
121	111.12	>45	94.06	>45	98.38	>45
122	109.89	>45	92.73	>45	90.04	>45
123	3.12	>45	73.59	>45	9.69	>45
124	4.55	>45	88.87	>45	96.23	>45
319	74.25	>45	97.10	>45	4.96	>45
319	63.83	>45	89.16	>45	10.94	>45
125	92.36	>45	77.68	>45	94.83	>45
126	73.29	>45	69.80	>45	79.08	30.00
127	99.27	>45	66.46	>45	88.59	>45
128	81.43	>45	1.12	>45	1.89	>45
128	60.60	45	23.56	>45	3.32	>45
129	3.25	>45	75.60	>45	93.05	>45
130	2.75	>45	97.82	>45	99.82	>45
131	39.81	25.79	96.48	>45	98.92	>45
132	7.45	>45	115.10	>45	94.34	>45
133	26.72	>45	61.21	37.29	74.75	>45
134	93.94	>45	107.77	>45	98.55	>45
135	99.53	>45	92.42	>45	91.64	>45
136	73.60	>45	34.33	>45	17.07	>45
137	96.83	>45	90.19	>45	50.61	22.33
138	3.94	>45	54.49	37.32	4.57	>45
139	25.30	>45	87.50	>45	75.11	>45
140	3.96	>45	77.37	>45	3.46	>45
140	4.98	>45	75.00	45	10.16	1.30
141	1.77	>45	86.53	>45	78.91	>45
142	1.11	>45	80.83	>45	26.00	>45
143	95.01	>45	79.38	>45	96.06	>45
144	100.96	>45	79.00	>45	84.27	>45
145	51.17	15.85	78.31	>45	86.51	>45

146	3.28	>45	60.81	37.75	25.62	>45
147	9.34	>45	74.14	>45	86.70	>45
148	99.90	>45	79.55	>45	86.53	>45
149	90.68	>45	69.75	>45	38.72	>45
150	5.16	>45	74.48	>45	86.15	>45
151	2.67	>45	75.63	>45	20.68	>45
152	2.37	>45	83.39	>45	60.91	>45
153	2.75	>45	75.76	>45	87.51	>45
154	1.20	>45	68.90	>45	3.25	>45
155	1.65	>45	98.25	>45	67.35	33.77
162	100.35	>45	84.54	>45	76.89	>45
163	71.84	>45	55.99	36.51	24.77	>45
164	96.96	>45	102.20	>45	73.90	>45
165	2.01	>45	94.44	>45	80.23	>45
166	105.73	>45	90.07	>45	68.87	>45
167	57.28	38.39	6.11	>45	2.38	>45
168	4.90	>45	114.58	>45	1.99	>45
168	8.34	>45	74.07	45	14.85	>45
169	99.67	>45	78.78	>45	84.20	>45
170	67.97	40.39	103.19	>45	85.13	>45
171	6.77	>45	74.21	40.42	-0.14	>45
172	3.99	>45	89.39	>45	68.80	41.10
173	99.75	>45	78.07	>45	42.09	29.77
174	89.17	>45	79.07	>45	10.95	>45
175	3.00	>45	77.47	>45	77.96	>45
176	3.62	>45	107.22	>45	83.50	>45
177	40.70	>45	97.88	>45	86.13	>45
178	7.39	>45	114.07	>45	85.67	>45
179	76.70	38.71	106.53	>45	85.02	>45
180	107.78	>45	102.85	>45	82.28	>45
181	20.70	>45	88.32	>45	81.40	>45
182	124.27	>45	113.27	>45	79.82	>45
183	101.71	>45	101.67	>45	84.88	>45
184	3.07	>45	86.33	>45	2.41	>45
184	0.87	>45	50.65	45	11.92	>45
185	93.51	>45	97.91	>45	72.91	>45
186	35.40	>45	86.16	>45	73.51	30.01
187	97.42	>45	72.13	>45	2.91	>45
188	4.70	>45	78.63	>45	4.51	>45
189	98.14	>45	88.10	>45	68.58	>45
190	100.94	>45	83.53	>45	19.31	>45
191	89.31	>45	81.79	>45	6.72	>45
192	95.03	>45	84.60	>45	76.82	>45
193	89.35	>45	80.72	>45	85.76	>45
194	60.71	>45	74.07	>45	63.24	>45

195	3.86	>45	75.08	>45	9.78	>45
196	93.87	>45	86.58	>45	75.88	>45
197	4.80	>45	66.87	>45	61.44	>45
198	2.96	>45	71.25	>45	36.45	>45
199	24.34	>45	27.85	>45	3.87	>45
200	2.69	>45	79.67	>45	64.72	41.10
201	85.29	>45	79.67	>45	65.14	32.88
202	94.93	>45	74.09	>45	74.20	>45
203	100.03	>45	84.83	>45	80.12	>45
204	79.30	>45	30.36	>45	0.25	>45
204	50.38	>45	21.99	>45	2.95	>45
205	94.02	>45	31.70	>45	1.01	>45
206	5.25	>45	93.66	>45	19.89	>45
207	5.39	>45	86.42	>45	72.56	>45
208	96.63	>45	14.04	>45	5.68	>45
209	3.74	>45	101.51	>45	78.88	>45
210	2.27	>45	30.48	>45	3.39	>45
211	2.65	>45	39.99	>45	6.95	>45
212	100.82	>45	76.79	>45	76.28	>45
213	94.72	>45	86.35	>45	85.33	>45
214	15.08	>45	65.73	41.00	74.58	>45
215	48.68	>45	88.23	>45	78.96	>45
216	61.84	35.11	83.82	>45	75.59	>45
217	10.39	>45	57.90	36.93	12.62	>45
218	4.63	>45	48.31	>45	25.15	>45
219	3.50	>45	95.22	>45	89.83	>45
220	3.10	>45	87.27	>45	13.65	>45
221	113.54	>45	100.56	>45	93.18	>45
222	3.59	>45	40.42	>45	1.92	>45
223	2.22	>45	68.23	40.65	67.37	40.97
224	2.54	>45	26.70	>45	1.12	>45
225	20.97	>45	94.06	>45	88.95	>45
226	1.24	>45	33.20	>45	0.69	>45
227	1.24	>45	63.76	38.33	6.17	>45
228	21.30	>45	51.80	41.00	2.72	>45
229	89.56	>45	66.51	>45	71.18	>45
230	2.63	>45	78.48	>45	44.00	>45
231	29.53	>45	80.00	>45	3.11	>45
232	4.20	>45	81.04	>45	51.17	41.10
233	18.46	>45	73.65	>45	74.91	>45
234	84.80	>45	68.91	>45	76.83	>45
235	84.04	>45	74.46	>45	87.47	>45
236	8.46	>45	77.23	>45	3.14	>45
237	18.53	>45	71.76	>45	45.34	32.63
238	4.93	>45	70.06	>45	69.63	30.00

239	29.21	>45	75.58	>45	6.02	>45
240	4.30	>45	66.85	>45	12.95	>45
241	6.15	>45	91.61	>45	16.97	>45
242	95.59	>45	101.23	>45	79.22	>45
243	94.60	>45	94.50	>45	72.11	>45
244	3.34	>45	15.54	>45	2.85	>45
244	1.29	>45	8.51	>45	2.47	>45
245	95.26	>45	77.70	>45	66.96	>45
246	13.06	>45	77.22	>45	66.03	>45
247	98.49	>45	79.89	>45	72.46	>45
248	73.12	>45	3.09	>45	13.59	>45
249	88.69	>45	80.12	>45	61.88	41.67
250	4.41	>45	86.09	>45	14.48	>45
251	7.80	>45	83.15	>45	20.59	>45
252	27.85	>45	80.73	>45	39.69	>45
253	106.42	>45	62.07	>45	63.11	>45
254	92.77	>45	69.80	>45	83.13	>45
255	96.25	>45	72.70	>45	64.50	30.02
256	4.16	>45	76.04	>45	72.11	>45
261	94.41	>45	73.42	>45	82.31	>45
262	23.99	>45	41.84	>45	10.38	>45
263	8.71	>45	18.81	>45	7.20	>45
264	15.52	>45	56.37	40.76	7.97	>45
265	103.04	>45	76.74	>45	10.96	>45
265	83.99	45	54.38	45	3.97	>45
266	7.17	>45	12.42	>45	9.90	>45
267	4.64	>45	58.58	37.75	11.33	>45
268	4.39	>45	79.03	>45	8.68	>45
268	0.14	>45	65	45	2.67	>45
269	6.62	>45	38.78	>45	8.38	>45
269	4.57	>45	25.11	>45	5.30	>45
270	63.00	41.85	82.42	>45	12.30	>45
271	11.7	>45	67.9	>45	53.6	>45
272	40.3	>45	70.8	>45	51.9	>45
273	78.7	>45	67.9	>45	55.0	>45
274	75.9	>45	75.3	>45	67.0	>45
275	11.24	>45	76.51	>45	78.05	>45
276	6.27	>45	61.16	>45	18.81	14.51
277	94.36	>45	76.49	>45	74.99	>45
278	21.08	>45	32.22	>45	10.55	>45
279	83.07	>45	43.86	>45	21.97	>45
280	17.18	>45	11.48	>45	8.86	>45
281	60.23	33.84	84.97	>45	18.03	>45
281	32.09	>45	68.90	45	12.39	>45
282	110.18	>45	90.54	>45	56.23	28.87

283	24.43	>45	34.91	34.65	9.83	>45
284	12.40	>45	4.81	>45	6.80	>45
285	105.26	>45	45.62	>45	30.09	>45
286	5.18	>45	13.04	>45	8.76	>45
286	4.35	>45	14.44	>45	9.55	>45
287	93.89	>45	72.51	>45	66.81	>45
288	7.14	>45	8.71	>45	7.52	>45
289	45.87	>45	62.01	>45	77.71	>45
290	20.6	>45	3.3	>45	8.8	>45
291	15.6	>45	5.0	>45	8.5	>45
291	3.95	>45	0.30	>45	3.29	>45
292	13.6	>45	9.5	>45	10.2	>45
293	66.4	34.9	12.3	>45	11.9	>45
294	4.5	>45	16.6	>45	7.8	>45
294	2.84	>45	23.31	>45	6.57	>45
295	18.4	>45	14.4	>45	9.2	>45
296	99.1	>45	86.6	>45	22.6	>45
297	42.0	25.2	5.7	>45	9.2	>45
298	6.6	>45	92.3	>45	21.3	>45
299	17.5	>45	89.6	>45	30.1	>45
299	13.58	>45	62.80	45	22.61	>45
300	79.7	>45	78.1	>45	36.0	>45
301	99.4	>45	96.2	>45	21.0	>45
302	6.7	>45	71.1	36.1	9.4	>45
302	5.26	>45	50.17	45	10.64	>45
303	14.2	>45	94.3	>45	15.6	>45
303	8.50	>45	65	45	20.68	>45
304	14.7	>45	74.9	>45	51.6	>45
305	6.6	>45	73.2	>45	18.4	>45
305	4.23	>45	55.27	45	5.95	>45
306	33.2	>45	67.6	>45	17.6	>45
306	36.88	>45	63.32	45	5.23	>45
307	7.8	>45	78.2	>45	52.5	>45
307	4.08	>45	70.58	45	27.45	>45
308	63.7	>45	81.6	>45	15.5	>45
308	49.30	27.20	61.05	45	6.81	>45
309	8.0	>45	80.6	>45	14.7	>45
310	7.1	>45	71.2	>45	66.6	>45
311	90.8	>45	72.9	>45	60.5	>45
316	89.26	45	69.01	45	80	45
317	8.3	>45	30.0	>45	20.6	>45
318	89.1	>45	77.6	>45	33.7	>45
319	86.3	>45	81.7	>45	19.6	>45
319	84.75	45	75.42	45	4.56	>45
320	28.5	>45	74.7	>45	76.0	>45

321	14.0	>45	71.6	>45	74.1	>45
322	9.0	>45	73.6	>45	29.8	>45
323	89.1	>45	76.1	>45	73.5	>45
324	90.5	>45	74.9	>45	68.7	>45
325	79.2	>45	73.7	>45	67.2	>45
326	7.5	>45	77.1	>45	26.5	>45
327	74.8	>45	66.5	>45	68.0	>45
328	21.9	>45	86.6	>45	80.5	>45
329	12.5	>45	16.2	>45	13.4	>45
331	13.7	>45	41.9	>45	24.9	>45
332	77.0	>45	59.7	>45	31.5	>45
333	81.2	>45	55.6	>45	62.3	>45
334	84.4	>45	49.3	>45	66.7	>45
335	81.5	>45	54.0	>45	61.2	>45
336	86.7	>45	56.9	>45	74.1	>45
337	86.4	>45	49.6	>45	61.6	>45
338	85.2	>45	60.0	>45	76.3	>45
339	85.7	>45	56.1	>45	75.4	>45
340	88.9	>45	55.0	>45	65.9	>45
341	91.7	>45	45.2	>>45	45.6	>45
342	80.9	>45	75.9	>45	43.5	>45
343	84.7	>45	59.1	>45	23.2	>45
344	7.14	>45	n/a	n/a	1.1	>45
345	6.63	>45	n/a	n/a	2.2	>45
346	12.12	>45	n/a	n/a	1.1	>45
348	74.78	>45	n/a	n/a	59.2	45
349	84.00	>45	n/a	n/a	0.2	>45
350	71.00	>45	n/a	n/a	56.3	45
351	68.60	>45	n/a	n/a	57.3	45
352	71.57	>45	n/a	n/a	44.5	>45
354	NT	NT	30.16	>45	4.29	>45
355	NT	NT	71.31	>45	3.68	>45
356	NT	NT	51.18	>45	2.88	>45
357	NT	NT	64.32	>45	2.31	>45
358	NT	NT	59.61	>45	4.53	>45
359	NT	NT	55.70	>45	0.81	>45
360	NT	NT	64.03	>45	2.38	>45
361	NT	NT	67.22	>45	0.95	>45
362	NT	NT	67.00	>45	2.26	>45
363	NT	NT	64.44	>45	1.99	>45
364	NT	NT	70.82	>45	2.22	>45
365	NT	NT	58.08	>45	23.74	>45
495	NT	NT	-	>45	-	1.917
496	NT	NT	-	>45	-	0.445
497	NT	NT	-	>45	-	11.33

498	NT	NT	-	>45	-	>45
499	NT	NT	-	>45	-	1.103
500	NT	NT	-	>45	-	>45
501	NT	NT	-	12.16	-	21.27
502	NT	NT	-	>45	-	38.94
503	NT	NT	-	>45	-	0.316
504	NT	NT	-	>45	-	14.84
505	NT	NT	-	>45	-	0.669
506	NT	NT	-	>45	-	0.81
507	NT	NT	-	>45	-	2.443
508	NT	NT	-	>45	-	>45
509	NT	NT	-	>45	-	>45
510	NT	NT	-	>45	-	4.16
511	NT	NT	-	>45	-	3.39
512	NT	NT	-	>45	-	>45
513	NT	NT	-	>45	-	>45
514	NT	NT	-	>45	-	>45
515	NT	NT	-	16.53	-	>45
516	NT	NT	-	>45	-	>45
517	NT	NT	-	>45	-	>45
518	NT	NT	-	>45	-	2.95
519	NT	NT	-	>45	-	>45
520	NT	NT	-	>45	-	>45
521	NT	NT	-	>45	-	8.794
522	NT	NT	-	>45	-	>45
523	NT	NT	-	>45	-	>45
524	NT	NT	-	>45	-	2.499
745	NT	NT	-	>45	-	>45
525	NT	NT	-	>45	-	>45
526	NT	NT	-	>45	-	>45
527	NT	NT	-	0.958	-	1.46
528	NT	NT	-	>45	-	>45
529	NT	NT	-	>45	-	>45
530	NT	NT	-	>45	-	>45
531	NT	NT	-	>45	-	>45
532	NT	NT	-	>45	-	2.15
533	NT	NT	-	>45	-	3.331
534	NT	NT	-	>45	-	36.8
535	NT	NT	-	>45	-	>45
536	NT	NT	-	>45	-	>45
537	NT	NT	-	>45	-	>45
538	NT	NT	-	>45	-	>45
539	NT	NT	-	>45	-	>45
540	NT	NT	-	>45	-	>45
541	NT	NT	-	>45	-	>45

542	NT	NT	-	>45	-	7.331
543	NT	NT	-	>45	-	45
544	NT	NT	-	>45	-	10.03
545	NT	NT	-	>45	-	18.95
546	NT	NT	-	>45	-	0.019
547	NT	NT	-	>45	-	44.3
548	NT	NT	-	>45	-	0.01
549	NT	NT	-	>45	-	1.211
550	NT	NT	-	>45	-	>45
551	NT	NT	-	>45	-	>45
552	NT	NT	-	>45	-	>45
553	NT	NT	-	5.708	-	0.885
554	NT	NT	-	4.079	-	1.071
555	NT	NT	-	>45	-	>45
556	NT	NT	-	>45	-	>45
557	NT	NT	-	>45	-	6.03
558	NT	NT	-	>45	-	1.072
559	NT	NT	-	>45	-	1.191
560	NT	NT	-	>45	-	>45
561	NT	NT	-	>45	-	29.43
562	NT	NT	-	>45	-	1.496
563	NT	NT	-	>45	-	>45
564	NT	NT	-	>45	-	4.234
565	NT	NT	-	>45	-	>45
567	NT	NT	-	>45	-	>45
568	NT	NT	-	>45	-	>45
569	NT	NT	-	>45	-	>45
570	NT	NT	-	>45	-	26.35
571	NT	NT	-	>45	-	>45
572	NT	NT	-	>45	-	14.99
573	NT	NT	-	>45	-	5.601
574	NT	NT	-	>45	-	2.282
575	NT	NT	-	>45	-	4.681
576	NT	NT	-	>45	-	0.028
577	NT	NT	-	>45	-	>45
578	NT	NT	-	8.457	-	1.487
579	NT	NT	-	>45	-	>45
580	NT	NT	-	14.08	-	0.022
581	NT	NT	-	>45	-	>45
582	NT	NT	-	>45	-	0.176
583	NT	NT	-	>45	-	0.989
584	NT	NT	-	>45	-	5.338
585	NT	NT	-	>45	-	1.807
586	NT	NT	-	>45	-	3.768
587	NT	NT	-	>45	-	4.92

588	NT	NT	-	>45	-	1.861
589	NT	NT	-	>45	-	0.356
590	NT	NT	-	>45	-	>45
591	NT	NT	-	>45	-	>45
592	NT	NT	-	>45	-	>45
593	NT	NT	-	>45	-	>45
594	NT	NT	-	>45	-	11.8
595	NT	NT	-	>45	-	>45
596	NT	NT	-	>45	-	>45
597	NT	NT	-	>45	-	>45
598	NT	NT	-	>45	-	>45
599	NT	NT	-	>45	-	>45
600	NT	NT	-	>45	-	>45
601	NT	NT	-	>45	-	5.686
602	NT	NT	-	15.94	-	2.744
603	NT	NT	-	7.258	-	2.411
604	NT	NT	-	>45	-	6.12
605	NT	NT	-	31.84	-	0.513
606	NT	NT	-	>45	-	0.737
607	NT	NT	-	>45	-	0.511
608	NT	NT	-	>45	-	>45
609	NT	NT	-	>45	-	>45
610	NT	NT	-	>45	-	2.157
611	NT	NT	-	>45	-	7.479
612	NT	NT	-	>45	-	2.385
613	NT	NT	-	>45	-	>45
614	NT	NT	-	>45	-	13.92
615	NT	NT	-	0.848	-	1.878
616	NT	NT	-	>45	-	>45
617	NT	NT	-	>45	-	0.121
618	NT	NT	-	>45	-	0.101
619	NT	NT	-	>45	-	0.291
620	NT	NT	-	>45	-	0.013
621	NT	NT	-	>45	-	0.042
622	NT	NT	-	>45	-	1.614
623	NT	NT	-	>45	-	0.854
624	NT	NT	-	>45	-	0.222
625	NT	NT	-	>45	-	0.122
626	NT	NT	-	>45	-	2.75
627	NT	NT	-	>45	-	6.686
628	NT	NT	-	>45	-	0.01
629	NT	NT	-	>45	-	0.03
630	NT	NT	-	10.24	-	0.014
631	NT	NT	-	>45	-	>45
632	NT	NT	-	>45	-	>45

633	NT	NT	-	>45	-	0.214
634	NT	NT	-	>45	-	45
635	NT	NT	-	>45	-	0.397
636	NT	NT	-	>45	-	1.801
637	NT	NT	-	>45	-	>45
638	NT	NT	-	>45	-	>45
639	NT	NT	-	>45	-	4.791
640	NT	NT	-	>45	-	3.98
641	NT	NT	-	>45	-	6.72
642	NT	NT	-	>45	-	0.211
643	NT	NT	-	>45	-	0.01
644	NT	NT	-	>45	-	>45
645	NT	NT	-	17.92	-	4.473
646	NT	NT	-	>45	-	1.184
647	NT	NT	-	>45	-	9.371
648	NT	NT	-	>45	-	>45
649	NT	NT	-	>45	-	0.259
650	NT	NT	-	4.359	-	0.013
651	NT	NT	-	>45	-	18.43
652	NT	NT	-	>45	-	>45
653	NT	NT	-	>45	-	>45
654	NT	NT	-	>45	-	>45
655	NT	NT	-	>45	-	>45
656	NT	NT	-	>45	-	>45
657	NT	NT	-	>45	-	9.109
658	NT	NT	-	>45	-	0.089
659	NT	NT	-	>45	-	4.201
660	NT	NT	-	>45	-	14.62
661	NT	NT	-	>45	-	1.541
662	NT	NT	-	>45	-	>45
663	NT	NT	-	>45	-	0.01
664	NT	NT	-	23.48	-	0.023
665	NT	NT	-	>45	-	5.006
666	NT	NT	-	>45	-	>45
667	NT	NT	-	>45	-	0.87
668	NT	NT	-	>45	-	0.719
669	NT	NT	-	>45	-	>45
670	NT	NT	-	>45	-	3.789
671	NT	NT	-	>45	-	>45
672	NT	NT	-	>45	-	0.441
673	NT	NT	-	>45	-	33.85
674	NT	NT	-	>45	-	>45
675	NT	NT	-	>45	-	0.01
676	NT	NT	-	>45	-	0.013
677	NT	NT	-	>45	-	>45

678	NT	NT	-	>45	-	3.868
679	NT	NT	-	>45	-	>45
680	NT	NT	-	>45	-	>45
681	NT	NT	-	>45	-	>45
682	NT	NT	-	>45	-	0.01
683	NT	NT	-	>45	-	10.15
684	NT	NT	-	>45	-	>45
685	NT	NT	-	>45	-	0.184
686	NT	NT	-	>45	-	>45
687	NT	NT	-	>45	-	>45
688	NT	NT	-	>45	-	1.504
689	NT	NT	-	>45	-	0.657
690	NT	NT	-	>45	-	0.131
691	NT	NT	-	>45	-	>45
692	NT	NT	-	>45	-	0.492
693	NT	NT	-	>45	-	1.666
694	NT	NT	-	>45	-	>45
695	NT	NT	-	>45	-	2.394
696	NT	NT	-	>45	-	0.08
697	NT	NT	-	>45	-	0.059
698	NT	NT	-	>45	-	0.026
699	NT	NT	-	>45	-	7.647
700	NT	NT	-	>45	-	0.703
701	NT	NT	-	>45	-	>45
702	NT	NT	-	>45	-	>45
703	NT	NT	-	>45	-	0.121
704	NT	NT	-	>45	-	1.677
705	NT	NT	-	14.37	-	0.174
706	NT	NT	-	>45	-	>45
707	NT	NT	-	>45	-	14.53
708	NT	NT	-	>45	-	>45
709	NT	NT	-	>45	-	4.774
710	NT	NT	-	>45	-	0.05
711	NT	NT	-	>45	-	>45
712	NT	NT	-	>45	-	0.016
713	NT	NT	-	5.583	-	0.01
714	NT	NT	-	>45	-	0.23
715	NT	NT	-	>45	-	0.048
716	NT	NT	-	>45	-	>45
717	NT	NT	-	>45	-	1.698
718	NT	NT	-	>45	-	0.635
719	NT	NT	-	>45	-	>45
720	NT	NT	-	>45	-	1.966
721	NT	NT	-	>45	-	1.653
722	NT	NT	-	>45	-	1.374

723	NT	NT	-	>45	-	>45
724	NT	NT	-	>45	-	1.249
725	NT	NT	-	5.99	-	0.011
726	NT	NT	-	5.65	-	0.01
727	NT	NT	-	>45	-	>45
728	NT	NT	-	>45	-	0.126
729	NT	NT	-	>45	-	>45
730	NT	NT	-	>45	-	0.718
731	NT	NT	-	>45	-	>45
732	NT	NT	-	>45	-	31.82
733	NT	NT	-	>45	-	2.727
734	NT	NT	-	>45	-	>45
735	NT	NT	-	3.99	-	0.01
736	NT	NT	-	32.65	-	0.26
737	NT	NT	-	>45	-	>45
738	NT	NT	-	>45	-	>45
739	NT	NT	-	>45	-	>45
740	NT	NT	-	>45	-	1.43
741	NT	NT	-	>45	-	7.756
742	NT	NT	-	>45	-	5.048
743	NT	NT	-	>45	-	14.78
744	NT	NT	-	>45	-	>45

Table 6. Inhibition of SCD1 and SCD5 by Compounds of the Invention

#	SCD1 IC50 (μM)	SCD5 IC50 (μM)	#	SCD1 IC50 (μM)	SCD5 IC50 (μM)
747	>45	26.801	858	>45	0.262
748	>45	2.140	859	>45	>4
749	>45	20.798	860	>45	0.478
750	3.25	0.010	861	14.96	0.010
751	>45	>45	862	33.83	0.010
752	>45	>45	863	>45	>45
753	>45	0.585	864	>45	>45
754	>45	16.472	865	>45	0.010
755	>45	5.413	866	>45	4.607
756	>45	4.363	867	>45	1.915
757	>45	4.951	868	>45	0.967
758	>45	5.271	869	>45	1.64
759	>45	>45	870	>45	4.26
760	>45	>45	871	>45	9.54
761	>45	>45	872	>45	8.06
762	>45	5.253	873	>45	41.27
763	29.49	18.001	874	>45	0.05

#	SCD1 IC50 (μM)	SCD5 IC50 (μM)	#	SCD1 IC50 (μM)	SCD5 IC50 (μM)
764	>45	16.700	875	>45	0.02
765	32.91	19.277	876	>45	0.01
766	>45	>45	877	>45	0.08
767	>45	0.010	878	>45	0.005
768	>45	>45	879	5.50	0.01
769	>45	>45	880	>45	0.010
770	>45	>45	881	>45	0.01
771	>45	>45	882	6.56	1.91
772	>45	>45	883	>45	1.00
773	>45	21.475	884	>45	0.01
774	>45	>45	885	25.38	0.01
775	>45	0.022	886	10.62	0.06
776	>45	0.025	887	>45	0.01
777	4.16	0.010	888	>45	0.01
778	>45	0.012	889	13.31	1.90
779	>45	15.285	890	22.69	0.01
780	>45	0.027	891	>45	0.01
781	>45	4.800	892	>45	0.01
782	>45	0.149	893	>45	0.01
783	>45	>45	894	>45	0.07
784	0.95	0.010	895	>45	0.01
785	9.21	0.041	896	>45	0.01
786	>45	>45	897	>45	0.06
787	31.50	0.108	898	>45	0.07
788	>45	6.218	899	>45	25.98
789	>45	0.010	900	>45	13.08
790	>45	0.053	901	>45	>45
791	>45	0.010	902	>45	0.01
792	8.83	0.010	903	>45	0.01
793	>45	>45	904	>45	7.62
794	>45	>45	905	>45	>45
795	>45	0.010	906	>45	0.89
796	>45	1.589	907	>45	0.04
797	>45	0.133	908	>45	0.19
798	>45	>45	909	>45	2.85
799	>45	0.010	910	>45	0.01
801	>45	0.363	911	>45	>45
802	>45	14.209	912	>45	1.98
803	12.88	0.679	913	>45	13.79

#	SCD1 IC50 (μM)	SCD5 IC50 (μM)	#	SCD1 IC50 (μM)	SCD5 IC50 (μM)
804	>45	>45	914	>45	6.17
805	>45	9.360	915	>45	10.12
806	>45	>45	916	1.96	0.01
807	>45	0.247	917	>45	0.10
808	>45	5.816	918	>45	0.80
809	>45	0.124	919	>45	0.18
810	>45	2.497	920	11.67	0.10
811	>45	0.679	921	>45	3.40
812	>45	0.010	922	>45	6.56
813	>45	0.010	923	>45	>45
814	>45	>45	924	>45	4.09
815	>45	>45	925	>45	>45
816	>45	7.186	926	>45	>45
817	4.13	0.010	927	>45	0.14
818	>45	0.560	928	>45	0.01
819	>45	3.725	929	>45	4.42
820	>45	3.744	930	>45	0.20
821	>45	5.058	931	>45	>45
822	>45	0.111	932	>45	0.01
823	>45	0.119	933	>45	0.20
824	>45	0.932	934	>45	0.01
825	>45	9.490	935	>45	>45
826	>45	1.990	936	>45	3.45
827	>45	>45	937	>45	>45
828	>45	0.067	938	>45	>45
829	>45	2.202	939	>45	10.91
830	>45	>45	940	>45	31.18
831	>45	1.202	941	>45	20.36
832	>45	11.644	942	>45	9.16
833	>45	>45	943	>45	>45
834	>45	>45	944	>45	2.22
835	>45	>45	945	>45	5.29
836	>45	1.438	946	>45	4.11
837	>45	12.527	947	>45	>45
838	>45	0.021	948	>45	>45
839	>45	0.035	949	>45	>45
840	>45	20.683	950	>45	>45
841	>45	0.209	951	>45	>45
842	>45	0.010	952	15.60	9.22

#	SCD1 IC50 (μM)	SCD5 IC50 (μM)	#	SCD1 IC50 (μM)	SCD5 IC50 (μM)
843	>45	0.033	953	>45	0.01
844	>45	0.015	954	>45	2.86
845	>45	0.637	955	>45	>45
846	>45	0.040	956	>45	2.46
847	>45	>45	957	27.91	0.01
848	>45	0.010	958	>45	34.53
849	>45	0.644	959	>45	>45
850	>45	0.010	960	20.36	0.01
851	>45	0.065	961	>45	>45
852	>45	5.358	962	>45	0.01
853	>45	0.010	963	>45	0.16
854	14.57	0.010	964	0.31	0.03
855	>45	>45	965	>45	0.01
856	>45	>45	966	>45	0.15
857	>45	26.801			

Other Embodiments

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.


All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.

Other embodiments are in the claims.

What is claimed is:


CLAIMS

1. A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia:



Formula Ia

wherein B is absent or has the structure:



Formula Ib

Formula Ic

Formula Id

Formula Ie

Formula If

the dashed line represents an optional double bond;

Het is $-\text{C}(\text{O})\text{NH}-$ or an optionally substituted optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl;

m is 0 or 1;

n is 0, 1, or 2;

o is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

p and r are, independently, 0 or 1;

X^1 and X^2 are each, independently, N or CR^6 ;

L^1 is $-\text{O}-$, $-\text{SO}_2-$, NR^2 , optionally substituted $\text{C}_1\text{-C}_6$ alkylene, optionally substituted $\text{C}_1\text{-C}_6$ alkenylene, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkylene, optionally substituted $\text{C}_3\text{-C}_7$ cycloalkyl, optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl, or optionally substituted $\text{C}_2\text{-C}_9$ heterocycle;

L^2 is absent, $-\text{O}-$, $-\text{SO}_2-$, NR^2 , or $-\text{CR}^2\text{R}^3-$;

R^1 is optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, optionally substituted $\text{C}_6\text{-C}_{10}$ aryl, optionally substituted $\text{C}_6\text{-C}_{10}$ aryl $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_3\text{-C}_7$ cycloalkyl, optionally substituted $\text{C}_3\text{-C}_7$ cycloalkyl $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl, optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_9$ heterocycle, or optionally substituted $\text{C}_2\text{-C}_9$ heterocycle $\text{C}_1\text{-C}_6$ alkyl;

R^2 and R^3 are each, independently, hydrogen, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, or combine with the carbon to which they are attached to form a carbonyl or an optionally substituted $\text{C}_3\text{-C}_7$ cycloalkyl;


each R^4 is, independently, halogen, hydroxyl, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, or two R^4 combine with the carbon two which they are attached to form a carbonyl or optionally substituted $\text{C}_3\text{-C}_7$ cycloalkyl;

R^5 is optionally substituted $\text{C}_6\text{-C}_{10}$ aryl, optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl, optionally substituted $\text{C}_2\text{-C}_9$ heterocycle, or optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl $\text{C}_1\text{-C}_6$ alkyl; and

each R^6 is, independently, hydrogen, halogen, hydroxy, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, or optionally substituted $\text{C}_1\text{-C}_6$ alkyl.

2. The compound, or pharmaceutically acceptable salt thereof, of claim 1, wherein B is absent.

3. The compound, or pharmaceutically acceptable salt thereof, of claim 1, wherein B has the structure of Formula Ib:



4. The compound, or pharmaceutically acceptable salt thereof, of claim 3, wherein X¹ is N and X² is CR⁶.

5. The compound, or pharmaceutically acceptable salt thereof, of claim 3 or 4, wherein o is 0, 1, or 2.

6. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 3-5, wherein R⁴ is halogen, optionally substituted C₁-C₆ alkyl, or two R⁴ combine with the carbon two which they are attached to form a carbonyl..

7. The compound, or pharmaceutically acceptable salt thereof, of claim 6, wherein halogen is fluoro.

8. The compound, or pharmaceutically acceptable salt thereof, of claim 6, wherein optionally substituted C₁-C₆ alkyl is methyl.

9. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 8, wherein R⁶ is hydrogen.

10. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 8, wherein R⁶ is halogen.

11. The compound, or pharmaceutically acceptable salt thereof, of claim 10, wherein halogen is fluoro.

12. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 8, wherein R⁶ is optionally substituted C₁-C₆ alkyl.

13. The compound, or pharmaceutically acceptable salt thereof, of claim 12, wherein optionally substituted C₁-C₆ alkyl is methyl.

14. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 13, wherein the dashed line represents a double bond.


15. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 13, wherein the dashed line represents a single bond.

16. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 15, wherein p is 1 and r is 1.

17. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 15, wherein p is 1 and r is 0.

18. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 15, wherein p is 0 and r is 0.

19. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 4 to 18, wherein B has the structure:



20. The compound, or pharmaceutically acceptable salt thereof, of claim 3, wherein X^1 is CR^6 and X^2 is N.

21. The compound, or pharmaceutically acceptable salt thereof, of claim 20, wherein o is 0, 1, or 2.

22. The compound, or pharmaceutically acceptable salt thereof, of claim 20 or 21, wherein R^4 is halogen, optionally substituted C_1 - C_6 alkyl, or two R^4 combine with the carbon two which they are attached to form a carbonyl.

23. The compound, or pharmaceutically acceptable salt thereof, of claim 22, wherein halogen is fluoro.

24. The compound, or pharmaceutically acceptable salt thereof, of claim 22, wherein optionally substituted C_1 - C_6 alkyl is methyl.

25. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 24, wherein R^6 is hydrogen.

26. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 24, wherein R⁶ is halogen.

27. The compound, or pharmaceutically acceptable salt thereof, of claim 26, wherein halogen is fluoro.

28. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 24, wherein R⁶ is optionally substituted C₁-C₆ alkyl.

29. The compound, or pharmaceutically acceptable salt thereof, of claim 28, wherein optionally substituted C₁-C₆ alkyl is methyl.

30. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 29, wherein the dashed line represents a double bond.


31. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 29, wherein the dashed line represents a single bond.

32. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 31, wherein p is 1 and r is 1.

33. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 31, wherein p is 1 and r is 0.

34. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 31, wherein p is 0 and r is 0.

35. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 20 to 34, wherein B has the structure:



36. The compound, or pharmaceutically acceptable salt thereof, of claim 3, wherein X¹ is N and X² is N.

37. The compound, or pharmaceutically acceptable salt thereof, of claim 36, wherein o is 0, 1, or 2.

38. The compound, or pharmaceutically acceptable salt thereof, of claim 36 or 37, wherein R⁴ is halogen, optionally substituted C₁-C₆ alkyl, or two R⁴ combine with the carbon two which they are attached to form a carbonyl.

39. The compound, or pharmaceutically acceptable salt thereof, of claim 38, wherein halogen is fluoro.


40. The compound, or pharmaceutically acceptable salt thereof, of claim 38, wherein optionally substituted C₁-C₆ alkyl is methyl.

41. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 36 to 40, wherein p is 1 and r is 1.

42. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 36 to 40, wherein p is 1 and r is 0.

43. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 36 to 40, wherein p is 1 and r is 2.

44. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 36 to 43, wherein B has the structure:



45. The compound, or pharmaceutically acceptable salt thereof, of claim 3, wherein X¹ is CR⁶ and X² is CR⁶.

46. The compound, or pharmaceutically acceptable salt thereof, of claim 45, wherein o is 0, 1, or 2.

47. The compound, or pharmaceutically acceptable salt thereof, of claim 45 or 46, wherein R⁴ is halogen, optionally substituted C₁-C₆ alkyl, or two R⁴ combine with the carbon two which they are attached to form a carbonyl.

48. The compound, or pharmaceutically acceptable salt thereof, of claim 47, wherein halogen is fluoro.

49. The compound, or pharmaceutically acceptable salt thereof, of claim 47, wherein optionally substituted C₁-C₆ alkyl is methyl.

50. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 49, wherein R⁶ is hydrogen.

51. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 49, wherein R⁶ is halogen.

52. The compound, or pharmaceutically acceptable salt thereof, of claim 51, wherein halogen is fluoro.

53. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 49, wherein R⁶ is optionally substituted C₁-C₆ alkyl.

54. The compound, or pharmaceutically acceptable salt thereof, of claim 53, wherein optionally substituted C₁-C₆ alkyl is methyl.

55. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 54, wherein the dashed line represents a double bond.


56. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 54, wherein the dashed line represents a single bond.

57. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 56, wherein p is 1 and r is 1.

58. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 56, wherein p is 1 and r is 0.

59. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 56, wherein p is 0 and r is 0.

60. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 45 to 59, wherein B has the structure:



61. The compound, or pharmaceutically acceptable salt thereof, of claim 1, wherein B has the structure of Formula Ic:




62. The compound, or pharmaceutically acceptable salt thereof, of claim 61, wherein X¹ is N and X² is N.

63. The compound, or pharmaceutically acceptable salt thereof, of claim 61 or 62, wherein o is 0.

64. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 61 to 63, wherein B has the structure:




65. The compound, or pharmaceutically acceptable salt thereof, of claim 1, wherein B has the structure of Formula Id:




66. The compound, or pharmaceutically acceptable salt thereof, of claim 65, wherein X¹ is N and X² is N.

67. The compound, or pharmaceutically acceptable salt thereof, of claim 65 or 66, wherein o is 0.

68. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 65 to 67, wherein B has the structure:




69. The compound, or pharmaceutically acceptable salt thereof, of claim 1, wherein B has the structure of Formula Ie:




70. The compound, or pharmaceutically acceptable salt thereof, of claim 69, wherein X¹ is N.

71. The compound, or pharmaceutically acceptable salt thereof, of claim 69 or 70, wherein o is 0.


72. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 69 to 71, wherein B has the structure:



73. The compound, or pharmaceutically acceptable salt thereof, of claim 1, wherein B has the structure of Formula If:




74. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 73, wherein Het is $-\text{C}(\text{O})\text{NH}-$ or:




wherein X^3 is O or S.

75. The compound, or pharmaceutically acceptable salt thereof, of claim 74, wherein Het is $-\text{C}(\text{O})\text{NH}-$.


76. The compound, or pharmaceutically acceptable salt thereof, of claim 74, wherein Het is




77. The compound, or pharmaceutically acceptable salt thereof, of claim 74, wherein Het is



78. The compound, or pharmaceutically acceptable salt thereof, of claim 74, wherein Het is



79. The compound, or pharmaceutically acceptable salt thereof, of claim 74, wherein Het is



80. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 79, wherein L^2 is absent.

81. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 79, wherein L^2 is $-\text{NR}^2-$.

82. The compound, or pharmaceutically acceptable salt thereof, of claim 81, wherein R^2 is hydrogen, methyl, or ethyl.

83. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 79, wherein L^2 is $-O-$.

84. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 79, wherein L^2 is $-SO_2-$.

85. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 79, wherein L^2 is $-CR^2R^3-$.

86. The compound, or pharmaceutically acceptable salt thereof, of claim 85, wherein R^2 and R^3 combine with the carbon to which they are attached to form a carbonyl.

87. The compound, or pharmaceutically acceptable salt thereof, of claim 85, wherein R^2 and R^3 combine with the carbon to which they are attached to form an optionally substituted C_3 - C_7 cycloalkyl.

88. The compound, or pharmaceutically acceptable salt thereof, of claim 87, wherein optionally substituted C_3 - C_7 cycloalkyl is cyclopropyl.

89. The compound, or pharmaceutically acceptable salt thereof, of claim 85, wherein R^2 and R^3 are both hydrogen.

90. The compound, or pharmaceutically acceptable salt thereof, of claim 85, wherein R^2 is hydrogen and R^3 is optionally substituted C_1 - C_6 alkylene.

91. The compound, or pharmaceutically acceptable salt thereof, of claim 90, wherein optionally substituted C_1 - C_6 alkylene is methylene.

92. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91, wherein n is 0.

93. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91, wherein n is 1.

94. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91 or 93, wherein L^1 is $-NR^2-$.

95. The compound, or pharmaceutically acceptable salt thereof, of claim 94, wherein R² is hydrogen or optionally substituted C₁-C₆ alkyl.

96. The compound, or pharmaceutically acceptable salt thereof, of claim 95, wherein optionally substituted C₁-C₆ is methyl or ethyl.

97. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91 or 93, wherein L¹ is -O-.


98. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91 or 93, wherein L¹ is -SO₂-.

99. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91 or 93, wherein L¹ is optionally substituted C₁-C₆ alkylene.

100. The compound, or pharmaceutically acceptable salt thereof, of claim 99, wherein optionally substituted C₁-C₆ alkylene is methylene.


101. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91 or 93, wherein L¹ is optionally substituted C₁-C₆ heteroalkylene.

102. The compound, or pharmaceutically acceptable salt thereof, of claim 101, wherein optionally substituted C₁-C₆ heteroalkylene is -NH-CH₂-, -O-CH₂-, -O-CH₂-CH₂-, -CH₂-O-CH₂-, -CH₂-O-,



103. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 91 or 93, wherein L¹ is optionally substituted C₂-C₉ heterocycle.

104. The compound, or pharmaceutically acceptable salt thereof, of claim 103, wherein




105. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₁-C₆ alkyl.

106. The compound, or pharmaceutically acceptable salt thereof, of claim 105, wherein optionally substituted C₁-C₆ alkyl is methyl, ethyl, isopropyl, tert-butyl, trifluoromethyl, pentafluoro-ethyl, 2-chloro-ethyl, 1-chloro-3-hydroxy-isopropyl, 2-methoxy-ethyl, or hexafluoro-isopropyl.

107. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₆-C₁₀ aryl.

108. The compound, or pharmaceutically acceptable salt thereof, of claim 107, wherein optionally substituted C₆-C₁₀ aryl is phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-cyano-phenyl, 3-cyano-phenyl, 4-cyano-phenyl, 3-isopropyl-phenyl, 4-isopropyl-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 4-methoxy-phenyl, 4-difluoromethoxy-phenyl, 4-trifluoromethoxy-phenyl, 2-chloro-5-fluoro-phenyl,




109. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₆-C₁₀ aryl C₁-C₆ alkyl.

110. The compound, or pharmaceutically acceptable salt thereof, of claim 109, wherein optionally substituted C₆-C₁₀ aryl C₁-C₆ alkyl is naphthylmethyl.

111. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₃-C₇ cycloalkyl.

112. The compound, or pharmaceutically acceptable salt thereof, of claim 111, wherein optionally substituted C₃-C₇ cycloalkyl is cyclopropyl, 1-ethyl-cyclopropyl, 1-fluoro-cyclopropyl, 1-methoxy-cyclopropyl, 1-hydroxy-cyclopropyl, 2,2-dimethyl-cyclopropyl, 2,2-difluoro-cyclopropyl, cyclobutyl, 1-





113. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₃-C₇ cycloalkyl C₁-C₆ alkyl.


115. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₂-C₉ heteroaryl.

[illegible]

117. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 104, wherein R¹ is optionally substituted C₂-C₉ heterocycle.









125. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 120, wherein R⁵ is an optionally substituted C₂-C₉ heterocycle.

126. The compound, or pharmaceutically acceptable salt thereof, of claim 125, wherein




127. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 120, wherein R⁵ is optionally substituted C₂-C₉ heteroaryl C₁-C₆ alkyl.

128. The compound, or pharmaceutically acceptable salt thereof, of claim 127, wherein



129. A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula I:



Formula I

wherein Het is an optionally substituted optionally substituted C₂-C₉ heteroaryl;

m is 0 or 1;

n is 0, 1, or 2;

o is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

X¹ and X² are each, independently, N or CR⁴;

L is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ alkenylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocycle;

R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocycle;

R² and R³ are each, independently, hydrogen, optionally substituted C₁-C₆ alkyl, or combine with the carbon to which they are attached to form a carbonyl;


each R⁴ is, independently, halogen, hydroxyl, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, or two R⁴ combine with the carbon two which they are attached to form a carbonyl;

R⁵ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl; and

each R⁶ is, independently, hydrogen or optionally substituted C₁-C₆ alkyl.

130. The compound, or a pharmaceutically acceptable salt thereof, of claim 129, wherein R² and R³ combine with the carbon to which they are attached to form a carbonyl.

131. The compound, or a pharmaceutically acceptable salt thereof, of claim 129 or 130 having the structure of Formula II or IIa:



Formula II

Formula IIa

wherein X³ is O or S.

132. The compound, or pharmaceutically acceptable salt thereof, of claim 131, wherein X³ is O.


133. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 132, wherein X^1 is N.

134. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 133, wherein X^2 is CR^6 .

135. The compound, or pharmaceutically acceptable salt thereof, of claim 134, wherein R^6 is hydrogen.

136. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 135, wherein R^5 is optionally substituted C_6 - C_{10} aryl.

137. The compound, or pharmaceutically acceptable salt thereof, of claim 136, wherein the compound has the structure of Formula III or IIIa:



Formula III


Formula IIIa

wherein p is 1, 2, 3, 4, or 5;

each R^7 is, independently, halogen, nitrile, OR^8 , or optionally substituted C_1 - C_6 alkyl; and

each R^8 is, independently, hydrogen or optionally substituted C_1 - C_6 alkyl.

138. The compound, or pharmaceutically acceptable salt thereof, of claim 137, wherein the compound has the structure of Formula IV or IVa:



Formula IV

Formula IVa


139. The compound, or pharmaceutically acceptable salt thereof, of claim 137 or 138, wherein each of R^{7a} and R^{7b} is OR^8 .

140. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 137 to 139, wherein each R^8 is optionally substituted C_1 - C_6 alkyl.


141. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 135, wherein R^5 is optionally substituted C_2 - C_9 heteroaryl.

142. The compound, or pharmaceutically acceptable salt thereof, of claim 141, wherein said optionally substituted C₂-C₉ heteroaryl is a bicyclic heteroaryl.

143. The compound, or pharmaceutically acceptable salt thereof, of claim 142, wherein said bicyclic heteroaryl is:




144. The compound, or pharmaceutically acceptable salt thereof, of claim 143, wherein said bicyclic heteroaryl is:



145. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 144, wherein R¹ is optionally substituted C₆-C₁₀ aryl or optionally substituted C₂-C₉ heteroaryl.

146. The compound, or pharmaceutically acceptable salt thereof, of claim 145, wherein R¹ is optionally substituted C₆-C₁₀ aryl.


147. The compound, or pharmaceutically acceptable salt thereof, of claim 146, wherein the compound has the structure of Formula V or Va:



wherein q is 1, 2, 3, 4, or 5; and

R⁹ is halogen or optionally substituted C₁-C₆ alkyl.

148. The compound, or pharmaceutically acceptable salt thereof, of claim 147, wherein the compound has the structure of Formula VI or VIa:



Formula VI

Formula VIa

149. The compound, or pharmaceutically acceptable salt thereof, of claim 135, wherein the R¹ is optionally substituted C₂-C₉ heteroaryl.

150. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 149, wherein n is 1.

151. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 150, wherein L¹ is optionally substituted C₁-C₆ heteroalkylene.


152. The compound, or pharmaceutically acceptable salt thereof, of claim 151, wherein L¹ is -NH-(CR¹⁰R¹¹)_r, wherein r is 1, 2, 3, 4, 5, or 6, and each R¹⁰ and R¹¹ is, independently, hydrogen or optionally substituted C₁-C₆ alkyl.

153. The compound, or pharmaceutically acceptable salt thereof, of claim 152, wherein L¹ is -NH-CH₂-, -NH-CR¹⁰R¹¹-, wherein each of R¹⁰ and R¹¹ is methyl, or -NH-CHR¹¹-, wherein R¹¹ is methyl.

154. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 153, wherein m is 1.

155. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 129 to 153, wherein L¹ is optionally substituted C₂-C₉ heterocycle.

156. The compound, or pharmaceutically acceptable salt thereof, of claim 155, wherein L¹ is



157. The compound, or pharmaceutically acceptable salt thereof, of claim 154 or 155, wherein m is 0.

158. A compound, or pharmaceutically acceptable salt thereof, having the structure of any one of compounds 1-966 in Table 1.

159. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 158, and a pharmaceutically acceptable excipient.

160. A method of treating a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 158 or a pharmaceutical composition of claim 159.

161. A method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 158.

162. The method of claim 161, wherein the toxicity is α -synuclein-related toxicity.

163. The method of claim 161, wherein the toxicity is ApoE4-related toxicity.

164. The method of any one of claims 161 to 163, wherein the cell is a mammalian neural cell.

165. A method of treating a stearyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1 to 158 or a pharmaceutical composition of claim 159.

FIG. 1A





FIG. 1B






FIG. 3A

FIG. 3B




FIG. 4




FIG. 5




FIG. 6




FIG. 7




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D





FIG. 9



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/058144

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☐ forming part of the international application as filed:
 - ☐ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
 - ☒ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/058144

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 6-19, 25-35, 41-44, 50-60, 64, 68, 72, 74-128, 133-157, 159-165
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Extra Sheet

Claims 1 and 2 have been analyzed subject to the restriction that the claims read on the structure of Formula Ia as described in the Lack of Unity of Invention (See Extra Sheet). The claims are restricted to a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia: wherein: B is absent; Het is -C(O)NH-; m is 0; n is 0; L1 is absent; L2 is absent; R1 is unsubstituted C1 alkyl; R5 is unsubstituted C6 aryl.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 and 2

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/058144

Continued from Box No. III Observations where unity of invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1-5, 20-24, 36-40, 45-49, 61-63, 65-67, 69-71, 73, 129-132, and 158 are drawn to a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia, and species thereof.

The first invention of Group I+ is restricted to a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia: wherein: B is absent; Het is -C(O)NH-; m is 0; n is 0; L2 is absent; R1 is unsubstituted C1 alkyl; R5 is unsubstituted C6 aryl. It is believed that claims 1 and 2 read on this first named invention and thus these claims will be searched without fee to the extent that they read on the above embodiment.

Applicant is invited to elect additional formula(e) for each additional compound to be searched in a specific combination by paying an additional fee for each set of election. Each additional elected formula(e) requires the selection of a single definition for each compound variable. An exemplary election would be a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia: wherein: B has the structure: Formula Ib; the dashed line represents a single bond; Het is -C(O)NH-; m is 0; n is 0; o is 0; p and r are independently, 0; X1 and X2 are each, independently, N; L2 is absent; R1 is unsubstituted C1 alkyl; R5 is unsubstituted C6 aryl. Additional formula(e) will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulae do not share a significant structural element requiring the selection of alternatives for the compound variables R1, R5, B, Het, L1, L2, m, and n, and accordingly these groups lack unity a priori.

Additionally, even if Groups I+ were considered to share the technical features of a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia and species thereof, these shared technical features do not represent a contribution over the prior art as disclosed by WO 2010/039186 A2 to Renovis, Inc.

WO 2010/039186 A2 to Renovis, Inc. teaches a compound, or pharmaceutically acceptable salt thereof, having the structure of Formula Ia (Pg. 88, See Table, compound ID 181, as shown).

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical feature.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/058144

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 403/14; C07D 271/02; C07D 413/14 (2018.01)

CPC - C07D 271/02; C07D 403/14; C07D 413/14 (2018.02)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HUESTIS et al., The Vinyl Moiety as a Handle for Regiocontrol in the Preparation of Unsymmetrical 2,3-Aliphatic-Substituted Indoles and Pyrroles, Angew. Chem. Int. Ed., Vol. 50, 29 December 2010, Pgs. 1338-1341	1, 2
A	WO 2010/039186 A2 (RENOVIS INC) 08 April 2010 (08.04.2010) entire document	1, 2
A	US 2013/0225529 A1 (RIGAS) 29 August 2013 (29.08.2013) entire document	1, 2
A	US 2012/0010186 A1 (LACHANCE et al) 12 January 2012 (12.01.2012) entire document	1, 2

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 February 2018

Date of mailing of the international search report

09 MAR 2018

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774